FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Martinez, ME
Kearney, DJ
Simpson, T
Felleman, BI
Bernardi, N
Sayre, G
AF Martinez, Michelle E.
Kearney, David J.
Simpson, Tracy
Felleman, Benjamin I.
Bernardi, Nicole
Sayre, George
TI Challenges to Enrollment and Participation in Mindfulness-Based Stress
Reduction Among Veterans: A Qualitative Study
SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; SUBSTANCE USE DISORDERS; COGNITIVE THERAPY;
CHRONIC PAIN; OF-LIFE; OEF/OIF VETERANS; MENTAL-HEALTH; CARE-SYSTEM;
MEDITATION; DEPRESSION
AB Background: Mindfulness-Based Stress Reduction (MBSR) is associated with reduced depressive symptoms, quality of life improvements, behavioral activation, and increased acceptance among veterans. This study was conducted to increase the reach and impact of a veterans' MBSR program by identifying barriers to enrollment and participation to inform modifications in program delivery. Objective: Verify or challenge suspected barriers, and identify previously unrecognized barriers, to enrollment and participation in MBSR among veterans. Design: A retrospective qualitative analysis of semistructured interviews. Setting/location: VA Puget Sound Health Care System (Seattle, WA). Subjects: 68 interviewed, and 48 coded and analyzed before reaching saturation. Approach: Content analysis of semistructured interviews. Results: Of the participants who enrolled, most (78%) completed the program and described MBSR positively. Veterans identified insufficient or inaccurate information, scheduling issues, and an aversion to groups as barriers to enrollment. Participants who discontinued the program cited logistics (e.g., scheduling and medical issues), negative reactions to instructors or group members, difficulty understanding the MBSR practice purposes, and struggling to find time for the practices as barriers to completion. Other challenges (cohort dynamics, teacher impact on group structure and focus, instructor lack of military service, and physical and psychological challenges) did not impede participation; we interpreted these as growth-facilitating challenges. Common conditions among veterans (chronic pain, posttraumatic stress disorder, and depression) were not described as barriers to enrollment or completion. Conclusions: Women-only MBSR groups and tele-health MBSR groups could improve accessibility to MBSR for veterans by addressing barriers such as commute anxiety, time restrictions, and an aversion to mixed gender groups among women. Educating MBSR teachers about veteran culture and health challenges faced by veterans, adding psychoeducation materials that relate mindfulness practice to conditions common among veterans, and improving visual aids for mindful movement exercises in the workbook could better accommodate veterans who participate in MBSR.
C1 [Martinez, Michelle E.; Felleman, Benjamin I.; Bernardi, Nicole; Sayre, George] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Kearney, David J.] VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA.
[Simpson, Tracy] VA Puget Sound Hlth Care Syst, Dept Mental Hlth, Seattle, WA USA.
[Kearney, David J.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
[Simpson, Tracy] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Sayre, George] Univ Washington, Sch Med, Dept Hlth Serv, Seattle, WA 98195 USA.
RP Kearney, DJ (reprint author), Seattle VAMC 111GI, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM david.kearney@VA.gov
FU VA Puget Sound Office of Patient Centered Care & Cultural Transformation
(OPCCCT)
FX We would like to thank and acknowledge Emily Hu, MS, and Victoria
Sanborn, MSW, for their contributions to this project. The study was
funded by the VA Puget Sound Office of Patient Centered Care & Cultural
Transformation (OPCC&CT).
NR 57
TC 0
Z9 0
U1 3
U2 15
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1075-5535
EI 1557-7708
J9 J ALTERN COMPLEM MED
JI J. Altern. Complement Med.
PD JUL 1
PY 2015
VL 21
IS 7
BP 409
EP 421
DI 10.1089/acm.2014.0324
PG 13
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA CU9RM
UT WOS:000363882600006
PM 26133205
ER
PT J
AU Iezzoni, LI
Kurtz, SG
Rao, SR
AF Iezzoni, Lisa I.
Kurtz, Stephen G.
Rao, Sowmya R.
TI Trends in Mammography Over Time for Women With and Without Chronic
Disability
SO JOURNAL OF WOMENS HEALTH
LA English
DT Article
ID PREVENTIVE SERVICES; MOBILITY IMPAIRMENTS; PHYSICAL-DISABILITIES;
BREAST-CANCER; ACCESS; BARRIERS; RECEIPT; LEVEL; CARE
AB Background: Women with disabilities often receive mammograms at lower rates than do nondisabled women, although this disparity varies by disability type and severity. Given the implementation of disability civil rights laws in the early 1990s, we examined whether disability disparities in mammogram use have diminished over time. Methods: We analyzed National Health Interview Survey responses of civilian, noninstitutionalized United States female residents 50 to 74 years old from selected years between 1998 and 2010. We identified seven chronic disability types using self-reported functional impairments, activity/participation limitations, and expected duration. We conducted bivariable and multivariable logistic regression analyses examining associations of self-reported mammogram use within the previous two years with sociodemographic factors and disability. Results: Most chronic disability rates rose over time. The most common disability was movement difficulties, with rates increasing from 35.6% (1998) to 39.8% (2010). Mammogram rates for all women remained relatively stable over time, ranging from 72% to 75%. Bivariable analyses generally found statistically significantly lower mammogram rates for women with disability versus nondisabled women. Over time, disparities grew significantly between women with any basic action difficulty or complex activity limitation and nondisabled women (p<0.01). In multivariable logistic analyses, having any difficulty with basic actions was significantly associated with lower adjusted odds of mammography; for example, adjusted odds [95% confidence interval]=0.5 [0.3-0.8], p=0.006, in the model involving movement disability. Conclusions: Little has changed since 1998 in mammogram rates for women with versus without disabilities. Women with certain disabilities continue to experience disparities in mammography testing.
C1 [Iezzoni, Lisa I.] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA.
[Iezzoni, Lisa I.] Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA.
[Kurtz, Stephen G.; Rao, Sowmya R.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA.
[Rao, Sowmya R.] Bedford Vet Affairs Med Ctr, Ctr Healthcare Org & Implementat Res, Bedford, MA USA.
RP Iezzoni, LI (reprint author), Massachusetts Gen Hosp, Mongan Inst Hlth Policy, 50 Staniford St,Room 901B, Boston, MA 02114 USA.
EM liezzoni@mgh.harvard.edu
FU National Cancer Institute [5 R01 CA160286-02]
FX This work was funded by the National Cancer Institute, 5 R01
CA160286-02.
NR 29
TC 0
Z9 0
U1 3
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-9996
EI 1931-843X
J9 J WOMENS HEALTH
JI J. Womens Health
PD JUL 1
PY 2015
VL 24
IS 7
BP 593
EP 601
DI 10.1089/jwh.2014.5181
PG 9
WC Public, Environmental & Occupational Health; Medicine, General &
Internal; Obstetrics & Gynecology; Women's Studies
SC Public, Environmental & Occupational Health; General & Internal
Medicine; Obstetrics & Gynecology; Women's Studies
GA CU9WH
UT WOS:000363896900011
PM 26083235
ER
PT J
AU Luckett, R
Pena, N
Vitonis, A
Bernstein, MR
Feldman, S
AF Luckett, Rebecca
Pena, Nancy
Vitonis, Allison
Bernstein, Marilyn R.
Feldman, Sarah
TI Effect of Patient Navigator Program on No-Show Rates at an Academic
Referral Colposcopy Clinic
SO JOURNAL OF WOMENS HEALTH
LA English
DT Article
ID INCOME MINORITY WOMEN; CERVICAL-CANCER; FOLLOW-UP; CONTROLLED-TRIAL;
CARE; DISPARITIES; ADHERENCE; IMPACT; BREAST; INTERVENTIONS
AB Background: Patient navigators have been used successfully to guide vulnerable patients through barriers to cancer care and reduce disparities in cancer outcomes. This study evaluated the effect of a patient navigator program on no-show rates at a tertiary care referral colposcopy center and explored factors associated with missed appointments. Methods: No-show rates prior and subsequent to implementation of the intervention were compared by chi-square test. We compared patient demographic, lifestyle, and diagnostic characteristics between patients who had ever and never missed appointments. We described patient-reported barriers to care. Results: Of 4,199 women evaluated in our clinic from January 2006 to December 2013, 2,441 (58%) had at least one missed appointment. African American, Hispanic, and publicly insured women tended to miss appointments more frequently than did white and privately insured women (p<0.0001). Patients who missed appointments tended to have more abnormal cytology (p<0.0001), cervical pathology (p=0.007), and vulvar pathology (p=0.001). No-show rates declined from 49.7% to 29.5% after implementation of the patient navigator program (p<0.0001). We found that 45% of patient no-shows were anticipated or a result of patient misunderstanding and could be mediated with targeted education by the patient navigator. Conclusions: Patient navigator programs at referral centers reduce no-show rates, thus improving patient follow-up, which may reduce disparities in cervical cancer screening and treatment.
C1 [Luckett, Rebecca; Vitonis, Allison; Feldman, Sarah] Brigham & Womens Hosp, Dept Obstet & Gynecol, Boston, MA 02115 USA.
[Pena, Nancy; Bernstein, Marilyn R.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Gynecol Oncol, Boston, MA 02115 USA.
RP Luckett, R (reprint author), 75 Francis St, Boston, MA 02115 USA.
EM rluckett@partners.org
NR 33
TC 5
Z9 5
U1 1
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-9996
EI 1931-843X
J9 J WOMENS HEALTH
JI J. Womens Health
PD JUL 1
PY 2015
VL 24
IS 7
BP 608
EP 615
DI 10.1089/jwh.2014.5111
PG 8
WC Public, Environmental & Occupational Health; Medicine, General &
Internal; Obstetrics & Gynecology; Women's Studies
SC Public, Environmental & Occupational Health; General & Internal
Medicine; Obstetrics & Gynecology; Women's Studies
GA CU9WH
UT WOS:000363896900013
PM 26173000
ER
PT J
AU Brauner, E
Holmes, BJ
Krane, JF
Nishino, M
Zurakowski, D
Hennessey, JV
Faquin, WC
Parangi, S
AF Brauner, Eran
Holmes, Brittany J.
Krane, Jeffrey F.
Nishino, Michiya
Zurakowski, David
Hennessey, James V.
Faquin, William C.
Parangi, Sareh
TI Performance of the Afirma Gene Expression Classifier in Hurthle Cell
Thyroid Nodules Differs from Other Indeterminate Thyroid Nodules
SO THYROID
LA English
DT Article
ID COMPARATIVE GENOMIC HYBRIDIZATION; CLINICAL-EXPERIENCE; CYTOLOGY;
CARCINOMAS; CANCER; NEOPLASMS; BENIGN; DIAGNOSIS; IMPACT
AB Background: The recently introduced Afirma gene expression classifier (AGEC) provides binary results (benign or suspicious) to guide management of cytologically indeterminate thyroid nodules. The AGEC is intended to reduce unnecessary surgeries for benign nodules, and management algorithms favor surgery for suspicious results. Limited data are available on the performance of this test for Hurthle cell nodules (HCNs). This study hypothesized that a predominance of Hurthle cells leads to an increased rate of suspicious AGEC results with a potential for overtreatment, despite a relatively low risk of malignancy. Methods: The pathology databases from three tertiary care facilities were queried from 2010 to 2014 for fine-needle aspirates (FNAs) diagnosed as suspicious for Hurthle cell neoplasm (SHCN) or atypia of undetermined significance/follicular lesion of undetermined significance concerning for Hurthle cell neoplasm (AFHCN). Cytology diagnoses were rendered internally prior to AGEC testing. The patient demographics, FNA diagnosis, AGEC result, surgical procedure, and pathologic outcomes were recorded. Results: The cohort consisted of 134 patients with HCNs. Prior to AGEC availability, 62 patients underwent surgery: 81% (50/62) of patients had surgery, and 34% (17/50) of the resected index nodules were malignant. After introduction of the AGEC, 72 patients underwent AGEC testing: 65% (47/72) of patients had surgery, and 13% (6/46) of the resected nodules were malignant. Thirty-two percent (23/72) of patients had a benign AGEC result and did not undergo surgery, and 4% (3/72) had surgery despite a benign AGEC result with benign final pathology, whereas 63% (45/72) of patients had suspicious AGEC results, with 96% of these patients (43/45) undergoing surgery, and 14% (6/43) of these index nodules were malignant. Conclusions: While 32% of tested patients declined surgery based on a benign AGEC, 86% of patients with suspicious AGEC findings had unnecessary surgery, reflecting a substantially lower rate of malignancy from what was previously reported for all indeterminate nodules. Given the approximate pretest malignancy risk of 25-35% for an FNA diagnosis of SHCN or AFHCN, a suspicious AGEC diagnosis does not increase the probability of malignancy in an HCN, and patients should be counseled accordingly.
C1 [Brauner, Eran; Parangi, Sareh] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Holmes, Brittany J.; Faquin, William C.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Krane, Jeffrey F.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Nishino, Michiya] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA.
[Zurakowski, David] Boston Childrens Hosp, Dept Surg, Boston, MA USA.
[Zurakowski, David] Boston Childrens Hosp, Dept Anesthesia, Boston, MA USA.
[Hennessey, James V.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA.
RP Faquin, WC (reprint author), Massachusetts Gen Hosp, Dept Pathol, Warren 219,55 Fruit St, Boston, MA 02114 USA.
EM wfaquin@partners.org
FU Clair and Emanuel G. Rosenblatt Fund; American Healthcare Professionals
and Friends for Medicine in Israel (APF)
FX Eran Brauner is sponsored by a grant from the Clair and Emanuel G.
Rosenblatt Fund and American Healthcare Professionals and Friends for
Medicine in Israel (APF). This work was presented in abstract format at
the United States and Canadian Academy of Pathology 2015 Annual Meeting
in Boston, MA.
NR 31
TC 16
Z9 16
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1050-7256
EI 1557-9077
J9 THYROID
JI Thyroid
PD JUL 1
PY 2015
VL 25
IS 7
BP 789
EP 796
DI 10.1089/thy.2015.0049
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CU9TB
UT WOS:000363887000007
PM 25962906
ER
PT J
AU Marcos, S
Alejandre, N
Lamela, J
Dorronsoro, C
Kochevar, IE
AF Marcos, Susana
Alejandre, Nicolas
Lamela, Jorge
Dorronsoro, Carlos
Kochevar, Irene E.
TI Toward New Engagement Paradigms For Intraocular Lenses: Light-Initiated
Bonding of Capsular Bag to Lens Materials
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE A-IOLs; lens capsule; photobonding; physiological optics
ID CROSS-LINKING; PHOTOCHEMICAL KERATODESMOS; CORNEAL INCISIONS;
ROSE-BENGAL; TISSUE; ACCOMMODATION; FORCE; EYES
AB PURPOSE. Successful intraocular lens procedures, that is, implantation of accommodating intraocular lenses (A-IOL), require firm engagement of the IOL haptics to the capsular bag. We evaluated the use of photochemical bonding to engage IOL materials to the capsular bag.
METHODS. Freshly enucleated eyes of New Zealand rabbits were used in two types of photobonding experiments using Rose Bengal (RB) photoinitiation and green light (532-nm) irradiation. First, RB-stained capsular bag strips were photobonded ex vivo to IOL polymer [poly(2-hydroxyethyl methacrylate) pHEMA] strips in an atmosphere of air and of nitrogen. Second, IOLs were implanted intracapsularly and photobonded intraocularly. Irradiation times were between 30 and 180 seconds, and laser irradiance was between 0.25 and 0.65 W/cm(2). The strength of the bonding was tested using a custom-developed uniaxial extensiometry system and the breakage load (the load that caused breakage per bonded area) was calculated.
RESULTS. The breakage load of ex vivo capsule-pHEMA bonds increased exponentially with irradiation time, using 0.45 W/cm(2). In air, the average breakage load across all conditions was 1 g/mm(2) and 1.6 times lower than that in a nitrogen atmosphere. Intraocularly, RB-stained IOLs were strongly photobonded to the capsule bag with breakage loads > 0.8 g/mm(2).
CONCLUSIONS. Breakage of the photobonded linkage between IOL material and capsular bag required loads substantially greater than the maximum force of ciliary muscle, suggesting that this technology may introduce a new paradigm for engagement of A-IOLs. The bonding produced in air was stronger than that in nitrogen atmosphere, suggesting that oxygen is involved in the chemical mechanism for photobonding.
C1 [Marcos, Susana; Alejandre, Nicolas; Lamela, Jorge; Dorronsoro, Carlos] CSIC, Inst Opt, Madrid 28006, Spain.
[Alejandre, Nicolas] Fdn Jimenez Diaz, E-28040 Madrid, Spain.
[Kochevar, Irene E.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Kochevar, Irene E.] Harvard Univ, Sch Med, Boston, MA USA.
RP Lamela, J (reprint author), CSIC, Inst Opt, C Serrano 121, Madrid 28006, Spain.
EM jorge.lamela82@gmail.com
RI Dorronsoro, Carlos/A-2297-2011
NR 27
TC 2
Z9 2
U1 1
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2015
VL 56
IS 8
BP 4249
EP 4256
DI 10.1167/iovs.15-17070
PG 8
WC Ophthalmology
SC Ophthalmology
GA CT5WV
UT WOS:000362882700009
PM 26161986
ER
PT J
AU Ghafoori, E
Kabir, MM
Cao, J
Shvilkin, A
Tereshchenko, LG
AF Ghafoori, Elyar
Kabir, Muammar M.
Cao, Jian
Shvilkin, Alexei
Tereshchenko, Larisa G.
TI Construction of intracardiac vectorcardiogram from implantable
cardioverter-defibrillator intracardiac electrograms
SO JOURNAL OF ELECTROCARDIOLOGY
LA English
DT Article
DE Implantable cardioverter defibrillator; Vectorcardiography; Intracardiac
electrogram
ID VENTRICULAR TACHYARRHYTHMIAS
AB We constructed an intracardiac vectorcardiogram from 3 configurations of intracardiac cardiovertor defibrilator (ICD) electrograms (EGMs). Six distinctive 3 lead combinations were selected out of five leads: can to right ventricular coil (RVC); RVC to superior vena cava coil (SVC); atrial lead tip (A-tip) to right ventricular (RV)-ring; can to RV-ring; RV-tip to RVC, in a patient with dual chamber ICD. Surface spatial QRS-T angle (119.8 degrees) was similar to intracardiac spatial QRS-T angle derived from ICD EGMs combination A (101.3 degrees), B (96.1 degrees), C (92.8 degrees), D (95.2), E (99.0), F (96.2) and median (101.5). Future validation of the novel method is needed. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Ghafoori, Elyar; Kabir, Muammar M.; Tereshchenko, Larisa G.] Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Portland, OR 97239 USA.
[Cao, Jian] Medtronic Inc, Minneapolis, MN USA.
[Shvilkin, Alexei] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiovasc Med, Boston, MA 02115 USA.
RP Tereshchenko, LG (reprint author), Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, 3181 SW Sam Jackson Pk Rd,UHN62, Portland, OR 97239 USA.
EM tereshch@ohsu.edu
OI Shvilkin, Alexei/0000-0003-3662-9938; Tereshchenko,
Larisa/0000-0002-6976-1313
FU National Institute of Health [1R01HL118277]
FX This research was supported in part by the National Institute of Health
#1R01HL118277 (LGT).
NR 9
TC 0
Z9 0
U1 1
U2 1
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 0022-0736
EI 1532-8430
J9 J ELECTROCARDIOL
JI J. Electrocardiol.
PD JUL-AUG
PY 2015
VL 48
IS 4
BP 669
EP 671
DI 10.1016/j.jelectrocard.2015.05.008
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CU3OG
UT WOS:000363434100028
PM 25987408
ER
PT J
AU Brown, RT
Miao, YH
Mitchell, SL
Bharel, M
Patel, M
Ard, KL
Grande, LJ
Blazey-Martin, D
Floru, D
Steinman, MA
AF Brown, Rebecca T.
Miao, Yinghui
Mitchell, Susan L.
Bharel, Monica
Patel, Mitkumar
Ard, Kevin L.
Grande, Laura J.
Blazey-Martin, Deborah
Floru, Daniella
Steinman, Michael A.
TI Health Outcomes of Obtaining Housing Among Older Homeless Adults
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID EMERGENCY-DEPARTMENT VISITS; MINI-MENTAL-STATE; POPULATION; INDEX;
INTERVENTIONS; INDIVIDUALS; VALIDATION; DEPRESSION; IMPROVE; ILLNESS
AB Objectives. We determined the impact of obtaining housing on geriatric conditions and acute care utilization among older homeless adults.
Methods. We conducted a 12-month prospective cohort study of 250 older homeless adults recruited from shelters in Boston, Massachusetts, between January and June 2010. We determined housing status at follow-up, determined number of emergency department visits and hospitalizations over 12 months, and examined 4 measures of geriatric conditions at baseline and 12 months. Using multivariable regression models, we evaluated the association between obtaining housing and our outcomes of interest.
Results. At 12-month follow-up, 41% of participants had obtained housing. Compared with participants who remained homeless, those with housing had fewer depressive symptoms. Other measures of health status did not differ by housing status. Participants who obtained housing had a lower rate of acute care use, with an adjusted annualized rate of acute care visits of 2.5 per year among participants who obtained housing and 5.3 per year among participants who remained homeless.
Conclusions. Older homeless adults who obtained housing experienced improved depressive symptoms and reduced acute care utilization compared with those who remained homeless.
C1 [Brown, Rebecca T.; Steinman, Michael A.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
[Miao, Yinghui] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Mitchell, Susan L.] Hebrew SeniorLife Inst Aging Res, Boston, MA USA.
[Bharel, Monica] Boston Hlth Care Homeless Program, Boston, MA USA.
[Ard, Kevin L.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Patel, Mitkumar] St Elizabeths Med Ctr, Dept Med, Boston, MA USA.
[Grande, Laura J.] Vet Affairs Boston Healthcare Syst, Psychol Serv, Boston, MA USA.
[Blazey-Martin, Deborah] Tufts Med Ctr, Dept Med, Boston, MA USA.
[Floru, Daniella] Lemuel Shattuck Hosp, Div Geriatr Med, Boston, MA USA.
RP Brown, RT (reprint author), San Francisco VA Med Ctr, 4150 Clement St,UCSF Box VA-181G, San Francisco, CA 94121 USA.
EM rebecca.brown@ucsf.edu
FU National Institute on Aging [K23 AG045290, P30 AG044281, K24 AG033640];
National Center for Advancing Translational Sciences through the
University of California, San Francisco, Clinical and Translational
Science Institute [KL2 TR000143]; National Institute on Aging; American
Federation for Aging Research [1K23 AG030999]
FX R. T. Brown was supported by the National Institute on Aging (K23
AG045290 and P30 AG044281) and by the National Center for Advancing
Translational Sciences through the University of California, San
Francisco, Clinical and Translational Science Institute (KL2 TR000143).
S. L. Mitchell was supported by the National Institute on Aging (K24
AG033640). M. A. Steinman was supported by the National Institute on
Aging and the American Federation for Aging Research (1K23 AG030999).
NR 43
TC 2
Z9 2
U1 4
U2 10
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUL
PY 2015
VL 105
IS 7
BP 1482
EP 1488
DI 10.2105/AJPH.2014.302539
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CT6FX
UT WOS:000362909400038
PM 25973822
ER
PT J
AU De Maria, G
AF De Maria, Gayle
TI Multiple types of resistance to new lung cancer drug identified
SO CHIMICA OGGI-CHEMISTRY TODAY
LA English
DT Editorial Material
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
RP De Maria, G (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU TEKNOSCIENZE PUBL
PI MILANO
PA VIALE BRIANZA 22, 20127 MILANO, ITALY
SN 0392-839X
EI 1973-8250
J9 CHIM OGGI
JI Chim. Oggi-Chem. Today
PD JUL-AUG
PY 2015
VL 33
IS 4
BP 52
EP 52
PG 1
WC Biotechnology & Applied Microbiology; Chemistry, Multidisciplinary
SC Biotechnology & Applied Microbiology; Chemistry
GA CT7AN
UT WOS:000362965500012
ER
PT J
AU Najmi, LA
Aukrust, I
Flannick, J
Molnes, J
Burtt, N
Molven, A
Johansson, S
Bjorkhaug, L
Altshuler, D
Njolstad, P
AF Najmi, L. A.
Aukrust, I.
Flannick, J.
Molnes, J.
Burtt, N.
Molven, A.
Johansson, S.
Bjorkhaug, L.
Altshuler, D.
Njolstad, P.
TI Functional investigations of the monogenic diabetes gene HNF1A identify
rare variants as risk factors for type 2 diabetes in a general
population
SO FEBS JOURNAL
LA English
DT Meeting Abstract
CT 40th Congress of the Federation-of-European-Biochemical-Societies (FEBS)
- The Biochemical Basis of Life
CY JUL 04-09, 2015
CL Berlin, GERMANY
SP Federat European Biochemical Soc
C1 [Najmi, L. A.; Njolstad, P.] Univ Bergen, Clin Sci, Bergen, Norway.
[Najmi, L. A.; Aukrust, I.; Johansson, S.] Haukeland Hosp, Ctr Med Genet & Mol Med, N-5021 Bergen, Norway.
[Najmi, L. A.; Bjorkhaug, L.] Univ Bergen, Biomed, Bergen, Norway.
[Aukrust, I.; Molnes, J.] Univ Bergen, KG Jebsen Ctr Diabet Res, Dept Clin Sci, Bergen, Norway.
[Flannick, J.] Broad Inst Harvard, Program Med & Populat Genet, Cambridge, MA USA.
[Flannick, J.] MIT, Cambridge, MA 02139 USA.
[Molnes, J.; Njolstad, P.] Haukeland Hosp, Dept Pediat, N-5021 Bergen, Norway.
[Burtt, N.] Univ Cambridge, Broad Inst Harvard, Cambridge, MA USA.
[Burtt, N.] Univ Cambridge, MIT, Cambridge, MA USA.
[Molven, A.] Univ Bergen, Med Clin, Bergen, Norway.
[Molven, A.] Haukeland Hosp, Pathol, N-5021 Bergen, Norway.
[Altshuler, D.] Harvard Univ, Sch Med, Genet, Boston, MA USA.
[Altshuler, D.] Massachusetts Gen Hosp, Mol Biol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1742-464X
EI 1742-4658
J9 FEBS J
JI FEBS J.
PD JUL
PY 2015
VL 282
SU 1
SI SI
MA P03-035
BP 79
EP 79
PG 1
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA CT1PC
UT WOS:000362570601081
ER
PT J
AU Marti, AP
Coelho, ALD
do Rosario, AC
Pardo, JR
Gonzalez, PFM
Bautista, DH
AF Perez Marti, A.
De Sousa Coelho, A. L.
Carrilho do Rosario, A.
Relat Pardo, J.
Marrero Gonzalez, P. F.
Haro Bautista, D.
TI FGF21 is down regulated by fasting in mice under leucine deficient diet
SO FEBS JOURNAL
LA English
DT Meeting Abstract
CT 40th Congress of the Federation-of-European-Biochemical-Societies (FEBS)
- The Biochemical Basis of Life
CY JUL 04-09, 2015
CL Berlin, GERMANY
SP Federat European Biochemical Soc
C1 [Perez Marti, A.; De Sousa Coelho, A. L.; Carrilho do Rosario, A.; Relat Pardo, J.; Marrero Gonzalez, P. F.; Haro Bautista, D.] Univ Barcelona, Biochem & Mol Biol Pharm, Barcelona, Spain.
[De Sousa Coelho, A. L.] Joslin Diabet Ctr, Med, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1742-464X
EI 1742-4658
J9 FEBS J
JI FEBS J.
PD JUL
PY 2015
VL 282
SU 1
SI SI
MA P03-067
BP 88
EP 88
PG 1
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA CT1PC
UT WOS:000362570601112
ER
PT J
AU Sieverdes, JC
Nemeth, LS
Magwood, GS
Baliga, PK
Chavin, KD
Brunner-Jackson, B
Patel, SK
Ruggiero, KJ
Treiber, FA
AF Sieverdes, John Christopher
Nemeth, Lynne S.
Magwood, Gayenell S.
Baliga, Prabhakar K.
Chavin, Kenneth D.
Brunner-Jackson, Brenda
Patel, Sachin K.
Ruggiero, Kenneth J.
Treiber, Frank A.
TI Patient-Centered mHealth Living Donor Transplant Education Program for
African Americans: Development and Analysis
SO JMIR RESEARCH PROTOCOLS
LA English
DT Article
DE kidney transplantation; living donors; mobile apps; qualitative
research; telemedicine
ID SELF-DETERMINATION THEORY; QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL;
KIDNEY-TRANSPLANTATION; RENAL-TRANSPLANTATION; INTRINSIC MOTIVATION;
HEALTH-CARE; INTERVENTION; CANDIDATES; RECIPIENTS
AB Background: There is a critical need to expand the pool of available kidneys for African Americans who are on the transplant wait-list due to the disproportionally lower availability of deceased donor kidneys compared with other races/ethnic groups. Encouraging living donation is one method to fill this need. Incorporating mHealth strategies may be a way to deliver educational and supportive services to African American transplant-eligible patients and improve reach to those living in remote areas or unable to attend traditional group-session-based programs. Before program development, it is essential to perform formative research with target populations to determine acceptability and cultivate a patient-centered and culturally relevant approach to be used for program development.
Objective: The objectives of this study were to investigate African American kidney transplant recipients' and kidney donors'/potential donors' attitudes and perceptions toward mobile technology and its viability in an mHealth program aimed at educating patients about the process of living kidney donation.
Methods: Using frameworks from the technology acceptance model and self-determination theory, 9 focus groups (n=57) were administered to African Americans at a southeastern medical center, which included deceased/living donor kidney recipients and living donors/potential donors. After a demonstration of a tablet-based video education session and explanation of a group-based videoconferencing session, focus groups examined members' perceptions about how educational messages should be presented on topics pertaining to the process of living kidney donation and the transplantation. Questionnaires were administered on technology use and perceptions of the potential program communication platform. Transcripts were coded and themes were examined using NVivo 10 software.
Results: Qualitative findings found 5 major themes common among all participants. These included the following: (1) strong support for mobile technology use; (2) different media formats were preferred; (3) willingness to engage in video chats, but face-to-face interaction sometimes preferred; (4) media needs to be user friendly; (5) high prevalence of technology access. Our results show that recipients were willing to spend more time on education than the donors group, they wanted to build conversation skills to approach others, and preferred getting information from many sources, whereas the donor group wanted to hear from other living donors. The questionnaires revealed 85% or more of the sample scored 4+ on a 5-point Liken scale, which indicates high degree of interest to use the proposed program, belief that other mHealth technologies would help with adherence to medical regimens, and doctors would make regimen adjustments quicker. In addition, high utilization of mobile technology was reported; 71.9% of the participants had a mobile phone and 43.9% had a tablet.
Conclusions: Our study supports the use of an mHealth education platform for African Americans to learn about living donation. However, potential recipients and potential donors have differing needs, and therefore, programs should be tailored to each target audience.
C1 [Sieverdes, John Christopher; Brunner-Jackson, Brenda; Patel, Sachin K.; Ruggiero, Kenneth J.; Treiber, Frank A.] Med Univ S Carolina, Coll Nursing, Technol Applicat Ctr Healthful Lifestyles, Charleston, SC 29425 USA.
[Nemeth, Lynne S.; Magwood, Gayenell S.] Med Univ S Carolina, Coll Nursing, Charleston, SC 29425 USA.
[Baliga, Prabhakar K.; Chavin, Kenneth D.] Med Univ S Carolina, Coll Med, Dept Surg, Div Transplant Surg, Charleston, SC 29425 USA.
[Ruggiero, Kenneth J.] Ralph H Johnson VA Med Ctr, Psychiat Inst, Charleston, SC USA.
[Treiber, Frank A.] Med Univ S Carolina, Coll Med, Charleston, SC 29425 USA.
RP Treiber, FA (reprint author), Med Univ S Carolina, Coll Nursing, Technol Applicat Ctr Healthful Lifestyles, 99 Jonathan Lucas St,MSC 160, Charleston, SC 29425 USA.
EM treiberf@musc.edu
RI Emchi, Karma/Q-1952-2016;
OI Brunner-Jackson, Brenda/0000-0002-1518-758X; Magwood,
Gayenell/0000-0002-2451-4888; Nemeth, Lynne/0000-0001-8691-1400
FU NCATS NIH HHS [UL1 TR000062]; NIDDK NIH HHS [R01 DK098777]
NR 44
TC 1
Z9 1
U1 2
U2 6
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA
SN 1929-0748
J9 JMIR RES PROTOC
JI JMIR RES. Protoc.
PD JUL-SEP
PY 2015
VL 4
IS 3
AR UNSP e84
DI 10.2196/resprot.3715
PG 14
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA CT3TR
UT WOS:000362730300019
PM 26265532
ER
PT J
AU Sweeney, C
AF Sweeney, C.
TI NEW INSIGHTS IN GCT
SO ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article; Proceedings Paper
CT ANZUP Annual Scientific Meeting, Redefining Personalised Medicine
CY JUL 12-14, 2015
CL Sydney, AUSTRALIA
C1 [Sweeney, C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1743-7555
EI 1743-7563
J9 ASIA-PAC J CLIN ONCO
JI Asia-Pac. J. Clin. Oncol.
PD JUL
PY 2015
VL 11
SU 2
SI SI
MA 7
BP 23
EP 23
PG 1
WC Oncology
SC Oncology
GA CT4WL
UT WOS:000362808000008
ER
PT J
AU Sweeney, C
AF Sweeney, C.
TI IMMEDIATE DOCETAXEL IN METASTATIC PROSTATE CANCER
SO ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article; Proceedings Paper
CT ANZUP Annual Scientific Meeting, Redefining Personalised Medicine
CY JUL 12-14, 2015
CL Sydney, AUSTRALIA
C1 [Sweeney, C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1743-7555
EI 1743-7563
J9 ASIA-PAC J CLIN ONCO
JI Asia-Pac. J. Clin. Oncol.
PD JUL
PY 2015
VL 11
SU 2
SI SI
MA 6
BP 23
EP 23
PG 1
WC Oncology
SC Oncology
GA CT4WL
UT WOS:000362808000007
ER
PT J
AU Sweeney, C
AF Sweeney, C.
TI PRECISION MEDICINE IN PROSTATE CANCER: HOW CLOSE ARE WE?
SO ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article; Proceedings Paper
CT ANZUP Annual Scientific Meeting, Redefining Personalised Medicine
CY JUL 12-14, 2015
CL Sydney, AUSTRALIA
C1 [Sweeney, C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1743-7555
EI 1743-7563
J9 ASIA-PAC J CLIN ONCO
JI Asia-Pac. J. Clin. Oncol.
PD JUL
PY 2015
VL 11
SU 2
SI SI
MA 1
BP 22
EP 22
PG 1
WC Oncology
SC Oncology
GA CT4WL
UT WOS:000362808000002
ER
PT J
AU Morgans, AK
van Bommel, ACM
Stowell, C
Abrahm, JL
Basch, E
Bekelman, JE
Berry, DL
Bossi, A
Davis, ID
de Reijke, TM
Denis, LJ
Evans, SM
Fleshner, NE
George, DJ
Kiefert, J
Lin, DW
Matthew, AG
McDermott, R
Payne, H
Roos, IAG
Schrag, D
Steuber, T
Tombal, B
van Basten, J
van der Hoeven, JJM
Penson, D
AF Morgans, A. K.
van Bommel, A. C. M.
Stowell, C.
Abrahm, J. L.
Basch, E.
Bekelman, J. E.
Berry, D. L.
Bossi, A.
Davis, I. D.
de Reijke, T. M.
Denis, L. J.
Evans, S. M.
Fleshner, N. E.
George, D. J.
Kiefert, J.
Lin, D. W.
Matthew, A. G.
McDermott, R.
Payne, H.
Roos, I. A. G.
Schrag, D.
Steuber, T.
Tombal, B.
van Basten, J.
van der Hoeven, J. J. M.
Penson, D.
TI DEVELOPMENT OF A STANDARDIZED SET OF PATIENT-CENTERED OUTCOMES FOR
ADVANCED PROSTATE CANCER: AN INTERNATIONAL EFFORT FOR A UNIFIED APPROACH
SO ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article; Proceedings Paper
CT ANZUP Annual Scientific Meeting, Redefining Personalised Medicine
CY JUL 12-14, 2015
CL Sydney, AUSTRALIA
C1 [Morgans, A. K.] Vanderbilt Univ, Med Ctr, Nashville, TN 37235 USA.
[van Bommel, A. C. M.; Stowell, C.] Int Consortium Hlth Outcomes Measurement, Cambridge, MA USA.
[van Bommel, A. C. M.] Dutch Inst Clin Auditing, Leiden, Netherlands.
[Stowell, C.] Monash Univ, Box Hill, Vic, Australia.
[Stowell, C.] Eastern Hlth, Box Hill, Vic, Australia.
[Abrahm, J. L.; Berry, D. L.; Schrag, D.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Basch, E.] Univ N Carolina, Chapel Hill, NC USA.
[Bekelman, J. E.] Univ Penn, Philadelphia, PA 19104 USA.
[Bossi, A.] Gustave Roussy Canc Inst, Villejuif, France.
[Davis, I. D.] Monash Univ, Eastern Hlth Clin Sch, Melbourne, Vic 3004, Australia.
[Davis, I. D.] Eastern Hlth, Dept Canc Serv, Box Hill, Vic, Australia.
[de Reijke, T. M.] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands.
[Denis, L. J.] Oncol Ctr Antwerp, Antwerp, Belgium.
[Denis, L. J.] US TOO Belgium, Antwerp, Belgium.
[Evans, S. M.] Monash Univ, Melbourne, Vic 3004, Australia.
[Fleshner, N. E.; Matthew, A. G.] Univ Toronto, Toronto, ON, Canada.
[George, D. J.] Duke Univ, Med Ctr, Durham, NC USA.
[Kiefert, J.] US TOO Int, Des Plaines, IL USA.
[Lin, D. W.] Univ Washington, Seattle, WA 98195 USA.
[McDermott, R.] St Vincents Univ Hosp, Dublin 4, Ireland.
[Payne, H.] Univ Coll London Hosp, London, England.
[Roos, I. A. G.] Canc Act Victoria, Melbourne, Vic, Australia.
[Steuber, T.] Univ Hamburg Hosp, Hamburg, Germany.
[Tombal, B.] Catholic Univ Louvain, Clin Univ St Luc, B-1200 Brussels, Belgium.
[van Basten, J.] Canisius Wilhelmina Hosp, Nijmegen, Netherlands.
[van der Hoeven, J. J. M.] Leiden Univ, Med Ctr, Leiden, Netherlands.
[Penson, D.] VA Tennessee Valley Geriatr Res Educ, Nashville, TN USA.
[Penson, D.] Clin Ctr GRECC, Nashville, TN USA.
[Penson, D.] Vanderbilt Univ, Med Ctr, Nashville, TN 37235 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1743-7555
EI 1743-7563
J9 ASIA-PAC J CLIN ONCO
JI Asia-Pac. J. Clin. Oncol.
PD JUL
PY 2015
VL 11
SU 2
SI SI
MA 23
BP 29
EP 29
PG 1
WC Oncology
SC Oncology
GA CT4WL
UT WOS:000362808000024
ER
PT J
AU Shore, N
Smith, MR
Lipton, A
Brown, JE
Oudard, S
Carducci, M
Saad, F
Damiao, R
Zhu, L
Warner, D
Fizazi, K
AF Shore, N.
Smith, M. R.
Lipton, A.
Brown, J. E.
Oudard, S.
Carducci, M.
Saad, F.
Damiao, R.
Zhu, L.
Warner, D.
Fizazi, K.
TI BONE TURNOVER MARKER LEVELS AND OUTCOMES IN MEN WITH PROSTATE CANCER AND
BONE METASTASES TREATED WITH BONE ANTIRESORPTIVE AGENTS
SO ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article; Proceedings Paper
CT ANZUP Annual Scientific Meeting, Redefining Personalised Medicine
CY JUL 12-14, 2015
CL Sydney, AUSTRALIA
C1 [Shore, N.] Carolina Urol Res Ctr, Myrtle Beach, SC USA.
[Smith, M. R.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Lipton, A.] Penn State Univ, Milton S Hershey Med Ctr, Hersbey, PA USA.
[Brown, J. E.] Univ Sheffield, Weston Pk Hosp, Canc Res Ctr, Sheffield, S Yorkshire, England.
[Oudard, S.] Georges Pompidou Hosp, Paris, France.
[Carducci, M.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
[Saad, F.] Univ Montreal, Ctr Hosp, Montreal, PQ, Canada.
[Damiao, R.] Univ Pedro Ernesto, Rio De Janeiro, Brazil.
[Zhu, L.; Warner, D.] Amgen Inc, Thousand Oaks, CA USA.
[Fizazi, K.] Univ Paris Sud, Inst Gustave Roussy, Paris, France.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1743-7555
EI 1743-7563
J9 ASIA-PAC J CLIN ONCO
JI Asia-Pac. J. Clin. Oncol.
PD JUL
PY 2015
VL 11
SU 2
SI SI
MA 120
BP 40
EP 41
PG 2
WC Oncology
SC Oncology
GA CT4WL
UT WOS:000362808000052
ER
PT J
AU Pulliam, L
Gupta, A
AF Pulliam, Lynn
Gupta, Archana
TI Modulation of Cellular Function Through Immune-Activated Exosomes
SO DNA AND CELL BIOLOGY
LA English
DT Review
ID EXTRACELLULAR VESICLES; DENDRITIC CELLS; T-CELLS; MICROVESICLES;
MACROPHAGES; MICRORNAS; MIR-155; INDUCTION; PHENOTYPE; MIGRATION
AB Extracellular vesicles classified as exosomes, microvesicles, or apoptotic bodies based on size are shed from most cells under normal as well as pathological conditions. They are released into the surrounding milieu, including plasma, urine, saliva, and tissues. Exosomes are highly enriched in microRNAs (miRs), which function in recipient cells by regulating posttranscriptional processing of targeted genes. Interaction of a miR with its mRNA target typically results in suppression of its gene expression. Peripheral inflammatory conditions can modulate miR expression in immune cells such as circulating monocytes that can influence their migration and differentiation. Changes within monocyte-derived macrophage miR expression can influence exosome content and further affect end-organ target cells.
C1 [Pulliam, Lynn] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Lab Med, San Francisco, CA 94121 USA.
[Pulliam, Lynn] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Med, San Francisco, CA 94121 USA.
[Gupta, Archana] Syst Biosci SBI, Mountain View, CA USA.
RP Pulliam, L (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Lab Med, 4150 Clement St, San Francisco, CA 94121 USA.
EM lynn.pulliam@ucsf.edu
FU NIH [MH085538, MH096673]
FX The experiments from the authors in this article were funded by the NIH
to LP (MH085538, MH096673).
NR 40
TC 4
Z9 5
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1044-5498
EI 1557-7430
J9 DNA CELL BIOL
JI DNA Cell Biol.
PD JUL 1
PY 2015
VL 34
IS 7
BP 459
EP 463
DI 10.1089/dna.2015.2884
PG 5
WC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
GA CT0SJ
UT WOS:000362506500001
PM 25945690
ER
PT J
AU Danford, DA
Martin, AB
Danford, CJ
Kaul, S
Marshall, AM
Kutty, S
AF Danford, David A.
Martin, Ameeta B.
Danford, Christopher J.
Kaul, Sheetal
Marshall, Amanda M.
Kutty, Shelby
TI Clinical Implications of a Multivariate Stratification Model for the
Estimation of Prognosis in Ventricular Septal Defect
SO JOURNAL OF PEDIATRICS
LA English
DT Article
ID CONGENITAL HEART-DISEASE; SPONTANEOUS CLOSURE; NATURAL-HISTORY; SURGICAL
CLOSURE; SEX DIFFERENCE; PREDICTORS; MORTALITY; STENOSIS; CHILDREN;
SURVIVAL
AB Objectives To derive and validate a multivariate stratification model for prediction of survival free from intervention (SFFI) in ventricular septal defect (VSD). A secondary aim is for this model to serve as proof of concept for derivation of a more general congenital heart disease prognostic model, of which the VSD model will be the first component.
Study design For 12 years, 2334 subjects with congenital heart disease were prospectively and consecutively enrolled. Of these, 675 had VSD and form the derivation cohort. One hundred seven other subjects with VSD followed in another practice formed the validation cohort. The derivation cohort was serially stratified based on clinical and demographic features correlating with SFFI.
Results Six strata were defined, the most favorable predicting nearly 100% SFFI at 10 years, and the least favorable, a high likelihood of event within weeks. Strata with best SFFI had many subjects with nearly normal physiology, muscular VSD location, or prior intervention. In the validation cohort, the relation between predicted and actual SFFI at 6 months, 1 year, 2 years, and 5 years follow-up had areas under the receiver operating characteristic curves 0.800 or greater.
Conclusions A prediction model for SFFI in VSD has been derived and validated. It has potential for clinical application to the benefit of patients and families, medical trainees, and practicing physicians.
C1 [Danford, David A.; Kaul, Sheetal; Marshall, Amanda M.; Kutty, Shelby] Univ Nebraska Med Ctr, Coll Med, Childrens Hosp & Med Ctr, Omaha, NE 68198 USA.
[Martin, Ameeta B.] St Elizabeth Hosp, Dept Cardiol, Lincoln, NE USA.
[Danford, Christopher J.] Massachusetts Gen Hosp, Dept Internal Med, Boston, MA 02114 USA.
RP Kutty, S (reprint author), Univ Nebraska Med Ctr, 8200 Dodge St, Omaha, NE 68198 USA.
EM skutty@unmc.edu
OI KUTTY, SHELBY/0000-0001-9428-0979
NR 36
TC 1
Z9 1
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-3476
EI 1097-6833
J9 J PEDIATR-US
JI J. Pediatr.
PD JUL
PY 2015
VL 167
IS 1
BP 103
EP U468
DI 10.1016/j.jpeds.2015.04.005
PG 7
WC Pediatrics
SC Pediatrics
GA CS9ZS
UT WOS:000362453900026
PM 25935817
ER
PT J
AU Hoen, AG
Li, J
Moulton, LA
O'Toole, GA
Housman, ML
Koestler, DC
Guill, MF
Moore, JH
Hibberd, PL
Morrison, HG
Sogin, ML
Karagas, MR
Madan, JC
AF Hoen, Anne G.
Li, Jing
Moulton, Lisa A.
O'Toole, George A.
Housman, Molly L.
Koestler, Devin C.
Guill, Margaret F.
Moore, Jason H.
Hibberd, Patricia L.
Morrison, Hilary G.
Sogin, Mitchell L.
Karagas, Margaret R.
Madan, Juliette C.
TI Associations between Gut Microbial Colonization in Early Life and
Respiratory Outcomes in Cystic Fibrosis
SO JOURNAL OF PEDIATRICS
LA English
DT Article
ID PULMONARY EXACERBATIONS; OROPHARYNGEAL CULTURES; YOUNG-CHILDREN;
PSEUDOMONAS-AERUGINOSA; INTESTINAL MICROBIOTA; BACTERIAL COMMUNITIES;
INFLAMMATORY DISEASE; IMMUNE-SYSTEM; DELIVERY MODE; INFANTS
AB Objective To examine patterns of microbial colonization of the respiratory and intestinal tracts in early life in infants with cystic fibrosis (CF) and their associations with breastfeeding and clinical outcomes.
Study design A comprehensive, prospective longitudinal analysis of the upper respiratory and intestinal microbiota in a cohort of infants and young children with CF followed from birth was performed. Genus-level microbial community composition was characterized using 16S-targeted pyrosequencing, and relationships with exposures and outcomes were assessed using linear mixed-effects models, time-to-event analysis, and principal components analysis.
Results Sequencing of 120 samples from 13 subjects collected from birth to 34 months revealed relationships between breastfeeding, microbial diversity in the respiratory and intestinal tracts, and the timing of onset of respiratory complications, including exacerbations and colonization with Pseudomonas aeruginosa. Fluctuations in the abundance of specific bacterial taxa preceded clinical outcomes, including a significant decrease in bacteria of the genus Parabacteroides within the intestinal tract prior to the onset of chronic P aeruginosa colonization. Specific assemblages of bacteria in intestinal samples, but not respiratory samples, were associated with CF exacerbation in early life, indicating that the intestinal microbiome may play a role in lung health.
Conclusions Our findings relating breastfeeding to respiratory outcomes, gut diversity to prolonged periods of health, and specific bacterial communities in the gut prior to respiratory complications in CF highlight a connection between the intestinal microbiome and health and point to potential opportunities for antibiotic or probiotic interventions. Further studies in larger cohorts validating these findings are needed.
C1 [Hoen, Anne G.; Li, Jing; Moore, Jason H.] Dartmouth Coll, Geisel Sch Med Dartmouth, Inst Quantitat Biomed Sci, Computat Genet Lab, Hanover, NH 03755 USA.
[Hoen, Anne G.; Karagas, Margaret R.] Dartmouth Coll, Geisel Sch Med Dartmouth, Dept Epidemiol, Hanover, NH 03755 USA.
[Moulton, Lisa A.; Guill, Margaret F.] Dartmouth Hitchcock Med Ctr, Dept Pediat, Div Allergy & Pediat Pulmonol, Lebanon, NH 03766 USA.
[O'Toole, George A.; Housman, Molly L.] Geisel Sch Med Dartmouth, Dept Microbiol & Immunol, Hanover, NH USA.
[Koestler, Devin C.] Univ Kansas, Med Ctr, Dept Biostat, Kansas City, KS 66103 USA.
[Hibberd, Patricia L.] Massachusetts Gen Hosp, Dept Pediat, Div Global Hlth, Boston, MA 02114 USA.
[Morrison, Hilary G.; Sogin, Mitchell L.] Marine Biol Lab, Josephine Bay Paul Ctr Comparat Mol Biol & Evolut, Woods Hole, MA 02543 USA.
[Madan, Juliette C.] Dartmouth Hitchcock Med Ctr, Dept Pediat, Div Neonatol, Lebanon, NH 03766 USA.
RP Madan, JC (reprint author), Childrens Hosp Dartmouth, Dept Pediat, Div Neonatol, 1 Med Ctr Dr, Lebanon, NH 03756 USA.
EM Juliette.C.Madan@Dartmouth.Edu
OI Morrison, Hilary/0000-0003-0281-326X
FU Cystic Fibrosis Foundation; Harry Shwachman Career Development Award;
Joshua Burnett Career Development Award through the Hitchcock
Foundation; Geisel School of Medicine at Dartmouth Department of
Pediatrics; Neukom Institute; Cystic Fibrosis Foundation Research
Development Program [STAN-TO07R0]; National Institutes of Health
[K01LM011985, R01AI59694, R37AI83256-06, 4UH3DK083993, K24AT003683,
P20GM104410, P01ES022832]; Environmental Protection Agency [RD-83459901]
FX Supported by the Cystic Fibrosis Foundation and the Harry Shwachman
Career Development Award, The Joshua Burnett Career Development Award
through the Hitchcock Foundation, the Geisel School of Medicine at
Dartmouth Department of Pediatrics (to J.M.), the Neukom Institute (to
G.O. and J.M.), the Cystic Fibrosis Foundation Research Development
Program (STAN-TO07R0 [to G.O.]) the National Institutes of Health
(K01LM011985 [to A.H.], R01AI59694 [J.M.], R37AI83256-06 [G.O.],
4UH3DK083993 [M.S. and H.M.], K24AT003683 [to P.H.], P20GM104410 [to
A.H., M.K., J.M.], P01ES022832 [to M.K.]), and Environmental Protection
Agency (RD-83459901 [to M.K.]).
NR 78
TC 22
Z9 22
U1 1
U2 6
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-3476
EI 1097-6833
J9 J PEDIATR-US
JI J. Pediatr.
PD JUL
PY 2015
VL 167
IS 1
BP 138
EP U520
DI 10.1016/j.jpeds.2015.02.049
PG 13
WC Pediatrics
SC Pediatrics
GA CS9ZS
UT WOS:000362453900033
PM 25818499
ER
PT J
AU O'Donnell, K
Mansbach, JM
LoVecchio, F
Cheng, J
Piedra, PA
Clark, S
Sullivan, AF
Camargo, CA
AF O'Donnell, Katherine
Mansbach, Jonathan M.
LoVecchio, Frank
Cheng, John
Piedra, Pedro A.
Clark, Sunday
Sullivan, Ashley F.
Camargo, Carlos A., Jr.
CA Multictr Airway Res Collaboration
MARC-30 Investigator
TI Use of Cough and Cold Medications in Severe Bronchiolitis before and
after a Health Advisory Warning against Their Use
SO JOURNAL OF PEDIATRICS
LA English
DT Article
ID PROSPECTIVE MULTICENTER
AB We compared the use of cough and cold medications in 2 multicenter studies of young children hospitalized with bronchiolitis before and after the 2008 Food and Drug Administration cough and cold medications advisory. Although cough and cold medication use decreased after the advisory, nearly 20% of children age 12-23.9 months with severe bronchiolitis received cough and cold medications.
C1 [O'Donnell, Katherine; Mansbach, Jonathan M.] Harvard Univ, Sch Med, Dept Med, Div Gen Pediat,Boston Childrens Hosp, Boston, MA USA.
[LoVecchio, Frank] Maricopa Cty Gen Hosp, Dept Emergency Med, Phoenix, AZ USA.
[Cheng, John] Childrens Healthcare Atlanta Egleston, Dept Pediat Emergency Med, Atlanta, GA USA.
[Piedra, Pedro A.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.
[Piedra, Pedro A.] Baylor Coll Med, Dept Microbiol, Houston, TX 77030 USA.
[Clark, Sunday] Weill Cornell Med Coll, Dept Emergency Med, New York, NY USA.
[Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA.
RP O'Donnell, K (reprint author), Boston Childrens Hosp, Dept Med, 300 Longwood Ave, Boston, MA 02115 USA.
EM katherine.odonnell2@childrens.harvard.edu
FU Thrasher Research Fund; Merck; National Institutes of Health [U01
AI-67693, K23 AI-77801]
FX MARC-25 was supported by the Thrasher Research Fund and an unrestricted
data analysis grant from Merck. MARC-30 was supported by the National
Institutes of Health (U01 AI-67693 and K23 AI-77801). The content of
this manuscript is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institute of
Allergy and Infectious Diseases or the National Institutes of Health.
J.M. and P.P. served as consultants for Regeneron. The other authors
declare no conflicts of interest.
NR 8
TC 2
Z9 2
U1 1
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-3476
EI 1097-6833
J9 J PEDIATR-US
JI J. Pediatr.
PD JUL
PY 2015
VL 167
IS 1
BP 196
EP U296
DI 10.1016/j.jpeds.2015.03.037
PG 5
WC Pediatrics
SC Pediatrics
GA CS9ZS
UT WOS:000362453900044
PM 25888349
ER
PT J
AU Wyvekens, N
Topkar, VV
Khayter, C
Joung, JK
Tsai, SQ
AF Wyvekens, Nicolas
Topkar, Ved V.
Khayter, Cyd
Joung, J. Keith
Tsai, Shengdar Q.
TI Dimeric CRISPR RNA-Guided FokI-dCas9 Nucleases Directed by Truncated
gRNAs for Highly Specific Genome Editing
SO HUMAN GENE THERAPY
LA English
DT Article
ID CAS NUCLEASES; DNA CLEAVAGE; TARGET; ENDONUCLEASE; IDENTIFICATION;
NICKASES; CELLS
AB Monomeric clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) nucleases have been widely adopted for simple and robust targeted genome editing but also have the potential to induce high-frequency off-target mutations. In principle, two orthogonal strategies for reducing off-target cleavage, truncated guide RNAs (tru-gRNAs) and dimerization-dependent RNA-guided FokI-dCas9 nucleases (RFNs), could be combined as tru-RFNs to further improve genome editing specificity. Here we identify a robust tru-RFN architecture that shows high activity in human cancer cell lines and embryonic stem cells. Additionally, we demonstrate that tru-gRNAs reduce the undesirable mutagenic effects of monomeric FokI-dCas9. Tru-RFNs combine the advantages of two orthogonal strategies for improving the specificity of CRISPR/Cas nucleases and therefore provide a highly specific platform for performing genome editing.
C1 [Wyvekens, Nicolas; Topkar, Ved V.; Khayter, Cyd; Joung, J. Keith; Tsai, Shengdar Q.] Massachusetts Gen Hosp, Mol Pathol Unit, Charlestown, MA 02129 USA.
[Wyvekens, Nicolas; Topkar, Ved V.; Khayter, Cyd; Joung, J. Keith; Tsai, Shengdar Q.] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02129 USA.
[Wyvekens, Nicolas; Topkar, Ved V.; Khayter, Cyd; Joung, J. Keith; Tsai, Shengdar Q.] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Charlestown, MA 02129 USA.
[Joung, J. Keith; Tsai, Shengdar Q.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Tsai, SQ (reprint author), Massachusetts Gen Hosp, Mol Pathol Unit, 149,13th St,6th Floor, Charlestown, MA 02129 USA.
EM jjoung@mgh.harvard.edu; stsai4@mgh.harvard.edu
FU National Institutes of Health (NIH) [DP1 GM105378]; NIH [P50 HG005550,
R01 AR063070, F32 GM105189]; Jim and Ann Orr Massachusetts General
Hospital Research Scholar Award
FX This work was funded by a National Institutes of Health (NIH) Director's
Pioneer Award (DP1 GM105378), NIH P50 HG005550, NIH R01 AR063070, and
the Jim and Ann Orr Massachusetts General Hospital Research Scholar
Award. S.Q.T. was supported by NIH F32 GM105189.
NR 26
TC 32
Z9 36
U1 4
U2 29
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043-0342
EI 1557-7422
J9 HUM GENE THER
JI Hum. Gene Ther.
PD JUL 1
PY 2015
VL 26
IS 7
BP 425
EP 431
DI 10.1089/hum.2015.084
PG 7
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
Experimental Medicine
GA CS4YT
UT WOS:000362083000005
PM 26068112
ER
PT J
AU Holden, TR
Smith, MA
Bartels, CM
Campbell, TC
Yu, MG
Kind, AJH
AF Holden, Timothy R.
Smith, Maureen A.
Bartels, Christie M.
Campbell, Toby C.
Yu, Menggang
Kind, Amy J. H.
TI Hospice Enrollment, Local Hospice Utilization Patterns, and
Rehospitalization in Medicare Patients
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Article
ID OF-LIFE CARE; HEALTH-CARE; PATIENTS PREFERENCES; REGIONAL-VARIATIONS;
MENTAL-HEALTH; LAST YEAR; END; CANCER; DEATH; QUALITY
AB Background: Rehospitalizations are prevalent and associated with decreased quality of life. Although hospice has been advocated to reduce rehospitalizations, it is not known how area-level hospice utilization patterns affect rehospitalization risk. Objectives: The study objective was to examine the association between hospice enrollment, local hospice utilization patterns, and 30-day rehospitalization in Medicare patients. Methods: With a retrospective cohort design, 1,997,506 hospitalizations were assessed between 2005 and 2009 from a 5% national sample of Medicare beneficiaries. Local hospice utilization was defined using tertiles representing the percentage of all deaths occurring in hospice within each Hospital Service Area (HSA). Cox proportional hazard models were used to assess the relationship between 30-day rehospitalization, hospice enrollment, and local hospice utilization, adjusting for patient sociodemographics, medical history, and hospital characteristics. Results: Rates of patients dying in hospice were 27% in the lowest hospice utilization tertile, 41% in the middle tertile, and 53% in the highest tertile. Patients enrolled in hospice had lower rates of 30-day rehospitalization than those not enrolled (2.2% versus 18.8%; adjusted hazard ratio [HR], 0.12; 95% confidence interval [CI], 0.118-0.131). Patients residing in areas of low hospice utilization were at greater rehospitalization risk than those residing in areas of high utilization (19.1% versus 17.5%; HR, 1.05; 95% CI, 1.04-1.06), which persisted beyond that accounted for by individual hospice enrollment. Conclusions: Area-level hospice utilization is inversely proportional to rehospitalization rates. This relationship is not fully explained by direct hospice enrollment, and may reflect a spillover effect of the benefits of hospice extending to nonenrollees.
C1 [Holden, Timothy R.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53705 USA.
[Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53705 USA.
[Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Family Med, Madison, WI 53705 USA.
[Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI 53705 USA.
[Bartels, Christie M.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Rheumatol, Madison, WI 53705 USA.
[Campbell, Toby C.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Hematol Oncol & Palliat Care Med Div, Madison, WI 53705 USA.
[Yu, Menggang] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53705 USA.
[Kind, Amy J. H.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Geriatr, Madison, WI 53705 USA.
[Kind, Amy J. H.] US Dept Vet Affairs, William S Middleton Hosp, Geriatr Res Educ & Clin Ctr, Madison, WI USA.
RP Kind, AJH (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Geriatr, 2500 Overlook Terrace, Madison, WI 53705 USA.
EM ajk@medicine.wisc.edu
FU National Institutes of Health (NIH) T32 Training Grant
[5T32HS000083-15]; University of Wisconsin (UW) Health Innovation
Program; National Institute on Aging Beeson Career Development Award -
National Institute on Aging [K23AG034551]; American Federation for Aging
Research; John A. Hartford Foundation; Atlantic Philanthropies; Starr
Foundation; National Institute of Arthritis and Musculoskeletal and Skin
Diseases Mentored Patient-Oriented Research Career Development Award
[K23 AR062381]; UW Health Innovation Program; Clinical and Translational
Science Award (CTSA) program through National Center for Advancing
Translational Sciences (NCATS) [1UL1RR025011]; UW School of Medicine and
Public Health from The Wisconsin Partnership Program; National Center
for Advancing Translational Sciences (NCATS) [9U54TR000021]
FX Thank you to Katie Ronk for data management and variable creation,
Jacquelyn Mirr for manuscript preparation, and to Bill Buckingham for
map creation. Funding for this project was provided by National
Institutes of Health (NIH) T32 Training Grant 5T32HS000083-15 and the
University of Wisconsin (UW) Health Innovation Program. Dr. Kind is
supported by a National Institute on Aging Beeson Career Development
Award (K23AG034551, PI Kind), funded by National Institute on Aging, The
American Federation for Aging Research, The John A. Hartford Foundation,
The Atlantic Philanthropies, and The Starr Foundation. Dr. Christie
Bartels is supported by National Institute of Arthritis and
Musculoskeletal and Skin Diseases Mentored Patient-Oriented Research
Career Development Award K23 AR062381. Further support was provided by
the UW Health Innovation Program and the Clinical and Translational
Science Award (CTSA) program, previously through the National Center for
Research Resources (NCRR) grant 1UL1RR025011, and now by the National
Center for Advancing Translational Sciences (NCATS), grant 9U54TR000021.
Additional funding for this project was provided by the UW School of
Medicine and Public Health from The Wisconsin Partnership Program.
NR 47
TC 1
Z9 1
U1 2
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
EI 1557-7740
J9 J PALLIAT MED
JI J. Palliat. Med.
PD JUL 1
PY 2015
VL 18
IS 7
BP 601
EP 612
DI 10.1089/jpm.2014.0395
PG 12
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA CS2EM
UT WOS:000361880600007
PM 25879990
ER
PT J
AU Vargas, M
Servillo, G
Pelosi, P
Kacmarek, RM
AF Vargas, Maria
Servillo, Giuseppe
Pelosi, Paolo
Kacmarek, Robert M.
TI Are New Devices for Percutaneous Dilatational Tracheostomy Really
Needed? Yes
SO RESPIRATORY CARE
LA English
DT Letter
ID LUMEN ENDOTRACHEAL-TUBE; ULTRASOUND; TIME
C1 [Vargas, Maria; Servillo, Giuseppe] Univ Naples Federico II, Dept Neurosci & Reprod & Odontostomatol Sci, Naples, Italy.
[Pelosi, Paolo] Univ Genoa, Dept Surg Sci & Integrated Diagnost, Ist Ricovero & Cura Carattere Sci, Azienda Osped,Univ San Martino IST, Genoa, Italy.
[Kacmarek, Robert M.] Massachusetts Gen Hosp, Dept Anesthesiol & Crit Care, Dept Resp Care, Boston, MA 02114 USA.
RP Vargas, M (reprint author), Univ Naples Federico II, Dept Neurosci & Reprod & Odontostomatol Sci, Naples, Italy.
RI Vargas, Maria/H-6876-2014; Servillo, Giuseppe/M-9132-2016
OI Vargas, Maria/0000-0001-7652-970X; Servillo,
Giuseppe/0000-0002-4618-3434
NR 9
TC 0
Z9 0
U1 0
U2 0
PU DAEDALUS ENTERPRISES INC
PI IRVING
PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA
SN 0020-1324
EI 1943-3654
J9 RESP CARE
JI Respir. Care
PD JUL
PY 2015
VL 60
IS 7
BP E133
EP E133
DI 10.4187/respcare.04232
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA CS7MC
UT WOS:000362266700008
PM 26113571
ER
PT J
AU Friedlander, AH
El Saden, SM
Hazboun, RC
Chang, TI
Wong, WK
Garrett, NR
AF Friedlander, A. H.
El Saden, S. M.
Hazboun, R. C.
Chang, T. I.
Wong, W. K.
Garrett, N. R.
TI Detection of carotid artery calcification on the panoramic images of
post-menopausal females is significantly associated with severe
abdominal aortic calcification: a risk indicator of future adverse
vascular events
SO DENTOMAXILLOFACIAL RADIOLOGY
LA English
DT Article
DE atherosclerosis; panoramic radiography; carotid arteries; abdominal
aorta; abdominal radiography
ID ATHEROSCLEROSIS; STROKE; RADIOGRAPHS; PROGRESSION; FRAMINGHAM;
ROTTERDAM; ATHEROMA; DEPOSITS; DISEASE
AB Objectives: Outcome studies among post-menopausal females with calcified carotid artery plaque (CCAP) on their panoramic images have not been previously undertaken. We sought to compare the extent of abdominal aortic calcification (AAC) on lateral lumbar spine radiographs (LLSRs), among groups of females with (CCAP+) and without (CCAP) carotid lesions on their panoramic images. "Severe" levels of AAC have previously been validated as a risk indicator of future adverse cardiovascular events.
Methods: This cross-sectional case control study included a "CCAP+ group" consisting of females more than 50 years of age having the carotid lesion diagnosed by their dentists and an atherogenic risk factor (age, body mass index, hypertension, diabetes and dyslipidaemia)matched "CCAP- group". A physician radiologist, using the Framingham index, evaluated the LLSRs for the magnitude of AAC. Summary statistics for key variables were computed and conditional logistic regression techniques were considered.
Results: Members of the CCAP+ group were significantly (p = 0.038) more likely to demonstrate "severe" levels of AAC on their LLSRs than members of the CCAP group.
Conclusions: This is the first published study demonstrating that CCAP on panoramic images of post-menopausal females is significantly associated with "severe" levels of AACs on LLSRs independent of traditional risk factors. Given that these levels of AAC are a validated risk indicator of future myocardial infarction and stroke, dentists must evaluate the panoramic images of post-menopausal females for the presence of CCAP. Patients with carotid atheromas should be referred to their physicians for further evaluation given the systemic implications.
C1 [Friedlander, A. H.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Grad Med Educ, Los Angeles, CA 90095 USA.
[Friedlander, A. H.; Chang, T. I.] Univ Calif Los Angeles, Sch Dent, Dept Oral & Maxillofacial Surg, Los Angeles, CA 90024 USA.
[El Saden, S. M.] Vet Affairs Greater Los Angeles Healthcare Syst, Imaging Serv, Los Angeles, CA USA.
[El Saden, S. M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol, Los Angeles, CA 90095 USA.
[Hazboun, R. C.; Chang, T. I.] Vet Affairs Greater Los Angeles Healthcare Syst, Oral & Maxillofacial Surg Div, Dent Serv, Los Angeles, CA USA.
[Wong, W. K.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA.
[Garrett, N. R.] Univ Calif Los Angeles, Sch Dent, Deans Off, Los Angeles, CA 90024 USA.
RP Friedlander, AH (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Dept Grad Med Educ, Los Angeles, CA 90095 USA.
EM arthur.friedlander@va.gov
FU National Center for Research Resources, National Institutes of Health
[CO6 RR-14529-01]
FX Elements of this investigation were conducted in a facility constructed
with support from Research Facilities Improvement Program grant number
CO6 RR-14529-01 from the National Center for Research Resources,
National Institutes of Health.
NR 27
TC 1
Z9 2
U1 0
U2 0
PU BRITISH INST RADIOLOGY
PI LONDON
PA 36 PORTLAND PLACE, LONDON W1N 4AT, ENGLAND
SN 0250-832X
EI 1476-542X
J9 DENTOMAXILLOFAC RAD
JI Dentomaxillofac. Radiol.
PD JUL
PY 2015
VL 44
IS 7
AR 20150094
DI 10.1259/dmfr.20150094
PG 7
WC Dentistry, Oral Surgery & Medicine; Radiology, Nuclear Medicine &
Medical Imaging
SC Dentistry, Oral Surgery & Medicine; Radiology, Nuclear Medicine &
Medical Imaging
GA CR9AI
UT WOS:000361645200006
PM 25945511
ER
PT J
AU Luke, B
Stern, JE
Kotelchuck, M
Declercq, ER
Hornstein, MD
Gopal, D
Hoang, L
Diop, H
AF Luke, Barbara
Stern, Judy E.
Kotelchuck, Milton
Declercq, Eugene R.
Hornstein, Mark D.
Gopal, Daksha
Hoang, Lan
Diop, Hafsatou
TI Adverse pregnancy outcomes after in vitro fertilization: effect of
number of embryos transferred and plurality at conception
SO FERTILITY AND STERILITY
LA English
DT Article
DE Assisted reproductive technology; embryos transferred; fetal heartbeats;
birth outcomes
ID ASSISTED-REPRODUCTIVE-TECHNOLOGY; LOW-BIRTH-WEIGHT; EARLY FETAL LOSSES;
PERINATAL OUTCOMES; MASSACHUSETTS OUTCOMES; MULTIPLE BIRTHS; TWIN
PREGNANCY; DATABASE; GESTATION; SINGLETON
AB Objective: To evaluate risks for adverse pregnancy outcomes by number of embryos transferred (ET) and fetal heartbeats (FHB) in assisted reproductive technology-conceived singleton live births.
Design: Longitudinal cohort using cycles reported to the Society for Assisted Reproductive Technology Clinic Outcomes Reporting System between 2004 and 2008 among women who were treated and gave birth in Massachusetts.
Setting: Not applicable.
Patient(s): Assisted reproductive technology data on 6,073 births between 2004 and 2008 were linked to vital records and hospital data. Likelihood of ET >= vs. 1-2, FHB > 1 vs. 1, and risks of preterm birth (PTB, < 37 weeks' gestation), low birth weight (LBW, < 2,500 g), and small-for-gestational-age birth weight (SGA, < 10th percentile) with FHB > 1 were modeled with binary logistic regression using a backward-stepping algorithm, and presented as adjusted odds ratios (95% confidence intervals).
Intervention(s): None.
Main Outcome Measure(s): ET >= 3, FHB > 1, PTB, LBW, and SGA.
Result(s): Higher ET was significantly more likely with older maternal age, intracytoplasmic sperm injection, assisted hatching, cleavage-stage embryos, and thawed embryos. The likelihood of FHB > 1 with >= 3 ET vs. 1-2 ET was 2.04 (1.68-2.48). Risks of PTB and LBW with FHB > 1 were 1.63 (1.27-2.09) and 1.81 (1.36-2.39), respectively; the risk of SGA was not significant. Nulliparity was associated with higher risks of PTB (1.34 [1.12-1.59]), LBW (1.48 [1.20-1.83]), and SGA (2.17 [1.69-2.78]).
Conclusion(s): Number of embryos transferred was strongly associated with FHBs, with twice the risk of FHB > 1 with >= 3 ET vs. 1-2 ET. Increasing FHBs were associated with significantly greater risks for PTB and LBW outcomes. (C)2015 by American Society for Reproductive Medicine.
C1 [Luke, Barbara] Michigan State Univ, Dept Obstet Gynecol & Reprod Biol, E Lansing, MI 48824 USA.
[Stern, Judy E.] Geisel Sch Med Dartmouth, Dept Obstet & Gynecol, Lebanon, NH USA.
[Kotelchuck, Milton] Harvard Univ, Sch Med, MassGen Hosp Children, Boston, MA USA.
[Declercq, Eugene R.; Gopal, Daksha; Hoang, Lan] Boston Univ, Sch Publ Hlth, Dept Community Hlth Sci, Boston, MA USA.
[Hornstein, Mark D.] Brigham & Womens Hosp, Dept Obstet & Gynecol, Boston, MA 02115 USA.
[Hornstein, Mark D.] Harvard Univ, Sch Med, Boston, MA USA.
[Diop, Hafsatou] Massachusetts Dept Publ Hlth, Boston, MA USA.
RP Luke, B (reprint author), Michigan State Univ, Dept Obstet Gynecol & Reprod Biol, 965 Fee Rd,East Fee Hall,Room 628, E Lansing, MI 48824 USA.
EM lukeb@msu.edu
FU Society for Assisted Reproductive Technology; National Institutes of
Health; American Society for Reproductive Medicine; National Institutes
of Health [R01HD0672700, R01HD0645950]; Eunice Kennedy Shriver National
Institute of Child Health and Human Development [R01HD064595, R01
HD067270]
FX B.L. reports personal fees from the Society for Assisted Reproductive
Technology. J.E.S. received grants from the National Institutes of
Health and the American Society for Reproductive Medicine. M.K. received
grants from the National Institutes of Health (R01HD0672700 and
R01HD0645950). M.D.H. is on the medical advisory board of WINFertility
and receives author royalties from UpToDate. E.R.D. has nothing to
disclose. D.G. has nothing to disclose. L.H. has nothing to disclose.
H.D. has nothing to disclose.; The project described was supported by
grants R01HD064595 and R01 HD067270 from the Eunice Kennedy Shriver
National Institute of Child Health and Human Development. The content is
solely the responsibility of the authors and does not necessarily
represent the official views of the Eunice Kennedy Shriver National
Institute of Child Health and Human Development or the National
Institutes of Health.
NR 43
TC 7
Z9 7
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
EI 1556-5653
J9 FERTIL STERIL
JI Fertil. Steril.
PD JUL
PY 2015
VL 104
IS 1
BP 79
EP 86
DI 10.1016/j.fertnstert.2015.04.006
PG 8
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA CS1RF
UT WOS:000361844700017
PM 25956368
ER
PT J
AU Childress, KJ
Lawson, AK
Ghant, MS
Mendoza, G
Cardozo, ER
Confino, E
Marsh, EE
AF Childress, Krista J.
Lawson, Angela K.
Ghant, Marissa S.
Mendoza, Gricelda
Cardozo, Eden R.
Confino, Edmond
Marsh, Erica E.
TI First contact: the intersection of demographics, knowledge, and
appraisal of treatment at the initial infertility visit
SO FERTILITY AND STERILITY
LA English
DT Article
DE Anxiety; appraisal; infertility; knowledge; treatment
ID FERTILITY TREATMENT; WOMENS KNOWLEDGE; CHILDBEARING; TECHNOLOGY;
AWARENESS; DISCONTINUE; ADJUSTMENT; ATTITUDES; STUDENTS; REASONS
AB Objective: To determine the impact of the initial infertility visit on treatment-related knowledge, patient anxiety, and appraisals of treatment.
Design: Prospective survey.
Setting: Academic medical center.
Patient(s): Two hundred thirty-four English-speaking women aged 18-50 years attending their first infertility visit.
Intervention(s): Participants completed a survey assessing health literacy, knowledge, anxiety, and appraisals of the treatment process before and after their infertility visit.
Main Outcome Measure(s): Knowledge of infertility and treatment and anxiety and appraisal scores.
Result(s): Most participants were white and earned >$ 100,000/year and had at least a college education. Baseline knowledge of reproductive anatomy, assisted reproductive technology (ART), and fertility factors was modest but improved after the initial visit. Factors associated with higher knowledge included higher education and income, white or Asian ethnicity, and English as a primary language. Patient appraisals of treatment represented by the positive (Challenge) and negative (Threat and Loss) subscale scores on the Appraisal of Life Events (ALE) scale changed over time Negative appraisals of treatment and anxiety scores decreased and positive appraisals of treatment increased after the initial visit. Lower knowledge was associated with higher positive appraisal scores; lower health literacy was associated with higher anxiety and appraisal scores (positive and negative) after the visit. Black women had higher Challenge scores compared with white and Asian women. Hispanic women had higher anxiety scores than non-Hispanic women.
Conclusion(s): Infertility patients have modest baseline knowledge of fertility and infertility treatment. The initial infertility visit can improve this knowledge and decrease both negative appraisals of treatment and anxiety levels. Differences in knowledge and appraisal were seen across ethnic groups and other demographic variables. Physicians should individualize patient counseling to improve patients' knowledge and provide realistic treatment expectations while also reducing patient anxiety. (C) 2015 by American Society for Reproductive Medicine.
C1 [Childress, Krista J.; Lawson, Angela K.; Ghant, Marissa S.; Mendoza, Gricelda; Confino, Edmond; Marsh, Erica E.] Northwestern Univ, Feinberg Sch Med, Div Reprod Endocrinol & Infertil, Dept Obstet & Gynecol, Chicago, IL 60611 USA.
[Cardozo, Eden R.] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, Boston, MA 02114 USA.
RP Marsh, EE (reprint author), Northwestern Univ, Feinberg Sch Med, 676 N St Clair,Suite 1845, Chicago, IL 60611 USA.
EM erica-marsh@northwestern.edu
FU National Institutes of Health [P01HD57877]; Feinberg School of Medicine,
Northwestern University; Northwestern Memorial Hospital; Robert Wood
Johnson Foundation; NIH Women's Reproductive Health Research Scholar
Program at Northwestern [K12HD050121]
FX Supported by the National Institutes of Health (grant P01HD57877) (to
E.E.M.), the Feinberg School of Medicine, Northwestern University,
Northwestern Memorial Hospital, Robert Wood Johnson Foundation, grant
(to E.E.M.), and NIH K12HD050121 Women's Reproductive Health Research
Scholar Program at Northwestern (to E.E.M.).
NR 37
TC 0
Z9 0
U1 2
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
EI 1556-5653
J9 FERTIL STERIL
JI Fertil. Steril.
PD JUL
PY 2015
VL 104
IS 1
BP 180
EP 187
DI 10.1016/j.fertnstert.2015.04.002
PG 8
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA CS1RF
UT WOS:000361844700031
PM 26003271
ER
PT J
AU Cole, PD
Finkelstein, Y
Stevenson, KE
Blonquist, TM
Vijayanathan, V
Silverman, LB
Neuberg, DS
Sallan, SE
Robaey, P
Waber, DP
AF Cole, Peter D.
Finkelstein, Yaron
Stevenson, Kristen E.
Blonquist, Traci M.
Vijayanathan, Veena
Silverman, Lewis B.
Neuberg, Donna S.
Sallan, Stephen E.
Robaey, Philippe
Waber, Deborah P.
TI Polymorphisms in Genes Related to Oxidative Stress Are Associated With
Inferior Cognitive Function After Therapy for Childhood Acute
Lymphoblastic Leukemia
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID CONSORTIUM PROTOCOL 00-01; FARBER CANCER INSTITUTE; DANA-FARBER;
NEUROPSYCHOLOGICAL OUTCOMES; METHOTREXATE NEUROTOXICITY; INTRATHECAL
METHOTREXATE; NEUROCOGNITIVE OUTCOMES; CEREBROSPINAL-FLUID; STANDARD
RISK; CHILDREN
AB Purpose Survivors of childhood acute lymphoblastic leukemia (ALL) exhibit increased rates of neurocognitive deficits. This study was conducted to test whether interpatient variability in neurocognitive outcomes can be explained by polymorphisms in candidate genes conferring susceptibility to neurocognitive decline.
Methods Neurocognitive testing was conducted in 350 pediatric leukemia survivors, treated on Dana-Farber Cancer Institute ALL Consortium Protocols 95-01 or 00-01. Genomic DNA was isolated from bone marrow collected at remission. Candidate polymorphisms were selected on the basis of prior literature, targeting genes related to drug metabolism, oxidative damage, altered neurotransmission, neuroinflammation, and folate physiology. Single nucleotide polymorphisms were detected using either a customized multiplexed Sequenom MassARRAY assay or polymerase chain reaction-based allelic discrimination assays. Multivariable logistic regression models were used to estimate the effects of genotype on neurocognitive outcomes, adjusted for the effects of demographic and treatment variables. False-discovery rate correction was made for multiple hypothesis testing, indicated as a Q value.
Results Inferior cognitive or behavioral outcomes were associated with polymorphisms in three genes related to oxidative stress and/or neuroinflammation: NOS3 (IQ, Q = 0.008; Vocabulary Q = 0.011; Matrix Reasoning Q = 0.008), SLCO2A1 (IQ Q = 0.043; Digit Span Q = 0.006; Block Design Q = 0.076), and COMT (Behavioral Assessment System for Children-2 Attention Q = 0.080; and Hyperactivity Q = 0.084). Survivors homozygous for NOS3 894T, with at least one SLCO2A1 variant G allele or with at least one GSTP1 variant allele, had lower mean estimated IQ scores than those without these genotypes.
Conclusion These data are consistent with the hypothesis that oxidative damage contributes to chemotherapy-associated neurocognitive decline among children with leukemia.
C1 [Cole, Peter D.; Vijayanathan, Veena] Albert Einstein Coll Med, Bronx, NY 10461 USA.
[Finkelstein, Yaron] Univ Toronto, Hosp Sick Children, Toronto, ON M5G 1X8, Canada.
[Robaey, Philippe] Childrens Hosp Eastern Ontario, Ottawa, ON K1H 8L1, Canada.
[Stevenson, Kristen E.; Blonquist, Traci M.; Neuberg, Donna S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Silverman, Lewis B.; Sallan, Stephen E.] Harvard Univ, DFCI, Boston Childrens Hosp, Sch Med, Boston, MA 02115 USA.
[Waber, Deborah P.] Harvard Univ, DFCI, Sch Med, Boston, MA 02115 USA.
RP Cole, PD (reprint author), Albert Einstein Coll Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.
EM Peter.Cole@Einstein.YU.edu
FU NCI NIH HHS [P30 CA013330, P01 CA068484]; NICHD NIH HHS [IH P30 HD18655,
P30 HD018655]
NR 49
TC 8
Z9 8
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD JUL 1
PY 2015
VL 33
IS 19
BP 2205
EP U117
DI 10.1200/JCO.2014.59.0273
PG 9
WC Oncology
SC Oncology
GA CR8UV
UT WOS:000361630500013
PM 25987702
ER
PT J
AU Cohen, LS
Viguera, AC
McInerney, KA
Kwiatkowski, MA
Murphy, SK
Lemon, EL
Hernandez-Diaz, S
AF Cohen, Lee S.
Viguera, Adele C.
McInerney, Kathryn A.
Kwiatkowski, Molly A.
Murphy, Shannon K.
Lemon, Elizabeth L.
Hernandez-Diaz, Sonia
TI Establishment of the National Pregnancy Registry for Atypical
Antipsychotics
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID EXPOSED PREGNANCIES; DRUGS; PREVALENCE; EXPERIENCE; LACTATION; INFANTS;
SAFETY
AB Objective: Atypical antipsychotics are widely used by reproductive-age women to treat a spectrum of psychiatric illnesses. Despite widespread use of this class of agents in women of childbearing potential, reproductive safety data across these medicines remain limited. The National Pregnancy Registry for Atypical Antipsychotics (NPRAA) at Massachusetts General Hospital was established in 2008 to address this knowledge gap.
Method: Data are prospectively collected from pregnant women, ages 18-45 years, using 3 phone interviews conducted at the following times: (1) proximate to the time of enrollment, (2) 7 months' gestation, and (3) 2-3 months postpartum. Subjects include pregnant women with histories of fetal exposure to second-generation antipsychotics and a comparison group of nonexposed pregnant women. Medical record release authorization is obtained for obstetric, labor and delivery, and newborn pediatric (up to 6 months of age) records. Information regarding the presence of major malformations is abstracted from the medical records along with other data regarding neonatal and maternal health outcomes. Identified cases of congenital malformations are sent to a dysmorphologist blinded to drug exposure for final adjudication.
Results: As of May 2014, 428 subjects have enrolled in the NPRAA. Efforts continue to increase enrollment for the purpose of enhancing the capacity to define risk estimates of in utero exposure to atypical antipsychotics.
Conclusions: The NPRAA gathers prospective data regarding risk for critical outcomes following use of atypical antipsychotics during pregnancy. The NPRAA offers a systematic way to collect reproductive safety information that informs the care of women who use these agents to sustain psychiatric well-being.
C1 [Cohen, Lee S.; Viguera, Adele C.; McInerney, Kathryn A.; Kwiatkowski, Molly A.; Murphy, Shannon K.; Lemon, Elizabeth L.] Massachusetts Gen Hosp, Ctr Womens Mental Hlth, Boston, MA 02114 USA.
[Viguera, Adele C.] Cleveland Clin, Neurol Inst, Cleveland, OH 44106 USA.
[McInerney, Kathryn A.; Hernandez-Diaz, Sonia] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
RP Cohen, LS (reprint author), 185 Cambridge St,Ste 2000, Boston, MA 02114 USA.
EM lcohen2@mgh.harvard.edu
FU AstraZeneca (Wilmington, Delaware); Bristol-Myers Squibb/Otsuka
(Hopewell, New Jersey); Ortho-McNeil-Janssen Pharmaceuticals, Inc
(Raritan, New Jersey); Pfizer, Inc (New York, NY); Sunovion
Pharmaceuticals, Inc (Fort Lee, New Jersey)
FX The National Pregnancy Registry for Atypical Antipsychotics has received
funding from AstraZeneca (Wilmington, Delaware; 2009-2014);
Bristol-Myers Squibb/Otsuka (Hopewell, New Jersey; 2008-present);
Ortho-McNeil-Janssen Pharmaceuticals, Inc (Raritan, New Jersey;
2009-2014); Pfizer, Inc (New York, NY; 2009-2011); and Sunovion
Pharmaceuticals, Inc (Fort Lee, New Jersey; 2011-present).
NR 28
TC 6
Z9 6
U1 1
U2 1
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
EI 1555-2101
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD JUL
PY 2015
VL 76
IS 7
BP 986
EP 989
DI 10.4088/JCP.14br09418
PG 4
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA CR7MU
UT WOS:000361535200030
PM 25939066
ER
PT J
AU Biederman, J
AF Biederman, Joseph
TI Further Evidence for Robust Familiality of Pediatric Bipolar I Disorder:
Results From a Very Large Controlled Family Study of Pediatric Bipolar I
Disorder and a Meta-Analysis
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Letter
C1 Massachusetts Gen Hosp, Clin & Res Program Pediat Psychopharmacol & Adult, Boston, MA 02114 USA.
RP Biederman, J (reprint author), Massachusetts Gen Hosp, Clin & Res Program Pediat Psychopharmacol & Adult, Boston, MA 02114 USA.
EM jbiederman@partners.org
NR 1
TC 0
Z9 0
U1 0
U2 0
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
EI 1555-2101
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD JUL
PY 2015
VL 76
IS 7
BP E891
EP E892
DI 10.4088/JCP.14lcx09028
PG 2
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA CR7MU
UT WOS:000361535200009
PM 26231018
ER
PT J
AU Hamner, MB
AF Hamner, Mark B.
TI Smoking Cessation in Homeless Veterans
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Editorial Material
ID TOBACCO; SMOKERS
C1 Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA.
RP Hamner, MB (reprint author), Ralph H Johnson VA Med Ctr, 109 Bee St, Charleston, SC 29401 USA.
EM mark.hamner@va.gov
NR 8
TC 0
Z9 0
U1 1
U2 1
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
EI 1555-2101
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD JUL
PY 2015
VL 76
IS 7
BP E911
EP E912
DI 10.4088/JCP.14com09726
PG 2
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA CR7MU
UT WOS:000361535200019
PM 26231027
ER
PT J
AU Purohit, MP
Zafonte, RD
Sherman, LM
Davis, RB
Giwerc, MY
Shenton, ME
Yeh, GY
AF Purohit, Maulik P.
Zafonte, Ross D.
Sherman, Laura M.
Davis, Roger B.
Giwerc, Michelle Y.
Shenton, Martha E.
Yeh, Gloria Y.
TI Neuropsychiatric Symptoms and Expenditure on Complementary and
Alternative Medicine
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID COMMON NEUROLOGICAL CONDITIONS; MIND-BODY THERAPIES; STRESS REDUCTION;
DEPRESSION; TRIAL; ADULTS; MEDITATION; MIGRAINE; ANXIETY; PAIN
AB Objective: Neuropsychiatric symptoms affect 37% of US adults. These symptoms are often refractory to standard therapies, and patients may consequently opt for complementary and alternative medicine therapies (CAM). We sought to determine the demand for CAM by those with neuropsychiatric symptoms compared to those without neuropsychiatric symptoms as measured by out-of-pocket expenditure.
Method: We compared CAM expenditure between US adults with and without neuropsychiatric symptoms (n = 23,393) using the 2007 National Health Interview Survey. Symptoms included depression, anxiety, insomnia, attention deficits, headaches, excessive sleepiness, and memory loss. CAM was defined per guidelines from the National Institutes of Health as mind-body therapies, biological therapies, manipulation therapies, or alternative medical systems. Expenditure on CAM by those without neuropsychiatric symptoms was compared to those with neuropsychiatric symptoms.
Results: Of the adults surveyed, 37% had >= 1 neuropsychiatric symptom and spent $14.8 billion out-of-pocket on CAM. Those with >= 1 neuropsychiatric symptom were more likely than those without neuropsychiatric symptoms to spend on CAM (27.4% vs 20.3%, P < .001). Likelihood to spend on CAM increased with number of symptoms (27.2% with >= 3 symptoms, P < .001). After adjustment was made for confounders using logistic regression, those with >= 1 neuropsychiatric symptom remained more likely to spend on CAM (odds ratio [OR] = 1.34; 95% CI, 1.22-1.48), and the likelihood increased to 1.55 (95% CI, 1.34-1.79) for >= 3 symptoms. Anxiety (OR = 1.40 [95% CI, 1.22-1.60]) and excessive sleepiness (OR = 1.36 [95% CI, 1.21-1.54]) were the most closely associated with CAM expenditure.
Conclusions: Those with >= 1 neuropsychiatric symptom had disproportionately higher demand for CAM than those without symptoms. Research regarding safety, efficacy, and cost-effectiveness of CAM is limited; therefore, future research should evaluate these issues given the tremendous demand for these treatments. (C) Copyright 2015 Physicians Postgraduate Press, Inc.
C1 [Purohit, Maulik P.; Zafonte, Ross D.; Sherman, Laura M.] Harvard Univ, Sch Med, Spaulding Rehabil Hosp Network, Boston, MA USA.
[Purohit, Maulik P.; Zafonte, Ross D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Purohit, Maulik P.; Davis, Roger B.; Yeh, Gloria Y.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Purohit, Maulik P.; Zafonte, Ross D.; Giwerc, Michelle Y.; Shenton, Martha E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Purohit, Maulik P.] Ft Belvoir Community Hosp, Intrepid Spirit One, Natl Intrepid Ctr Excellence NICoE, Ft Belvoir, VA USA.
[Purohit, Maulik P.] Def Vet Brain Injury Ctr, Ft Belvoir, VA USA.
RP Purohit, MP (reprint author), Spaulding Rehabil Hosp Network, 300 First Ave, Charlestown, MA 02129 USA.
EM maulik.p.purohit.civ@mail.mil
FU institutional National Research Service award from the National Center
for Complementary and Alternative Medicine (NCCAM) at the National
Institutes of Health (NIH) [T32AT000051]; Investigator Award
[5R24HD065688-02]; National Institute of Disability and Research;
Department of Defense; Mid-Career investigator award [K24AT000589];
Harvard Catalyst (NIH) [UL1 RR 025758]
FX Dr Purohit was supported by an institutional National Research Service
award #T32AT000051 from the National Center for Complementary and
Alternative Medicine (NCCAM) at the National Institutes of Health (NIH).
Dr Zafonte was supported by an Investigator Award 5R24HD065688-02, the
National Institute of Disability and Research, and the Department of
Defense. Dr Davis was supported by a Mid-Career investigator award
K24AT000589 and by Harvard Catalyst (NIH award #UL1 RR 025758)
NR 33
TC 2
Z9 2
U1 1
U2 4
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
EI 1555-2101
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD JUL
PY 2015
VL 76
IS 7
BP E870
EP E876
DI 10.4088/JCP.13m08682
PG 7
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA CR7MU
UT WOS:000361535200005
PM 26231014
ER
PT J
AU Herr, DJ
Aune, SE
Menick, DR
AF Herr, Daniel J.
Aune, Sverre E.
Menick, Donald R.
TI Induction and Assessment of Ischemia-reperfusion Injury in
Langendorff-perfused Rat Hearts
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Medicine; Issue 101; Ischemia reperfusion; isolated heart; cardiac
preconditioning; infarct staining; histone deacetylase; cardiac function
ID INHIBITION; PROTECTION; MYOCARDIUM; MECHANISM; STRESS
AB The biochemical events surrounding ischemia reperfusion injury in the acute setting are of great importance to furthering novel treatment options for myocardial infarction and cardiac complications of thoracic surgery. The ability of certain drugs to precondition the myocardium against ischemia reperfusion injury has led to multiple clinical trials, with little success. The isolated heart model allows acute observation of the functional effects of ischemia reperfusion injury in real time, including the effects of various pharmacological interventions administered at any time-point before or within the ischemia-reperfusion injury window. Since brief periods of ischemia can precondition the heart against ischemic injury, in situ aortic cannulation is performed to allow for functional assessment of non-preconditioned myocardium. A saline filled balloon is placed into the left ventricle to allow for real-time measurement of pressure generation. Ischemic injury is simulated by the cessation of perfusion buffer flow, followed by reperfusion. The duration of both ischemia and reperfusion can be modulated to examine biochemical events at any given time-point. Although the Langendorff isolated heart model does not allow for the consideration of systemic events affecting ischemia and reperfusion, it is an excellent model for the examination of acute functional and biochemical events within the window of ischemia reperfusion injury as well as the effect of pharmacological intervention on cardiac pre-and postconditioning. The goal of this protocol is to demonstrate how to perform in situ aortic cannulation and heart excision followed by ischemia/reperfusion injury in the Langendorff model.
C1 [Herr, Daniel J.; Aune, Sverre E.; Menick, Donald R.] Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med Cardiol, Charleston, SC 29403 USA.
[Menick, Donald R.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Menick, DR (reprint author), Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med Cardiol, Charleston, SC 29403 USA.
EM menickd@musc.edu
OI Herr, Daniel/0000-0002-5593-4965
FU South Carolina Clinical & Translational Research (SCTR) Institute;
Medical University of South Carolina, NIH/NCATS [UL1 TR000062]; VA merit
award [BX002327-01]; NIH/NCATS [TL1 TR000061]; NIH [T32 GM008716, T32
HL07260]
FX This publication was supported by the South Carolina Clinical &
Translational Research (SCTR) Institute, with an academic home at the
Medical University of South Carolina, NIH/NCATS Grant Number UL1
TR000062. Further support was provided by VA merit award BX002327-01 to
DRM. DJH was supported by NIH/NCATS Grant Number TL1 TR000061 and by NIH
Grant Number T32 GM008716. SEA was supported by NIH Grant Number T32
HL07260.
NR 18
TC 1
Z9 1
U1 0
U2 2
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD JUL
PY 2015
IS 101
AR e52908
DI 10.3791/52908
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CR7ND
UT WOS:000361536200039
PM 26274877
ER
PT J
AU Nguyen, PL
Shin, H
Yousefi, K
Thompson, DJ
Hornberger, J
Hyatt, AS
Badani, KK
Morgan, TM
Feng, FY
AF Nguyen, Paul L.
Shin, Heesun
Yousefi, Kasra
Thompson, Darby J.
Hornberger, John
Hyatt, Andrew S.
Badani, Ketan K.
Morgan, Todd M.
Feng, Felix Y.
TI Impact of a Genomic Classifier of Metastatic Risk on Postprostatectomy
Treatment Recommendations by Radiation Oncologists and Urologists
SO UROLOGY
LA English
DT Article
ID PROSTATE-CANCER; RADICAL PROSTATECTOMY; ADJUVANT RADIOTHERAPY; PHYSICIAN
SPECIALTY; THERAPY; TRIAL
AB OBJECTIVE To evaluate how a genomic classifier (GC) that predicts the risk of metastasis after prostatectomy would impact adjuvant treatment recommendations made by radiation oncologists and urologists. The 2 specialties often disagree about postprostatectomy adjuvant treatment recommendations.
MATERIALS AND METHODS Twenty-six radiation oncologists and 20 urologists with genitourinary oncology expertise reviewed de-identified clinical results from 11 patients after radical prostatectomy and made adjuvant treatment recommendations. The same cases were later randomized and reassigned, and treatment recommendations were made using the clinical information and GC test results together.
RESULTS Using clinical information alone, observation was recommended in 42% of decisions made by urologists vs 23% by radiation oncologists (P < .0001). The GC test results altered 35% and 45% of treatment recommendations made by radiation oncologists and urologists, respectively. Multivariate analysis showed GC risk was the strongest factor influencing treatment recommendations by both specialties, with an adjusted odds ratio of 4.17 (95% confidence interval [CI], 2.26-7.70) and 6.51 (95% CI, 4.29-9.88) for radiation oncologists and urologists, respectively. GC results indicating high metastatic risk resulted in intensification of treatment, whereas low metastatic risk resulted in less aggressive recommendations. The GC results increased interdisciplinary agreement in treatment recommendations, as the odds of a recommendation for adjuvant treatment by urologists vs radiation oncologists increased from 0.27 (95% CI, 0.17-0.44) to 0.46 (95% CI, 0.29-0.75) after results of the GC test were available.
CONCLUSION The GC test significantly influenced adjuvant postprostatectomy treatment recommendations, reduced disagreement between radiation oncologists and urologists, and has the potential to enhance personalization of postprostatectomy care. (C) 2015 Elsevier Inc.
C1 Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
GenomeDx Biosci, Vancouver, BC, Canada.
EMMES Canada, Burnaby, BC, Canada.
Cedar Associates, Menlo Pk, CA USA.
Stanford Univ, Dept Med, Stanford, CA 94305 USA.
Columbia Univ, Med Ctr, Dept Urol, New York, NY USA.
Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA.
Univ Michigan, Radiat Oncol, Ann Arbor, MI 48109 USA.
RP Nguyen, PL (reprint author), Dana Farber Brigham & Womens Canc Ctr, 75 Francis St, Boston, MA 02115 USA.
EM pnguyen@LROC.harvard.edu
FU GenomeDx Biosciences; National Research Council Canada Industrial
Research Assistance Program [765817]; Prostate Cancer Foundation; Fitz's
Cancer Warriors
FX This study was supported by GenomeDx Biosciences and the National
Research Council Canada Industrial Research Assistance Program (grant
no. 765817). Partial support was also provided by the Prostate Cancer
Foundation, David and Cynthia Chapin, Fitz's Cancer Warriors, Frank and
Anne Simons, and a grant from an anonymous family foundation.
NR 17
TC 6
Z9 6
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0090-4295
EI 1527-9995
J9 UROLOGY
JI Urology
PD JUL
PY 2015
VL 86
IS 1
BP 35
EP 40
DI 10.1016/j.urology.2015.04.004
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA CS2LP
UT WOS:000361902700011
PM 26142578
ER
PT J
AU Beatty, AL
Ku, IA
Bibbins-Domingo, K
Christenson, RH
DeFilippi, CR
Ganz, P
Ix, JH
Lloyd-Jones, D
Omland, T
Sabatine, MS
Schiller, NB
Shlipak, MG
Skali, H
Takeuchi, M
Vittinghoff, E
Whooley, MA
AF Beatty, Alexis L.
Ku, Ivy A.
Bibbins-Domingo, Kirsten
Christenson, Robert H.
DeFilippi, Christopher R.
Ganz, Peter
Ix, Joachim H.
Lloyd-Jones, Donald
Omland, Torbjorn
Sabatine, Marc S.
Schiller, Nelson B.
Shlipak, Michael G.
Skali, Hicham
Takeuchi, Madoka
Vittinghoff, Eric
Whooley, Mary A.
TI Traditional Risk Factors Versus Biomarkers for Prediction of Secondary
Events in Patients With Stable Coronary Heart Disease: From the Heart
and Soul Study
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE coronary disease; epidemiology; prevention; risk prediction
ID GLOMERULAR-FILTRATION-RATE; CHRONIC KIDNEY-DISEASE; TROPONIN-T ASSAY;
ARTERY-DISEASE; CARDIOVASCULAR RISK; NATRIURETIC-PEPTIDE;
MYOCARDIAL-INFARCTION; MULTIPLE BIOMARKERS; ATRIAL-FIBRILLATION; WORKING
GROUP
AB Background-Patients with stable coronary heart disease (CHD) have widely varying prognoses and treatment options. Validated models for risk stratification of patients with CHD are needed. We sought to evaluate traditional and novel risk factors as predictors of secondary cardiovascular (CV) events, and to develop a prediction model that could be used to risk stratify patients with stable CHD.
Methods and Results-We used independent derivation (912 participants in the Heart and Soul Study) and validation (2876 participants in the PEACE trial) cohorts of patients with stable CHD to develop a risk prediction model using Cox proportional hazards models. The outcome was CV events, defined as myocardial infarction, stroke, or CV death. The annual rate of CV events was 3.4% in the derivation cohort and 2.2% in the validation cohort. With the exception of smoking, traditional risk factors (including age, sex, body mass index, hypertension, dyslipidemia, and diabetes) did not emerge as the top predictors of secondary CV events. The top 4 predictors of secondary events were the following: N-terminal pro-type brain natriuretic peptide, high-sensitivity cardiac troponin T, urinary albumin: creatinine ratio, and current smoking. The 5-year C-index for this 4-predictor model was 0.73 in the derivation cohort and 0.65 in the validation cohort. As compared with variables in the Framingham secondary events model, the Heart and Soul risk model resulted in net reclassification improvement of 0.47 (95% CI 0.25 to 0.73) in the derivation cohort and 0.18 (95% CI 0.01 to 0.40) in the validation cohort.
Conclusions-Novel risk factors are superior to traditional risk factors for predicting 5-year risk of secondary events in patients with stable CHD.
C1 [Beatty, Alexis L.; Ku, Ivy A.; Bibbins-Domingo, Kirsten; Ganz, Peter; Schiller, Nelson B.; Shlipak, Michael G.; Whooley, Mary A.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Bibbins-Domingo, Kirsten; Shlipak, Michael G.; Vittinghoff, Eric; Whooley, Mary A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Beatty, Alexis L.] VA Puget Sound Hlth Care Syst, Cardiol Sect, Seattle, WA 98108 USA.
[Beatty, Alexis L.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
[Ku, Ivy A.; Bibbins-Domingo, Kirsten; Ganz, Peter] San Francisco Gen Hosp, San Francisco, CA 94110 USA.
[Ku, Ivy A.; Takeuchi, Madoka] Kaiser Permanente Med Ctr, Dept Cardiol, San Francisco, CA USA.
[Christenson, Robert H.] Univ Maryland, Dept Pathol, Sch Med, Baltimore, MD 21201 USA.
[DeFilippi, Christopher R.] Univ Maryland, Dept Med, Sch Med, Baltimore, MD 21201 USA.
[Ix, Joachim H.] Vet Affairs San Diego Healthcare Syst, Nephrol Sect, San Diego, CA USA.
[Ix, Joachim H.] Univ Calif San Diego, Div Nephrol & Hypertens, Dept Med, San Diego, CA 92103 USA.
[Ix, Joachim H.] Univ Calif San Diego, Div Prevent Med, Dept Family & Prevent Med, San Diego, CA 92103 USA.
[Lloyd-Jones, Donald] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA.
[Lloyd-Jones, Donald] Northwestern Univ, Bluhm Cardiovasc Inst, Feinberg Sch Med, Chicago, IL 60611 USA.
[Lloyd-Jones, Donald] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA.
[Omland, Torbjorn] Akershus Univ Hosp, Div Med, Lorenskog, Norway.
[Omland, Torbjorn] Univ Oslo, Lorenskog, Norway.
[Sabatine, Marc S.] Harvard Univ, Brigham & Womens Hosp, TIMI Study Grp, Cardiovasc Div,Dept Med,Med Sch, Boston, MA 02115 USA.
[Sabatine, Marc S.; Skali, Hicham] Harvard Univ, Brigham & Womens Hosp, Div Cardiovasc, Sch Med, Boston, MA 02115 USA.
[Shlipak, Michael G.; Whooley, Mary A.] Vet Affairs Med Ctr, Gen Internal Med Sect, San Francisco, CA 94121 USA.
RP Beatty, AL (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-111, Seattle, WA 98108 USA.
EM beattya@uw.edu
FU National Heart, Lung, and Blood Institute [F32 HL110518, F32 HL097461,
R01 HL079235, N01HC65149, R01 HL094390]; National Center for Advancing
Translational Sciences of the National Institutes of Health [KL2
TR000143]; Sha Family Fellowship in Cardiovascular Research; Department
of Veterans Affairs; American Federation for Aging Research; Robert Wood
Johnson Foundation; Ischemia Research and Education Foundation; Knoll
Pharmaceuticals; Abbott Laboratories; Roche Diagnostics
FX Dr Beatty was supported by the National Heart, Lung, and Blood Institute
(F32 HL110518) and the National Center for Advancing Translational
Sciences of the National Institutes of Health (KL2 TR000143). Dr Ku was
supported by the National Heart, Lung, and Blood Institute (F32
HL097461) and the Sha Family Fellowship in Cardiovascular Research. The
Heart and Soul Study was supported by the Department of Veterans
Affairs; the National Heart, Lung, and Blood Institute (R01 HL079235);
the American Federation for Aging Research; the Robert Wood Johnson
Foundation; and the Ischemia Research and Education Foundation. The
PEACE trial was supported by a contract (N01HC65149) from the National
Heart, Lung, and Blood Institute and by Knoll Pharmaceuticals and Abbott
Laboratories. Dr Sabatine and measurement of hs-CRP in PEACE was
supported by the National Heart, Lung, and Blood Institute (R01
HL094390). Roche Diagnostics provided support for NT-proBNP and troponin
T testing in both cohorts. The funding organizations had no role in the
design and conduct of the study, in the collection, analysis, and
interpretation of the data, or in the preparation, review, or approval
of the manuscript.
NR 48
TC 4
Z9 4
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD JUL
PY 2015
VL 4
IS 7
AR e001646
DI 10.1161/JAHA.114.001646
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CR6WR
UT WOS:000361489400006
ER
PT J
AU Lin, CB
Cox, M
Olson, DM
Britz, GW
Constable, M
Fonarow, GC
Schwamm, L
Peterson, ED
Shah, BR
AF Lin, Cheryl B.
Cox, Margueritte
Olson, DaiWai M.
Britz, Gavin W.
Constable, Mark
Fonarow, Gregg C.
Schwamm, Lee
Peterson, Eric D.
Shah, Bimal R.
TI Perception Versus Actual Performance in Timely Tissue Plasminogen
Activation Administration in the Management of Acute Ischemic Stroke
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE hospital perception; quality improvement; quality of care; stroke;
thrombolytics
ID QUALITY-OF-CARE; GUIDELINES PROGRAM; ASSOCIATION; OUTCOMES; ATTACK;
IMPROVEMENT
AB Background-Timely thrombolytic therapy can improve stroke outcomes. Nevertheless, the ability of US hospitals to meet guidelines for intravenous tissue plasminogen activator (tPA) remains suboptimal. What is unclear is whether hospitals accurately perceive their rate of tPA "door-to-needle" (DTN) time within 60 minutes and how DTN rates compare across different hospitals.
Methods and Results-DTN performance was defined by the percentage of treated patients who received tPA within 60 minutes of arrival. Telephone surveys were obtained from staff at 141 Get With The Guidelines hospitals, representing top, middle, and low DTN performance. Less than one-third (29.1%) of staff accurately identified their DTN performance. Among middle- and low-performing hospitals (n=92), 56 sites (60.9%) overestimated their performance; 42% of middle performers and 85% of low performers overestimated their performance. Sites that overestimated tended to have lower annual volumes of tPA administration (median 8.4 patients [25th to 75th percentile 5.9 to 11.8] versus 10.2 patients [25th to 75th percentile 8.2 to 17.3], P=0.047), smaller percentages of eligible patients receiving tPA (84.7% versus 89.8%, P=0.008), and smaller percentages of DTN <= 60 minutes among treated patients (10.6% versus 16.6%, P=0.002).
Conclusions-Hospitals often overestimate their ability to deliver timely tPA to treated patients. Our findings indicate the need to routinely provide comparative provider performance rates as a key step to improving the quality of acute stroke care.
C1 [Lin, Cheryl B.] Floating Hosp Children, Tufts Med Ctr, Boston, MA USA.
[Cox, Margueritte] Duke Clin Res Inst, Durham, NC 27705 USA.
[Olson, DaiWai M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Britz, Gavin W.; Constable, Mark; Peterson, Eric D.; Shah, Bimal R.] Duke Univ, Med Ctr, Durham, NC USA.
[Fonarow, Gregg C.] Ronald Reagan Univ Calif Los Angeles, Med Ctr, Los Angeles, CA USA.
[Schwamm, Lee] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Shah, BR (reprint author), Duke Clin Res Inst, 2400 Pratt St, Durham, NC 27705 USA.
EM Bimal.shah@duke.edu
FU Agency for Healthcare Research and Quality [U18HS016964]
FX This project was supported by cooperative agreement number U18HS016964
from the Agency for Healthcare Research and Quality. The content is
solely the responsibility of the authors and does not necessarily
represent the official views of the Agency for Healthcare Research and
Quality.
NR 20
TC 0
Z9 0
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD JUL
PY 2015
VL 4
IS 7
AR e001298
DI 10.1161/JAHA.114.001298
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CR6WR
UT WOS:000361489400004
ER
PT J
AU Lin, XC
Zhang, X
Guo, JJ
Roberts, CK
McKenzie, S
Wu, WC
Liu, SM
Song, YQ
AF Lin, Xiaochen
Zhang, Xi
Guo, Jianjun
Roberts, Christian K.
McKenzie, Steve
Wu, Wen-Chih
Liu, Simin
Song, Yiqing
TI Effects of Exercise Training on Cardiorespiratory Fitness and Biomarkers
of Cardiometabolic Health: A Systematic Review and Meta-Analysis of
Randomized Controlled Trials
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE biomarker; cardiometabolic health; cardiovascular disease prevention;
exercise training
ID CORONARY-HEART-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; CARDIOVASCULAR
RISK-FACTORS; TYPE-2 DIABETES-MELLITUS; HIGH-INTENSITY EXERCISE;
IMPROVED INSULIN SENSITIVITY; OBESE POSTMENOPAUSAL WOMEN; MODERATE
AEROBIC EXERCISE; RESTING METABOLIC-RATE; MIDDLE-AGED ADULTS
AB Background-Guidelines recommend exercise for cardiovascular health, although evidence from trials linking exercise to cardiovascular health through intermediate biomarkers remains inconsistent. We performed a meta-analysis of randomized controlled trials to quantify the impact of exercise on cardiorespiratory fitness and a variety of conventional and novel cardiometabolic biomarkers in adults without cardiovascular disease.
Methods and Results-Two researchers selected 160 randomized controlled trials (7487 participants) based on literature searches of Medline, Embase, and Cochrane Central (January 1965 to March 2014). Data were extracted using a standardized protocol. A random-effects meta-analysis and systematic review was conducted to evaluate the effects of exercise interventions on cardiorespiratory fitness and circulating biomarkers. Exercise significantly raised absolute and relative cardiorespiratory fitness. Lipid profiles were improved in exercise groups, with lower levels of triglycerides and higher levels of high-density lipoprotein cholesterol and apolipoprotein A1. Lower levels of fasting insulin, homeostatic model assessment-insulin resistance, and glycosylated hemoglobin A1c were found in exercise groups. Compared with controls, exercise groups had higher levels of interleukin-18 and lower levels of leptin, fibrinogen, and angiotensin II. In addition, we found that the exercise effects were modified by age, sex, and health status such that people aged <50 years, men, and people with type 2 diabetes, hypertension, dyslipidemia, or metabolic syndrome appeared to benefit more.
Conclusions-This meta-analysis showed that exercise significantly improved cardiorespiratory fitness and some cardiometabolic biomarkers. The effects of exercise were modified by age, sex, and health status. Findings from this study have significant implications for future design of targeted lifestyle interventions.
C1 [Lin, Xiaochen; Wu, Wen-Chih; Liu, Simin] Brown Univ, Sch Publ Hlth, Dept Epidemiol, Providence, RI 02903 USA.
[Wu, Wen-Chih; Liu, Simin] Brown Univ, Alpert Med Sch, Dept Med, Div Cardiol, Providence, RI 02903 USA.
[Wu, Wen-Chih; Liu, Simin] Brown Univ, Alpert Med Sch, Dept Med, Vet Affairs Med Ctr, Providence, RI 02903 USA.
[Zhang, Xi; Song, Yiqing] Indiana Univ, Richard M Fairbanks Sch Publ Hlth, Dept Epidemiol, Indianapolis, IN 46204 USA.
[Guo, Jianjun] China Inst Sport Sci, Ctr Youth Sport Res & Dev, Beijing, Peoples R China.
[Roberts, Christian K.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA.
[McKenzie, Steve] Indiana Univ Purdue Univ, Dept Kinesiol, Ctr Phys Act Wellness & Prevent, Indianapolis, IN 46202 USA.
[Liu, Simin] Rhode Isl Hosp, Dept Med, Div Endocrinol, Providence, RI 02903 USA.
RP Liu, SM (reprint author), Brown Univ, Dept Epidemiol & Med, 121 South Main St, Providence, RI 02903 USA.
EM Simin_liu@brown.edu; yiqsong@iu.edu
RI Lin, Xiaochen/P-6460-2015
FU Indiana University Health-Indiana University School of Medicine
Strategic Research Initiative Grant; National Institutes of Health (NIH)
[R01DK09406, P50HL105188]; Brown University
FX The study was supported by the Indiana University Health-Indiana
University School of Medicine Strategic Research Initiative Grant (Zhang
and Song), R01DK09406 (Roberts) and P50HL105188 (Roberts) from the
National Institutes of Health (NIH), and Brown University. The NIH,
Brown University, or Indiana University had no role in the design and
conduct of the study; the collection, management, analysis, and
interpretation of the data; or the preparation, review, or approval of
the manuscript.
NR 217
TC 22
Z9 22
U1 9
U2 31
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD JUL
PY 2015
VL 4
IS 7
AR e002014
DI 10.1161/JAHA.115.002014
PG 28
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CR6WR
UT WOS:000361489400031
ER
PT J
AU Sosnovik, DE
AF Sosnovik, David E.
TI Seeing What We Build-The Need for New Imaging Techniques in Myocardial
Regeneration
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Editorial Material
ID MESENCHYMAL STEM-CELLS; IN-VIVO; INFARCTED MYOCARDIUM; THERAPY;
SURVIVAL; HEART; MODEL
C1 [Sosnovik, David E.] Harvard Univ, Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Sch Med,Dept Radiol, Boston, MA USA.
[Sosnovik, David E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr,Cardiol Div, Boston, MA USA.
RP Sosnovik, DE (reprint author), Martinos Ctr Biomed Imaging, 149 13th St, Charlestown, MA 02129 USA.
EM sosnovik@nmr.mgh.harvard.edu
NR 14
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD JUL
PY 2015
VL 4
IS 7
AR e002306
DI 10.1161/JAHA.115.002306
PG 4
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CR6WR
UT WOS:000361489400042
ER
PT J
AU Stern, TA
AF Stern, Theodore A.
TI This issue: Geriatric Psychopharmacology
SO PSYCHIATRIC ANNALS
LA English
DT Editorial Material
C1 [Stern, Theodore A.] Harvard Univ, Sch Med, Psychiat Field Psychosomat Med, Cambridge, MA 02138 USA.
[Stern, Theodore A.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Stern, Theodore A.] Avery D Weisman Psychiat Consultat Serv, New York, NY USA.
[Stern, Theodore A.] Massachusetts Gen Hosp, Off Clin Careers, Boston, MA 02114 USA.
[Stern, Theodore A.] Acad Psychosomat Med, New York, NY USA.
RP Stern, TA (reprint author), Harvard Univ, Sch Med, Psychiat Field Psychosomat Med, Cambridge, MA 02138 USA.
EM TStern@Partners.org
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0048-5713
EI 1938-2456
J9 PSYCHIAT ANN
JI Psychiatr. Ann.
PD JUL
PY 2015
VL 45
IS 7
BP 333
EP 334
DI 10.3928/00485713-20150626-03
PG 2
WC Psychiatry
SC Psychiatry
GA CR6OV
UT WOS:000361467900003
ER
PT J
AU Carlo, AD
Alpert, JE
AF Carlo, Andrew D.
Alpert, Jonathan E.
TI Geriatric Psychopharmacology: Pharmacokinetic and Pharmacodynamic
Considerations
SO PSYCHIATRIC ANNALS
LA English
DT Article
ID ADVERSE DRUG-REACTIONS; LIVER-MICROSOMES; ELDERLY-PATIENTS; AGE;
METABOLISM; RISK
AB Older adults represent the fastest growing demographic in both developing and developed countries. Understanding pharmacokinetic and pharmacodynamic principles relevant to psychopharmacology in geriatric patients is increasingly important to optimize psychiatric treatment. This review discusses the four pharmacokinetic processes (absorption, distribution, metabolism, and excretion) with regard to age-related changes. These include a generally slower rate of absorption, increases in the ratio of adipose to lean body mass and volume of distribution of medications, reductions in phase I metabolism, and decreases in renal function. In addition, this review discusses pharmacodynamic factors relevant to pharmacotherapy in older age, such as changes in receptor density and homeostatic and regulatory mechanisms. Geriatric psychopharmacology will benefit from an expanding evidence base as research on pharmacokinetics and pharmacodynamics increasingly includes older individuals.
C1 [Carlo, Andrew D.] Massachusetts Gen Hosp, Psychiat, Boston, MA 02114 USA.
[Alpert, Jonathan E.] Massachusetts Gen Hosp, Psychiat Clin Serv, Boston, MA 02114 USA.
[Alpert, Jonathan E.] Harvard Univ, Sch Med, Depress Clin & Res Program, Cambridge, MA 02138 USA.
[Alpert, Jonathan E.] Harvard Univ, Sch Med, Psychiat, Cambridge, MA 02138 USA.
[Alpert, Jonathan E.] Harvard Univ, Sch Med, Field Depress Studies, Cambridge, MA 02138 USA.
RP Carlo, AD (reprint author), Massachusetts Gen Hosp, Wang ACC 812,15 Parkman St, Boston, MA 02114 USA.
EM acarlo@partners.org
OI Alpert, Jonathan/0000-0002-4332-908X
NR 30
TC 0
Z9 0
U1 0
U2 5
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0048-5713
EI 1938-2456
J9 PSYCHIAT ANN
JI Psychiatr. Ann.
PD JUL
PY 2015
VL 45
IS 7
BP 336
EP 341
DI 10.3928/00485713-20150626-04
PG 6
WC Psychiatry
SC Psychiatry
GA CR6OV
UT WOS:000361467900004
ER
PT J
AU McCall, C
Winkelman, JW
AF McCall, Catherine
Winkelman, John W.
TI The Use of Hypnotics to Treat Sleep Problems in the Elderly
SO PSYCHIATRIC ANNALS
LA English
DT Article
ID CHRONIC PRIMARY INSOMNIA; OLDER-ADULTS; OUTPATIENT TRIAL; METAANALYSIS;
RAMELTEON; EFFICACY; SAFETY; DEPRESSION; DISORDERS; MORTALITY
AB Sleep problems are common in the elderly, with a prevalence of close to 50% in those older than age 65 years. Older adults may suffer from disturbances of sleep that are related to medical problems, to psychiatric illness, to primary sleep disorders, to use or withdrawal from drugs/medications, and/or to poor sleep habits. Loss of sleep in older adults is associated with significant morbidity, low quality of life, and mortality. When approaching the diagnosis and management of sleep disorders in elderly patients, it is important to evaluate and treat comorbid conditions. Pharmacologic treatments for sleep, although increasingly common, present significant challenges due to age-related changes in drug metabolism and clearance, side effects, and drug-drug interactions. When possible, it is preferable to manage sleep problems with nonpharmacologic approaches. This review discusses current pharmacologic and nonpharmacologic treatments for sleep problems in the elderly.
C1 [McCall, Catherine] Brigham & Womens Hosp, Harvard Longwood Psychiat Residency Training Prog, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.
[McCall, Catherine; Winkelman, John W.] Harvard Univ, Sch Med, Psychiat, Cambridge, MA 02138 USA.
[Winkelman, John W.] Massachusetts Gen Hosp, Dept Psychiat, Sleep Disorders Clin Res Program, Boston, MA 02114 USA.
RP Winkelman, JW (reprint author), Massachusetts Gen Hosp, 1 Bowdoin Sq,9th Floor, Boston, MA 02114 USA.
EM jwwinkelman@partners.org
FU UCB Pharma; Xenopart; INSYS Therapeutics; Merck Co.; Flex Pharma
FX Disclosure: John W. Winkelman has received consulting fees from UCB
Pharma, Xenopart, INSYS Therapeutics, Merck & Co., and Flex Pharma; has
performed contracted research for Purdue, Xenopart, UCB Pharma, and
Neurometrix; and has provided expert testimony for Canter Colburn. The
remaining author has no relevant financial relationships to disclose.
NR 31
TC 0
Z9 0
U1 2
U2 7
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0048-5713
EI 1938-2456
J9 PSYCHIAT ANN
JI Psychiatr. Ann.
PD JUL
PY 2015
VL 45
IS 7
BP 342
EP 347
DI 10.3928/00485713-20150626-05
PG 6
WC Psychiatry
SC Psychiatry
GA CR6OV
UT WOS:000361467900005
ER
PT J
AU Rothenberg, KG
Wiechers, IR
AF Rothenberg, Kasia Gustaw
Wiechers, Ilse R.
TI Antipsychotics for Neuropsychiatric Symptoms of Dementia-Safety and
Efficacy in the Context of Informed Consent
SO PSYCHIATRIC ANNALS
LA English
DT Article
ID SEVERE ALZHEIMERS-DISEASE; PLACEBO-CONTROLLED TRIALS; POPULATION-BASED
COHORT; ATYPICAL ANTIPSYCHOTICS; ADVERSE OUTCOMES; CATIE-AD; DRUGS;
RISK; METAANALYSIS; MEDICATIONS
AB Appropriate use of antipsychotic medications in older adults with dementia can be challenging due to several important safety concerns. This article reviews the risks and benefits of using antipsychotic medications in the treatment of patients with neuropsychiatric symptoms of dementia through the framework of an informed-consent conversation. Informed-consent discussions help provide patients, surrogate decision-makers, and caregivers with the essential data necessary to make informed treatment choices.
C1 [Rothenberg, Kasia Gustaw] Yale Univ, Sch Med, Geriatr Psychiat, New Haven, CT 06520 USA.
[Wiechers, Ilse R.] Northeast Program Evaluat Ctr, West Haven, CT USA.
[Wiechers, Ilse R.] US Dept Vet Affairs, Psychotrop Drug Safety Initiat, Off Mental Hlth Operat, Washington, DC USA.
[Wiechers, Ilse R.] Yale Univ, Sch Med, Psychiat, New Haven, CT 06520 USA.
RP Wiechers, IR (reprint author), VA Connecticut Healthcare Syst, NEPEC 182,950 Campbell Ave, West Haven, CT 06516 USA.
EM Ilse.Wiechers@va.gov
NR 33
TC 0
Z9 0
U1 1
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0048-5713
EI 1938-2456
J9 PSYCHIAT ANN
JI Psychiatr. Ann.
PD JUL
PY 2015
VL 45
IS 7
BP 348
EP 353
DI 10.3928/00485713-20150626-06
PG 6
WC Psychiatry
SC Psychiatry
GA CR6OV
UT WOS:000361467900006
ER
PT J
AU Atri, A
Stern, TA
AF Atri, Alireza
Stern, Theodore A.
TI Psychopharmacologic Agents to Enhance Cognition in Alzheimer's Disease
SO PSYCHIATRIC ANNALS
LA English
DT Article
ID PLACEBO-CONTROLLED TRIAL; PATIENTS RECEIVING DONEPEZIL;
CHOLINESTERASE-INHIBITORS; MEMANTINE TREATMENT; DOUBLE-BLIND;
OPEN-LABEL; COMBINATION THERAPY; MODERATELY-SEVERE; VITAMIN-E;
GALANTAMINE TREATMENT
AB Cognitive dysfunction in people with Alzheimer's disease (AD) significantly affects their interactions, independence, behavior, health, wellness, and quality of life; care providers also experience quality of life issues as a result. This review summarizes clinical data on agents associated with cognitive enhancement in AD, particularly the currently approved anti-AD medications including the acetyl cholinesterase inhibitors (ChEIs) (donepezil, galantamine, and rivastigmine) and the N-methyl-d-aspartate antagonist, memantine. Initiation and maintenance of stage-appropriate monotherapy or combination therapy with a ChEI and memantine provides the best pharmacologic approach to stem the expected inexorable course of cognitive decline. Discontinuation of agents that impair cognition and treatment of comorbid conditions (eg, sleep disorders, dehydration, depression, anxiety, pain, as well as metabolic, hormone, and vitamin derangements) may also improve cognition. The preponderance of evidence regarding ChEIs, memantine, and vitamin E strongly supports modest, but clinically relevant, "disease-course modifying" effects of cognitive enhancement (eg, improvement, stabilization, or shifting of the trajectory of cognitive or functional decline) in patients who receive appropriate and persistent treatment.
C1 [Atri, Alireza] Ray Dolby Brain Hlth Ctr, Res & Educ, San Francisco, CA 94114 USA.
[Atri, Alireza] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA.
[Atri, Alireza] Massachusetts Gen Hosp, Neurol, Memory Disorders Unit, Dept Neurol, Boston, MA 02114 USA.
[Atri, Alireza] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Stern, Theodore A.] Harvard Univ, Sch Med, Psychiat Field Psychosomat Med Consultat, Cambridge, MA 02138 USA.
[Stern, Theodore A.] Massachusetts Gen Hosp, Off Clin Careers, Boston, MA 02114 USA.
RP Atri, A (reprint author), Ray Dolby Brain Hlth Ctr, CPMC Davies Campus,45 Castro St,Suite 220, San Francisco, CA 94114 USA.
EM atria@cpmcri.org
FU Actavis/Forest Laboratories; Merck Co.; Lundbeck; Academy of
Psychosomatic Medicine
FX Disclosure: Alireza Atri discloses royalties received from Oxford
University Press; consulting fees received from Actavis/Forest
Laboratories, Merck & Co., and Lundbeck; and an institutional research
contract from Lundbeck. Theodore A. Stern discloses a salary received
from the Academy of Psychosomatic Medicine and royalties received from
Elsevier and Massachusetts General Hospital.
NR 103
TC 0
Z9 0
U1 1
U2 6
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0048-5713
EI 1938-2456
J9 PSYCHIAT ANN
JI Psychiatr. Ann.
PD JUL
PY 2015
VL 45
IS 7
BP 354
EP 367
DI 10.3928/00485713-20150626-07
PG 14
WC Psychiatry
SC Psychiatry
GA CR6OV
UT WOS:000361467900007
ER
PT J
AU Novak, M
Winkelman, JW
Unruh, M
AF Novak, Marta
Winkelman, John W.
Unruh, Mark
TI Restless Legs Syndrome in Patients With Chronic Kidney Disease
SO SEMINARS IN NEPHROLOGY
LA English
DT Review
DE Chronic kidney disease; dialysis; kidney transplantation; quality of
life; restless legs syndrome; sleep
ID PLACEBO-CONTROLLED TRIAL; STAGE RENAL-DISEASE; QUALITY-OF-LIFE;
AMINOMETHYL)-1-CYCLOHEXANE ACETIC-ACID; PERIODIC LIMB MOVEMENTS;
DOUBLE-BLIND; HEMODIALYSIS-PATIENTS; DIALYSIS PATIENTS; GABAPENTIN
ENACARBIL; SLEEP DISORDERS
AB Symptoms of restless legs syndrome (RLS) are common in patients with chronic kidney disease (CKD) on dialysis; symptoms of RLS are estimated to affect up to 25% of patients on dialysis when the international RLS diagnostic criteria are applied. RLS is a neurologic disorder with a circadian rhythmicity characterized by an overwhelming urge to move the legs during rest, which can be relieved temporarily by movement. RLS has been associated with an increase in sleep disturbance, higher cardiovascular morbidity, decreased quality of life, and an increased risk of death in patients with CKD. Although the exact pathophysiology of RLS is unknown, it is thought to involve an imbalance in iron metabolism and dopamine neurotransmission in the brain. The symptoms of moderate to severe RLS can be treated with several pharmacologic agents; however, data specific to patients on dialysis with RLS are lacking. The purpose of this article is to examine the relationship between, and complications of, RLS and CKD both in dialysis and nondialysis patients, and discuss the treatment options for patients on dialysis with RLS. (C) 2015 Published by Elsevier Inc.
C1 [Novak, Marta] Univ Toronto, Dept Psychiat, Univ Hlth Network, Toronto, ON, Canada.
[Novak, Marta] Semmelweis Univ, Inst Behav Sci, H-1085 Budapest, Hungary.
[Winkelman, John W.] Massachusetts Gen Hosp, Dept Psychiat, Sleep Disorders Clin Res Program, Boston, MA 02114 USA.
[Unruh, Mark] Univ New Mexico, Sch Med, Div Nephrol, Albuquerque, NM 87131 USA.
RP Novak, M (reprint author), Univ Hlth Network, Dept Psychiat, 200 Elizabeth St,EN8-212A, Toronto, ON M5G 2C4, Canada.
EM marta.novak@uhn.ca
FU UCB Pharma
FX Supported by UCB Pharma. The content of this article reflects the
opinions and clinical experience of the authors only. UCB Pharma was
offered the opportunity to comment on this article; changes resulting
from the comments were made on the basis of scientific and editorial
merit.
NR 98
TC 4
Z9 4
U1 1
U2 5
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0270-9295
EI 1558-4488
J9 SEMIN NEPHROL
JI Semin. Nephrol.
PD JUL
PY 2015
VL 35
IS 4
BP 347
EP 358
DI 10.1016/j.semnephrol.2015.06.006
PG 12
WC Urology & Nephrology
SC Urology & Nephrology
GA CR5ZA
UT WOS:000361421700006
PM 26355253
ER
PT J
AU Coulter, RWS
Kenst, KS
Bowen, DJ
Scout
AF Coulter, Robert W. S.
Kenst, Karey S.
Bowen, Deborah J.
Scout
TI CONTINUED DISPARITIES IN LESBIAN, GAY, AND BISEXUAL RESEARCH FUNDING AT
NIH RESPONSE
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Letter
C1 [Coulter, Robert W. S.] Univ Pittsburgh, Dept Behav & Community Hlth Sci, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA.
[Kenst, Karey S.] Massachusetts Gen Hosp, Dispar Solut Ctr, Mongan Inst Hlth Policy, Boston, MA 02114 USA.
[Bowen, Deborah J.] Univ Washington, Dept Bioeth & Humanities, Sch Publ Hlth, Seattle, WA USA.
[Scout] CenterLink Community LGBT Ctr, Network LGBT Hlth Equ, Ft Lauderdale, FL USA.
RP Coulter, RWS (reprint author), Univ Pittsburgh, Dept Behav & Community Hlth Sci, Grad Sch Publ Hlth, 130 DeSoto St, Pittsburgh, PA 15261 USA.
EM robert.ws.coulter@gmail.com
OI Coulter, Robert/0000-0001-8350-0075
FU NIDA NIH HHS [F31 DA037647]
NR 1
TC 0
Z9 0
U1 0
U2 0
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUL
PY 2015
VL 105
SU 3
BP E2
EP E3
DI 10.2105/AJPH.2014.302316
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CQ9LH
UT WOS:000360935700002
PM 25905847
ER
PT J
AU Bharel, M
Santiago, ER
Forgione, SN
Leon, CK
Weinreb, L
AF Bharel, Monica
Santiago, Emely R.
Forgione, Sanju Nembang
Leon, Casey K.
Weinreb, Linda
TI Eliminating Health Disparities: Innovative Methods to Improve Cervical
Cancer Screening in a Medically Underserved Population
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID HOMELESS WOMEN; LOS-ANGELES; BEHAVIORS; ADULTS; NEEDS; CARE; RISK
AB Homeless women have disproportionately lower rates of cervical cancer screening and higher rates of cervical cancer. In 2008, only 19% of the homeless women seen by Boston Health Care for the Homeless Program (BHCHP) were screened for cervical cancer. To improve screening, BHCHP implemented a 6-part intervention that incorporates point-of-care service, multidisciplinary screening, improved health maintenance forms, population management, process improvement, and increased provider and patient education. This resulted in a significant increase in cervical cancer screening, from 19% in 2008 to 50% in 2013. When compared with national and local cervical cancer screening trends, BHCHP surpassed improvement rates seen in other vulnerable populations. Simple and innovative interventions proved to be the most effective and practical methods of improving screening.
C1 [Bharel, Monica; Santiago, Emely R.; Forgione, Sanju Nembang; Leon, Casey K.] Boston Hlth Care Homeless Program, Boston, MA USA.
[Bharel, Monica] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Bharel, Monica] Boston Med Ctr, Boston, MA USA.
[Weinreb, Linda] Univ Massachusetts, Med Ctr, Dept Family Med, Boston, MA 02125 USA.
RP Leon, CK (reprint author), 780 Albany St, Boston, MA 02446 USA.
EM cleon@bhchp.org
NR 14
TC 1
Z9 1
U1 2
U2 9
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUL
PY 2015
VL 105
SU 3
BP S438
EP S442
DI 10.2105/AJPH.2014.302417
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CQ9LH
UT WOS:000360935700023
PM 25905832
ER
PT J
AU McCarthy, AM
Yang, JN
Armstrong, K
AF McCarthy, Anne Marie
Yang, Jianing
Armstrong, Katrina
TI Increasing Disparities in Breast Cancer Mortality From 1979 to 2010 for
US Black Women Aged 20 to 49 Years
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID ETHNIC-DIFFERENCES; MAMMOGRAPHY USE; YOUNG-WOMEN; SURVIVAL; POPULATION;
SUBTYPES; HEALTH; WHITE; RATES; RACE
AB Racial disparities in breast cancer mortality persist, and young Black women have higher disease incidence compared with White women. We compared trends in breast cancer mortality for young Black and White women with mortality trends for other common diseases from 1979 to 2010. In contrast to other cancers, ischemic heart disease, and stroke, the breast cancer mortality disparity has widened over the past 30 years, suggesting that unique aspects of disease biology, prevention, and treatment may explain persistent racial differences for young women.
C1 [McCarthy, Anne Marie; Armstrong, Katrina] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[McCarthy, Anne Marie; Armstrong, Katrina] Harvard Univ, Sch Med, Boston, MA USA.
[Yang, Jianing] Univ Penn, Philadelphia, PA 19104 USA.
RP McCarthy, AM (reprint author), Massachusetts Gen Hosp, 50 Staniford St,940F, Boston, MA 02114 USA.
EM amccarthy8@partners.org
FU National Institutes of Health/National Cancer Institute [1U54CA163313]
FX This work was supported by the National Institutes of Health/National
Cancer Institute (grant 1U54CA163313: Population-Based Research
Optimizing Screening Through Personalized Regimens).
NR 25
TC 7
Z9 7
U1 0
U2 6
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUL
PY 2015
VL 105
SU 3
BP S446
EP S448
DI 10.2105/AJPH.2014.302297
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CQ9LH
UT WOS:000360935700025
PM 25905842
ER
PT J
AU Gros, DF
AF Gros, Daniel F.
TI Design challenges in transdiagnostic psychotherapy research: Comparing
Transdiagnostic Behavior Therapy (TBT) to existing evidence-based
psychotherapy in veterans with affective disorders
SO CONTEMPORARY CLINICAL TRIALS
LA English
DT Article
DE Transdiagnostic; Comorbidity; RDoC; Psychotherapy; Transdiagnostic
Behavior Therapy; TBT
ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; RESEARCH
DOMAIN CRITERIA; PRIMARY-CARE; CLINICAL-TRIALS; PSYCHOMETRIC PROPERTIES;
ACTIVATION TREATMENTS; SYMPTOM OVERLAP; MOOD DISORDERS; PANIC DISORDER
AB Background: To address the limitations of disorder-specific approaches, newer transdiagnostic approaches to psychotherapy have been developed to provide a single treatment that is capable of addressing several, related disorders. However, the recruitment of multiple diagnoses presents many challenges to the traditional design of psychotherapy randomized controlled trials (RCTs).
Objective: The goal of the manuscript is to present the challenges and rationale for designing a RCT for transdiagnostic treatment to inform and aid in the development of future investigations.
Methods: A recently funded and ongoing RCT for Transdiagnostic Behavior Therapy (TBT) is used as an example to discuss the related design challenges. The TBT study involves the recruitment of 96 veteran participants with any of the following eight principal diagnoses: posttraumatic stress disorder, panic disorder, social anxiety disorder, obsessive compulsive disorder, generalized anxiety disorder, specific phobia, major depressive disorder, or persistent depressive disorder. Within the TBT study, participants will complete a semi-structured diagnostic interview and a series of transdiagnostic self-report measures to determine eligibility and assess baseline symptomatology. Qualifying participants will be randomized to TBT or control psychotherapy. Additional assessments will be completed at post-treatment and 6-month follow-up.
Conclusions: Due to the transdiagnostic nature of the sample, adjustments to the recruitment and randomization procedures, selection of measures, selection of control psychotherapy, and analysis plan were required. These adjustments have implications to future trials on transdiagnostic psychotherapy protocols as well as future research in line with the transdiagnostic focus of the National Institute of Mental Health's Research Domain Criteria (RDoC) funding strategy. Published by Elsevier Inc.
C1 [Gros, Daniel F.] Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv 116, Charleston, SC 29401 USA.
[Gros, Daniel F.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
RP Gros, DF (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA.
EM grosd@musc.edu
FU Department of Veterans Affairs Clinical Sciences Research and
Development Career Development Award [CX000845]
FX This study is supported by Department of Veterans Affairs Clinical
Sciences Research and Development Career Development Award CX000845 (PI:
Gros). The views expressed in this article are those of the authors and
do not necessarily reflect the position or policy of the Department of
Veterans Affairs or the United States government There are no conflicts
of interest to disclose.
NR 45
TC 2
Z9 2
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1551-7144
EI 1559-2030
J9 CONTEMP CLIN TRIALS
JI Contemp. Clin. Trials
PD JUL
PY 2015
VL 43
BP 114
EP 119
DI 10.1016/j.cct.2015.05.011
PG 6
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA CQ7HI
UT WOS:000360773200015
PM 26003434
ER
PT J
AU Staehr-Rye, AK
Eikermann, M
AF Staehr-Rye, Anne K.
Eikermann, Matthias
TI Eliminate postoperative respiratory complications: preoperative
screening opens the door to clinical pathways that individualise
perioperative treatment
SO EUROPEAN JOURNAL OF ANAESTHESIOLOGY
LA English
DT Editorial Material
ID NEUROMUSCULAR BLOCKING-AGENTS; NATIONWIDE INPATIENT SAMPLE; PULMONARY
COMPLICATIONS; ABDOMINAL-SURGERY; OUTCOMES; SCORE; VENTILATION;
VALIDATION; COHORT; RISK
C1 [Staehr-Rye, Anne K.; Eikermann, Matthias] Massachusetts Gen Hosp, Dept Anaesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Staehr-Rye, Anne K.] Univ Copenhagen, Herlev Hosp, Dept Anaesthesiol, DK-2730 Herlev, Denmark.
[Eikermann, Matthias] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA.
[Eikermann, Matthias] Univ Duisburg Essen, Essen, Germany.
RP Eikermann, M (reprint author), Massachusetts Gen Hosp, Dept Anaesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA.
EM meikermann@partners.org
NR 15
TC 2
Z9 2
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0265-0215
EI 1365-2346
J9 EUR J ANAESTH
JI Eur. J. Anaesth.
PD JUL
PY 2015
VL 32
IS 7
BP 455
EP 457
DI 10.1097/EJA.0000000000000210
PG 3
WC Anesthesiology
SC Anesthesiology
GA CQ8BO
UT WOS:000360831300002
PM 26389546
ER
PT J
AU Ding, SA
Simonson, DC
Wewalka, M
Halperin, F
Foster, K
Goebel-Fabbri, A
Hamdy, O
Clancy, K
Lautz, D
Vernon, A
Goldfine, AB
AF Ding, Su-Ann
Simonson, Donald C.
Wewalka, Marlene
Halperin, Florencia
Foster, Kathleen
Goebel-Fabbri, Ann
Hamdy, Osama
Clancy, Kerri
Lautz, David
Vernon, Ashley
Goldfine, Allison B.
TI Adjustable Gastric Band Surgery or Medical Management in Patients With
Type 2 Diabetes: A Randomized Clinical Trial
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID BARIATRIC SURGERY; BYPASS-SURGERY; OBESE-PATIENTS; LIFE-STYLE;
FOLLOW-UP; MELLITUS; WEIGHT; REDUCTION; MORTALITY; THERAPY
AB Context: Recommendations for surgical, compared with lifestyle and pharmacologically based, approaches for type 2 diabetes (T2D) management remain controversial.
Objective: The objective was to compare laparoscopic adjustable gastric band (LAGB) to an intensive medical diabetes and weight management (IMWM) program for T2D.
Design: This was designed as a prospective, randomized clinical trial.
Setting: The setting was two Harvard Medical School-affiliated academic institutions.
Interventions and Participants: A 12-month randomized trial comparing LAGB (n = 23) vs IMWM (n = 22) in persons aged 21-65 years with body mass index of 30-45 kg/m(2), T2D diagnosed more than 1 year earlier, and glycated hemoglobin (HbA(1c)) >= 6.5% on antihyperglycemic medication(s).
Main Outcome Measure: The proportion meeting the prespecified primary glycemic endpoint, defined as HbA(1c) < 6.5% and fasting glucose < 7.0 mmol/L at 12 months, on or off medication.
Results: After randomization, five participants did not undergo the surgical intervention. Of the 40 initiating intervention (22 males/18 females; age, 51 +/- 10 y; bodymassindex, 36.5 +/- 3.7kg/m(2); diabetes duration, 9 +/- 5 y; HbA(1c), 8.2 +/- 1.2%; 40% on insulin), the proportion meeting the primary glycemic endpoint was achieved in 33% of the LAGB patients and 23% of the IMWM patients (P = .457). HbA(1c) reduction was similar between groups at both 3 and 12 months (-1.2 +/- 0.3 vs -1.0 +/- 0.3%; P = .496). Weight loss was similar at 3 months but greater 12 months after LAGB (-13.5 +/- 1.7 vs -8.5 +/- 1.6 kg; P = .027). Systolic blood pressure reduction was greater after IMWM than LAGB, whereas changes in diastolic blood pressure, lipids, fitness, and cardiovascular risk scores were similar between groups. Patient-reported health status, assessed using the Short Form-36, Impact of Weight on Quality of Life, and Problem Areas in Diabetes, all improved similarly between groups.
Conclusions: LAGB and a multidisciplinary IMWM program have similar 1-year benefits on diabetes control, cardiometabolic risk, and patient satisfaction, which should be considered in the context of other factors, such as personal preference, when selecting treatment options with obese T2D patients. Longer duration studies are important to understand emergent differences.
C1 [Ding, Su-Ann; Simonson, Donald C.; Wewalka, Marlene; Halperin, Florencia; Goebel-Fabbri, Ann; Hamdy, Osama; Lautz, David; Vernon, Ashley; Goldfine, Allison B.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Ding, Su-Ann; Wewalka, Marlene; Halperin, Florencia; Foster, Kathleen; Goebel-Fabbri, Ann; Hamdy, Osama; Goldfine, Allison B.] Joslin Diabet Ctr, Boston, MA 02215 USA.
[Simonson, Donald C.; Halperin, Florencia; Clancy, Kerri; Lautz, David; Vernon, Ashley; Goldfine, Allison B.] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Goldfine, AB (reprint author), One Joslin Pl, Boston, MA 02215 USA.
EM allison.goldfine@joslin.harvard.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases
[RC1-DK086918, R56-DK095451, P30-DK03836]; Patient-Centered Outcomes
Research Institute [CE-1304-6756]; Marietta Blau Grant from the
Osterreichischer Austausdienst [ICM-2010-02797]; Herbert Graetz Fund;
Joslin Clinical Research Center
FX This work was supported by the National Institute of Diabetes and
Digestive and Kidney Diseases (RC1-DK086918, R56-DK095451, and
P30-DK03836), Patient-Centered Outcomes Research Institute
(CE-1304-6756), the Marietta Blau Grant ICM-2010-02797 from the
Osterreichischer Austausdienst, and the Herbert Graetz Fund. Covidien
provided funds for surgical costs of participants randomized to surgery
with BMI < 35 kg/m2. Lifescan, a Division of Johnson &
Johnson, provided home glucose monitoring supplies. Nestle Nutrition Inc
provided Boost. Novo Nordisk provided FDA-approved medications to be
administered according to label. We also acknowledge support from the
Joslin Clinical Research Center and thank its philanthropic donors. No
funding source had a role in trial design, conduct, data analysis, or
manuscript preparation.
NR 39
TC 18
Z9 18
U1 2
U2 4
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD JUL
PY 2015
VL 100
IS 7
BP 2546
EP 2556
DI 10.1210/jc.2015-1443
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CQ8EZ
UT WOS:000360840600024
PM 25909333
ER
PT J
AU Tsai, JN
Zhu, YL
Foley, K
Lee, H
Burnett-Bowie, SA
Neer, RM
Leder, BZ
AF Tsai, Joy N.
Zhu, Yuli
Foley, Katelyn
Lee, Hang
Burnett-Bowie, Sherri-Ann
Neer, Robert M.
Leder, Benjamin Z.
TI Comparative Resistance to Teriparatide-Induced Bone Resorption With
Denosumab or Alendronate
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID PARATHYROID-HORMONE; POSTMENOPAUSAL WOMEN; MINERAL DENSITY;
OSTEOPOROSIS; ACTIVATION; MEN; PTH
AB Context: In postmenopausal osteoporotic women, denosumab fully inhibits teriparatide-induced bone resorption at approved doses. This property of denosumab is distinct from that of alendronate and likely contributes to the efficacy of combination denosumab and teriparatide therapy. Whether denosumab fully inhibits bone resorption when challenged by a higher dose of teriparatide is unknown.
Objective: We aimed to define the comparative ability of denosumab and alendronate to block the acute proresorptive effects of high-dose teriparatide.
Design, Setting, and Participants: In this randomized controlled trial, bone resorption (serum C-telopeptide [CTX]) wasmeasured in 25 postmenopausal women prior to and 4 hours after a single 40-mu g sc teriparatide injection. Subjects then received either a single injection of denosumab 60 mg or oral alendronate 70 mg weekly for 8 weeks. After 8 weeks, serum CTX was again measured before and 4 hours after a teriparatide a 40-mu g injection.
Outcomes: The primary outcome was the between-group difference in the teriparatide-induced change in CTX from baseline to week 8.
Results: At baseline, 40 mu g of teriparatide induced similar 4-hour increases in mean CTX in both groups (alendronate 47% +/- 14%, denosumab 46% +/- 16%). After 8 weeks, teriparatide was still able to stimulate bone resorption in women treated with alendronate (mean CTX increase of 43% +/- 29%) but not in women treated with denosumab (-7% (+/-) 11%; P < .001 for between group comparison).
Conclusions: Denosumab, but not alendronate, fully inhibits the ability of high-dose teriparatide to increase bone resorption acutely. These results suggest that combining denosumab with a more potent anabolic stimulus may result in greater separation between bone resorption and formation and hence greater increases in bone mass.
C1 [Tsai, Joy N.; Zhu, Yuli; Foley, Katelyn; Burnett-Bowie, Sherri-Ann; Neer, Robert M.; Leder, Benjamin Z.] Massachusetts Gen Hosp, Dept Med, Endocrine Unit, Boston, MA 02114 USA.
[Lee, Hang] Massachusetts Gen Hosp, Biostat Ctr, Boston, MA 02114 USA.
RP Tsai, JN (reprint author), 50 Blossom St,Thier 1051, Boston, MA 02114 USA.
EM jntsai@mgh.harvard.edu
FU National Center for Advancing Translational Science [1UL1TR001102-01, 8
UL1 TR000170-05]; Amgen Inc
FX This work was supported by Amgen Inc and by Grants 1UL1TR001102-01 and 8
UL1 TR000170-05 to the Harvard Clinical and Translational Science Center
from the National Center for Advancing Translational Science.
NR 20
TC 4
Z9 4
U1 1
U2 2
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD JUL
PY 2015
VL 100
IS 7
BP 2718
EP 2723
DI 10.1210/jc.2015-1541
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CQ8EZ
UT WOS:000360840600044
PM 25933031
ER
PT J
AU Linnemann, AK
Neuman, JC
Battiola, TJ
Wisinski, JA
Kimple, ME
Davis, DB
AF Linnemann, Amelia K.
Neuman, Joshua C.
Battiola, Therese J.
Wisinski, Jaclyn A.
Kimple, Michelle E.
Davis, Dawn Belt
TI Glucagon-Like Peptide-1 Regulates Cholecystokinin Production in
beta-Cells to Protect From Apoptosis
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article
ID FAT-FED MICE; INSULIN-SECRETION; PANCREATIC-ISLETS; RECEPTOR; GLP-1;
GENE; MASS; TRANSCRIPTION; ACTIVATION; HORMONES
AB Cholecystokinin (CCK) is a classic gut hormone that is also expressed in the pancreatic islet, where it is highly up-regulated with obesity. Loss of CCK results in increased beta-cell apoptosis in obese mice. Similarly, islet alpha-cells produce increased amounts of another gut peptide, glucagon-like peptide 1 (GLP-1), in response to cytokine and nutrient stimulation. GLP-1 also protects beta-cells from apoptosis via cAMP-mediated mechanisms. Therefore, we hypothesized that the activation of islet-derived CCK and GLP-1 may be linked. We show here that both human and mouse islets secrete active GLP-1 as a function of body mass index/obesity. Furthermore, GLP-1 can rapidly stimulate beta-cell CCK production and secretion through direct targeting by the cAMP-modulated transcription factor, cAMP response element binding protein (CREB). We find that cAMP-mediated signaling is required for Cck expression, but CCK regulation by cAMP does not require stimulatory levels of glucose or insulin secretion. We also show that CREB directly targets the Cck promoter in islets from obese (Leptin(ob/ob)) mice. Finally, we demonstrate that the ability of GLP-1 to protect beta-cells from cytokine-induced apoptosis is partially dependent on CCK receptor signaling. Taken together, our work suggests that in obesity, active GLP-1 produced in the islet stimulates CCK production and secretion in a paracrine manner via cAMP and CREB. This intraislet incretin loop may be one mechanism whereby GLP-1 protects beta-cells from apoptosis.
C1 [Linnemann, Amelia K.; Battiola, Therese J.; Wisinski, Jaclyn A.; Kimple, Michelle E.; Davis, Dawn Belt] Univ Wisconsin, Dept Med, Div Endocrinol, Madison, WI 53705 USA.
[Neuman, Joshua C.] Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA.
[Davis, Dawn Belt] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA.
RP Davis, DB (reprint author), Univ Wisconsin, 4147 MFCB,MC5148,1685 Highland Ave, Madison, WI 53705 USA.
EM dbd@medicine.wisc.edu
FU National Institutes of Health, National Institute of Diabetes, Digestive
and Kidney Diseases (NIH-NIDDK) [1K01DK102492]; National Institute on
Aging [5T32AG000213]; NIH-NIDDK [1RO1DK102598, DK083442]; United States
Department of Veterans Affairs [1101BX001880]; University of Wisconsin;
Wisconsin Partnership Program
FX This work was supported by the National Institutes of Health, National
Institute of Diabetes, Digestive and Kidney Diseases (NIH-NIDDK) Grant
1K01DK102492 (to A.K.L.); the National Institute on Aging Grant
5T32AG000213 (to J.C.N.); the NIH-NIDDK Grant 1RO1DK102598 (to M.E.K.);
and the NIH-NIDDK Grant DK083442, the United States Department of
Veterans Affairs Grant 1101BX001880, the University of Wisconsin, and
the Wisconsin Partnership Program (D.B.D.).
NR 37
TC 6
Z9 6
U1 1
U2 5
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0888-8809
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD JUL
PY 2015
VL 29
IS 7
BP 978
EP 987
DI 10.1210/me.2015-1030
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA CR0DH
UT WOS:000360987900004
PM 25984632
ER
PT J
AU Wen, PY
AF Wen, Patrick Y.
TI Controversies in neuro-oncology: role of whole-brain radiation therapy
in the treatment of newly diagnosed brain metastases
SO NEURO-ONCOLOGY
LA English
DT Editorial Material
ID TRIAL
C1 [Wen, Patrick Y.] Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, Boston, MA 02115 USA.
[Wen, Patrick Y.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
RP Wen, PY (reprint author), Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, Boston, MA 02115 USA.
EM patrick_wen@dfci.harvard.edu
NR 5
TC 0
Z9 1
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
EI 1523-5866
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUL
PY 2015
VL 17
IS 7
BP 915
EP 915
DI 10.1093/neuonc/nov102
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA CR0BM
UT WOS:000360983200003
PM 26092876
ER
PT J
AU Ayata, C
Lauritzen, M
AF Ayata, Cenk
Lauritzen, Martin
TI SPREADING DEPRESSION, SPREADING DEPOLARIZATIONS, AND THE CEREBRAL
VASCULATURE
SO PHYSIOLOGICAL REVIEWS
LA English
DT Review
ID CORTICAL BLOOD-FLOW; NITRIC-OXIDE SYNTHASE; GENE-RELATED PEPTIDE;
METHYL-D-ASPARTATE; FAMILIAL HEMIPLEGIC MIGRAINE; MITOCHONDRIAL
PERMEABILITY TRANSITION; ANEURYSMAL SUBARACHNOID HEMORRHAGE;
NEAR-INFRARED SPECTROSCOPY; OXIDATION-REDUCTION STATE; PIAL ARTERIOLAR
DILATION
AB Spreading depression (SD) is a transient wave of near-complete neuronal and glial depolarization associated with massive transmembrane ionic and water shifts. It is evolutionarily conserved in the central nervous systems of a wide variety of species from locust to human. The depolarization spreads slowly at a rate of only millimeters per minute by way of grey matter contiguity, irrespective of functional or vascular divisions, and lasts up to a minute in otherwise normal tissue. As such, SD is a radically different breed of electrophysiological activity compared with everyday neural activity, such as action potentials and synaptic transmission. Seventy years after its discovery by Leao, the mechanisms of SD and its profound metabolic and hemodynamic effects are still debated. What we did learn of consequence, however, is that SD plays a central role in the pathophysiology of a number of diseases including migraine, ischemic stroke, intracranial hemorrhage, and traumatic brain injury. An intriguing overlap among them is that they are all neurovascular disorders. Therefore, the interplay between neurons and vascular elements is critical for our understanding of the impact of this homeostatic breakdown in patients. The challenges of translating experimental data into human pathophysiology notwithstanding, this review provides a detailed account of bidirectional interactions between brain parenchyma and the cerebral vasculature during SD and puts this in the context of neurovascular diseases.
C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol & Stroke Serv,Neurovasc Res Lab, Boston, MA USA.
Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol,Neurosci Intens Care Unit, Boston, MA USA.
Univ Copenhagen, Dept Neurosci & Pharmacol, DK-2200 Copenhagen, Denmark.
Univ Copenhagen, Ctr Healthy Aging, DK-2200 Copenhagen, Denmark.
Glostrup Cty Hosp, Dept Clin Neurophysiol, Glostrup, Denmark.
RP Ayata, C (reprint author), 149 13th St,Rm 6403, Charlestown, MA 02129 USA.
EM cayata@partners.org; mlaurit@sund.ku.dk
FU National Institutes of Health [NS061505, NS055104, NS35611]; Fondation
Leducq; Heitman Foundation; Ellison Foundation; Lundbeck Foundation;
NOVO-Nordisk Foundation; Nordea Foundation for the Center for Healthy
Aging; Foundation Leducq; Danish Medical Research Council
FX C. Ayata was supported by the National Institutes of Health Grants
NS061505, NS055104, and NS35611; Fondation Leducq; The Heitman
Foundation; and The Ellison Foundation. M. Lauritzen was supported by
the Lundbeck Foundation, the NOVO-Nordisk Foundation, the Nordea
Foundation for the Center for Healthy Aging, Foundation Leducq, and the
Danish Medical Research Council.
NR 532
TC 29
Z9 30
U1 1
U2 17
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0031-9333
EI 1522-1210
J9 PHYSIOL REV
JI Physiol. Rev.
PD JUL
PY 2015
VL 95
IS 3
BP 953
EP 993
DI 10.1152/physrev.00027.2014
PG 41
WC Physiology
SC Physiology
GA CQ9HV
UT WOS:000360925500007
PM 26133935
ER
PT J
AU Mitchell, JC
Dick, MB
Wood, AE
Tapp, AM
Ziegler, R
AF Mitchell, Joel C.
Dick, Malcolm B.
Wood, Amanda E.
Tapp, Andre M.
Ziegler, Raphael
TI The Utility of the Dementia Severity Rating Scale in Differentiating
Mild Cognitive Impairment and Alzheimer Disease From Controls
SO ALZHEIMER DISEASE & ASSOCIATED DISORDERS
LA English
DT Article
DE dementia assessment; mild cognitive impairment; Alzheimer disease;
screening; Dementia Severity Rating Scale
ID ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE;
DEPRESSION; CARE; RECOMMENDATIONS; INDIVIDUALS; PERFORMANCE; PREVALENCE;
COMMUNITY
AB The current study investigated the utility of the Dementia Severity Rating Scale (DSRS) total score to identify individuals at the earliest stage of impairment (ie, mild cognitive impairment/MCI). In addition, the authors sought to investigate how well the measure correlates with an expanded battery of cognitive tests and other measures of functional abilities. Of the 320 participants included in this study, 85 were normal controls, 96 had single-domain or multiple-domain amnestic MCI, and 139 had possible or probable Alzheimer disease (AD). Each participant underwent a thorough cognitive, neurological, and physical examination. Results from this study indicated that the DSRS total scores differed significantly between the 3 groups (P<0.001) and accurately identified 81% of the control group, 60% of the MCI group, and 78% of the AD group in a post hoc discriminant analysis. When combined with a brief cognitive measure (ie, Consortium to Establish a Registry for Alzheimer's Disease Word List 5 min recall test), the DSRS accurately identified 98% of the control group, 76% of the MCI group, and 82% of the AD group. Implications for clinical practice and proposed areas of future research are discussed.
C1 [Mitchell, Joel C.; Wood, Amanda E.; Tapp, Andre M.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Mitchell, Joel C.; Wood, Amanda E.; Tapp, Andre M.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Dick, Malcolm B.; Ziegler, Raphael] Univ Calif Irvine, Inst Memory Impairments & Neurol Disorders, Irvine, CA USA.
RP Mitchell, JC (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM joel.mitchell@va.gov
FU National Institute on Aging (NIA) [P50 AG16573]
FX Supported by the National Institute on Aging (NIA) (grant number P50
AG16573 to the University of California at Irvine, Alzheimer's Disease
Research Center).
NR 39
TC 0
Z9 0
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0893-0341
J9 ALZ DIS ASSOC DIS
JI Alzheimer Dis. Assoc. Dis.
PD JUL-SEP
PY 2015
VL 29
IS 3
BP 222
EP 228
DI 10.1097/WAD.0000000000000057
PG 7
WC Clinical Neurology; Pathology
SC Neurosciences & Neurology; Pathology
GA CQ5PX
UT WOS:000360658900007
PM 25187220
ER
PT J
AU Bledsoe, JR
Shinagare, SA
Deshpande, V
AF Bledsoe, Jacob R.
Shinagare, Shweta A.
Deshpande, Vikram
TI Difficult Diagnostic Problems in Pancreatobiliary Neoplasia
SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
LA English
DT Article
ID ACINAR-CELL-CARCINOMA; INTRADUCTAL TUBULOPAPILLARY NEOPLASMS; ONCOCYTIC
PAPILLARY NEOPLASM; FROZEN-SECTION DIAGNOSIS; INTRAEPITHELIAL NEOPLASIA;
DUCTAL ADENOCARCINOMA; DIFFERENTIAL-DIAGNOSIS; CHRONIC-PANCREATITIS;
GROOVE PANCREATITIS; MUCINOUS NEOPLASMS
AB Context.-Many common diagnostic dilemmas are encountered in pancreatobiliary pathology, frequently resulting in uncertainty on behalf of the pathologist and referral for a second opinion.
Objectives.-To review 4 common diagnostic dilemmas encountered in the practice of pancreatobiliary pathology: (1) pancreatic ductal adenocarcinoma versus chronic pancreatitis; (2) pancreatic ductal carcinoma versus adenocarcinomas arising in the ampulla and intrapancreatic common bile duct; (3) the distinction of uncommon intraductal neoplasms-intraductal oncocytic papillary neoplasm, intraductal tubulopapillary neoplasm, and intraductal acinar cell carcinoma; and (4) intrahepatic cholangiocarcinoma versus metastatic carcinoma.
Data Sources.-A review of pertinent literature, along with the authors' personal experience, based on institutional and consultation materials.
Conclusions.-Important diagnostic features for a few challenging problems in pancreatobiliary pathology are reviewed. Careful study of the microscopic features along with awareness of differential diagnoses and diagnostic pitfalls generally allows distinction of these entities. We also highlight established and novel ancillary studies that help to arrive at an accurate diagnosis.
C1 [Bledsoe, Jacob R.; Deshpande, Vikram] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Shinagare, Shweta A.] Tufts Med Ctr, Dept Pathol & Lab Med, Boston, MA USA.
RP Deshpande, V (reprint author), Massachusetts Gen Hosp, Dept Pathol, Warren Bldg 2-256,55 Fruit St, Boston, MA 02114 USA.
EM vdeshpande@partners.org
NR 58
TC 6
Z9 6
U1 1
U2 1
PU COLL AMER PATHOLOGISTS
PI NORTHFIELD
PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA
SN 0003-9985
EI 1543-2165
J9 ARCH PATHOL LAB MED
JI Arch. Pathol. Lab. Med.
PD JUL
PY 2015
VL 139
IS 7
BP 848
EP 857
DI 10.5858/arpa.2014-0205-RA
PG 10
WC Medical Laboratory Technology; Medicine, Research & Experimental;
Pathology
SC Medical Laboratory Technology; Research & Experimental Medicine;
Pathology
GA CQ5NX
UT WOS:000360653200006
PM 26125425
ER
PT J
AU Laudadio, J
McNeal, JL
Boyd, SD
Le, LP
Lockwood, C
McCloskey, CB
Sharma, G
Voelkerding, KV
Haspel, RL
AF Laudadio, Jennifer
McNeal, Jeffrey L.
Boyd, Scott D.
Le, Long Phi
Lockwood, Christina
McCloskey, Cindy B.
Sharma, Gaurav
Voelkerding, Karl V.
Haspel, Richard L.
TI Design of a Genomics Curriculum Competencies for Practicing Pathologists
SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
LA English
DT Article
ID ESSENTIAL-NURSING-COMPETENCES; PERSONALIZED MEDICINE; GENETICS;
ASSOCIATION; RESIDENTS; AGENDA; ERA
AB Context.-The field of genomics is rapidly impacting medical care across specialties. To help guide test utilization and interpretation, pathologists must be knowledgeable about genomic techniques and their clinical utility. The technology allowing timely generation of genomic data is relatively new to patient care and the clinical laboratory, and therefore, many currently practicing pathologists have been trained without any molecular or genomics exposure. Furthermore, the exposure that current and recent trainees receive in this field remains inconsistent.
Objective.-To assess pathologists' learning needs in genomics and to develop a curriculum to address these educational needs.
Design.-A working group formed by the College of American Pathologists developed an initial list of genomics competencies (knowledge and skills statements) that a practicing pathologist needs to be successful. Experts in genomics were then surveyed to rate the importance of each competency. These data were used to create a final list of prioritized competencies. A subset of the working group defined subtopics and tasks for each competency. Appropriate delivery methods for the educational material were also proposed.
Results.-A final list of 32 genomics competency statements was developed. A prioritized curriculum was created with designated subtopics and tasks associated with each competency.
Conclusions.-We present a genomics curriculum designed as a first step toward providing practicing pathologists with the competencies needed to practice successfully.
C1 [Laudadio, Jennifer] Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA.
[McNeal, Jeffrey L.] Coll Amer Pathologists, CAP Learning, Northfield, IL USA.
[Boyd, Scott D.] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA.
[Le, Long Phi] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Le, Long Phi] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Lockwood, Christina] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA.
[McCloskey, Cindy B.] Univ Oklahoma, Coll Med, Dept Pathol, Oklahoma City, OK 73190 USA.
[Sharma, Gaurav] Henry Ford Hlth Syst, Dept Pathol & Lab Med, Detroit, MI USA.
[Voelkerding, Karl V.] Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT USA.
[Voelkerding, Karl V.] ARUP Inst Clin & Expt Pathol, Salt Lake City, UT USA.
[Haspel, Richard L.] Harvard Univ, Sch Med, Dept Pathol, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
RP Haspel, RL (reprint author), Harvard Univ, Sch Med, Dept Pathol, Beth Israel Deaconess Med Ctr, 330 Brookline Ave,Yamins 309, Boston, MA 02215 USA.
EM rhaspel@bidmc.harvard.edu
NR 19
TC 1
Z9 1
U1 1
U2 2
PU COLL AMER PATHOLOGISTS
PI NORTHFIELD
PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA
SN 0003-9985
EI 1543-2165
J9 ARCH PATHOL LAB MED
JI Arch. Pathol. Lab. Med.
PD JUL
PY 2015
VL 139
IS 7
BP 894
EP 900
DI 10.5858/arpa.2014-0253-CP
PG 7
WC Medical Laboratory Technology; Medicine, Research & Experimental;
Pathology
SC Medical Laboratory Technology; Research & Experimental Medicine;
Pathology
GA CQ5NX
UT WOS:000360653200011
PM 26125429
ER
PT J
AU Keyt, H
Faverio, P
Restrepo, MI
AF Keyt, H.
Faverio, P.
Restrepo, M. I.
TI Selective digestive decontamination saves lives whilst preventing
resistance Response
SO INDIAN JOURNAL OF MEDICAL RESEARCH
LA English
DT Letter
ID INTENSIVE-CARE-UNIT; TRACT; TRIAL; PNEUMONIA
C1 [Keyt, H.; Restrepo, M. I.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Keyt, H.; Restrepo, M. I.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Faverio, P.] Univ Milano Bicocca, Dept Hlth Sci, San Gerardo Hosp, Resp Unit, Monza, Italy.
RP Keyt, H (reprint author), South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
EM restrepom@uthscsa.edu
NR 11
TC 0
Z9 0
U1 0
U2 0
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
INDIA
SN 0971-5916
J9 INDIAN J MED RES
JI Indian J. Med. Res.
PD JUL
PY 2015
VL 142
PG 2
WC Immunology; Medicine, General & Internal; Medicine, Research &
Experimental
SC Immunology; General & Internal Medicine; Research & Experimental
Medicine
GA CQ5NQ
UT WOS:000360652400016
ER
PT J
AU Choi, S
Taylor, KP
Chatzigeorgiou, M
Hu, ZT
Schafer, WR
Kaplan, JM
AF Choi, Seungwon
Taylor, Kelsey P.
Chatzigeorgiou, Marios
Hu, Zhitao
Schafer, William R.
Kaplan, Joshua M.
TI Sensory Neurons Arouse C. elegans Locomotion via Both Glutamate and
Neuropeptide Release
SO PLOS GENETICS
LA English
DT Article
ID SLEEP-LIKE STATE; NEMATODE CAENORHABDITIS-ELEGANS; BEHAVIORAL
QUIESCENCE; NERVOUS-SYSTEM; SOCIAL-BEHAVIOR; RECEPTOR; CIRCUIT; HOMOLOG;
UNC-13; NMDA
AB C. elegans undergoes periods of behavioral quiescence during larval molts (termed lethargus) and as adults. Little is known about the circuit mechanisms that establish these quiescent states. Lethargus and adult locomotion quiescence is dramatically reduced in mutants lacking the neuropeptide receptor NPR-1. Here, we show that the aroused locomotion of npr-1 mutants results from the exaggerated activity in multiple classes of sensory neurons, including nociceptive (ASH), touch sensitive (ALM and PLM), and stretch sensing (DVA) neurons. These sensory neurons accelerate locomotion via both neuropeptide and glutamate release. The relative contribution of these sensory neurons to arousal differs between larval molts and adults. Our results suggest that a broad network of sensory neurons dictates transitions between aroused and quiescent behavioral states.
C1 [Choi, Seungwon; Taylor, Kelsey P.; Hu, Zhitao; Kaplan, Joshua M.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Choi, Seungwon; Taylor, Kelsey P.; Hu, Zhitao; Kaplan, Joshua M.] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA.
[Choi, Seungwon; Taylor, Kelsey P.; Hu, Zhitao; Kaplan, Joshua M.] Harvard Univ, Sch Med, Biol & Biomed Sci Program, Boston, MA USA.
[Chatzigeorgiou, Marios; Schafer, William R.] MRC Lab Mol Biol, Div Cell Biol, Cambridge, England.
RP Choi, S (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
EM kaplan@molbio.mgh.harvard.edu
OI Schafer, William/0000-0002-6676-8034
FU Kwanjeong Educational Foundation; NSF; [NIH DK80215]; [MRC
MC-A022-5PB9]
FX This work was supported by Predoctoral Fellowships from the Kwanjeong
Educational Foundation (SC) and the NSF (KPT) (https://www.nsfgrfp.org),
and by research grants to JMK (NIH DK80215) (grants.nih.gov) and WRS
(MRC MC-A022-5PB9). (www.mrc.ac.uk). The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 43
TC 7
Z9 7
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD JUL
PY 2015
VL 11
IS 7
AR e1005359
DI 10.1371/journal.pgen.1005359
PG 20
WC Genetics & Heredity
SC Genetics & Heredity
GA CQ5CZ
UT WOS:000360622200029
PM 26154367
ER
PT J
AU Gao, L
Li, DT
Ma, K
Zhang, WJ
Xu, T
Fu, C
Jing, CB
Jia, XE
Wu, S
Sun, X
Dong, M
Deng, M
Chen, Y
Zhu, WG
Peng, JR
Wan, FY
Zhou, Y
Zon, LI
Pan, WJ
AF Gao, Lei
Li, Dantong
Ma, Ke
Zhang, Wenjuan
Xu, Tao
Fu, Cong
Jing, Changbin
Jia, Xiaoe
Wu, Shuang
Sun, Xin
Dong, Mei
Deng, Min
Chen, Yi
Zhu, Wenge
Peng, Jinrong
Wan, Fengyi
Zhou, Yi
Zon, Leonard I.
Pan, Weijun
TI TopBP1 Governs Hematopoietic Stem/Progenitor Cells Survival in Zebrafish
Definitive Hematopoiesis
SO PLOS GENETICS
LA English
DT Article
ID DNA-DAMAGE RESPONSE; REPLICATION CHECKPOINT CONTROL; BONE-MARROW
FAILURE; BLOOD STEM-CELLS; TRANSGENIC ZEBRAFISH; AORTIC ENDOTHELIUM;
GENOME INTEGRITY; PROGENITOR CELLS; FANCONI-ANEMIA; ATR ACTIVATION
AB In vertebrate definitive hematopoiesis, nascent hematopoietic stem/progenitor cells (HSPCs) migrate to and reside in proliferative hematopoietic microenvironment for transitory expansion. In this process, well-established DNA damage response pathways are vital to resolve the replication stress, which is deleterious for genome stability and cell survival. However, the detailed mechanism on the response and repair of the replication stress-induced DNA damage during hematopoietic progenitor expansion remains elusive. Here we report that a novel zebrafish mutant(cas003) with nonsense mutation in topbp1 gene encoding topoisomerase II beta binding protein 1 (TopBP1) exhibits severe definitive hematopoiesis failure. Homozygous topbp1(cas003) mutants manifest reduced number of HSPCs during definitive hematopoietic cell expansion, without affecting the formation and migration of HSPCs. Moreover, HSPCs in the caudal hematopoietic tissue (an equivalent of the fetal liver in mammals) in topbp1(cas003) mutant embryos are more sensitive to hydroxyurea (HU) treatment. Mechanistically, subcellular mislocalization of TopBP1(cas003) protein results in ATR/Chk1 activation failure and DNA damage accumulation in HSPCs, and eventually induces the p53-dependent apoptosis of HSPCs. Collectively, this study demonstrates a novel and vital role of TopBP1 in the maintenance of HSPCs genome integrity and survival during hematopoietic progenitor expansion.
C1 [Gao, Lei; Li, Dantong; Ma, Ke; Zhang, Wenjuan; Xu, Tao; Fu, Cong; Jing, Changbin; Jia, Xiaoe; Wu, Shuang; Dong, Mei; Deng, Min; Pan, Weijun] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Key Lab Stem Cell Biol, Shanghai, Peoples R China.
[Gao, Lei; Li, Dantong; Ma, Ke; Zhang, Wenjuan; Xu, Tao; Fu, Cong; Jing, Changbin; Jia, Xiaoe; Wu, Shuang; Dong, Mei; Deng, Min; Pan, Weijun] Shanghai Jiao Tong Univ, Sch Med, Shanghai 200030, Peoples R China.
[Sun, Xin; Wan, Fengyi] Johns Hopkins Univ, Dept Biochem & Mol Biol, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Chen, Yi] Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Hematol, State Key Lab Med Genom,RuiJin Hosp, Shanghai 200030, Peoples R China.
[Zhu, Wenge] George Washington Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC USA.
[Peng, Jinrong] Zhejiang Univ, Coll Anim Sci, Minist Educ, Key Lab Mol Anim Nutr, Hangzhou 310003, Zhejiang, Peoples R China.
[Wan, Fengyi] Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA.
[Wan, Fengyi] Johns Hopkins Med Inst, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA.
[Zhou, Yi; Zon, Leonard I.] Harvard Univ, Childrens Hosp, Stem Cell Program, Hematol Oncol Program,Sch Med, Boston, MA 02115 USA.
[Zhou, Yi; Zon, Leonard I.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Gao, L (reprint author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Key Lab Stem Cell Biol, Shanghai, Peoples R China.
EM weijunpan@sibs.ac.cn
OI Peng, Jinrong/0000-0002-0793-4848
FU National Natural Science Foundation of China [31371461, 31301209,
31301196]; Science and Technology Commission of Shanghai Municipality
[13JC1406400]; National Thousand Talents Program for Distinguished Young
Scholars
FX This work was supported by the National Natural Science Foundation of
China (31371461 to WP; 31301209 to CJ; 31301196 to MDo,
http://www.nsfc.gov.cn/), the Science and Technology Commission of
Shanghai Municipality (13JC1406400; WP, http://www.stcsm.gov.cn/), and
the National Thousand Talents Program for Distinguished Young Scholars
(WP, http://www.1000plan.org/). The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
NR 87
TC 4
Z9 6
U1 3
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD JUL
PY 2015
VL 11
IS 7
AR e1005346
DI 10.1371/journal.pgen.1005346
PG 30
WC Genetics & Heredity
SC Genetics & Heredity
GA CQ5CZ
UT WOS:000360622200022
PM 26131719
ER
PT J
AU Staller, K
Barshop, K
Ananthakrishnan, AN
Kuo, B
AF Staller, Kyle
Barshop, Kenneth
Ananthakrishnan, Ashwin N.
Kuo, Braden
TI Rectosigmoid Localization of Radiopaque Markers Does Not Correlate with
Prolonged Balloon Expulsion in Chronic Constipation: Results from a
Multicenter Cohort
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
ID PELVIC FLOOR DYSSYNERGIA; COLONIC MOTILITY; IDIOPATHIC CONSTIPATION;
TRANSIT CONSTIPATION; ANORECTAL MANOMETRY; CLINICAL-PRACTICE;
CONTROLLED-TRIAL; BIOFEEDBACK; DISORDERS; REPRODUCIBILITY
AB OBJECTIVES: Ingestion of radiopaque markers (ROMs) is a common means of assessing colonic transit time in chronic constipation. Because anorectal manometry (ARM) testing for pelvic floor dysfunction is mostly limited to academic centers, clinicians frequently use rectosigmoid accumulation of markers as a surrogate for pelvic floor dysfunction. We sought to determine whether rectosigmoid localization of markers on a ROM study correlated with measures of pelvic floor dysfunction by ARM and balloon expulsion testing.
METHODS: We assembled a multicenter, retrospective cohort of patients diagnosed with chronic constipation who underwent both transit testing by ROM transit testing and ARM with balloon expulsion testing. We compared the proportion of patients with outlet obstruction by rectoanal pressure gradient or prolonged balloon expulsion stratified by marker location.
RESULTS: There were 610 patients with both ROM testing and ARM with balloon expulsion testing. The mean age was 44 years and 526 were women (86%). Eighty-one (13%) patients had markers confined to the rectosigmoid area alone and were compared with 529 patients with markers elsewhere (51%) or no retained markers (49%). Of those with markers confined to the rectosigmoid colon, 48 (59%) had a prolonged balloon expulsion compared with 276 (52%) who did not have rectosigmoid markers (P = 0.28). The mean rectoanal gradient for patients with markers in the rectosigmoid colon was -29 +/- 46 mm Hg compared with -34 +/- 59 mm Hg for all others (P = 0.59).
CONCLUSIONS: Among patients with chronic constipation undergoing ROM transit testing, there is no association between rectosigmoid location of markers and rectoanal gradient or prolonged balloon expulsion.
C1 [Staller, Kyle; Ananthakrishnan, Ashwin N.; Kuo, Braden] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
[Staller, Kyle; Ananthakrishnan, Ashwin N.; Kuo, Braden] Harvard Univ, Sch Med, Boston, MA USA.
[Barshop, Kenneth] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA.
RP Staller, K (reprint author), Massachusetts Gen Hosp, Div Gastroenterol, 55 Fruit St, Boston, MA 02114 USA.
EM kstaller@mgh.harvard.edu
OI Staller, Kyle/0000-0003-4925-4290
FU National Institutes of Health [K23 DK097142]
FX A.N.A. is supported by a grant from the National Institutes of Health
(K23 DK097142).
NR 24
TC 1
Z9 1
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD JUL
PY 2015
VL 110
IS 7
BP 1049
EP 1055
DI 10.1038/ajg.2015.140
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CP9FV
UT WOS:000360200100017
PM 25964224
ER
PT J
AU Sonnenberg, A
Genta, RM
AF Sonnenberg, Amnon
Genta, Robert M.
TI Low Prevalence of Colon Polyps in Chronic Inflammatory Conditions of the
Colon
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
ID HELICOBACTER-PYLORI; ESOPHAGEAL EOSINOPHILIA; MICROSCOPIC COLITIS;
PATHOLOGY DATABASE; COLORECTAL-CANCER; RISK; DISORDERS; DISEASE
AB OBJECTIVES: Previous studies have reported a low prevalence of colon polyps in patients with microscopic colitis. The aim of the study was to test whether such inverse associations applied to other inflammatory diseases of the colon.
METHODS: In a case-control study among 130,204 patients undergoing colonoscopy for the work-up of diarrhea, we compared the prevalence of colon polyps in a case population of patients with inflammatory bowel disease (IBD), microscopic colitis, histologic signs of active colitis, diverticulitis, or ischemic colitis, and in a control population with normal colon mucosa. Case and control subjects were compared using odds ratios and their 95% confidence intervals adjusted for age and sex.
RESULTS: In 11,176 patients with microscopic colitis, the prevalence of hyperplastic polyps, serrated adenomas, and tubular adenomas were all reduced: odds ratios= 0.46 (95% confidence intervals= 0.43-0.49), 0.24 (0.19-0.30), and 0.35 (0.33-0.38), respectively. In 4,435 patients with IBD, the corresponding values were: 0.18 (0.15-0.21), 0.24 (0.16-0.35), and 0.18 (0.15-0.21), respectively. In 6,501 patients with histologically active colitis, the corresponding values were: 0.58 (0.53-0.63), 0.57 (0.46-0.70), and 0.63 (0.58-0.68), respectively. No such consistent reduction in polyp prevalence was found in patients with diverticulitis or ischemic colitis.
CONCLUSIONS: Chronic inflammatory conditions of the colon are associated with a decreased prevalence of colon polyps.
C1 [Sonnenberg, Amnon; Genta, Robert M.] Miraca Life Sci, Irving, TX USA.
[Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Genta, Robert M.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
RP Sonnenberg, A (reprint author), Portland VA Med Ctr, Dept Gastroenterol, P3 GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM sonnenbe@ohsu.edu
NR 14
TC 7
Z9 8
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD JUL
PY 2015
VL 110
IS 7
BP 1056
EP 1061
DI 10.1038/ajg.2015.130
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CP9FV
UT WOS:000360200100018
PM 25916222
ER
PT J
AU Buettner, C
Davis, RB
Phillips, RS
Mittleman, MA
AF Buettner, C.
Davis, R. B.
Phillips, R. S.
Mittleman, M. A.
TI COQ10 DOES NOT IMPROVE STATIN MYALGIA-A RANDOMIZED CONTROLLED TRIAL
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 83rd Congress of the European-Atherosclerosis-Society (EAS)
CY MAR 22-25, 2015
CL Glasgow, SCOTLAND
SP European Atherosclerosis Soc
C1 [Buettner, C.; Davis, R. B.; Phillips, R. S.] Harvard Univ, Sch Med, BIDMC, Med, Boston, MA USA.
[Mittleman, M. A.] Harvard Univ, Sch Med, BIDMC, Cardiol, Boston, MA USA.
NR 0
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2015
VL 241
IS 1
MA EAS-0814
BP E206
EP E206
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA CP7WS
UT WOS:000360100600677
ER
PT J
AU Buettner, C
Morioka, T
Lee, AJ
Bertisch, S
AF Buettner, C.
Morioka, T.
Lee, A. J.
Bertisch, S.
TI VITAMIN D STATUS MODIFIES THE ASSOCIATION BETWEEN STATIN USE AND
MUSCULOSKELETAL PAIN: A POPULATION BASED STUDY
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 83rd Congress of the European-Atherosclerosis-Society (EAS)
CY MAR 22-25, 2015
CL Glasgow, SCOTLAND
SP European Atherosclerosis Soc
C1 [Buettner, C.; Bertisch, S.] Harvard Univ, Sch Med, Med, BIDMC, Boston, MA USA.
[Morioka, T.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Bethesda, MD 20814 USA.
[Lee, A. J.] Harvard Univ, Sch Med, BIDMC, Harvard Clin & Translat Sci Ctr, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2015
VL 241
IS 1
MA EAS-0821
BP E20
EP E20
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA CP7WS
UT WOS:000360100600064
ER
PT J
AU Agrawal, S
Agarwal, S
Arnason, T
Saini, S
Belghitik, J
AF Agrawal, Shefali
Agarwal, Sheela
Arnason, Thomas
Saini, Sanjay
Belghitik, Jacques
TI Management of Hepatocellular Adenoma: Recent Advances
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE Hepatocellular Adenoma; Malignant Transformation; Hemorrhage; Liver
Resection; Conservative Management; Pregnancy
ID FOCAL NODULAR HYPERPLASIA; LIVER-CELL ADENOMAS; MULTIPLE HEPATIC
ADENOMAS; GLYCOGEN-STORAGE-DISEASE; PERCUTANEOUS RADIOFREQUENCY
ABLATION; TRANSCATHETER ARTERIAL EMBOLIZATION; PORTOSYSTEMIC VENOUS
SHUNT; SINGLE-CENTER EXPERIENCE; MALIGNANT-TRANSFORMATION; SUBTYPE
CLASSIFICATION
AB Hepatocellular adenoma (HCA) is a rare benign liver cell neoplasm that occurs more frequently in young women with a history of prolonged use of oral contraceptives. Surgical resection is considered because of the risk of hemorrhage in 25% and of malignant transformation in 5% of patients with HCA. HCA is a heterogeneous disease comprising 3 subtypes with distinct molecular and complication profiles. The inflammatory or telangiectatic subtype is at increased risk for hemorrhage, the 13-catenin-activated subtype is at increased risk for malignant transformation, and the hepatocyte nuclear factor-la-inactivated or steatotic subtype is at the least risk for complications. One-third of the patients with HCA have multiple tumors on imaging with no increased risk of complications. Magnetic resonance imaging is the modality of choice for the diagnosis and subtype characterization of HCA. Systematic resection of H CA is recommended in male patients owing to the higher incidence of malignant transformation, and surgical excision in women should be reserved for tumors 5 cm or larger associated with an increased risk of complications. Cessation of hormonal therapy and radiologic surveillance in women with HCA tumors smaller than 5 cm shows that the vast majority of HCA remain stable or undergo spontaneous regression. Percutaneous core needle biopsy is of limited value because the therapeutic strategy is based primarily on patient sex and tumor size. Transarterial embolization is the initial treatment for HCA complicated by hemorrhage. Pregnancy should not be discouraged in the presence of HCA, however, frequent sonographic surveillance is recommended.
C1 [Agrawal, Shefali] Indraprastha Apollo Hosp, Dept Surg Oncol, Hepatobiliary & Pancreat Surg, New Delhi, India.
[Agarwal, Sheela; Saini, Sanjay] Massachusetts Gen Hosp, Dept Radiol, Div Abdominal Imaging & Intervent, Boston, MA 02114 USA.
[Arnason, Thomas] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Arnason, Thomas] Harvard Univ, Sch Med, Boston, MA USA.
[Belghitik, Jacques] Univ Paris, Beaujon Hosp, Dept Hepatobiliary & Transplant Surg, F-92110 Clichy, France.
RP Belghitik, J (reprint author), Univ Paris, Beaujon Hosp, Dept Hepatobiliary & Transplant Surg, 100 Blvd Gen Leclerc, F-92110 Clichy, France.
EM jacques.belghiti@bjn.aphp.fr
OI Agrawal, Shefali/0000-0002-2502-7651
NR 104
TC 3
Z9 4
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1542-3565
EI 1542-7714
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD JUL
PY 2015
VL 13
IS 7
BP 1221
EP 1230
DI 10.1016/j.cgh.2014.05.023
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CP7FY
UT WOS:000360053800119
PM 24909909
ER
PT J
AU Wani, S
Hall, M
Keswani, RN
Aslanian, HR
Casey, B
Burbridge, R
Chak, A
Chen, AM
Cote, G
Edmundowicz, SA
Faulx, AL
Hollander, TG
Lee, LS
Mullady, D
Murad, F
Muthusamy, VR
Pfau, PR
Scheiman, JM
Tokar, J
Wagh, MS
Watson, R
Early, D
AF Wani, Sachin
Hall, Matthew
Keswani, Rajesh N.
Aslanian, Harry R.
Casey, Brenna
Burbridge, Rebecca
Chak, Amitabh
Chen, Ann M.
Cote, Gregory
Edmundowicz, Steven A.
Faulx, Ashley L.
Hollander, Thomas G.
Lee, Linda S.
Mullady, Daniel
Murad, Faris
Muthusamy, V. Raman
Pfau, Patrick R.
Scheiman, James M.
Tokar, Jeffrey
Wagh, Mihir S.
Watson, Rabindra
Early, Dayna
TI Variation in Aptitude of Trainees in Endoscopic Ultrasonography, Based
on Cumulative Sum Analysis
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE RATE US Study; Training; Competency; Cumulative Sum Analysis
ID AMERICAN SOCIETY; EUS; RECOMMENDATIONS; COMPETENCE; ULTRASOUND
AB BACKGROUND & AIMS: Studies have reported substantial variation in the competency of advanced endoscopy trainees, indicating a need for more supervised training in endoscopic ultrasound (EUS). We used a standardized, validated, data collection tool to evaluate learning curves and measure competency in EUS among trainees at multiple centers.
METHODS: In a prospective study performed at 15 centers, 17 trainees with no prior EUS experience were evaluated by experienced attending endosonographers at the 25th and then every 10th upper EUS examination, over a 12-month training period. A standardized data collection form was used (using a 5-point scoring system) to grade the EUS examination. Cumulative sum analysis was applied to produce a learning curve for each trainee; it tracked the overall performance based on median scores at different stations and also at each station. Competency was defined by a median score of 1, with acceptable and unacceptable failure rates of 10% and 20%, respectively.
RESULTS: Twelve trainees were included in the final analysis. Each of the trainees performed 265 to 540 EUS examinations (total, 4257 examinations). There was a large amount of variation in their learning curves: 2 trainees crossed the threshold for acceptable performance (at cases 225 and 245), 2 trainees had a trend toward acceptable performance (after 289 and 355 cases) but required continued observation, and 8 trainees needed additional training and observation. Similar results were observed at individual stations.
CONCLUSIONS: A specific case load does not ensure competency in EUS; 225 cases should be considered the minimum caseload for training because we found that no trainee achieved competency before this point. Ongoing training should be provided for trainees until competency is confirmed using objective measures.
C1 [Wani, Sachin; Hall, Matthew] Univ Colorado, Anschutz Med Ctr, Div Gastroenterol & Hepatol, Aurora, CO 80045 USA.
[Keswani, Rajesh N.] Northwestern Univ, Div Gastroenterol & Hepatol, Chicago, IL 60611 USA.
[Aslanian, Harry R.] Yale Univ, Div Gastroenterol & Hepatol, New Haven, CT USA.
[Casey, Brenna; Lee, Linda S.] Massachusetts Gen Hosp, Div Gastroenterol & Hepatol, Boston, MA 02114 USA.
[Casey, Brenna; Lee, Linda S.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Burbridge, Rebecca] Duke Univ, Div Gastroenterol & Hepatol, Durham, NC USA.
[Chak, Amitabh; Faulx, Ashley L.] Univ Hosp Case Med Ctr, Div Gastroenterol & Hepatol, Cleveland, OH USA.
[Chen, Ann M.] Stanford Univ, Div Gastroenterol & Hepatol, Stanford, CA 94305 USA.
[Cote, Gregory] Indiana Univ Hosp, Div Gastroenterol & Hepatol, Indianapolis, IN 46202 USA.
[Edmundowicz, Steven A.; Hollander, Thomas G.; Mullady, Daniel; Murad, Faris; Early, Dayna] Washington Univ, Sch Med, Div Gastroenterol & Hepatol, St Louis, MO USA.
[Muthusamy, V. Raman; Watson, Rabindra] Univ Calif Los Angeles, David Geffen Sch Med, Div Gastroenterol & Hepatol, Los Angeles, CA 90095 USA.
[Pfau, Patrick R.] Univ Wisconsin, Sch Med, Div Gastroenterol & Hepatol, Madison, WI USA.
[Scheiman, James M.] Univ Michigan, Div Gastroenterol & Hepatol, Ann Arbor, MI 48109 USA.
[Tokar, Jeffrey] Fox Chase Canc Ctr, Div Gastroenterol & Hepatol, Philadelphia, PA 19111 USA.
[Wagh, Mihir S.] Univ Florida, Div Gastroenterol & Hepatol, Gainesville, FL USA.
RP Wani, S (reprint author), Univ Colorado, Anschutz Med Ctr, Div Gastroenterol & Hepatol, Mail Stop F735,1635 Aurora Court,Room 2-031, Aurora, CO 80045 USA.
EM sachinwani10@yahoo.com
FU NCI NIH HHS [P50 CA150964, U54 CA163060]
NR 13
TC 12
Z9 12
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1542-3565
EI 1542-7714
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD JUL
PY 2015
VL 13
IS 7
BP 1318
EP +
DI 10.1016/j.cgh.2014.11.008
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CP7FY
UT WOS:000360053800132
PM 25460557
ER
PT J
AU Allen, KF
Gaier, ED
Wiggs, JL
AF Allen, Keri F.
Gaier, Eric D.
Wiggs, Janey L.
TI Genetics of Primary Inherited Disorders of the Optic Nerve: Clinical
Applications
SO COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
LA English
DT Article
ID OPEN-ANGLE GLAUCOMA; AXENFELD-RIEGER SYNDROME; NORMAL-TENSION GLAUCOMA;
CONGENITAL GLAUCOMA; UNITED-STATES; MITOCHONDRIAL DISORDERS; CYP1B1
MUTATIONS; MOUSE MODEL; NEUROPATHY; SPECTRUM
AB Inherited disorders of the optic nerve significantly impact vision in children and adults. The optic nerve disorders most commonly encountered clinically are glaucoma and primary optic neuropathy including Leber's hereditary optic neuropathy (LHON) and autosomal dominant or Kjer's optic atrophy. Current knowledge of the genetics of optic neuropathy and glaucoma makes it possible to test for mutations in disease-causing genes allowing for presymptomatic testing and risk assessment, and recent advances have revealed important disease mechanisms that may suggest potential therapeutic targets. In this perspective, we describe the current approaches and limitations to genetic testing for these disorders and provide an update on the development of gene-based therapies.
C1 [Allen, Keri F.; Gaier, Eric D.; Wiggs, Janey L.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA 02114 USA.
RP Wiggs, JL (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA 02114 USA.
EM janey_wiggs@meei.harvard.edu
FU NEI NIH HHS [P30 EY014104, R01 EY009847]
NR 58
TC 5
Z9 5
U1 1
U2 7
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 2157-1422
J9 CSH PERSPECT MED
JI Cold Spring Harb. Perspect. Med.
PD JUL
PY 2015
VL 5
IS 7
AR a017277
DI 10.1101/cshperspect.a017277
PG 10
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CQ1WU
UT WOS:000360391700001
PM 26134840
ER
PT J
AU Stengel, A
Karasawa, H
Tache, Y
AF Stengel, Andreas
Karasawa, Hiroshi
Tache, Yvette
TI The role of brain somatostatin receptor 2 in the regulation of feeding
and drinking behavior
SO HORMONES AND BEHAVIOR
LA English
DT Review
DE Body weight; Brain-gut axis; Food intake; Hypothalamus; Satiation;
Satiety; Somatostatin receptor; Stress; Water intake
ID CENTRAL-NERVOUS-SYSTEM; CORTICOTROPIN-RELEASING-FACTOR; STRESS-INDUCED
INHIBITION; FOOD-INTAKE; NEUROPEPTIDE-Y; GROWTH-HORMONE; RAT-BRAIN;
MESSENGER-RNA; IN-VITRO; OREXINS HYPOCRETINS
AB Somatostatin was discovered four decades ago as hypothalamic factor inhibiting growth hormone release. Subsequently, somatostatin was found to be widely distributed throughout the brain and to exert pleiotropic actions via interaction with five somatostatin receptors (sst(1-5)) that are also widely expressed throughout the brain. Interestingly, in contrast to the predominantly inhibitory actions of peripheral somatostatin, the activation of brain sst(2) signaling by intracerebroventricular injection of stable somatostatin agonists potently stimulates food intake and independently, drinking behavior in rodents. The orexigenic response involves downstream orexin-1, neuropeptide Y-1 and mu receptor signaling while the dipsogenic effect is mediated through the activation of the brain angiotensin 1 receptor. Brain sst2 activation is part of mechanisms underlying the stimulation of feeding and more prominently water intake in the dark phase and is able to counteract the anorexic response to visceral stressors. Published by Elsevier Inc.
C1 [Stengel, Andreas] Charite Univ Med Berlin, Charite Ctr Internal Med & Dermatol, Div Gen Internal & Psychosomat Med, Berlin, Germany.
[Tache, Yvette] Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Ctr Neurobiol Stress & Womens Hlth, Dept Med,Digest Dis Div, Los Angeles, CA 90024 USA.
[Tache, Yvette] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90073 USA.
RP Tache, Y (reprint author), VA GLA Healthcare Syst, Ctr Neurobiol Stress, Cure Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM ytache@mednet.ucla.edu
FU NIH Center [DK-41301]; German Research Foundation [STE 1765/3-1];
Charite University [UFF 88-226-168]
FX This work was supported by NIH Center Grant DK-41301 (Animal Core), VA
Research Career Scientist (Y.T.), German Research Foundation STE
1765/3-1 (A.S.) and Charite University Funding UFF 88-226-168 (A.S.).
NR 111
TC 4
Z9 4
U1 2
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0018-506X
EI 1095-6867
J9 HORM BEHAV
JI Horm. Behav.
PD JUL
PY 2015
VL 73
BP 15
EP 22
DI 10.1016/j.yhbeh.2015.05.009
PG 8
WC Behavioral Sciences; Endocrinology & Metabolism
SC Behavioral Sciences; Endocrinology & Metabolism
GA CP9YM
UT WOS:000360251800003
PM 26026616
ER
PT J
AU Kalim, S
Ortiz, G
Trottier, CA
Deferio, JJ
Karumanchi, SA
Thadhani, RI
Berg, AH
AF Kalim, Sahir
Ortiz, Guillermo
Trottier, Caitlin A.
Deferio, Joseph J.
Karumanchi, S. Ananth
Thadhani, Ravi I.
Berg, Anders H.
TI The Effects of Parenteral Amino Acid Therapy on Protein Carbamylation in
Maintenance Hemodialysis Patients
SO JOURNAL OF RENAL NUTRITION
LA English
DT Article
ID STAGE RENAL-DISEASE; KIDNEY-DISEASE; NUTRITION; MORTALITY; KINETICS;
OUTCOMES; FAILURE; UREMIA
AB Objective: Protein carbamylation is a urea-driven post-translational protein modification associated with mortality in dialysis patients. Free amino acids (AAs) are competitive inhibitors of protein carbamylation and animal studies suggest increasing AA concentrations reduces carbamylation burden. We hypothesized that AA therapy in maintenance hemodialysis patients would reduce carbamylation, carrying the potential to improve clinical outcomes.
Design: Prospective pilot clinical trial (NCT1612429).
Setting: The study was conducted from March 2013 to March 2014 in outpatient dialysis facilities in the Boston metropolitan area.
Subjects and Intervention: We enrolled 23 consecutively consenting hemodialysis subjects, infusing the first 12 individuals with 250 cc of AAs 3 times per week postdialysis over 8 weeks. The remaining 11 subjects served as controls.
Main Outcome Measure: Change in carbamylated albumin (C-Alb), a measure of total body carbamylation burden, between baseline and 8 weeks was the primary outcome.
Results: The treated and control groups had similar clinical characteristics and similar baseline C-Alb levels (mean +/- SE 9.5 +/- 2.4 and 9.3 +/- 1.3 mmol/mol, respectively; P = .61). The treated arm showed a significant reduction in C-Alb compared with controls at 4 weeks (8.4% reduction in the treated arm vs. 4.3% increase in controls; P = .03) and the effect was greater by 8 weeks (15% reduction in the treated vs. 1% decrease in controls; P = .01).
Conclusion: In this pilot study, AA therapy appeared safe and effective at reducing C-Alb levels in hemodialysis patients compared with no treatment. The impact of reduced protein carbamylation on clinical outcomes should be further investigated. (C) 2015 by the National Kidney Foundation, Inc. All rights reserved.
C1 [Kalim, Sahir; Ortiz, Guillermo; Trottier, Caitlin A.; Deferio, Joseph J.; Thadhani, Ravi I.] Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA.
[Kalim, Sahir; Ortiz, Guillermo; Trottier, Caitlin A.; Deferio, Joseph J.; Karumanchi, S. Ananth; Thadhani, Ravi I.; Berg, Anders H.] Harvard Univ, Sch Med, Boston, MA USA.
[Karumanchi, S. Ananth] Beth Israel Deaconess Med Ctr, Div Nephrol, Boston, MA 02215 USA.
[Karumanchi, S. Ananth] Beth Israel Deaconess Med Ctr, Dept Med, Vasc Biol Res Ctr, Boston, MA 02215 USA.
[Berg, Anders H.] Beth Israel Deaconess Med Ctr, Dept Pathol, Div Clin Chem, Boston, MA 02215 USA.
RP Kalim, S (reprint author), Massachusetts Gen Hosp, Div Nephrol, 165 Cambridge St,Suite 302, Boston, MA 02114 USA.
EM skalim@partners.org
FU National Kidney Foundation; NIH [KL2TR001100, K24 DK094872, K08
HL121801]
FX S.K. received support from the National Kidney Foundation Young
Investigator award and NIH award KL2TR001100; R.T. receives support from
NIH award K24 DK094872.; S.A.K. receives support from the Howard Hughes
Medical Institute; A.H.B. received support from NIH award K08 HL121801.
NR 26
TC 4
Z9 5
U1 1
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1051-2276
EI 1532-8503
J9 J RENAL NUTR
JI J. Renal Nutr.
PD JUL
PY 2015
VL 25
IS 4
BP 388
EP 392
DI 10.1053/j.jrn.2015.01.019
PG 5
WC Nutrition & Dietetics; Urology & Nephrology
SC Nutrition & Dietetics; Urology & Nephrology
GA CQ0KA
UT WOS:000360282800012
PM 25753604
ER
PT J
AU Delgado, C
AF Delgado, Cynthia
TI Characterization of Physical Activity and Sitting Time Among Patients on
Hemodialysis Using a New Physical Activity Instrument (vol 25, pg 25,
2015)
SO JOURNAL OF RENAL NUTRITION
LA English
DT Correction
C1 [Delgado, Cynthia] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA 94121 USA.
RP Delgado, C (reprint author), San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA 94121 USA.
NR 1
TC 0
Z9 0
U1 1
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1051-2276
EI 1532-8503
J9 J RENAL NUTR
JI J. Renal Nutr.
PD JUL
PY 2015
VL 25
IS 4
BP 397
EP 397
PG 1
WC Nutrition & Dietetics; Urology & Nephrology
SC Nutrition & Dietetics; Urology & Nephrology
GA CQ0KA
UT WOS:000360282800016
ER
PT J
AU Fitzgerald, A
Johnson, M
Hirsch, J
Rich, MA
Fidler, R
AF Fitzgerald, Abi
Johnson, Meshell
Hirsch, Jan
Rich, Mary-Ann
Fidler, Richard
TI Inconsistent shock advisories for monomorphic VT and Torsade de Pointes
- A prospective experimental study on AEDs and defibrillators
SO RESUSCITATION
LA English
DT Article
DE Defibrillation; Automated external defibrillator; AED; Ventricular
arrhythmias; Ventricular tachycardia; Torsade de Pointes
ID AMERICAN-HEART-ASSOCIATION; HOSPITAL CARDIAC-ARREST
AB Background: Cardiovascular disease and sudden cardiac arrest are the leading causes of death in the United States. Early defibrillation is key to successful resuscitation for patients who experience shockable rhythms during a cardiac arrest. It is therefore vital that the shock advisory of AEDs (automated external defibrillators) or defibrillators in AED mode be reliable and appropriate. The goal of this study was to better understand the performance of multiple lay-rescuer and hospital professional defibrillators in AED mode in their analysis of ventricular arrhythmias. The measurable objectives of this study sought to quantify:
1. No shock advisory for sinus rhythms at any rate.
2. Recognition and shock advisory for ventricular fibrillation (VF).
3. Recognition and shock advisory for monomorphic ventricular tachycardia (VT).
4. Recognition and shock advisory for Torsades de Pointes (TdP).
Methods: This is a prospective evaluation of two AEDs and four semi-automatic, hospital professional defibrillators. This study represents post-marketing evaluation of FDA approved devices. Each defibrillator was connected to multiple rhythm simulators and presented with simulated ECG waveforms 20 consecutive times at various rates when possible.
Results: All four defibrillators and both AEDs tested consistently recognized normal sinus rhythm (NSR) from all rhythm sources, and did not recommend a shock for NSR at any rate (from 80 to 220 bpm). All four defibrillators and both AEDs recognized VF from all rhythm sources tested and recommended a shock 100% of the time. Variations were found in the shock advisory rates among defibrillators when testing simulated VT heart rates at or below 150 bpm. One AED tested did not consistently advise a shock for monomorphic VT or TdP at any tested rate.
Conclusion: Lay-rescuer AEDs and professional hospital defibrillators tested in AED mode did not reliably recommend a shock for sustained monomorphic VT or TdP at certain rates, despite the fact that it is a critical component of the currently recommended treatment. These findings require further examination of the risk benefit analysis of shocking or not shocking rhythms such as TdP or pulseless VT. Published by Elsevier Ireland Ltd.
C1 [Fitzgerald, Abi; Johnson, Meshell; Hirsch, Jan; Rich, Mary-Ann; Fidler, Richard] San Francisco VA Med Ctr, Simulat Lab, San Francisco, CA 94121 USA.
RP Fitzgerald, A (reprint author), San Francisco VA Med Ctr, Simulat Lab, 4150 Clement St, San Francisco, CA 94121 USA.
EM abirankin@gmail.com
OI Rich, Mary-Ann/0000-0002-1660-9887
FU United States Department of Veterans Affairs, Biomedical Laboratory
Research and Development Program [IK2 BX001707]
FX Dr. M. Johnson is supported by Career Development Award #IK2 BX001707
from the United States Department of Veterans Affairs, Biomedical
Laboratory Research and Development Program. This material is the result
of work supported with resources and the use of facilities at the San
Francisco VA Medical Center.
NR 11
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0300-9572
J9 RESUSCITATION
JI Resuscitation
PD JUL
PY 2015
VL 92
BP 137
EP 140
DI 10.1016/j.resuscitation.2015.02.016
PG 4
WC Critical Care Medicine; Emergency Medicine
SC General & Internal Medicine; Emergency Medicine
GA CQ1JD
UT WOS:000360352500035
PM 25724355
ER
PT J
AU Welling, M
Chen, HH
Munoz, J
Musheev, MU
Kester, L
Junker, JP
Mischerikow, N
Arbab, M
Kuijk, E
Silberstein, L
Kharchenko, PV
Geens, M
Niehrs, C
van de Velde, H
van Oudenaarden, A
Heck, AJR
Geijsen, N
AF Welling, Maaike
Chen, Hsu-Hsin
Munoz, Javier
Musheev, Michael U.
Kester, Lennart
Junker, Jan Philipp
Mischerikow, Nikolai
Arbab, Mandana
Kuijk, Ewart
Silberstein, Lev
Kharchenko, Peter V.
Geens, Mieke
Niehrs, Christof
van de Velde, Hilde
van Oudenaarden, Alexander
Heck, Albert J. R.
Geijsen, Niels
TI DAZL regulates Tet1 translation in murine embryonic stem cells
SO EMBO REPORTS
LA English
DT Article
DE 2i conditions; Dazl; DNA hydroxymethylation; naive pluripotency; TET1
ID GROUND-STATE PLURIPOTENCY; PRIMORDIAL GERM-CELLS; DNA DEMETHYLATION;
SINGLE-CELL; NAIVE PLURIPOTENCY; SELF-RENEWAL; IN-VIVO;
5-METHYLCYTOSINE; DIFFERENTIATION; METHYLATION
AB Embryonic stem cell (ESC) cultures display a heterogeneous gene expression profile, ranging from a pristine naive pluripotent state to a primed epiblast state. Addition of inhibitors of GSK3 and MEK (so-called 2i conditions) pushes ESC cultures toward a more homogeneous naive pluripotent state, but the molecular underpinnings of this naive transition are not completely understood. Here, we demonstrate that DAZL, an RNA-binding protein known to play a key role in germ-cell development, marks a subpopulation of ESCs that is actively transitioning toward naive pluripotency. Moreover, DAZL plays an essential role in the active reprogramming of cytosine methylation. We demonstrate that DAZL associates with mRNA of Tet1, a catalyst of 5-hydroxylation of methyl-cytosine, and enhances Tet1 mRNA translation. Overexpression of DAZL in heterogeneous ESC cultures results in elevated TET1 protein levels as well as increased global hydroxymethylation. Conversely, null mutation of Dazl severely stunts 2i-mediated TET1 induction and hydroxymethylation. Our results provide insight into the regulation of the acquisition of naive pluripotency and demonstrate that DAZL enhances TET1-mediated cytosine hydroxymethylation in ESCs that are actively reprogramming to a pluripotent ground state.
C1 [Welling, Maaike; Kester, Lennart; Junker, Jan Philipp; Arbab, Mandana; Kuijk, Ewart; van Oudenaarden, Alexander; Geijsen, Niels] Hubrecht Inst KNAW, Utrecht, Netherlands.
[Welling, Maaike; Kester, Lennart; Junker, Jan Philipp; Arbab, Mandana; Kuijk, Ewart; van Oudenaarden, Alexander; Geijsen, Niels] Univ Med Ctr Utrecht, Utrecht, Netherlands.
[Chen, Hsu-Hsin; Silberstein, Lev] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
[Chen, Hsu-Hsin; Silberstein, Lev] Harvard Stem Cell Inst, Cambridge, MA USA.
[Munoz, Javier; Mischerikow, Nikolai; Heck, Albert J. R.] Univ Utrecht, Bijvoet Ctr Biomol Res, Biomol Mass Spectrometry & Prote, Utrecht, Netherlands.
[Munoz, Javier; Mischerikow, Nikolai; Heck, Albert J. R.] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Utrecht, Netherlands.
[Munoz, Javier; Mischerikow, Nikolai; Heck, Albert J. R.] Netherlands Prote Ctr, Utrecht, Netherlands.
[Musheev, Michael U.; Niehrs, Christof] Inst Mol Biol, Mainz, Germany.
[Kharchenko, Peter V.] Harvard Univ, Sch Med, Ctr Biomed Informat, Boston, MA USA.
[Geens, Mieke; van de Velde, Hilde] Vrije Univ Brussel, Res Grp Reprod & Genet, Brussels, Belgium.
[Niehrs, Christof] DKFZ ZMBH Alliance, Div Mol Embryol, Heidelberg, Germany.
[Geijsen, Niels] Univ Utrecht, Fac Vet Med, Dept Compan Anim, Utrecht, Netherlands.
RP Geijsen, N (reprint author), Hubrecht Inst KNAW, Utrecht, Netherlands.
EM n.geijsen@hubrecht.eu
RI Geens, Mieke/N-5576-2015; Munoz, Javier/I-4891-2012; Junker, Jan
Philipp/A-9754-2010
OI Geens, Mieke/0000-0003-2849-1406; Munoz, Javier/0000-0003-3288-3496;
Junker, Jan Philipp/0000-0002-2826-8290
FU Netherlands Proteomics Centre, embedded in the Netherlands Genomics
Initiative; Netherlands Organization for Scientific Research (NWO)
[91796323]; grant from the Netherlands Institute for Regenerative
Medicine
FX We thank Sarah Opitz for critically reading the manuscript, Nune
Schelling for technical support, and Lucas Kaaij for help with
statistical analysis. We also thank Laura Prickett-Rice and Kat
Folz-Donahue at the HSCI FACS facility at Mass. General Hospital; Stefan
van der Elst at the Hubrecht Institute FACS facility for help with cell
sorting; Anko de Graaf of the Hubrecht Institute imaging facility; and
David Egan of the Cell Screening facility at the UMCU. MW is supported
by a grant from the Netherlands Institute for Regenerative Medicine. JM
and AJRH acknowledge support by the Netherlands Proteomics Centre,
embedded in the Netherlands Genomics Initiative. This work was funded in
part by The Netherlands Organization for Scientific Research (NWO,
project 91796323).
NR 53
TC 4
Z9 4
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-221X
EI 1469-3178
J9 EMBO REP
JI EMBO Rep.
PD JUL
PY 2015
VL 16
IS 7
BP 791
EP 802
DI 10.15252/embr.201540538
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA CL9VI
UT WOS:000357325800006
PM 26077710
ER
PT J
AU Jain, RK
Fukumura, D
Duda, DG
AF Jain, Rakesh K.
Fukumura, Dai
Duda, Dan G.
TI Role of Tumor Microenvironment in Tumor Progression and Treatment
Response: A 30 Years' Journey
SO CANCER JOURNAL
LA English
DT Editorial Material
C1 [Jain, Rakesh K.; Fukumura, Dai; Duda, Dan G.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
RP Jain, RK (reprint author), Massachusetts Gen Hosp, Steele Labs, 100 Blossom St,Cox 7, Boston, MA 02114 USA.
EM jain@steele.mgh.harvard.edu
FU NCI NIH HHS [P01 CA080124, R01 CA115767, R01 CA159258]
NR 7
TC 2
Z9 2
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1528-9117
EI 1540-336X
J9 CANCER J
JI Cancer J.
PD JUL-AUG
PY 2015
VL 21
IS 4
BP 235
EP 236
DI 10.1097/PPO.0000000000000136
PG 2
WC Oncology
SC Oncology
GA CP3YY
UT WOS:000359820200001
PM 26222072
ER
PT J
AU Batista, A
Riedemann, L
Vardam, T
Jain, RK
AF Batista, Ana
Riedemann, Lars
Vardam, Trupti
Jain, Rakesh K.
TI Targeting the Tumor Microenvironment to Enhance Pediatric Brain Cancer
Treatment
SO CANCER JOURNAL
LA English
DT Review
DE Brain cancers; pediatric brain tumors; pediatric oncology; targeted
stromal therapies; tumor microenvironment
ID ENDOTHELIAL GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; BEVACIZUMAB PLUS
IRINOTECAN; HIGH-GRADE GLIOMAS; GLIOBLASTOMA PATIENTS; DENDRITIC CELLS;
T-CELLS; BLOOD PERFUSION; DOSE-ESCALATION; IMMUNE CELLS
AB Strategies targeting the microenvironment of pediatric brain cancers have the potential to improve the efficacy of standard and genome-based molecular therapeutics. These strategies also have the potential of helping resolve many of the challenges associated with developing new drugs and running clinical trials for relatively small pediatric brain tumor population. Disrupting vital paracrine and physical interactions between cancer cells and surrounding stroma, targeting and normalizing the abnormal tumor vasculature, and/or inducing antitumor immunity represent some of the most promising approaches. A comprehensive characterization of the pediatric brain tumor microenvironment's composition and function and its modulation by chemoradiation and molecularly targeted therapies is warranted to develop and effectively implement these approaches.
C1 Massachusetts Gen Hosp, Edwin L Steele Labs, Dept Radiat Oncol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Jain, RK (reprint author), Massachusetts Gen Hosp, Edwin L Steele Labs, 100 Blossom St,Cox 7, Boston, MA 02114 USA.
EM jain@steele.mgh.harvard.edu
RI Riedemann, Lars/J-5725-2014
OI Riedemann, Lars/0000-0002-9510-1845
FU National Cancer Institute [P01 CA080124, R01 CA163815]; National
Foundation for Cancer Research; Alex's Lemonade Stand Foundation
FX The findings presented in this review were supported with grants from
the National Cancer Institute (P01 CA080124, R01 CA163815), National
Foundation for Cancer Research, and Alex's Lemonade Stand Foundation.
NR 90
TC 1
Z9 1
U1 4
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1528-9117
EI 1540-336X
J9 CANCER J
JI Cancer J.
PD JUL-AUG
PY 2015
VL 21
IS 4
BP 307
EP 313
DI 10.1097/PPO.0000000000000125
PG 7
WC Oncology
SC Oncology
GA CP3YY
UT WOS:000359820200012
PM 26222083
ER
PT J
AU Gerstner, ER
Emblem, KE
Sorensen, GA
AF Gerstner, Elizabeth R.
Emblem, Kyrre E.
Sorensen, Gregory A.
TI Vascular Magnetic Resonance Imaging in Brain Tumors During
Antiangiogenic Therapy-Are We There Yet?
SO CANCER JOURNAL
LA English
DT Review
DE Glioblastoma (GBM); MRI; tumor vascular
ID CEREBRAL BLOOD-VOLUME; NEWLY-DIAGNOSED GLIOBLASTOMA; CONTRAST-ENHANCED
MRI; HIGH-GRADE GLIOMA; CLINICAL-TRIALS; ANTIVASCULAR THERAPIES;
RESPONSE ASSESSMENT; RADIATION NECROSIS; MALIGNANT GLIOMAS; ANGIOGENESIS
AB Abnormal tumor vasculature is a potent mediator of treatment resistance because it results in heterogeneous perfusion, hypoxia, increased interstitial fluid pressure, and incomplete penetration of cytotoxic chemotherapies. Targeting this abnormal tumor vasculature is a promising therapeutic strategy, but results with antiangiogenic drugs in brain cancer have been mixed. Vasculature's response to treatment is a dynamic physiological process that can change rapidly throughout treatment, so it requires noninvasive techniques to serially monitor these changes in order to improve outcome. We review the role of vascular magnetic resonance imaging to measure tumor response to treatment and highlight opportunities and future avenues for expanding these promising techniques.
C1 [Gerstner, Elizabeth R.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Gerstner, Elizabeth R.] Harvard Univ, Sch Med, Boston, MA USA.
[Emblem, Kyrre E.] Oslo Univ Hosp, Intervent Ctr, Oslo, Norway.
[Sorensen, Gregory A.] Siemens Healthcare, Malvern, PA USA.
RP Gerstner, ER (reprint author), Massachusetts Gen Hosp, Stephen E & Catherine Pappas Ctr Neurooncol, Yawkey 9E,55 Fruit St, Boston, MA 02114 USA.
EM egerstner@mgh.harvard.edu
RI Emblem, Kyrre/H-6691-2012
OI Emblem, Kyrre/0000-0002-6580-9519
FU South Eastern Norway Regional Health Authority [2013069]
FX Grant was provided by South Eastern Norway Regional Health Authority
(grant 2013069) to K.E.E.
NR 62
TC 0
Z9 1
U1 2
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1528-9117
EI 1540-336X
J9 CANCER J
JI Cancer J.
PD JUL-AUG
PY 2015
VL 21
IS 4
BP 337
EP 342
DI 10.1097/PPO.0000000000000128
PG 6
WC Oncology
SC Oncology
GA CP3YY
UT WOS:000359820200016
PM 26222087
ER
PT J
AU Paterson, NE
Darby, WC
Sandhu, PS
AF Paterson, Neil E.
Darby, W. Connor
Sandhu, Preetpal S.
TI N,N-Dimethyltryptamine-Induced Psychosis
SO CLINICAL NEUROPHARMACOLOGY
LA English
DT Review
DE DMT; Cannabis; hallucinogen; substance-induced psychosis; quetiapine
ID PHARMACOKINETICS; AYAHUASCA; HUMANS; ABUSE
AB Background: N,N-dimethyltryptamine (DMT) is a 5-hydroxytryptamine 2A and 1A receptor agonist that exhibits potent psychoactive properties in humans. Recreational use of this drug has increased precipitously and is likely to result in an increase in patients presenting with substance-induced psychoses. The present case provides an early example of substance-induced psychosis attributable to repeated use of DMT.
Case: A 42-year-old white man, with no significant past psychiatric history, was brought to the emergency department by the police and was found to exhibit disinhibited behavior, elevated affect, disorganized thought process, and delusions of reference. Laboratory studies revealed elevated creatinine kinase level indicative of rhabdomyolysis. The patient endorsed recent and repeated use of DMT, as well as long-term Cannabis (marijuana) use. Over the course of the next 3 weeks, the patient was successfully treated with quetiapine for psychosis, divalproex sodium (Depakote) for impulsivity, gabapentin for anxiety, and hydroxyzine for sleep, which resulted in the resolution of his symptoms and development of reasonable insight and judgment. Approximately 6 months after discharge, the patient remained treatment compliant, as well as drug and symptom free.
Conclusions: This case report illustrates an important example of substance-induced psychosis that resolved with antipsychotic treatment in a 42-year-old white man with no past psychiatric history likely attributable to the use of DMT. Given the increasing use of this substance, the emergency department, primary care, and inpatient services are likely to see a significant increase in similar cases.
C1 [Paterson, Neil E.; Darby, W. Connor] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Psychiat Residency Training Program, Los Angeles, CA USA.
[Sandhu, Preetpal S.] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA.
RP Sandhu, PS (reprint author), W Los Angeles Vet Affairs Med Ctr, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM Preetpal.Sandhu@va.gov
NR 17
TC 0
Z9 0
U1 2
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0362-5664
EI 1537-162X
J9 CLIN NEUROPHARMACOL
JI Clin. Neuropharmacol.
PD JUL-AUG
PY 2015
VL 38
IS 4
BP 141
EP 143
DI 10.1097/WNF.0000000000000078
PG 3
WC Clinical Neurology; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA CP3JJ
UT WOS:000359774900005
PM 26166234
ER
PT J
AU Arnason, JE
Brown, JR
AF Arnason, Jon E.
Brown, Jennifer R.
TI Obinutuzumab: its use in the management of chronic lymphocytic leukemia
SO EXPERT OPINION ON ORPHAN DRUGS
LA English
DT Article
DE CD20; chronic lymphocytic leukemia; obinutuzumab; rituximab
ID B-CELL MALIGNANCIES; PLUS CHLORAMBUCIL; RITUXIMAB; CYTOTOXICITY;
OFATUMUMAB; GA101; FLUDARABINE; ANTIBODY; THERAPY; CHEMOIMMUNOTHERAPY
AB Introduction: Chronic lymphocytic leukemia (CLL) is the most common leukemia. Over the last 40 years, the evolution of chemotherapeutic options and the addition of the anti-CD20 antibody rituximab have improved response rates significantly. Obinutuzumab, a next generation CD20 antibody, continues that evolution.
Areas covered: In this review, we discuss the pre-clinical and recent clinical experiences with obintuzumab and discuss its potential future role in the management of CLL as well as the interest in combining this next generation CD20 antibody with B-cell receptor pathway inhibitors. Obinutuzumab has a number of modifications that increase its efficacy relative to rituximab resulting in improved antibody-dependent cell-mediated cytotoxicity and direct cell death. These biological attributes have translated into improved clinical responses. The clinical superiority of obinutuzumab relative to rituximab is best demonstrated in the CLL11 trial. In this randomized Phase III trial, for patients requiring upfront CLL treatment, the combination of obinutuzumab and chlorambucil was found to result in improved response and progression-free survival relative to the combination of rituximab and chlorambucil.
Expert opinion: Obinutuzumab has clear pre-clinical and clinical superiority to rituximab and will be a central agent in the evolving management of CLL.
C1 [Arnason, Jon E.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Brown, Jennifer R.] Harvard Univ, Sch Med, Dana Farber Canc Inst, CLL Ctr, Boston, MA 02115 USA.
RP Brown, JR (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, CLL Ctr, 44 Binney St, Boston, MA 02115 USA.
EM Jennifer_Brown@dfci.harvard.edu
NR 45
TC 0
Z9 0
U1 1
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2167-8707
J9 EXPERT OPIN ORPHAN D
JI Exp. Opin. Orphan Drugs
PD JUL
PY 2015
VL 3
IS 7
BP 843
EP 853
DI 10.1517/21678707.2015.1045488
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CP4MW
UT WOS:000359857300009
ER
PT J
AU Menendez, ME
Ring, D
Heng, M
AF Menendez, Mariano E.
Ring, David
Heng, Marilyn
TI Proximal humerus fracture with injury to the axillary artery: A
population-based study
SO INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
LA English
DT Article
DE Proximal humerus fracture; Axillary artery injury; Vascular injury;
Epidemiology; Prevalence; Outcomes
ID UNITED-STATES; VASCULAR TRAUMA; OUTCOMES; NECK; EPIDEMIOLOGY;
MANAGEMENT; THROMBOSIS; SAMPLE; CARE
AB Background: The available evidence regarding axillary artery injury as a result of proximal humerus fracture consists of individual case reports or small series. This study used nationally representative data to determine the prevalence and predictors of axillary artery injury secondary to proximal humerus fracture, and to characterise its influence on inpatient mortality, length of stay, cost and discharge disposition.
Methods: An estimated 388,676 inpatients with a proximal humerus fracture were identified in the Nationwide Inpatient Sample between 2002 and 2011, 331 with concomitant axillary artery injury (8.5 per 10,000). Multivariable regression modelling was used to identify independent predictors of axillary artery injury and to assess its relationship with inpatient outcomes.
Results: Factors associated with axillary artery injury were male sex (odds ratio (OR): 1.6, 95% confidence interval (CI): 1.2-2.0), atherosclerosis (OR: 3.7, 95% CI: 2.5-5.4), open fracture (OR: 2.9, 95% CI: 1.9-4.5) and the presence of concomitant injuries, including brachial plexus injury (OR: 109, 95% CI: 79-151), shoulder dislocation (OR: 3.4, 95% CI: 2.0-5.8), scapula fracture (OR: 3.4, 95% CI: 2.1-5.4) and rib fracture (OR: 2.5, 95% CI: 1.6-4.0). Axillary artery injury was associated with increased length of stay, costs and mortality, but it did not affect discharge disposition.
Conclusion: Our study provides important baseline information regarding the epidemiology of axillary artery injury secondary to proximal humerus fracture. Prompt identification of at-risk patients upon admission might lead to improved diagnosis and management of this vascular injury. Level of Evidence: Prognostic level II. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Menendez, Mariano E.; Ring, David; Heng, Marilyn] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthopaed Surg, Boston, MA USA.
RP Ring, D (reprint author), Massachusetts Gen Hosp, Yawkey Ctr, Orthopaed Hand & Upper Extrem Serv, Suite 2100,55 Fruit St, Boston, MA 02114 USA.
EM dring@partners.org
OI Ring, David/0000-0002-6506-4879
NR 41
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020-1383
EI 1879-0267
J9 INJURY
JI Injury-Int. J. Care Inj.
PD JUL
PY 2015
VL 46
IS 7
BP 1367
EP 1371
DI 10.1016/j.injury.2015.04.026
PG 5
WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery
SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery
GA CP8EK
UT WOS:000360124800031
PM 25986664
ER
PT J
AU Chaus, GW
Heng, M
Smith, RM
AF Chaus, George W.
Heng, Marilyn
Smith, Raymond M.
TI Occult internal iliac arterial injury identified during open reduction
internal fixation of an acetabular fracture: A report of two cases
SO INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
LA English
DT Article
DE Acetabular fracture; Vascular injury; Internal iliac artery
ID PELVIC RING DISRUPTIONS; VASCULAR INJURY; COMPLICATIONS; THROMBOSIS;
PATTERN; TRAUMA
AB We present two cases of occult internal iliac arterial injury identified during operative reduction of a widely displaced posterior column posterior wall acetabular fracture. This complication was not recognised until reduction of the column fracture. There were no preoperative signs or symptoms indicative of a vascular injury. These cases emphasise the heightened awareness one must have when treating widely displaced posterior column fractures of the acetabulum, especially those fractures with extension into the greater sciatic notch, as previously formed clot can become dislodged and hemostasis lost. We also present management options when this complication occurs. We believe any surgeon treating acetabular fractures should be aware of this serious and potentially fatal complication. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Chaus, George W.; Heng, Marilyn; Smith, Raymond M.] Harvard Univ, Dept Orthopaed, Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Chaus, GW (reprint author), Harvard Univ, Dept Orthopaed, Massachusetts Gen Hosp, Yawkey Ctr, Suite 3C, Boston, MA 02114 USA.
EM George.Chaus@me.com
NR 20
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020-1383
EI 1879-0267
J9 INJURY
JI Injury-Int. J. Care Inj.
PD JUL
PY 2015
VL 46
IS 7
BP 1417
EP 1422
DI 10.1016/j.injury.2015.04.030
PG 6
WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery
SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery
GA CP8EK
UT WOS:000360124800042
PM 25986669
ER
PT J
AU Gunduz, A
Morita, H
Rossi, PJ
Allen, WL
Alterman, RL
Bronte-Stewart, H
Butson, CR
Charles, D
Deckers, S
de Hemptinne, C
DeLong, M
Dougherty, D
Ellrich, J
Foote, KD
Giordano, J
Goodman, W
Greenberg, BD
Greene, D
Gross, R
Judy, JW
Karst, E
Kent, A
Kopell, B
Lang, A
Lozano, A
Lungu, C
Lyon, KE
Machado, A
Martens, H
McIntyre, C
Min, HK
Neimat, J
Ostrem, J
Pannu, S
Ponce, F
Pouratian, N
Reymers, D
Schrock, L
Sheth, S
Shih, L
Stanslaski, S
Steinke, GK
Stypulkowski, P
Troster, AI
Verhagen, L
Walker, H
Okun, MS
AF Gunduz, Aysegul
Morita, Hokuto
Rossi, P. Justin
Allen, William L.
Alterman, Ron L.
Bronte-Stewart, Helen
Butson, Christopher R.
Charles, David
Deckers, Sjaak
de Hemptinne, Coralie
DeLong, Mahlon
Dougherty, Darin
Ellrich, Jens
Foote, Kelly D.
Giordano, James
Goodman, Wayne
Greenberg, Benjamin D.
Greene, David
Gross, Robert
Judy, Jack W.
Karst, Edward
Kent, Alexander
Kopell, Brian
Lang, Anthony
Lozano, Andres
Lungu, Codrin
Lyon, Kelly E.
Machado, Andre
Martens, Hubert
McIntyre, Cameron
Min, Hoon-Ki
Neimat, Joseph
Ostrem, Jill
Pannu, Sat
Ponce, Francisco
Pouratian, Nader
Reymers, Donnie
Schrock, Lauren
Sheth, Sameer
Shih, Ludy
Stanslaski, Scott
Steinke, G. Karl
Stypulkowski, Paul
Troester, Alexander I.
Verhagen, Leo
Walker, Harrison
Okun, Michael S.
TI Proceedings of the Second Annual Deep Brain Stimulation Think Tank:
What's in the Pipeline
SO INTERNATIONAL JOURNAL OF NEUROSCIENCE
LA English
DT Review
DE deep brain stimulation; Movement disorders; Neuroethics;
Electrophysiology; neurotechnology
ID HIGH-FREQUENCY STIMULATION; HUMAN SUBTHALAMIC NUCLEUS; SHORT-LATENCY
ACTIVATION; PRIMARY MOTOR CORTEX; PARKINSONS-DISEASE; NONMOTOR SYMPTOMS;
GLOBUS-PALLIDUS; THALAMIC SEGMENTATION; CLINICAL ARTICLE; BOLD
ACTIVATION
AB The proceedings of the 2nd Annual Deep Brain Stimulation Think Tank summarize the most contemporary clinical, electrophysiological, and computational work on DBS for the treatment of neurological and neuropsychiatric disease and represent the insights of a unique multidisciplinary ensemble of expert neurologists, neurosurgeons, neuropsychologists, psychiatrists, scientists, engineers and members of industry. Presentations and discussions covered a broad range of topics, including advocacy for DBS, improving clinical outcomes, innovations in computational models of DBS, understanding of the neurophysiology of Parkinson's disease (PD) and Tourette syndrome (TS) and evolving sensor and device technologies.
C1 [Gunduz, Aysegul; Morita, Hokuto; Rossi, P. Justin; Allen, William L.; Foote, Kelly D.; Judy, Jack W.; Okun, Michael S.] Univ Florida, Gainesville, FL USA.
[Alterman, Ron L.; Shih, Ludy] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Bronte-Stewart, Helen] Stanford Univ, Stanford, CA 94305 USA.
[Butson, Christopher R.; Schrock, Lauren] Univ Utah, Salt Lake City, UT USA.
[Charles, David; Neimat, Joseph] Vanderbilt Univ, Nashville, TN 37235 USA.
[Deckers, Sjaak; Ellrich, Jens; Martens, Hubert] Sapiens Steering Brain Stimulat, Eindhoven, Netherlands.
[de Hemptinne, Coralie; Ostrem, Jill] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[DeLong, Mahlon; Gross, Robert] Emory Univ, Atlanta, GA 30322 USA.
[Dougherty, Darin] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Giordano, James] Georgetown Univ, Med Ctr, Washington, DC 20007 USA.
[Goodman, Wayne; Kopell, Brian] Mt Sinai Hosp, New York, NY 10029 USA.
[Greenberg, Benjamin D.] Brown Univ, Providence, RI 02912 USA.
[Greene, David] Neuropace Univ, Mountain View, CA USA.
[Karst, Edward] St Jude Med, Sylmar, CA USA.
[Kent, Alexander] St Jude Med, Sunnyvale, CA USA.
[Lang, Anthony; Lozano, Andres] Univ Toronto, Toronto, ON, Canada.
[Lungu, Codrin] NIH, Bethesda, MD 20892 USA.
[Lyon, Kelly E.] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA.
[Machado, Andre] Cleveland Clin, Cleveland, OH 44106 USA.
[McIntyre, Cameron] Case Western Reserve Univ, Cleveland, OH 44106 USA.
[Min, Hoon-Ki] Mayo Clin, Rochester, MN USA.
[Pannu, Sat] Lawrence Livermore Natl Lab, Livermore, CA USA.
[Ponce, Francisco; Troester, Alexander I.] Barrow Neurol Inst, Phoenix, AZ 85013 USA.
[Pouratian, Nader] Univ Calif Los Angeles, Los Angeles, CA USA.
[Reymers, Donnie] Funct Neuromodulat Ltd, Toronto, ON, Canada.
[Sheth, Sameer] Columbia Univ, New York, NY USA.
[Stanslaski, Scott; Stypulkowski, Paul] Medtronic, Minneapolis, MN USA.
[Steinke, G. Karl] Boston Sci Neuromodulat, Valencia, CA USA.
[Verhagen, Leo] Rush Univ, Med Ctr, Chicago, IL 60612 USA.
[Walker, Harrison] Univ Alabama Birmingham, Birmingham, AL USA.
RP Okun, MS (reprint author), Univ Florida, Dept Neurol, Gainesville, FL 32611 USA.
EM okun@neurology.ufl.edu
RI Gunduz, Aysegul/Q-2336-2016;
OI Okun, Michael/0000-0002-6247-9358
FU Medtronic, Inc.; Allergan; Ipsen; Merz; Medtronic; Alliance for Patient
Access for education or consulting services; Cyberonics; Eli Lilly;
Roche; St. Jude; Boston Scientific; Neuropace; Brain Canada; Canadian
Institutes of Health Research; Edmond J Safra Philanthropic Foundation;
Michael J. Fox Foundation; Ontario Brain Institute; National Parkinson
Foundation; Parkinson Society Canada; Tourette Syndrome Association; W.
Garfield Weston Foundation; MRI Interventions; St Jude Medical; Glaxo
Smith Kone; NIH; NPF; Parkinson Alliance; Smallwood Foundation;
Bachmann-Strauss Foundation; UP Foundation
FX AG: Grant support from Medtronic, Inc.; HK: None; PJR: None; WLA: None;
RLA: Consultant for Medtronic, Inc.; HB-S: None; CRB: Consultant for St
Jude Medical, Boston Scientific; IP related to DBS; DC: Vanderbilt
receives income from grants or contracts from Allergan, Ipsen, Merz and
Medtronic for research led by DC; DC receives income from Allergan,
Ipsen, Medtronic and, the Alliance for Patient Access for education or
consulting services; SD: Employee and shareholder of Sapiens Steering
Brain Stimulation GmbH (Medtronic Eindhoven Design Center); CDH: None;
MDL: None; DD: Grant support from Medtronic, Cyberonics, Eli Lilly,
Roche, Honoraria from Medtronic, Insys, Johnson & Johnson; JE: Chief
Medical Officer at Sapiens Steering Brain Stimulation GmbH; KDF: Grant
support from Medtronic, St. Jude, Boston Scientific, Neuropace;
Consultant for Medtronic, Neuropace; JG: None; WG: None; BDG: None; DG:
Employee of Neuropace; RG: None; JJ: None; EK. Employee of St. Jude
Medical; AK: Employee of St. Jude Medical; BK. Consultant for Medtronic,
St Jude Neuromodulation, MRI Interventions; ALang: Consultant for
Abbvie, Allon Therapeutics, Avanir Pharmaceuticals, Biogen Idec,
Boerhinger-Ingelheim, Ceregene, Lilly, Medtronic, Merck, Novartis,
NeuroPhage Pharmaceuticals, Teva, UCB; Honoraria from Medtronic, Teva,
UCB, AbbVie; Grant support from Brain Canada, Canadian Institutes of
Health Research, Edmond J Safra Philanthropic Foundation, Michael J. Fox
Foundation, the Ontario Brain Institute, National Parkinson Foundation,
Parkinson Society Canada, Tourette Syndrome Association, W. Garfield
Weston Foundation; Publishing royalties from Saunders, Wiley-Blackwell,
Johns Hopkins Press, Cambridge University Press; ALozano: Consultant for
Medtronic, St Jude and Boston Scientific, Co-Founder of Functional
Neuromodulation; CL: None; KL: Consultant for Medtronic, St. Jude
Medical; AM: IP in Enspire, ATI, Cardionomics, Grant support from
Medtronic, Inc., Consultant for Functional Neuromodulation, Spinal
Modulation; HM: Employee and shareholder of Sapiens Steering Brain
Stimulation GmbH (Medtronic Eindhoven Design Center); CM: IP in Boston
Scientific Neuromodulation; Consultant for Boston Scientific
Neuromodulation; Shareholder in Autonomic Technologies, Inc.,
Cardionomics, Inc., Neuros Medical, Inc., Surgical Information Sciences,
Inc.; BM: None; HKM: None; JN: Grant support from Medtronic, Inc.;
Consultant for Medtronic, Inc., Montens Inc.; JO: Grant support from
Boston Scientific, MRI Interventions, St Jude Medical, Medtronic; SP:
None; FP: Consultant for Medtronic, Inc; NP: None; DR: Employee of
Neuromodulation, Inc; LSchrock: Site PI for the Boston Scientific
INTREPID DBS trial; SSheth: None; LShih: None; SStanslanski: Employee of
Medtronic, Inc.; GKS: Employee of Boston Scientific Neuromodulation; PS:
Employee of Medtronic, Inc.; AT: Consultant for St Jude Medical, Boston
Scientific, Theravance, Teva; Grant support from Glaxo Smith Kone,
Speaker for Medtronic; Royalties from Oxford University Press; LV: None;
HW: None; MSO: Consultant for National Parkinson Foundation; Grant
support from NIH, NPF, Michael J. Fox Foundation, Parkinson Alliance,
Smallwood Foundation, Bachmann-Strauss Foundation, Tourette Syndrome
Association, UP Foundation.
NR 79
TC 5
Z9 5
U1 2
U2 19
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0020-7454
EI 1563-5279
J9 INT J NEUROSCI
JI Int. J. Neurosci.
PD JUL
PY 2015
VL 125
IS 7
BP 475
EP 485
DI 10.3109/00207454.2014.999268
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA CP4WV
UT WOS:000359884200001
PM 25526555
ER
PT J
AU Mughal, TI
Barbui, T
Abdel-Wahab, O
Kralovics, R
Jamieson, C
Kvasnicka, HM
Mullaly, A
Rampal, R
Mesa, R
Kiladjian, JJ
Deininger, M
Prchal, J
Hehlmann, R
Saglio, G
Van Etten, RA
AF Mughal, Tariq I.
Barbui, Tiziano
Abdel-Wahab, Omar
Kralovics, Robert
Jamieson, Catriona
Kvasnicka, Hans-Michael
Mullaly, Ann
Rampal, Raajit
Mesa, Ruben
Kiladjian, Jean-Jacques
Deininger, Michael
Prchal, Josef
Hehlmann, Ruediger
Saglio, Giuseppe
Van Etten, Richard A.
TI Novel insights into the biology and treatment of chronic
myeloproliferative neoplasms
SO LEUKEMIA & LYMPHOMA
LA English
DT Review
DE Myeloid leukemias and dysplasias; molecular genetics; signaling
therapies; prognostication; myeloproliferative disorders
ID CHRONIC MYELOID-LEUKEMIA; WORLD-HEALTH-ORGANIZATION; DEEP MOLECULAR
RESPONSE; JANUS KINASE 2; POLYCYTHEMIA-VERA; JAK2 INHIBITOR; ESSENTIAL
THROMBOCYTHEMIA; AVAILABLE THERAPY; CONTROLLED-TRIAL; TYROSINE KINASE
AB Myeloproliferative neoplasms (MPNs) are clonal disorders of hematopoiesis characterized by a high frequency of genetic alterations, and include chronic myeloid leukemia (CML) and the BCR-ABL1-negative MPNs. Herein we summarize recent advances and controversies in our understanding of the biology and therapy of these disorders, as discussed at the 8th post-American Society of Hematology CML-MPN workshop. The principal areas addressed include the breakthrough discovery of CALR mutations in patients with JAK2/MPL wild type MPN, candidate therapies based on novel genetic findings in leukemic transformation and new therapeutic targets in MPNs, and an appraisal of bone marrow histopathology in MPNs with a focus on the potential new clinical entity of "masked" polycythemia vera. An update on clinical trials of Janus kinase (JAK) inhibitors is presented as well as current understanding regarding the definitions and mechanisms of resistance to JAK inhibitors, and updated information on the safety and efficacy of discontinuation of tyrosine kinase inhibitors in patients with CML.
C1 [Mughal, Tariq I.] Tufts Univ, Med Ctr, Boston, MA 02111 USA.
[Barbui, Tiziano] Papa Giovani XXIII Hosp & Res Ctr, Bergamo, Italy.
[Abdel-Wahab, Omar; Rampal, Raajit] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Kralovics, Robert] CeMM Res Ctr Mol Med, Vienna, Austria.
[Jamieson, Catriona] Univ San Diego, La Jolla, CA USA.
[Kvasnicka, Hans-Michael] Goethe Univ Frankfurt, Senckenberg Inst Pathol, D-60054 Frankfurt, Germany.
[Mullaly, Ann] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mesa, Ruben] Mayo Clin, Ctr Canc, Scottsdale, AZ USA.
[Kiladjian, Jean-Jacques] Hop St Louis, Paris, France.
[Deininger, Michael; Prchal, Josef] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
[Hehlmann, Ruediger] Heidelberg Univ, Mannheim, Germany.
[Saglio, Giuseppe] Orbassano Univ Hosp, Turin, Italy.
[Van Etten, Richard A.] Univ Calif Irvine, Irvine, CA USA.
RP Mughal, TI (reprint author), Tufts Univ, Med Ctr, Div Hematol & Oncol, Boston, MA 02111 USA.
EM tmughal911@hotmail.com
RI Kvasnicka, Hans Michael/E-7993-2011;
OI Kvasnicka, Hans Michael/0000-0002-3081-1395; Kralovics,
Robert/0000-0002-6997-8539
FU NCI NIH HHS [P01 CA108671, R01 CA090576, R01 CA178397]
NR 61
TC 3
Z9 3
U1 2
U2 7
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1042-8194
EI 1029-2403
J9 LEUKEMIA LYMPHOMA
JI Leuk. Lymphoma
PD JUL
PY 2015
VL 56
IS 7
BP 1938
EP 1948
DI 10.3109/10428194.2014.974594
PG 11
WC Oncology; Hematology
SC Oncology; Hematology
GA CP4YO
UT WOS:000359888700007
PM 25330439
ER
PT J
AU Petsalaki, E
Helbig, AO
Gopal, A
Pasculescu, A
Roth, FP
Pawson, T
AF Petsalaki, Evangelia
Helbig, Andreas O.
Gopal, Anjali
Pasculescu, Adrian
Roth, Frederick P.
Pawson, Tony
TI SELPHI: correlation-based identification of kinase-associated networks
from global phospho-proteomics data sets
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID PHOSPHORYLATION NETWORKS; SYSTEMATIC DISCOVERY; ACQUIRED-RESISTANCE;
SIGNALING NETWORKS; PHOSPHOPROTEOMICS; SOFTWARE; RESOURCE; GENE;
GEFITINIB; ERLOTINIB
AB While phospho-proteomics studies have shed light on the dynamics of cellular signaling, they mainly describe global effects and rarely explore mechanistic details, such as kinase/substrate relationships. Tools and databases, such as NetworKIN and PhosphoSitePlus, provide valuable regulatory details on signaling networks but rely on prior knowledge. They therefore provide limited information on less studied kinases and fewer unexpected relationships given that better studied signaling events can mask condition-or cell-specific 'network wiring'. SELPHI is a web-based tool providing in-depth analysis of phospho-proteomics data that is intuitive and accessible to non-bioinformatics experts. It uses correlation analysis of phospho-sites to extract kinase/phosphatase and phospho-peptide associations, and highlights the potential flow of signaling in the system under study. We illustrate SELPHI via analysis of phospho-proteomics data acquired in the presence of erlotinib-a tyrosine kinase inhibitor (TKI)-in cancer cells expressing TKIresistant and -sensitive variants of the Epidermal Growth Factor Receptor. In this data set, SELPHI revealed information overlooked by the reporting study, including the known role of MET and EPHA2 kinases in conferring resistance to erlotinib in TKI sensitive strains. SELPHI can significantly enhance the analysis of phospho-proteomics data contributing to improved understanding of sample-specific signaling networks. SELPHI is freely available via http://llama.mshri.on.ca/SELPHI.
C1 [Petsalaki, Evangelia; Helbig, Andreas O.; Gopal, Anjali; Pasculescu, Adrian; Roth, Frederick P.; Pawson, Tony] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X8, Canada.
[Helbig, Andreas O.] Hosp Sick Children, Program Dev & Stem Cell Biol, Toronto, ON M5G 1X5, Canada.
[Roth, Frederick P.] Univ Toronto, Donnelly Ctr, Toronto, ON M5G 1X8, Canada.
[Roth, Frederick P.] Univ Toronto, Dept Mol Genet, Toronto, ON M5G 1X8, Canada.
[Roth, Frederick P.] Univ Toronto, Dept Comp Sci, Toronto, ON M5G 1X8, Canada.
[Roth, Frederick P.] Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02215 USA.
[Roth, Frederick P.] Canadian Inst Adv Res, Toronto, ON M5G 1Z8, Canada.
RP Roth, FP (reprint author), Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X8, Canada.
EM petsalakis@lunenfeld.ca; fritz.roth@utoronto.ca
RI Pawson, Tony/E-4578-2013; Roth, Frederick/H-6308-2011;
OI Petsalaki, Evangelia/0000-0002-8294-2995; Roth,
Frederick/0000-0002-6628-649X
FU Ontario Research Fund Research Excellence [RE-05-029, GL2-01-025,
ORF-RE-037]; Krembil Foundation; NIH/NHGRI [HG001715, HG004233]; Canada
Excellence Research Chairs Program; Avon Foundation
FX Ontario Research Fund Research Excellence [RE-05-029, GL2-01-025 to T.P.
ORF-RE-037 to T.P. and F.P.R.]; Krembil Foundation; NIH/NHGRI [HG001715,
HG004233]; Canada Excellence Research Chairs Program; Avon Foundation.
Canadian Institutes of Health Research [MOP-6849 to T.P.]. Funding for
open access charge: Canada Excellence Research Chairs Program.
NR 41
TC 1
Z9 1
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD JUL 1
PY 2015
VL 43
IS W1
BP W276
EP W282
DI 10.1093/nar/gkv459
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA CP3IP
UT WOS:000359772700043
PM 25948583
ER
PT J
AU Sadreyev, IR
Ji, F
Cohen, E
Ruvkun, G
Tabach, Y
AF Sadreyev, Ilyas R.
Ji, Fei
Cohen, Emiliano
Ruvkun, Gary
Tabach, Yuval
TI PhyloGene server for identification and visualization of co-evolving
proteins using normalized phylogenetic profiles
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID PREDICTION; CILIA
AB Proteins that function in the same pathways, protein complexes or the same environmental conditions can show similar patterns of sequence conservation across phylogenetic clades. In species that no longer require a specific protein complex or pathway, these proteins, as a group, tend to be lost or diverge. Analysis of the similarity in patterns of sequence conservation across a large set of eukaryotes can predict functional associations between different proteins, identify new pathway members and reveal the function of previously uncharacterized proteins. We used normalized phylogenetic profiling to predict protein function and identify new pathway members and disease genes. The phylogenetic profiles of tens of thousands conserved proteins in the human, mouse, Caenorhabditis elegans and Drosophila genomes can be queried on our new web server, PhyloGene. PhyloGene provides intuitive and user-friendly platform to query the patterns of conservation across 86 animal, fungal, plant and protist genomes. A protein query can be submitted either by selecting the name from whole-genome protein sets of the intensively studied species or by entering a protein sequence. The graphic output shows the profile of sequence conservation for the query and the most similar phylogenetic profiles for the proteins in the genome of choice. The user can also download this output in numerical form.
C1 [Sadreyev, Ilyas R.; Ji, Fei; Ruvkun, Gary] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Ji, Fei; Ruvkun, Gary] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
[Cohen, Emiliano; Tabach, Yuval] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Dev Biol & Canc Res, Inst Med Res Israel Canada, IL-91010 Jerusalem, Israel.
RP Tabach, Y (reprint author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Dev Biol & Canc Res, Inst Med Res Israel Canada, IL-91010 Jerusalem, Israel.
EM yuvaltab@ekmd.huji.ac.il
FU Hebrew University
FX Hebrew University start-up funds.
NR 13
TC 2
Z9 2
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD JUL 1
PY 2015
VL 43
IS W1
BP W154
EP W159
DI 10.1093/nar/gkv452
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA CP3IP
UT WOS:000359772700024
PM 25958392
ER
PT J
AU Qiu, ZF
Mishra, A
Li, M
Farnsworth, SL
Guerra, B
Lanford, RE
Hornsby, PJ
AF Qiu, Zhifang
Mishra, Anuja
Li, Miao
Farnsworth, Steven L.
Guerra, Bernadette
Lanford, Robert E.
Hornsby, Peter J.
TI Marmoset induced pluripotent stem cells: Robust neural differentiation
following pretreatment with dimethyl sulfoxide
SO STEM CELL RESEARCH
LA English
DT Article
ID BIOMEDICAL-RESEARCH; LINES; BIOLOGY
AB The marmoset is an important nonhuman primate model for regenerative medicine. For experimental autologous cell therapy based on induced pluripotent (iPS) cells in the marmoset, cells must be able to undergo robust and reliable directed differentiation that will not require customization for each specific iPS cell clone. When marmoset iPS cells were aggregated in a hanging drop format for 3 days, followed by exposure to dual SMAD inhibitors and retinoic acid in monolayer culture for 3 days, we found substantial variability in the response of different iPS cell clones. However, when clones were pretreated with 0.05-2% dimethyl sulfoxide (DMSO) for 24 hours, all clones showed a very similar maximal response to the directed differentiation scheme. Peak responses were observed at 0.5% DMSO in two clones and at 1% DMSO in a third clone. When patterns of gene expression were examined by microarray analysis, hierarchical clustering showed very similar responses in all 3 clones when they were pretreated with optimal DMSO concentrations. The change in phenotype following exposure to DMSO and the 6 day hanging drop/monolayer treatment was confirmed by immunocytochemistry. Analysis of DNA content in DMSO-exposed cells indicated that it is unlikely that DMSO acts by causing cells to exit from the cell cycle. This approach should be generally valuable in the directed neural differentiation of pluripotent cells for experimental cell therapy. Published by Elsevier B.V.
C1 [Qiu, Zhifang; Mishra, Anuja; Li, Miao; Farnsworth, Steven L.; Hornsby, Peter J.] South Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA.
[Qiu, Zhifang; Mishra, Anuja; Li, Miao; Farnsworth, Steven L.; Hornsby, Peter J.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst, Dept Physiol, San Antonio, TX 78229 USA.
[Guerra, Bernadette; Lanford, Robert E.] Southwest Natl Primate Res Ctr, San Antonio, TX USA.
[Guerra, Bernadette; Lanford, Robert E.] Texas Biomed Res Inst, San Antonio, TX USA.
RP Hornsby, PJ (reprint author), South Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA.
EM hornsby@uthscsa.edu
FU VA grant [I01BX001454]; NIH [R21AG033286, R03AG045481]; Owens Medical
Research Foundation; Ted Nash Long Life Foundation; China Scholarship
Council
FX This work was supported by VA grant I01BX001454, NIH grants R21AG033286
and R03AG045481, and by grants from the Owens Medical Research
Foundation and the Ted Nash Long Life Foundation. Miao Li acknowledges
the support of the China Scholarship Council.
NR 20
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1873-5061
EI 1876-7753
J9 STEM CELL RES
JI Stem Cell Res.
PD JUL
PY 2015
VL 15
IS 1
BP 141
EP 150
DI 10.1016/j.scr.2015.05.010
PG 10
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA CP6JZ
UT WOS:000359994400014
PM 26070112
ER
PT J
AU Yamaguchi, J
Liss, AS
Sontheimer, A
Mino-Kenudson, M
Fernandez-del Castillo, C
Warshaw, AL
Thayer, SP
AF Yamaguchi, Junpei
Liss, Andrew S.
Sontheimer, Alexandra
Mino-Kenudson, Mari
Fernandez-del Castillo, Carlos
Warshaw, Andrew L.
Thayer, Sarah P.
TI Pancreatic duct glands (PDGs) are a progenitor compartment responsible
for pancreatic ductal epithelial repair
SO STEM CELL RESEARCH
LA English
DT Article
ID STEM-CELLS; GROWTH-FACTOR; INJURY; REGENERATION; GENE; IDENTIFICATION;
LOCALIZATION; EXPRESSION; PITFALLS; HEDGEHOG
AB Pancreatic duct glands (PDGs) have molecular features known to mark stem cell niches, but their function remains to be determined. To investigate the role of PDGs as a progenitor niche, PDGs were analyzed in both humans and mice. Cells were characterized by immunohistochemistry and microarray analysis. In vivo proliferative activity and migration of PDG cells were evaluated using a BrdU tag-and-chase strategy in a mouse model of pancreatitis. In vitro migration assays were used to determine the role of trefoil factor (TFF) -1 and 2 in cell migration. Proliferative activity in the pancreatic epithelium in response to inflammatory injury is identified principally within the PDG compartment. These proliferating cells then migrate out of the PDG compartment to populate the pancreatic duct. Most of the pancreatic epithelial migration occurs within 5 days and relies, in part, on TFF-1 and -2. After migration, PDG cells lose their PDG-specific markers and gain a more mature pancreatic ductal phenotype. Expression analysis of the PDG epithelium reveals enrichment of embryonic and stem cell pathways. These results suggest that PDGs are an epithelial progenitor compartment that gives rise to mature differentiated progeny that migrate to the pancreatic duct. Thus PDGs are a progenitor niche important for pancreatic epithelial regeneration. (C) 2015 The Authors. Published by Elsevier B.V.
C1 [Yamaguchi, Junpei; Liss, Andrew S.; Sontheimer, Alexandra; Fernandez-del Castillo, Carlos; Warshaw, Andrew L.; Thayer, Sarah P.] Massachusetts Gen Hosp, Dept Surg, Andrew L Warshaw Inst Pancreat Canc Res, Boston, MA 02114 USA.
[Mino-Kenudson, Mari] Massachusetts Gen Hosp, Dept Pathol, Andrew L Warshaw Inst Pancreat Canc Res, Boston, MA 02114 USA.
[Thayer, Sarah P.] Univ Nebraska Med Ctr, Dept Surg, Div Surg Oncol, Omaha, NE 68198 USA.
RP Thayer, SP (reprint author), Univ Nebraska Med Ctr, 986345 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM sarah.thayer@UNMC.edu
RI YAMAGUCHI, Junpei/E-4440-2015
FU Andrew L. Warshaw, MD Institute for Pancreatic Cancer Research,
Massachusetts General Hospital; [NIH-P01CA117969]
FX This work was supported by the Andrew L. Warshaw, MD Institute for
Pancreatic Cancer Research, Massachusetts General Hospital, and by
NIH-P01CA117969 to SPT. We would like to Thank Dr. Timothy Wang, Dorothy
L. and Daniel H. Silberberg Professor of Medicine and Chief, Division of
Digestive and Liver Diseases, Columbia University, for kindly providing
TKK2 knockout mice.
NR 42
TC 6
Z9 7
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1873-5061
EI 1876-7753
J9 STEM CELL RES
JI Stem Cell Res.
PD JUL
PY 2015
VL 15
IS 1
BP 190
EP 202
DI 10.1016/j.scr.2015.05.006
PG 13
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA CP6JZ
UT WOS:000359994400019
PM 26100232
ER
PT J
AU Knapp, H
Chan, K
AF Knapp, Herschel
Chan, Kee
TI HIV Rapid Testing in a VA Emergency Department Setting: Cost Analysis at
5 Years
SO VALUE IN HEALTH
LA English
DT Article
DE AIDS; cost analysis; emergency; HIV; screening
ID OF-VETERANS-AFFAIRS; HEALTH-CARE-SYSTEM; UNITED-STATES; IMPLEMENTATION
AB Objectives: To conduct a comprehensive cost-minimization analysis to comprehend the financial attributes of the first 5 years of an implementation wherein emergency department (ED) registered nurses administered HIV oral rapid tests to patients. Methods: A health science research implementation team coordinated with ED stakeholders and staff to provide training, implementation guidelines, and support to launch ED registered nurse administered HIV oral rapid testing. Deidentified quantitative data were gathered from the electronic medical records detailing quarterly HIV rapid test rates in the Ell setting spanning the first 5 years. Comprehensive cost analyses were conducted to evaluate the financial impact of this implementation. Results: At 5 years, a total of 2,620 tests were conducted with a quarterly mean of 131 +/- 81. Despite quarterly variability in testing rates, regression analysis revealed an average increase of 3.58 tests per quarter. Over the course of this implementation, Veterans Health Administration policy transitioned from written to verbal consent for HIV testing, serving to reduce the time and cost(s) associated with the testing process. Conclusions: Our data indicated salient health outcome benefits for patients with respect to the potential for earlier detection, and associated long-run cost savings. (C) 2015 Published by Elsevier inc. on behalf of international Society for Pharmacoeconomics and Outcomes Research (ISPOR).
C1 [Knapp, Herschel] Vet Affairs VA Qual Enhancement Res Initiat HIV &, Los Angeles, CA USA.
[Knapp, Herschel] Ctr Study Healthcare Provider Behav, Los Angeles, CA USA.
[Knapp, Herschel] Greater Los Angeles Hlth Serv Res & Dev HSR&D Ctr, Los Angeles, CA USA.
[Knapp, Herschel] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Chan, Kee] Univ Illinois, Sch Publ Hlth, Chicago, IL 60612 USA.
[Chan, Kee] Edith Nourse Rogers Mem Vet Hosp Home, Bedford, MA 01730 USA.
[Chan, Kee] CHOIR, Boston, MA 02118 USA.
RP Knapp, H (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 210,Room 210, Los Angeles, CA 90073 USA.
EM Herschel.Knapp@va.gov
NR 10
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
EI 1524-4733
J9 VALUE HEALTH
JI Value Health
PD JUL
PY 2015
VL 18
IS 5
BP 735
EP 737
DI 10.1016/j.jval.2015.02.019
PG 3
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA CP7VR
UT WOS:000360097700023
PM 26297102
ER
PT J
AU Bell, DL
Leslie-Mazwi, TM
Yoo, AJ
Rabinov, JD
Butler, WE
Bell, JE
Hirsch, JA
AF Bell, D. L.
Leslie-Mazwi, T. M.
Yoo, A. J.
Rabinov, J. D.
Butler, W. E.
Bell, J. E.
Hirsch, J. A.
TI Application of a Novel Brain Arteriovenous Malformation Endovascular
Grading Scale for Transarterial Embolization
SO AMERICAN JOURNAL OF NEURORADIOLOGY
LA English
DT Article
ID MULTIMODALITY TREATMENT; ONYX EMBOLIZATION; RANDOMIZED-TRIAL;
COMPLICATIONS; SYSTEM; MANAGEMENT; FISTULAS; AVMS
AB BACKGROUND AND PURPOSE: The advent of modern neuroendovascular techniques has highlighted the need for a simple, effective, and reliable brain arteriovenous malformation endovascular grading scale. A novel scale of this type has recently been described. It incorporates the number of feeding arteries, eloquence, and the presence of an arteriovenous fistula component. Our aim is to assess the validity of this grading scale.
MATERIALS AND METHODS: We retrospectively reviewed all suspected brain arteriovenous malformations at Massachusetts General Hospital from 2005 to 2013, identifying 126 patients who met the inclusion criteria. Spearman correlations between endovascular and Spetzler-Martin grading scales and long-term outcomes were performed. Median endovascular grades were compared between treatment modalities and endovascular outcomes. Binary regression analysis was performed with major endovascular complications as a dichotomized dependent variable. Intraclass correlation coefficients were calculated for interobserver reliability of the endovascular grading scale.
RESULTS: A significant Spearman correlation between the endovascular grade and the Spetzler-Martin grade was demonstrated (rho = 0.5, P < .01). Differences in the median endovascular grades between the endovascular cure (median = 2) and endovascular complication groups (median = 4) (P < .05) and between the endovascular cure and successful multimodal treatment groups (median = 3) (P < .05) were demonstrated. The endovascular grade was the only independent predictor of complications (OR = 0.5, P < .01). The intraclass correlation coefficient of the endovascular grade was 0.71 (P < .01).
CONCLUSIONS: Validation of a brain arteriovenous malformation endovascular grading scale demonstrated that endovascular grades of = age 65 who presented to Dana-Farber Cancer Institute between 2006 and 2011 and completed a baseline quality of life questionnaire. Questions corresponding to functional status and symptoms and extracted clinical-pathologic data from medical records. Kaplan-Meier and Cox proportional hazards models were used to estimate survival.
Results: One hundred fourteen patients consented and were available for analysis. Median age was 73 years, and the majority of patients were White, were male, and had a Charlson comorbidity score of <2. Few patients (24%) had an IPSS score consistent with lower-risk disease and the majority received chemotherapy. In addition to IPSS score and history of prior chemotherapy or radiation, significant univariate predictors of survival included low serum albumin, Charlson score, performance status, ability to take a long walk, and interference of physical symptoms in family life. The multivariate model that best predicted mortality included low serum albumin (HR = 2.3; 95% CI: 1.06-5.14), therapy-related MDS (HR = 2.1; 95% CI: 1.16-4.24), IPSS score (HR = 1.7; 95% CI: 1.14-2.49), and ease taking a long walk (HR = 0.44; 95% CI: 0.23-0.90).
Conclusions: In this study of older adults with MDS, we found that low serum albumin and physical function added important prognostic information to the IPSS score. Self-reported physical function was more predictive than physician-assigned performance status. Published by Elsevier Ltd.
C1 [Fega, K. Rebecca] Univ Arizona, Coll Med Phoenix, Phoenix, AZ USA.
[Abel, Gregory A.; Motyckova, Gabriela; DeAngelo, Daniel J.; Steensma, David P.; Galinsky, Ilene; Wadleigh, Martha; Stone, Richard M.; Driver, Jane A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Sherman, Alexander E.] Univ Cincinnati, Coll Med, Cincinnati, OH USA.
[Driver, Jane A.] Boston VA Med Ctr, Geriatr Res Educ & Clin Ctr, Boston, MA 02130 USA.
[Driver, Jane A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Aging,Dept Med, Boston, MA 02115 USA.
RP Driver, JA (reprint author), Boston VA Med Ctr, Geriatr Res Educ & Clin Ctr, 150 S Huntington Ave, Boston, MA 02130 USA.
EM jdriver@partners.org
FU Dana Farber Cancer Institute; MSTAR Program (American Federation for
Aging Research/NIH Grant) [1T35AG038027-02 9]; Veterans' Administration
Career Development Award
FX This research was funded by a grant from the Dana Farber Cancer
Institute (JAD) and the MSTAR Program (American Federation for Aging
Research/NIH Grant #1T35AG038027-02 9); KAS, AES). Dr. Driver gratefully
acknowledges support from a Veterans' Administration Career Development
Award).
NR 40
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1879-4068
EI 1879-4076
J9 J GERIATR ONCOL
JI J. Geriatr. Oncol.
PD JUL
PY 2015
VL 6
IS 4
BP 288
EP 298
DI 10.1016/j.jgo.2015.05.003
PG 11
WC Oncology; Geriatrics & Gerontology
SC Oncology; Geriatrics & Gerontology
GA CO9QW
UT WOS:000359511600006
PM 26073533
ER
PT J
AU Naik, AD
Uy, N
Anaya, DA
Moye, J
AF Naik, Aanand D.
Uy, Natalie
Anaya, Daniel A.
Moye, Jennifer
TI The effects of age, education, and treatment on physical, sexual and
body concern symptoms among multimorbid, colorectal cancer survivors
SO JOURNAL OF GERIATRIC ONCOLOGY
LA English
DT Article
DE Cancer survivors; Colorectal cancer; Multimorbidity; Quality of life;
Symptoms
ID QUALITY-OF-LIFE; PSYCHOLOGICAL DISTRESS; RECTAL-CANCER; COLON-CANCER;
COMORBIDITY
AB Objective: Less is known about longitudinal changes in quality of life between treatment completion and early survivorship among multimorbid cancer survivors. The current study describes longitudinal changes in quality of life among a multimorbid cohort of US Veterans diagnosed and treated for colorectal cancer.
Materials and Methods: A sample of 68 multimorbid adults with colon and/or rectal cancer who received one or more treatment options (surgery, chemo or radiation therapy) was recruited. Participants were not excluded by cancer stage unless they reported being in hospice or similar status. Comprehensive assessments of quality of life and treatment side-effects were conducted 6, 12, and 18 months after diagnosis. Descriptive statistics characterized treatment side-effects and changes in quality-of-life domains longitudinally. Multivariate Analysis of Variance identified sociodemographic and clinical variables associated with quality of life changes.
Results: Many physical symptoms improved from 6 to 18 months following diagnosis, while some remained stable. Sexual symptoms worsened, attributable to increasing rates of dysfunction in older patients. Low education attainment was predictive of worse physical symptoms (F = 5.59, p = .023) and associated with body concerns (F = 5.7; p = .005) over time. Advanced cancer stage (F = 4.94; p < .04) and receipt of chemotherapy (F = 4.21; p < .05) independently predicted body concerns in multivariate analyses.
Conclusion: Endorsement of physical and sexual symptoms and body concerns occurs in different patterns over time among multimorbid colorectal cancer survivors. Low education attainment is consistently associated with physical symptoms and body concerns. Cancer stage and chemotherapy are predictive of body concerns, but not physical or sexual symptoms. Published by Elsevier Ltd.
C1 [Naik, Aanand D.; Uy, Natalie; Anaya, Daniel A.] Houston VA HSR&D Ctr Innovat Qual Effectiveness &, Michael E DeBakey VA Med Ctr MEDVAMC 152, Houston, TX 77030 USA.
[Naik, Aanand D.; Uy, Natalie] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Anaya, Daniel A.] Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA.
[Moye, Jennifer] VA Boston Healthcare Syst, Geriatr Mental Hlth, Brockton Div, Brockton, MA 02301 USA.
[Moye, Jennifer] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Naik, AD (reprint author), Houston VA HSR&D Ctr Innovat Qual Effectiveness &, Michael E DeBakey VA Med Ctr MEDVAMC 152, 2002 Holcombe Blvd, Houston, TX 77030 USA.
EM anaik@bcm.edu; Natalie.Uy@bcm.edu; Daniel.anaya@va.gov;
Jennifer.Moye@va.gov
RI Moye, Jennifer/F-2240-2017
OI Moye, Jennifer/0000-0002-3434-347X
FU Department of Veterans Affairs Rehabilitation Research and Development
Service [5I01RX000104]
FX Funding for this project was provided by the Department of Veterans
Affairs Rehabilitation Research and Development Service #5I01RX000104.
This material is also the result of work supported with resources and
the use of facilities at the Boston VA Medical Center and the Houston VA
HSR&D Center for Innovations in Quality, Effectiveness, and Safety
(CIN13-413) at the Michael E. DeBakey VA Medical Center. We thank the
members of the Veterans Cancer Rehabilitation Study (Vetcares) Research
team for assistance in subject recruitment and data collection. We are
indebted to the Veterans who have participated in our research studies
and allow us to contribute to their health care. The funders played no
role in study design; in the collection, analysis and interpretation of
data; in the writing of the report; and/or in the decision to submit the
paper for publication.
NR 18
TC 0
Z9 0
U1 2
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1879-4068
EI 1879-4076
J9 J GERIATR ONCOL
JI J. Geriatr. Oncol.
PD JUL
PY 2015
VL 6
IS 4
BP 299
EP 306
DI 10.1016/j.jgo.2015.04.001
PG 8
WC Oncology; Geriatrics & Gerontology
SC Oncology; Geriatrics & Gerontology
GA CO9QW
UT WOS:000359511600007
PM 25920578
ER
PT J
AU Berman, NC
Fang, A
Hansen, N
Wilhelm, S
AF Berman, Noah Chase
Fang, Angela
Hansen, Natasha
Wilhelm, Sabine
TI Cognitive-based therapy for OCD: Role of behavior experiments and
exposure processes
SO JOURNAL OF OBSESSIVE-COMPULSIVE AND RELATED DISORDERS
LA English
DT Article
DE Cognitive therapy; Behavioral experiment; Expectancy mismatch; OCD
ID OBSESSIVE-COMPULSIVE DISORDER; RANDOMIZED CONTROLLED-TRIAL; PSYCHOMETRIC
VALIDATION; INTRUSIONS INVENTORY; OVERVALUED IDEAS; QUESTIONNAIRE;
RELIABILITY; ADOLESCENTS; PREVENTION; MECHANISMS
AB The current manuscript describes the rationale and pragmatics for conducting exposures (termed "behavioral experiments") in Cognitive Therapy (CT) for OCD. Given that the cognitive model of OCD focuses upon the assumptions and belief systems (e.g., threat perception) that underlie the misinterpretation of unwanted intrusions, CT employs cognitive strategies, such as behavioral experiments, to modify maladaptive interpretations and produce symptom reduction. We outline how to prepare for behavioral experiments through psychoeducation and empirically supported assessment procedures. Next, we describe how to operationalize the behavioral experiment and propose patient and therapist-related behaviors that will facilitate (or interfere with) the experiment's success. Lastly, we discuss how to process the findings of the behavioral experiment by integrating other CT strategies, such as calculation of harm and the downward arrow, to consolidate learning and ultimately strengthen and generalize skills use. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Berman, Noah Chase; Fang, Angela; Hansen, Natasha; Wilhelm, Sabine] Massachusetts Gen Hosp, OCD & Related Disorders Program, Boston, MA 02114 USA.
RP Berman, NC (reprint author), Massachusetts Gen Hosp, OCD & Related Disorders Program, 185 Cambridge St,Suite 2000, Boston, MA 02114 USA.
EM nberman@mgh.harvard.edu
OI Fang, Angela/0000-0002-7666-9988
NR 39
TC 2
Z9 2
U1 5
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2211-3649
J9 J OBSESS-COMPULS REL
JI J. Obsessive-Compuls. Relat. Disord.
PD JUL
PY 2015
VL 6
BP 158
EP 166
DI 10.1016/j.jocrd.2015.01.001
PG 9
WC Psychiatry
SC Psychiatry
GA CP1CB
UT WOS:000359612400021
ER
PT J
AU Grashow, R
Sparrow, D
Hu, H
Weisskopf, MG
AF Grashow, Rachel
Sparrow, David
Hu, Howard
Weisskopf, Marc G.
TI Cumulative lead exposure is associated with reduced olfactory
recognition performance in elderly men: The Normative Aging Study
SO NEUROTOXICOLOGY
LA English
DT Article
DE Olfaction; Aging; Bone lead; HFE; ApoE; GSTP1
ID S-TRANSFERASE POLYMORPHISMS; PREDICTS COGNITIVE DECLINE; SMELL
IDENTIFICATION TEST; DWELLING OLDER-ADULTS; PARKINSONS-DISEASE;
ALZHEIMERS-DISEASE; BONE LEAD; ODOR IDENTIFICATION; APOLIPOPROTEIN-E;
INORGANIC LEAD
AB Introduction: Olfactory dysfunction has been identified as an early warning sign for Alzheimer's disease, Parkinson's disease, dementia and more. A few occupational and environmental exposures have also been associated with reduced olfactory function, although the effects of long term environmental exposure to lead on olfactory dysfunction have not been explored. Here we performed olfactory recognition testing in elderly men in a community-dwelling cohort and examined the association with cumulative lead exposure, as assessed by lead in tibial and patellar bone.
Methods: Olfactory recognition was measured in 165 men from the Normative Aging Study (NAS) who had previously taken part in bone lead measurements using K-X-ray fluorescence (KXRF). Olfactory recognition was measured using the University of Pennsylvania Smell Identification Test (UPSIT). Associations between olfactory recognition, global cognition and cumulative lead exposure were estimated using linear regression, with additional adjustment for age, smoking, and functional polymorphism status for hemochromatosis (HFE), transferrin (TfC2), glutathione-s-transferase Pi1 (GSTP1) and apolipoprotein E (APOE) genotypes. Sensitivity analyses explored olfactory recognition in men with high global cognitive function as measured using the Mini-Mental Status Exam (MMSE).
Results: The average age of the NAS participants at the time of olfactory recognition testing was 80.3 (standard deviation or SD = 5.7) years. Mean tibia lead was 16.3 (SD = 12.0) mu g/g bone, mean patella lead was 22.4 (SD = 14.4) mu g/g bone, and mean UPSIT score was 26.9 out of 40 (SD = 7.0). Consistent with previous findings, age at olfaction testing was negatively associated with UPSIT score. Tibia (but not patella) bone lead was negatively associated with olfaction recognition (per 15 mu g/g tibia lead: beta = -1.57; 95% CI: -2.93, -0.22; p = 0.02) in models adjusted for smoking and age. Additional adjustment for education did not significantly change results. Of all the genes explored, only the presence of one or more HFE variant alleles was significantly associated with olfaction recognition (HFE beta = 2.26; 95% CI: 0.09, 4.43; p = 0.04). In a model containing the HFE term and a lead term, the tibia lead parameter estimate dropped by 21% (per 15 mu g/g tibia lead: beta = -1.25; 95% CI: -2.64, 0.14; p = 0.08) while the HFE term dropped 15% (beta = 1.91; 95% CI: -0.28, 4.10; p = 0.09). None of the other gene terms were associated with olfactory recognition in this cohort, nor were any gene-lead interaction terms significant. Additional sensitivity analysis in men with MMSE scores of 25 or higher (n = 149) showed a similar but slightly attenuated association between lead and olfactory recognition (per 15 mu g/g tibia lead beta = -1.39; 95% CI: -3.00, 0.22; p = 0.09).
Conclusion: Cumulative exposure to lead is associated with reduced olfactory recognition in a cohort of elderly men. The association was similar but not significant in men with better cognitive function as measured by the MMSE. Iron metabolism gene status may also affect olfactory function. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Grashow, Rachel; Weisskopf, Marc G.] Harvard Univ, Dept Environm Hlth, TH Chan Sch Publ Hlth, Boston, MA 02115 USA.
[Grashow, Rachel] Northeastern Univ, Dept Civil & Environm Engn, Boston, MA 02115 USA.
[Sparrow, David] Boston Univ, Sch Publ Hlth, VA Boston Healthcare Syst, Boston, MA USA.
[Sparrow, David] Boston Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA 02118 USA.
[Sparrow, David] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.
[Hu, Howard] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.
RP Grashow, R (reprint author), Northeastern Univ, Dept Civil & Environm Engn, 360 Huntington Ave,Stearns 513, Boston, MA 02115 USA.
EM r.grashow@neu.edu
OI Hu, Howard/0000-0002-3676-2707
FU NIEHS [T32 ES007069, R01 ES005257, P01-ES000002]; VA Research Career
Scientist award; Cooperative Studies Program/Epidemiology Research and
Information Center of the US Department of Veterans Affairs
FX This study was supported by grants NIEHS T32 ES007069, R01 ES005257,
P01-ES000002 and a VA Research Career Scientist award to David Sparrow.
The VA Normative Aging Study is supported by the Cooperative Studies
Program/Epidemiology Research and Information Center of the US
Department of Veterans Affairs and is a component of the Massachusetts
Veterans Epidemiology Research and Information Center, Boston,
Massachusetts.
NR 79
TC 0
Z9 1
U1 4
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0161-813X
EI 1872-9711
J9 NEUROTOXICOLOGY
JI Neurotoxicology
PD JUL
PY 2015
VL 49
BP 158
EP 164
DI 10.1016/j.neuro.2015.06.006
PG 7
WC Neurosciences; Pharmacology & Pharmacy; Toxicology
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology
GA CO5DQ
UT WOS:000359180200019
PM 26121922
ER
PT J
AU Blaine, RE
Fisher, JO
Taveras, EM
Geller, AC
Rimm, EB
Land, T
Perkins, M
Davison, KK
AF Blaine, Rachel E.
Fisher, Jennifer Orlet
Taveras, Elsie M.
Geller, Alan C.
Rimm, Eric B.
Land, Thomas
Perkins, Meghan
Davison, Kirsten K.
TI Reasons Low-Income Parents Offer Snacks to Children: How Feeding
Rationale Influences Snack Frequency and Adherence to Dietary
Recommendations
SO NUTRIENTS
LA English
DT Article
DE snacks; parenting; childhood obesity prevention; child feeding
ID DEMONSTRATION MA-CORD; CHILDHOOD OBESITY; YOUNG-CHILDREN; WEIGHT STATUS;
FOOD-HABITS; PREVENTION; MASSACHUSETTS; OVERWEIGHT; ASSOCIATION;
PERCEPTIONS
AB Although American children snack more than ever before, the parental role in promoting snacking is not well understood. In 2012-2013 at baseline in an intervention study to prevent childhood obesity in low-income Massachusetts communities, n = 271 parents of children aged 2-12 years completed surveys regarding nutritive and non-nutritive reasons they offered children snacks, demographics, and dietary factors. An analysis of variance demonstrated that parents reported offering snacks (mean/week; standard deviation (SD)) for nutritive reasons like promoting growth (x = 2.5; SD 2.2) or satisfying hunger (x = 2.4; SD 2.1) almost twice as often as non-nutritive reasons like keeping a child quiet (x = 0.7; SD 1.5) or celebrating events/holidays (x = 0.8; SD 1.1). Parents reported giving young children (2-5 years) more snacks to reward behavior (1.9 vs. 1.1, p < 0.001), keep quiet (1.0 vs. 0.5, p < 0.001), and celebrate achievements (1.7 vs. 1.0, p < 0.001) than parents of older children (6-12 years). Multivariable logistic regression models were used to obtain adjusted odds ratios, which indicated reduced child adherence to dietary recommendations when parents offered snacks to reward behavior (Odds Ratio (OR) = 0.83; 95% Confidence Interval (CI) 0.70-0.99), celebrate events/holidays (OR = 0.72; 95% CI 0.52-0.99), or achievements (OR = 0.82; 95% CI 0.68-0.98). Parental intentions around child snacking are likely important targets for obesity prevention efforts.
C1 [Blaine, Rachel E.] Calif State Univ Long Beach, Dept Family & Consumer Sci, Long Beach, CA 90840 USA.
[Blaine, Rachel E.; Rimm, Eric B.; Davison, Kirsten K.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Fisher, Jennifer Orlet] Temple Univ, Dept Publ Hlth, Ctr Obes Res & Educ, Coll Publ Hlth, Philadelphia, PA 19140 USA.
[Taveras, Elsie M.; Perkins, Meghan] MassGen Hosp Children, Div Gen Acad Pediat, Dept Pediat, Boston, MA 02114 USA.
[Geller, Alan C.] Harvard HT Chan Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02115 USA.
[Land, Thomas] Massachusetts Dept Publ Hlth, Off Data Management & Outcomes Assessment, Boston, MA 02108 USA.
RP Blaine, RE (reprint author), Calif State Univ Long Beach, Dept Family & Consumer Sci, 1250 Bellflower Blvd,FCS FA-15, Long Beach, CA 90840 USA.
EM rachel.blaine@csulb.edu; jofisher@temple.edu;
elsie.taveras@mgh.harvard.edu; ageller@hsph.harvard.edu;
erimm@hsph.harvard.edu; thomas.land@state.ma.us;
meperkins@mgh.harvard.edu; kdavison@hsph.harvard.edu
FU Centers for Disease Control and Prevention (CDC), National Center for
Chronic Disease Prevention and Health Promotion [U18DP003370]; National
Institutes of Health (NIH) [T32 CA 0900]
FX This study was supported by the Centers for Disease Control and
Prevention (CDC), National Center for Chronic Disease Prevention and
Health Promotion (Award #U18DP003370). Rachel E. Blaine, a doctoral
graduate, was supported by a National Institutes of Health (NIH)
Doctoral Training Grant in Cancer Epidemiology: T32 CA 0900 at the
Harvard T.H. Chan School of Public Health. The work is solely the
responsibility of the authors and does not represent official views of
the CDC or the NIH.
NR 42
TC 1
Z9 1
U1 2
U2 6
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 2072-6643
J9 NUTRIENTS
JI Nutrients
PD JUL
PY 2015
VL 7
IS 7
BP 5982
EP 5999
DI 10.3390/nu7075265
PG 18
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA CO7OQ
UT WOS:000359349800056
PM 26197335
ER
PT J
AU Abu Sayeed, M
Bufano, MK
Xu, P
Eckhoff, G
Charles, RC
Alam, MM
Sultana, T
Rashu, MR
Berger, A
Gonzalez-Escobedo, G
Mandlik, A
Bhuiyan, TR
Leung, DT
LaRocque, RC
Harris, JB
Calderwood, SB
Qadri, F
Vann, WF
Kovac, P
Ryan, ET
AF Abu Sayeed, Md.
Bufano, Meagan Kelly
Xu, Peng
Eckhoff, Grace
Charles, Richelle C.
Alam, Mohammad Murshid
Sultana, Tania
Rashu, Md. Rasheduzzaman
Berger, Amanda
Gonzalez-Escobedo, Geoffrey
Mandlik, Anjali
Bhuiyan, Taufiqur Rahman
Leung, Daniel T.
LaRocque, Regina C.
Harris, Jason B.
Calderwood, Stephen B.
Qadri, Firdausi
Vann, W. F.
Kovac, Pavol
Ryan, Edward T.
TI A Cholera Conjugate Vaccine Containing O-specific Polysaccharide (OSP)
of V. cholerae O1 Inaba and Recombinant Fragment of Tetanus Toxin Heavy
Chain (OSP:rTTHc) Induces Serum, Memory and Lamina Proprial Responses
against OSP and Is Protective in Mice
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID NEONATAL FC-RECEPTOR; B-CELL RESPONSES; FREE MOUSE MODEL;
VIBRIO-CHOLERAE; ORAL IMMUNIZATION; IMMUNE-RESPONSES; TRANSCUTANEOUS
IMMUNIZATION; CHEMOENZYMATIC SYNTHESIS; HOUSEHOLD CONTACTS;
CONTROLLED-TRIAL
AB Background
Vibrio cholerae is the cause of cholera, a severe watery diarrhea. Protection against cholera is serogroup specific. Serogroup specificity is defined by the O-specific polysaccharide (OSP) component of lipopolysaccharide (LPS).
Methodology
Here we describe a conjugate vaccine for cholera prepared via squaric acid chemistry from the OSP of V. cholerae O1 Inaba strain PIC018 and a recombinant heavy chain fragment of tetanus toxin (OSP:rTTHc). We assessed a range of vaccine doses based on the OSP content of the vaccine (10-50 mu g), vaccine compositions varying by molar loading ratio of OSP to rTTHc (3:1, 5:1, 10:1), effect of an adjuvant, and route of immunization.
Principle Findings
Immunized mice developed prominent anti-OSP and anti-TT serum IgG responses, as well as vibriocidal antibody and memory B cell responses following intramuscular or intradermal vaccination. Mice did not develop anti-squarate responses. Intestinal lamina proprial IgA responses targeting OSP occurred following intradermal vaccination. In general, we found comparable immune responses in mice immunized with these variations, although memory B cell and vibriocidal responses were blunted in mice receiving the highest dose of vaccine (50 mu g). We found no appreciable change in immune responses when the conjugate vaccine was administered in the presence or absence of immunoadjuvant alum. Administration of OSP:rTTHc resulted in 55% protective efficacy in a mouse survival cholera challenge model.
Conclusion
We report development of an Inaba OSP:rTTHc conjugate vaccine that induces memory responses and protection against cholera in mice. Development of an effective cholera conjugate vaccine that induces high level and long-term immune responses against OSP would be beneficial, especially in young children who respond poorly to polysaccharide antigens.
C1 [Abu Sayeed, Md.; Bufano, Meagan Kelly; Alam, Mohammad Murshid; Sultana, Tania; Rashu, Md. Rasheduzzaman; Berger, Amanda; Gonzalez-Escobedo, Geoffrey; Mandlik, Anjali; Bhuiyan, Taufiqur Rahman; Leung, Daniel T.; LaRocque, Regina C.; Harris, Jason B.; Calderwood, Stephen B.; Ryan, Edward T.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Abu Sayeed, Md.; Alam, Mohammad Murshid; Sultana, Tania; Rashu, Md. Rasheduzzaman; Bhuiyan, Taufiqur Rahman; Qadri, Firdausi] Int Ctr Diarrhoeal Dis Res, Ctr Vaccine Sci, Dhaka, Bangladesh.
[Xu, Peng] Natl Inst Diabet Digest & Kidney Dis NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD USA.
[Eckhoff, Grace; Charles, Richelle C.; Kovac, Pavol; Ryan, Edward T.] Harvard Univ, Sch Med, Boston, MA USA.
[Leung, Daniel T.] Univ Utah, Sch Med, Div Infect Dis, Salt Lake City, UT USA.
[Harris, Jason B.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Calderwood, Stephen B.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA USA.
[Vann, W. F.] US FDA, Ctr Biol Evaluat & Res, Lab Bacterial Toxins, Bethesda, MD USA.
[Ryan, Edward T.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
RP Abu Sayeed, M (reprint author), Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
EM etryan@mgh.harvard.edu
RI Kovac, Pavol/B-8813-2008; Xu, Peng/K-7036-2012
OI Kovac, Pavol/0000-0001-5044-3449;
FU National Institutes of Health; National Institute of Allergy and
Infectious Diseases [UO1 AI106878, U01 AI058935, K08 AI089721]; Fogarty
International Center [TW005572]; NIH; NIDDK
FX This research was supported by core grants to the icddr,b and through
programs funded by the National Institutes of Health, including the
National Institute of Allergy and Infectious Diseases (UO1 AI106878 [ETR
and FQ], U01 AI058935 [SBC, FQ and ETR], and K08 AI089721 [RCC]), the
Fogarty International Center, Training Grant in Vaccine Development and
Public Health (TW005572 [MAS, MMA, TS, MRR, TRB and FQ]), and the
Intramural Research Program of the NIH and NIDDK (PX and PK). The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 54
TC 0
Z9 0
U1 3
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JUL
PY 2015
VL 9
IS 7
AR e0003881
DI 10.1371/journal.pntd.0003881
PG 18
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA CO3SM
UT WOS:000359079700013
ER
PT J
AU Niell, BL
Bennett, D
Sharma, A
Gazelle, GS
AF Niell, Bethany L.
Bennett, Debbie
Sharma, Amita
Gazelle, G. Scott
TI Extramammary Findings on Breast MR Examinations: Frequency, Clinical
Relevance, and Patient Outcomes
SO RADIOLOGY
LA English
DT Article
ID RESONANCE-IMAGING USE; RANDOMIZED CONTROLLED-TRIAL; ACR INCIDENTAL
FINDINGS; HIGH FAMILIAL RISK; EXTRACARDIAC FINDINGS; CT COLONOGRAPHY;
WHITE PAPER; CANCER; MAMMOGRAPHY; MANAGEMENT
AB Purpose: To evaluate the frequency of extramammary findings on breast magnetic resonance (MR) images, recommendations for further imaging evaluation of each finding, and the subsequent effect on patient outcomes and health care expenditures.
Materials and Methods: Institutional review board approval was acquired for this HIPAA-compliant study. Informed consent was waived. Review of the institutional database identified 2324 breast MR examinations performed in women from January 1, 2010, to December 31, 2010. Breast MR imaging reports were reviewed for extramammary findings. Extramammary findings were categorized by using the computed tomography (CT) colonography reporting and data system (C-RADS). The electronic medical record was reviewed for each patient with a C-RADS category E3 and E4 finding to assess clinical relevance and pathologic outcome. If an E3 or E4 finding was previously described and evaluated, the finding was downgraded and assigned a final C-RADS E2 category. The cost of additional imaging was estimated by using the Medicare physician fee schedule. Statistical significance was assessed by using chi(2) statistics. A P value less than.05 indicated statistical significance, and 95% exact confidence intervals (CIs) were constructed.
Results: Extramammary findings were identified in 391 of 2324 breast MR examinations (16.8%), which included 105 patients (4.5%) with E3 or E4 findings. Of the 2324 patients, 86 patients (3.7% [95% CI: 3.0%, 4.5%]) were recommended to undergo further imaging. After undergoing evaluation for additional imaging, a clinically important finding was found in nine patients (0.4% [95% CI: 0.2%, 0.7%]). Most frequently, hepatic lesions were the indication for additional imaging. Abdominal MR examinations accounted for 55% of costs related to additional imaging. Averaged across the entire cohort, further imaging evaluation and follow-up of incidental findings contributed an additional $16 to each breast MR imaging performed.
Conclusion: Additional imaging evaluation for E3 and E4 extramammary findings at breast MR imaging can identify clinically important disease without substantially increasing cost. (C) RSNA, 2015
C1 [Niell, Bethany L.; Bennett, Debbie; Gazelle, G. Scott] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,Avon Comprehens Breast Evaluat Ctr, Boston, MA 02114 USA.
[Sharma, Amita] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02114 USA.
[Gazelle, G. Scott] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA.
RP Niell, BL (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,Avon Comprehens Breast Evaluat Ctr, 55 Fruit St,Wang Bldg Suite 240, Boston, MA 02114 USA.
EM bniell@partners.org
FU GE Healthcare
FX B.L.N. disclosed no relevant relationships. D.B. disclosed no relevant
relationships. A.S. disclosed no relevant relationships. G.S.G.
Activities related to the present article: disclosed no relevant
relationships. Activities not related to the present article: author
disclosed personal fees for consultancy from GE Healthcare. Other
relationships: disclosed no relevant relationships.
NR 26
TC 3
Z9 3
U1 0
U2 1
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0033-8419
J9 RADIOLOGY
JI Radiology
PD JUL
PY 2015
VL 276
IS 1
BP 56
EP 64
DI 10.1148/radiol.14141539
PG 9
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CP2LL
UT WOS:000359708400006
PM 25584711
ER
PT J
AU Scott, JA
Palmer, EL
Connolly, LP
AF Scott, James A.
Palmer, Edwin L.
Connolly, Leonard P.
TI Reading the Writing in Radiology: 1923-2013
SO RADIOLOGY
LA English
DT Article
AB The style and tone of the writing in Radiology has changed over the years since its first publication in 1923. Many of the tonal changes have occurred transiently and likely in relation to political and professional issues in play at a particular time. Others represent more consistent trends in the evolution of the professional writing style. In this report, we analyze the tone of the editorial content from 1923 to 2013 in a historical context as well as progressive changes in readability parameters involving both editorial and technical content.
C1 [Scott, James A.] Massachusetts Gen Hosp, Dept Radiol, Div Nucl Med, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Scott, JA (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Nucl Med, 55 Fruit St, Boston, MA 02114 USA.
EM scott@helix.mgh.harvard.edu
NR 9
TC 0
Z9 0
U1 0
U2 0
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0033-8419
J9 RADIOLOGY
JI Radiology
PD JUL
PY 2015
VL 276
IS 1
BP 250
EP 257
DI 10.1148/radiol.15141940
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CP2LL
UT WOS:000359708400028
PM 25734555
ER
PT J
AU Mitchell, JE
Steffen, K
Engel, S
King, WC
Chen, JY
Winters, K
Sogg, S
Sondag, C
Kalarchian, M
Elder, K
AF Mitchell, James E.
Steffen, Kristine
Engel, Scott
King, Wendy C.
Chen, Jia-Yuh
Winters, Ken
Sogg, Stephanie
Sondag, Cindy
Kalarchian, Melissa
Elder, Katherine
TI Addictive disorders after Roux-en-Y gastric bypass
SO SURGERY FOR OBESITY AND RELATED DISEASES
LA English
DT Article
DE Addictive use disorders; Alcohol use disorders; Bariatric surgery
ID SWEDISH OBESE SUBJECTS; BARIATRIC SURGERY; LONGITUDINAL ASSESSMENT;
BEHAVIORAL ADDICTIONS; EXERCISE ADDICTION; MENTAL-DISORDERS; ALCOHOL;
PREVALENCE; EPIDEMIOLOGY; DEPENDENCE
AB Background: Recent literature suggests that some patients may develop addictive disorders after bariatric surgery, in particular after Roux-en-Y gastric bypass (RYGB). These may include traditional addictions and so called "behavioral addictions," although prevalence data on the latter have not been published. The objective of this study was to establish the prevalence of addictive behaviors in adults after RYGB.
Methods: Participants from a large observational study of bariatric surgery who had undergone RYGB were recruited to complete additional measures. Of 241 consented participants, 201 provided data (i.e., Structured Clinical Interview for DSM-IV Axis I [SCID], additional Impulsive Control Disorder Modules, and various self-report measures, including the Alcohol Use Disorder Identification Test [AUDIT]) to assess status before surgery and in the first 3 postoperative years.
Results: Based on the SCID, 16 (8.0%) developed alcohol use disorder [AUD] within 3 years post-RYGB, 7 (43.8%) of whom had no history of AUD. When both the SOD and AUDIT were used to identify AUD, the corresponding numbers/percentages were 32 (18.4%) and 13 (40.6%). Data on other behavioral addictive disorders indicated 19 (9.5%) had a postsurgery disorder, 6 (31.6%) of whom had no history.
Conclusion: These data add to a growing literature suggesting there is a substantial risk for the development of AUD after bariatric surgery. Understanding the risk for nondrug-related addictive disorders requires more data from larger studies before clear conclusions can be drawn. (C) 2015 American Society for Metabolic and Bariatric Surgery. All rights reserved.
C1 [Mitchell, James E.; Steffen, Kristine; Engel, Scott; Sondag, Cindy] NRI, Fargo, ND 58103 USA.
[Mitchell, James E.; Steffen, Kristine; Engel, Scott; Sondag, Cindy] Univ N Dakota, Sch Med, Fargo, ND USA.
[King, Wendy C.; Chen, Jia-Yuh] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA.
[Winters, Ken] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA.
[Sogg, Stephanie] Massachusetts Gen Hosp, Weight Ctr, Boston, MA 02114 USA.
[Sogg, Stephanie] Harvard Univ, Sch Med, Boston, MA USA.
[Kalarchian, Melissa] Duquesne Univ, Pittsburgh, PA 15219 USA.
[Elder, Katherine] Univ Pacific, Hillsboro, OR USA.
RP Mitchell, JE (reprint author), NRI, 120 8th St South, Fargo, ND 58103 USA.
EM jmitchell@nrifargo.com
OI King, Wendy/0000-0002-0740-0029; Kalarchian, Melissa/0000-0003-2099-9299
FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
[U01 DK066557, U01-DK66667, UL1-RR024996, U01-DK66568, M01 RR-00037,
U01-DK66471, U01-DK66526, U01-DK66585, UL1-RR024153, U01-DK66555];
National Institute of Drug Abuse; National Institute for Alcoholism and
Alcohol Abuse [U01-DK66471]
FX LABS-2 was funded by a cooperative agreement by the National Institute
of Diabetes and Digestive and Kidney Diseases (NIDDK) grants U01
DK066557 (data coordinating center); U01-DK66667 and UL1-RR024996
(Columbia-Presbyterian in collaboration with Cornell University Medical
Center Clinical and Translational Research Center [CIRC]); U01-DK66568
and M01 RR-00037 (University of Washington in collaboration with Cornell
University Medical Center CTRC); U01-DK66471 (Neuropsychiatric Research
Institute); U01-DK66526 (East Carolina University); U01-DK66585 and
UL1-RR024153 (University of Pittsburgh Medical Center in collaboration
with Cornell University Medical Center CTRC); and U01-DK66555 (Oregon
Health & Science University). This particular part of the LABS-2 study
was also funded by a Supplement from the National Institute of Drug
Abuse and the National Institute for Alcoholism and Alcohol Abuse to
U01-DK66471 (Neuropsychiatric Research Institute).
NR 38
TC 6
Z9 6
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1550-7289
EI 1878-7533
J9 SURG OBES RELAT DIS
JI Surg. Obes. Relat. Dis.
PD JUL-AUG
PY 2015
VL 11
IS 4
BP 897
EP 905
DI 10.1016/j.soard.2014.10.026
PG 9
WC Surgery
SC Surgery
GA CO7HF
UT WOS:000359329500032
PM 25862182
ER
PT J
AU Zeng, XQ
Shi, HJ
Wang, JP
Cui, SZ
Tang, HS
Zhang, XL
AF Zeng, Xiaoqi
Shi, Huijuan
Wang, Jiping
Cui, Shuzhong
Tang, Hongsheng
Zhang, Xiangliang
TI Long noncoding RNA aberrant expression profiles after cytoreductive
surgery and hyperthermic intraperitoneal chemotherapy of AGC ascertained
by microarray analysis
SO TUMOR BIOLOGY
LA English
DT Article
DE Advanced gastric cancer (AGC); Cytoreductive surgery (CRS); Hyperthermic
intraperitoneal chemotherapy (HIPEC); LncRNAs
ID GASTRIC-CANCER; PERITONEAL CARCINOMATOSIS; CELL-PROLIFERATION;
POOR-PROGNOSIS; C-MYC; PROMOTES; TRANSCRIPTION; HOTAIR; METASTASIS;
INVASION
AB Long noncoding RNAs (lncRNAs) have been shown to be involved in the development and progression of advanced gastric cancer (AGC). However, the roles of lncRNAs in advanced gastric cancer during the process of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are not well understood. A high-throughput microarray analysis was performed to compare the expression profiles of lncRNAs and messenger RNAs (mRNAs) in AGC serum samples during the process of CRS+HIPEC. Several potentially AGC-associated lncRNAs were verified by real-time quantitative reverse transcription polymerase chain reaction (PCR) analysis. Using abundant and varied probes, we were able to assess 33,045 lncRNAs and 30,215 mRNAs in our microarray. We found that 566 lncRNAs were differentially expressed (2-fold change) in AGC serum samples, indicating the significantly up-or down-regulated lncRNAs play important roles in AGC during the process of CRS+HIPEC. Quantitative PCR results further verified that eight lncRNAs were aberrantly expressed in AGC serum samples after CRS+HIEC compared with matched serum sample before CRS+HIPEC. Among them, BC031243 and RP11-356I2.2 were the most aberrantly expressed lncRNAs, as estimated by quantitative PCR in six pairs of AGC serum samples. Our study demonstrated the expression patterns of lncRNAs in AGC serums before and after CRS+HIPEC by microarray. These results revealed that lncRNAs were differentially expressed during the process of CRS+HIPEC, suggesting that they might play key roles in tumor development.
C1 [Zeng, Xiaoqi; Cui, Shuzhong; Tang, Hongsheng; Zhang, Xiangliang] Guangzhou Med Univ, Affiliated Canc Hosp, Dept Abdominal Surg, Sect 2, Guangzhou 510095, Guangdong, Peoples R China.
[Shi, Huijuan] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pathol, Guangzhou 510080, Guangdong, Peoples R China.
[Wang, Jiping] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
[Wang, Jiping] Harvard Univ, Sch Med, Boston, MA USA.
[Wang, Jiping] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Wang, Jiping] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
RP Zhang, XL (reprint author), Guangzhou Med Univ, Affiliated Canc Hosp, Dept Abdominal Surg, Sect 2, 78 Hengzhigang Rd, Guangzhou 510095, Guangdong, Peoples R China.
EM zhxl7229@163.com
FU Guangdong Province Natural Science Fund [S2013010016662]; health bureau
of Guangdong province [A2014224, B2014196]; Science and Technology
Planning Project of Guangdong Province [2013B021800284]; National
Natural Science Foundation of China [81201932, 81372493]
FX This work was supported by Guangdong Province Natural Science Fund (No.
S2013010016662), the health bureau of Guangdong province (Nos. A2014224
and B2014196), Science and Technology Planning Project of Guangdong
Province (No. 2013B021800284), and the National Natural Science
Foundation of China (Nos. 81201932 and 81372493).
NR 30
TC 3
Z9 3
U1 0
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JUL
PY 2015
VL 36
IS 7
BP 5021
EP 5029
DI 10.1007/s13277-015-3153-4
PG 9
WC Oncology
SC Oncology
GA CP0MI
UT WOS:000359569000020
PM 25652469
ER
PT J
AU Mathisen, DJ
AF Mathisen, Douglas J.
TI 50TH ANNIVERSARY LANDMARK COMMENTARY ON GRILLO HC. TRACHEAL TUMORS:
SURGICAL MANAGEMENT. ANN THORAC SURG 1978;26:112-25
SO ANNALS OF THORACIC SURGERY
LA English
DT Editorial Material
C1 Massachusetts Gen Hosp, Thorac Surg, Boston, MA 02114 USA.
RP Mathisen, DJ (reprint author), Massachusetts Gen Hosp, Thorac Surg, 55 Fruit St,Blake 1570, Boston, MA 02114 USA.
EM dmathisen@mgh.harvard.edu
NR 1
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD JUL
PY 2015
VL 100
IS 1
BP 6
EP 7
DI 10.1016/j.athoracsur.2015.05.049
PG 3
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA CN9UZ
UT WOS:000358796800012
PM 26140755
ER
PT J
AU Garcia, JM
Chen, JA
Guillory, B
Donehower, LA
Smith, RG
Lamb, DJ
AF Garcia, Jose M.
Chen, Ji-an
Guillory, Bobby
Donehower, Lawrence A.
Smith, Roy G.
Lamb, Dolores J.
TI Ghrelin Prevents Cisplatin-Induced Testicular Damage by Facilitating
Repair of DNA Double Strand Breaks Through Activation of p53 in Mice
SO BIOLOGY OF REPRODUCTION
LA English
DT Article
DE GHSR; growth hormone secretagogue; infertility; testis
ID HORMONE SECRETAGOGUE RECEPTOR; GERM-CELL CANCER; RAT TESTIS; C57/BL/6J
MICE; MESSENGER-RNA; MOUSE TESTIS; FOOD-INTAKE; CHEMOTHERAPY;
EXPRESSION; APOPTOSIS
AB Cisplatin administration induces DNA damage resulting in germ cell apoptosis and subsequent testicular atrophy. Although 50 percent of male cancer patients receiving cisplatin-based chemotherapy develop long-term secondary infertility, medical treatment to prevent spermatogenic failure after chemotherapy is not available. Under normal conditions, testicular p53 promotes cell cycle arrest, which allows time for DNA repair and reshuffling during meiosis. However, its role in the setting of cisplatin-induced infertility has not been studied. Ghrelin administration ameliorates the spermatogenic failure that follows cisplatin administration in mice, but the mechanisms mediating these effects have not been well established. The aim of the current study was to characterize the mechanisms of ghrelin and p53 action in the testis after cisplatin-induced testicular damage. Here we show that cisplatin induces germ cell damage through inhibition of p53-dependent DNA repair mechanisms involving gamma-H2AX and ataxia telangiectasia mutated protein kinase. As a result, testicular weight and sperm count and motility were decreased with an associated increase in sperm DNA damage. Ghrelin administration prevented these sequelae by restoring the normal expression of gamma-H2AX, ataxia telangiectasia mutated, and p53, which in turn allows repair of DNA double stranded breaks. In conclusion, these findings indicate that ghrelin has the potential to prevent or diminish infertility caused by cisplatin and other chemotherapeutic agents by restoring p53-dependent DNA repair mechanisms.
C1 [Garcia, Jose M.; Chen, Ji-an; Guillory, Bobby] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, CTRID, Div Endocrinol Diabet & Metab,Dept Med,MCL, Houston, TX 77030 USA.
[Chen, Ji-an] Third Mil Med Univ, Coll Prevent Med, Dept Hlth Educ, Chongqing, Peoples R China.
[Garcia, Jose M.; Lamb, Dolores J.] Baylor Coll Med, Ctr Reprod Med, Houston, TX 77030 USA.
[Garcia, Jose M.; Smith, Roy G.; Lamb, Dolores J.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
[Garcia, Jose M.; Guillory, Bobby; Smith, Roy G.] Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA.
[Donehower, Lawrence A.; Lamb, Dolores J.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.
[Smith, Roy G.] Scripps Res Inst Florida, Dept Metab & Aging, Jupiter, FL USA.
[Lamb, Dolores J.] Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA.
RP Garcia, JM (reprint author), Michael E DeBakey VA Med Ctr, Div Endocrinol Diabet & Metab, 2002 Holcombe Blvd,Bldg 109,Rm 210, Houston, TX 77030 USA.
EM Jgarcia1@bcm.edu
FU NICHD [U54-HD28934]
FX We thank the University of Virginia Center for Research in Reproduction
Ligand Assay and Analysis Core (supported by NICHD U54-HD28934) and
Baylor DERC (P30 DK079638) for their help.
NR 61
TC 5
Z9 5
U1 1
U2 5
PU SOC STUDY REPRODUCTION
PI MADISON
PA 1691 MONROE ST,SUITE # 3, MADISON, WI 53711-2021 USA
SN 0006-3363
EI 1529-7268
J9 BIOL REPROD
JI Biol. Reprod.
PD JUL 1
PY 2015
VL 93
IS 1
AR 24
DI 10.1095/biolreprod.115.129759
PG 8
WC Reproductive Biology
SC Reproductive Biology
GA CO8SP
UT WOS:000359441800018
PM 26019260
ER
PT J
AU Piotrowska, Z
Niederst, MJ
Karlovich, CA
Wakelee, HA
Neal, JW
Mino-Kenudson, M
Fulton, L
Hata, AN
Lockerman, EL
Kalsy, A
Digumarthy, S
Muzikansky, A
Raponi, M
Garcia, AR
Mulvey, HE
Parks, MK
DiCecca, RH
Dias-Santagata, D
Iafrate, AJ
Shaw, AT
Allen, AR
Engelman, JA
Sequist, LV
AF Piotrowska, Zofia
Niederst, Matthew J.
Karlovich, Chris A.
Wakelee, Heather A.
Neal, Joel W.
Mino-Kenudson, Mari
Fulton, Linnea
Hata, Aaron N.
Lockerman, Elizabeth L.
Kalsy, Anuj
Digumarthy, Subba
Muzikansky, Alona
Raponi, Mitch
Garcia, Angel R.
Mulvey, Hillary E.
Parks, Melissa K.
DiCecca, Richard H.
Dias-Santagata, Dora
Iafrate, A. John
Shaw, Alice T.
Allen, Andrew R.
Engelman, Jeffrey A.
Sequist, Lecia V.
TI Heterogeneity Underlies the Emergence of EGFR(T790) Wild-Type Clones
Following Treatment of T790M-Positive Cancers with a Third-Generation
EGFR Inhibitor
SO CANCER DISCOVERY
LA English
DT Article
ID CELL LUNG-CANCER; TYROSINE KINASE INHIBITORS; ACQUIRED-RESISTANCE;
INTRATUMOR HETEROGENEITY; DRUG-COMBINATIONS; MET AMPLIFICATION;
MUTATIONS; GEFITINIB; TUMORS; ADENOCARCINOMAS
AB Rociletinib is a third-generation EGFR inhibitor active in lung cancers with T790M, the gatekeeper mutation underlying most first-generation EGFR drug resistance. We biopsied patients at rociletinib progression to explore resistance mechanisms. Among 12 patients with T790M-positive cancers at rociletinib initiation, six had T790-wild-type rociletinib-resistant biopsies. Two T790-wild-type cancers underwent small cell lung cancer transformation; three T790M-positive cancers acquired EGFR amplification. We documented T790-wild-type and T790M-positive clones coexisting within a single pre-rociletinib biopsy. The pretreatment fraction of T790M-positive cells affected response to rociletinib. Longitudinal circulating tumor DNA (ctDNA) analysis revealed an increase in plasma EGFR-activating mutation, and T790M heralded rociletinib resistance in some patients, whereas in others the activating mutation increased but T790M remained suppressed. Together, these findings demonstrate the role of tumor heterogeneity when therapies targeting a singular resistance mechanism are used. To further improve outcomes, combination regimens that also target T790-wild-type clones are required.
SIGNIFICANCE: This report documents that half of T790M-positive EGFR-mutant lung cancers treated with rociletinib are T790-wild-type upon progression, suggesting that T790-wild-type clones can emerge as the dominant source of resistance. We show that tumor heterogeneity has important clinical implications and that plasma ctDNA analyses can sometimes predict emerging resistance mechanisms. (C) 2015 AACR.
C1 [Piotrowska, Zofia; Niederst, Matthew J.; Mino-Kenudson, Mari; Fulton, Linnea; Hata, Aaron N.; Lockerman, Elizabeth L.; Kalsy, Anuj; Digumarthy, Subba; Muzikansky, Alona; Garcia, Angel R.; Mulvey, Hillary E.; Parks, Melissa K.; DiCecca, Richard H.; Dias-Santagata, Dora; Iafrate, A. John; Shaw, Alice T.; Engelman, Jeffrey A.; Sequist, Lecia V.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Karlovich, Chris A.; Raponi, Mitch; Allen, Andrew R.] Clovis Oncol, San Francisco, CA USA.
[Wakelee, Heather A.; Neal, Joel W.] Stanford Univ, Stanford Canc Inst, Stanford, CA 94305 USA.
[Piotrowska, Zofia; Niederst, Matthew J.; Mino-Kenudson, Mari; Hata, Aaron N.; Digumarthy, Subba; Muzikansky, Alona; Dias-Santagata, Dora; Iafrate, A. John; Engelman, Jeffrey A.; Sequist, Lecia V.] Harvard Univ, Sch Med, Boston, MA USA.
RP Sequist, LV (reprint author), Massachusetts Gen Hosp, Dept Med, 32 Fruit St,Yawkey 7B, Boston, MA 02114 USA.
EM lvsequist@partners.org
FU NIH [R01CA137008]; Department of Defense; LunGevity; Uniting Against
Lung Cancer; Lung Cancer Research Foundation; Targeting a Cure for Lung
Cancer; Be a Piece of the Solution; Clovis Oncology
FX This study was funded by support from NIH R01CA137008 (to J.A.
Engelman), the Department of Defense (to L.V. Sequist and J.A.
Engelman), LunGevity (to L.V. Sequist, J.A. Engelman, and J.W. Neal),
Uniting Against Lung Cancer (to Z. Piotrowska and M.J. Niederst), the
Lung Cancer Research Foundation (to M.J. Niederst), Targeting a Cure for
Lung Cancer, and Be a Piece of the Solution. Plasma analyses were funded
by Clovis Oncology.
NR 28
TC 80
Z9 81
U1 5
U2 20
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
EI 2159-8290
J9 CANCER DISCOV
JI Cancer Discov.
PD JUL
PY 2015
VL 5
IS 7
BP 713
EP 722
DI 10.1158/2159-8290.CD-15-0399
PG 10
WC Oncology
SC Oncology
GA CO7CY
UT WOS:000359316800021
PM 25934077
ER
PT J
AU Paiva, C
Godbersen, JC
Berger, A
Brown, JR
Danilov, AV
AF Paiva, C.
Godbersen, J. C.
Berger, A.
Brown, J. R.
Danilov, A. V.
TI Targeting neddylation induces DNA damage and checkpoint activation and
sensitizes chronic lymphocytic leukemia B cells to alkylating agents
SO CELL DEATH & DISEASE
LA English
DT Article
ID NEDD8-ACTIVATING ENZYME-INHIBITOR; PHASE-II TRIAL; S-PHASE; UBIQUITIN
LIGASES; CANCER-CELLS; CLL CELLS; MLN4924; BENDAMUSTINE; APOPTOSIS;
PROLIFERATION
AB Microenvironment-mediated upregulation of the B-cell receptor (BCR) and nuclear factor-kappa B (NF-kappa B) signaling in CLL cells resident in the lymph node and bone marrow promotes apoptosis evasion and clonal expansion. We recently reported that MLN4924 (pevonedistat), an investigational agent that inhibits the NEDD8-activating enzyme (NAE), abrogates stromal-mediated NF-kappa B pathway activity and CLL cell survival. However, the NAE pathway also assists degradation of multiple other substrates. MLN4924 has been shown to induce DNA damage and cell cycle arrest, but the importance of this mechanism in primary neoplastic B cells has not been studied. Here we mimicked the lymph node microenvironment using CD40 ligand (CD40L)-expressing stroma and interleukin-21 (IL-21) to find that inducing proliferation of the primary CLL cells conferred enhanced sensitivity to NAE inhibition. Treatment of the CD40-stimulated CLL cells with MLN4924 resulted in deregulation of Cdt1, a DNA replication licensing factor, and cell cycle inhibitors p21 and p27. This led to DNA damage, checkpoint activation and G2 arrest. Alkylating agents bendamustine and chlorambucil enhanced MLN4924-mediated DNA damage and apoptosis. These events were more prominent in cells stimulated with IL-21 compared with CD40L alone, indicating that, following NAE inhibition, the culture conditions were able to direct CLL cell fate from an NF-kappa B inhibition to a Cdt1 induction program. Our data provide insight into the biological consequences of targeting NAE in CLL and serves as further rationale for studying the clinical activity of MLN4924 in CLL, particularly in combination with alkylating agents.
C1 [Paiva, C.; Danilov, A. V.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97239 USA.
[Godbersen, J. C.] Geisel Sch Med Dartmouth, Hanover, NH USA.
[Berger, A.] Takeda Pharmaceut Co Ltd, Millennium Pharmaceut Inc, Cambridge, MA USA.
[Brown, J. R.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA.
RP Danilov, AV (reprint author), Oregon Hlth & Sci Univ, OHSU Knight Canc Inst, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM danilov@ohsu.edu
FU Lymphoma Research Foundation; Leukemia Lymphoma Society; American Cancer
Society
FX We thank Drs. Eric Lightcap, Christopher Danes and Alan Eastman for
their very helpful review of this manuscript. This work was supported by
the Lymphoma Research Foundation Clinical Investigator Career
Development Award to AVD. JRB is supported by the Leukemia Lymphoma
Society and the American Cancer Society and is a Scholar in Clinical
Research of the Leukemia and Lymphoma Society.
NR 45
TC 3
Z9 3
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JUL
PY 2015
VL 6
AR e1807
DI 10.1038/cddis.2015.161
PG 12
WC Cell Biology
SC Cell Biology
GA CN9SH
UT WOS:000358788800007
PM 26158513
ER
PT J
AU Moy, ML
Collins, RJ
Martinez, CH
Kadri, R
Roman, P
Holleman, RG
Kim, HM
Nguyen, HQ
Cohen, MD
Goodrich, DE
Giardino, ND
Richardson, CR
AF Moy, Marilyn L.
Collins, Riley J.
Martinez, Carlos H.
Kadri, Reema
Roman, Pia
Holleman, Robert G.
Kim, Hyungjin Myra
Nguyen, Huong Q.
Cohen, Miriam D.
Goodrich, David E.
Giardino, Nicholas D.
Richardson, Caroline R.
TI An Internet-Mediated Pedometer-Based Program Improves Health-Related
Quality-of-Life Domains and Daily Step Counts in COPD A Randomized
Controlled Trial
SO CHEST
LA English
DT Article
ID OBSTRUCTIVE PULMONARY-DISEASE; CHRONIC LUNG-DISEASE; PHYSICAL-ACTIVITY;
WALKING PROGRAM; ONLINE COMMUNITY; US COHORT; REHABILITATION;
MAINTENANCE; TIOTROPIUM; MORTALITY
AB BACKGROUND: Low levels of physical activity (PA) are associated with poor outcomes in people with COPD. Interventions to increase PA could improve outcomes.
METHODS: We tested the efficacy of a novel Internet-mediated, pedometer-based exercise intervention. Veterans with COPD (N = 239) were randomized in a 2:1 ratio to the (1) intervention group (Omron HJ-720 ITC pedometer and Internet-mediated program) or (2) wait-list control group (pedometer). The primary outcome was health-related quality of life (HRQL), assessed by the St. George's Respiratory Questionnaire (SGRQ), at 4 months. We examined the SGRQ total score (SGRQ-TS) and three domain scores: Symptoms, Activities, and Impact. The secondary outcome was daily step counts. Linear regression models assessed the effect of intervention on outcomes.
RESULTS: Participants had a mean age of 67 +/- 9 years, and 94% were men. There was no significant between-group difference in mean 4-month SGRQ-TS (2.3 units, P = .14). Nevertheless, a significantly greater proportion of intervention participants than control subjects had at least a 4-unit improvement in SGRQ-TS, the minimum clinically important difference (53% vs 39%, respectively, P = .05). For domain scores, the intervention group had a lower (reflecting better HRQL) mean than the control group by 4.6 units for Symptoms (P = .046) and by 3.3 units for Impact (P = .049). There was no significant difference in Activities score between the two groups. Compared with the control subjects, intervention participants walked 779 more steps per day at 4 months (P - .005).
CONCLUSIONS: An Internet-mediated, pedometer-based walking program can improve domains of HRQL and daily step counts at 4 months in people with COPD.
C1 [Moy, Marilyn L.] VA Boston Healthcare Syst, Dept Vet Affairs, Rehabil Res & Dev Serv, Boston, MA USA.
[Moy, Marilyn L.] VA Boston Healthcare Syst, Pulm & Crit Care Med Sect, Boston, MA USA.
[Moy, Marilyn L.] Harvard Univ, Sch Med, Boston, MA USA.
[Collins, Riley J.] Univ Michigan, Sch Med, Ann Arbor, MI 48104 USA.
[Martinez, Carlos H.] Univ Michigan Hlth Syst, Pulm & Crit Care Div, Ann Arbor, MI USA.
[Kadri, Reema; Roman, Pia; Holleman, Robert G.; Kim, Hyungjin Myra; Goodrich, David E.; Richardson, Caroline R.] VA Ann Arbor Healthcare Syst, VA Ctr Clin Management Res, Hlth Serv Res & Dev Ctr Innovat, Ann Arbor, MI USA.
[Kim, Hyungjin Myra] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48104 USA.
[Nguyen, Huong Q.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA.
[Cohen, Miriam D.] VA New York Harbor, Brooklyn, NY USA.
[Giardino, Nicholas D.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48104 USA.
[Richardson, Caroline R.] Univ Michigan, Dept Family Med, Ann Arbor, MI 48104 USA.
RP Richardson, CR (reprint author), Univ Michigan, Dept Family Med, 1018 Fuller St, Ann Arbor, MI 48104 USA.
EM caroli@umich.edu
OI Collins, Rachel/0000-0002-1559-8135; Goodrich, David/0000-0003-3232-2189
FU Department of Veterans Affairs, Health Services Research and Development
Service [IIR 09-366]; Department of Veterans Affairs, Rehabilitation
Research and Development Service [F6847W]; National Institutes of Health
Heart, Lung, and Blood Institute [T32 HL007749-20]
FX This study was funded by the Department of Veterans Affairs, Health
Services Research and Development Service [Grant IIR 09-366 to Dr
Richardson]; the Department of Veterans Affairs, Rehabilitation Research
and Development Service [Career Development Award F6847W to Dr Moy]; and
the National Institutes of Health Heart, Lung, and Blood Institute
[Grant T32 HL007749-20 to Dr Martinez].
NR 50
TC 8
Z9 8
U1 3
U2 15
PU AMER COLL CHEST PHYSICIANS
PI GLENVIEW
PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA
SN 0012-3692
J9 CHEST
JI Chest
PD JUL
PY 2015
VL 148
IS 1
BP 128
EP 137
DI 10.1378/chest.14-1466
PG 10
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA CO2QZ
UT WOS:000359003000034
PM 25811395
ER
PT J
AU Vargas, M
Pelosi, P
Kacmarek, RM
Servillo, G
AF Vargas, Maria
Pelosi, Paolo
Kacmarek, Robert M.
Servillo, Giuseppe
TI Assessment of Ventilation During the Performance of Elective
Endoscopic-Guided Percutaneous Tracheostomy What's New 10 Years Later?
Response
SO CHEST
LA English
DT Letter
ID LUMEN ENDOTRACHEAL-TUBE
C1 [Vargas, Maria; Servillo, Giuseppe] Univ Naples Federico II, Dept Neurosci Reprod & Odontostomatol Sci, I-80100 Naples, Italy.
[Pelosi, Paolo] Univ Genoa, AOU IRCCS San Martino IST, Dept Surg Sci & Integrated Diagnost, Genoa, Italy.
[Kacmarek, Robert M.] Massachusetts Gen Hosp, Dept Anesthesiol & Crit Care, Boston, MA 02114 USA.
[Kacmarek, Robert M.] Massachusetts Gen Hosp, Dept Resp Care, Boston, MA 02114 USA.
RP Servillo, G (reprint author), Univ Naples Federico II, Dept Neurosci Reprod & Odontostomatol Sci, Via Pansini 16,Via Pansini, I-80100 Naples, Italy.
EM servillo@unina.it
RI Vargas, Maria/H-6876-2014; Servillo, Giuseppe/M-9132-2016
OI Vargas, Maria/0000-0001-7652-970X; Servillo,
Giuseppe/0000-0002-4618-3434
NR 5
TC 0
Z9 0
U1 0
U2 0
PU AMER COLL CHEST PHYSICIANS
PI GLENVIEW
PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA
SN 0012-3692
J9 CHEST
JI Chest
PD JUL
PY 2015
VL 148
IS 1
BP E27
EP E28
DI 10.1378/chest.15-0511
PG 2
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA CO2QZ
UT WOS:000359003000008
PM 26149560
ER
PT J
AU Mody, L
Meddings, J
Edson, BS
McNamara, SE
Trautner, BW
Stone, ND
Krein, SL
Saint, S
AF Mody, Lona
Meddings, Jennifer
Edson, Barbara S.
McNamara, Sara E.
Trautner, Barbara W.
Stone, Nimalie D.
Krein, Sarah L.
Saint, Sanjay
TI Enhancing Resident Safety by Preventing Healthcare-Associated Infection:
A National Initiative to Reduce Catheter-Associated Urinary Tract
Infections in Nursing Homes
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE nursing homes; post-acute care facilities; patient safety; CAUTIs
ID LONG-TERM-CARE; QUALITY IMPROVEMENT; FACILITIES; MORTALITY;
IMPLEMENTATION; COLONIZATION; SURVEILLANCE; DEFINITIONS; GUIDELINE;
CRITERIA
AB Preventing healthcare-associated infection (HAI) is a key contributor to enhancing resident safety in nursing homes. In 2013, the U.S. Department of Health and Human Services approved a plan to enhance resident safety by reducing HAIs in nursing homes, with particular emphasis on reducing indwelling catheter use and catheter-associated urinary tract infection (CAUTI). Lessons learned from a recent multimodal Targeted Infection Prevention program in a group of nursing homes as well as a national initiative to prevent CAUTI in over 950 acute care hospitals called "On the CUSP: STOP CAUTI" will now be implemented in nearly 500 nursing homes in all 50 states through a project funded by the Agency for Healthcare Research and Quality (AHRQ). This "AHRQ Safety Program in Long-Term Care: HAIs/CAUTI" will emphasize professional development in catheter utilization, catheter care and maintenance, and antimicrobial stewardship as well as promoting patient safety culture, team building, and leadership engagement. We anticipate that an approach integrating technical and socio-adaptive principles will serve as a model for future initiatives to reduce other infections, multidrug resistant organisms, and noninfectious adverse events among nursing home residents.
C1 [Mody, Lona] Univ Michigan, Sch Med, Geriatr Res Educ & Clin Ctr, Vet Affairs Ann Arbor Healthcare Syst, Ann Arbor, MI 48109 USA.
[Mody, Lona; McNamara, Sara E.] Univ Michigan, Sch Med, Div Geriatr & Palliat Care Med, Ann Arbor, MI 48109 USA.
[Meddings, Jennifer; Krein, Sarah L.; Saint, Sanjay] Univ Michigan, Sch Med, Div Gen Med, Ann Arbor, MI 48109 USA.
[Meddings, Jennifer] Univ Michigan, Sch Med, Department Internal Med, Div Gen Pediat, Ann Arbor, MI 48109 USA.
[Meddings, Jennifer] Univ Michigan, Sch Med, Dept Pediat & Communicable Dis, Div Gen Pediat, Ann Arbor, MI 48109 USA.
[Edson, Barbara S.] Hlth Res & Educ Trust, Chicago, IL USA.
[Edson, Barbara S.] Baylor Coll Med, Ctr Innovat Qual Effectiveness & Safety IQuESt, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA.
[Trautner, Barbara W.] Baylor Coll Med, Dept Med, Sect Infect Dis, Houston, TX USA.
[Edson, Barbara S.] Baylor Coll Med, Dept Surg, Houston, TX USA.
[Stone, Nimalie D.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA.
[Krein, Sarah L.; Saint, Sanjay] Ctr Clin Management Res, Ann Arbor, MI USA.
[Saint, Sanjay] Vet Affairs Ann Arbor Healthcare Syst, Med Serv, Ann Arbor, MI USA.
RP Mody, L (reprint author), Univ Michigan, Sch Med, Div Geriatr & Palliat Care Med, 300 N Ingalls Rd,Rm 905, Ann Arbor, MI 48109 USA.
EM lonamody@umich.edu
FU Agency for Healthcare Research and Quality (AHRQ), US Department of
Health and Human Services [HHSA 2902010000251]; National Institutes of
Health (NIH) [R01 AG032298, R01 AG41780, R18 HS019979, NIH DK092293];
University of Michigan Claude D. Pepper Older Americans Independence
Center (NIA) [P30 AG024824]; AHRQ [1K08-HS019767-01]; National
Institutes of Health Clinical Loan Repayment Program; Department of
Veterans Affairs [VA] [RRP 12-433]; Center for Innovations in Quality,
Effectiveness and Safety at the Michael E. DeBakey VA Medical Center,
Houston, Texas [CIN13-413]
FX This work was supported by a contract from the Agency for Healthcare
Research and Quality (AHRQ), US Department of Health and Human Services,
Contract Number: HHSA 2902010000251. Other Funding/Support provided by
the National Institutes of Health (NIH) (R01 AG032298, R01 AG41780, R18
HS019979 to L. M.; NIH DK092293 to B. W. T.); the University of Michigan
Claude D. Pepper Older Americans Independence Center (NIA P30 AG024824
to L. M.); AHRQ (1K08-HS019767-01to J. M.); National Institutes of
Health Clinical Loan Repayment Program (2009-2015 to J. M.); Department
of Veterans Affairs [VA RRP 12-433 to B. W. T.]; Center for Innovations
in Quality, Effectiveness and Safety at the Michael E. DeBakey VA
Medical Center, Houston, Texas [CIN13-413 to B. W. T.].
NR 51
TC 9
Z9 9
U1 1
U2 14
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD JUL 1
PY 2015
VL 61
IS 1
BP 86
EP 94
DI 10.1093/cid/civ236
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA CO7EX
UT WOS:000359323500015
PM 25814630
ER
PT J
AU La Madrid, AM
Hashizume, R
Kieran, MW
AF Morales La Madrid, Andres
Hashizume, Rintaro
Kieran, Mark W.
TI Future clinical trials in DIPG: bringing epigenetics to the clinic
SO FRONTIERS IN ONCOLOGY
LA English
DT Review
DE DIPG; epigenetics; clinical trials; children
ID INTRINSIC PONTINE GLIOMA; ACTIVATING ACVR1 MUTATIONS; CANCER; THERAPY;
INHIBITION; SUBGROUPS
AB In spite of major recent advances in diffuse intrinsic pontine glioma (DIPG) molecular characterization, this body of knowledge has not yet translated into better treatments. To date, more than 250 clinical trials evaluating radiotherapy along with conventional cytotoxic chemotherapy as well as newer biologic agents have failed to improve the dismal outcome when compared to palliative radiation alone. The biology of DIPG remained unknown until recently when the neurosurgical expertise along with the recognition by the scientific and clinical community of the importance of tissue sampling at diagnosis; ideally, in the context of a clinical trial and by trained neurosurgical teams to maximize patient safety. These pre-treatment tumor samples, and others coming from tissue obtained post-mortem, have yielded new insights into DIPG molecular pathogenesis. We now know that DIPG comprises a heterogeneous disease with variable molecular phenotypes, different from adult high-grade glioma, other non-pontine pediatric high-grade gliomas, and even between pontine gliomas. The discovery of histone H3.3 or H3.1 mutations has been an important step forward in understanding tumor formation, maintenance, and progression. Pharmacologic reversal of DIPG histone demethylation therefore offers an important potential intervention strategy for the treatment of DIPG. To date, clinical trials of newly diagnosed or progressive DIPG with epigenetic (histone) modifiers have been unsuccessful. Whether this failure represents limited activity of the agents used, their CNS penetration, redundant pathways within the tumor, or the possibility that histone mutations are necessary only to initiate DIPGs but not maintain their growth, suggest that a great deal still needs to be elucidated in both the underlying biology of these pathways and the drugs designed to target them. In this review, we will discuss the role of both epigenetic and genetic mutations within DIPG and the development of treatment strategies directed against the unique abnormalities present in this disease.
C1 [Morales La Madrid, Andres] Hosp St Joan de Deu, Dept Pediat Hematol & Oncol, Pediat Neurooncol, Barcelona, Spain.
[Hashizume, Rintaro] Northwestern Univ, Dept Neurol Surg, Feinberg Sch Med, Chicago, IL 60611 USA.
[Hashizume, Rintaro] Northwestern Univ, Dept Biochem & Mol Genet, Feinberg Sch Med, Chicago, IL 60611 USA.
[Kieran, Mark W.] Boston Childrens Hosp, Dana Farber Canc Inst, Dept Pediat Hematol Oncol, Pediat Neurooncol, Boston, MA USA.
RP La Madrid, AM (reprint author), St Joan de Deu Childrens Hosp, Dept Pediat Hematol & Oncol, Neurooncol Unit, Passeig St Joan de Deu 2, Barcelona 08950, Spain.
EM amorales@hsjdbcn.org; mark_kieran@dfci.harvard.edu
NR 30
TC 0
Z9 0
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD JUL 1
PY 2015
VL 5
AR 148
DI 10.3389/fonc.2015.00148
PG 5
WC Oncology
SC Oncology
GA CO4RQ
UT WOS:000359148700001
ER
PT J
AU Mutumba, M
Musiime, V
Tsai, AC
Byaruhanga, J
Kiweewa, F
Bauermeister, JA
Snow, RC
AF Mutumba, Massy
Musiime, Victor
Tsai, Alexander C.
Byaruhanga, Judith
Kiweewa, Francis
Bauermeister, Jose A.
Snow, Rachel C.
TI Disclosure of HIV Status to Perinatally Infected Adolescents in Urban
Uganda: A Qualitative Study on Timing, Process, and Outcomes
SO JANAC-JOURNAL OF THE ASSOCIATION OF NURSES IN AIDS CARE
LA English
DT Article
DE adolescents; Africa; children; HIV care; infectious diseases; pediatrics
ID HEALTH-CARE; CHILDREN; ZIMBABWE
AB Disclosure of HIV status to children and adolescents living with HIV remains a challenge in pediatric HIV care. Many of the current disclosure guidelines from national and international bodies recommend that perinatally infected children be informed of their HIV status prior to adolescence, but rates of disclosure in both high- and low-income countries remains low. The applicability of the recommendations to low-income countries remains largely unknown, as few studies have explored the disclosure process in these settings. Our purpose was to explore disclosure experiences of HIV-infected adolescents in Uganda. Disclosure was a largely one-time event conducted by health care providers. The average age at disclosure was 13 years. Disclosure elicited a diverse array of positive and negative reactions, including suicidal ideation; reactions were closely associated with participant age, gender, knowledge about HIV, and health status at time of disclosure. Interventions to promote locally effective, process-oriented approaches to early disclosure are needed. Copyright (C) 2015 Association of Nurses in AIDS Care
C1 [Mutumba, Massy] Univ Michigan, Sch Publ Hlth, Ctr Sexual & Hlth Dispar, Ann Arbor, MI 48109 USA.
[Musiime, Victor] Makerere Univ, Coll Hlth Sci, Dept Pediat, Kampala, Uganda.
[Musiime, Victor] Joint Clin Res Ctr, Kampala, Uganda.
[Tsai, Alexander C.] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA.
[Tsai, Alexander C.] Massachusetts Gen Hosp, Div Global Psychiat, Boston, MA 02114 USA.
[Tsai, Alexander C.] Mbarara Univ Sci & Technol, Mbarara, Uganda.
[Byaruhanga, Judith] Joint Clin Res Ctr, Kampala, Uganda.
[Kiweewa, Francis] Makerere Univ, Walter Reed Project, Res & Sci Affairs, Kampala, Uganda.
[Bauermeister, Jose A.; Snow, Rachel C.] Univ Michigan, Sch Publ Hlth, Dept Hlth Behav & Hlth Educ, Ann Arbor, MI 48109 USA.
RP Mutumba, M (reprint author), Univ Michigan, Sch Publ Hlth, Ctr Sexual & Hlth Dispar, Ann Arbor, MI 48109 USA.
OI Mutumba, Massy/0000-0002-0636-891X; Tsai, Alexander/0000-0001-6397-7917;
Bauermeister, Jose/0000-0002-9276-2306
FU University of Michigan
FX This study was facilitated through grants from various institutions at
the University of Michigan. We are especially grateful for the
management and staff at the Joint Clinical Research Center, Kampala,
especially the Pediatric Clinic for their willingness to share their
time and insights. Special thanks also to all the respondents who so
willingly labored through the interviews and focus group discussions to
share their unique insights.
NR 33
TC 3
Z9 3
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1055-3290
EI 1552-6917
J9 J ASSOC NURSE AIDS C
JI J. Assoc. Nurses Aids Care
PD JUL-AUG
PY 2015
VL 26
IS 4
BP 472
EP 484
DI 10.1016/j.jana.2015.02.001
PG 13
WC Nursing
SC Nursing
GA CO2QI
UT WOS:000359001300018
PM 26066697
ER
PT J
AU Gant-Clark, V
Skipper, J
McCrackin, M
Gaillard, S
Coxe, DN
AF Gant-Clark, Vanessa
Skipper, Janice
McCrackin, Monica
Gaillard, Stacy
Coxe, D. Nicole
TI Veterans and HIV Screening Rates: Why Veterans Are Not Getting Tested, a
Veterans Affairs Nursing Academic Partnership (VANAP) Study
SO JANAC-JOURNAL OF THE ASSOCIATION OF NURSES IN AIDS CARE
LA English
DT Article
DE barriers to HIV screening; HIV testing; veterans; Veterans Affairs
Nursing Academic Partnership
C1 [Gant-Clark, Vanessa; Skipper, Janice; Gaillard, Stacy] Ralph H Johnson VA Med Ctr VAMC, Clin Fac, VANAP, Charleston, SC 29401 USA.
[McCrackin, Monica; Coxe, D. Nicole] Ralph H Johnson VAMC, Charleston, SC USA.
RP Gant-Clark, V (reprint author), Ralph H Johnson VA Med Ctr VAMC, Clin Fac, VANAP, Charleston, SC 29401 USA.
FU Center for Community Health Partnerships for the Community Engaged
Scholars Program (MUSC)
FX This study was an initiative of the Veterans Affairs Nursing Academic
Partnership (VANAP) Clinical Nursing Faculty, and their academic
partners, the Medical University of South Carolina's College of Nursing
(MUSC CON) in cooperation with the VA Office of Academic Affiliations.
It was funded by a collaborative grant from the Center for Community
Health Partnerships for the Community Engaged Scholars Program (MUSC,
2012). Charlene Pope, PhD, MPH, RN, Associate Nurse Executive for
Research at the Ralph H. Johnson VA Medical Center (VAMC), was
instrumental in the grant writing and mentoring through the
institutional review board process. During the implementation of the
method, MUSC CON Community Health Students were involved for three
different semesters. They were instrumental in conducting focus groups,
marketing, recruiting, and data collection. Low Country AIDS Services
provided initial data regarding the state of South Carolina's HIV
infection test results, broken down by counties. Ms. Lynn Nes, PhD, RN,
provided assistance with the NVivo program. Dr. Jan York, PhD, RN,
brought expertise in the writing for journal specificity. Preston
Church, MD, Chief of Infectious Diseases at Ralph H. Johnson VAMC, was
supportive in assisting veterans with access to care. Stephen Lesieur,
MSN, RN, and Erica Grate-Simmons, MSN, RN, were contributing VANAP
Faculty. Finally, we wish to thank our veterans for their continued
service to our country and their enthusiasm in helping conduct this
research study.
NR 10
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1055-3290
EI 1552-6917
J9 J ASSOC NURSE AIDS C
JI J. Assoc. Nurses Aids Care
PD JUL-AUG
PY 2015
VL 26
IS 4
BP 485
EP 491
DI 10.1016/j.jana.2015.03.002
PG 7
WC Nursing
SC Nursing
GA CO2QI
UT WOS:000359001300019
PM 26066698
ER
PT J
AU Llico, AF
Zanartu, M
Gonzalez, AJ
Wodicka, GR
Mehta, DD
Van Stan, JH
Hillman, RE
AF Llico, Andres F.
Zanartu, Matias
Gonzalez, Agustin J.
Wodicka, George R.
Mehta, Daryush D.
Van Stan, Jarrad H.
Hillman, Robert E.
TI Real-time estimation of aerodynamic features for ambulatory voice
biofeedback
SO JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA
LA English
DT Article
ID VOCAL HYPERFUNCTION
AB The development of ambulatory voice monitoring devices has the potential to improve the diagnosis and treatment of voice disorders. In this proof-of-concept study, real-time biofeedback is incorporated into a smartphone-based platform that records and processes neck surface acceleration. The focus is on utilizing aerodynamic measures of vocal function as a basis for biofeedback. This is done using regressed Z-scores to compare recorded values to normative estimates based on sound pressure level and fundamental frequency. Initial results from the analysis of different voice qualities suggest that accelerometer-based estimates of aerodynamic parameters can be used for real-time ambulatory biofeedback. (C) 2015 Acoustical Society of America
C1 [Llico, Andres F.; Zanartu, Matias; Gonzalez, Agustin J.] Univ Tecn Federico Santa Maria, Dept Elect Engn, Valparaiso, Chile.
[Wodicka, George R.] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA.
[Mehta, Daryush D.; Van Stan, Jarrad H.; Hillman, Robert E.] Massachusetts Gen Hosp, Ctr Laryngeal Surg & Voice Rehabil, Boston, MA 02114 USA.
[Wodicka, George R.] Purdue Univ, Sch Elect & Comp Engn, W Lafayette, IN 47907 USA.
[Mehta, Daryush D.; Hillman, Robert E.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Mehta, Daryush D.; Van Stan, Jarrad H.; Hillman, Robert E.] MGH Inst Hlth Profess, Boston, MA 02114 USA.
RP Zanartu, M (reprint author), Univ Tecn Federico Santa Maria, Dept Elect Engn, Valparaiso, Chile.
EM andres.llico@usm.cl; matias.zanartu@usm.cl; agustin.gonzalez@usm.cl;
wodicka@purdue.edu; mehta.daryush@mgh.harvard.edu; jvanstan@mghihp.edu;
hillman.robert@mgh.harvard.edu
RI Zanartu, Matias/I-3133-2012; researchers, ac3e/N-2008-2016
OI Zanartu, Matias/0000-0001-5581-4392;
FU NIH-NIDCD [R33 DC011588, F31 DC014412]; MIT MISTI [MIT-Chile 2745333];
Voice Health Institute; CONICYT [FONDECYT 11110147, Basal FB0008]
FX This work was supported by NIH-NIDCD Grants Nos. R33 DC011588 and F31
DC014412, CONICYT grants FONDECYT 11110147 and Basal FB0008, MIT MISTI
Grant No. MIT-Chile 2745333, and a grant from the Voice Health
Institute. A.F.L. acknowledges support provided by CONICYT and UTFSM.
The contents of this paper are solely the responsibility of the authors
and do not necessarily represent the official views of the NIH.
NR 10
TC 2
Z9 2
U1 0
U2 2
PU ACOUSTICAL SOC AMER AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0001-4966
EI 1520-8524
J9 J ACOUST SOC AM
JI J. Acoust. Soc. Am.
PD JUL
PY 2015
VL 138
IS 1
BP EL14
EP EL19
DI 10.1121/1.4922364
PG 6
WC Acoustics; Audiology & Speech-Language Pathology
SC Acoustics; Audiology & Speech-Language Pathology
GA CO1QB
UT WOS:000358929000003
PM 26233054
ER
PT J
AU Tse, JR
Zhang, ZY
Long, JL
AF Tse, Justin R.
Zhang, Zhaoyan
Long, Jennifer L.
TI Effects of vocal fold epithelium removal on vibration in an excised
human larynx model
SO JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA
LA English
DT Article
ID PHONATION THRESHOLD PRESSURE
AB This study investigated the impact of selective epithelial injury on phonation in an excised human larynx apparatus. With intact epithelium, the vocal folds exhibited a symmetrical vibration pattern with complete glottal closure during vibration. The epithelium was then enzymatically removed from one, then both vocal folds, which led to left-right asymmetric vibration and a decreased closed quotient. Although the mechanisms underlying these vibratory changes are unclear, these results demonstrate that some component of an intact surface layer may play an important role in achieving normal symmetric vibration and glottal closure. (C) 2015 Acoustical Society of America
C1 [Tse, Justin R.; Zhang, Zhaoyan; Long, Jennifer L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Head & Neck Surg, Los Angeles, CA 90095 USA.
[Long, Jennifer L.] VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90074 USA.
RP Long, JL (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Head & Neck Surg, CHS Room 62-132,650 Charles Young Dr, Los Angeles, CA 90095 USA.
EM jrtse@mednet.ucla.edu; zyzhang@ucla.edu; jlong@mednet.ucla.edu
RI Zhang, Zhaoyan/E-5215-2013;
OI Zhang, Zhaoyan/0000-0002-2379-6086; Long, Jennifer/0000-0002-4185-2328
FU National Institute on Deafness and Other Communication Disorders at the
National Institutes of Health [R01DC011299]; Department of Veteran's
Affairs Career Development Award [IK2BX001944]; AOmegaA Carolyn L.
Kuckien Student Research Fellowship
FX This study was supported by Research Grant No. R01DC011299 from the
National Institute on Deafness and Other Communication Disorders at the
National Institutes of Health (Z.Z.); Research Grant No. IK2BX001944
from the Department of Veteran's Affairs Career Development Award
(J.L.L.); and the A Omega A Carolyn L. Kuckien Student Research
Fellowship (J.R.T.). We would like to thank Dr. Yue Xuan for technical
support.
NR 12
TC 3
Z9 3
U1 0
U2 0
PU ACOUSTICAL SOC AMER AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0001-4966
EI 1520-8524
J9 J ACOUST SOC AM
JI J. Acoust. Soc. Am.
PD JUL
PY 2015
VL 138
IS 1
BP EL60
EP EL64
DI 10.1121/1.4922765
PG 5
WC Acoustics; Audiology & Speech-Language Pathology
SC Acoustics; Audiology & Speech-Language Pathology
GA CO1QB
UT WOS:000358929000011
PM 26233062
ER
PT J
AU Caceres, CF
O'Reilly, KR
Mayer, KH
Baggaley, R
AF Caceres, Carlos F.
O'Reilly, Kevin R.
Mayer, Kenneth H.
Baggaley, Rachel
TI PrEP implementation: moving from trials to policy and practice
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Editorial Material
DE HIV; PrEP; key populations; scale-up; implementation science
AB Introduction: It is increasingly clear that the HIV response will not be sustainable if the number of infections is not significantly reduced.
Discussion: For two decades, research has been ongoing to identify new behavioural and biomedical strategies to prevent HIV infection. In the past few years, the efficacy of several new strategies has been demonstrated, including oral pre-exposure prophylaxis (PrEP; i.e. daily use of tenofovir/emtricitabine). Because several social, political and logistic barriers remain, however, optimal PrEP implementation will require a better dissemination of new evidence in a number of areas and additional implementation research from various disciplinary perspectives (i.e. social science, policy and ethics; health systems; and economics, including cost-effectiveness studies). Discussion of new evidence on those topics, as well as case studies of potential PrEP implementation in diverse environments, can improve the understanding of the role that PrEP may play in addressing the global HIV/AIDS epidemic.
In light of these needs, the Network for Multidisciplinary Studies in ARV-based HIV Prevention (NEMUS) and the World Health Organization (WHO) were honoured to co-organize a special issue of JIAS aimed at contributing to a scholarly discussion of current conditions surrounding PrEP implementation, potential impact and efficiency, social science concerns and the study of PrEP implementation in specific country cases. The papers included in this monograph identify and cover many of the main aspects of the complex yet promising discussions around PrEP implementation today.
Conclusions: This is a collection of timely contributions from global leaders in HIV research and policy that addresses geographic diversity, uses a trans-disciplinary approach and covers a variety of the complex issues raised by PrEP. As this publication will become accessible to all, we hope that it will remain a valuable resource for policy makers, programme managers, researchers and activists around the world at a moment of a paradigm shift of the global response to HIV.
C1 [Caceres, Carlos F.] Cayetano Heredia Univ, Ctr Interdisciplinary Studies Sexual AIDS & Soc, Lima 18, Peru.
[O'Reilly, Kevin R.; Baggaley, Rachel] WHO, HIV Programme, CH-1211 Geneva, Switzerland.
[Mayer, Kenneth H.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr Boston, Fenway Hlth, Boston, MA USA.
RP Caceres, CF (reprint author), Cayetano Heredia Univ, Ctr Interdisciplinary Studies Sexual AIDS & Soc, Av Armendariz 445, Lima 18, Peru.
EM Carlos.caceres@upch.pe
OI Caceres, Carlos/0000-0002-8101-0790
FU NIAID NIH HHS [R01 AI099727]; NIMH NIH HHS [R21 MH102135]; World Health
Organization [001]
NR 10
TC 9
Z9 9
U1 2
U2 7
PU INT AIDS SOCIETY
PI GENEVA
PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND
SN 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2015
VL 18
SU 3
BP 1
EP 4
AR 20222
DI 10.7448/IAS.18.4.20222
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA CN8FQ
UT WOS:000358675400001
PM 26198349
ER
PT J
AU Ajibola, G
Shapiro, R
Zash, R
Holmes, L
Batlang, O
Ramogothobeng, K
Chilisa, F
Bennett, K
Makhema, J
Lockman, S
Powis, K
AF Ajibola, Gbolahan
Shapiro, Roger
Zash, Rebecca
Holmes, Lewis
Batlang, Oganne
Ramogothobeng, Kerapetse
Chilisa, Florence
Bennett, Kara
Makhema, Joseph
Lockman, Shahin
Powis, Kathleen
TI Importance of programmatic longitudinal surveillance for identification
of congenital anomalies among infants exposed to HIV-1 and
antiretrovirals: findings from the Mpepu Study, Botswana
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Ajibola, Gbolahan; Zash, Rebecca; Batlang, Oganne; Ramogothobeng, Kerapetse; Chilisa, Florence; Makhema, Joseph; Lockman, Shahin; Powis, Kathleen] Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana.
[Shapiro, Roger; Lockman, Shahin; Powis, Kathleen] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
[Shapiro, Roger; Zash, Rebecca] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA.
[Holmes, Lewis] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
[Bennett, Kara] Bennett Stat Consulting, Ballston Lake, NY USA.
[Lockman, Shahin] Brigham & Womens Hosp, Infect Dis Unit, Boston, MA 02115 USA.
[Powis, Kathleen] Massachusetts Gen Hosp, Dept Internal Med, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INT AIDS SOCIETY
PI GENEVA
PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND
SN 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2015
VL 18
SU 4
MA MOPDB0104
DI 10.7448/IAS.18.5.20428
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA CN8FS
UT WOS:000358675700146
ER
PT J
AU Karn, J
Das, B
Dobrowolski, C
Scully, E
Deeks, S
Gandhi, M
Johnston, R
AF Karn, Jonathan
Das, Biswajit
Dobrowolski, Curtis
Scully, Eileen
Deeks, Steven
Gandhi, Monica
Johnston, Rowena
TI Oestrogen blocks HIV re-emergence from latency and points to
gender-specific differences in HIV reservoirs
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Karn, Jonathan; Das, Biswajit; Dobrowolski, Curtis] Case Western Reserve Univ, Sch Med, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA.
[Scully, Eileen] Brigham & Womens, Boston, MA USA.
[Scully, Eileen] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Deeks, Steven; Gandhi, Monica] UCSF Sch Med, San Francisco, CA USA.
[Johnston, Rowena] Fdn AIDS Res, AmfAR, New York, NY USA.
EM jonathan.karn@case.edu
NR 0
TC 0
Z9 0
U1 1
U2 4
PU INT AIDS SOCIETY
PI GENEVA
PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND
SN 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD JUL
PY 2015
VL 18
SU 4
MA TUAA0205LB
DI 10.7448/IAS.18.5.20543
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA CN8FS
UT WOS:000358675700056
ER
PT J
AU Lin, AP
Abbas, S
Kim, SW
Ortega, M
Bouamar, H
Escobedo, Y
Varadarajan, P
Qin, YJ
Sudderth, J
Schulz, E
Deutsch, A
Mohan, S
Ulz, P
Neumeister, P
Rakheja, D
Gao, XL
Hinck, A
Weintraub, ST
DeBerardinis, RJ
Sill, H
Dahia, PLM
Aguiar, RCT
AF Lin, An-Ping
Abbas, Saman
Kim, Sang-Woo
Ortega, Manoela
Bouamar, Hakim
Escobedo, Yissela
Varadarajan, Prakash
Qin, Yuejuan
Sudderth, Jessica
Schulz, Eduard
Deutsch, Alexander
Mohan, Sumitra
Ulz, Peter
Neumeister, Peter
Rakheja, Dinesh
Gao, Xiaoli
Hinck, Andrew
Weintraub, Susan T.
DeBerardinis, Ralph J.
Sill, Heinz
Dahia, Patricia L. M.
Aguiar, Ricardo C. T.
TI D2HGDH regulates alpha-ketoglutarate levels and dioxygenase function by
modulating IDH2
SO NATURE COMMUNICATIONS
LA English
DT Article
ID B-CELL LYMPHOMA; D-2-HYDROXYGLUTARIC ACIDURIA; L-2-HYDROXYGLUTARATE
DEHYDROGENASE; GENETIC-HETEROGENEITY; TUMOR-CELLS; MUTATIONS; CANCER;
2-HYDROXYGLUTARATE; ONCOMETABOLITE; PATHWAY
AB Isocitrate dehydrogenases (IDH) convert isocitrate to alpha-ketoglutarate (alpha-KG). In cancer, mutant IDH1/2 reduces alpha-KG to D2-hydroxyglutarate (D2-HG) disrupting alpha-KG-dependent dioxygenases. However, the physiological relevance of controlling the interconversion of D2-HG into alpha-KG, mediated by D2-hydroxyglutarate dehydrogenase (D2HGDH), remains obscure. Here we show that wild-type D2HGDH elevates alpha-KG levels, influencing histone and DNA methylation, and HIF1 alpha hydroxylation. Conversely, the D2HGDH mutants that we find in diffuse large B-cell lymphoma are enzymatically inert. D2-HG is a low-abundance metabolite, but we show that it can meaningfully elevate alpha-KG levels by positively modulating mitochondrial IDH activity and inducing IDH2 expression. Accordingly, genetic depletion of IDH2 abrogates D2HGDH effects, whereas ectopic IDH2 rescues D2HGDH-deficient cells. Our data link D2HGDH to cancer and describe an additional role for the enzyme: the regulation of IDH2 activity and alpha-KG-mediated epigenetic remodelling. These data further expose the intricacies of mitochondrial metabolism and inform on the pathogenesis of D2HGDH-deficient diseases.
C1 [Lin, An-Ping; Abbas, Saman; Kim, Sang-Woo; Ortega, Manoela; Bouamar, Hakim; Escobedo, Yissela; Varadarajan, Prakash; Qin, Yuejuan; Dahia, Patricia L. M.; Aguiar, Ricardo C. T.] Univ Texas Hlth Sci Ctr San Antonio, Div Hematol & Med Oncol, Dept Med, San Antonio, TX 78229 USA.
[Sudderth, Jessica; Rakheja, Dinesh; DeBerardinis, Ralph J.] Univ Texas Southwestern, Dept Pediat, Childrens Med Ctr, Res Inst, Dallas, TX 75390 USA.
[Schulz, Eduard; Deutsch, Alexander; Neumeister, Peter; Sill, Heinz] Med Univ Graz, Div Hematol, A-8036 Graz, Austria.
[Mohan, Sumitra; Ulz, Peter] Med Univ Graz, Inst Human Genet, A-8036 Graz, Austria.
[Rakheja, Dinesh] Univ Texas SW Med Ctr Dallas, Dept Pathol & Pediat, Dallas, TX 75390 USA.
[Gao, Xiaoli; Hinck, Andrew; Weintraub, Susan T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
[Dahia, Patricia L. M.; Aguiar, Ricardo C. T.] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA.
[Dahia, Patricia L. M.; Aguiar, Ricardo C. T.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA.
[Aguiar, Ricardo C. T.] South Texas Vet Hlth Care Syst, Audie Murphy VA Hosp, San Antonio, TX 78229 USA.
RP Aguiar, RCT (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Hematol & Med Oncol, Dept Med, San Antonio, TX 78229 USA.
EM aguiarr@uthscsa.edu
OI Sill, Heinz/0000-0003-0993-4371; Ulz, Peter/0000-0001-5941-1160
FU NIH [R01-CA138747]; CPRIT [RP140452]; Voelcker Fund; Leukamiehilfe
Steiermark; Cancer Center support grant [P30 CA054174]; UTHSCSA;
National Institutes of Health [1S10RR031586-01]
FX We thank Marsha Kinney and the Pathology Core Laboratory at the
University of Texas HSC San Antonio for procurement of the primary DLBCL
samples; C. Beham-Schmid for providing bone marrow specimens; K. Lind
and S. Hofer for VNTR analyses. This work was supported by an NIH grant
R01-CA138747 (to R.C.T.A.), a CPRIT award RP140452 (to R.C.T.A.), Young
Investigator Awards from the Voelcker Fund (to P.L.M.D. and R.C.T.A.),
Leukamiehilfe Steiermark (to H.S.), and a Cancer Center support grant
P30 CA054174. Mass spectrometry analyses were conducted in the
metabolomics component of the UTHSCSA Mass Spectrometry Laboratory,
supported by UTHSCSA and by an award from the National Institutes of
Health, 1S10RR031586-01 (S.T.W.).
NR 45
TC 6
Z9 6
U1 1
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUL
PY 2015
VL 6
AR 7768
DI 10.1038/ncomms8768
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CO0RK
UT WOS:000358859700005
PM 26178471
ER
PT J
AU Reddy, VB
Sun, SH
Azimi, E
Elmariah, SB
Dong, XZ
Lerner, EA
AF Reddy, Vemuri B.
Sun, Shuohao
Azimi, Ehsan
Elmariah, Sarina B.
Dong, Xinzhong
Lerner, Ethan A.
TI Redefining the concept of protease-activated receptors: cathepsin S
evokes itch via activation of Mrgprs
SO NATURE COMMUNICATIONS
LA English
DT Article
ID MOLECULAR-CLONING; ATOPIC-DERMATITIS; PAIN; MECHANISM; GPCRS;
HYPERALGESIA; PSORIASIS; PRURITUS; PEPTIDE; NEURONS
AB Sensory neurons expressing Mas-related G-protein-coupled receptors (Mrgprs) mediate histamine-independent itch. We show that the cysteine protease cathepsin S activates MrgprC11 and evokes receptor-dependent scratching in mice. In contrast to its activation of conventional protease-activated receptors, cathepsin S-mediated activation of MrgprC11 did not involve the generation of a tethered ligand. We demonstrate further that different cysteine proteases selectively activate specific mouse and human Mrgpr family members. This expansion of our understanding by which proteases interact with G-protein-coupled receptors (GPCRs) redefines the concept of what constitutes a protease-activated receptor. The findings also implicate proteases as ligands to members of this orphan receptor family while providing new insights into how cysteine proteases contribute to itch.
C1 [Reddy, Vemuri B.; Azimi, Ehsan; Elmariah, Sarina B.; Lerner, Ethan A.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Dept Dermatol, Boston, MA 02129 USA.
[Sun, Shuohao; Dong, Xinzhong] Johns Hopkins Univ, Dept Neurosci, Baltimore, MD 21205 USA.
RP Lerner, EA (reprint author), Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Dept Dermatol, Boston, MA 02129 USA.
EM elerner@mgh.harvard.edu
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases;
National Institutes of Neurological Disease and Stroke of the National
Institutes of Health [R01AR05744, R21AR067399, R01NS054791]; LEO Pharma;
Dermatology Foundation; Women's Dermatologic Society; National Eczema
Association
FX Research reported in this publication was supported by the National
Institute of Arthritis and Musculoskeletal and Skin Diseases and the
National Institutes of Neurological Disease and Stroke of the National
Institutes of Health under Award Numbers R01AR05744 and R21AR067399 to
E.A.L. and R01NS054791 to X.D. The content is solely the responsibility
of the authors and does not necessarily represent the official views of
the National Institutes of Health. X.D. is an Early Career Scientist of
the Howard Hughes Medical Institute. Support was also provided by a
grant from LEO Pharma to E.A.L. S.B.E. is the recipient of a Career
Development Award from the Dermatology Foundation and received support
from the Women's Dermatologic Society. E.A. is the recipient of a grant
from the National Eczema Association.
NR 37
TC 9
Z9 9
U1 2
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUL
PY 2015
VL 6
AR 7864
DI 10.1038/ncomms8864
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CO0SD
UT WOS:000358861700004
PM 26216096
ER
PT J
AU Rehani, MM
AF Rehani, M. M.
TI LOOKING INTO FUTURE: CHALLENGES IN RADIATION PROTECTION IN MEDICINE
SO RADIATION PROTECTION DOSIMETRY
LA English
DT Article
ID COMPUTED-TOMOGRAPHY; CANCER-RISK; CT SCANS; EXPOSURE; TRACKING;
CHILDHOOD
AB Radiation protection in medicine is becoming more and more important with increasing wider use of X-rays, documentation of effects besides the potential for long-term carcinogenic effects. With computed tomography (CT) likely to become sub-mSv in coming years, positron emission tomography (PET), single photon emission computed tomography (SPECT) and some of the nuclear medical examination will become focus of attraction as high-dose examinations, even though they are less-frequent ones. Clarity will be needed on radiation effects at levels of radiation doses encountered in a couple of CT scans and if effects are really cumulative. There is challenge to develop radiation metrics that can be used as easily as units of temperature and length and avoidance of multiple meaning of a single dose metric. Other challenges include development of biological indicators of radiation dose, transition from dose to a representative phantom to dose to individual patient, system for tracking of radiation exposure history of patient, avoidance of radiation-induced skin injury in patients and radiation cataract in staff, cutting down inappropriate referrals for radiological examinations, confidence building in patient and patient safety in radiotherapy.
C1 [Rehani, M. M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Rehani, M. M.] Harvard Univ, Sch Med, Boston, MA USA.
RP Rehani, MM (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM madan.rehani@gmail.com
NR 19
TC 2
Z9 2
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0144-8420
EI 1742-3406
J9 RADIAT PROT DOSIM
JI Radiat. Prot. Dosim.
PD JUL
PY 2015
VL 165
IS 1-4
BP 3
EP 6
DI 10.1093/rpd/ncv071
PG 4
WC Environmental Sciences; Public, Environmental & Occupational Health;
Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical
Imaging
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Nuclear Science & Technology; Radiology, Nuclear Medicine &
Medical Imaging
GA CN5DF
UT WOS:000358449300002
PM 25848110
ER
PT J
AU Rehani, MM
AF Rehani, M. M.
TI RADIATION EFFECTS AND RISKS: OVERVIEW AND A NEW RISK PERCEPTION INDEX
SO RADIATION PROTECTION DOSIMETRY
LA English
DT Article
AB Uncertainty provides opportunities for differences in perception, and radiation risks at low level of exposures involved in few computed tomography scans fall in this category. While there is good agreement among national and international organisations on risk probability of cancer, risk perception has barely been dealt with by these organisations. Risk perception is commonly defined as the subjective judgment that people make about the characteristics and severity of a risk. Severity and latency are important factors in perception. There is a need to connect all these. Leaving risk perception purely as a subjective judgement provides opportunities for people to amplifying risk. The author postulates a risk perception index as severity divided by latency that becomes determining factor for risk perception. It is hoped that this index will bring rationality in risk perception.
C1 [Rehani, M. M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Rehani, M. M.] Harvard Univ, Sch Med, Boston, MA USA.
RP Rehani, MM (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM madan.rehani@gmail.com
NR 6
TC 0
Z9 0
U1 1
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0144-8420
EI 1742-3406
J9 RADIAT PROT DOSIM
JI Radiat. Prot. Dosim.
PD JUL
PY 2015
VL 165
IS 1-4
BP 7
EP 9
DI 10.1093/rpd/ncv117
PG 3
WC Environmental Sciences; Public, Environmental & Occupational Health;
Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical
Imaging
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Nuclear Science & Technology; Radiology, Nuclear Medicine &
Medical Imaging
GA CN5DF
UT WOS:000358449300003
PM 25836696
ER
PT J
AU Rehani, MM
Holmberg, O
AF Rehani, M. M.
Holmberg, O.
TI IAEA EXPERIENCE IN COMMUNICATING RADIATION RISKS THROUGH THE RPOP
WEBSITE
SO RADIATION PROTECTION DOSIMETRY
LA English
DT Article
ID PROTECTION
AB The authors report here their successful experience of communicating information to health professionals, patients and the public on benefits and risks of ionising radiation in medical applications. The approaches used have been based on giving importance to clinical benefits against risks, as well as safety in use against risk of use. Communicating brief messages against catchy questions with positive and pragmatic approach resulted in making website on radiation protection of patients (RPOP) as the top website of the world in this area. Credibility of information has been maintained. The results show immense outreach in 213 countries/territories.
C1 [Rehani, M. M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Rehani, M. M.] Harvard Univ, Sch Med, Boston, MA USA.
[Rehani, M. M.] Exint Atom Energy Agcy, Vienna, Austria.
[Holmberg, O.] IAEA, A-1400 Vienna, Austria.
RP Rehani, MM (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM madan.rehani@gmail.com
NR 4
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0144-8420
EI 1742-3406
J9 RADIAT PROT DOSIM
JI Radiat. Prot. Dosim.
PD JUL
PY 2015
VL 165
IS 1-4
BP 22
EP 24
DI 10.1093/rpd/ncv042
PG 3
WC Environmental Sciences; Public, Environmental & Occupational Health;
Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical
Imaging
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Nuclear Science & Technology; Radiology, Nuclear Medicine &
Medical Imaging
GA CN5DF
UT WOS:000358449300007
PM 25813478
ER
PT J
AU Rehani, MM
AF Rehani, M. M.
TI TRACKING OF EXAMINATION AND DOSE: OVERVIEW
SO RADIATION PROTECTION DOSIMETRY
LA English
DT Article
ID PATIENT EXPOSURE TRACKING; RADIATION-EXPOSURE; SMART CARD
AB This paper reviews the developments in tracking of patient exposures and dose after the earlier paper published in the same journal in 2011. A global survey in which 76 countries responded indicated strong interest in programme and another survey among referring physicians showed vast majority (71.7 %) of physicians expressing that awareness of previous history of CT scans would always or mostly lead them to a better decision on referring patients for CT scans. A sizable number of countries have system of assigning permanent ID to individuals and nearly half of them use this ID in medical records. This can easily permit tracking of exposures. Templates for tracking at different levels of health care have been provided, and experience from a country where tracking is routinely practised has been published.
C1 [Rehani, M. M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Rehani, M. M.] Harvard Univ, Sch Med, Boston, MA USA.
[Rehani, M. M.] Exint Atom Energy Agcy, Vienna, Austria.
RP Rehani, MM (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM madan.rehani@gmail.com
NR 10
TC 4
Z9 4
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0144-8420
EI 1742-3406
J9 RADIAT PROT DOSIM
JI Radiat. Prot. Dosim.
PD JUL
PY 2015
VL 165
IS 1-4
BP 50
EP 52
DI 10.1093/rpd/ncv026
PG 3
WC Environmental Sciences; Public, Environmental & Occupational Health;
Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical
Imaging
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Nuclear Science & Technology; Radiology, Nuclear Medicine &
Medical Imaging
GA CN5DF
UT WOS:000358449300014
PM 25790824
ER
PT J
AU Rehani, MM
AF Rehani, Madan M.
TI DOSE SURVEYS AND DRLS: CRITICAL LOOK AND WAY FORWARD
SO RADIATION PROTECTION DOSIMETRY
LA English
DT Article
AB The main purpose of dose surveys has been to detect and bring down wide variation in radiation doses for any particular radiological examination and to avoid doses that are on higher side. Diagnostic reference levels (DRLs) have been used for over two decades as an aid in this objective. With very limited success that has been achieved through DRL, the author has recently described a new term 'acceptable quality dose' (AQD) that is aimed at optimisation within the DRL, is facility initiated and takes into account all three important parameters-image quality, dose and patient's body build. It is hoped that AQD will be found easy to establish, will be a useful tool to achieve optimisation in the facilities and will serve as the standard dose.
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA.
RP Rehani, MM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA.
EM madan.rehani@gmail.com
NR 15
TC 1
Z9 1
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0144-8420
EI 1742-3406
J9 RADIAT PROT DOSIM
JI Radiat. Prot. Dosim.
PD JUL
PY 2015
VL 165
IS 1-4
BP 67
EP 69
DI 10.1093/rpd/ncv063
PG 3
WC Environmental Sciences; Public, Environmental & Occupational Health;
Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical
Imaging
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Nuclear Science & Technology; Radiology, Nuclear Medicine &
Medical Imaging
GA CN5DF
UT WOS:000358449300018
PM 25809110
ER
PT J
AU Vassileva, J
Rehani, M
Kostova-Lefterova, D
Al-Naemi, HM
Al Suwaidi, JS
Arandjic, D
Bashier, EHO
Renha, SK
El-Nachef, L
Aguilar, JG
Gershan, V
Gershkevitsh, E
Gruppetta, E
Hustuc, A
Jauhari, A
Kharita, MH
Khelassi-Toutaoui, N
Khosravi, HR
Khoury, H
Kralik, I
Mahere, S
Mazuoliene, J
Mora, P
Muhogora, W
Muthuvelu, P
Nikodemova, D
Novak, L
Pallewatte, A
Pekarovic, D
Shaaban, M
Shelly, E
Stepanyan, K
Thelsy, N
Visrutaratna, P
Zaman, A
AF Vassileva, J.
Rehani, M.
Kostova-Lefterova, D.
Al-Naemi, H. M.
Al Suwaidi, J. S.
Arandjic, D.
Bashier, E. H. O.
Kodlulovich Renha, S.
El-Nachef, L.
Aguilar, J. G.
Gershan, V.
Gershkevitsh, E.
Gruppetta, E.
Hustuc, A.
Jauhari, A.
Kharita, Mohammad Hassan
Khelassi-Toutaoui, N.
Khosravi, H. R.
Khoury, H.
Kralik, I.
Mahere, S.
Mazuoliene, J.
Mora, P.
Muhogora, W.
Muthuvelu, P.
Nikodemova, D.
Novak, L.
Pallewatte, A.
Pekarovic, D.
Shaaban, M.
Shelly, E.
Stepanyan, K.
Thelsy, N.
Visrutaratna, P.
Zaman, A.
TI A STUDY TO ESTABLISH INTERNATIONAL DIAGNOSTIC REFERENCE LEVELS FOR
PAEDIATRIC COMPUTED TOMOGRAPHY
SO RADIATION PROTECTION DOSIMETRY
LA English
DT Article
ID RADIATION-EXPOSURE; LATIN-AMERICA; 40 COUNTRIES; CT EXPOSURE; IAEA
SURVEY; RISK; CHILDREN; CANCER; EUROPE; ASIA
AB The article reports from the largest international dose survey in paediatric computed tomography (CT) in 32 countries and proposes international diagnostic reference levels (DRLs) in terms of computed tomography dose index (CTDIvol) and dose length product (DLP). It also assesses whether mean or median values of individual facilities should be used. A total of 6115 individual patient data were recorded among four age groups: <1 y, >1-5 y, >5-10 y and >10-15 y. CTDIw, CTDIvol and DLP from the CT console were recorded in dedicated forms together with patient data and technical parameters. Statistical analysis was performed, and international DRLs were established at rounded 75th percentile values of distribution of median values from all CT facilities. The study presents evidence in favour of using median rather than mean of patient dose indices as the representative of typical local dose in a facility, and for establishing DRLs as third quartile of median values. International DRLs were established for paediatric CT examinations for routine head, chest and abdomen in the four age groups. DRLs for CTDIvol are similar to the reference values from other published reports, with some differences for chest and abdomen CT. Higher variations were observed between DLP values, based on a survey of whole multi-phase exams. It may be noted that other studies in literature were based on single phase only. DRLs reported in this article can be used in countries without sufficient medical physics support to identify non-optimised practice. Recommendations to improve the accuracy and importance of future surveys are provided.
C1 [Vassileva, J.] IAEA, A-1400 Vienna, Austria.
[Rehani, M.] Harvard Univ, Sch Med, Boston, MA USA.
[Rehani, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Kostova-Lefterova, D.] Natl Ctr Radiobiol & Radiat Protect, Sofia, Bulgaria.
[Al-Naemi, H. M.] Hamad Med Corp, Doha, Qatar.
[Al Suwaidi, J. S.] Dubai Hlth Author, Med Educ Dept, Dubai, U Arab Emirates.
[Arandjic, D.] Vinca Inst Nucl Sci, Radiat Protect Dept, Belgrade, Serbia.
[Bashier, E. H. O.] Sudan Atom Energy Commiss, Khartoum, Sudan.
[Kodlulovich Renha, S.] Natl Nucl Energy Commiss, Rio De Janeiro, Brazil.
[El-Nachef, L.] Lebanese Atom Eneregy Commiss, Beirut, Lebanon.
[Aguilar, J. G.] Natl Inst Nucl Res, La Marquesa, Ocoyoacac, Mexico.
[Gershan, V.] Ss Cyril & Methodius Univ, Inst Phys, Skopje, Macedonia.
[Gershkevitsh, E.] North Estonia Med Ctr, Tallinn, Estonia.
[Gruppetta, E.] Mater Dei Hosp, Msida, Malta.
[Hustuc, A.] Natl Ctr Publ Hlth, Kishinev, Moldova.
[Jauhari, A.] Pusat Kajian Radiog Dan Imajing, Depok, Indonesia.
[Kharita, Mohammad Hassan] Atom Energy Commiss Syria, Damascus, Syria.
[Khelassi-Toutaoui, N.] Ctr Rech Nucl Alger, Dept Phys Med, Algiers, Algeria.
[Khosravi, H. R.] Iranian Nucl Regulatory Author, Natl Radiat Protect Dept, Tehran, Iran.
[Khoury, H.] Univ Fed Pernambuco, Recife, PE, Brazil.
[Kralik, I.] State Off Radiol & Nucl Safety, Zagreb, Croatia.
[Mahere, S.] Children Clin Univ Hosp, Riga, Latvia.
[Mazuoliene, J.] Hosp Lithuanian Univ Hlth Sci Kauno Klin, Kaunas, Lithuania.
[Mora, P.] Univ Costa Rica, Ctr Invest Ciencias Atom Nucl & Mol, San Jose, Costa Rica.
[Muhogora, W.] Tanzania Atom Energy Commiss, Arusha, Tanzania.
[Muthuvelu, P.] Minist Hlth Malaysia, Putrajaya Wilayah Persek, Malaysia.
[Nikodemova, D.] Slovak Med Univ, Bratislava, Slovakia.
[Novak, L.] Natl Radiat Protect Inst, Prague, Czech Republic.
[Pallewatte, A.] Natl Hosp Sri Lanka, Dept Radiol, Colombo, Sri Lanka.
[Pekarovic, D.] Univ Med Ctr, Clin Radiol Inst, Ljubljana, Slovenia.
[Shaaban, M.] Al Sabah Hosp, Kuwait, Kuwait.
[Shelly, E.] Minist Hlth, Med Technol & Infrastruct Adm, Jerusalem, Israel.
[Stepanyan, K.] Res Ctr Radiat Med & Burns, Yerevan, Armenia.
[Thelsy, N.] Minist Hlth, Yangon, Myanmar.
[Visrutaratna, P.] Chiang Mai Univ, Fac Med, Dept Radiol, Chiang Mai 50000, Thailand.
[Zaman, A.] PAEC, Inst Nucl Med & Oncol, Lahore, Pakistan.
RP Vassileva, J (reprint author), IAEA, A-1400 Vienna, Austria.
EM j.vassileva@iaea.org
NR 31
TC 3
Z9 3
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0144-8420
EI 1742-3406
J9 RADIAT PROT DOSIM
JI Radiat. Prot. Dosim.
PD JUL
PY 2015
VL 165
IS 1-4
BP 70
EP 80
DI 10.1093/rpd/ncv116
PG 11
WC Environmental Sciences; Public, Environmental & Occupational Health;
Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical
Imaging
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Nuclear Science & Technology; Radiology, Nuclear Medicine &
Medical Imaging
GA CN5DF
UT WOS:000358449300019
PM 25836685
ER
PT J
AU Vassileva, J
Rehani, M
AF Vassileva, J.
Rehani, M.
TI PATIENT GROUPING FOR DOSE SURVEYS AND ESTABLISHMENT OF DIAGNOSTIC
REFERENCE LEVELS IN PAEDIATRIC COMPUTED TOMOGRAPHY
SO RADIATION PROTECTION DOSIMETRY
LA English
DT Article
ID LATIN-AMERICA; 40 COUNTRIES; CT EXPOSURE; IAEA SURVEY; EUROPE; ASIA
AB There has been confusion in literature on whether paediatric patients should be grouped according to age, weight or other parameters when dealing with dose surveys. The present work aims to suggest a pragmatic approach to achieve reasonable accuracy for performing patient dose surveys in countries with limited resources. The analysis is based on a subset of data collected within the IAEA survey of paediatric computed tomography (CT) doses, involving 82 CT facilities from 32 countries in Asia, Europe, Africa and Latin America. Data for 6115 patients were collected, in 34.5 % of which data for weight were available. The present study suggests that using four age groups, <1, >1-5, >5-10 and >10-15 y, is realistic and pragmatic for dose surveys in less resourced countries and for the establishment of DRLs. To ensure relevant accuracy of results, data for >30 patients in a particular age group should be collected if patient weight is not known. If a smaller sample is used, patient weight should be recorded and the median weight in the sample should be within 5-10 % from the median weight of the sample for which the DRLs were established. Comparison of results from different surveys should always be performed with caution, taking into consideration the way of grouping of paediatric patients. Dose results can be corrected for differences in patient weight/age group.
C1 [Vassileva, J.] IAEA, A-1400 Vienna, Austria.
[Rehani, M.] Harvard Univ, Sch Med, Boston, MA USA.
[Rehani, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Vassileva, J (reprint author), IAEA, A-1400 Vienna, Austria.
EM j.vassileva@iaea.org
NR 28
TC 1
Z9 1
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0144-8420
EI 1742-3406
J9 RADIAT PROT DOSIM
JI Radiat. Prot. Dosim.
PD JUL
PY 2015
VL 165
IS 1-4
BP 81
EP 85
DI 10.1093/rpd/ncv113
PG 5
WC Environmental Sciences; Public, Environmental & Occupational Health;
Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical
Imaging
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Nuclear Science & Technology; Radiology, Nuclear Medicine &
Medical Imaging
GA CN5DF
UT WOS:000358449300020
PM 25836695
ER
PT J
AU Rehani, MM
AF Rehani, M. M.
TI EYE DOSE ASSESSMENT AND MANAGEMENT: OVERVIEW
SO RADIATION PROTECTION DOSIMETRY
LA English
DT Article
ID INTERVENTIONAL RADIOLOGY; LENS DOSIMETRY; NUCLEAR-MEDICINE; RADIATION;
POSITIONS; HOSPITALS; CATARACT; WORKERS
AB Some publications have shown that Hp((0.07)) or even Hp((10)) can be used as good operational quantities for X-rays in view of difficulties with Hp(3). With increasing awareness, there is tendency to use whatever dosimeter is available with correction factor to estimate eye lens dose. The best position for an eye lens dosimeter has been reported to be at the side of the head nearest to the radiation source, close to the eye. Recent studies have reported eye doses with cone beam CT (CBCT) both for patients and staff, and there are many papers reporting eye lens doses to staff in nuclear medicine. To minimise the dose to eyes, the user can take advantage of a feature of CBCT of projections acquired over an angular span of 1808 plus cone angle of the X-ray tube and with tube under scan arcs.
C1 [Rehani, M. M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Rehani, M. M.] Harvard Univ, Sch Med, Boston, MA USA.
RP Rehani, MM (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM madan.rehani@gmail.com
NR 20
TC 1
Z9 1
U1 3
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0144-8420
EI 1742-3406
J9 RADIAT PROT DOSIM
JI Radiat. Prot. Dosim.
PD JUL
PY 2015
VL 165
IS 1-4
BP 276
EP 278
DI 10.1093/rpd/ncv048
PG 3
WC Environmental Sciences; Public, Environmental & Occupational Health;
Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical
Imaging
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Nuclear Science & Technology; Radiology, Nuclear Medicine &
Medical Imaging
GA CN5DF
UT WOS:000358449300062
PM 25813481
ER
PT J
AU Wong, JC
Li, WJ
Gao, X
AF Wong, Janice C.
Li, Weijuan
Gao, Xiang
TI Restless Legs Syndrome as a Prognostic Tool for Cardiovascular Disease
SO SLEEP
LA English
DT Editorial Material
ID CLINICAL CHARACTERISTICS; WOMEN; HYPERTENSION; ASSOCIATION; POPULATION;
OBESITY; RISK
C1 [Wong, Janice C.] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA.
[Wong, Janice C.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Wong, Janice C.] Harvard Univ, Sch Med, Boston, MA USA.
[Li, Weijuan] Penn State Univ, Albert Einstein Coll Med, Dept Med, University Pk, PA 16802 USA.
[Gao, Xiang] Penn State Univ, Dept Nutr Hlth, University Pk, PA 16802 USA.
RP Gao, X (reprint author), Penn State Univ, Dept Nutr Sci, 109 Chandlee Lab, University Pk, PA 16802 USA.
EM xxg14@psu.edu
NR 14
TC 0
Z9 0
U1 0
U2 1
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 0161-8105
EI 1550-9109
J9 SLEEP
JI Sleep
PD JUL 1
PY 2015
VL 38
IS 7
BP 995
EP 996
AR PII sp-00285-15
DI 10.5665/sleep.4790
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA CO0JO
UT WOS:000358837000001
PM 26085294
ER
PT J
AU Pace-Schott, EF
AF Pace-Schott, Edward F.
TI Analog Flashbacks
SO SLEEP
LA English
DT Editorial Material
ID POSTTRAUMATIC-STRESS-DISORDER; TRAUMA FILM PARADIGM; EMOTIONAL MEMORY;
REM-SLEEP; CONDITIONED FEAR; PTSD SYMPTOMS; EXTINCTION; CONSOLIDATION;
PROPRANOLOL; RECONSOLIDATION
C1 [Pace-Schott, Edward F.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
[Pace-Schott, Edward F.] Massachusetts Gen Hosp, Charlestown, MA USA.
RP Pace-Schott, EF (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Psychiat, East 149 13th St,Room 2624, Charlestown, MA 02129 USA.
EM epace-schott@mgh.harvard.edu
NR 48
TC 1
Z9 1
U1 1
U2 7
PU AMER ACAD SLEEP MEDICINE
PI WESTCHESTER
PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA
SN 0161-8105
EI 1550-9109
J9 SLEEP
JI Sleep
PD JUL 1
PY 2015
VL 38
IS 7
BP 997
EP 999
AR PII sp-00284-15
DI 10.5665/sleep.4792
PG 3
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA CO0JO
UT WOS:000358837000002
PM 26085293
ER
PT J
AU Mehta, SJ
Polsky, D
Zhu, JS
Lewis, JD
Kolstad, JT
Loewenstein, G
Volpp, KG
AF Mehta, Shivan J.
Polsky, Daniel
Zhu, Jingsan
Lewis, James D.
Kolstad, Jonathan T.
Loewenstein, George
Volpp, Kevin G.
TI ACA-Mandated Elimination of Cost Sharing for Preventive Screening Has
Had Limited Early Impact
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID DIRECTED HEALTH PLANS; MYOCARDIAL-INFARCTION; MEDICATION ADHERENCE;
COLONOSCOPY; COPAYMENTS; INSURANCE; SERVICES; CARE
AB Objectives: The Affordable Care Act eliminated patient cost sharing for evidence-based preventive care, yet the impact of this policy on colonoscopy and mammography rates is unclear. We examined the elimination of cost sharing among small business beneficiaries of Humana, a large national insurer.
Study Design: This was a retrospective interrupted time series analysis of whether the change in cost-sharing policy was associated with a change in screening utilization, using grandfathered plans as a comparison group.
Methods: We compared beneficiaries in small business non-grandfathered plans that were required to eliminate cost sharing (intervention) with those in grandfathered plans that did not have to change cost sharing (control). There were 63,246 men and women aged 50 to 64 years eligible for colorectal cancer screening, and 30,802 women aged 50 to 64 years eligible for breast cancer screening. The primary outcome variables were rates of colonoscopy and mammography per person-month, with secondary analysis of colonoscopy rates coded as preventive only.
Results: There was no significant change in the level or slope of colonoscopy and mammography utilization for intervention plans relative to the control plans. There was also no significant relevant change among those colonoscopies coded as preventive.
Conclusions: The results suggest that the implementation of the policy is not having its intended effects, as cost sharing rates for colonoscopy and mammography did not change substantially, and utilization of colonoscopy and mammography changed little, following this new policy approach.
C1 [Mehta, Shivan J.; Polsky, Daniel; Lewis, James D.; Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA.
[Lewis, James D.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Lewis, James D.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
[Mehta, Shivan J.; Polsky, Daniel; Zhu, Jingsan; Lewis, James D.; Kolstad, Jonathan T.; Loewenstein, George; Volpp, Kevin G.] Univ Penn, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA.
[Mehta, Shivan J.; Volpp, Kevin G.] Penn Med Ctr Hlth Care Innovat, Philadelphia, PA USA.
[Kolstad, Jonathan T.; Volpp, Kevin G.] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA.
[Loewenstein, George] Carnegie Mellon Univ, Dept Social & Decis Sci, Pittsburgh, PA 15213 USA.
[Volpp, Kevin G.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
RP Mehta, SJ (reprint author), Univ Penn, Perelman Sch Med, 1318 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM shivan.mehta@uphs.upenn.edu
FU Humana, National Institutes of Health [K24 DK078228, T32 DK007740]
FX Humana, National Institutes of Health (K24 DK078228, T32 DK007740).
NR 24
TC 3
Z9 3
U1 0
U2 6
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD JUL
PY 2015
VL 21
IS 7
BP 511
EP U59
PG 10
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA CN8CC
UT WOS:000358664000007
PM 26247741
ER
PT J
AU Hershenberg, R
Paulson, D
Gros, DF
Acierno, R
AF Hershenberg, Rachel
Paulson, Daniel
Gros, Daniel F.
Acierno, Ron
TI Does Amount and Type of Activity Matter in Behavioral Activation? A
Preliminary Investigation of the Relationship between Pleasant,
Functional, and Social Activities and Outcome
SO BEHAVIOURAL AND COGNITIVE PSYCHOTHERAPY
LA English
DT Article
DE Behavioral activation; positive events; functional events; social
events; depression; bereavement
ID BECK DEPRESSION INVENTORY; COMPLICATED GRIEF; POSTPARTUM DEPRESSION;
THERAPEUTIC EXPOSURE; COGNITIVE THERAPY; DAILY EVENTS; BEREAVEMENT;
DISORDER; ADULTS; METAANALYSIS
AB Background: Accumulating evidence supports behavioral activation (BA) as an effective stand-alone treatment for improving depression and related conditions, though little is known about the factors that influence positive outcomes. Such research is ripe for future dissemination and implementation efforts, particularly among vulnerable older adult populations in need of such efficacious and transportable treatments. Aims: Given the central but largely unexamined role that increasing activities plays in BA, we investigated the association between participation in weekly activities and treatment outcome. Method: As a preliminary study of this research question, we report on a sample of 20 older adults with symptoms of depression and complicated bereavement who completed 5 weeks of BA, pre-and posttreatment measures, and weekly planners of BA activities. All activities were coded as either functional or pleasurable (by participants) and if they were social in nature (by trained coders). Results: Overall, BA was associated with reductions in symptomatology. However, participants' total number of reported activities, and their relative proportion of functional, pleasurable, and social activities, did not significantly relate to their improvement in symptoms. Conclusion: One interpretation of the findings suggests that countering avoidance more generally, potentially independent of the specific type or total amount of activation activities, may be associated with amelioration of symptomatology.
C1 [Hershenberg, Rachel] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
[Hershenberg, Rachel] Univ Penn, Philadelphia, PA 19104 USA.
[Paulson, Daniel] Univ Cent Florida, Orlando, FL 32816 USA.
[Gros, Daniel F.; Acierno, Ron] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Gros, Daniel F.; Acierno, Ron] Med Univ S Carolina, Charleston, SC USA.
RP Hershenberg, R (reprint author), Philadelphia VA Med Ctr, 3900 Woodland Ave, Philadelphia, PA 19104 USA.
EM rhersh@mail.med.upenn.edu
FU National Institute of Aging [R21-AG023495-01A2]; VISN 4 Mental Illness
Research, Education, and Clinical Center, Philadelphia Veterans Affairs
Medical Center, Philadelphia, PA, USA
FX This work was partially supported by a grant from the National Institute
of Aging (R21-AG023495-01A2). This paper was prepared with the support
of the VISN 4 Mental Illness Research, Education, and Clinical Center,
Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, USA. The
views expressed in the article are those of the authors and do not
necessarily reflect the position or policy of the Department of Veterans
Affairs or the United States government. There were no conflicts of
interest related to this project or its authors. We would like to thank
Carl Lejuez and Julia Rossi for their feedback during the preparation of
this manuscript.
NR 45
TC 2
Z9 2
U1 2
U2 8
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1352-4658
EI 1469-1833
J9 BEHAV COGN PSYCHOTH
JI Behav. Cognit. Psychther.
PD JUL
PY 2015
VL 43
IS 4
BP 396
EP 411
DI 10.1017/S1352465813001185
PG 16
WC Psychology, Clinical
SC Psychology
GA CN8VM
UT WOS:000358723500002
PM 24621452
ER
PT J
AU Glavey, SV
Huynh, D
Reagan, MR
Manier, S
Moschetta, M
Kawano, Y
Roccaro, AM
Ghobrial, IM
Joshi, L
O'Dwyer, ME
AF Glavey, Siobhan V.
Huynh, Daisy
Reagan, Michaela R.
Manier, Salomon
Moschetta, Michele
Kawano, Yawara
Roccaro, Aldo M.
Ghobrial, Irene M.
Joshi, Lokesh
O'Dwyer, Michael E.
TI The cancer glycome: Carbohydrates as mediators of metastasis
SO BLOOD REVIEWS
LA English
DT Review
DE Post-translational modification; Glycans; Glycosylation; Glycome;
Cancer; Trafficking; Metastasis
ID SIALYL-TN ANTIGENS; N-ACETYLGLUCOSAMINYLTRANSFERASE-V; BETA-1-6 BRANCHED
OLIGOSACCHARIDES; SELECTIN LIGAND EXPRESSION; MULTIPLE-MYELOMA CELLS;
HUMAN BREAST-CARCINOMA; TUMOR PROGRESSION; GENE-EXPRESSION; ADHESION
MOLECULES; PANCREATIC-CANCER
AB Glycosylation is a frequent post-translational modification which results in the addition of carbohydrate determinants, "glycans", to cell surface proteins and lipids. These glycan structures form the "glycome" and play an integral role in cell-cell and cell-matrix interactions through modulation of adhesion and cell trafficking.
Glycosylation is increasingly recognized as a modulator of the malignant phenotype of cancer cells, where the interaction between cells and the tumor micro-environment is altered to facilitate processes such as drug resistance and metastasis. Changes in glycosylation of cell surface adhesion molecules such as selectin ligands, integrins and mucins have been implicated in the pathogenesis of several solid and hematological malignancies, often with prognostic implications. In this review we focus on the functional significance of alterations in cancer cell glycosylation, in terms of cell adhesion, trafficking and the metastatic cascade and provide insights into the prognostic and therapeutic implications of recent findings in this fast-evolving niche. (c) 2015 Elsevier Ltd. All rights reserved.
C1 [Glavey, Siobhan V.; Huynh, Daisy; Reagan, Michaela R.; Manier, Salomon; Moschetta, Michele; Kawano, Yawara; Roccaro, Aldo M.; Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Glavey, Siobhan V.; Joshi, Lokesh; O'Dwyer, Michael E.] Natl Univ Ireland Univ Coll Galway, Glycosci Res Grp, Galway, Ireland.
[O'Dwyer, Michael E.] Natl Univ Ireland Univ Coll Galway, Dept Hematol, Galway, Ireland.
[O'Dwyer, Michael E.] Galway Univ Hosp, Galway, Ireland.
RP O'Dwyer, ME (reprint author), Natl Univ Ireland Univ Coll Galway, Dept Hematol, Galway, Ireland.
EM siobhan_glavey@dfci.harvard.edu; Daisy_Huynh@DFCI.HARVARD.EDU;
MichaelaR_Reagan@DFCI.HARVARD.EDU; Salomon_Manier@DFCI.HARVARD.EDU;
MICHELE_MOSCHETTA@DFCI.HARVARD.EDU; Yawara_Kawano@DFCI.HARVARD.EDU;
Aldo_Roccaro@dfci.harvard.edu; irene_ghobrial@dfci.harvard.edu;
lokesh.joshi@nuigalway.ie; michael.odwyer@nuigalway.ie
RI Reagan, Michaela/E-3549-2017;
OI Roccaro, Aldo/0000-0002-1872-5128; o'dwyer, michael/0000-0002-6173-7140;
Reagan, Michaela/0000-0003-2884-6481
FU Science Foundation Ireland [08/SRC/B1393, 07/SK/B1250]; EU [260600];
Health Research Board [CSA/2012/10]
FX LJ acknowledges the Science Foundation Ireland [Alimentary Glycoscience
Research Cluster, grant number 08/SRC/B1393 and Stokes Professor for
Glycosciences, grant number 07/SK/B1250] and EU-FP7 GlycoHIT (grant
number 260600) for their support. MO'D acknowledges the support of the
Health Research Board, grant number CSA/2012/10.
NR 158
TC 18
Z9 19
U1 6
U2 54
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0268-960X
EI 1532-1681
J9 BLOOD REV
JI Blood Rev.
PD JUL
PY 2015
VL 29
IS 4
BP 269
EP 279
DI 10.1016/j.blre.2015.01.003
PG 11
WC Hematology
SC Hematology
GA CN5IB
UT WOS:000358461900007
PM 25636501
ER
PT J
AU Braga-Neto, P
Pedroso, JL
Barsottini, OGP
Schmahmann, JD
AF Braga-Neto, Pedro
Pedroso, Jose Luiz
Barsottini, Orlando G. P.
Schmahmann, Jeremy D.
TI Cognition in SCA21 reflects developmental and adult onset cerebellar
cognitive affective syndrome
SO BRAIN
LA English
DT Letter
ID MACHADO-JOSEPH-DISEASE; SPINOCEREBELLAR ATAXIA TYPE-3; DYSFUNCTION;
NONMOTOR; FEATURES; DEFICITS
C1 [Braga-Neto, Pedro] Univ Estadual Ceara, Ctr Hlth Sci, BR-60714903 Fortaleza, Ceara, Brazil.
[Braga-Neto, Pedro; Pedroso, Jose Luiz; Barsottini, Orlando G. P.] Univ Fed Sao Paulo, Dept Neurol, Ataxia Unit, Sao Paulo, Brazil.
[Schmahmann, Jeremy D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med,Lab Neuroanat & Cerebellar Neurobiol, Ataxia Unit,Cognit Behav Neurol Unit,Dept Neurol, Boston, MA 02114 USA.
RP Braga-Neto, P (reprint author), Univ Estadual Ceara, Ctr Hlth Sci, Ave Dr Silas Munguba,1700,Campus Itaperi, BR-60714903 Fortaleza, Ceara, Brazil.
EM pbraganeto@gmail.com
RI Braga-Neto, Pedro/C-5951-2013; Barsottini, O/E-9117-2010; Pedroso,
Jose/F-1757-2013
OI Braga-Neto, Pedro/0000-0001-9186-9243;
FU NIMH NIH HHS [R01MH67980]
NR 25
TC 1
Z9 1
U1 1
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD JUL 1
PY 2015
VL 138
AR e364
DI 10.1093/brain/awu382
PN 7
PG 3
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA CN6HY
UT WOS:000358536600005
PM 25576310
ER
PT J
AU Vidaurre, OG
Haines, JD
Sand, IK
Adula, KP
Huynh, JL
McGraw, CA
Zhang, F
Varghese, M
Sotirchos, E
Bhargava, P
Venkata, V
Bandaru, R
Pasinetti, G
Zhang, WJ
Inglese, M
Calabresi, PA
Wu, G
Miller, AE
Haughey, NJ
Lublin, FD
Casaccia, P
AF Vidaurre, Oscar G.
Haines, Jeffery D.
Sand, Ilana Katz
Adula, Kadidia P.
Huynh, Jimmy L.
McGraw, Corey A.
Zhang, Fan
Varghese, Merina
Sotirchos, Elias
Bhargava, Pavan
Venkata, Veera
Bandaru, Ratnam
Pasinetti, Giulio
Zhang, Weijia
Inglese, Matilde
Calabresi, Peter A.
Wu, Gang
Miller, Aaron E.
Haughey, Norman J.
Lublin, Fred D.
Casaccia, Patrizia
TI Cerebrospinal fluid ceramides from patients with multiple sclerosis
impair neuronal bioenergetics (vol 137, pg 2271, 2014)
SO BRAIN
LA English
DT Correction
C1 [Pasinetti, Giulio] James J Peters Vet Affairs Med Ctr, Geriatr Res & Clin Ctr, Bronx, NY USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD JUL 1
PY 2015
VL 138
AR e367
DI 10.1093/brain/awv090
PN 7
PG 1
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA CN6HY
UT WOS:000358536600008
ER
PT J
AU Reed, GW
Guo, JP
Cannon, CP
Kumar, A
Aranki, S
Shekar, P
Agnihotri, A
Maree, AO
McLean, DS
Rosenfield, K
AF Reed, Grant W.
Guo, Jianping
Cannon, Christopher P.
Kumar, Amit
Aranki, Sary
Shekar, Prem
Agnihotri, Arvind
Maree, Andrew O.
McLean, Dalton S.
Rosenfield, Kenneth
TI Platelet Function Testing and Prediction of Bleeding in Patients Exposed
to Clopidogrel Undergoing Coronary Artery Surgery Reply
SO CLINICAL CARDIOLOGY
LA English
DT Letter
ID RISK
C1 [Reed, Grant W.] Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44106 USA.
[Reed, Grant W.; Guo, Jianping] Brigham & Womens Hosp, TIMI Study Grp, Cardiovasc Div, Boston, MA 02115 USA.
[Kumar, Amit] Lahey Clin Fdn, Dept Cardiovasc Med, Burlington, MA USA.
[Aranki, Sary; Shekar, Prem] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
[Agnihotri, Arvind] St Elizabeths Med Ctr, Dept Surg, Brighton, MA USA.
[Maree, Andrew O.] St James Hosp, Div Cardiol, Dublin 8, Ireland.
[McLean, Dalton S.] Le Bauer Cardiol, Greensboro, NC USA.
[Rosenfield, Kenneth] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA.
RP Reed, GW (reprint author), Cleveland Clin, Dept Cardiovasc Med, Cleveland, OH 44106 USA.
NR 4
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0160-9289
EI 1932-8737
J9 CLIN CARDIOL
JI Clin. Cardiol.
PD JUL
PY 2015
VL 38
IS 7
BP 444
EP U63
DI 10.1002/clc.22413
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CN7IH
UT WOS:000358607300008
PM 26216006
ER
PT J
AU Weiner, RB
Baggish, AL
AF Weiner, Rory B.
Baggish, Aaron L.
TI Cardiovascular Adaptation and Remodeling to Rigorous Athletic Training
SO CLINICS IN SPORTS MEDICINE
LA English
DT Article
DE Cardiac remodeling; Exercise; Sports; Endurance
ID LEFT-VENTRICULAR HYPERTROPHY; PHYSIOLOGICAL CARDIAC-HYPERTROPHY;
PROFESSIONAL SOCCER PLAYERS; AORTIC ROOT SIZE; CLINICAL-SIGNIFICANCE;
ETHNIC-DIFFERENCES; DIASTOLIC FUNCTION; REFERENCE VALUES; WALL
THICKNESS; RIGHT ATRIAL
AB Exercise-induced cardiac remodeling is a complex process by which the cardinal hemodynamic stresses of pressure and volume lead to a host of structural or functional adaptations. In aggregate, the constellation of changes that accompany this process serve to facilitate athletic performance by minimizing the cardiac work inherent in athletic activity. Although several key determinants of athletic cardiac adaptation have been described, observed variability across athlete cohorts remains an incompletely understood area. Ongoing and future work are required to further understand this process and ultimately to determine where the boundary lies between adaptive physiology and maladaptive disease.
C1 [Weiner, Rory B.; Baggish, Aaron L.] Massachusetts Gen Hosp, Cardiovasc Performance Program, Boston, MA 02114 USA.
RP Baggish, AL (reprint author), Massachusetts Gen Hosp, Cardiovasc Performance Program, Yawkey Suite 5B,55 Fruit St, Boston, MA 02114 USA.
EM abaggish@partners.org
NR 78
TC 3
Z9 3
U1 2
U2 9
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0278-5919
EI 1556-228X
J9 CLIN SPORT MED
JI Clin. Sports Med.
PD JUL
PY 2015
VL 34
IS 3
BP 405
EP +
DI 10.1016/j.csm.2015.03.007
PG 16
WC Sport Sciences
SC Sport Sciences
GA CN5FO
UT WOS:000358455400005
PM 26100418
ER
PT J
AU Jelly, CA
Alston, TA
AF Jelly, Christina A.
Alston, Theodore A.
TI The Heart of Diabetes
SO CRITICAL CARE MEDICINE
LA English
DT Editorial Material
DE beta-adrenoceptor; Ahlquist (Raymond P. Ahlquist); leptin; metreleptin;
obesity
ID OBESITY PARADOX; PLASMA LEPTIN; SEPSIS; STIMULATION
C1 [Jelly, Christina A.; Alston, Theodore A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02138 USA.
RP Jelly, CA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02138 USA.
NR 15
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD JUL
PY 2015
VL 43
IS 7
BP 1552
EP 1554
DI 10.1097/CCM.0000000000001048
PG 3
WC Critical Care Medicine
SC General & Internal Medicine
GA CN2XK
UT WOS:000358285900035
PM 26079241
ER
PT J
AU Peyrot, M
Egede, LE
Funnel, MM
Hsu, WC
Ruggiero, L
Siminerio, LM
Stuckey, HL
AF Peyrot, Mark
Egede, Leonard E.
Funnel, Martha M.
Hsu, William C.
Ruggiero, Laurie
Siminerio, Linda M.
Stuckey, Heather L.
TI Ethnic differences in family member diabetes involvement and
psychological outcomes: results from the second Diabetes Attitudes,
Wishes and Needs (DAWN2) study in the USA
SO CURRENT MEDICAL RESEARCH AND OPINION
LA English
DT Article
DE DAWN2; Ethnic disparities; Psychological outcomes; Quality of life;
Well-being
ID QUALITY-OF-LIFE; DISEASE MANAGEMENT; EUROPEAN-AMERICAN;
AFRICAN-AMERICAN; LATINO PATIENTS; CARE; PEOPLE
AB Objective:
To assess differences among USA ethnic groups in psychological status of adult family members (FMs) and their involvement with the diabetes of another adult.
Research methods:
Data are from the FM survey of the USA DAWN2 study, including 105 White non-Hispanics, 47 African Americans, 46 Hispanic Americans and 40 Chinese Americans. All FMs lived with and cared for an adult with diabetes. Analysis of covariance controlled for respondent and patient characteristics to assess ethnic group differences (P< 0.05). Multiple regression analyses identified significant (P<0.05) independent correlates of psychological outcomes.
Main outcome measures:
FM psychological outcomes measured include well-being, quality of life (QoL), impact of diabetes on life domains, diabetes distress, and burden.
Clinical trial registration: NCT01507116.
Results:
White non-Hispanics reported less diabetes burden and distress, more negative life impact, and lower wellbeing than FMs from ethnic minority groups. African Americans reported the highest well-being and lowest negative life impact, Chinese Americans reported the most diabetes burden, Hispanic Americans reported the highest distress. There were no ethnic group differences in QoL. Ethnic minority FMs reported having more involvement with diabetes, greater support success, and more access to a diabetes support network than White non-Hispanics. Higher FM diabetes involvement was associated with negative psychological outcomes, while diabetes education, support success and diabetes support network size were associated with better psychological outcomes. Potential limitations are the sample sizes and representativeness.
Conclusions:
Minority ethnic FMs experienced both advantages and disadvantages in psychological outcomes relative to each other and to White non-Hispanics. Ethnic minority FMs had more involvement in diabetes care, support success and support from others, with the first associated with worse and the latter two with better psychological outcomes. Additional studies are needed with larger samples and broader representation of ethnic groups to better understand these associations and identify areas for intervention.
C1 [Peyrot, Mark] Loyola Univ Maryland, Baltimore, MD 21210 USA.
[Egede, Leonard E.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Funnel, Martha M.] Univ Michigan, Sch Med, Ann Arbor, MI USA.
[Hsu, William C.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA.
[Ruggiero, Laurie] Univ Illinois, Sch Publ Hlth, Inst Hlth Res & Policy, Chicago, IL USA.
[Siminerio, Linda M.] Univ Pittsburgh, Inst Diabet, Pittsburgh, PA USA.
[Stuckey, Heather L.] Penn State Univ, Coll Med, Hershey, PA USA.
RP Peyrot, M (reprint author), Loyola Univ Maryland, 4501 N Charles St, Baltimore, MD 21210 USA.
EM mark.peyrot@gmail.com
FU Novo Nordisk A/S, Bagsvaerd, Denmark
FX This study was funded by Novo Nordisk A/S, Bagsvaerd, Denmark.
NR 30
TC 2
Z9 2
U1 0
U2 3
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0300-7995
EI 1473-4877
J9 CURR MED RES OPIN
JI Curr. Med. Res. Opin.
PD JUL
PY 2015
VL 31
IS 7
BP 1297
EP 1307
DI 10.1185/03007995.2015.1043251
PG 11
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA CN4HW
UT WOS:000358392200006
PM 25907127
ER
PT J
AU Pilotte, AP
AF Pilotte, Amy Potter
TI Current management of patients with gastrointestinal stromal tumor
receiving the multitargeted tyrosine kinase inhibitor sunitinib
SO CURRENT MEDICAL RESEARCH AND OPINION
LA English
DT Review
DE GIST; Sarcoma; Side-effect management; Sunitinib; Tyrosine kinase
inhibitors
ID RENAL-CELL CARCINOMA; FOOT SKIN REACTION; TARGETED THERAPIES; TREATMENT
PATTERNS; IMATINIB MESYLATE; ADJUVANT IMATINIB; RANDOMIZED-TRIAL;
SAFETY; HYPERTENSION; EFFICACY
AB Background:
Gastrointestinal stromal tumor (GIST), a form of soft tissue sarcoma, is often detected incidentally or at an advanced stage. The tyrosine kinase inhibitor sunitinib malate (Sutent*) is established as second-line treatment for the management of GIST after disease progression on, or intolerance to, first-line imatinib treatment. Several published reviews give guidance on management of side effects in patients with advanced renal cell carcinoma treated with sunitinib, but fewer publications cover side-effect management in patients with GIST.
Scope:
Using published articles and abstracts, prescribing information, and personal experience in managing patients with GIST at a specialized center of excellence for cancer care, I review side-effect management recommendations for patients with GIST treated with sunitinib and provide an overview of GIST.
Findings:
Sunitinib has a well described side-effect profile: most side effects occurring in patients with GIST can be easily managed by standard medical intervention and/or dose modification.
Conclusion:
Care of patients with GIST can be enhanced through communication, support, knowledge, and education, with the goal of providing effective therapy and optimal symptom control.
C1 [Pilotte, Amy Potter] Dana Farber Canc Inst, Ctr Sarcoma & Bone Oncol, Boston, MA 02115 USA.
[Pilotte, Amy Potter] Rhode Isl Hosp, Ctr Comprehens Canc, Providence, RI USA.
RP Pilotte, AP (reprint author), Rhode Isl Hosp, Comprehens Canc Ctr East Greenwich, 1454 South Cty Trail, East Greenwich, RI 02818 USA.
EM amyspotter@gmail.com
FU Pfizer
FX Editorial assistance for this study was funded by Pfizer. The manuscript
was written, the content was controlled, and the decision to submit the
paper for publication was made solely by the author, who received no
financial support or other compensation related to the development of
this paper. Pfizer Inc., the manufacturer of sunitinib and the sponsor
of many of the studies described in this manuscript, reviewed the paper
for scientific accuracy.
NR 72
TC 0
Z9 0
U1 0
U2 3
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0300-7995
EI 1473-4877
J9 CURR MED RES OPIN
JI Curr. Med. Res. Opin.
PD JUL
PY 2015
VL 31
IS 7
BP 1363
EP 1376
DI 10.1185/03007995.2015.1045470
PG 14
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA CN4HW
UT WOS:000358392200012
PM 25912466
ER
PT J
AU Mahoney, DF
LaRose, S
Mahoney, EL
AF Mahoney, Diane F.
LaRose, Sharon
Mahoney, Edward L.
TI Family caregivers' perspectives on dementia-related dressing
difficulties at home: The preservation of self model
SO DEMENTIA-INTERNATIONAL JOURNAL OF SOCIAL RESEARCH AND PRACTICE
LA English
DT Article
DE activities of daily living; Alzheimer's disease; family caregiving;
medical textiles; major neurocognitive disorder
ID ALZHEIMERS-DISEASE; ISSUES; CARE
AB Alzheimer's caregiving literature acknowledges dressing as a major daily stressor but research on this topic is negligible. A qualitative grounded theory approach was used to explore Alzheimer's family caregivers' perspectives about issues that arise when their family members lose the ability to dress independently. Three focus groups and seven individual interviews were conducted and audio recorded with 25 information rich caregivers. Constant comparative analyses and coding of the transcripts identified six major themes leading to a Preservation of Self Model: Care Recipient to Care Giver' that portrays the caregiving trajectory. Initially, caregivers tried to protect the self dignity of the family member by maintaining usual routines and absorbing blame for difficulties. Dressing battles' occurred and caregivers learned management through trial and error. Crossing adult-child-gender role boundaries escalated discomfort. When facing unrelenting demands, concern shifted to preservation of the caregivers' health and self. Results suggest that caregivers would benefit from more pro-active dressing counseling to shorten the trial and error periods, dressing aids more relevant to dementia and more knowledgeable helpers. The preservation model can facilitate understanding of the caregiving trajectory and guide intervention support.
C1 [Mahoney, Diane F.] MGH Inst Hlth Profess, Gerontechnol Res & Dev, Boston, MA 02129 USA.
[LaRose, Sharon; Mahoney, Edward L.] MGH Inst Hlth Profess, Boston, MA 02129 USA.
[LaRose, Sharon] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Mahoney, Edward L.] EDDEE Consulting, Charlestown, MA USA.
RP Mahoney, DF (reprint author), MGH Inst Hlth Profess, Sch Nursing, 36 1st Ave, Boston, MA 02129 USA.
EM dmahoney@mghihp.edu
OI Mahoney, Diane/0000-0002-6415-475X
FU Alzheimer's Association of the United States of America, ETAC grant
[11-200316]
FX This work was supported by Alzheimer's Association of the United States
of America, 2011 ETAC grant 11-200316.
NR 36
TC 1
Z9 1
U1 2
U2 7
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1471-3012
EI 1741-2684
J9 DEMENTIA-LONDON
JI Dement.-Int. J. soc. Res. Pract.
PD JUL
PY 2015
VL 14
IS 4
BP 494
EP 512
DI 10.1177/1471301213501821
PG 19
WC Gerontology
SC Geriatrics & Gerontology
GA CN6LM
UT WOS:000358546300008
PM 24339112
ER
PT J
AU Gradus, JL
Farkas, DK
Svensson, E
Ehrenstein, V
Lash, TL
Milstein, A
Adler, N
Sorensen, HT
AF Gradus, Jaimie L.
Farkas, Dora Koermendine
Svensson, Elisabeth
Ehrenstein, Vera
Lash, Timothy L.
Milstein, Arnold
Adler, Nancy
Sorensen, Henrik Toft
TI Posttraumatic stress disorder and cancer risk: a nationwide cohort study
SO EUROPEAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE Stress disorders; Posttraumatic; Neoplasms; Cohort studies
ID BREAST-CANCER; PSYCHOSOCIAL FACTORS; REGISTER; MORTALITY; DENMARK;
BURDEN; SYSTEM
AB The association between stress and cancer incidence has been studied for more than seven decades. Despite plausible biological mechanisms and evidence from laboratory studies, findings from clinical research are conflicting. The objective of this study was to examine the association between PTSD and various cancer outcomes. This nation-wide cohort study included all Danish-born residents of Denmark from 1995 to 2011. The exposure was PTSD diagnoses (n = 4131). The main outcomes were cancer diagnoses including: (1) all malignant neoplasms; (2) hematologic malignancies; (3) immune-related cancers; (4) smoking- and alcohol-related cancers; (5) cancers at all other sites. Standardized incidence ratios (SIR) were calculated. Null associations were found between PTSD and nearly all cancer diagnoses examined, both overall [SIR for all cancers = 1.0, 95 % confidence interval (CI) = 0.88, 1.2] and in analyses stratified by gender, age, substance abuse history and time since PTSD diagnosis. This study is the most comprehensive examination to date of PTSD as a predictor of many cancer types. Our data show no evidence of an association between PTSD and cancer in this nationwide cohort.
C1 [Gradus, Jaimie L.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA 02130 USA.
[Gradus, Jaimie L.] Boston Univ, Dept Psychiat, Boston, MA 02215 USA.
[Gradus, Jaimie L.] Boston Univ, Dept Epidemiol, Boston, MA 02215 USA.
[Gradus, Jaimie L.; Farkas, Dora Koermendine; Svensson, Elisabeth; Ehrenstein, Vera; Lash, Timothy L.; Sorensen, Henrik Toft] Aarhus Univ Hosp, Dept Clin Epidemiol, DK-8000 Aarhus, Denmark.
[Lash, Timothy L.] Emory Univ, Dept Epidemiol, Atlanta, GA 30322 USA.
[Milstein, Arnold] Stanford Univ, Clin Excellence Res Ctr, Stanford, CA 94305 USA.
[Adler, Nancy] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
RP Gradus, JL (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD, 150 S Huntington Ave 116B-3, Boston, MA 02130 USA.
EM Jaimie.gradus@va.gov
OI Gradus, Jaimie/0000-0003-1459-5327
FU National Institute of Mental Health [1R21MH094551-01A1]
FX This work was supported by a National Institute of Mental Health
(1R21MH094551-01A1).
NR 25
TC 0
Z9 0
U1 0
U2 11
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0393-2990
EI 1573-7284
J9 EUR J EPIDEMIOL
JI Eur. J. Epidemiol.
PD JUL
PY 2015
VL 30
IS 7
BP 563
EP 568
DI 10.1007/s10654-015-0032-7
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CN7XU
UT WOS:000358649900005
PM 25957083
ER
PT J
AU Baggish, AL
AF Baggish, Aaron L.
TI Athletic Left Atrial Dilation Size Matters?
SO JACC-CARDIOVASCULAR IMAGING
LA English
DT Editorial Material
DE athlete; echocardiography; left atrium
ID HEART; FIBRILLATION
C1 Massachusetts Gen Hosp, Cardiovasc Performance Program, Boston, MA 02114 USA.
RP Baggish, AL (reprint author), Massachusetts Gen Hosp, Cardiovasc Performance Program, Yawkey Suite 5B,55 Fruit St, Boston, MA 02114 USA.
EM abaggish@partners.org
NR 13
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1936-878X
EI 1876-7591
J9 JACC-CARDIOVASC IMAG
JI JACC-Cardiovasc. Imag.
PD JUL
PY 2015
VL 8
IS 7
BP 763
EP 765
DI 10.1016/j.jcmg.2014.12.031
PG 3
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA CN4JK
UT WOS:000358396200002
PM 26183550
ER
PT J
AU Lee, JM
Buist, DSM
Houssami, N
Dowling, EC
Halpern, EF
Gazelle, GS
Lehman, CD
Henderson, LM
Hubbard, RA
AF Lee, Janie M.
Buist, Diana S. M.
Houssami, Nehmat
Dowling, Emily C.
Halpern, Elkan F.
Gazelle, G. Scott
Lehman, Constance D.
Henderson, Louise M.
Hubbard, Rebecca A.
TI Five-Year Risk for Interval-Invasive Second Breast Cancer
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID PERSONAL HISTORY; MAMMOGRAPHIC SURVEILLANCE; LOCOREGIONAL RECURRENCES;
RANDOMIZED-TRIALS; TUMOR RECURRENCE; LASAGNA PLOTS; SCREENING MRI;
FOLLOW-UP; WOMEN; THERAPY
AB Background: Earlier detection of second breast cancers after primary breast cancer (PBC) treatment improves survival, yet mammography is less accurate in women with prior breast cancer. The purpose of this study was to examine women presenting clinically with second breast cancers after negative surveillance mammography (interval cancers), and to estimate the five-year risk of interval-invasive second cancers for women with varying risk profiles.
Methods: We evaluated a prospective cohort of 15 114 women with 47 717 surveillance mammograms diagnosed with stage 0-II unilateral PBC from 1996 through 2008 at facilities in the Breast Cancer Surveillance Consortium. We used discrete time survival models to estimate the association between odds of an interval-invasive second breast cancer and candidate predictors, including demographic, PBC, and imaging characteristics. All statistical tests were two-sided.
Results: The cumulative incidence of second breast cancers after five years was 54.4 per 1000 women, with 325 surveillance-detected and 138 interval-invasive second breast cancers. The five-year risk of interval-invasive second cancer for women with referent category characteristics was 0.60%. For women with the most and least favorable profiles, the five-year risk ranged from 0.07% to 6.11%. Multivariable modeling identified grade II PBC (odds ratio [OR] = 1.95, 95% confidence interval [CI] = 1.15 to 3.31), treatment with lumpectomy without radiation (OR = 3.27, 95% CI = 1.91 to 5.62), interval PBC presentation (OR = 2.01, 95% CI 1.28 to 3.16), and heterogeneously dense breasts on mammography (OR = 1.54, 95% CI = 1.01 to 2.36) as independent predictors of interval-invasive second breast cancers.
Conclusions: PBC diagnosis and treatment characteristics contribute to variation in subsequent-interval second breast cancer risk. Consideration of these factors may be useful in developing tailored post-treatment imaging surveillance plans.
C1 [Lee, Janie M.; Lehman, Constance D.] Univ Washington, Dept Radiol, Seattle Canc Care Alliance, Seattle, WA 98195 USA.
[Lee, Janie M.; Dowling, Emily C.; Halpern, Elkan F.; Gazelle, G. Scott] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Lee, Janie M.; Dowling, Emily C.; Halpern, Elkan F.; Gazelle, G. Scott] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA.
[Buist, Diana S. M.; Hubbard, Rebecca A.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA.
[Houssami, Nehmat] Univ Sydney, Sydney Med Sch, Sch Publ Hlth, Screening & Test Evaluat Program, Sydney, NSW 2006, Australia.
[Henderson, Louise M.] Univ N Carolina, Dept Radiol, Chapel Hill, NC USA.
RP Lee, JM (reprint author), Seattle Canc Care Alliance, 825 Eastlake Ave East,G2-600, Seattle, WA 98109 USA.
EM jmlee58@uw.edu
FU National Cancer Institute [P01CA154292]; Breast Cancer Surveillance
Consortium [HHSN261201100031C]; National Institutes of Health
[K07CA128816]; National Breast Cancer Foundation (NBCF Australia)
FX This work was supported by a National Cancer Institute-funded Program
Project grant (P01CA154292) and the Breast Cancer Surveillance
Consortium (HHSN261201100031C). Additional support was provided by
National Institutes of Health grant K07CA128816 (to JML) and the
National Breast Cancer Foundation (NBCF Australia to NH).
NR 52
TC 2
Z9 2
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
EI 1460-2105
J9 JNCI-J NATL CANCER I
JI JNCI-J. Natl. Cancer Inst.
PD JUL
PY 2015
VL 107
IS 7
AR djv109
DI 10.1093/jnci/djv109
PG 9
WC Oncology
SC Oncology
GA CN9QC
UT WOS:000358782900012
ER
PT J
AU Lin, CC
Gray, PJ
Jemal, A
Efstathiou, JA
AF Lin, Chun Chieh
Gray, Phillip J.
Jemal, Ahmedin
Efstathiou, Jason A.
TI Androgen Deprivation With or Without Radiation Therapy for Clinically
Node-Positive Prostate Cancer
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID RADICAL PROSTATECTOMY; DATA-BASE; FOLLOW-UP; RADIOTHERAPY; TRIAL;
SUPPRESSION; GUIDELINES; REGISTRIES; DIAGNOSIS; QUALITY
AB Background: Clinically lymph node-positive (cN+) prostate cancer (PCa) is an often-fatal disease. Its optimal management remains largely undefined given a lack of prospective, randomized data to inform practice. We sought to describe modern practice patterns in the management of cN+ PCa and assess the effect of adding radiation therapy (RT) to androgen deprivation therapy (ADT) on survival using the National Cancer Data Base.
Methods: Patients with cN+ PCa and without distant metastases diagnosed between 2004 and 2011 were included. Five-year overall survival for patients diagnosed between 2004 and 2006 and treated with ADT alone or ADT+RT were compared. Propensity score (PS) matching was used to balance baseline characteristics, and Cox multivariate regression analysis was used to estimate hazard ratios (HRs) for all-cause mortality.
Results: Of 3540 total patients, 32.2% were treated with ADT alone and 51.4% received ADT+RT. Compared with ADT alone, patients treated with ADT+RT were younger and more likely to have private insurance, lower comorbidity scores, higher Gleason scores, and lower PSA values. After PS matching, 318 patients remained in each group. Compared with ADT alone, ADT+RT was associated with a 50% decreased risk of five-year all-cause mortality (HR = 0.50, 95% CI = 0.37 to 0.67, two-sided P < .001; crude OS rate: 71.5% vs 53.2%).
Conclusions: Using a large national database, we have identified a statistically significant survival benefit for patients with cN+ PCa treated with ADT+RT. These data, if appropriately validated by randomized trials, suggest that a substantial proportion of such patients at high risk for prostate cancer death may be undertreated, warranting a reevaluation of current practice guidelines.
C1 [Lin, Chun Chieh; Jemal, Ahmedin] Amer Canc Soc, Surveillance & Hlth Serv Res Program, Intramural Res, Atlanta, GA 30329 USA.
[Gray, Phillip J.; Efstathiou, Jason A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA USA.
RP Efstathiou, JA (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 100 Blossom St,Cox 3, Boston, MA 02114 USA.
EM jefstathiou@partners.org
FU American Cancer Society Intramural Research Department; Prostate Cancer
Foundation Young Investigator Award
FX This work was supported by the American Cancer Society Intramural
Research Department and a Prostate Cancer Foundation Young Investigator
Award (JAE).
NR 31
TC 10
Z9 10
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
EI 1460-2105
J9 JNCI-J NATL CANCER I
JI JNCI-J. Natl. Cancer Inst.
PD JUL
PY 2015
VL 107
IS 7
AR djv119
DI 10.1093/jnci/djv119
PG 10
WC Oncology
SC Oncology
GA CN9QC
UT WOS:000358782900013
ER
PT J
AU Iscla, I
Wray, R
Blount, P
Larkins-Ford, J
Conery, AL
Ausubel, FM
Ramu, S
Kavanagh, A
Huang, JX
Blaskovich, MA
Cooper, MA
Obregon-Henao, A
Orme, I
Tjandra, ES
Stroeher, UH
Brown, MH
Macardle, C
van Holst, N
Tong, CL
Slattery, AD
Gibson, CT
Raston, CL
Boulos, RA
AF Iscla, Irene
Wray, Robin
Blount, Paul
Larkins-Ford, Jonah
Conery, Annie L.
Ausubel, Frederick M.
Ramu, Soumya
Kavanagh, Angela
Huang, Johnny X.
Blaskovich, Mark A.
Cooper, Matthew A.
Obregon-Henao, Andres
Orme, Ian
Tjandra, Edwin S.
Stroeher, Uwe H.
Brown, Melissa H.
Macardle, Cindy
van Holst, Nick
Tong, Chee Ling
Slattery, Ashley D.
Gibson, Christopher T.
Raston, Colin L.
Boulos, Ramiz A.
TI A new antibiotic with potent activity targets MscL
SO JOURNAL OF ANTIBIOTICS
LA English
DT Article
ID MECHANOSENSITIVE CHANNEL; ESCHERICHIA-COLI; PARABENS; RESIDUE; PROTEIN;
DYES
AB The growing problem of antibiotic-resistant bacteria is a major threat to human health. Paradoxically, new antibiotic discovery is declining, with most of the recently approved antibiotics corresponding to new uses for old antibiotics or structurally similar derivatives of known antibiotics. We used an in silico approach to design a new class of nontoxic antimicrobials for the bacteria-specific mechanosensitive ion channel of large conductance, MscL. One antimicrobial of this class, compound 10, is effective against methicillin-resistant Staphylococcus aureus with no cytotoxicity in human cell lines at the therapeutic concentrations. As predicted from in silico modeling, we show that the mechanism of action of compound 10 is at least partly dependent on interactions with MscL. Moreover we show that compound 10 cured a methicillin-resistant S. aureus infection in the model nematode Caenorhabditis elegans. Our work shows that compound 10, and other drugs that target MscL, are potentially important therapeutics against antibiotic-resistant bacterial infections.
C1 [Iscla, Irene; Wray, Robin; Blount, Paul] UT Southwestern Med Ctr, Dept Physiol, Dallas, TX USA.
[Larkins-Ford, Jonah; Conery, Annie L.; Ausubel, Frederick M.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Ramu, Soumya; Kavanagh, Angela; Huang, Johnny X.; Blaskovich, Mark A.; Cooper, Matthew A.] Univ Queensland, Inst Mol Biosci, St Lucia, Qld, Australia.
[Obregon-Henao, Andres; Orme, Ian] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.
[Tjandra, Edwin S.] Univ Western Australia, Sch Anim Biol, Crawley, WA, Australia.
[Stroeher, Uwe H.; Brown, Melissa H.] Flinders Univ S Australia, Sch Biol Sci, Bedford Pk, SA 5042, Australia.
[Macardle, Cindy; van Holst, Nick] Flinders Univ S Australia, Flinders Med Sci & Technol Immunol Allergy & Arth, Bedford Pk, SA 5042, Australia.
[Blount, Paul; Tong, Chee Ling; Slattery, Ashley D.; Gibson, Christopher T.; Raston, Colin L.; Boulos, Ramiz A.] Flinders Univ S Australia, Ctr NanoScale Sci & Technol, Sch Chem & Phys Sci, Bedford Pk, SA 5042, Australia.
RP Blount, P (reprint author), Flinders Univ S Australia, Ctr NanoScale Sci & Technol, Sch Chem & Phys Sci, Bedford Pk, SA 5042, Australia.
EM Paul.blount@UTSouthwestern.edu; ramiz.boulos@flinders.edu.au
RI Gibson, Christopher/G-3626-2010; Cooper, Matthew/C-7988-2009; Huang,
Johnny/A-4041-2012;
OI Gibson, Christopher/0000-0003-3334-5059; Iscla,
Irene/0000-0001-8936-430X; Macardle, Cindy/0000-0001-9880-4258; Cooper,
Matthew/0000-0003-3147-3460; Blaskovich, Mark/0000-0001-9447-2292;
Raston, Colin/0000-0003-4753-0079
FU Welch Foundation [I-1420]; Cancer Prevention & Research Institute of
Texas [RP100146]; National Institutes of Health [AI08080701, GM061028,
P01 AI083214]; National American Heart Association [12SDG8740012];
Wellcome Trust Seeding Drug Discovery Award [094977/Z/10/Z]; NHMRC
Principal Research Fellowship [APP1059354]; NHMRC Project Grant
[535053]; Australian Research Council; Government of South Australia;
Australian Microscopy and Microanalysis Research Facility (AMMRF)
FX The in vivo growth inhibition experiments and the electrophysiology
experiments were supported by Grant I-1420 of the Welch Foundation,
Grant RP100146 from the Cancer Prevention & Research Institute of Texas,
and Grants AI08080701 and GM061028 from the National Institutes of
Health. The C. elegans experiments were supported by grant P01 AI083214
from the National Institutes of Health. II is supported by Grant
12SDG8740012 from the National American Heart Association. The funding
bodies had no role in study design, data collection and analysis,
decision to publish or preparation of the manuscript. The content is
solely the responsibility of the authors and does not necessarily
represent the official views of the National Institutes of Health. MAB,
JXH, SR and AK were supported by a Wellcome Trust Seeding Drug Discovery
Award (094977/Z/10/Z), and MAC by an NHMRC Principal Research Fellowship
(APP1059354). UHS is supported by NHMRC Project Grant 535053. We
gratefully acknowledge support of this work by the Australian Research
Council and the Government of South Australia. RAB gratefully
acknowledges supervision from Allan J McKinley during his Honors year
when the modeling work was undertaken. SEM analysis was carried out at
Adelaide Microscopy and AFM studies were carried out using facilities in
the School of Chemical and Physical Sciences, Flinders University. Both
of these microscopy facilities are supported by the Australian
Microscopy and Microanalysis Research Facility (AMMRF). Flow Cytometry
experiments were carried out at Flow Cytometry Immunology facility at
Flinders Medical Centre. Ramizol is a Trademark fully registered in
Australia.
NR 35
TC 5
Z9 6
U1 1
U2 12
PU JAPAN ANTIBIOTICS RESEARCH ASSOC
PI TOKYO
PA 2 20 8 KAMIOSAKI SHINAGAWA KU, TOKYO, 141, JAPAN
SN 0021-8820
J9 J ANTIBIOT
JI J. Antibiot.
PD JUL
PY 2015
VL 68
IS 7
BP 453
EP 462
DI 10.1038/ja.2015.4
PG 10
WC Biotechnology & Applied Microbiology; Immunology; Microbiology;
Pharmacology & Pharmacy
SC Biotechnology & Applied Microbiology; Immunology; Microbiology;
Pharmacology & Pharmacy
GA CN7HR
UT WOS:000358605700005
PM 25649856
ER
PT J
AU Padole, A
Singh, S
Lira, D
Blake, MA
Pourjabbar, S
Khawaja, RDA
Choy, G
Saini, S
Do, S
Kalra, MK
AF Padole, Atul
Singh, Sarabjeet
Lira, Diego
Blake, Michael A.
Pourjabbar, Sarvenaz
Khawaja, Ranish Deedar Ali
Choy, Garry
Saini, Sanjay
Do, Synho
Kalra, Mannudeep K.
TI Assessment of Filtered Back Projection, Adaptive Statistical, and
Model-Based Iterative Reconstruction for Reduced Dose Abdominal Computed
Tomography
SO JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY
LA English
DT Article
ID CHEST CT; OPTIMIZATION; PROTECTION
AB Purpose
To compare standard of care and reduced dose (RD) abdominal computed tomography (CT) images reconstructed with filtered back projection (FBP), adaptive statistical iterative reconstruction (ASIR), model-based iterative reconstruction (MBIR) techniques.
Materials and Methods
In an Institutional Review Board-approved, prospective clinical study, 28 patients (mean age 59 +/- 13 years ), undergoing clinically indicated routine abdominal CT on a 64-channel multi-detector CT scanner, gave written informed consent for acquisition of an additional RD (<1 milli-Sievert) abdomen CT series. Sinogram data of RD series were reconstructed with FBP, ASIR, and MBIR and compared with FBP images of standard dose abdomen CT. Two radiologists performed randomized, independent, and blinded comparison for lesion detection, lesion margin, visibility of normal structures, and diagnostic confidence.
Results
Mean CT dose index volume was 10 +/- 3.4 mGy and 1.3 +/- 0.3 mGy for standard and RD CT, respectively. There were 73 "true positive" lesions detected on standard of care CT. Nine lesions (<8 mm in size) were missed on RD abdominal CT images which included liver lesions, liver cysts, kidney cysts, and paracolonic abscess. These lesions were missed regardless of patient size and types of iterative reconstruction techniques used for reconstruction of RD data sets. The visibility of lesion margin was suboptimal in (23/28) patients with RD FBP, (15/28) patients with RD ASIR, and (14/28) patients with RD MBIR compared to standard of care FBP images (P < 0.001). Diagnostic confidence for the assessment of lesions on RD images was suboptimal in most patients regardless of iterative reconstruction techniques.
Conclusions
Clinically significant lesions (< 8 mm) can be missed on abdominal CT examinations acquired at a CT dose index volume of 1.3 mGy regardless of patients' size and reconstruction techniques (FBP, ASIR, and MBIR).
C1 [Padole, Atul; Singh, Sarabjeet; Lira, Diego; Blake, Michael A.; Pourjabbar, Sarvenaz; Khawaja, Ranish Deedar Ali; Choy, Garry; Saini, Sanjay; Do, Synho; Kalra, Mannudeep K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02114 USA.
RP Padole, A (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, 55 Fruit St,Founders 202, Boston, MA 02114 USA.
EM apadole@partners.org
FU Radiological Society of North America (RSNA) Research and Education
Foundation's Educational Scholar grant; GE Healthcare; Siemens
Healthcare; Philips Healthcare; Society of Thoracic Radiology
FX M.K.K. and S.S. have received Radiological Society of North America
(RSNA) Research and Education Foundation's Educational Scholar grant.
S.S. has received research grant from GE Healthcare, Siemens Healthcare,
Philips Healthcare, and Society of Thoracic Radiology. None of the other
coauthors have any pertinent financial disclosures and had complete
unrestricted access to the data at all times.
NR 19
TC 4
Z9 4
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0363-8715
EI 1532-3145
J9 J COMPUT ASSIST TOMO
JI J. Comput. Assist. Tomogr.
PD JUL-AUG
PY 2015
VL 39
IS 4
BP 462
EP 467
DI 10.1097/RCT.0000000000000231
PG 6
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CN7CJ
UT WOS:000358591000002
PM 25734468
ER
PT J
AU Khawaja, RDA
Singh, S
Blake, M
Harisinghani, M
Choy, G
Karosmanoglu, A
Padole, A
Pourjabbar, S
Do, S
Kalra, MK
AF Khawaja, Ranish Deedar Ali
Singh, Sarabjeet
Blake, Michael
Harisinghani, Mukesh
Choy, Gary
Karosmanoglu, Ali
Padole, Atul
Pourjabbar, Saravenaz
Do, Synho
Kalra, Mannudeep K.
TI Ultralow-Dose Abdominal Computed Tomography: Comparison of 2 Iterative
Reconstruction Techniques in a Prospective Clinical Study
SO JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY
LA English
DT Article
ID FILTERED BACK-PROJECTION; IMAGE-QUALITY; RADIATION-EXPOSURE; CT
ANGIOGRAPHY; LIVER PHANTOM; ALGORITHM; MDCT; FEASIBILITY; REDUCTION;
SUMMIT
AB Purpose
To assess lesion detection and image quality of ultralow-dose (ULD) abdominal computed tomography (CT) reconstructed with filtered back projection (FBP) and 2 iterative reconstruction techniques: hybrid-based iDose, and image-based SafeCT.
Materials and Methods
In this institutional review board-approved ongoing prospective clinical study, 41 adult patients provided written informed consent for an additional ULD abdominal CT examination immediately after standard dose (SD) CT exam on a 256-slice multidetector computed tomography (iCT, Philips-Healthcare). The SD examination (size-specific dose estimate, 10 +/- 3 mGy) was performed at 120 kV with automatic exposure control, and reconstructed with FBP. The ULD examination (1.5 +/- 0.4 mGy) was performed at 120 kV and fixed tube current of 17 to 20 mAs/slice to achieve ULD radiation dose, with the rest of the scan parameters same as SD examination. The ULD data were reconstructed with (a) FBP, (b) iDose, and (c) SafeCT. Lesions were detected on ULD FBP series and compared to SD FBP "reference-standard" series. True lesions, pseudolesions, and missed lesions were recorded. Four abdominal radiologists independently blindly performed subjective image quality. Objective image quality included image noise calculation and noise spectral density plots.
Results
All true lesions (n, 52: liver metastases, renal cysts, diverticulosis) in SD FBP images were detected in ULD images. Although there were no missed or pseudolesions on ULD iDose and ULD SafeCT images, appearance of small low-contrast hepatic lesions was suboptimal. The ULD FBP images were unacceptable across all patients for both lesion detection and image quality. In patients with a body mass index (BMI) of 25 kg/m(2) or less, ULD iDose and ULD SafeCT images were acceptable for image quality that was close to SD FBP for both normal and abnormal abdominal and pelvic structures. With increasing BMI, the image quality of ULD images was deemed unacceptable due to photo starvation. Evaluation of kidney stones with ULD iDose/SafeCT images was found acceptable regardless of patient size. Image noise levels were significantly lower in ULD iDose and ULD SafeCT images compared to ULD FBP (P < 0.01).
Conclusions
Preliminary results show that ULD abdominal CT reconstructed with iterative reconstruction techniques is achievable in smaller patients (BMI <= 25 kg/m(2)) but remains a challenge for overweight to obese patients. Lesion detection is similar in full-dose SD FBP and ULD iDose/SafeCT images, with suboptimal visibility of low-contrast lesions in ULD images.
C1 [Khawaja, Ranish Deedar Ali; Singh, Sarabjeet; Padole, Atul; Pourjabbar, Saravenaz; Do, Synho; Kalra, Mannudeep K.] Massachusetts Gen Hosp, MGH Imaging, Boston, MA 02114 USA.
[Blake, Michael; Harisinghani, Mukesh; Choy, Gary; Karosmanoglu, Ali] Massachusetts Gen Hosp, Div Abdominal Imaging, Boston, MA 02114 USA.
[Blake, Michael; Harisinghani, Mukesh; Choy, Gary; Karosmanoglu, Ali] Harvard Univ, Sch Med, Boston, MA USA.
RP Khawaja, RDA (reprint author), 25 New Chardon St,4th Floor, Boston, MA 02114 USA.
EM ranish.khawaja@gmail.com
FU GE Healthcare; Philips Healthcare; Radiological Society of North America
(RSNA)
FX S.S. received research grant from GE Healthcare, Philips Healthcare and
the Radiological Society of North America (RSNA). S.D. received research
grant from Philips Healthcare. The other authors declare no conflict of
interest.
NR 41
TC 4
Z9 4
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0363-8715
EI 1532-3145
J9 J COMPUT ASSIST TOMO
JI J. Comput. Assist. Tomogr.
PD JUL-AUG
PY 2015
VL 39
IS 4
BP 489
EP 498
DI 10.1097/RCT.0000000000000248
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CN7CJ
UT WOS:000358591000007
PM 26182223
ER
PT J
AU Hayano, K
Tian, F
Kambadakone, AR
Yoon, SS
Duda, DG
Ganeshan, B
Sahani, DV
AF Hayano, Koichi
Tian, Fang
Kambadakone, Avinash R.
Yoon, Sam S.
Duda, Dan G.
Ganeshan, Balaji
Sahani, Dushyant V.
TI Texture Analysis of Non-Contrast-Enhanced Computed Tomography for
Assessing Angiogenesis and Survival of Soft Tissue Sarcoma
SO JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY
LA English
DT Article
ID PROGNOSTIC-FACTORS; LOCAL RECURRENCE; CT TEXTURE; TUMOR HETEROGENEITY;
FRENCH-FEDERATION; POTENTIAL MARKER; CANCER; EXTREMITY; THERAPY; GRADE
AB Objective
To evaluate the role of computed tomographic (CT) texture analysis in assessing tumor angiogenesis and survival of soft tissue sarcoma (STS).
Methods
In 20 patients with STSs, tumor texture parameters, which were measured on pretherapeutic CT using CT texture analysis software with the spatial scale filter extracting fine to coarse texture, were compared with microvessel density, plasma vascular endothelial growth factor (VEGF), soluble VEGF receptor-1, and overall survival (OS).
Results
Mean of positive pixels (MPP) showed a positive correlation with microvessel density (P = 0.02). Entropy at medium texture scales (spatial scale filter = 3, 4, 5) showed positive correlations with VEGF (P = 0.03, P = 0.009, and P = 0.02, respectively), and entropy without filtration showed a positive correlation with soluble VEGF receptor-1 (P = 0.02). In the univariate analysis, kurtosis at a medium texture scale and MPP showed significant correlations with OS (P = 0.04 and P = 0.007), and multivariate analysis demonstrated that MPP was an independent prognostic factor (P = 0.01).
Conclusion
Texture parameters are associated with tumor angiogenesis and OS in STS.
C1 [Hayano, Koichi; Tian, Fang; Kambadakone, Avinash R.; Sahani, Dushyant V.] Massachusetts Gen Hosp, Dept Radiol, Div Abdominal Imaging & Intervent, Boston, MA 02114 USA.
[Tian, Fang] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western, Dept Radiol, Shanghai, Peoples R China.
[Yoon, Sam S.] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA.
[Duda, Dan G.] Massachusetts Gen Hosp, Steele Lab, Boston, MA 02114 USA.
[Ganeshan, Balaji] UCL, Inst Nucl Med, London WC1E 6BT, England.
RP Sahani, DV (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Abdominal Imaging & Intervent, 55 Fruit St,White 270, Boston, MA 02114 USA.
EM dsahani@partners.org
FU National Institutes of Health [1 R21 CA117128, 1R01 CA158301]
FX Supported by National Institutes of Health Grants 1 R21 CA117128 and
1R01 CA158301 (S.S.Y.). One of the authors (B.G.) is the scientific
director of TexRAD and provided technical advices for the software used
for this analysis. All other authors have no conflicts of interest.
NR 35
TC 0
Z9 0
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0363-8715
EI 1532-3145
J9 J COMPUT ASSIST TOMO
JI J. Comput. Assist. Tomogr.
PD JUL-AUG
PY 2015
VL 39
IS 4
BP 607
EP 612
DI 10.1097/RCT.0000000000000239
PG 6
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CN7CJ
UT WOS:000358591000025
PM 25793653
ER
PT J
AU Yonker, LM
Cigana, C
Hurley, BP
Bragonzi, A
AF Yonker, Lael M.
Cigana, Cristina
Hurley, Bryan P.
Bragonzi, Alessandra
TI Host-pathogen interplay in the respiratory environment of cystic
fibrosis
SO JOURNAL OF CYSTIC FIBROSIS
LA English
DT Review
DE Cystic fibrosis; Host-pathogen interaction; Microbiota; Innate and
adaptive immunity; Lung disease
ID PSEUDOMONAS-AERUGINOSA BIOFILMS; NEUTROPHIL TRANSEPITHELIAL MIGRATION;
TRANSMEMBRANE CONDUCTANCE REGULATOR; BRONCHIAL EPITHELIAL-CELLS;
FACTOR-KAPPA-B; STAPHYLOCOCCUS-AUREUS; AIRWAY INFLAMMATION;
DOUBLE-BLIND; POLYMORPHONUCLEAR LEUKOCYTES; EXTRACELLULAR TRAPS
AB Significant advances have been made in the understanding of disease progression in cystic fibrosis (CF), revealing a complex interplay between host and pathogenic organisms. The diverse CF microbiota within the airway activates an aberrant immune response that is ineffective in clearing infection. An appreciation of how the CF host immune system interacts with these organisms is crucial to understanding the pathogenesis of CF pulmonary disease. Here we discuss the microbial complexity present in the lungs of individuals with CF, review emerging concepts of innate and adaptive immune responses to pathogens that chronically inhabit the CF lung, and discuss therapies that target the aberrant inflammatory response that characterizes CF. A greater understanding of the underlying mechanisms will shed light on pathogenesis and guide more targeted therapies in the future that serve to reduce infection, minimize lung pathology, and improve the quality of life for patients with CF. (C) 2015 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
C1 [Yonker, Lael M.; Hurley, Bryan P.] Harvard Univ, Sch Med, Massachusetts Gen Hosp Children, Mucosal Immunol & Biol Res Ctr,Pediat, Charlestown, MA USA.
[Cigana, Cristina; Bragonzi, Alessandra] IRCCS San Raffaele Sci Inst, Div Immunol Transplantat & Infect Dis, Infect & Cyst Fibrosis Unit, Milan, Italy.
RP Hurley, BP (reprint author), Massachusetts Gen Hosp, Mucosal Immunol & Biol Res Ctr, CNY 114 114-3503, Charlestown, MA 02129 USA.
EM bphurley@partners.org; bragonzi.alessandra@hsr.it
RI Cigana, Cristina/D-2883-2016;
OI Cigana, Cristina/0000-0003-0436-9721; Bragonzi,
Alessandra/0000-0002-5808-7669
FU Ministero della Salute [GR/2009/1579812]; Italian Cystic Fibrosis
Research Foundation; NIH/NIAID [R01 AI095338]; Delegazione FFC di Milano
[FFC#9/2014, FFC#14/2013]; Department of Pediatrics at MGHfC
FX Supported by the Ministero della Salute (project. GR/2009/1579812) to
AB, and Italian Cystic Fibrosis Research Foundation with the
contribution of the Delegazione FFC di Milano (FFC#9/2014) to AB and
(FFC#14/2013) to CC. Support for BPH and LMY include NIH/NIAID R01
AI095338 and the Department of Pediatrics at MGHfC respectively.
NR 103
TC 8
Z9 8
U1 1
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1569-1993
EI 1873-5010
J9 J CYST FIBROS
JI J. Cyst. Fibros
PD JUL
PY 2015
VL 14
IS 4
BP 431
EP 439
DI 10.1016/j.jcf.2015.02.008
PG 9
WC Respiratory System
SC Respiratory System
GA CO0CX
UT WOS:000358818800003
PM 25800687
ER
PT J
AU Putman, MS
Baker, JF
Uluer, A
Herlyn, K
Lapey, A
Sicilian, L
Tillotson, AP
Gordon, CM
Merkel, PA
Finkelstein, JS
AF Putman, Melissa S.
Baker, Joshua F.
Uluer, Ahmet
Herlyn, Karen
Lapey, Allen
Sicilian, Leonard
Tillotson, Angela Pizzo
Gordon, Catherine M.
Merkel, Peter A.
Finkelstein, Joel S.
TI Trends in bone mineral density in young adults with cystic fibrosis over
a 15 year period
SO JOURNAL OF CYSTIC FIBROSIS
LA English
DT Article
DE Cystic fibrosis; Osteoporosis; Dual energy X-ray absorptiometry; Bone
turnover markers; Vitamin D
ID VERTEBRAL FRACTURES; BODY-COMPOSITION; PREVALENCE; CHILDREN;
OSTEOPOROSIS; ADOLESCENTS; OSTEOPENIA; KYPHOSIS; CFTR
AB Background: Improvements in clinical care have led to increased life expectancy in patients with cystic fibrosis (CF) over the past several decades. Whether these improvements have had significant effects on bone health in patients with CF is unclear.
Methods: This is a cross-sectional study comparing clinical characteristics and bone mineral density (BMD) measured by dual energy X-ray absorptiometry (DXA) in adults with CF evaluated in 1995-1999 to age-, race-, and gender-matched patients with CF evaluated in 2011-2013 at the same center on calibrated DXA machines.
Results: The cohorts were similar in terms of age, BM, pancreatic insufficiency, presence of F508del mutation, and reproductive history. In the most recent cohort, pulmonary function was superior; and fewer patients had vitamin D deficiency or secondary hyperparathyroidism. Areal BMD measures of the PA spine, lateral spine, and distal radius were similarly low in the two cohorts.
Conclusions: Although pulmonary function and vitamin D status were better in patients in the present-day cohort, areal BMD of the spine was reduced in a significant number of patients and was no different in patients with CF today than in the late 1990s. Further attention to optimizing bone health may be necessary to prevent CF-related bone disease. (C) 2015 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
C1 [Putman, Melissa S.; Finkelstein, Joel S.] Massachusetts Gen Hosp, Endocrine Unit, Dept Med, Boston, MA 02114 USA.
[Putman, Melissa S.; Gordon, Catherine M.] Boston Childrens Hosp, Div Endocrinol, Boston, MA USA.
[Baker, Joshua F.; Merkel, Peter A.] Univ Penn, Div Rheumatol, Philadelphia, PA 19104 USA.
[Uluer, Ahmet] Boston Childrens Hosp, Div Resp Dis, Boston, MA USA.
[Herlyn, Karen] Univ Hosp Schleswig Holstein, Poliklin Rheumatol, Campus Luebeck, Germany.
[Lapey, Allen] Massachusetts Gen Hosp, Dept Pediat, Div Pulm, Boston, MA 02114 USA.
[Sicilian, Leonard] Massachusetts Gen Hosp, Dept Med, Div Pulm, Boston, MA 02114 USA.
[Tillotson, Angela Pizzo] Mercy Hosp, Mattina R Proctor Diabet Ctr, Portland, ME USA.
[Gordon, Catherine M.] Hasbro Childrens Hosp, Div Adolescent Med & Endocrinol, Providence, RI USA.
RP Putman, MS (reprint author), Massachusetts Gen Hosp, Endocrine Unit, 50 Blossom St,THR-1051, Boston, MA 02114 USA.
EM msputman@partners.org
FU Cystic Fibrosis Foundation; Boomer Esaison Heroes Foundation;
Mallinckrodt General Clinical Research Center Massachusetts General
Hospital; NIH [M01 RR 01066]; Harvard Clinical and Translational Science
Center [8 UL1 TR000170-05, 1 UL1TR001102-01, 1 UL1RR025758-04]; Vertex
Pharmaceuticals; Endocrine Society Amgen Fellowship; VA Clinical Science
Research and Development; NIH including a Clinical Associate Physician
Award from the National Center for Research Resources (NCRR); National
Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
[K24-AR-02224]
FX This work was supported in part by a research grant from The Cystic
Fibrosis Foundation, The Boomer Esaison Heroes Foundation, and the
Mallinckrodt General Clinical Research Center Massachusetts General
Hospital, NIH Grant M01 RR 01066. This project was also supported by the
Harvard Clinical and Translational Science Center (Grant numbers 8 UL1
TR000170-05, 1 UL1TR001102-01, and 1 UL1RR025758-04). A Vertex
Pharmaceuticals Investigator Initiated Studies Grant provided partial
support for procedures in this study. Dr. Putman was supported by an NIH
T32 award and the Endocrine Society Amgen Fellowship Award. Dr. Baker is
supported by a VA Clinical Science Research and Development Career
Development Award. Dr. Merkel was supported by grants from the NIH
including a Clinical Associate Physician Award from the National Center
for Research Resources (NCRR) and a Mid-Career Development Award in
Clinical Investigation (K24-AR-02224) from the National Institute of
Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
NR 30
TC 4
Z9 4
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1569-1993
EI 1873-5010
J9 J CYST FIBROS
JI J. Cyst. Fibros
PD JUL
PY 2015
VL 14
IS 4
BP 526
EP 532
DI 10.1016/j.jcf.2015.01.011
PG 7
WC Respiratory System
SC Respiratory System
GA CO0CX
UT WOS:000358818800016
PM 25698451
ER
PT J
AU Abbott, J
Elborn, JS
Georgiopoulos, AM
Goldbeck, L
Marshall, BC
Sabadosa, KA
Smith, BA
Quittner, AL
AF Abbott, J.
Elborn, J. S.
Georgiopoulos, A. M.
Goldbeck, L.
Marshall, B. C.
Sabadosa, K. A.
Smith, B. A.
Quittner, A. L.
TI Cystic Fibrosis Foundation and European Cystic Fibrosis Society, Survey
of cystic fibrosis mental health care delivery
SO JOURNAL OF CYSTIC FIBROSIS
LA English
DT Article
DE Depression; Anxiety; Screening
ID QUALITY-OF-LIFE; COMPARING RESPONSE RATES; CHRONIC DISEASES;
LUNG-FUNCTION; DEPRESSION; ANXIETY; METAANALYSIS; ASSOCIATION;
CAREGIVERS; ADHERENCE
AB Background: Psychological morbidity in individuals with cystic fibrosis (CF) and their caregivers is common. The Cystic Fibrosis Foundation (CFF) and European Cystic Fibrosis Society (ECFS) Guidelines Committee on Mental Health sought the views of CF health care professionals concerning mental health care delivery.
Methods: An online survey which focused on the current provision and barriers to mental health care was distributed to CF health care professionals.
Results: Of the 1454 respondents, many did not have a colleague trained in mental health issues and 20% had no one on their team whose primary role was focused on assessing or treating these issues. Insufficient resources and a lack of competency were reported in relation to mental health referrals. Seventy-three percent of respondents had no experience with mental health screening. Of those who did, they utilized 48 different, validated scales.
Conclusions: These data have informed the decision-making, dissemination and implementation strategies of the Mental Health Guidelines Committee sponsored by the CFF and ECFS. (C) 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
C1 [Abbott, J.] Univ Cent Lancashire, Sch Psychol, Preston PR1 2HE, Lancs, England.
[Elborn, J. S.] Queens Univ, Sch Med, Belfast BT7 1NN, Antrim, North Ireland.
[Georgiopoulos, A. M.] Massachusetts Gen Hosp, Dept Child & Adolescent Psychiat, Boston, MA 02114 USA.
[Goldbeck, L.] Univ Ulm, Med Ctr, Child & Adolescent Psychiat, D-89075 Ulm, Germany.
[Marshall, B. C.] Cyst Fibrosis Fdn, Dept Med, Maryland, MD 20814 USA.
[Sabadosa, K. A.] Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH 03766 USA.
[Smith, B. A.] SUNY Buffalo, Dept Psychiat, Buffalo, NY 14202 USA.
[Quittner, A. L.] Univ Miami, Dept Psychol, Coral Gables, FL 33146 USA.
RP Abbott, J (reprint author), Univ Cent Lancashire, Sch Psychol, Preston PR1 2HE, Lancs, England.
EM jabbott@uclan.ac.uk
OI elborn, joseph/0000-0002-2323-442X
FU Cystic Fibrosis Foundation; European Cystic Fibrosis Society
FX We are grateful to Christine Dubois for her time and expertise in
mailing out the survey and to the Cystic Fibrosis Foundation and the
European Cystic Fibrosis Society for their sponsorship.
NR 30
TC 9
Z9 9
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1569-1993
EI 1873-5010
J9 J CYST FIBROS
JI J. Cyst. Fibros
PD JUL
PY 2015
VL 14
IS 4
BP 533
EP 539
DI 10.1016/j.jcf.2014.12.015
PG 7
WC Respiratory System
SC Respiratory System
GA CO0CX
UT WOS:000358818800017
PM 25592657
ER
PT J
AU Jacques, SL
Walsh, JT
AF Jacques, Steven L.
Walsh, Joseph T.
TI Entropy and enthalpy for triggering cutaneous erythema
SO JOURNAL OF INNOVATIVE OPTICAL HEALTH SCIENCES
LA English
DT Article
DE Skin; erythema; thermal; entropy; enthalpy
AB The molar entropy (Delta S) and molar enthalpy (Delta H) for the denaturation event that triggers cutaneous erythema was determined to be Delta S = 190 J/(mole K) and Delta H = 146.9 x 10(3) J/mole. The experiment involved placing heated water against the skin of the forearm, for a range of temperatures and exposure times. Exposing the skin to 45 degrees C for 22 s was at the threshold for producing erythema, which was similar to the threshold for a slight degree of pain.
C1 [Jacques, Steven L.; Walsh, Joseph T.] Massachusetts Gen Hosp, Wellman Labs, Boston, MA 02114 USA.
[Walsh, Joseph T.] Harvard Univ, Sch Med, MIT, Cambridge, MA 02138 USA.
RP Jacques, SL (reprint author), Oregon Hlth & Sci Univ, 3303 SW Bond Ave, Portland, OR 97239 USA.
EM jacquess@ohsu.edu
NR 1
TC 0
Z9 0
U1 0
U2 0
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 1793-5458
EI 1793-7205
J9 J INNOV OPT HEAL SCI
JI J. Innov. Opt. Health Sci.
PD JUL
PY 2015
VL 8
IS 4
SI SI
AR 1550026
DI 10.1142/S1793545815500261
PG 4
WC Optics; Radiology, Nuclear Medicine & Medical Imaging
SC Optics; Radiology, Nuclear Medicine & Medical Imaging
GA CN4VB
UT WOS:000358427300008
ER
PT J
AU Lagerqvist, EL
Finnin, BA
Elliott, DA
Anderson, DJ
Wu, SM
Pouton, CW
Haynes, JM
AF Lagerqvist, E. L.
Finnin, B. A.
Elliott, D. A.
Anderson, D. J.
Wu, S. M.
Pouton, C. W.
Haynes, J. M.
TI Comparing mouse and human pluripotent stem cell derived cardiac cells:
Both systems have advantages for pharmacological and toxicological
screening
SO JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS
LA English
DT Article
DE Calcium imaging; Oscillation frequency; Stem cell-derived
cardiomyocytes; Ischemia; Toxicity
ID RABBIT SINOATRIAL NODE; CONDUCTION SYSTEM; ATRIOVENTRICULAR NODE;
PACEMAKER FUNCTION; PRECURSOR CELLS; PURKINJE-CELLS; BREAST-CANCER;
HEART; CARDIOMYOCYTES; CA2+
AB Pluripotent stem cells offer an unparalleled opportunity to investigate cardiac physiology, pharmacology, toxicology and pathophysiology. In this paper we describe the use of both mouse (Nkx2-5(eGFP/w)) and human (NKX2-5(eGFP/w)) pluripotent stem cell reporter lines, differentiated toward cardiac lineage, for live single cell high acquisition rate calcium imaging. We also assess the potential of NKX2-5(eGFP/w) cardiac lineage cells for use toxicological screening as well as establish their sensitivity to a shift between low and high oxygen environments. Differentiated mouse Nkx2-5(eGFP/w) cells demonstrated a wide range of spontaneous oscillation rates that could be reduced by ryanodine (10 mu M), thapsigargin (1 mu M) and ZD7288 (10 mu M). In contrast human NKX2-5(eGFP/w) cell activity was only reduced by thapsigargin (1 mu M). Human cell survival was sensitive to the addition of trastuzumab and doxorubicin, while the switch from a low to a high oxygen environment affected oscillation frequency. We suggest that the human NKX2-5(eGFP/w) cells are less suitable for studies of compounds affecting cardiac pacemaker activity than mouse Nkx2-5(eGFP/w) cells, but are very suitable for cardiac toxicity studies. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Lagerqvist, E. L.; Finnin, B. A.; Pouton, C. W.; Haynes, J. M.] Monash Univ, Monash Inst Pharmaceut Sci, Drug Discovery Biol, Melbourne, Vic 3004, Australia.
[Elliott, D. A.; Anderson, D. J.] Monash Univ, Murdoch Childrens Res Inst, Clayton, Vic, Australia.
[Wu, S. M.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
RP Haynes, JM (reprint author), 381 Royal Parade, Parkville, Vic 3052, Australia.
EM john.haynes@monash.edu
OI , john/0000-0003-3075-1553; Pouton, Colin/0000-0003-0224-3308
FU Australian Stem Cell Centre
FX This work was supported by the Australian Stem Cell Centre. We thank the
Monash University Core Flow Cytometry Facility Flowcore for their FACS
work.
NR 63
TC 1
Z9 1
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1056-8719
EI 1873-488X
J9 J PHARMACOL TOX MET
JI J. Pharmacol. Toxicol. Methods
PD JUL-AUG
PY 2015
VL 74
BP 17
EP 25
DI 10.1016/j.vascn.2015.04.009
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA CN6MM
UT WOS:000358548900003
PM 25957031
ER
PT J
AU Lorenz, TK
Harte, CB
Meston, CM
AF Lorenz, Tierney K.
Harte, Christopher B.
Meston, Cindy M.
TI Changes in Autonomic Nervous System Activity are Associated with Changes
in Sexual Function in Women with a History of Childhood Sexual Abuse
SO JOURNAL OF SEXUAL MEDICINE
LA English
DT Article
DE Childhood Sexual Abuse; Heart Rate Variability; Sexual Function;
Autonomic Nervous System; Expressive Writing
ID HEART-RATE-VARIABILITY; FUNCTION INDEX FSFI; DEPRESSION; AROUSAL;
SATISFACTION; DYSFUNCTION; VALIDATION; FAILURE; INDIVIDUALS; EXPERIENCES
AB Introduction. Women with histories of childhood sexual abuse (CSA) have higher rates of sexual difficulties, as well as high sympathetic nervous system response to sexual stimuli.
Aim. The study aims to examine whether treatment-related changes in autonomic balance, as indexed by heart rate variability (HRV), were associated with changes in sexual arousal and orgasm function.
Methods. In study 1, we measured HRV while writing a sexual essay in 42 healthy, sexually functional women without any history of sexual trauma. These data, along with demographics, were used to develop HRV norms equations. In study 2, 136 women with a history of CSA were randomized to one of three active expressive writing treatments that focused on their trauma, sexuality, or daily life (control condition). We recorded HRV while writing a sexual essay at pretreatment, posttreatment, and 2-week, and 1- and 6-month follow-ups; we also calculated the expected HRV for each participant based on the norms equations from study 1.
Main Outcome Measures. The main outcome measures used were HRV, Female Sexual Function Index, Sexual Satisfaction ScaleWomen.
Results. The difference between expected and observed HRV decreased over time, indicating that, posttreatment, CSA survivors displayed HRV closer to the expected HRV of a demographics-matched woman with no history of sexual trauma. Also, over time, participants whose HRV became less dysregulated showed the biggest gains in sexual arousal and orgasm function. These effects were consistent across condition.
Conclusions. Treatments that reduce autonomic imbalance may improve sexual well-being among CSA populations. Lorenz TK, Harte CB, and Meston CM. Changes in autonomic nervous system activity are associated with changes in sexual function in women with a history of childhood sexual abuse.
C1 [Lorenz, Tierney K.] Indiana Univ, Kinsey Inst Res Sex Gender & Reprod, Bloomington, IN USA.
[Harte, Christopher B.] VA Boston Healthcare Syst, Res Serv, Boston, MA USA.
[Harte, Christopher B.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA.
[Meston, Cindy M.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA.
RP Meston, CM (reprint author), Univ Texas Austin, Dept Psychol, 1 Univ Stn A8000, Austin, TX 78712 USA.
EM meston@psy.utexas.edu
FU National Institute of Child Health and Human Development (NICHD) [RO1
HD051676, T32HD049336]
FX This research was supported by a grant from the National Institute of
Child Health and Human Development (NICHD, RO1 HD051676) to Cindy M.
Meston. Tierney Lorenz was supported by a grant from the NICHD
(T32HD049336). The views presented here are solely those of the authors
and do necessarily not represent the official views of the National
Institutes of Health or the Department of Veterans Affairs.
NR 46
TC 0
Z9 0
U1 2
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1743-6095
EI 1743-6109
J9 J SEX MED
JI J. Sex. Med.
PD JUL
PY 2015
VL 12
IS 7
BP 1545
EP 1554
DI 10.1111/jsm.12908
PG 10
WC Urology & Nephrology
SC Urology & Nephrology
GA CN5QM
UT WOS:000358484300004
PM 25963394
ER
PT J
AU Ellingsen, DM
AF Ellingsen, Dan-Mikael
TI How Do C-Tactile Skin Afferents Contribute to Erotic Affect?
SO JOURNAL OF SEXUAL MEDICINE
LA English
DT Letter
ID TOUCH
C1 [Ellingsen, Dan-Mikael] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Charlestown, MA 02114 USA.
[Ellingsen, Dan-Mikael] Univ Oslo, Dept Psychol, Oslo, Norway.
RP Ellingsen, DM (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Charlestown, MA 02114 USA.
NR 4
TC 1
Z9 1
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1743-6095
EI 1743-6109
J9 J SEX MED
JI J. Sex. Med.
PD JUL
PY 2015
VL 12
IS 7
BP 1656
EP 1656
DI 10.1111/jsm.12929
PG 1
WC Urology & Nephrology
SC Urology & Nephrology
GA CN5QM
UT WOS:000358484300022
PM 26061119
ER
PT J
AU Folmer, RL
Theodoroff, S
AF Folmer, Robert L.
Theodoroff, Sarah
TI Response to: "All treatments in tinnitus are Experimental, Controversial
and Futuristic" by De Ridder et al (2015)
SO JOURNAL OF THE AMERICAN ACADEMY OF AUDIOLOGY
LA English
DT Letter
ID TRANSCRANIAL MAGNETIC STIMULATION; EFFICACY
C1 [Folmer, Robert L.; Theodoroff, Sarah] Oregon Hlth & Sci Univ, NCRAR, Portland VA Med Ctr, Dept Otolaryngol, Portland, OR 97201 USA.
RP Folmer, RL (reprint author), Oregon Hlth & Sci Univ, NCRAR, Portland VA Med Ctr, Dept Otolaryngol, Portland, OR 97201 USA.
NR 10
TC 0
Z9 0
U1 0
U2 3
PU AMER ACAD AUDIOLOGY
PI RESTON
PA 11730 PLAZA DR, STE 300, RESTON, VA 20190 USA
SN 1050-0545
EI 2157-3107
J9 J AM ACAD AUDIOL
JI J. Am. Acad. Audiol.
PD JUL-AUG
PY 2015
VL 26
IS 7
BP 678
EP 679
DI 10.3766/jaaa.14049
PG 2
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA CN5JL
UT WOS:000358465500009
PM 26218056
ER
PT J
AU Huh, J
Kim, KW
Park, SJ
Kim, HJ
Lee, JS
Ha, HK
Tirumani, H
Ramaiya, NH
AF Huh, Jimi
Kim, Kyung Won
Park, Seong Joon
Kim, Hyoung Jung
Lee, Jong Seok
Ha, Hyun Kwon
Tirumani, Harsha
Ramaiya, Nikhil H.
TI Imaging Features of Primary Tumors and Metastatic Patterns of the
Extraskeletal Ewing Sarcoma Family of Tumors in Adults: A 17-Year
Experience at a Single Institution
SO KOREAN JOURNAL OF RADIOLOGY
LA English
DT Article
DE Ewing sarcoma family of tumors; Extraskeletal Ewing sarcoma; Computed
tomography; Imaging
ID TISSUE
AB Objective: To comprehensively analyze the spectrum of imaging features of the primary tumors and metastatic patterns of the Extraskeletal Ewing sarcoma family of tumors (EES) in adults.
Materials and Methods: We performed a computerized search of our hospital's data-warehouse from 1996 to 2013 using codes for Ewing sarcoma and primitive neuroectodermal tumors as well as the demographic code for 18 years of age. We selected subjects who were histologically confirmed to have Ewing sarcoma of extraskeletal origin. Imaging features of the primary tumor and metastatic disease were evaluated for lesion location, size, enhancement pattern, necrosis, margin, and invasion of adjacent organs.
Results: Among the 70 patients (mean age, 35.8 +/- 15.6 years; range, 18-67 years) included in our study, primary tumors of EES occurred in the soft tissue and extremities (n = 20), abdomen and pelvis (n = 18), thorax (n = 14), paravertebral space (n = 8), head and neck (n = 6), and an unknown primary site (n = 4). Most primary tumors manifested as large and bulky soft-tissue masses (mean size, 9.0 cm; range, 1.3-23.0 cm), frequently invading adjacent organs (45.6%) and showed heterogeneous enhancement (73.7%), a well-defined (66.7%) margin, and partial necrosis/cystic degeneration (81.9 %). Notably, 29 patients had metastatic disease detected at their initial diagnosis. The most frequent site of metastasis was lymph nodes (75.9%), followed by bone (31.0%), Lung (20.7%), abdominal solid organs (13.8%), peritoneum (13.8%), pleura (6.9%), and brain (3.4%).
Conclusion: Primary tumors of EES can occur anywhere and mostly manifest as large and bulky, soft-tissue masses. Lymph nodes are the most frequent metastasis sites.
C1 [Huh, Jimi; Kim, Kyung Won; Kim, Hyoung Jung; Lee, Jong Seok; Ha, Hyun Kwon] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiol, Seoul 138736, South Korea.
[Park, Seong Joon] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul 138736, South Korea.
[Tirumani, Harsha; Ramaiya, Nikhil H.] Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Imaging,Med Sch, Boston, MA 02115 USA.
RP Kim, KW (reprint author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiol, 88 Olymp Ro 43 Gil, Seoul 138736, South Korea.
EM medimash@gmail.com
FU Ministry of Health & Welfare, Republic of Korea [HI14C1090]; National
Research Foundation of Korea (NRF) - Ministry of Science, ICT, & Future
Planning [2014R1A1A1006823]
FX This study was supported by a grant from the Ministry of Health &
Welfare, Republic of Korea (Grant No. HI14C1090) and a grant from the
National Research Foundation of Korea (NRF) funded by the Ministry of
Science, ICT, & Future Planning (No. 2014R1A1A1006823).
NR 15
TC 2
Z9 2
U1 1
U2 4
PU KOREAN RADIOLOGICAL SOC
PI SEOUL
PA 121-8 YANGJAE-DONG, SEOCHO-GU, SEOUL 137-130, SOUTH KOREA
SN 1229-6929
EI 2005-8330
J9 KOREAN J RADIOL
JI Korean J. Radiol.
PD JUL-AUG
PY 2015
VL 16
IS 4
BP 783
EP 790
DI 10.3348/kjr.2015.16.4.783
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CN5GZ
UT WOS:000358459100010
PM 26175577
ER
PT J
AU Karaosmanoglu, AD
Onur, MR
Shirkhoda, A
Ozmen, M
Hahn, PF
AF Karaosmanoglu, Ali Devrim
Onur, Mehmet Ruhi
Shirkhoda, Ali
Ozmen, Mustafa
Hahn, Peter F.
TI Unusual Malignant Solid Neoplasms of the Kidney: Cross-Sectional Imaging
Findings
SO KOREAN JOURNAL OF RADIOLOGY
LA English
DT Editorial Material
DE Kidney; Malignant tumors; Computed tomography; Magnetic resonance
imaging
ID RADIOLOGIC-PATHOLOGICAL CORRELATION; FIBROUS HISTIOCYTOMA; SYNOVIAL
SARCOMA; CARCINOID-TUMORS; CT; OSTEOSARCOMA; EXPERIENCE; DIAGNOSIS;
FEATURES; RARE
AB Malignant kidney neoplasms are the most frequently encountered solid kidney masses. Although renal cell carcinoma is the major renal malignancy, other solid malignant renal masses should be considered in the differential diagnosis of solid renal masses that do not contain a macroscopic fatty component. In this pictorial essay, we present the imaging findings of a primitive neuroectodermal tumor, primary liposarcoma of the kidney, primary neuroendocrine tumor, Leiomyosarcoma, synovial sarcoma, malignant fibrous histiocytoma, sclerosing fibrosarcoma and renal metastasis of osteosarcoma.
C1 [Karaosmanoglu, Ali Devrim; Hahn, Peter F.] Harvard Univ, Massachusetts Gen Hosp, Dept Radiol, Sch Med, Boston, MA 02114 USA.
[Onur, Mehmet Ruhi] Hacettepe Univ, Sch Med, Dept Radiol, TR-06100 Ankara, Turkey.
[Shirkhoda, Ali] Univ Calif Irvine, Sch Med, Dept Radiol, Irvine, CA 92697 USA.
[Ozmen, Mustafa] Hacettepe Univ, Fac Med, Dept Radiol, TR-06100 Ankara, Turkey.
RP Onur, MR (reprint author), Hacettepe Univ, Sch Med, Dept Radiol, TR-06100 Ankara, Turkey.
EM ruhionur@yahoo.com
NR 35
TC 1
Z9 2
U1 0
U2 2
PU KOREAN RADIOLOGICAL SOC
PI SEOUL
PA 121-8 YANGJAE-DONG, SEOCHO-GU, SEOUL 137-130, SOUTH KOREA
SN 1229-6929
EI 2005-8330
J9 KOREAN J RADIOL
JI Korean J. Radiol.
PD JUL-AUG
PY 2015
VL 16
IS 4
BP 853
EP 859
DI 10.3348/kjr.2015.16.4.853
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CN5GZ
UT WOS:000358459100018
PM 26175585
ER
PT J
AU Bar-Nur, O
Verheul, C
Sommer, AG
Brumbaugh, J
Schwarz, BA
Lipchina, I
Huebner, AJ
Mostoslavsky, G
Hochedlinger, K
AF Bar-Nur, Ori
Verheul, Cassandra
Sommer, Andreia G.
Brumbaugh, Justin
Schwarz, Benjamin A.
Lipchina, Inna
Huebner, Aaron J.
Mostoslavsky, Gustavo
Hochedlinger, Konrad
TI Lineage conversion induced by pluripotency factors involves transient
passage through an iPSC stage
SO NATURE BIOTECHNOLOGY
LA English
DT Article
ID SMALL MOLECULES FACILITATE; NEURAL STEM-CELLS; MOUSE FIBROBLASTS;
DEFINED FACTORS; GENERATION; NANOG
AB Brief expression of pluripotency-associated factors such as Oct4, Klf4, Sox2 and c-Myc (OKSM), in combination with differentiation-inducing signals, has been reported to trigger transdifferentiation of fibroblasts into other cell types. Here we show that OKSM expression in mouse fibroblasts gives rise to both induced pluripotent stem cells (iPSCs) and induced neural stem cells (iNSCs) under conditions previously shown to induce only iNSCs. Fibroblast-derived iNSC colonies silenced retroviral transgenes and reactivated silenced X chromosomes, both hallmarks of pluripotent stem cells. Moreover, lineage tracing with an Oct4-CreER labeling system demonstrated that virtually all iNSC colonies originated from cells transiently expressing Oct4, whereas ablation of Oct4(+) cells prevented iNSC formation. Lastly, an alternative transdifferentiation cocktail that lacks Oct4 and was reportedly unable to support induced pluripotency yielded iPSCs and iNSCs carrying the Oct4-CreER-derived lineage label. Together, these data suggest that iNSC generation from fibroblasts using OKSM and other pluripotency-related reprogramming factors requires passage through a transient iPSC state.
C1 [Bar-Nur, Ori; Verheul, Cassandra; Brumbaugh, Justin; Schwarz, Benjamin A.; Lipchina, Inna; Huebner, Aaron J.; Hochedlinger, Konrad] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
[Bar-Nur, Ori; Verheul, Cassandra; Brumbaugh, Justin; Schwarz, Benjamin A.; Lipchina, Inna; Huebner, Aaron J.; Hochedlinger, Konrad] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Bar-Nur, Ori; Verheul, Cassandra; Brumbaugh, Justin; Schwarz, Benjamin A.; Lipchina, Inna; Huebner, Aaron J.; Hochedlinger, Konrad] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
[Bar-Nur, Ori; Verheul, Cassandra; Brumbaugh, Justin; Schwarz, Benjamin A.; Lipchina, Inna; Huebner, Aaron J.; Hochedlinger, Konrad] Howard Hughes Med Inst, Chevy Chase, MD USA.
[Bar-Nur, Ori; Verheul, Cassandra; Brumbaugh, Justin; Schwarz, Benjamin A.; Lipchina, Inna; Huebner, Aaron J.; Hochedlinger, Konrad] Harvard Stem Cell Inst, Cambridge, MA USA.
[Sommer, Andreia G.; Mostoslavsky, Gustavo] Boston Univ, Sch Med, Ctr Regenerat Med CReM, Boston, MA 02118 USA.
[Sommer, Andreia G.; Mostoslavsky, Gustavo] Boston Med Ctr, Boston, MA USA.
RP Hochedlinger, K (reprint author), Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
EM khochedlinger@mgh.harvard.edu
FU EGL foundation; Postdoctoral Fellowship Award by MGH Executive Committee
on Research Fund; US National Institutes of Health (NIH)
[1F32HD078029-01A1, 1F32HD079225-01A1]; NIH [R01HD058013]; Howard Hughes
Medical Institute; [T32 (5-T32-CA-9216-33)]
FX We thank members of the Hochedlinger laboratory for critical evaluation
and discussion of this manuscript. We thank E. Apostolou and S. Cheloufi
for helpful comments and N. Maherali for suggesting the idea of X
chromosome reactivation. We are also grateful to B. Payer and J. Lee for
providing tail-tip fibroblasts carrying an X-linked GFP reporter and to
A. Brack for sharing Rosa26-lsl-DTA mice. We are grateful to L.
Prickett, M. Weglarz and K. Folz-Donahue at the MGH/HSCI flow cytometry
core for their constant assistance and support. O.B.-N, is supported by
a Gruss-Lipper postdoctoral fellowship from the EGL foundation. B.A.S.
has been supported by a T32 (5-T32-CA-9216-33) grant and through a
Postdoctoral Fellowship Award by the MGH Executive Committee on Research
Fund for Medical Discovery. J.B. and I.L. are supported by Ruth L.
Kirschstein F32 Post-doctoral Fellowships from the US National
Institutes of Health (NIH) (1F32HD078029-01A1 to J.B. and
1F32HD079225-01A1 to I.L.). Support to K.H. is from the NIH
(R01HD058013) and Howard Hughes Medical Institute.
NR 27
TC 30
Z9 30
U1 3
U2 10
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1087-0156
EI 1546-1696
J9 NAT BIOTECHNOL
JI Nat. Biotechnol.
PD JUL
PY 2015
VL 33
IS 7
BP 761
EP 768
DI 10.1038/nbt.3247
PG 8
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA CN4JJ
UT WOS:000358396100033
PM 26098450
ER
PT J
AU Graham, DB
Becker, CE
Doan, A
Goel, G
Villablanca, EJ
Knights, D
Mok, A
Ng, ACY
Doench, JG
Root, DE
Clish, CB
Xavier, RJ
AF Graham, Daniel B.
Becker, Christine E.
Doan, Aivi
Goel, Gautam
Villablanca, Eduardo J.
Knights, Dan
Mok, Amanda
Ng, Aylwin C. Y.
Doench, John G.
Root, David E.
Clish, Clary B.
Xavier, Ramnik J.
TI Functional genomics identifies negative regulatory nodes controlling
phagocyte oxidative burst
SO NATURE COMMUNICATIONS
LA English
DT Article
ID INFLAMMATORY-BOWEL-DISEASE; CHRONIC GRANULOMATOUS-DISEASE; NADPH
OXIDASE; RHEUMATOID-ARTHRITIS; SIGNALING PATHWAYS; INTERFERON-GAMMA;
DENDRITIC CELLS; VAV PROTEINS; HOST-DEFENSE; COMPLEX
AB The phagocyte oxidative burst, mediated by Nox2 NADPH oxidase-derived reactive oxygen species, confers host defense against a broad spectrum of bacterial and fungal pathogens. Loss-of-function mutations that impair function of the Nox2 complex result in a life-threatening immunodeficiency, and genetic variants of Nox2 subunits have been implicated in pathogenesis of inflammatory bowel disease (IBD). Thus, alterations in the oxidative burst can profoundly impact host defense, yet little is known about regulatory mechanisms that fine-tune this response. Here we report the discovery of regulatory nodes controlling oxidative burst by functional screening of genes within loci linked to human inflammatory disease. Implementing a multi-omics approach, we define transcriptional, metabolic and ubiquitin-cycling nodes controlled by Rbpj, Pfkl and Rnf145, respectively. Furthermore, we implicate Rnf145 in proteostasis of the Nox2 complex by endoplasmic reticulum-associated degradation. Consequently, ablation of Rnf145 in murine macrophages enhances bacterial clearance, and rescues the oxidative burst defects associated with Ncf4 haploinsufficiency.
C1 [Graham, Daniel B.; Doan, Aivi; Villablanca, Eduardo J.; Mok, Amanda; Ng, Aylwin C. Y.; Doench, John G.; Root, David E.; Clish, Clary B.; Xavier, Ramnik J.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
[Graham, Daniel B.; Villablanca, Eduardo J.; Xavier, Ramnik J.] Harvard Univ, Dept Med, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA.
[Becker, Christine E.; Goel, Gautam; Villablanca, Eduardo J.; Xavier, Ramnik J.] Harvard Univ, Ctr Computat & Integrat Biol, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA.
[Knights, Dan] Univ Minnesota, Dept Comp Sci & Engn, Minneapolis, MN 55455 USA.
[Ng, Aylwin C. Y.; Xavier, Ramnik J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
[Ng, Aylwin C. Y.; Xavier, Ramnik J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Study Inflammatory Bowel Dis, Boston, MA 02114 USA.
[Xavier, Ramnik J.] MIT, Ctr Microbiome Informat & Therapeut, Cambridge, MA 02139 USA.
RP Graham, DB (reprint author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
EM dgraham@broadinstitute.org; xavier@molbio.mgh.harvard.edu
OI Villablanca, Eduardo/0000-0001-9522-9729; Mok,
Amanda/0000-0001-6981-1547
FU Leona M. and Harry B. Helmsley Charitable Trust; Crohn's and Colitis
Foundation of America Genetics Initiative; National Institutes of Health
[DK043351]
FX We are grateful to Dr Agnes Gardet for her help in designing, optimizing
and completing the screen, and Bihua Li for technical assistance. We
thank Drs Jeffrey Silva and Matthew Stokes at Cell Signaling Technology
for expert assistance with proteomics. In addition, we thank Drs Moran
Yassour, Isabel Latorre and Natalia Nedelsky for critical comments and
advice. R.J.X. was supported by funding from The Leona M. and Harry B.
Helmsley Charitable Trust, the Crohn's and Colitis Foundation of America
Genetics Initiative and the National Institutes of Health grant
DK043351.
NR 50
TC 4
Z9 4
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUL
PY 2015
VL 6
AR 7838
DI 10.1038/ncomms8838
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CO0RZ
UT WOS:000358861300002
PM 26194095
ER
PT J
AU Schumacher, FR
Schmit, SL
Jiao, S
Edlund, CK
Wang, HS
Zhang, B
Hsu, L
Huang, SC
Fischer, CP
Harju, JF
Idos, GE
Lejbkowicz, F
Manion, FJ
McDonnell, K
McNeil, CE
Melas, M
Rennert, HS
Shi, W
Thomas, DC
Van Den Berg, DJ
Hutter, CM
Aragaki, AK
Butterbach, K
Caan, BJ
Carlson, CS
Chanock, SJ
Curtis, KR
Fuchs, CS
Gala, M
Giocannucci, EL
Gogarten, SM
Hayes, RB
Henderson, B
Hunter, DJ
Jackson, RD
Kolonel, LN
Kooperberg, C
Kury, S
LaCroix, A
Laurie, CC
Laurie, CA
Lemire, M
Levine, D
Ma, J
Makar, KW
Qu, CH
Taverna, D
Ulrich, CM
Wu, KN
Kono, S
West, DW
Berndt, SI
Bezieau, S
Brenner, H
Campbell, PT
Chan, AT
Chang-Claude, J
Coetzee, GA
Conti, DV
Duggan, D
Figueiredo, JC
Fortini, BK
Gallinger, SJ
Gauderman, WJ
Giles, G
Green, R
Haile, R
Harrison, TA
Hoffmeister, M
Hopper, JL
Hudson, TJ
Jacobs, E
Iwasaki, M
Jee, SH
Jenkins, M
Jia, WH
Joshi, A
Li, L
Lindor, NM
Matsuo, K
Moreno, V
Mukherjee, B
Newcomb, PA
Potter, JD
Raskin, L
Rennert, G
Rosse, S
Severi, G
Schoen, RE
Seminara, D
Shu, XO
Slattery, ML
Tsugane, S
White, E
Xiang, YB
Zanke, BW
Zheng, W
Le Marchand, L
Casey, G
Gruber, SB
Peters, U
AF Schumacher, Fredrick R.
Schmit, Stephanie L.
Jiao, Shuo
Edlund, Christopher K.
Wang, Hansong
Zhang, Ben
Hsu, Li
Huang, Shu-Chen
Fischer, Christopher P.
Harju, John F.
Idos, Gregory E.
Lejbkowicz, Flavio
Manion, Frank J.
McDonnell, Kevin
McNeil, Caroline E.
Melas, Marilena
Rennert, Hedy S.
Shi, Wei
Thomas, Duncan C.
Van Den Berg, David J.
Hutter, Carolyn M.
Aragaki, Aaron K.
Butterbach, Katja
Caan, Bette J.
Carlson, Christopher S.
Chanock, Stephen J.
Curtis, Keith R.
Fuchs, Charles S.
Gala, Manish
Giocannucci, Edward L.
Gogarten, Stephanie M.
Hayes, Richard B.
Henderson, Brian
Hunter, David J.
Jackson, Rebecca D.
Kolonel, Laurence N.
Kooperberg, Charles
Kury, Sebastian
LaCroix, Andrea
Laurie, Cathy C.
Laurie, Cecelia A.
Lemire, Mathiew
Levine, David
Ma, Jing
Makar, Karen W.
Qu, Conghui
Taverna, Darin
Ulrich, Cornelia M.
Wu, Kana
Kono, Suminori
West, Dee W.
Berndt, Sonja I.
Bezieau, Stephane
Brenner, Hermann
Campbell, Peter T.
Chan, Andrew T.
Chang-Claude, Jenny
Coetzee, Gerhard A.
Conti, David V.
Duggan, David
Figueiredo, Jane C.
Fortini, Barbara K.
Gallinger, Steven J.
Gauderman, W. James
Giles, Graham
Green, Roger
Haile, Robert
Harrison, Tabitha A.
Hoffmeister, Michael
Hopper, John L.
Hudson, Thomas J.
Jacobs, Eric
Iwasaki, Motoki
Jee, Sun Ha
Jenkins, Mark
Jia, Wei-Hua
Joshi, Amit
Li, Li
Lindor, Noralene M.
Matsuo, Keitaro
Moreno, Victor
Mukherjee, Bhramar
Newcomb, Polly A.
Potter, John D.
Raskin, Leon
Rennert, Gad
Rosse, Stephanie
Severi, Gianluca
Schoen, Robert E.
Seminara, Daniela
Shu, Xiao-Ou
Slattery, Martha L.
Tsugane, Shoichiro
White, Emily
Xiang, Yong-Bing
Zanke, Brent W.
Zheng, Wei
Le Marchand, Loic
Casey, Graham
Gruber, Stephen B.
Peters, Ulrike
TI Genome-wide association study of colorectal cancer identifies six new
susceptibility loci
SO NATURE COMMUNICATIONS
LA English
DT Article
ID NEGATIVE REGULATOR LRIG1; GENOTYPE IMPUTATION; PANCREATIC-CANCER; RISK
LOCUS; METAANALYSIS; SCAN; 8Q24; CARCINOMA; VARIANTS; RECEPTOR
AB Genetic susceptibility to colorectal cancer is caused by rare pathogenic mutations and common genetic variants that contribute to familial risk. Here we report the results of a two-stage association study with 18,299 cases of colorectal cancer and 19,656 controls, with follow-up of the most statistically significant genetic loci in 4,725 cases and 9,969 controls from two Asian consortia. We describe six new susceptibility loci reaching a genome-wide threshold of P<5.0E - 08. These findings provide additional insight into the underlying biological mechanisms of colorectal cancer and demonstrate the scientific value of large consortia-based genetic epidemiology studies.
C1 [Schumacher, Fredrick R.; Schmit, Stephanie L.; Edlund, Christopher K.; Huang, Shu-Chen; Idos, Gregory E.; McDonnell, Kevin; McNeil, Caroline E.; Melas, Marilena; Thomas, Duncan C.; Van Den Berg, David J.; Henderson, Brian; Coetzee, Gerhard A.; Conti, David V.; Figueiredo, Jane C.; Fortini, Barbara K.; Gauderman, W. James; Raskin, Leon; Rennert, Gad; Casey, Graham; Gruber, Stephen B.] Univ So Calif, Keck Sch Med, USC Norris Comprehens Canc Ctr, Dept Prevent Med, Los Angeles, CA 90089 USA.
[Schmit, Stephanie L.; Gruber, Stephen B.] Univ So Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90089 USA.
[Jiao, Shuo; Hsu, Li; Aragaki, Aaron K.; Carlson, Christopher S.; Curtis, Keith R.; Kooperberg, Charles; LaCroix, Andrea; Makar, Karen W.; Qu, Conghui; Ulrich, Cornelia M.; Harrison, Tabitha A.; Rosse, Stephanie; White, Emily; Peters, Ulrike] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98124 USA.
[Wang, Hansong; Le Marchand, Loic] Univ Hawaii Canc Ctr, Program Epidemiol, Honolulu, HI 96822 USA.
[Zhang, Ben] Third Mil Med Univ, Southwest Hosp, Dept Gen Surg, Chongqing 400038, Peoples R China.
[Fischer, Christopher P.; Harju, John F.; Manion, Frank J.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48105 USA.
[Lejbkowicz, Flavio; Rennert, Hedy S.; Rennert, Gad] Carmel Hosp, Dept Community Med & Epidemiol, IL-34361 Haifa, Israel.
[Lejbkowicz, Flavio; Rennert, Hedy S.; Rennert, Gad] Clalit Hlth Serv Natl Canc Control Ctr, IL-34361 Haifa, Israel.
[Shi, Wei] Childrens Hosp, Dept Surg, Los Angeles, CA 90027 USA.
[Hutter, Carolyn M.] NCI, Div Canc Control & Populat Sci, NIH, Rockville, MD 20892 USA.
[Butterbach, Katja; Brenner, Hermann; Hoffmeister, Michael] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, D-69121 Heidelberg, Germany.
[Caan, Bette J.] Kaiser Permanente Med Care Program Northern Calif, Div Res, Oakland, CA 94612 USA.
[Chanock, Stephen J.; Berndt, Sonja I.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[Fuchs, Charles S.] Brigham & Womens Hosp, Dept Med, Brookline, MA 02115 USA.
[Fuchs, Charles S.] Dana Farber Canc Inst, Dept Med Oncol, Brookline, MA 02115 USA.
[Gala, Manish; Chan, Andrew T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
[Giocannucci, Edward L.; Chan, Andrew T.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Giocannucci, Edward L.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.
[Gogarten, Stephanie M.; Laurie, Cathy C.; Laurie, Cecelia A.; Levine, David] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Hayes, Richard B.] NYU, Sch Med, Dept Populat Hlth, Div Epidemiol, New York, NY 10016 USA.
[Hunter, David J.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Program Genet Epidemiol & Stat Genet, Boston, MA 02115 USA.
[Jackson, Rebecca D.] Ohio State Univ, Dept Med, Columbus, OH 43210 USA.
[Kolonel, Laurence N.] Univ Hawaii Manoa, Off Publ Hlth Studies, Honolulu, HI 96822 USA.
[Kury, Sebastian] CHU Nantes, Serv Genet Med, F-44093 Nantes, France.
[Lemire, Mathiew] Ontario Inst Canc Res, Toronto, ON M5G 0A3, Canada.
[Ma, Jing] Harvard Univ, Sch Publ Hlth, Boston, MA 02114 USA.
[Taverna, Darin] Phoenix Coll, Phoenix, AZ 85013 USA.
[Ulrich, Cornelia M.] German Canc Res Ctr, Div Prevent Oncol, D-69120 Heidelberg, Germany.
[Ulrich, Cornelia M.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA.
[Wu, Kana] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Kono, Suminori; Matsuo, Keitaro] Kyushu Univ, Dept Prevent Med, Fukuoka 8128582, Japan.
[West, Dee W.] Inst Publ Hlth, Canc Registry Greater Calif, Sacramento, CA 95825 USA.
[Bezieau, Stephane] Ctr Hosp Univ Hotel Dieu, F-44093 Nantes, France.
[Campbell, Peter T.; Jacobs, Eric] Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA.
[Chang-Claude, Jenny] German Canc Res Ctr, Div Canc Epidemiol, Unit Genet Epidemiol, D-69121 Heidelberg, Germany.
[Conti, David V.] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90089 USA.
[Duggan, David] Translat Genom Res Inst, Genet Basis Human Dis Div, Phoenix, AZ 85004 USA.
[Gallinger, Steven J.] Mt Sinai Hosp, Zane Cohen Ctr Digest Dis, Toronto, ON M5T 3L9, Canada.
[Giles, Graham; Severi, Gianluca] Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic 3004, Australia.
[Green, Roger] Mem Univ Newfoundland, Discipline Genet, St John, NF A1B 3V6, Canada.
[Haile, Robert] Stanford Univ, Dept Med, Div Oncol, Stanford, CA 94305 USA.
[Hopper, John L.] Univ Melbourne, Ctr MEGA Epidemiol, Carlton, Vic 3010, Australia.
[Hudson, Thomas J.] Ontario Inst Canc Res, Dept Genom, Toronto, ON M5G 0A3, Canada.
[Iwasaki, Motoki; Tsugane, Shoichiro] Natl Canc Ctr, Res Ctr Canc Prevent & Screening, Tokyo 1040045, Japan.
[Jee, Sun Ha] Yonsei Univ, Grad Sch Publ Hlth, Dept Epidemiol & Hlth Promot, Seoul 120749, South Korea.
[Jenkins, Mark] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Ctr Biostat & Epidemiol, Parkville, Vic 3010, Australia.
[Jia, Wei-Hua] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China.
[Joshi, Amit] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Li, Li] Case Western Reserve Univ, Dept Family Med & Community Hlth, Cleveland, OH 44106 USA.
[Lindor, Noralene M.] Mayo Clin, Dept Hlth Sci Res, Scottsdale, AZ 85259 USA.
[Moreno, Victor] IDIBELL, Catalan Inst Oncol, Canc Epidemiol Serv, Barcelona 08908, Spain.
[Mukherjee, Bhramar] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA.
[Newcomb, Polly A.; Potter, John D.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Canc Prevent Program, Seattle, WA 98109 USA.
[Raskin, Leon; Zheng, Wei] Vanderbilt Univ, Sch Med, Vanderbilt Epidemiol Ctr, Div Epidemiol, Nashville, TN 37203 USA.
[Raskin, Leon; Shu, Xiao-Ou; Zheng, Wei] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Nashville, TN 37203 USA.
[Rennert, Gad] Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-3200003 Haifa, Israel.
[Severi, Gianluca] HuGeF, I-10126 Turin, Italy.
[Schoen, Robert E.] Univ Pittsburgh, Med Ctr, Dept Internal Med, Pittsburgh, PA 15213 USA.
[Seminara, Daniela] NCI, Epidemiol & Genom Res Program, Div Canc Control & Populat Sci, NIH, Bethesda, MD 20892 USA.
[Shu, Xiao-Ou] Vanderbilt Univ, Sch Med, Div Epidemiol, Nashville, TN 37203 USA.
[Slattery, Martha L.] Univ Utah, Hlth Sci Ctr, Dept Internal Med, Salt Lake City, UT 84132 USA.
[Xiang, Yong-Bing] Shanghai Canc Inst, Dept Epidemiol, Shanghai 220025, Peoples R China.
[Zanke, Brent W.] Univ Ottawa, Ottawa, ON K1N 6N5, Canada.
[Zanke, Brent W.] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON K1Y 4E9, Canada.
RP Gruber, SB (reprint author), Univ So Calif, Keck Sch Med, USC Norris Comprehens Canc Ctr, Dept Prevent Med, Los Angeles, CA 90089 USA.
EM sgruber@usc.edu
RI Hoffmeister, Michael/B-5745-2012; Bezieau, stephane/G-5621-2015; Raskin,
Leon/P-5765-2015; Jenkins, Mark/P-7803-2015; U-ID, Kyushu/C-5291-2016;
Gallinger, Steven/E-4575-2013; Brenner, Hermann/B-4627-2017;
OI Hoffmeister, Michael/0000-0002-8307-3197; KURY,
Sebastien/0000-0001-5497-0465; Potter, John/0000-0001-5439-1500;
Bezieau, stephane/0000-0003-0095-1319; Raskin, Leon/0000-0003-1195-7214;
Jenkins, Mark/0000-0002-8964-6160; Gogarten,
Stephanie/0000-0002-7231-9745; Hayes, Richard/0000-0002-0918-661X;
Moreno, Victor/0000-0002-2818-5487; Brenner,
Hermann/0000-0002-6129-1572; Giles, Graham/0000-0003-4946-9099
FU National Cancer Institute, National Institutes of Health under RFA
[CA-09-002, NIH/NCI U19 CA148107]
FX CORECT: this work was supported by the National Cancer Institute,
National Institutes of Health under RFA # CA-09-002, NIH/NCI U19
CA148107. The content of this manuscript does not necessarily reflect
the views or policies of the National Cancer Institute or any of the
collaborating centres in the CORECT consortium, nor does mention of
trade names, commercial products or organizations imply endorsement by
the US Government or the CORECT Consortium. ASTERISK: we are very
grateful to Dr Bruno Buecher without whom this project would not have
existed. We also thank all those who agreed to participate in this
study, including the patients and the healthy control persons, as well
as all the physicians, technicians and students. DACHS: we thank all
participants and cooperating clinicians, and Ute Handte-Daub, Renate
Hettler-Jensen, Utz Benscheid, Muhabbet Celik and Ursula Eilber for
excellent technical assistance. GECCO: we thank all those at the GECCO
Coordinating Center for helping bring together the data and people that
made this project possible. HPFS, NHS and PHS: we acknowledge Patrice
Soule and Hardeep Ranu of the Dana-Farber Harvard Cancer Center
High-Throughput Polymorphism Core who assisted in the genotyping for
NHS, HPFS and PHS under the supervision of Dr Immaculata Devivo and Dr
David Hunter, Qin (Carolyn) Guo and Lixue Zhu who assisted in
programming for NHS and HPFS and Haiyan Zhang who assisted in
programming for the PHS. We thank the participants and staff of the
Nurses' Health Study and the Health Professionals Follow-Up Study, for
their valuable contributions as well as the following state cancer
registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL,
IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA,
RI, SC, TN, TX, VA, WA, WY. In addition, this study was approved by the
Connecticut Department of Public Health (DPH) Human Investigations
Committee. Certain data used in this publication were obtained from the
DPH. We assume full responsibility for analyses and interpretation of
these data. PLCO: we thank Drs Christine Berg and Philip Prorok,
Division of Cancer Prevention, National Cancer Institute, the Screening
Center investigators and staff or the Prostate, Lung, Colorectal and
Ovarian (PLCO) Cancer Screening Trial, Mr. Tom Riley and staff,
Information Management Services Inc., Ms Barbara O'Brien and staff,
Westat Inc. and Drs Bill Kopp, Wen Shao and staff, SAIC-Frederick. Most
importantly, we acknowledge the study participants for their
contributions for making this study possible. The statements contained
herein are solely those of the authors and do not represent or imply
concurrence or endorsement by NCI. PMH: we thank the study participants
and staff of the Hormones and Colon Cancer study. WHI: we thank the WHI
investigators and staff for their dedication, and the study participants
for making the program possible. A full listing of WHI investigators can
be found at
https://cleo.whi.org/researchers/Documents%20%20Write%20a%20Paper/WHI%20
Investigator%20Short%20List.pdf. ACC: we thank all study participants
and research staff of all studies for their contributions and commitment
to this project, Regina Courtney for DNA preparation and Jing He for
data processing.
NR 54
TC 14
Z9 14
U1 4
U2 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUL
PY 2015
VL 6
AR 7138
DI 10.1038/ncomms8138
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CO0NZ
UT WOS:000358850000001
PM 26151821
ER
PT J
AU Henly, SJ
McCarthy, DO
Wyman, JF
Heitkemper, MM
Redeker, NS
Titler, MG
McCarthy, AM
Stone, PW
Moore, SM
Alt-White, AC
Conley, YP
Dunbar-Jacob, J
AF Henly, Susan J.
McCarthy, Donna O.
Wyman, Jean F.
Heitkemper, Margaret M.
Redeker, Nancy S.
Titler, Marita G.
McCarthy, Ann Marie
Stone, Patricia W.
Moore, Shirley M.
Alt-White, Anna C.
Conley, Yvette P.
Dunbar-Jacob, Jacqueline
TI Emerging areas of science: Recommendations for Nursing Science Education
from the Council for the Advancement of Nursing Science Idea Festival
SO NURSING OUTLOOK
LA English
DT Article
DE Nursing research; Nursing science
ID TEAM SCIENCE; HEALTH; COLLABORATION; SCIENTISTS
AB The Council for the Advancement of Nursing Science aims to "facilitate and recognize life-long nursing science career development" as an important part of its mission. In light of fast-paced advances in science and technology that are inspiring new questions and methods of investigation in the health sciences, the Council for the Advancement of Nursing Science convened the Idea Festival for Nursing Science Education and appointed the Idea Festival Advisory Committee (IFAC) to stimulate dialogue about linking PhD education with a renewed vision for preparation of the next generation of nursing scientists. Building on the 2005 National Research Council report Advancing The Nation's Health Needs and the 2010 American Association of Colleges of Nursing Position Statement on the Research-Focused Doctorate Pathways to Excellence, the IFAC specifically addressed the capacity of PhD programs to prepare nursing scientists to conduct cutting-edge research in the following key emerging and priority areas of health sciences research: omics and the microbiome; health behavior, behavior change, and biobehavioral science; patient-reported outcomes; big data, e-science, and informatics; quantitative sciences; translation science; and health economics. The purpose of this article is to (a) describe IFAC activities, (b) summarize 2014 discussions hosted as part of the Idea Festival, and (c) present IFAC recommendations for incorporating these emerging areas of science and technology into research-focused doctoral programs committed to preparing graduates for lifelong, competitive careers in nursing science. The recommendations address clearer articulation of program focus areas; inclusion of foundational knowledge in emerging areas of science in core courses on nursing science and research methods; faculty composition; prerequisite student knowledge and skills; and in-depth, interdisciplinary training in supporting area of science content and methods.
C1 [Henly, Susan J.; Wyman, Jean F.] Univ Minnesota, Sch Nursing, Minneapolis, MN 55455 USA.
[McCarthy, Donna O.] Marquette Univ, Coll Nursing, Milwaukee, WI 53233 USA.
[Heitkemper, Margaret M.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA.
[Redeker, Nancy S.] Yale Univ, Sch Nursing, West Haven, CT USA.
[Titler, Marita G.] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA.
[McCarthy, Ann Marie] Univ Iowa, Coll Nursing, Iowa City, IA 52242 USA.
[Stone, Patricia W.] Columbia Univ, Sch Nursing, New York, NY USA.
[Moore, Shirley M.] Case Western Reserve Univ, Frances Payne Bolton Sch Nursing, Cleveland, OH 44106 USA.
[Alt-White, Anna C.] US Dept Vet Affairs, Off Nursing Serv, Washington, DC USA.
[Conley, Yvette P.; Dunbar-Jacob, Jacqueline] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA.
RP Henly, SJ (reprint author), Univ Minnesota, Sch Nursing, 5-140 WDH,308 Harvard St SE, Minneapolis, MN 55455 USA.
EM henly003@umn.edu
RI Redeker, Nancy/Q-8252-2016;
OI Redeker, Nancy/0000-0001-7817-2708; Moore, Shirley
M./0000-0003-2712-6896; Henly, Susan/0000-0002-2995-4161
NR 28
TC 14
Z9 14
U1 3
U2 24
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0029-6554
EI 1528-3968
J9 NURS OUTLOOK
JI Nurs. Outlook
PD JUL-AUG
PY 2015
VL 63
IS 4
BP 398
EP 407
DI 10.1016/j.outlook.2015.04.007
PG 10
WC Nursing
SC Nursing
GA CN6NT
UT WOS:000358552200006
PM 26187079
ER
PT J
AU Henly, SJ
McCarthy, DO
Wyman, JF
Stone, PW
Redeker, NS
McCarthy, AM
Alt-White, AC
Dunbar-Jacob, J
Titler, MG
Moore, SM
Heitkemper, MM
Conley, YP
AF Henly, Susan J.
McCarthy, Donna O.
Wyman, Jean F.
Stone, Patricia W.
Redeker, Nancy S.
McCarthy, Ann Marie
Alt-White, Anna C.
Dunbar-Jacob, Jacqueline
Titler, Marita G.
Moore, Shirley M.
Heitkemper, Margaret M.
Conley, Yvette P.
TI Integrating emerging areas of nursing science into PhD programs
SO NURSING OUTLOOK
LA English
DT Article
DE Nursing research; Nursing science; Nursing scientist education;
Research-focused doctorate
ID TRANSLATIONAL RESEARCH; DOCTORAL EDUCATION; HUMAN GENOME; HEALTH;
PATIENT; INFORMATION; MODEL; COMMUNICATION; ADVANCEMENT; MICROBIOME
AB The Council for the Advancement of Nursing Science aims to "facilitate and recognize life-long nursing science career development" as an important part of its mission. In light of fast-paced advances in science and technology that are inspiring new questions and methods of investigation in the health sciences, the Council for the Advancement of Nursing Science convened the Idea Festival for Nursing Science Education and appointed the Idea Festival Advisory Committee to stimulate dialogue about linking PhD education with a renewed vision for preparation of the next generation of nursing scientists. Building on the 2010 American Association of Colleges of Nursing Position Statement "The Research-Focused Doctoral Program in Nursing: Pathways to Excellence," Idea Festival Advisory Committee members focused on emerging areas of science and technology that impact the ability of research-focused doctoral programs to prepare graduates for competitive and sustained programs of nursing research using scientific advances in emerging areas of science and technology. The purpose of this article is to describe the educational and scientific contexts for the Idea Festival, which will serve as the foundation for recommendations for incorporating emerging areas of science and technology into research-focused doctoral programs in nursing.
C1 [Henly, Susan J.; Wyman, Jean F.] Univ Minnesota, Sch Nursing, Minneapolis, MN 55455 USA.
[McCarthy, Donna O.] Marquette Univ, Milwaukee, WI 53233 USA.
[Stone, Patricia W.] Columbia Univ, Sch Nursing, New York, NY USA.
[Redeker, Nancy S.] Yale Univ, Sch Nursing, West Haven, CT USA.
[McCarthy, Ann Marie] Univ Iowa, Coll Nursing, Iowa City, IA 52242 USA.
[Alt-White, Anna C.] US Dept Vet Affairs, Off Nursing Serv, Washington, DC USA.
[Dunbar-Jacob, Jacqueline; Conley, Yvette P.] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA.
[Titler, Marita G.] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA.
[Moore, Shirley M.] Case Western Reserve Univ, Frances Payne Bolton Sch Nursing, Cleveland, OH 44106 USA.
[Heitkemper, Margaret M.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA.
RP Henly, SJ (reprint author), Univ Minnesota, Sch Nursing, 5-140 WDH,308 Harvard St SE, Minneapolis, MN 55455 USA.
EM henly003@umn.edu
RI Redeker, Nancy/Q-8252-2016;
OI Redeker, Nancy/0000-0001-7817-2708; Henly, Susan/0000-0002-2995-4161
NR 89
TC 14
Z9 14
U1 5
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0029-6554
EI 1528-3968
J9 NURS OUTLOOK
JI Nurs. Outlook
PD JUL-AUG
PY 2015
VL 63
IS 4
BP 408
EP 416
DI 10.1016/j.outlook.2015.04.010
PG 9
WC Nursing
SC Nursing
GA CN6NT
UT WOS:000358552200007
PM 26187080
ER
PT J
AU Henly, SJ
McCarthy, DO
Wyman, JF
Alt-White, AC
Stone, PW
McCarthy, AM
Redeker, NS
Dunbar-Jacob, J
Titler, MG
Conley, YP
Heitkemper, MM
Moore, SM
AF Henly, Susan J.
McCarthy, Donna O.
Wyman, Jean F.
Alt-White, Anna C.
Stone, Patricia W.
McCarthy, Ann Marie
Redeker, Nancy S.
Dunbar-Jacob, Jacqueline
Titler, Marita G.
Conley, Yvette P.
Heitkemper, Margaret M.
Moore, Shirley M.
TI Emerging areas of nursing science and PhD education for the 21st
century: Response to commentaries
SO NURSING OUTLOOK
LA English
DT Article
DE Doctoral education; Health; Nursing science; Nursing research;
Research-focused doctorate
ID BIOBEHAVIORAL RESEARCH; IDEA FESTIVAL; HEALTH; PROGRAMS;
RECOMMENDATIONS; SCIENTISTS; BIOLOGY; FUTURE; HOLISM
AB We respond to commentaries from the American Academy of Nursing, the American Association of Colleges of Nursing, and the National Institute of Nursing Research on our thoughts about integrating emerging areas of science into nursing PhD programs. We identify areas of agreement and focus our response on cross-cutting issues arising from cautions about the unique focus of nursing science and how best to proceed with incorporation of emerging areas of science into nursing PhD programs.
C1 [Henly, Susan J.; Wyman, Jean F.] Univ Minnesota, Sch Nursing, Minneapolis, MN 55455 USA.
[McCarthy, Donna O.] Marquette Univ, Milwaukee, WI 53233 USA.
[Alt-White, Anna C.] US Dept Vet Affairs, Off Nursing Serv, Washington, DC USA.
[Stone, Patricia W.] Columbia Univ, Sch Nursing, New York, NY USA.
[McCarthy, Ann Marie] Univ Iowa, Coll Nursing, Iowa City, IA 52242 USA.
[Redeker, Nancy S.] Yale Univ, Sch Nursing, West Haven, CT USA.
[Dunbar-Jacob, Jacqueline; Conley, Yvette P.] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA.
[Titler, Marita G.] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA.
[Heitkemper, Margaret M.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA.
[Moore, Shirley M.] Case Western Reserve Univ, Frances Payne Bolton Sch Nursing, Cleveland, OH 44106 USA.
RP Henly, SJ (reprint author), Univ Minnesota, Sch Nursing, 5-140 WDH,308 Harvard St SE, Minneapolis, MN 55455 USA.
EM henly003@umn.edu
RI Redeker, Nancy/Q-8252-2016;
OI Redeker, Nancy/0000-0001-7817-2708; Henly, Susan/0000-0002-2995-4161
NR 42
TC 2
Z9 2
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0029-6554
EI 1528-3968
J9 NURS OUTLOOK
JI Nurs. Outlook
PD JUL-AUG
PY 2015
VL 63
IS 4
BP 439
EP 445
DI 10.1016/j.outlook.2015.05.003
PG 7
WC Nursing
SC Nursing
GA CN6NT
UT WOS:000358552200012
PM 26187083
ER
PT J
AU LeBaron, VT
Iribarren, SJ
Perri, S
Beck, SL
AF LeBaron, Virginia T.
Iribarren, Sarah J.
Perri, Seneca
Beck, Susan L.
TI A practical field guide to conducting nursing research in low- and
middle-income countries
SO NURSING OUTLOOK
LA English
DT Article
DE Global health; International research; Developing countries; Low- and
middle-income countries; Research methods; Nursing
ID CANCER PAIN MANAGEMENT; CROSS-CULTURAL RESEARCH; ETHICAL CONSIDERATIONS;
SOUTH-AFRICA; COLLABORATION; CHALLENGES; INDIA
AB Objectives: The purpose of this report is to offer practical guidance to nurse investigators interested in international research in low- and middle-income countries (LMICs). Lessons learned and strategies for planning and implementing an international research project are addressed.
Methods: Four nurse researchers who conducted studies in diverse international settings (Argentina, India, South Africa, and Tanzania) describe their collective experiences regarding study planning and implementation; data collection using a variety of methods; and cultural, contextual and ethical considerations.
Results: Nurses who undertake international health research projects, particularly in LMICs, can face unique challenges and opportunities. Recommendations for success include advance planning, remaining flexible, having a backup plan, cultivating an attitude of curiosity and cultural humility, establishing collaborative and respectful partnerships, and budgeting adequate time.
Conclusions: Nurse scientists often receive little training and support to conduct international research. Guidance to undertake research projects in LMICs can build capacity for nurses to make significant contributions to global health.
C1 [LeBaron, Virginia T.] Dana Farber Canc Inst, Boston, MA 02215 USA.
[LeBaron, Virginia T.] Univ Massachusetts, Coll Nursing & Hlth Sci, Boston, MA 02125 USA.
[Iribarren, Sarah J.] Columbia Univ, Sch Nursing, New York, NY USA.
[Perri, Seneca] Univ Utah, Biomed Informat, Salt Lake City, UT USA.
[Beck, Susan L.] Univ Utah, Coll Nursing, Salt Lake City, UT 84112 USA.
RP LeBaron, VT (reprint author), Dana Farber Canc Inst, 450 Brookline Ave,LW 517, Boston, MA 02215 USA.
EM virginia_lebaron@dfci.harvard.edu
FU American Cancer Society [117214-DSCN-09-141-01-SCN,
121673-DSCNR-09-141-03-SCN]; University of Utah Graduate Program;
Fulbright-Nehru Research Scholar Program; National Institute of Nursing
Research NRSA [F31NR012614]; Sigma Theta Tau Gamma Rho Chapter;
NIH/Fogarty International Clinical Research Scholar program; NIH Fogarty
Center International Challenge Award [5RC1TW008567-02]; CIES/Fulbright
Research Scholar Program Sub-Saharan Africa; NIH [1U54CA156734,
1T32NR014205-01]
FX The original research projects referenced in this article were supported
by American Cancer Society (grant no. 117214-DSCN-09-141-01-SCN and
grant no. 121673-DSCNR-09-141-03-SCN), the University of Utah Graduate
Program, and the Fulbright-Nehru Research Scholar Program (Virginia T.
LeBaron); National Institute of Nursing Research NRSA (grant no.
F31NR012614), Sigma Theta Tau Gamma Rho Chapter, research collaboration
established through NIH/Fogarty International Clinical Research Scholar
program (Sarah J. Iribarren); NIH Fogarty Center International Challenge
Award (grant no. 5RC1TW008567-02) (Seneca Perri): and CIES/Fulbright
Research Scholar Program Sub-Saharan Africa (Susan L. Beck). Drs.
LeBaron and Iribarren are both currently funded by NIH grants
(1U54CA156734; 1T32NR014205-01, respectively).
NR 35
TC 2
Z9 2
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0029-6554
EI 1528-3968
J9 NURS OUTLOOK
JI Nurs. Outlook
PD JUL-AUG
PY 2015
VL 63
IS 4
BP 462
EP 473
DI 10.1016/j.outlook.2015.02.003
PG 12
WC Nursing
SC Nursing
GA CN6NT
UT WOS:000358552200015
PM 26187086
ER
PT J
AU Amar, AF
Tuccinardi, N
Heislein, J
Simpson, S
AF Amar, Angela F.
Tuccinardi, Nicole
Heislein, Julie
Simpson, Somatra
TI Friends Helping Friends: A nonrandomized control trial of a peer-based
response to dating violence
SO NURSING OUTLOOK
LA English
DT Article
DE Partner violence; Prevention; Sexual violence
ID SEXUAL ASSAULT PREVENTION; BYSTANDER INTERVENTION; EDUCATION; BEHAVIOR;
CONSEQUENCES; PROGRAM; IMPACT; MODEL; RAPE
AB Dating violence is a significant problem for older adolescents with implications for the survivor's health. Survivors disclose the violence to friends who are often ill equipped to help them manage the consequences. The purpose of this pilot study was to evaluate the effectiveness and feasibility of Friends Helping Friends, a community-level education program to teach older adolescents to recognize and intervene in dating violence. A convenience sample of 101 students aged 18 to 22 years were nonrandomly allocated to a treatment or control group and completed pre- and post-test measures. Compared with the control group, treatment group participants reported increased perceived responsibility to help, skills to act as a bystander, and intention to help and decreased rape myth acceptance. Friends Helping Friends shows promise as an effective strategy for older adolescent females in the prevention and response to dating violence.
C1 [Amar, Angela F.] Emory Univ, Nell Hodgson Woodruff Sch Nursing, Atlanta, GA 30322 USA.
[Tuccinardi, Nicole] Whidden Hosp, Everett, MA USA.
[Heislein, Julie] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Simpson, Somatra] Community Counseling Bristol Cty, Bristol Cty, MA USA.
RP Amar, AF (reprint author), Emory Univ, Nell Hodgson Woodruff Sch Nursing, 1520 Clifton Rd, Atlanta, GA 30322 USA.
EM angela.amar@emory.edu
FU Robert Wood Johnson Nurse Faculty Scholar grant [64204]
FX Supported in part by a Robert Wood Johnson Nurse Faculty Scholar grant
(grant no. 64204).
NR 33
TC 0
Z9 0
U1 8
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0029-6554
EI 1528-3968
J9 NURS OUTLOOK
JI Nurs. Outlook
PD JUL-AUG
PY 2015
VL 63
IS 4
BP 496
EP 503
DI 10.1016/j.outlook.2015.01.004
PG 8
WC Nursing
SC Nursing
GA CN6NT
UT WOS:000358552200019
PM 26187089
ER
PT J
AU Boswell, MV
Manchikanti, L
Kaye, AD
Bakshi, S
Gharibo, CG
Gupta, S
Jha, S
Nampiaparampil, DE
Simopoulos, TT
Hirsch, JA
AF Boswell, Mark V.
Manchikanti, Laxmaiah
Kaye, Alan D.
Bakshi, Sanjay
Gharibo, Christopher G.
Gupta, Sanjeeva
Jha, Sachin Sunny
Nampiaparampil, Devi E.
Simopoulos, Thomas T.
Hirsch, Joshua A.
TI A Best-Evidence Systematic Appraisal of the Diagnostic Accuracy and
Utility of Facet (Zygapophysial) Joint Injections in Chronic Spinal Pain
SO PAIN PHYSICIAN
LA English
DT Review
DE Chronic spinal pain; lumbar facet or zygapophysial joint pain; cervical
facet or zygapophysial joint pain; thoracic facet or zygapophysial joint
pain; facet joint nerve blocks; medial branch blocks; controlled
comparative local anesthetic blocks
ID LOW-BACK-PAIN; MEDIAL BRANCH BLOCKS; LOCAL-ANESTHETIC BLOCKS;
GENE-RELATED PEPTIDE; 2-YEAR FOLLOW-UP; CERVICAL DORSAL RAMI;
FALSE-POSITIVE RATE; LONG-TERM RELIEF; NECK PAIN; NERVE BLOCKS
AB Background: Spinal zygapophysial, or facet, joints are a source of axial spinal pain and referred pain in the extremities. Conventional clinical features and other noninvasive diagnostic modalities are unreliable in diagnosing zygapophysial joint pain.
Study Design: A systematic review of the diagnostic accuracy of spinal facet joint nerve blocks. Objective: To determine the diagnostic accuracy of spinal facet joint nerve blocks in chronic spinal pain.
Methods: A methodological quality assessment of included studies was performed using Quality Appraisal of Reliability Studies (QAREL). Only diagnostic accuracy studies meeting at least 50% of the designated inclusion criteria were utilized for analysis. The level of evidence was classified as Level I to V based on the grading of evidence utilizing best evidence synthesis. Data sources included relevant literature identified through searches of PubMed and other electronic searches published from 1966 through March 2015, Cochrane reviews, and manual searches of the bibliographies of known primary and review articles.
Outcome Measures: Studies must have been performed utilizing controlled local anesthetic blocks. The criterion standard must have been at least 50% pain relief from baseline scores and the ability to perform previously painful movements.
Results: The available evidence is Level I for lumbar facet joint nerve blocks with the inclusion of a total of 17 studies with dual diagnostic blocks, with at least 75% pain relief with an average prevalence of 16% to 41% and false-positive rates of 25% to 44%. The evidence for diagnosis of cervical facet joint pain with cervical facet joint nerve blocks is Level II based on a total of 11 controlled diagnostic accuracy studies, with significant variability among the prevalence in a heterogenous population with internal inconsistency. The prevalence rates ranged from 36% to 67% with at least 80% pain relief as the criterion standard and a false-positive rate of 27% to 63%. The level of evidence for the diagnostic accuracy of thoracic facet joint nerve blocks is Level II with 80% or higher pain relief as the criterion standard with a prevalence ranging from 34% to 48% and false-positive rates ranging from 42% to 48%.
Limitations: The shortcomings of this systematic review include a paucity of literature related to the thoracic spine, continued debate on an appropriate gold standard, appropriateness of diagnostic blocks, and utility.
Conclusion: The evidence is Level I for the diagnostic accuracy of lumbar facet joint nerve blocks, Level II for cervical facet joint nerve blocks, and Level II for thoracic facet joint nerve blocks in assessment of chronic spinal pain.
C1 [Boswell, Mark V.] Univ Louisville, Dept Anesthesiol & Perioperat Med, Louisville, KY 40202 USA.
[Manchikanti, Laxmaiah] Pain Management Ctr Paducah, Paducah, KY USA.
[Manchikanti, Laxmaiah] Univ Louisville, Anesthesiol & Perioperat Med, Louisville, KY 40202 USA.
[Kaye, Alan D.] LSU Hlth Sci Ctr, Dept Anesthesia, New Orleans, LA USA.
[Bakshi, Sanjay] Manhattan Spine & Pain Med, New York, NY USA.
[Gharibo, Christopher G.] NYU, Sch Med, Dept Anesthesiol, NYU Langone Hosp Joint Dis,Pain Med, New York, NY 10016 USA.
[Gharibo, Christopher G.] NYU, Sch Med, Dept Anesthesiol, NYU Langone Hosp Joint Dis,Anesthesiol & Orthoped, New York, NY 10016 USA.
[Gupta, Sanjeeva] Bradford Teaching Hosp NHS Fdn Trust, Bradford Royal Infirm, Pain Med & Anaesthesia, Bradford, W Yorkshire, England.
[Jha, Sachin Sunny] RUMC, Chicago, IL USA.
[Nampiaparampil, Devi E.] NYU, Sch Med, Rehabil Med, New York, NY USA.
[Simopoulos, Thomas T.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02215 USA.
[Hirsch, Joshua A.] Massachusetts Gen Hosp, Intervent Care, Boston, MA 02114 USA.
[Hirsch, Joshua A.] Massachusetts Gen Hosp, NeuroIntervent Spine, Boston, MA 02114 USA.
[Hirsch, Joshua A.] Massachusetts Gen Hosp, Intervent Radiol, Boston, MA 02114 USA.
[Hirsch, Joshua A.] Massachusetts Gen Hosp, NeuroIntervent Serv & Neuroendovasc Program, Boston, MA 02114 USA.
[Hirsch, Joshua A.] Harvard Univ, Sch Med, Boston, MA USA.
RP Boswell, MV (reprint author), Univ Louisville, Dept Anesthesiol & Perioperat Med, 530 S Jackson St,Room C2A01, Louisville, KY 40202 USA.
EM boswellmv@earthlink.net
NR 212
TC 7
Z9 8
U1 0
U2 2
PU AM SOC INTERVENTIONAL PAIN PHYSICIANS
PI PADUCAH
PA 81 LAKEVIEW DR, PADUCAH, KY 42001 USA
SN 1533-3159
J9 PAIN PHYSICIAN
JI Pain Physician
PD JUL-AUG
PY 2015
VL 18
IS 4
BP E497
EP E533
PG 37
WC Anesthesiology; Clinical Neurology
SC Anesthesiology; Neurosciences & Neurology
GA CO1FS
UT WOS:000358900300003
PM 26218947
ER
PT J
AU Manchikanti, L
Benyamin, R
Helm, S
Hirsch, JA
AF Manchikanti, Laxmaiah
Benyamin, Ramsin
Helm, Standiford, II
Hirsch, Joshua A.
TI Epidural Ahesiolysis Provides Misinformation
SO PAIN PHYSICIAN
LA English
DT Letter
ID CENTRAL SPINAL STENOSIS; LOW-BACK-PAIN; EQUIVALENCE CONTROLLED-TRIAL;
LUMBAR SURGERY SYNDROME; ACTIVE-CONTROL TRIAL; 2-YEAR FOLLOW-UP;
DOUBLE-BLIND; PERCUTANEOUS ADHESIOLYSIS; INJECTIONS; MANAGEMENT
C1 [Manchikanti, Laxmaiah] Univ Louisville, Anesthesiol & Perioperat Med, Louisville, KY 40292 USA.
[Manchikanti, Laxmaiah] Pain Management Ctr Paducah, Paducah, KY 42003 USA.
[Benyamin, Ramsin] Millennium Pain Ctr, Bloomington, IL 61701 USA.
[Helm, Standiford, II] Helm Ctr Pain Management Ctr, Laguna Hills, CA 92637 USA.
[Hirsch, Joshua A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, NeuroIntervent Spine Serv, Boston, MA USA.
[Hirsch, Joshua A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Intervent Care, Boston, MA USA.
[Hirsch, Joshua A.] Harvard Univ, Sch Med, Radiol, Boston, MA USA.
RP Manchikanti, L (reprint author), Univ Louisville, Anesthesiol & Perioperat Med, Louisville, KY 40292 USA.
EM drlm@thepainmd.com; ramsinbenyamin@yahoo.com; drhelm@thehelmcenter.com;
HIrsch@snisonline.org
NR 16
TC 0
Z9 1
U1 0
U2 0
PU AM SOC INTERVENTIONAL PAIN PHYSICIANS
PI PADUCAH
PA 81 LAKEVIEW DR, PADUCAH, KY 42001 USA
SN 1533-3159
J9 PAIN PHYSICIAN
JI Pain Physician
PD JUL-AUG
PY 2015
VL 18
IS 4
BP E670
EP E671
PG 2
WC Anesthesiology; Clinical Neurology
SC Anesthesiology; Neurosciences & Neurology
GA CO1FS
UT WOS:000358900300020
PM 26218964
ER
PT J
AU Manchikanti, L
Kaye, AD
Boswell, MV
Bakshi, S
Gharibo, CG
Grami, V
Grider, JS
Gupta, S
Jha, S
Mann, DP
Nampiaparampil, DE
Sharma, ML
Shroyer, LN
Singh, V
Soin, A
Vallejo, R
Wargo, BW
Hirsch, JA
AF Manchikanti, Laxmaiah
Kaye, Alan D.
Boswell, Mark V.
Bakshi, Sanjay
Gharibo, Christopher G.
Grami, Vahid
Grider, Jay S.
Gupta, Sanjeeva
Jha, Sachin Sunny
Mann, Dharam P.
Nampiaparampil, Devi E.
Sharma, Manohar Lal
Shroyer, Lindsay N.
Singh, Vijay
Soin, Amol
Vallejo, Ricardo
Wargo, Bradley W.
Hirsch, Joshua A.
TI A Systematic Review and Best Evidence Synthesis of Effectiveness of
Therapeutic Facet Joint Interventions in Managing Chronic Spinal Pain
SO PAIN PHYSICIAN
LA English
DT Review
DE Spinal pain; chronic low back pain; chronic neck pain; chronic thoracic
pain; intraarticular facet joint blocks; facet joint nerve blocks;
conventional radiofrequency neurotomy; pulsed radiofrequency neurolysis
ID LOW-BACK-PAIN; MEDIAL BRANCH BLOCKS; INTERLAMINAR EPIDURAL INJECTIONS;
ACTIVE-CONTROL TRIAL; 2-YEAR FOLLOW-UP; CLINICALLY IMPORTANT DIFFERENCE;
CERVICAL ZYGAPOPHYSEAL JOINTS; LUMBAR DISC HERNIATION; BLIND
CONTROLLED-TRIAL; CHRONIC NECK PAIN
AB Background: The therapeutic spinal facet joint interventions generally used for the treatment of axial spinal pain of facet joint origin are intraarticular facet joint injections, facet joint nerve blocks, and radiofrequency neurotomy. Despite interventional procedures being common as treatment strategies for facet joint pathology, there is a paucity of literature investigating these therapeutic approaches.
Systematic reviews assessing the effectiveness of various therapeutic facet joint interventions have shown there to be variable evidence based on the region and the modality of treatment utilized. Overall, the evidence ranges from limited to moderate.
Objective: To evaluate and update the clinical utility of therapeutic lumbar, cervical, and thoracic facet joint interventions in managing chronic spinal pain.
Study Design: A systematic review of therapeutic lumbar, cervical, and thoracic facet joint interventions for the treatment of chronic spinal pain.
Methods: The available literature on lumbar, cervical, and thoracic facet joint interventions in managing chronic spinal pain was reviewed. The quality assessment criteria utilized were the Cochrane Musculoskeletal Review Group criteria and Interventional Pain Management Techniques - Quality Appraisal of Reliability and Risk of Bias Assessment (IPM - QRB) for randomized trials and Interventional Pain Management Techniques - Quality Appraisal of Reliability and Risk of Bias Assessment for Nonrandomized Studies (IPM - QRBNR) for observational studies.
The level of evidence was classified at 5 levels from Level I to Level V.
Data sources included relevant literature identified through searches on PubMed and EMBASE from 1966 through March 2015, and manual searches of the bibliographies of known primary and review articles.
Outcome Measures: The primary outcome measure was pain relief (short-term relief = up to 6 months and long-term > 6 months). Secondary outcome measures were improvement in functional status, psychological status, return to work, and reduction in opioid intake consumption.
Results: A total of 21 randomized controlled trials meeting appropriate inclusion criteria were assessed in this evaluation. A total of 5 observational studies were assessed.
In the lumbar spine, for long-term effectiveness, there is Level II evidence for radiofrequency neurotomy and lumbar facet joint nerve blocks, whereas the evidence is Level III for lumbosacral intraarticular injections. In the cervical spine, for long-term improvement, there is Level II evidence for cervical radiofrequency neurotomy and cervical facet joint nerve blocks, and Level IV evidence for cervical intraarticular injections.
In the thoracic spine there is Level II evidence for thoracic facet joint nerve blocks and Level IV evidence for radiofrequency neurotomy for long-term improvement.
Limitations: The limitations of this systematic review include an overall paucity of high quality studies and more specifically the lack of investigations related to thoracic facet joint injections.
Conclusion: Based on the present assessment for the management of spinal facet joint pain, the evidence for long-term improvement is Level II for lumbar and cervical radiofrequency neurotomy, and therapeutic facet joint nerve blocks in the cervical, thoracic, and lumbar spine; Level III for lumbar intraarticular injections; and Level IV for cervical intraarticular injections and thoracic radiofrequency neurotomy.
C1 [Manchikanti, Laxmaiah] Pain Management Ctr Paducah, Paducah, KY USA.
[Manchikanti, Laxmaiah] Univ Louisville, Louisville, KY 40292 USA.
[Kaye, Alan D.] LSU Hlth Sci Ctr, New Orleans, LA USA.
[Boswell, Mark V.] Univ Louisville, Dept Anesthesiol & Perioperat Med, Louisville, KY 40292 USA.
[Bakshi, Sanjay] Manhattan Spine & Pain Med, New York, NY USA.
[Gharibo, Christopher G.] NYU, Sch Med, NYU Langone Hosp Joint Dis, New York, NY USA.
[Grami, Vahid] Geisinger Med Ctr, Intervent Pain Ctr Woodbine, Danville, PA 17822 USA.
[Grider, Jay S.] Univ Kentucky, UK Healthcare Pain Serv, Lexington, KY USA.
[Gupta, Sanjeeva] Bradford Teaching Hosp NHS Fdn Trust, Bradford, W Yorkshire, England.
[Jha, Sachin Sunny] RUMC, Chicago, IL USA.
[Mann, Dharam P.] Garden State Pain Management, Whiting, NJ USA.
[Nampiaparampil, Devi E.] NYU, Sch Med, New York, NY USA.
[Sharma, Manohar Lal] Walton Ctr Neurol & Neurosurg NHS Fdn Trust, Liverpool, Merseyside, England.
[Shroyer, Lindsay N.] Florida Pain Management Associates, Sebastian, FL USA.
[Singh, Vijay] Spine Pain Diagnost Associates, Niagara, WI USA.
[Soin, Amol] Ohio Pain Clin, Centerville, OH USA.
[Vallejo, Ricardo] Millennium Pain Ctr, Bloomington, IL USA.
[Vallejo, Ricardo] Illinois State Univ, Normal, IL 61761 USA.
[Wargo, Bradley W.] McFarland Clin, Mary Greeley Med Ctr, Dept Pain Med, Ames, IA USA.
[Hirsch, Joshua A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Hirsch, Joshua A.] Harvard Univ, Sch Med, Boston, MA USA.
RP Manchikanti, L (reprint author), 2831 Lone Oak Rd, Paducah, KY 42003 USA.
EM drlm@thepainmd.com
FU Cephalon/Teva; BioDelivery Sciences International, Inc.; Mundipharma
Research GmbH Co.; AstraZeneca; Purdue Pharma, LP; Theravance
FX Dr. Vallejo receives research support from Cephalon/Teva, BioDelivery
Sciences International, Inc., Mundipharma Research GmbH & Co.,
AstraZeneca, Purdue Pharma, LP, and Theravance, and is a consultant for
Nevro and Kimberly-Clark.
NR 219
TC 12
Z9 13
U1 0
U2 6
PU AM SOC INTERVENTIONAL PAIN PHYSICIANS
PI PADUCAH
PA 81 LAKEVIEW DR, PADUCAH, KY 42001 USA
SN 1533-3159
J9 PAIN PHYSICIAN
JI Pain Physician
PD JUL-AUG
PY 2015
VL 18
IS 4
BP E535
EP E582
PG 48
WC Anesthesiology; Clinical Neurology
SC Anesthesiology; Neurosciences & Neurology
GA CO1FS
UT WOS:000358900300004
PM 26218948
ER
PT J
AU Fisher, JG
Sparks, EA
Khan, FA
Alexander, JL
Asaro, LA
Wypij, D
Gaies, M
Modi, BP
Duggan, C
Agus, MSD
Yu, YM
Jaksic, T
AF Fisher, Jeremy G.
Sparks, Eric A.
Khan, Faraz A.
Alexander, Jamin L.
Asaro, Lisa A.
Wypij, David
Gaies, Michael
Modi, Biren P.
Duggan, Christopher
Agus, Michael S. D.
Yu, Yong-Ming
Jaksic, Tom
TI Tight Glycemic Control With Insulin Does Not Affect Skeletal Muscle
Degradation During the Early Postoperative Period Following Pediatric
Cardiac Surgery
SO PEDIATRIC CRITICAL CARE MEDICINE
LA English
DT Article
DE catabolism; children; critical illness; insulin; proteolysis; tight
glycemic control
ID CRITICALLY-ILL PATIENTS; 3-METHYLHISTIDINE EXCRETION;
PROTEIN-METABOLISM; RANDOMIZED-TRIAL; BURN INJURY; PROTEOLYTIC ACTIVITY;
NUTRITIONAL SUPPORT; URINARY-EXCRETION; INTENSIVE-CARE; MAJOR SURGERY
AB Objective: Critical illness is associated with significant catabolism, and persistent protein loss correlates with increased morbidity and mortality. Insulin is a potent anticatabolic hormone; high-dose insulin decreases skeletal muscle protein breakdown in critically ill pediatric surgical patients. However, insulin's effect on protein catabolism when given at clinically utilized doses has not been studied. The objective was to evaluate the effect of postoperative tight glycemic control and clinically dosed insulin on skeletal muscle degradation in children after cardiac surgery with cardiopulmonary bypass.
Design: Secondary analysis of a two-center, prospective randomized trial comparing tight glycemic control with standard care. Randomization was stratified by study center.
Patients: Children 0-36 months who were admitted to the ICU after cardiac surgery requiring cardiopulmonary bypass.
Interventions: In the tight glycemic control arm, insulin was titrated to maintain blood glucose between 80 and 110 mg/dL. Patients in the control arm received standard care. Skeletal muscle breakdown was quantified by a ratio of urinary 3-methylhistidine to urinary creatinine.
Measurements and Main Results: A total of 561 patients were included: 281 in the tight glycemic control arm and 280 receiving standard care. There was no difference in 3-methylhistidine to creatinine between groups (tight glycemic control, 249 127 vs standard care, 253 +/- 112, mean +/- sd in mol/g; p = 0.72). In analyses restricted to the patients in tight glycemic control arm, higher 3-methylhistidine to creatinine correlated with younger age, as well as lower weight, weight-for-age z score, length, and body surface area (p < 0.005 for each) and lower postoperative day 3 serum creatinine (r = -0.17; p = 0.02). Sex, prealbumin, and albumin were not associated with 3-methylhistidine to creatinine. During urine collection, 245 patients (87%) received insulin. However, any insulin exposure did not impact 3-methylhistidine to creatinine (t test, p = 0.45), and there was no dose-dependent effect of insulin on 3-methylhistidine to creatinine (r = -0.03; p = 0.60).
Conclusion: Although high-dose insulin has an anabolic effect in experimental conditions, at doses necessary to achieve normoglycemia, insulin appears to have no discernible impact on skeletal muscle degradation in critically ill pediatric cardiac surgical patients.
C1 [Fisher, Jeremy G.; Sparks, Eric A.; Khan, Faraz A.; Modi, Biren P.; Jaksic, Tom] Boston Childrens Hosp, Ctr Adv Intestinal Rehabil, Boston, MA 02115 USA.
[Fisher, Jeremy G.; Sparks, Eric A.; Khan, Faraz A.; Modi, Biren P.; Jaksic, Tom] Boston Childrens Hosp, Dept Surg, Boston, MA 02115 USA.
[Fisher, Jeremy G.; Sparks, Eric A.; Khan, Faraz A.; Wypij, David; Modi, Biren P.; Duggan, Christopher; Agus, Michael S. D.; Yu, Yong-Ming; Jaksic, Tom] Harvard Univ, Sch Med, Boston, MA USA.
[Alexander, Jamin L.; Agus, Michael S. D.] Boston Childrens Hosp, Div Med Crit, Boston, MA 02115 USA.
[Asaro, Lisa A.; Wypij, David] Boston Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA.
[Wypij, David] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Gaies, Michael] Univ Michigan, CS Mott Childrens Hosp, Div Pediat Cardiol, Ann Arbor, MI 48109 USA.
[Gaies, Michael] Univ Michigan, Sch Med, Ann Arbor, MI USA.
[Duggan, Christopher] Boston Childrens Hosp, Ctr Adv Intestinal Rehabil, Boston, MA 02115 USA.
[Duggan, Christopher] Boston Childrens Hosp, Div Gastroenterol & Nutr, Boston, MA 02115 USA.
[Yu, Yong-Ming] Shriners Hosp Children, Boston, MA USA.
[Yu, Yong-Ming] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Jaksic, T (reprint author), Boston Childrens Hosp, Dept Surg, 300 Longwood Ave,Fegan 3, Boston, MA 02115 USA.
EM tom.jaksic@childrens.harvard.edu
FU National Heart, Lung, and Blood Institute; National Institute of
Diabetes and Digestive and Kidney Disease; Nutrition and Obesity Center
at Harvard; National Institutes of Health [5P30DK040561-17]; Safe
Pediatric Euglycemia after Cardiac Surgery ClinicalTrials. gov
[NCT00443599]; National Institutes of Health
FX Supported, in part, by the National Heart, Lung, and Blood Institute,
the National Institute of Diabetes and Digestive and Kidney Disease, and
others; Safe Pediatric Euglycemia after Cardiac Surgery ClinicalTrials.
gov number, NCT00443599; Nutrition and Obesity Center at Harvard;
National Institutes of Health, 5P30DK040561-17.; The authors received
support for article research from the National Institutes of Health.
Their institutions received grant support from the National Heart, Lung,
and Blood Institute.
NR 44
TC 2
Z9 2
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1529-7535
EI 1947-3893
J9 PEDIATR CRIT CARE ME
JI Pediatr. Crit. Care Med.
PD JUL
PY 2015
VL 16
IS 6
BP 515
EP 521
DI 10.1097/PCC.0000000000000413
PG 7
WC Critical Care Medicine; Pediatrics
SC General & Internal Medicine; Pediatrics
GA CN2YQ
UT WOS:000358289700003
PM 25850865
ER
PT J
AU Baek, JH
Park, JI
Ahn, J
Roh, SW
Heo, JY
Fava, M
Mischoulon, D
Jeon, HJ
AF Baek, Ji Hyun
Park, Jong-Ik
Ahn, Jeonghoon
Roh, Sung-won
Heo, Jung-Yoon
Fava, Maurizio
Mischoulon, David
Jeon, Hong Jin
TI Review of Suicide Prevention Programs: Massachusetts, United States, in
Comparison with Seoul
SO PSYCHIATRY INVESTIGATION
LA English
DT Review
DE Suicide; Suicide prevention strategy
ID NATIONWIDE
AB Suicide is a tragedy that has massive impact on society In order to prevent suicide, active government intervention is necessary. The suicide rate in Seoul is rapidly increasing and is more than five times higher than that in the state of Massachusetts (MA) during the last decade, especially in the elderly. The suicide prevention program of MA is one of the most effective suicide prevention programs in the United States. The program views suicide as a preventable public health problem, and emphasizes treatment of depression and de-stigmatization of mental health illnesses to prevent suicide. Also, through active collaboration with mental health professionals, they try to identify at risk populations and help them to get medical interventions. The program also actively collaborates with the regional coalition program and the Samaritans in taking care of the elderly, and supports the elderly in feeling worthwhile after retirement by helping them to work for communities as volunteers. For its part, the Seoul suicide prevention program puts more emphasis on "life respect culture" and "emotional support to high risk individuals by regular visiting". The annual budget of the Seoul suicide prevention program is one-quarter and that for mental health is about one-twentieth that of MA. Considering the high suicide rate and lower mental health service usage in Seoul, it is crucial to raise awareness of depression and decrease the stigma on mental illnesses. Furthermore, educational efforts with long-term investment in research on suicide are necessary.
C1 [Baek, Ji Hyun; Heo, Jung-Yoon; Jeon, Hong Jin] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Psychiat,Depress Ctr, Seoul 135710, South Korea.
[Baek, Ji Hyun] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Bipolar Clin & Res Program, Boston, MA USA.
[Park, Jong-Ik] Kangwon Natl Univ, Coll Med, Dept Psychiat, Chunchon, South Korea.
[Ahn, Jeonghoon] Natl Evidence Based Healthcare Collaborating Agcy, Seoul, South Korea.
[Roh, Sung-won] Seoul Natl Hosp, Seoul, South Korea.
[Fava, Maurizio; Mischoulon, David; Jeon, Hong Jin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Depress Clin & Res Program, Boston, MA USA.
[Jeon, Hong Jin] Samsung Adv Inst Hlth Sci & Technol, Dept Med Device Management & Res, Seoul, South Korea.
[Jeon, Hong Jin] Samsung Adv Inst Hlth Sci & Technol, Dept Clin Res Design, Seoul, South Korea.
[Jeon, Hong Jin] Samsung Adv Inst Hlth Sci & Technol, Dept Evaluat, Seoul, South Korea.
RP Jeon, HJ (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Psychiat,Depress Ctr, 81 Irwon Ro, Seoul 135710, South Korea.
EM jeonhj@skku.edu
OI Ahn, Jeonghoon/0000-0002-0177-0192
FU Small Research Society Fund from Policy Research Institute of the Korean
NeuroPsychiatric Association; Basic Science Research Program through the
National Research Foundation of Korea (NRF) - Ministry of Education,
Science and Technology [2011-0013064]; Samsung Medical Center Clinical
Research Development Program (CRDP) [SMO1131461]
FX This research was supported by the Small Research Society Fund from the
Policy Research Institute of the Korean NeuroPsychiatric Association. It
was also supported by the Basic Science Research Program through the
National Research Foundation of Korea (NRF) funded by the Ministry of
Education, Science and Technology (No. 2011-0013064) and the Samsung
Medical Center Clinical Research Development Program (CRDP) Grant
SMO1131461. We thank Mr. Alan Holmlund, Director, and Ms. Christine M.
Farrell-O'Reilly, Deputy Director of Suicide Prevention Program,
Massachusetts Department of Public Health for their great comments and
review the manuscript.
NR 21
TC 1
Z9 1
U1 2
U2 11
PU KOREAN NEUROPSYCHIATRIC ASSOC
PI SEOUL
PA RN 522, G-FIVE CENTRAL PLAZA 1685-8 SEOCHO 4-DONG, SEOCHO-GU, SEOUL,
137-882, SOUTH KOREA
SN 1738-3684
EI 1976-3026
J9 PSYCHIAT INVEST
JI Psychiatry Investig.
PD JUL
PY 2015
VL 12
IS 3
BP 281
EP 287
DI 10.4306/pi.2015.12.3.281
PG 7
WC Psychiatry
SC Psychiatry
GA CN5JN
UT WOS:000358465700001
PM 26207119
ER
PT J
AU Maughan-Brown, B
Godlonton, S
Thornton, R
Venkataramani, AS
AF Maughan-Brown, Brendan
Godlonton, Susan
Thornton, Rebecca
Venkataramani, Atheendar S.
TI What Do People Actually Learn from Public Health Campaigns? Incorrect
Inferences About Male Circumcision and Female HIV Infection Risk Among
Men and Women in Malawi
SO AIDS AND BEHAVIOR
LA English
DT Article
DE Male circumcision; Female HIV risk; Risk beliefs; Information; HIV
prevention; Southern Africa
ID RANDOMIZED CONTROLLED-TRIAL; PREVENTION; TRANSMISSION; ATTITUDES;
AFRICA; UGANDA; RAKAI
AB Qualitative studies and polling data from sub-Saharan Africa indicate that many individuals may mistakenly believe that male circumcision directly protects women from contracting HIV. This study examines whether individuals who learn that male circumcision reduces female-to-male HIV transmission also erroneously infer a reduction in direct male-to-female transmission risk (i.e. from an HIV-positive man to an uninfected woman). We used data on Malawian men (n = 917) randomized to receive information about voluntary medical male circumcision (VMMC) and HIV risk in 2008 and a random sample of their wives (n = 418). We found that 72 % of men and 82 % of women who believed that male circumcision reduces HIV risk for men also believed that it reduces HIV risk for women. Regression analyses indicated that men randomly assigned to receive information about the protective benefits of circumcision were more likely to adopt the erroneous beliefs, and that the underlying mechanism was the formation of the belief that male circumcision reduces HIV risk for men. The results suggest the need for VMMC campaigns to make explicit that male circumcision does not directly protect women from HIV-infection.
C1 [Maughan-Brown, Brendan] Univ Cape Town, Southern Africa Labour & Dev Res Unit, ZA-7701 Cape Town, South Africa.
[Godlonton, Susan] Williams Coll, Dept Econ, Williamstown, MA 01267 USA.
[Godlonton, Susan] Int Food Policy Res Inst, Markets Trade & Inst Div, Washington, DC 20006 USA.
[Thornton, Rebecca] Univ Michigan, Dept Econ, Ann Arbor, MI 48109 USA.
[Venkataramani, Atheendar S.] Massachusetts Gen Hosp, Dept Med, Ctr Global Hlth, Boston, MA 02114 USA.
RP Venkataramani, AS (reprint author), Massachusetts Gen Hosp, Dept Med, Ctr Global Hlth, 100 Cambridge St,15th Floor, Boston, MA 02114 USA.
EM avenkataramani@partners.org
FU National Research Foundation (NRF); Massachusetts General Hospital
Global Primary Care Program; Michigan Center for Demography of Aging
(MiCDA); OVPR; Rackham at the University of Michigan; Institute for
Research on Women and Gender; NICHD Center Grant [R24]
FX We would like to thank Martin Abel, Nicola Branson, Arden Finn, David
Maughan-Brown, Rebecca Maughan-Brown, Elizabeth Gummerson, Edward Okeke,
and three anonymous referees for helpful comments and suggestions.
Brendan Maughan-Brown is grateful for funding from the National Research
Foundation (NRF) Research Chair in Poverty and Inequality Research for
his Postdoctoral Research Fellowship. Atheendar S. Venkataramani is
grateful to the Massachusetts General Hospital Global Primary Care
Program for travel and research support. We acknowledge the extensive
contributions of the field team including James Amani, Sheena Kayira,
Collins Kwizombe, Denise Matthijsse, Ernest Mlenga, and Christopher
Nyirenda. We also thank assistance from Kondwani Chidziwisano, Jessica
Kraft, Erica Marks, Julie Moran, Jason Stanley, and Kondwani Tomoko.
Funding for this study was provided by Michigan Center for Demography of
Aging (MiCDA), OVPR and Rackham at the University of Michigan as well as
the Institute for Research on Women and Gender. Godlonton and Thornton
gratefully acknowledge use of the services and facilities of the
Population Studies Center at the University of Michigan, funded by NICHD
Center Grant R24.
NR 24
TC 1
Z9 1
U1 0
U2 2
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1090-7165
EI 1573-3254
J9 AIDS BEHAV
JI AIDS Behav.
PD JUL
PY 2015
VL 19
IS 7
BP 1170
EP 1177
DI 10.1007/s10461-014-0882-0
PG 8
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA CN2KA
UT WOS:000358248600005
PM 25155700
ER
PT J
AU Jack, CR
Barnes, J
Bernstein, MA
Borowski, BJ
Brewer, J
Clegg, S
Dale, AM
Carmichael, O
Ching, C
DeCarli, C
Desikan, RS
Fennema-Notestine, C
Fjell, AM
Fletcher, E
Fox, NC
Gunter, J
Gutman, BA
Holland, D
Hua, X
Insel, P
Kantarci, K
Killiany, RJ
Krueger, G
Leung, KK
Mackin, S
Maillard, P
Malone, IB
Mattsson, N
McEvoy, L
Modat, M
Mueller, S
Nosheny, R
Ourselin, S
Schuff, N
Senjem, ML
Simonson, A
Thompson, PM
Rettmann, D
Vemuri, P
Walhovd, K
Zhao, YS
Zuk, S
Weiner, M
AF Jack, Clifford R., Jr.
Barnes, Josephine
Bernstein, Matt A.
Borowski, Bret J.
Brewer, James
Clegg, Shona
Dale, Anders M.
Carmichael, Owen
Ching, Christopher
DeCarli, Charles
Desikan, Rahul S.
Fennema-Notestine, Christine
Fjell, Anders M.
Fletcher, Evan
Fox, Nick C.
Gunter, Jeff
Gutman, Boris A.
Holland, Dominic
Hua, Xue
Insel, Philip
Kantarci, Kejal
Killiany, Ron J.
Krueger, Gunnar
Leung, Kelvin K.
Mackin, Scott
Maillard, Pauline
Malone, Ian B.
Mattsson, Niklas
McEvoy, Linda
Modat, Marc
Mueller, Susanne
Nosheny, Rachel
Ourselin, Sebastien
Schuff, Norbert
Senjem, Matthew L.
Simonson, Alix
Thompson, Paul M.
Rettmann, Dan
Vemuri, Prashanthi
Walhovd, Kristine
Zhao, Yansong
Zuk, Samantha
Weiner, Michael
TI Magnetic resonance imaging in Alzheimer's Disease Neuroimaging
Initiative 2
SO ALZHEIMERS & DEMENTIA
LA English
DT Review
DE Alzheimer's disease; Alzheimer's Disease Neuroimaging Initiative; ADNI;
Diffusion; MRI; Neuroimaging; Perfusion; Resting functional MRI
ID MILD COGNITIVE IMPAIRMENT; TENSOR-BASED MORPHOMETRY; PREDICT BRAIN
ATROPHY; CSF BIOMARKERS; AMYLOID-BETA; NATIONAL INSTITUTE; ASSOCIATION
WORKGROUPS; DIAGNOSTIC GUIDELINES; CLINICAL-TRIALS; NEURODEGENERATIVE
DISEASE
AB Introduction: Alzheimer's Disease Neuroimaging Initiative (ADNI) is now in its 10th year. The primary objective of the magnetic resonance imaging (MRI) core of ADNI has been to improve methods for clinical trials in Alzheimer's disease (AD) and related disorders.
Methods: We review the contributions of the MRI core from present and past cycles of ADNI (ADNI-1, -Grand Opportunity and -2). We also review plans for the future-ADNI-3.
Results: Contributions of the MRI core include creating standardized acquisition protocols and quality control methods; examining the effect of technical features of image acquisition and analysis on outcome metrics; deriving sample size estimates for future trials based on those outcomes; and piloting the potential utility of MR perfusion, diffusion, and functional connectivity measures in multicenter clinical trials.
Discussion: Over the past decade the MRI core of ADNI has fulfilled its mandate of improving methods for clinical trials in AD and will continue to do so in the future. (C) 2015 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association.
C1 [Jack, Clifford R., Jr.; Bernstein, Matt A.; Borowski, Bret J.; Gunter, Jeff; Kantarci, Kejal; Senjem, Matthew L.; Vemuri, Prashanthi; Zuk, Samantha] Mayo Clin, Dept Radiol, Rochester, MN 55905 USA.
[Barnes, Josephine; Clegg, Shona; Fox, Nick C.; Malone, Ian B.; Modat, Marc; Ourselin, Sebastien] UCL, Dementia Res Ctr, Inst Neurol, Dept Neurodegenerat Dis, London, England.
[Brewer, James; Dale, Anders M.; Gutman, Boris A.; Holland, Dominic; Hua, Xue] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.
[Carmichael, Owen; DeCarli, Charles; Fletcher, Evan; Maillard, Pauline] Univ Calif Davis, Dept Neurol, Davis, CA 95616 USA.
[Ching, Christopher; Thompson, Paul M.] Univ So Calif, Imaging Genet Ctr, Inst Neuroimaging & Informat, Dept Neurol, Marina Del Rey, CA USA.
[DeCarli, Charles; Fletcher, Evan; Maillard, Pauline] Univ Calif Davis, Ctr Neurosci, Davis, CA 95616 USA.
[Desikan, Rahul S.; Fennema-Notestine, Christine; McEvoy, Linda] Univ Calif San Diego, Dept Radiol, La Jolla, CA 92093 USA.
[Fennema-Notestine, Christine] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
[Fjell, Anders M.; Walhovd, Kristine] Univ Oslo, Dept Psychol, Oslo, Norway.
[Insel, Philip; Mackin, Scott; Mueller, Susanne; Nosheny, Rachel; Schuff, Norbert; Simonson, Alix; Weiner, Michael] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, Dept Radiol & Biomed Imaging, San Francisco, CA USA.
[Killiany, Ron J.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA.
[Krueger, Gunnar] Siemens Med Solut, Boston, MA USA.
[Leung, Kelvin K.; Modat, Marc; Ourselin, Sebastien] UCL, Ctr Med Image Comp, Translat Imaging Grp, London, England.
[Mackin, Scott; Weiner, Michael] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.
[Mattsson, Niklas] Univ Gothenburg, Inst Neurosci & Physiol, Clin Neurochem Lab, Molndal, Sweden.
[Mueller, Susanne; Nosheny, Rachel; Schuff, Norbert; Weiner, Michael] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA.
[Rettmann, Dan] GE Healthcare, MR Applicat & Workflow, Rochester, MN USA.
[Zhao, Yansong] Philips Healthcare, Cleveland, OH USA.
[Weiner, Michael] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Weiner, Michael] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
RP Jack, CR (reprint author), Mayo Clin, Dept Radiol, Rochester, MN 55905 USA.
EM jack.clifford@mayo.edu
RI Ourselin, Sebastien/K-6960-2015; Barnes, Josesphine/P-5698-2014; Fox,
Nick/B-1319-2009; Jack, Clifford/F-2508-2010;
OI Ourselin, Sebastien/0000-0002-5694-5340; Fox, Nick/0000-0002-6660-657X;
Jack, Clifford/0000-0001-7916-622X; Bernstein, Matt/0000-0003-3770-0441
FU NIA NIH HHS [R01 AG011378, R01 AG040060, R01 AG041851, U01 AG024904];
NIBIB NIH HHS [P41 EB015922]; NIMH NIH HHS [R01 MH098062]
NR 177
TC 6
Z9 6
U1 2
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1552-5260
EI 1552-5279
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD JUL
PY 2015
VL 11
IS 7
BP 740
EP 756
DI 10.1016/j.jalz.2015.05.002
PG 17
WC Clinical Neurology
SC Neurosciences & Neurology
GA CN1RS
UT WOS:000358198400004
PM 26194310
ER
PT J
AU Saykin, AJ
Shen, L
Yao, X
Kim, S
Nho, K
Risacher, SL
Ramanan, VK
Foroud, TM
Faber, KM
Sarwar, N
Munsie, LM
Hu, X
Soares, HD
Potkin, SG
Thompson, PM
Kauwe, JSK
Kaddurah-Daouk, R
Green, RC
Toga, AW
Weiner, MW
AF Saykin, Andrew J.
Shen, Li
Yao, Xiaohui
Kim, Sungeun
Nho, Kwangsik
Risacher, Shannon L.
Ramanan, Vijay K.
Foroud, Tatiana M.
Faber, Kelley M.
Sarwar, Nadeem
Munsie, Leanne M.
Hu, Xiaolan
Soares, Holly D.
Potkin, Steven G.
Thompson, Paul M.
Kauwe, John S. K.
Kaddurah-Daouk, Rima
Green, Robert C.
Toga, Arthur W.
Weiner, Michael W.
CA Alzheimer's Dis Neuroimaging Init
TI Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress,
opportunities, and plans
SO ALZHEIMERS & DEMENTIA
LA English
DT Review
DE Alzheimer's disease (AD); Mild cognitive impairment (MCI); Genome-wide
association studies (GWAS); Next generation sequencing (NGS); Copy
number variation (CNV); Biomarkers; Magnetic resonance imaging (MRI);
Positron emission tomography (PET); Cerebrospinal fluid (CSF); DNA; RNA;
Memory; Cognition; Bioethical issues; Precision medicine
ID GENOME-WIDE ASSOCIATION; MILD COGNITIVE IMPAIRMENT; PLURIPOTENT
STEM-CELLS; MANAGING INCIDENTAL FINDINGS; FAMILIAL ALZHEIMERS-DISEASE;
ALLELE-SPECIFIC PCR; APOLIPOPROTEIN-E; HUMAN-MEMORY; HIPPOCAMPAL
ATROPHY; CEREBROSPINAL-FLUID
AB Introduction: Genetic data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) have been crucial in advancing the understanding of Alzheimer's disease (AD) pathophysiology. Here, we provide an update on sample collection, scientific progress and opportunities, conceptual issues, and future plans.
Methods: Lymphoblastoid cell lines and DNA and RNA samples from blood have been collected and banked, and data and biosamples have been widely disseminated. To date, APOE genotyping, genome-wide association study (GWAS), and whole exome and whole genome sequencing data have been obtained and disseminated.
Results: ADNI genetic data have been downloaded thousands of times, and >300 publications have resulted, including reports of large-scale GWAS by consortia to which ADNI contributed. Many of the first applications of quantitative endophenotype association studies used ADNI data, including some of the earliest GWAS and pathway-based studies of biospecimen and imaging biomarkers, as well as memory and other clinical/cognitive variables. Other contributions include some of the first whole exome and whole genome sequencing data sets and reports in healthy controls, mild cognitive impairment, and AD.
Discussion: Numerous genetic susceptibility and protective markers for AD and disease biomarkers have been identified and replicated using ADNI data and have heavily implicated immune, mitochondrial, cell cycle/fate, and other biological processes. Early sequencing studies suggest that rare and structural variants are likely to account for significant additional phenotypic variation. Longitudinal analyses of transcriptomic, proteomic, metabolomic, and epigenomic changes will also further elucidate dynamic processes underlying preclinical and prodromal stages of disease. Integration of this unique collection of multiomics data within a systems biology framework will help to separate truly informative markers of early disease mechanisms and potential novel therapeutic targets from the vast background of less relevant biological processes. Fortunately, a broad swath of the scientific community has accepted this grand challenge. (C) 2015 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association.
C1 [Saykin, Andrew J.; Shen, Li; Yao, Xiaohui; Kim, Sungeun; Nho, Kwangsik; Risacher, Shannon L.; Ramanan, Vijay K.] Indiana Univ, Ctr Neuroimaging, Dept Radiol & Imaging Sci, Sch Med, Indianapolis, IN 46204 USA.
[Saykin, Andrew J.; Shen, Li; Kim, Sungeun; Nho, Kwangsik; Risacher, Shannon L.; Ramanan, Vijay K.; Foroud, Tatiana M.] Indiana Univ, Indiana Alzheimer Dis Ctr, Sch Med, Indianapolis, IN 46204 USA.
[Saykin, Andrew J.; Ramanan, Vijay K.; Foroud, Tatiana M.; Faber, Kelley M.] Indiana Univ, Dept Med & Mol Genet, Sch Med, Indianapolis, IN 46204 USA.
[Shen, Li] Indiana Univ, Ctr Computat Biol & Bioinformat, Sch Med, Indianapolis, IN 46204 USA.
[Yao, Xiaohui] Indiana Univ, Sch Informat & Comp, Purdue Univ, Indianapolis, IN 46204 USA.
[Sarwar, Nadeem] Eisai Ltd, Hatfield, Herts, England.
[Munsie, Leanne M.] Eli Lilly & Co, Indianapolis, IN 46285 USA.
[Hu, Xiaolan; Soares, Holly D.] Bristol Myers Squibb, Wallingford, CT USA.
[Potkin, Steven G.] Univ Calif Irvine, Dept Psychiat & Human Behav, Irvine, CA 92717 USA.
[Thompson, Paul M.] Univ So Calif, Dept Neurol, Keck Sch Med, Marina Del Rey, CA USA.
[Thompson, Paul M.] Univ So Calif, Imaging Genet Ctr, Keck Sch Med, Marina Del Rey, CA USA.
[Kauwe, John S. K.] Brigham Young Univ, Dept Biol, Provo, UT 84602 USA.
[Kauwe, John S. K.] Brigham Young Univ, Dept Neurosci, Provo, UT USA.
[Kaddurah-Daouk, Rima] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC USA.
[Kaddurah-Daouk, Rima] Duke Univ, Duke Inst Brain Sci, Durham, NC USA.
[Green, Robert C.] Partners Ctr Personalized Genet Med, Boston, MA USA.
[Green, Robert C.] Brigham & Womens Hosp, Div Genet, Dept Med, Boston, MA 02115 USA.
[Green, Robert C.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Toga, Arthur W.] Univ So Calif, Lab Neuroimaging, Inst Neuroimaging & Neuroinformat, Keck Sch Med, Los Angeles, CA USA.
[Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA.
[Weiner, Michael W.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Weiner, Michael W.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
[Weiner, Michael W.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA.
RP Saykin, AJ (reprint author), Indiana Univ, Ctr Neuroimaging, Dept Radiol & Imaging Sci, Sch Med, Indianapolis, IN 46204 USA.
EM asaykin@iupui.edu
OI Shen, Li/0000-0002-5443-0503
FU Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes
of Health) [U01 AG024904]; DOD ADNI (Department of Defense
[W81XWH-12-2-0012]; National Institute on Aging; National Institute of
Biomedical Imaging and Bioengineering; Canadian Institutes of Health
Research; National Institute on Aging [U24AG021886]; NIH [U01 AG024904,
R01 LM011360, RC2 AG036535, R01 AG19771, P30 AG10133, UL1 TR001108]; DOD
[W81XWH-14-2-0151]; NCAA [14132004]; Alzheimer's Association; NSF
[IIS-1117335]
FX Data collection and sharing for this project was funded by the
Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes
of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award
number W81XWH-12-2-0012). ADNI is funded by the National Institute on
Aging, the National Institute of Biomedical Imaging and Bioengineering,
and through generous contributions from the following: Alzheimer's
Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech;
BioClinica; Biogen Idec.; Bristol-Myers Squibb Company; Eisai Inc.; Elan
Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La
Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE
Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research &
Development, LLC.; Johnson & Johnson Pharmaceutical Research &
Development LLC.; Medpace; Merck & Co., Inc.; Meso Scale Diagnostics;
NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals
Corporation; Pfizer; Piramal Imaging; Servier; Synarc; and Takeda
Pharmaceutical Company. The Canadian Institutes of Health Research is
providing funds to support ADNI clinical sites in Canada. Private sector
contributions are facilitated by the Foundation for the National
Institutes of Health (www.fnih.org). The grantee organization is the
Northern Alzheimer's Disease Cooperative Study at the University of
California, San Diego. ADNI data are disseminated by the Laboratory for
Neuro Imaging at the University of Southern California. Samples from the
National Cell Repository for Alzheimer's Disease (NCRAD), which receives
government support under a cooperative agreement (U24AG021886) awarded
by the National Institute on Aging, were used in this study. Data
analysis was supported in part by NIH R01 LM011360, U01 AG024904, RC2
AG036535, R01 AG19771, P30 AG10133, UL1 TR001108, DOD W81XWH-14-2-0151,
NCAA 14132004, the Alzheimer's Association, and NSF IIS-1117335.
NR 173
TC 18
Z9 18
U1 6
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1552-5260
EI 1552-5279
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD JUL
PY 2015
VL 11
IS 7
BP 792
EP 814
DI 10.1016/j.jalz.2015.05.009
PG 23
WC Clinical Neurology
SC Neurosciences & Neurology
GA CN1RS
UT WOS:000358198400007
PM 26194313
ER
PT J
AU Hendrix, JA
Finger, B
Weiner, MW
Frisoni, GB
Iwatsubo, T
Rowe, CC
Kim, SY
Guinjoan, SM
Sevlever, G
Carrillo, MC
AF Hendrix, James A.
Finger, Brad
Weiner, Michael W.
Frisoni, Giovanni B.
Iwatsubo, Takeshi
Rowe, Christopher C.
Kim, Seong Yoon
Guinjoan, Salvador M.
Sevlever, Gustavo
Carrillo, Maria C.
TI The Worldwide Alzheimer's Disease Neuroimaging Initiative: An update
SO ALZHEIMERS & DEMENTIA
LA English
DT Review
DE Alzheimer's disease; Neuroimaging; Biomarkers; Cerebrospinal fluid
ID MILD COGNITIVE IMPAIRMENT; HIPPOCAMPAL VOLUME; AMYLOID-BETA;
CEREBROSPINAL-FLUID; LIFE-STYLE; PATHOLOGICAL CASCADE; COMMON VARIANTS;
ALPHA-SYNUCLEIN; A-BETA; BIOMARKERS
AB The Alzheimer's Disease Neuroimaging Initiative (ADNI), launched in 2004, has worked to accelerate drug development by validating imaging and blood/cerebrospinal fluid biomarkers for Alzheimer's disease clinical treatment trials. ADNI is a naturalistic (nontreatment) multisite longitudinal study. A true public-private partnership, the initiative has set a new standard for data sharing without embargo and for the use of biomarkers in dementia research. The ADNI effort in North America is not the only such effort in the world. The Alzheimer's Association recognized these global efforts and formed Worldwide ADNI (WW-ADNI). By creating a platform for international collaboration and cooperation, WW-ADNI's goals are to harmonize projects and results across geographical regions and to facilitate data management and availability to investigators around the world. WW-ADNI projects include those based in North America, Europe, Japan, Australia, Korea, and Argentina. (C) 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
C1 [Hendrix, James A.; Carrillo, Maria C.] Alzheimers Assoc, Med & Sci Relat, Chicago, IL 60631 USA.
[Finger, Brad] Independent Sci Writer, Evanston, IL USA.
[Weiner, Michael W.] San Francisco VA Med Ctr, CIND, Northern Calif Inst Res, San Francisco, CA USA.
[Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA.
[Frisoni, Giovanni B.] Univ Hosp, Lab Neuroimaging Aging, Geneva, Switzerland.
[Frisoni, Giovanni B.] Univ Geneva, Geneva, Switzerland.
[Iwatsubo, Takeshi] Univ Hosp, Grad Sch Med, Dept Neuropathol, Tokyo, Japan.
[Rowe, Christopher C.] Austin Hlth, Dept Mol Imaging, Melbourne, Australia.
[Kim, Seong Yoon] Asian Med Ctr, Dept Psychiat, Seoul, South Korea.
[Guinjoan, Salvador M.; Sevlever, Gustavo] Inst Invest Neurol Raul Carrea FLENI, Aging & Memory Ctr, Buenos Aires, DF, Argentina.
RP Hendrix, JA (reprint author), Alzheimers Assoc, Med & Sci Relat, Chicago, IL 60631 USA.
EM jhendrix@alz.org
RI Frisoni, Giovanni B/K-1360-2016
OI Frisoni, Giovanni B/0000-0002-6419-1753
FU National Institute on Aging; National Institute of Biomedical Imaging
and Bioengineering; Abbott; Alzheimer's Association; Alzheimer's Drug
Discovery Foundation; Amorfix Life Sciences Ltd.; AstraZeneca; Bayer
HealthCare; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb
Company; Eisai Inc.; Elan Pharmaceuticals Inc.; Eli Lilly and Company;
F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE
Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer
Immunotherapy Research & Development, LLC.; Johnson & Johnson
Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck Co.,
Inc.; Meso Scale Diagnostics, LLC.; Novartis Pharmaceuticals
Corporation; Pfizer Inc.; Servier; Synarc Inc.; Takeda Pharmaceutical
Company; Canadian Institutes of Health Research; European Commission;
EFPIA in the context of the IMI - Innovative Medicines Initiative
funding scheme; Ministry of Health, Labor and Welfare; Ministry of
Economy, Trade and Industry (through New Energy and Development
Organization), Japan; Astellas; Bristol Myers-Squibb; Chugai;
Daiichi-Sankyo; Dainippon-Sumitomo; Eisai; Eli-Lilly; MSD; Novartis;
Pfizer; Shionogi; Takeda; Tanabe-Mitsubishi; Australian Government
sources - CSIRO; Science Industry Endowment Fund; NHMRC; Dementia CRC;
CRC for Mental Health; Commercial sources - Janssen; Avid
Radiopharmaceuticals; Navidea Biopharmaceuticals; Korea Healthcare
technology R&D Project, Ministry of Health and Welfare, Republic of
Korea [HI12C0713]; FLENI foundation; Perez Companc Foundation; Pan
American Energy
FX NA-ADNI is funded by the National Institute on Aging, the National
Institute of Biomedical Imaging and Bioengineering, and through generous
contributions from the following: Abbott; Alzheimer's Association;
Alzheimer's Drug Discovery Foundation; Amorfix Life Sciences Ltd.;
AstraZeneca; Bayer HealthCare; BioClinica, Inc.; Biogen Idec Inc.;
Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals Inc.; Eli
Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company
Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen
Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson
Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co.,
Inc.; Meso Scale Diagnostics, LLC.; Novartis Pharmaceuticals
Corporation; Pfizer Inc.; Servier; Synarc Inc.; and Takeda
Pharmaceutical Company. The Canadian Institutes of Health Research is
providing funds to support ADNI clinical sites in Canada. Private sector
contributions are facilitated by the Foundation for the National
Institutes of Health (www.fnih.org). The grantee organization is the
Northern California Institute for Research and Education, and the study
is coordinated by the Alzheimer's Disease Cooperative Study at the
University of California, San Diego. Pharmacog/E-ADNI is funded by the
European Commission and EFPIA in the context of the IMI - Innovative
Medicines Initiative funding scheme.; J-ADNI-1 and J-ADNI-2 research
projects are supported by public funding from the Ministry of Health,
Labor and Welfare, and the Ministry of Economy, Trade and Industry
(through New Energy and Development Organization), Japan. Industry
Scientific Advisory Board of J-ADNI, comprised of 13 pharma companies
(Astellas, Bristol Myers-Squibb, Chugai, Daiichi-Sankyo,
Dainippon-Sumitomo, Eisai, Eli-Lilly, MSD, Novartis, Pfizer, Shionogi,
Takeda, Tanabe-Mitsubishi), contributed funding for J-ADNI-1/2 as a
public research.; Funding for AIBL has been provided by Australian
Government sources - CSIRO, the Science Industry Endowment Fund, NHMRC,
the Dementia CRC and the CRC for Mental Health; Commercial sources -
Janssen, GE Healthcare, Avid Radiopharmaceuticals, Navidea
Biopharmaceuticals; and Alzheimer's Association, The Alzheimer's Drug
Discovery Foundation, and an anonymous foundation.; Funding for K-ADNI
is provided by a grant of the Korea Healthcare technology R&D Project,
Ministry of Health and Welfare, Republic of Korea (HI12C0713).; Funding
for ARG-ADNI is provided by the FLENI foundation, the Perez Companc
Foundation and Pan American Energy.
NR 86
TC 5
Z9 5
U1 1
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1552-5260
EI 1552-5279
J9 ALZHEIMERS DEMENT
JI Alzheimers. Dement.
PD JUL
PY 2015
VL 11
IS 7
BP 850
EP 859
DI 10.1016/j.jalz.2015.05.008
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA CN1RS
UT WOS:000358198400012
PM 26194318
ER
PT J
AU Minguez-Alarcon, L
Afeiche, MC
Chiu, YH
Vanegas, JC
Williams, PL
Tanrikut, C
Toth, TL
Hauser, R
Chavarro, JE
AF Minguez-Alarcon, L.
Afeiche, M. C.
Chiu, Y. -H.
Vanegas, J. C.
Williams, P. L.
Tanrikut, C.
Toth, T. L.
Hauser, R.
Chavarro, J. E.
TI Male soy food intake was not associated with invitro fertilization
outcomes among couples attending a fertility center
SO ANDROLOGY
LA English
DT Article
DE epidemiology; ICSI; IVF; male reproductive health; soy intake
ID ESTROGEN-RECEPTOR-ALPHA; FREQUENCY QUESTIONNAIRE; SEMEN QUALITY; US
ADULTS; MEN; PHYTOESTROGEN; WOMEN; INFERTILITY; REPRODUCIBILITY;
VALIDITY
AB Male factor etiology may be a contributing factor in up to 60% of infertility cases. Dietary intake of phytoestrogens has been related to abnormal semen quality and hormone levels. However, its effect on couple fecundity is still unclear. Intake of soy products was assessed in 184 men from couples undergoing infertility treatment with invitro fertilization. Couples were recruited between February 2007 and May 2014 and prospectively followed to document treatment outcomes including fertilization, implantation, clinical pregnancy and live birth. Multivariate generalized linear mixed models with random intercepts, binomial distribution and logit link function were used to examine this relation while accounting for repeated treatment cycles and adjusting for potential confounders. Male partner's intake of soy foods and soy isoflavones was unrelated to fertilization rates, the proportions of poor quality embryos, accelerated or slow embryo cleavage rate, and implantation, clinical pregnancy and live birth. The adjusted live birth rates per initiated cycle (95% CI) for partners of men in increasing categories of soy food intake were 0.36 (0.28-0.45), 0.42 (0.29-0.56), 0.36 (0.24-0.51), and 0.37 (0.24-0.52), respectively. Soy food intake in men was not related to clinical outcomes among couples presenting at an infertility clinic. Data on the relation between phytoestrogens and male reproductive potential remain scarce and additional research is required to clarify its role in human reproduction.
C1 [Minguez-Alarcon, L.; Afeiche, M. C.; Hauser, R.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
[Chiu, Y. -H.; Chavarro, J. E.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Vanegas, J. C.] Pontificia Univ Javeriana, Sch Med, Bogota, Colombia.
[Williams, P. L.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Williams, P. L.; Hauser, R.; Chavarro, J. E.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Tanrikut, C.] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA.
[Tanrikut, C.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA.
[Toth, T. L.; Hauser, R.] Massachusetts Gen Hosp, Vincent Obstet & Gynecol, Boston, MA 02114 USA.
[Toth, T. L.; Hauser, R.; Chavarro, J. E.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Chavarro, J. E.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA.
RP Minguez-Alarcon, L (reprint author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
EM lminguez@hsph.harvard.edu
FU NIH from NIEHS [R01-ES009718]; NIH from NIDDK [P30 DK046200]; NIDDK [T32
DK 007703-16]
FX We thank the study participants whose continued dedication and
commitment make this work possible and the research nurses Jennifer B.
Ford, B.S.N., R.N. and Myra G. Keller, R.N.C., B.S.N. and senior
research assistant Ramace Dadd. This work was supported by NIH grants
R01-ES009718 from NIEHS, P30 DK046200 from NIDDK. MA was supported by a
Ruth L. Kirschstein National Research Service Award T32 DK 007703-16
from NIDDK.
NR 39
TC 4
Z9 4
U1 8
U2 14
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-2919
EI 2047-2927
J9 ANDROLOGY-US
JI Andrology
PD JUL
PY 2015
VL 3
IS 4
BP 702
EP 708
DI 10.1111/andr.12046
PG 7
WC Andrology
SC Endocrinology & Metabolism
GA CN3LZ
UT WOS:000358329300010
PM 26097060
ER
PT J
AU McKinley, ET
Watchmaker, JM
Chakravarthy, AB
Meyerhardt, JA
Engelman, JA
Walker, RC
Washington, MK
Coffey, RJ
Manning, HC
AF McKinley, Eliot T.
Watchmaker, Jennifer M.
Chakravarthy, A. Bapsi
Meyerhardt, Jeffrey A.
Engelman, Jeffrey A.
Walker, Ronald C.
Washington, M. Kay
Coffey, Robert J.
Manning, H. Charles
TI [F-18]-FLT PET to predict early response to neoadjuvant therapy in KRAS
wild-type rectal cancer: a pilot study
SO ANNALS OF NUCLEAR MEDICINE
LA English
DT Article
DE F-18-FLT; Rectal cancer; Cetuximab; EGFR; Treatment response
ID POSITRON-EMISSION-TOMOGRAPHY; GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER;
PHASE-II TRIAL; COLORECTAL-CANCER; IMAGING PROLIFERATION; INFUSION
REACTIONS; CETUXIMAB; MULTICENTER; IRINOTECAN
AB This pilot study evaluated the utility of 3'-deoxy-3'[18F]-fluorothymidine ([F-18]-FLT) positron emission tomography (PET) to predict response to neoadjuvant therapy that included cetuximab in patients with wild-type KRAS rectal cancers.
Baseline [F-18]-FLT PET was collected prior to treatment initiation. Follow-up [F-18]-FLT was collected after three weekly infusions of cetuximab, and following a combined regimen of cetuximab, 5-FU, and radiation. Imaging-matched biopsies were collected with each PET study.
Diminished [F-18]-FLT PET was observed in 3/4 of patients following cetuximab treatment alone and in all patients following combination therapy. Reduced [F-18]-FLT PET following combination therapy predicted disease-free status at surgery. Overall, [F-18]-FLT PET agreed with Ki67 immunoreactivity from biopsy samples and surgically resected tissue, and was predictive of treatment-induced rise in p27 levels.
These results suggest that [F-18]-FLT PET is a promising imaging biomarker to predict response to neoadjuvant therapy that included EGFR blockade with cetuximab in patients with rectal cancer.
C1 [McKinley, Eliot T.; Watchmaker, Jennifer M.; Walker, Ronald C.; Manning, H. Charles] Vanderbilt Univ, Sch Med, VUIIS, Nashville, TN 37232 USA.
[McKinley, Eliot T.; Coffey, Robert J.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA.
[Watchmaker, Jennifer M.; Manning, H. Charles] Vanderbilt Univ, Program Chem & Phys Biol, Nashville, TN 37232 USA.
[Chakravarthy, A. Bapsi; Walker, Ronald C.; Washington, M. Kay; Coffey, Robert J.] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Sch Med, Nashville, TN 37232 USA.
[Chakravarthy, A. Bapsi] Vanderbilt Univ, Dept Radiat Oncol, Sch Med, Nashville, TN 37232 USA.
[Meyerhardt, Jeffrey A.; Engelman, Jeffrey A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Walker, Ronald C.; Manning, H. Charles] Vanderbilt Univ, Sch Med, Dept Radiol & Radiol Sci, Nashville, TN 37232 USA.
[Walker, Ronald C.] Tennessee Valley VA Healthcare Syst, Serv Radiol, Nashville, TN USA.
[Washington, M. Kay] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA.
[Manning, H. Charles] Vanderbilt Univ, Sch Med, Dept Neurosurg, Nashville, TN 37232 USA.
[Manning, H. Charles] Vanderbilt Univ, Dept Biomed Engn, Nashville, TN 37232 USA.
RP Manning, HC (reprint author), Vanderbilt Univ, Sch Med, VUIIS, 1161 21st Ave S,AA1105 MCN, Nashville, TN 37232 USA.
EM henry.c.manning@vanderbilt.edu
FU National Institutes of Health [R25 CA136440, R25 CA092043, K25 CA127349,
P50 CA128323, P50 CA095103, R01 CA140628, RC1 CA145138, P30 DK058404,
P50 CA127003, UL1 TR000445]; Kleberg Foundation; Bristol Meyers Squib
FX The authors acknowledge funding from the National Institutes of Health
(R25 CA136440, R25 CA092043, K25 CA127349, P50 CA128323, P50 CA095103,
R01 CA140628, RC1 CA145138, P30 DK058404, P50 CA127003, UL1 TR000445),
the Kleberg Foundation, and Bristol Meyers Squib. The authors
acknowledge Frank Revetta for assistance with immunohistochemistry.
NR 32
TC 2
Z9 2
U1 1
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0914-7187
EI 1864-6433
J9 ANN NUCL MED
JI Ann. Nucl. Med.
PD JUL
PY 2015
VL 29
IS 6
BP 535
EP 542
DI 10.1007/s12149-015-0974-6
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CN1JJ
UT WOS:000358175300009
PM 25899481
ER
PT J
AU Kasenda, B
Ferreri, AJM
Marturano, E
Forst, D
Bromberg, J
Ghesquieres, H
Ferlay, C
Blay, JY
Hoang-Xuan, K
Pulczynski, EJ
Fossa, A
Okoshi, Y
Chiba, S
Fritsch, K
Omuro, A
O'Neill, BP
Bairey, O
Schandelmaier, S
Gloy, V
Bhatnagar, N
Haug, S
Rahner, S
Batchelor, TT
Illerhaus, G
Briel, M
AF Kasenda, B.
Ferreri, A. J. M.
Marturano, E.
Forst, D.
Bromberg, J.
Ghesquieres, H.
Ferlay, C.
Blay, J. Y.
Hoang-Xuan, K.
Pulczynski, E. J.
Fossa, A.
Okoshi, Y.
Chiba, S.
Fritsch, K.
Omuro, A.
O'Neill, B. P.
Bairey, O.
Schandelmaier, S.
Gloy, V.
Bhatnagar, N.
Haug, S.
Rahner, S.
Batchelor, T. T.
Illerhaus, G.
Briel, M.
TI First-line treatment and outcome of elderly patients with primary
central nervous system lymphoma (PCNSL)-a systematic review and
individual patient data meta-analysis
SO ANNALS OF ONCOLOGY
LA English
DT Review
DE primary central nervous system lymphoma; PCNSL; elderly patients;
individual patient data meta-analysis; systematic review
ID PRIMARY CNS LYMPHOMA; HIGH-DOSE METHOTREXATE; WHOLE-BRAIN RADIOTHERAPY;
KETTERING CANCER CENTER; NON-HODGKIN-LYMPHOMA; TERM-FOLLOW-UP; PHASE-II;
INITIAL TREATMENT; CHEMOTHERAPY; TRIAL
AB Background: To investigate prognosis and effects of first-line therapy in elderly primary central nervous system lymphoma (PCNSL) patients. Patients and methods: A systematic review of studies about first-line therapy in immunocompetent patients = 60 years with PCNSL until 2014 and a meta-analysis of individual patient data from eligible studies and international collaborators were carried out. Results: We identified 20 eligible studies; from 13 studies, we obtained individual data of 405 patients, which were pooled with data of 378 additional patients (N = 783). Median age and Karnofsky Performance Score (KPS) was 68 years (range: 60-90 years) and 60% (range: 10%-100%), respectively. Treatments varied greatly, 573 (73%) patients received high-dose methotrexate (HD-MTX)-based therapy. A total of 276 patients received whole-brain radiotherapy (median 36 Gy, range 28.5-70 Gy). KPS = 70% was the strongest prognostic factor for mortality [ hazard ratio (HR) 0.50, 95% confidence interval (CI) 0.41-0.62]. After a median follow-up of 40 months, HD-MTX-based therapy was associated with improved survival (HR 0.70, 95% CI 0.53-0.93). There was no difference between HD-MTX plus oral chemotherapy and more aggressive HD-MTX-based therapies (HR 1.39, 95% CI 0.90-2.15). Radiotherapy was associated with an improved survival, but correlated with an increased risk for neurological side-effects (odds ratio 5.23, 95% CI 2.33-11.74). Conclusions: Elderly PCNSL patients benefit from HD-MTX-based therapy, especially if combined with oral alkylating agents. More aggressive HD-MTX protocols do not seem to improve outcome. WBRT may improve outcome, but is associated with increased risk for neurological side-effects. Prospective trials for elderly PCNSL patients are warranted.
C1 [Kasenda, B.] Univ Basel Hosp, Dept Oncol, CH-4031 Basel, Switzerland.
[Kasenda, B.; Schandelmaier, S.; Gloy, V.; Briel, M.] Univ Basel Hosp, Basel Inst Clin Epidemiol & Biostat, CH-4031 Basel, Switzerland.
[Ferreri, A. J. M.; Marturano, E.] Ist Sci San Raffaele, Dept Oncohematol, Unit Lymphoid Malignancies, I-20132 Milan, Italy.
[Forst, D.; Batchelor, T. T.] Harvard Univ, Sch Med, Partners Neurol Residency Program, Boston, MA USA.
[Bromberg, J.] Erasmus MC Univ Med Ctr, Daniel del Hoed Canc Ctr, Dept Neurooncol, Rotterdam, Netherlands.
[Ghesquieres, H.; Ferlay, C.; Blay, J. Y.] Univ Lyon, Ctr Leon Berard, Dept Hematol, Lyon, France.
[Hoang-Xuan, K.; Omuro, A.] Univ Paris 06, Dept Neurol Mazarin, LOC Natl Expert Ctr, APHP,IHU,CRICM,GH Pitie Salpetriere, Paris, France.
[Pulczynski, E. J.] Aarhus Univ Hosp, Nord Lymphoma Grp, Dept Haematol, DK-8000 Aarhus, Denmark.
[Fossa, A.] Radium Hosp, Nord Lymphoma Grp, Norwegian Dept Oncol, Oslo, Norway.
[Okoshi, Y.; Chiba, S.] Univ Tsukuba, Fac Med, Dept Hematol, Tsukuba, Ibaraki, Japan.
[Fritsch, K.] Univ Hosp Freiburg, Dept Hematol Oncol, Freiburg, Germany.
[O'Neill, B. P.] Mayo Clin & Mayo Grad Sch Med, Dept Neurol, Rochester, MN USA.
[Bairey, O.] Beilinson Med Ctr, Rabin Med Ctr, Inst Hematol, Tel Aviv, Israel.
[Bairey, O.] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.
[Bhatnagar, N.; Briel, M.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada.
[Haug, S.] Univ Hosp Freiburg, Psychiat & Psychotherapy, Freiburg, Germany.
[Rahner, S.] Univ Freiburg, Fac Med, D-79106 Freiburg, Germany.
[Batchelor, T. T.] Massachusetts Gen Hosp, Stephen E & Catherine Pappas Ctr Neurooncol, Boston, MA 02114 USA.
[Illerhaus, G.] Eva Mayr Stihl Tumor Ctr, Stuttgart Canc Ctr, Stuttgart, Germany.
RP Kasenda, B (reprint author), Univ Basel Hosp, Dept Oncol, CH-4031 Basel, Switzerland.
EM benjamin.kasenda@gmail.com
RI Blay, Jean-Yves/N-3966-2016;
OI Blay, Jean-Yves/0000-0001-7190-120X; Briel, Matthias/0000-0002-2070-5230
FU Freiwillige Akademische Gesellschaft Basel in Switzerland
FX This study was supported by the Freiwillige Akademische Gesellschaft
Basel in Switzerland (no grant number).
NR 50
TC 9
Z9 9
U1 4
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD JUL
PY 2015
VL 26
IS 7
BP 1305
EP 1313
DI 10.1093/annonc/mdv076
PG 9
WC Oncology
SC Oncology
GA CN1HV
UT WOS:000358170400007
PM 25701456
ER
PT J
AU Mahal, BA
Chen, MH
Bennett, CL
Kattan, MW
Sartor, O
Stein, K
D'Amico, AV
Nguyen, PL
AF Mahal, B. A.
Chen, M. -H.
Bennett, C. L.
Kattan, M. W.
Sartor, O.
Stein, K.
D'Amico, A. V.
Nguyen, P. L.
TI High PSA anxiety and low health literacy skills: drivers of early use of
salvage ADT among men with biochemically recurrent prostate cancer after
radiotherapy?
SO ANNALS OF ONCOLOGY
LA English
DT Article
DE prostatic neoplasm; recurrence; health policy; androgen deprivation
therapy; salvage therapy
ID ANDROGEN DEPRIVATION THERAPY; HIV MEDICATION ADHERENCE; RADICAL
PROSTATECTOMY; TRIAL; CARE; SURVEILLANCE; SUPPRESSION; VALIDATION;
RADIATION; KNOWLEDGE
AB Background: Although commonly used, early initiation of salvage androgen deprivation therapy (ADT) has not been proven to enhance survival. We evaluated whether prostate- specific antigen (PSA) anxiety or health literacy are associated with use of early salvage ADT among men with recurrent prostate cancer after radiotherapy. Patients and Methods: The prospective Comprehensive, Observational, Multicenter, Prostate Adenocarcinoma Registry was used to study 375 men with biochemically recurrent prostate cancer after external beam radiation or brachytherapy. Multivariable logistic regression was used to determine whether PSA anxiety and health literacy are associated with salvage ADT as initial management after biochemical recurrence. Results: Sixty- eight men (18.1%) received salvage ADT as initial management for PSA recurrence. Men with high PSA anxiety were twice as likely to receive salvage ADT compared with men who did not have high PSA anxiety on both univariable [ 28.8% versus 13.1%; odds ratio (OR) 2.15; 95% confidence interval (CI) 1.16- 4.00; P = 0.015] and multivariable analysis [ adjusted OR (AOR) 2.36; 95% CI 1.21- 4.62; P = 0.012]. Furthermore, men who had higher levels of health literacy were nearly half as likely to undergo salvage ADT compared with men who had lower levels of health literacy on univariable analysis (15.2% versus 26.3%; OR 0.50; 95% CI 0.29- 0.88; P = 0.016), with a trend toward this association on multivariable analysis (AOR 0.58; 95% CI 0.32- 1.05; P = 0.07). Conclusions: Among men with PSA recurrence after radiotherapy, odds of use of salvage ADT were nearly twice as great among men with high PSA anxiety or low health literacy, suggesting that these men are receiving higher rates of unproven treatment. Given that early salvage ADT is costly, worsens quality of life, and has not been shown to improve survival, quality improvement strategies are needed for these individuals.
C1 [Mahal, B. A.] Harvard Univ, Boston, MA 02115 USA.
[Chen, M. -H.] Univ Connecticut, Dept Stat, Storrs, CT 06269 USA.
[Bennett, C. L.] South Carolina Coll Pharm, Charleston, SC USA.
[Bennett, C. L.] Hollings Canc Ctr, Charleston, SC USA.
[Kattan, M. W.] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA.
[Sartor, O.] Tulane Univ, Dept Med, New Orleans, LA 70118 USA.
[Sartor, O.] Tulane Univ, Dept Urol, New Orleans, LA 70118 USA.
[Stein, K.] Novartis, E Hanover, NJ USA.
[D'Amico, A. V.; Nguyen, P. L.] Harvard Univ, Dana Farber Canc Inst, Dept Radiat Oncol, Sch Med, Boston, MA 02115 USA.
[D'Amico, A. V.; Nguyen, P. L.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Nguyen, PL (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
EM pnguyen@LROC.harvard.edu
FU Prostate Cancer Foundation; Fitz's Cancer Warriors; anonymous family
foundation; National Cancer Institute [1R01CA165609-01A1]; South
Carolina SmartState Program; Doris Levkoff Meddin Medication Safety
Center
FX This work is supported by David and Cynthia Chapin, the Prostate Cancer
Foundation, Fitz's Cancer Warriors, Hugh Simons in honor of Frank and
Anne Simons, a grant from an anonymous family foundation. Additional
funding for CLB is from the National Cancer Institute
(1R01CA165609-01A1), the South Carolina SmartState Program, and the
Doris Levkoff Meddin Medication Safety Center.
NR 32
TC 2
Z9 2
U1 2
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD JUL
PY 2015
VL 26
IS 7
BP 1390
EP 1395
DI 10.1093/annonc/mdv185
PG 6
WC Oncology
SC Oncology
GA CN1HV
UT WOS:000358170400018
PM 25926039
ER
PT J
AU Lago-Hernandez, CA
Feldman, H
O'Donnell, E
Mahal, BA
Perez, V
Howard, S
Rosenthal, M
Cheng, SC
Nguyen, PL
Beard, C
D'Amico, AV
Sweeney, CJ
AF Lago-Hernandez, C. A.
Feldman, H.
O'Donnell, E.
Mahal, B. A.
Perez, V.
Howard, S.
Rosenthal, M.
Cheng, S. C.
Nguyen, P. L.
Beard, C.
D'Amico, A. V.
Sweeney, C. J.
TI A refined risk stratification scheme for clinical stage 1 NSGCT based on
evaluation of both embryonal predominance and lymphovascular invasion
SO ANNALS OF ONCOLOGY
LA English
DT Article
DE nonseminoma germ-cell tumor; clinical stage 1; relapse; embryonal
predominance; lymphovascular invasion; active surveillance
ID GERM-CELL TUMORS; RESEARCH-COUNCIL TRIAL; I TESTICULAR CANCER; ACTIVE
SURVEILLANCE; PROGNOSTIC-FACTORS; TESTIS CANCER; SEMINOMA; RELAPSE;
MANAGEMENT; CARCINOMA
AB Background: Active surveillance is an increasingly accepted approach for managing patients with germ-cell tumors (GCTs) after an orchiectomy. Here we investigate a time-to-relapse stratification scheme for clinical stage 1 (CS1) nonseminoma GCT (NSGCT) patients according to factors associated with relapse and identify a group of patients with a lower frequency and longer time-to-relapse who may require an alternative surveillance strategy. Patients and methods: We analyzed 266 CS1 GCT patients from the IRB-approved DFCI GCT database that exclusively underwent surveillance following orchiectomy from 1997 to 2013. We stratified NSGCT patients according to predominance of embryonal carcinoma (EmbP) and lymphovascular invasion (LVI), using a 0, 1, and 2 scoring system. Cox regression and conditional risk analysis were used to compare each NSGCT group to patients in the seminomatous germ-cell tumor (SGCT) category. Median time-to-relapse values were then calculated among those patients who underwent relapse. Relapse-free survival curves were generated using the Kaplan-Meier method. Results: Fifty (37%) NSGCT and 20 (15%) SGCT patients relapsed. The median time-to-relapse was 11.5 versus 6.3 months for the SGCT and NSGCT groups, respectively. For NSGCT patients, relapse rates were higher and median timeto- relapse faster with increasing number of risk factors (RFs). Relapse rates (%) and median time-to-relapse (months) were 25%/ 8.5 months, 41%/ 6.8 months and 78%/ 3.8 months for RF0, RF1 and RF2, respectively. We found a statistically significant difference between SGCT and patients with one or two RFs (P < 0.001) but not between SGCT and NSGCT RF0 (P = 0.108). Conclusion: NSGCT patients grouped by a risk score system based on EmbP and LVI yielded three groups with distinct relapse patterns -and patients with neither EmbP nor LVI appear to behave similar to SGCT.
C1 [Lago-Hernandez, C. A.; Mahal, B. A.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Lago-Hernandez, C. A.; Feldman, H.; O'Donnell, E.; Sweeney, C. J.] Dana Farber Canc Inst, Dept Med Oncol, Genitourinary Div, Boston, MA 02115 USA.
[Feldman, H.] Albert Einstein Coll Med, Bronx, NY USA.
[Mahal, B. A.; Nguyen, P. L.; Beard, C.; D'Amico, A. V.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
[Perez, V.] Univ Puerto Rico, Sch Med, San Juan, PR 00936 USA.
[Howard, S.; Rosenthal, M.] Dana Farber Canc Inst, Dept Imaging, Boston, MA 02115 USA.
[Cheng, S. C.] Dana Farber Canc Inst, Dept Biostat Computat Biol, Boston, MA 02115 USA.
RP Sweeney, CJ (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave 1230, Boston, MA 02115 USA.
EM christopher_sweeney@dfci.harvard.edu
FU Shawmut Design and Construction's Pan Mass Cycling Team
FX We want to give special thanks to Shawmut Design and Construction's Pan
Mass Cycling Team for their financial support.
NR 21
TC 3
Z9 3
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD JUL
PY 2015
VL 26
IS 7
BP 1396
EP 1401
DI 10.1093/annonc/mdv180
PG 6
WC Oncology
SC Oncology
GA CN1HV
UT WOS:000358170400019
PM 25888612
ER
PT J
AU Kris, MG
Camidge, DR
Giaccone, G
Hida, T
Li, BT
O'Connell, J
Taylor, I
Zhang, H
Arcila, ME
Goldberg, Z
Janne, PA
AF Kris, M. G.
Camidge, D. R.
Giaccone, G.
Hida, T.
Li, B. T.
O'Connell, J.
Taylor, I.
Zhang, H.
Arcila, M. E.
Goldberg, Z.
Jaenne, P. A.
TI Targeting HER2 aberrations as actionable drivers in lung cancers: phase
II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in
patients with HER2 - mutant or amplified tumors
SO ANNALS OF ONCOLOGY
LA English
DT Article
DE dacomitinib; HER2 mutations; HER2 amplification; lung cancers; tyrosine
kinase inhibitors
ID SOLID TUMORS; MUTATIONS; DOMAIN; ERBB2; ADENOCARCINOMAS; TRASTUZUMAB;
COMBINATION; THERAPY; EGFR
AB Background: HER2 mutations and amplifications have been identified as oncogenic drivers in lung cancers. Dacomitinib, an irreversible inhibitor of HER2, EGFR ( HER1), and HER4 tyrosine kinases, has demonstrated activity in cell- line models with HER2 exon 20 insertions or amplifications. Here, we studied dacomitinib in patients with HER2mutant or amplified lung cancers. Patients and methods: As a prespecified cohort of a phase II study, we included patients with stage IIIB/ IV lung cancers with HER2 mutations or amplification. We gave oral dacomitinib at 30- 45 mg daily in 28- day cycles. End points included partial response rate, overall survival, and toxicity. Results: We enrolled 30 patients with HER2- mutant ( n = 26, all in exon 20 including 25 insertions and 1 missense mutation) or HER2- amplified lung cancers ( n = 4). Three of 26 patients with tumors harboring HER2 exon 20 mutations [ 12%; 95% confidence interval ( CI) 2% to 30%] had partial responses lasting 3+, 11, and 14 months. No partial responses occurred in four patients with tumors with HER2 amplifications. The median overall survival was 9 months from the start of dacomitinib (95% CI 7-21 months) for patients with HER2 mutations and ranged from 5 to 22 months with amplifications. Treatment-related toxicities included diarrhea (90%; grade 3/ 4: 20%/ 3%), dermatitis (73%; grade 3/ 4: 3%/ 0%), and fatigue (57%; grade 3/ 4: 3%/ 0%). One patient died on study likely due to an interaction of dacomitinib with mirtazapine. Conclusions: Dacomitinib produced objective responses in patients with lung cancers with specific HER2 exon 20 insertions. This observation validates HER2 exon 20 insertions as actionable targets and justifies further study of HER2targeted agents in specific HER2-driven lung cancers.
C1 [Kris, M. G.; Li, B. T.] Mem Sloan Kettering Canc Ctr, Weill Cornell Med Coll, Dept Med, Thorac Oncol Serv,Div Solid Tumor Oncol, New York, NY 10021 USA.
[Camidge, D. R.] Univ Colorado, Dept Med Oncol, Denver, CO 80202 USA.
[Giaccone, G.] Georgetown Univ, Lombardi Canc Ctr, Washington, DC USA.
[Hida, T.] Aichi Canc Ctr, Dept Thorac Oncol, Chikusa Ku, Nagoya, Aichi 464, Japan.
[O'Connell, J.] Pfizer Inc, Pfizer Oncol, New York, NY USA.
[Taylor, I.] Pfizer Inc, Translat Oncol, Groton, CT USA.
[Zhang, H.] Pfizer Inc, Pfizer China Res & Dev Co Ltd, Shanghai, Peoples R China.
[Arcila, M. E.] Mem Sloan Kettering Canc Ctr, Dept Pathol, Mol Diagnost Serv, New York, NY 10021 USA.
[Goldberg, Z.] Pfizer Inc, Pfizer Oncol, San Diego, CA USA.
[Jaenne, P. A.] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA.
[Jaenne, P. A.] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA.
RP Kris, MG (reprint author), Mem Sloan Kettering Canc Ctr, 300 E 66th St, New York, NY 10065 USA.
EM krism@mskcc.org
RI Giaccone, Giuseppe/E-8297-2017;
OI Giaccone, Giuseppe/0000-0002-5023-7562; Kris, Mark/0000-0002-7317-5341;
Li, Bob/0000-0001-6661-8733
FU Pfizer, Inc.
FX This work was supported by Pfizer, Inc. No grant applied.
NR 30
TC 14
Z9 15
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD JUL
PY 2015
VL 26
IS 7
BP 1421
EP 1427
DI 10.1093/annonc/mdv186
PG 7
WC Oncology
SC Oncology
GA CN1HV
UT WOS:000358170400023
PM 25899785
ER
PT J
AU Zhu, Y
Romitti, PA
Conway, KMC
Shen, DH
Sun, LX
Browne, ML
Botto, LD
Lin, AE
Druschel, CM
AF Zhu, Yong
Romitti, Paul A.
Conway, Kristin M. Caspers
Shen, Dereck H.
Sun, Lixian
Browne, Marilyn L.
Botto, Lorenzo D.
Lin, Angela E.
Druschel, Charlotte M.
CA Natl Birth Defects Prevention Stud
TI Maternal periconceptional alcohol consumption and congenital heart
defects
SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY
LA English
DT Article
DE congenital heart defects; alcohol; pregnancy; epidemiology; birth
defects
ID VENTRICULAR SEPTAL-DEFECT; RISK-FACTORS; BIRTH-DEFECTS; UNITED-STATES;
CARDIOVASCULAR MALFORMATIONS; ETHANOL EXPOSURE; CARDIAC DEFECTS;
EARLY-PREGNANCY; BINGE DRINKING; PREVALENCE
AB BackgroundCongenital heart defects (CHDs) are the leading cause of infant death from birth defects. Animal studies suggest in utero alcohol exposure is a teratogen for cardiogenesis; however, results from epidemiologic studies are mixed.
MethodsData from the National Birth Defects Prevention Study were used to estimate associations between CHDs and case (n=7076) and control (n=7972) mother reports of periconceptional (1 month before pregnancy through the first trimester) alcohol consumption with expected delivery dates during 1997 to 2007. CHDs were examined by category (conotruncal, septal, left ventricular outflow tract obstruction, and right ventricular outflow tract obstruction, heterotaxy with CHD) and subtype (e.g., tetralogy of Fallot [TOF]). Alcohol measures examined were any consumption, maximum average drinks per month, binge drinking, and alcohol type. Adjusted odds ratios and 95% confidence intervals were estimated using unconditional logistic regression analysis.
ResultsIncreased risks, albeit marginally statistically significant, were observed for TOF and each maternal alcohol measure examined and for right ventricular outflow tract obstruction and heterotaxy with CHD and consumption of distilled spirits. Significantly reduced risks were observed for several CHD categories (septal defects, left ventricular outflow tract obstruction, and right ventricular outflow tract obstruction) and some corresponding subtypes with different alcohol measures. Significant risks were not observed for the other CHDs examined.
ConclusionAnalysis of this large, well-defined study sample did not show statistically significant increased risks between measures of maternal alcohol consumption and most CHDs examined. These findings may reflect, in part, limitations with retrospective exposure assessment or unmeasured confounders. Additional studies with continued improvement in measurement of alcohol consumption are recommended. Birth Defects Research (Part A) 103:617-629, 2015. (c) 2015 Wiley Periodicals, Inc.
C1 [Zhu, Yong; Romitti, Paul A.; Conway, Kristin M. Caspers; Shen, Dereck H.; Sun, Lixian] Univ Iowa, Dept Epidemiol, Iowa City, IA 52242 USA.
[Browne, Marilyn L.; Druschel, Charlotte M.] New York State Dept Hlth, Albany, NY USA.
[Browne, Marilyn L.; Druschel, Charlotte M.] SUNY Albany, Sch Publ Hlth, Rensselaer, NY USA.
[Botto, Lorenzo D.] Univ Utah, Dept Pediat, Salt Lake City, UT USA.
[Lin, Angela E.] MassGen Hosp Children, Genet Unit, Boston, MA USA.
RP Romitti, PA (reprint author), Univ Iowa, Coll Publ Hlth, Dept Epidemiol, S416 CPHB,145 N Riverside Dr, Iowa City, IA 52242 USA.
EM paul-romitti@uiowa.edu
FU NCBDD CDC HHS [U01DD001035, U01DD000492]; NIEHS NIH HHS [P30 ES005605];
PHS HHS [PA 96043, PA 02081]
NR 53
TC 4
Z9 4
U1 0
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1542-0752
EI 1542-0760
J9 BIRTH DEFECTS RES A
JI Birth Defects Res. Part A-Clin. Mol. Teratol.
PD JUL
PY 2015
VL 103
IS 7
BP 617
EP 629
DI 10.1002/bdra.23352
PG 13
WC Developmental Biology; Toxicology
SC Developmental Biology; Toxicology
GA CN3CY
UT WOS:000358302700007
PM 26118863
ER
PT J
AU Purdon, PL
Pavone, KJ
Akeju, O
Smith, AC
Sampson, AL
Lee, J
Zhou, DW
Solt, K
Brown, EN
AF Purdon, P. L.
Pavone, K. J.
Akeju, O.
Smith, A. C.
Sampson, A. L.
Lee, J.
Zhou, D. W.
Solt, K.
Brown, E. N.
TI The Ageing Brain: Age-dependent changes in the electroencephalogram
during propofol and sevoflurane general anaesthesia
SO BRITISH JOURNAL OF ANAESTHESIA
LA English
DT Article
DE ageing; brain monitoring; EEG; elderly; electroencephalography;
propofol; sevoflurane
ID INDUCED ALPHA-RHYTHM; INDUCED UNCONSCIOUSNESS; BURST SUPPRESSION;
BEHAVIORAL-EXPERIMENTS; BISPECTRAL ANALYSIS; COHERENCE ANALYSIS; EEG;
HEALTHY; STATE; CONSCIOUSNESS
AB Background: Anaesthetic drugs act at sites within the brain that undergo profound changes during typical ageing. We postulated that anaesthesia-induced brain dynamics observed in the EEG change with age.
Methods: We analysed the EEG in 155 patients aged 18-90 yr who received propofol (n=60) or sevoflurane (n=95) as the primary anaesthetic. The EEG spectrum and coherence were estimated throughout a 2 min period of stable anaesthetic maintenance. Age-related effects were characterized by analysing power and coherence as a function of age using linear regression and by comparing the power spectrum and coherence in young (18-to 38-yr-old) and elderly (70- to 90-yr-old) patients.
Results: Power across all frequency bands decreased significantly with age for both propofol and sevoflurane; elderly patients showed EEG oscillations similar to 2- to 3-fold smaller in amplitude than younger adults. The qualitative form of the EEG appeared similar regardless of age, showing prominent alpha (8-12 Hz) and slow (0.1-1 Hz) oscillations. However, alpha band dynamics showed specific age-related changes. In elderly compared with young patients, alpha power decreased more than slow power, and alpha coherence and peak frequency were significantly lower. Older patients were more likely to experience burst suppression.
Conclusions: These profound age-related changes in the EEG are consistent with known neurobiological and neuroanatomical changes that occur during typical ageing. Commercial EEG-based depth-of-anaesthesia indices do not account for age and are therefore likely to be inaccurate in elderly patients. In contrast, monitoring the unprocessed EEG and its spectrogram can account for age and individual patient characteristics.
C1 [Purdon, P. L.; Pavone, K. J.; Akeju, O.; Sampson, A. L.; Zhou, D. W.; Solt, K.; Brown, E. N.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Purdon, P. L.; Akeju, O.; Solt, K.; Brown, E. N.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Purdon, P. L.; Smith, A. C.; Brown, E. N.] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA.
[Lee, J.; Brown, E. N.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Brown, E. N.] MIT, Inst Med Engn & Sci, Cambridge, MA 02139 USA.
RP Purdon, PL (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
EM patrickp@nmr.mgh.harvard.edu; enb@neurostat.mit.edu
OI Solt, Ken/0000-0001-5328-2062
FU National Institutes of Health, Bethesda, MD, USA [DP2-OD006454,
DP1-OD003646, TR01-GM104948]; Foundation of Anesthesia Education and
Research, Rochester, MN, USA; Massachusetts General Hospital Faculty
Development Award, Boston, MA, USA; Department of Anesthesia, Critical
Care and Pain Medicine, Massachusetts General Hospital, Boston, MA, USA
FX National Institutes of Health, Bethesda, MD, USA [DP2-OD006454 (to
P.L.P.); DP1-OD003646 and TR01-GM104948 (to E.N.B.)]; Foundation of
Anesthesia Education and Research, Rochester, MN, USA (to O.A.);
Massachusetts General Hospital Faculty Development Award, Boston, MA,
USA (to O.A.); funds from the Department of Anesthesia, Critical Care
and Pain Medicine, Massachusetts General Hospital, Boston, MA, USA.
NR 66
TC 8
Z9 8
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0007-0912
EI 1471-6771
J9 BRIT J ANAESTH
JI Br. J. Anaesth.
PD JUL
PY 2015
VL 115
SU 1
SI SI
BP 46
EP 57
DI 10.1093/bja/aev213
PG 12
WC Anesthesiology
SC Anesthesiology
GA CN1JG
UT WOS:000358175000010
ER
PT J
AU Chemali, JJ
Kenny, JD
Olutola, O
Taylor, NE
Kimchi, EY
Purdon, PL
Brown, EN
Solt, K
AF Chemali, J. J.
Kenny, J. D.
Olutola, O.
Taylor, N. E.
Kimchi, E. Y.
Purdon, P. L.
Brown, E. N.
Solt, K.
TI Ageing delays emergence from general anaesthesia in rats by increasing
anaesthetic sensitivity in the brain
SO BRITISH JOURNAL OF ANAESTHESIA
LA English
DT Article
DE ageing; delayed emergence from anaesthesia; electroencephalography
ID POSTOPERATIVE COGNITIVE DYSFUNCTION; VOLATILE ANESTHETICS; AGE;
PROPOFOL; DELIRIUM; ISOFLURANE; METHYLPHENIDATE; SOLUBILITY; DECREASES;
POTENCY
AB Background: Little is known about ageing-related changes in the brain that affect emergence from general anaesthesia. We used young adult and aged Fischer 344 rats to test the hypothesis that ageing delays emergence from general anaesthesia by increasing anaesthetic sensitivity in the brain.
Methods: Time to emergence was determined for isoflurane (1.5 vol% for 45 min) and propofol (8 mg kg(-1) i.v.). The dose of isoflurane required to maintain loss of righting (LOR) was established in young adult and aged rats. The efficacy of methylphenidate to reverse LOR from general anaesthesia was tested. Separate young adult and aged rats with implanted electroencephalogram (EEG) electrodes were used to test whether ageing increases sensitivity to anaesthetic-induced burst suppression.
Results: Mean time to emergence from isoflurane anaesthesia was 47 s [95% CI 33, 60; young adult) compared with 243 s (95% CI 185, 308; aged). For propofol, mean time to emergence was 13.1 min (95% CI 11.9, 14.0; young adult) compared with 23.1 min (95% CI 18.8, 27.9; aged). These differences were statistically significant. When methylphenidate was administered after propofol, the mean time to emergence decreased to 6.6 min (95% CI 5.9, 7.1; young adult) and 10.2 min (95% CI 7.9, 12.3; aged). These reductions were statistically significant. Methylphenidate restored righting in all rats during continuous isoflurane anaesthesia. Aged rats had lower EEG power and were more sensitive to anaesthetic-induced burst suppression.
Conclusions: Ageing delays emergence from general anaesthesia. This is due, at least in part, to increased anaesthetic sensitivity in the brain. Further studies are warranted to establish the underlying causes.
C1 [Chemali, J. J.; Kenny, J. D.; Olutola, O.; Taylor, N. E.; Purdon, P. L.; Brown, E. N.; Solt, K.] Massachusetts Gen Hosp, Dept Anaesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Kimchi, E. Y.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Taylor, N. E.; Purdon, P. L.; Brown, E. N.; Solt, K.] Harvard Univ, Sch Med, Dept Anaesthesia, Boston, MA 02115 USA.
[Kimchi, E. Y.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA.
[Brown, E. N.] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA.
[Brown, E. N.] MIT, Inst Med Engn & Sci, Cambridge, MA 02139 USA.
RP Solt, K (reprint author), Massachusetts Gen Hosp, Dept Anaesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA.
EM ksolt@mgh.harvard.edu
OI Kenny, Jonathan/0000-0003-3745-3217; Solt, Ken/0000-0001-5328-2062
FU National Institutes of Health [TR01-GM104948, DP1-OD003646,
K08-GM094394, T32-NS048005]
FX This work was supported by National Institutes of Health grant numbers
TR01-GM104948 (E.N.B., K.S.), DP1-OD003646 (E.N.B.), K08-GM094394
(K.S.), and T32-NS048005 (E.K.).
NR 40
TC 4
Z9 4
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0007-0912
EI 1471-6771
J9 BRIT J ANAESTH
JI Br. J. Anaesth.
PD JUL
PY 2015
VL 115
SU 1
SI SI
BP 58
EP 65
DI 10.1093/bja/aev112
PG 8
WC Anesthesiology
SC Anesthesiology
GA CN1JG
UT WOS:000358175000011
ER
PT J
AU Akeju, O
Pavone, KJ
Thum, JA
Firth, PG
Westover, MB
Puglia, M
Shank, ES
Brown, EN
Purdon, PL
AF Akeju, O.
Pavone, K. J.
Thum, J. A.
Firth, P. G.
Westover, M. B.
Puglia, M.
Shank, E. S.
Brown, E. N.
Purdon, P. L.
TI Age-dependency of sevoflurane-induced electroencephalogram dynamics in
children
SO BRITISH JOURNAL OF ANAESTHESIA
LA English
DT Article
DE electroencephalography; pediatric; sevoflurane
ID HUMAN PREFRONTAL CORTEX; INDUCED ALPHA-RHYTHM; BISPECTRAL INDEX;
GENERAL-ANESTHESIA; THALAMOCORTICAL CONNECTIVITY; INDUCED
UNCONSCIOUSNESS; PEDIATRIC ANESTHESIA; NEUROMUSCULAR BLOCK; PROPOFOL
ANESTHESIA; COHERENCE ANALYSIS
AB Background: General anaesthesia induces highly structured oscillations in the electroencephalogram (EEG) in adults, but the anaesthesia-induced EEG in paediatric patients is less understood. Neural circuits undergo structural and functional transformations during development that might be reflected in anaesthesia-induced EEG oscillations. We therefore investigated age-related changes in the EEG during sevoflurane general anaesthesia in paediatric patients.
Methods: We analysed the EEG recorded during routine care of patients between 0 and 28 yr of age (n=54), using power spectral and coherence methods. The power spectrum quantifies the energy in the EEG at each frequency, while the coherence measures the frequency-dependent correlation or synchronization between EEG signals at different scalp locations. We characterized the EEG as a function of age and within 5 age groups: <1 yr old(n=4), 1-6yrold(n=12), >6-14 yr old(n=14), >14-21 yr old(n=11), >21-28 yr old(n=13).
Results: EEG power significantly increased from infancy through similar to 6 yr, subsequently declining to a plateau at approximately 21 yr. Alpha (8-13 Hz) coherence, a prominent EEG feature associated with sevoflurane-induced unconsciousness in adults, is absent in patients <1 yr.
Conclusions: Sevoflurane-induced EEG dynamics in children vary significantly as a function of age. These age-related dynamics likely reflect ongoing development within brain circuits that are modulated by sevoflurane. These readily observed paediatric-specific EEG signatures could be used to improve brain state monitoring in children receiving general anaesthesia.
C1 [Akeju, O.; Pavone, K. J.; Firth, P. G.; Puglia, M.; Shank, E. S.; Brown, E. N.; Purdon, P. L.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Firth, P. G.; Westover, M. B.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Akeju, O.; Thum, J. A.; Westover, M. B.; Puglia, M.; Shank, E. S.; Brown, E. N.; Purdon, P. L.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Brown, E. N.; Purdon, P. L.] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA.
[Brown, E. N.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Brown, E. N.] MIT, Inst Med Engn & Sci, Cambridge, MA 02139 USA.
RP Akeju, O (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
EM oluwaseun.akeju@mgh.harvard.edu; patrickp@nmr.mgh.harvard.edu
FU National Institutes of Health, Bethesda, MD USA [DP2-OD006454,
DP1-OD003646, TR01-GM104948]; Foundation of Anesthesia Education and
Research, Rochester, MN USA; Massachusetts General Hospital Faculty
Development Award, Boston, MA USA; Department of Anesthesia, Critical
Care and Pain Medicine, Massachusetts General Hospital, Boston, MA USA;
Partners Innovation Award, Partners Healthcare, Boston, MA USA
FX DP2-OD006454 (to P.L.P.); DP1-OD003646 and TR01-GM104948 (to E.N.B.)
from the National Institutes of Health, Bethesda, MD USA; Foundation of
Anesthesia Education and Research, Rochester, MN USA (to O.A.);
Massachusetts General Hospital Faculty Development Award, Boston, MA USA
(to O.A.); Funds from the Department of Anesthesia, Critical Care and
Pain Medicine, Massachusetts General Hospital, Boston, MA USA; Partners
Innovation Award, Partners Healthcare, Boston, MA USA (to P.L.P.).
NR 61
TC 4
Z9 4
U1 1
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0007-0912
EI 1471-6771
J9 BRIT J ANAESTH
JI Br. J. Anaesth.
PD JUL
PY 2015
VL 115
SU 1
SI SI
BP 66
EP 76
DI 10.1093/bja/aev114
PG 11
WC Anesthesiology
SC Anesthesiology
GA CN1JG
UT WOS:000358175000012
ER
PT J
AU Solt, K
AF Solt, K.
TI The role of dopamine in reanimation from general anaesthesia
SO BRITISH JOURNAL OF ANAESTHESIA
LA English
DT Meeting Abstract
CT 9th International Symposium on Memory and Awareness in Anesthesia (MAA)
CY JUL 20-23, 2014
CL Tokyo, JAPAN
ID ISOFLURANE ANESTHESIA; EMERGENCE; AROUSAL; SLEEP; METHYLPHENIDATE;
INVOLVEMENT; PATHWAYS; RATS
C1 [Solt, K.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
EM ksolt@mgh.harvard.edu
NR 19
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0007-0912
EI 1471-6771
J9 BRIT J ANAESTH
JI Br. J. Anaesth.
PD JUL
PY 2015
VL 115
SU 1
SI SI
BP 128
EP 128
PG 1
WC Anesthesiology
SC Anesthesiology
GA CN1JG
UT WOS:000358175000030
ER
PT J
AU Solt, K
Chemali, JJ
Olutola, O
Kenny, JD
Brown, EN
AF Solt, K.
Chemali, J. J.
Olutola, O.
Kenny, J. D.
Brown, E. N.
TI Aging delays emergence from general anaesthesia in rats
SO BRITISH JOURNAL OF ANAESTHESIA
LA English
DT Meeting Abstract
CT 9th International Symposium on Memory and Awareness in Anesthesia (MAA)
CY JUL 20-23, 2014
CL Tokyo, JAPAN
C1 [Solt, K.; Chemali, J. J.; Olutola, O.; Kenny, J. D.; Brown, E. N.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
EM ksolt@mgh.harvard.edu
NR 1
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0007-0912
EI 1471-6771
J9 BRIT J ANAESTH
JI Br. J. Anaesth.
PD JUL
PY 2015
VL 115
SU 1
SI SI
BP 134
EP 135
PG 2
WC Anesthesiology
SC Anesthesiology
GA CN1JG
UT WOS:000358175000041
ER
PT J
AU Grewal, SK
Chren, MM
Parvataneni, R
Stuart, SE
Galles, E
Linos, E
AF Grewal, S. K.
Chren, M. M.
Parvataneni, R.
Stuart, S. E.
Galles, E.
Linos, E.
TI 'What is it about your skin cancer that bothers you the most?': 700
patients respond
SO BRITISH JOURNAL OF DERMATOLOGY
LA English
DT Letter
ID SQUAMOUS-CELL CARCINOMA
C1 [Grewal, S. K.] Commonwealth Med Coll, Scranton, PA USA.
[Chren, M. M.; Parvataneni, R.; Stuart, S. E.; Linos, E.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.
[Chren, M. M.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Galles, E.] Univ Iowa, Carver Coll Med, Iowa City, IA USA.
RP Linos, E (reprint author), Univ Calif San Francisco, Dept Dermatol, 2340 Sutter St, San Francisco, CA 94143 USA.
EM linose@derm.ucsf.edu
OI Linos, Eleni/0000-0002-5856-6301; , Eleni/0000-0003-2538-0700
FU NCATS NIH HHS [KL2 TR000143]; NCRR NIH HHS [KL2RR024130]; NIAMS NIH HHS
[K24 AR052667, R01 AR054983]
NR 4
TC 1
Z9 1
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-0963
EI 1365-2133
J9 BRIT J DERMATOL
JI Br. J. Dermatol.
PD JUL
PY 2015
VL 173
IS 1
BP 296
EP 297
DI 10.1111/bjd.13618
PG 2
WC Dermatology
SC Dermatology
GA CN3IK
UT WOS:000358318700060
PM 25523523
ER
PT J
AU Bednar, F
Schofield, HK
Collins, MA
Yan, W
Zhang, YQ
Shyam, N
Eberle, JA
Almada, LL
Olive, KP
Bardeesy, N
Fernandez-Zapico, ME
Nakada, D
Simeone, DM
Morrison, SJ
di Magliano, MP
AF Bednar, Filip
Schofield, Heather K.
Collins, Meredith A.
Yan, Wei
Zhang, Yaqing
Shyam, Nikhil
Eberle, Jaime A.
Almada, Luciana L.
Olive, Kenneth P.
Bardeesy, Nabeel
Fernandez-Zapico, Martin E.
Nakada, Daisuke
Simeone, Diane M.
Morrison, Sean J.
di Magliano, Marina Pasca
TI Bmi1 is required for the initiation of pancreatic cancer through an
Ink4a-independent mechanism
SO CARCINOGENESIS
LA English
DT Article
ID CELL SELF-RENEWAL; DUCTAL ADENOCARCINOMA; ONCOGENIC KRAS; MICE;
PROLIFERATION; SENESCENCE; POLYCOMB; MOUSE; TUMORIGENESIS; REGENERATION
AB Bmi1, a Polycomb repressive complex member, is required for the initiation of pancreatic cancer, independently of its known ability to repress the p16 and p19 tumor suppressor genes. Additionally, we show that Bmi1 regulates reactive oxygen species accumulation in pancreatic cancer cells.Epigenetic dysregulation is involved in the initiation and progression of many epithelial cancers. BMI1, a component of the polycomb protein family, plays a key role in these processes by controlling the histone ubiquitination and long-term repression of multiple genomic loci. BMI1 has previously been implicated in pancreatic homeostasis and the function of pancreatic cancer stem cells. However, no work has yet addressed its role in the early stages of pancreatic cancer development. Here, we show that BMI1 is required for the initiation of murine pancreatic neoplasia using a novel conditional knockout of Bmi1 in combination with a Kras(G12D)-driven pancreatic cancer mouse model. We also demonstrate that the requirement for Bmi1 in pancreatic carcinogenesis is independent of the Ink4a/Arf locus and at least partially mediated by dysregulation of reactive oxygen species. Our data provide new evidence of the importance of this epigenetic regulator in the genesis of pancreatic cancer.
C1 [Bednar, Filip; Zhang, Yaqing; Simeone, Diane M.; di Magliano, Marina Pasca] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA.
[Schofield, Heather K.; Collins, Meredith A.; di Magliano, Marina Pasca] Univ Michigan, Program Cell & Mol Biol, Ann Arbor, MI 48109 USA.
[Schofield, Heather K.; Shyam, Nikhil] Univ Michigan, Med Scientist Training Program, Ann Arbor, MI 48109 USA.
[Yan, Wei] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
[Yan, Wei] Univ Michigan, Michigan Ctr Translat Pathol, Ann Arbor, MI 48109 USA.
[Eberle, Jaime A.; Olive, Kenneth P.] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Dept Med, New York, NY 10032 USA.
[Eberle, Jaime A.; Olive, Kenneth P.] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Dept Pathol, New York, NY 10032 USA.
[Almada, Luciana L.; Fernandez-Zapico, Martin E.] Mayo Clin, Div Oncol Res, Schulze Ctr Novel Therapeut, Rochester, MN 55905 USA.
[Bardeesy, Nabeel] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Nakada, Daisuke] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
[Simeone, Diane M.] Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA.
[Simeone, Diane M.; di Magliano, Marina Pasca] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
[Morrison, Sean J.] Univ Texas SW Med Ctr Dallas, Childrens Res Inst, Dept Pediat, Dallas, TX 75390 USA.
[Morrison, Sean J.] Univ Texas SW Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75390 USA.
[di Magliano, Marina Pasca] Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA.
RP di Magliano, MP (reprint author), Univ Michigan, Dept Surg, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
EM marinapa@umich.edu
FU American College of Surgeons Resident Research Scholarship; National
Institutes of Health [NIH T32 HD007505]; University of Michigan Program
in Cellular and Molecular Biology Training Grant [NIH T32 GM07315];
University of Michigan Center for Organogenesis Training Grant
[5-T32-HD007515]; National Cancer Institute [1R01CA151588-01]; American
Chemical Society [RSG-14-173-01-CSM]; Elsa Pardee Foundation; National
Pancreas Foundation Pilot Grant; Mayo Clinic Center for Cell Signaling
in Gastroenterology Grant [DK84567]; NIH [1R21CA188857]
FX F.B. was supported by the American College of Surgeons Resident Research
Scholarship and by National Institutes of Health (NIH T32 HD007505).
H.K.S. is supported by a University of Michigan Program in Cellular and
Molecular Biology Training Grant (NIH T32 GM07315). M.A.C. was supported
by a University of Michigan Program in Cellular and Molecular Biology
Training Grant (NIH T32 GM07315), a University of Michigan Center for
Organogenesis Training Grant (5-T32-HD007515). Research in the Pasca di
Magliano lab is supported by National Cancer Institute
(1R01CA151588-01), by American Chemical Society (RSG-14-173-01-CSM) and
by the Elsa Pardee Foundation. This project was supported by a National
Pancreas Foundation Pilot Grant. L.L.A. and M.E.F-Z. are supported by
Mayo Clinic Center for Cell Signaling in Gastroenterology Grant
(DK84567). K.P.O. is supported by NIH 1R21CA188857.
NR 38
TC 6
Z9 6
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD JUL
PY 2015
VL 36
IS 7
BP 730
EP 738
DI 10.1093/carcin/bgv058
PG 9
WC Oncology
SC Oncology
GA CN1JN
UT WOS:000358175700004
PM 25939753
ER
PT J
AU Patel, PA
Zhao, X
Fonarow, GC
Lytle, BL
Smith, EE
Xian, Y
Bhatt, DL
Peterson, ED
Schwamm, LH
Hernandez, AF
AF Patel, Priyesh A.
Zhao, Xin
Fonarow, Gregg C.
Lytle, Barbara L.
Smith, Eric E.
Xian, Ying
Bhatt, Deepak L.
Peterson, Eric D.
Schwamm, Lee H.
Hernandez, Adrian F.
TI Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation
Hospitalized With Ischemic Stroke or Transient Ischemic Attack
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Article
DE anticoagulation; anticoagulants; atrial fibrillation; ischemic attack;
transient; stroke
ID CLINICAL CLASSIFICATION SCHEMES; RISK STRATIFICATION SCHEMES;
AMERICAN-HEART-ASSOCIATION; COST-EFFECTIVENESS; NATIONWIDE COHORT;
GUIDELINES-STROKE; PREDICTING STROKE; DABIGATRAN; WARFARIN; VALIDATION
AB Background Novel oral anticoagulants (NOACs) have been shown to be at least as good as warfarin for preventing stroke or transient ischemic attack in patients with atrial fibrillation, yet diffusion of these therapies and patterns of use among atrial fibrillation patients with ischemic stroke and transient ischemic attack have not been well characterized.
Methods and Results Using data from Get With The Guidelines-Stroke, we identified a cohort of 61 655 atrial fibrillation patients with ischemic stroke or transient ischemic attack hospitalized between October 2010 and September 2012 and discharged on warfarin or NOAC (either dabigatran or rivaroxaban). Multivariable logistic regression was used to identify factors associated with NOAC versus warfarin therapy. In our study population, warfarin was prescribed to 88.9%, dabigatran to 9.6%, and rivaroxaban to 1.5%. NOAC use increased from 0.04% to a 16% to 17% plateau during the study period, although anticoagulation rates among eligible patients did not change appreciably (93.7% versus 94.1% from first quarter 2011 to second quarter 2012), suggesting a trend of switching from warfarin to NOACs rather than increased rates of anticoagulation among eligible patients. Several bleeding risk factors and CHA(2)DS(2)-VASc scores were lower among those discharged on NOAC versus warfarin therapy (47.9% versus 40.9% with CHA(2)DS(2)-VASc 5, P<0.001 for difference in CHA(2)DS(2)-VASc).
Conclusions NOACs have had modest but growing uptake over time among atrial fibrillation patients hospitalized with stroke or transient ischemic attack and are prescribed to patients with lower stroke risk compared with warfarin.
C1 [Patel, Priyesh A.; Zhao, Xin; Lytle, Barbara L.; Xian, Ying; Peterson, Eric D.; Hernandez, Adrian F.] Duke Clin Res Inst, Durham, NC 27705 USA.
[Fonarow, Gregg C.] Univ Calif Los Angeles, Dept Med, Los Angeles Med Ctr, Ronald Reagan Univ Calif, Los Angeles, CA 90024 USA.
[Smith, Eric E.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada.
[Bhatt, Deepak L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Schwamm, Lee H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Peterson, Eric D.; Hernandez, Adrian F.] Duke Univ, Med Ctr, Durham, NC USA.
RP Patel, PA (reprint author), Duke Clin Res Inst, 2400 Pratt St, Durham, NC 27705 USA.
EM priyesh.patel@dm.duke.edu
RI Hernandez, Adrian F./A-7818-2016
OI Hernandez, Adrian F./0000-0003-3387-9616
FU American Heart Association Young Investigator Database Research Seed
Grant; National Institutes of Health [T32-HL007101]
FX This study was funded by an American Heart Association Young
Investigator Database Research Seed Grant. P.A. Patel received
additional support from National Institutes of Health grant
T32-HL007101.
NR 30
TC 7
Z9 7
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-7705
EI 1941-7713
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD JUL
PY 2015
VL 8
IS 4
BP 383
EP 392
DI 10.1161/CIRCOUTCOMES.114.000907
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CN1XL
UT WOS:000358214000010
PM 26058721
ER
PT J
AU Dudok, DV
Nagdee, I
Cheung, K
Liu, H
Vedovelli, L
Ghinelli, E
Kenyon, K
Parapuram, S
Hutnik, CM
AF Dudok, David V.
Nagdee, Imraan
Cheung, Kevin
Liu, Hong
Vedovelli, Luca
Ghinelli, Emiliano
Kenyon, Kenneth
Parapuram, Sunil
Hutnik, Cindy M.
TI Effects of amniotic membrane extract on primary human corneal epithelial
and limbal cells
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Cornea; Corneal wound healing; Amniotic membrane
ID TGF-BETA; TRANSPLANTATION; SUPPRESSION; OPHTHALMOLOGY; FIBROBLASTS;
APOPTOSIS; KERATITIS; PROTEIN; BURNS
AB BackgroundTo assess the effects of amniotic membrane extract (AMX) on cellular activity of primary human corneal epithelial (HCE) cells under mechanical and oxidative stress, and on human limbal cells under oxidative stress.
MethodsCorneal mechanical stress was simulated with a linear scratch in confluent HCE cell plates, then incubated with 0.1% AMX for 48 and 72h. Subjecting HCE cultures to 0.5mmol/L tertiary-butylhydroperoxide for 1h simulated an oxidative stress. 0.1% AMX-treated cultures were compared with controls at 24 and 48h using cellular viability assay, along with 12-h AMX pretreatment and human limbal cell comparisons.
ResultsMechanical stress on HCE cultures revealed a statistically significant distance ratio at 48 and 72h in favour of 0.1% AMX-treated cultures (P=0.021 and 0.035, respectively). Oxidative stress did not reveal any significant difference in cellular viability of AMX-treated versus control cultures. Twelve hour AMX pre-treatment prior to oxidative stress revealed a significant difference after 24h from oxidative injury (73.3% AMXvs. 66.0% control, P=0.035), but not after 48h. Human limbal cells demonstrated significantly improved oxidative viability compared with HCE cells, with (91.0% vs. 82.0% control, P=0.017) and without 0.1% AMX pre-treatment (91.2% vs. 83.7% control, P=0.019).
ConclusionsHCE cells treated with AMX healed faster after mechanical insult, suggesting a potential benefit in acute corneal injuries. Under oxidative stress, human limbal cells, a more proliferative cell type, showed superior viability compared with HCE cells.
C1 [Dudok, David V.; Nagdee, Imraan; Cheung, Kevin; Liu, Hong; Parapuram, Sunil; Hutnik, Cindy M.] Univ Western Ontario, Ivey Eye Inst, London, ON N6A 4V2, Canada.
[Vedovelli, Luca] Massachusetts Gen Hosp, Div Nephrol Cell Biol Human Biol & Physiol, Boston, MA 02114 USA.
[Ghinelli, Emiliano; Kenyon, Kenneth] Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA USA.
[Kenyon, Kenneth] Tufts Univ, New England Med Ctr, Boston, MA 02111 USA.
RP Dudok, DV (reprint author), Univ Western Ontario, Ivey Eye Inst, 268 Grosvenor St, London, ON N6A 4V2, Canada.
EM david.dudok@gmail.com
OI Vedovelli, Luca/0000-0003-4847-2333
NR 23
TC 4
Z9 4
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JUL
PY 2015
VL 43
IS 5
BP 443
EP 448
DI 10.1111/ceo.12480
PG 6
WC Ophthalmology
SC Ophthalmology
GA CN0PQ
UT WOS:000358116200009
PM 25495256
ER
PT J
AU Phitayakorn, R
Levine, W
Petrusa, E
Daily, B
Eromo, E
Gee, D
Hemingway, M
Minehart, R
Pian-Smith, M
Gordon, JA
AF Phitayakorn, Roy
Levine, Wilton
Petrusa, Emil
Daily, Bethany
Eromo, Ersne
Gee, Denise
Hemingway, Maureen
Minehart, Rebecca
Pian-Smith, May
Gordon, James A.
TI Making It Real Development and integration of in situ simulation
operating rooms into the real operating room environment
SO IEEE PULSE
LA English
DT Article
C1 [Phitayakorn, Roy] Massachusetts Gen Hosp, MGH Learning Lab, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Perioperat & Patient Care Serv, Boston, MA 02114 USA.
RP Phitayakorn, R (reprint author), Massachusetts Gen Hosp, MGH Learning Lab, Boston, MA 02114 USA.
EM rphitayakorn@mgh.harvard.edu
OI Phitayakorn, Roy/0000-0002-8327-1484
NR 3
TC 0
Z9 0
U1 0
U2 3
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 2154-2287
J9 IEEE PULSE
JI IEEE Pulse
PD JUL-AUG
PY 2015
VL 6
IS 4
BP 10
EP 13
DI 10.1109/MPUL.2015.2428298
PG 4
WC Engineering, Biomedical
SC Engineering
GA CN1ZJ
UT WOS:000358219400003
PM 26186046
ER
PT J
AU Mukherjee, B
Sivaprakasam, M
AF Mukherjee, Biswarup
Sivaprakasam, Mohanasankar
TI An Eye Toward Improving A new training approach in ophthalmic anesthesia
provides qualitative and quantitative feedback
SO IEEE PULSE
LA English
DT Article
C1 [Mukherjee, Biswarup] Harvard Univ, Sch Med, Simulat Grp, Cambridge, MA 02138 USA.
[Mukherjee, Biswarup] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Sivaprakasam, Mohanasankar] Indian Inst Technol, Dept Elect Engn, Madras 600036, Tamil Nadu, India.
[Sivaprakasam, Mohanasankar] IIT Madras, Healthcare Technol Innovat Ctr, Madras, Tamil Nadu, India.
RP Mukherjee, B (reprint author), Harvard Univ, Sch Med, Simulat Grp, Cambridge, MA 02138 USA.
EM bmukherjee@mgh.harvard.edu; mohan@ee.iitm.ac.in
NR 3
TC 0
Z9 0
U1 0
U2 0
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 2154-2287
J9 IEEE PULSE
JI IEEE Pulse
PD JUL-AUG
PY 2015
VL 6
IS 4
BP 20
EP 25
DI 10.1109/MPUL.2015.2428297
PG 6
WC Engineering, Biomedical
SC Engineering
GA CN1ZJ
UT WOS:000358219400005
PM 26186048
ER
PT J
AU Shuster, M
Tse, JY
Smith, GP
AF Shuster, Marina
Tse, Julie Y.
Smith, Gideon P.
TI Breast carcinoma arising in ectopic breast tissue presenting as an
enlarging axillary nodule
SO INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY
LA English
DT Letter
C1 [Tse, Julie Y.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02215 USA.
[Smith, Gideon P.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02215 USA.
RP Shuster, M (reprint author), Harvard Univ, Sch Med, 89 Pk Dr,Apt 2, Boston, MA 02215 USA.
EM marina_shuster@hms.harvard.edu
NR 5
TC 0
Z9 0
U1 0
U2 0
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
INDIA
SN 0378-6323
EI 0973-3922
J9 INDIAN J DERMATOL VE
JI Indian J. Dermatol. Venereol. Leprol.
PD JUL-AUG
PY 2015
VL 81
IS 4
DI 10.4103/0378-6323.158655
PG 3
WC Dermatology
SC Dermatology
GA CM8HN
UT WOS:000357940000027
ER
PT J
AU Gao, L
Park, SJ
Jang, Y
Lee, S
Kim, CJ
Minami, Y
Ong, D
Soeda, T
Vergallo, R
Lee, H
Yu, B
Uemura, S
Jang, IK
AF Gao, Lei
Park, Seung-Jung
Jang, Yangsoo
Lee, Stephen
Kim, Chong-Jin
Minami, Yoshiyasu
Ong, Daniel
Soeda, Tsunenari
Vergallo, Rocco
Lee, Hang
Yu, Bo
Uemura, Shiro
Jang, Ik-Kyung
TI Comparison of Neoatherosclerosis and Neovascularization Between Patients
With and Without Diabetes An Optical Coherence Tomography Study
SO JACC-CARDIOVASCULAR INTERVENTIONS
LA English
DT Article
DE atherosclerosis; diabetes mellitus; drug-eluting stent
ID ELUTING STENT IMPLANTATION; ATHEROSCLEROTIC LESIONS; GLYCOSYLATED
HEMOGLOBIN; CORONARY STENTS; PLAQUE; PREDICTORS; RESTENOSIS;
INFLAMMATION; PROGRESSION; MELLITUS
AB OBJECTIVES This study aimed to investigate the characteristics of neoatherosclerosis (NA) in patients with diabetes mellitus (DM) after drug-eluting stent (DES) implantation using optical coherence tomography.
BACKGROUND NA is an important substrate for stent failure. In vivo NA characteristics in DM patients have not been investigated.
METHODS A total of 397 patients with 452 DES who underwent follow-up optical coherence tomography examination after DES implantation were enrolled. Characteristics of NA were compared between DM and non-DM patients. Neovascularization was defined as signal-poor holes or tubular structures with a diameter of 50 to 300 mm.
RESULTS A total of 123 DES with NA lesions in 115 patients were identified. The incidence of NA was similar between DM and non-DM patients (29.6% vs. 28.6%; p = 0.825). Compared with the non-DM group, neovascularization was more frequently observed in the DM group (55.1% vs. 32.4%; p = 0.012). The multivariate logistic model demonstrated that DM (odds ratio: 3.00; 95% confidence interval: 1.31 to 6.81; p = 0.009) and follow-up duration (odds ratio: 1.03; 95% confidence interval: 1.02 to 1.05; p < 0.001) were the independent predictors for neovascularization in NA lesions. DM patients with glycated hemoglobin >= 7.0% had a higher prevalence of thin-cap fibroatheroma compared with those with glycated hemoglobin <7.0% (40.0% vs. 8.3%; p = 0.01).
CONCLUSIONS The incidence of NA was similar between patients with and without DM. Neovascularization in NA lesions was more frequent in those with DM. Poorly controlled DM patients had a higher incidence of thin-cap fibroatheroma, compared with those with well-controlled DM. (C) 2015 by the American College of Cardiology Foundation.
C1 [Gao, Lei; Minami, Yoshiyasu; Ong, Daniel; Soeda, Tsunenari; Vergallo, Rocco; Jang, Ik-Kyung] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Park, Seung-Jung] Univ Ulsan, Coll Med, Asan Med Ctr, Div Cardiol, Seoul, South Korea.
[Jang, Yangsoo] Yonsei Univ, Coll Med, Severance Cardiovasc Hosp, Seoul, South Korea.
[Lee, Stephen] Univ Hong Kong, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China.
[Kim, Chong-Jin; Jang, Ik-Kyung] Kyung Hee Univ, Div Cardiol, Seoul, South Korea.
[Soeda, Tsunenari; Uemura, Shiro] Nara Med Univ, Dept Med 1, Nara, Japan.
[Lee, Hang] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Biostat Ctr, Boston, MA 02114 USA.
[Yu, Bo] Harbin Med Univ, Affiliated Hosp 2, Dept Cardiol, Key Lab Myocardial Ischemia,Chinese Minist Educ, Harbin, Peoples R China.
RP Jang, IK (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Cardiol, 55 Fruit St,GRB 800, Boston, MA 02114 USA.
EM IJANG@mgh.harvard.edu
FU St. Jude Medical; Boston Scientific; Medtronic; Italian Society of
Cardiology Award for Research Abroad; National Natural Science
Foundation of China [30871064]
FX Dr. Jang has received a research grant and honorarium from St. Jude
Medical; and has received research grants from Boston Scientific and
Medtronic. Dr. Vergallo was funded in part by the 2013 Italian Society
of Cardiology Award for Research Abroad. Dr. Yu has received a grant
from the National Natural Science Foundation of China (30871064). All
other authors have reported that they have no relationships relevant to
the contents of this paper to disclose.
NR 30
TC 2
Z9 3
U1 2
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1936-8798
EI 1876-7605
J9 JACC-CARDIOVASC INTE
JI JACC-Cardiovasc. Interv.
PD JUL
PY 2015
VL 8
IS 8
BP 1044
EP 1052
DI 10.1016/j.jcin.2015.02.020
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CN2OK
UT WOS:000358261300012
PM 26117465
ER
PT J
AU Jaff, MR
AF Jaff, Michael R.
TI What's a Doctor to Do? Balloon, Stents, Drugs, Drills, and Treadmills
Are We Closer to the Optimal Algorithm?
SO JACC-CARDIOVASCULAR INTERVENTIONS
LA English
DT Editorial Material
DE atherectomy; drug-coated balloon; peripheral artery disease; stent
ID PERIPHERAL ARTERY-DISEASE; SUPERVISED EXERCISE; REVASCULARIZATION;
CLAUDICATION; ANGIOPLASTY; OUTCOMES; CLEVER
C1 Massachusetts Gen Hosp, Paul & Phyllis Fireman Vasc Ctr, Boston, MA 02114 USA.
RP Jaff, MR (reprint author), Massachusetts Gen Hosp, Paul & Phyllis Fireman Vasc Ctr, 55 Fruit St,Warren 905, Boston, MA 02114 USA.
EM mjaff@partners.org
NR 7
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1936-8798
EI 1876-7605
J9 JACC-CARDIOVASC INTE
JI JACC-Cardiovasc. Interv.
PD JUL
PY 2015
VL 8
IS 8
BP 1113
EP 1114
DI 10.1016/j.jcin.2015.05.003
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA CN2OK
UT WOS:000358261300020
PM 26205447
ER
PT J
AU Chambers, KJ
Raol, N
Song, PC
Randolph, GW
Hartnick, CJ
AF Chambers, Kyle J.
Raol, Nikhila
Song, Phillip C.
Randolph, Gregory W.
Hartnick, Christopher J.
TI Laryngeal Reinnervation Using a Split-Hypoglossal Nerve Graft in a
Canine Model
SO JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY
LA English
DT Article
ID VOCAL FOLD PARALYSIS; QUALITY-OF-LIFE; CORD PARALYSIS; THYROARYTENOID
MUSCLES; THYROID-SURGERY; ELECTROMYOGRAPHY; IMPACT; VOICE; NEURORRHAPHY;
EXPERIENCE
AB IMPORTANCE Vocal fold immobility following injury to the recurrent laryngeal nerve (RLN) may lead to substantial morbidity. A reinnervation treatment strategy offers several theoretical benefits over static treatment options. This study evaluates the robustness of reinnervation of the larynx using a split-hypoglossal nerve graft in an animal model, with outcomes assessed by independent blinded review.
OBJECTIVES To assess whether a full-hypoglossal nerve graft to the RLN after RLN section can provide return of dynamic vocal fold motion in a canine model, and to validate that a split-hypoglossal nerve graft to the RLN may also provide dynamic vocal fold motion to rehabilitate laryngeal function in a canine model.
DESIGN, SETTING, AND SUBJECTS A pilot animal study to assess the feasibility and morbidity of laryngeal reinnervation following RLN injury with an end-to-end full-hypoglossal or split-hypoglossal nerve graft was performed at an animal care and research facility in 10 adult female dogs. The study dates were January to July 2013.
INTERVENTIONS We performed full-hypoglossal (full XII group [n = 5]) and split-hypoglossal (split XII group [ n = 5]) nerve grafts to the RLN in a canine model following RLN section.
MAIN OUTCOMES AND MEASURES Morbidity was evaluated through scored feeding observation. Laryngeal function was assessed by video laryngoscopy and evoked laryngeal electromyography was performed at baseline and 6 months after surgery. Video laryngoscopy was graded by independent reviewers blinded to study intervention.
RESULTS No clinically significant morbidity was identified after surgery. On review of video laryngoscopy, all 5 animals in the full XII group and all 5 animals in the split XII group demonstrated vocal fold motion by at least 1 independent reviewer. All 3 reviewers agreed on motion in 1 of 5 animals in the full XII group and in 1 of 5 animals in the split XII group. Stimulation of the hypoglossal nerve demonstrated neural connection on evoked laryngeal electromyography in all animals at 6 months.
CONCLUSIONS AND RELEVANCE This study confirms that a full-hypoglossal or split-hypoglossal nerve graft may restore vocal fold motion, without significant functional morbidity, following RLN section in a canine model.
C1 [Chambers, Kyle J.; Randolph, Gregory W.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, Boston, MA 02114 USA.
[Raol, Nikhila; Hartnick, Christopher J.] Harvard Univ, Sch Med, Dept Otolaryngol, Div Pediat Otolaryngol, Boston, MA 02114 USA.
[Song, Phillip C.] Harvard Univ, Sch Med, Dept Otolaryngol, Div Laryngol, Boston, MA 02114 USA.
[Song, Phillip C.] Harvard Univ, Sch Med, Dept Otolaryngol, Div Thyroid & Parathyroid Surg, Boston, MA 02114 USA.
RP Hartnick, CJ (reprint author), Harvard Univ, Sch Med, Dept Otolaryngol, Div Pediat Otolaryngol, 243 Charles St, Boston, MA 02114 USA.
EM christopher_hartnick@meei.harvard.edu
NR 41
TC 1
Z9 1
U1 2
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6181
EI 2168-619X
J9 JAMA OTOLARYNGOL
JI JAMA Otolaryngol-Head Neck Surg.
PD JUL
PY 2015
VL 141
IS 7
BP 620
EP 627
DI 10.1001/jamaoto.2015.0929
PG 8
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA CN0DB
UT WOS:000358081900006
PM 26042741
ER
PT J
AU Lee, J
AF Lee, Jarone
TI Trauma Patients Health Insurance Reform Is Only the Beginning
SO JAMA SURGERY
LA English
DT Editorial Material
C1 [Lee, Jarone] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA.
[Lee, Jarone] Harvard Univ, Sch Med, Dept Emergency Med, Boston, MA USA.
[Lee, Jarone] Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02114 USA.
RP Lee, J (reprint author), Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, 165 Cambridge St,Ste 810, Boston, MA 02114 USA.
EM lee.jarone@mgh.harvard.edu
NR 4
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6254
EI 2168-6262
J9 JAMA SURG
JI JAMA Surg.
PD JUL
PY 2015
VL 150
IS 7
BP 616
EP 616
DI 10.1001/jamasurg.2014.2470
PG 1
WC Surgery
SC Surgery
GA CM8ZU
UT WOS:000357994900004
PM 25945655
ER
PT J
AU Bauman, WA
Cirnigliaro, CM
La Fountaine, MF
Martinez, L
Kirshblum, SC
Spungen, AM
AF Bauman, William A.
Cirnigliaro, Christopher M.
La Fountaine, Michael F.
Martinez, LeighAnn
Kirshblum, Steven C.
Spungen, Ann M.
TI Zoledronic acid administration failed to prevent bone loss at the knee
in persons with acute spinal cord injury: an observational cohort study
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Spinal cord injury; Zoledronate; Bisphosphonates; Osteoporosis; Knee
ID X-RAY ABSORPTIOMETRY; DISUSE OSTEOPOROSIS; MINERAL DENSITY; PAMIDRONATE;
TERM; IMMOBILIZATION; TURNOVER; FRACTURE; INDIVIDUALS; METABOLISM
AB After acute spinal cord injury (SCI), rapid depletion of the sublesional skeleton occurs, particularly at the distal femur and proximal tibia. Subsequently, fragility fractures of the knee may occur. We determined the efficacy of zoledronic acid to prevent sublesional bone mineral density (BMD) loss at 6 and 12 months after acute SCI. Thirteen subjects with acute motor-complete SCI were prospectively studied: 6 patients received zoledronic acid (5 mg) and 7 subjects did not receive the drug (controls). Zoledronic acid was administered intravenously within 16 weeks of acute injury. Areal BMD was performed by dual energy X-ray absorptiometry at baseline, 6, and 12 months after administration of drug. The treatment group demonstrated sparing of BMD at the total hip at month 6 (p < 0.0006) and at month 12 (p < 0.01). In contrast to the findings at the hip, the treatment group had a greater loss of BMD compared to the control group at the distal femur and proximal tibia at month 6 (-7.9 % +/- 3.4 vs.-2.7 % +/- 5.0, respectively, p = 0.054; and -10.5 % +/- 6.4 vs. -4.8 % +/- 6.8, respectively, p = NS) and at month 12 (-18.5 % +/- 3.9 vs. -8.4 % +/- 7.2, respectively, p = 0.01; and -20.4 % +/- 8.8 vs.-7.9 % +/- 12.3, respectively, p = 0.06). A single dose of zoledronic acid administered soon after acute SCI reduced the %BMD loss at the hip, but appeared to have no effect to prevent %BMD loss at the knee, the site where fracture risk is greatest in persons with SCI.
C1 [Bauman, William A.; Cirnigliaro, Christopher M.; La Fountaine, Michael F.; Spungen, Ann M.] James J Peters VA Med Ctr, VA RR&D Natl Ctr Excellence Med Consequences Spin, Bronx, NY 10468 USA.
[Bauman, William A.; Spungen, Ann M.] James J Peters VA Med Ctr, Med Serv, Bronx, NY 10468 USA.
[Bauman, William A.; La Fountaine, Michael F.; Spungen, Ann M.] Icahn Sch Med Mt Sinai, Dept Med & Rehabil Med, New York, NY 10029 USA.
[La Fountaine, Michael F.] Seton Hall Univ, Dept Phys Therapy, Sch Hlth & Med Sci, S Orange, NJ USA.
[Martinez, LeighAnn; Kirshblum, Steven C.] Kessler Inst Rehabil, W Orange, NJ USA.
[Kirshblum, Steven C.] Univ Med & Dent New Jersey, Dept Phys Med & Rehabil, Newark, NJ 07103 USA.
RP Bauman, WA (reprint author), James J Peters VA Med Ctr, VA RR&D Natl Ctr Excellence Med Consequences Spin, 130 West Kingsbridge Rd, Bronx, NY 10468 USA.
EM william.bauman@va.gov
FU James J. Peters Veterans Affairs Medical Center; Kessler Institute for
Rehabilitation, West Orange, NJ; Rehabilitation Research & Development
Center of Excellence [B9212-C, B4162-C]; Veteran Affairs Rehabilitation
Research and Development Service [B9212-C, B4162-C]
FX The authors would like to thank the James J. Peters Veterans Affairs
Medical Center, Bronx, NY, Department of Veterans Affairs Rehabilitation
Research & Development Service, and Kessler Institute for
Rehabilitation, West Orange, NJ, for their support to perform this work.
Novartis Pharmaceuticals Corporation provided drug gratis to perform
this clinical trial. This work was funded by a Rehabilitation Research &
Development Center of Excellence for the Medical Consequences of Spinal
Cord Injury grant (#B9212-C, B4162-C). Veteran Affairs Rehabilitation
Research and Development Service (#B9212-C, #B4162-C) and the James J.
Peters Veterans Affairs Medical Center. Novartis Pharmaceuticals
graciously provided zoledronic acid (Reclast 5 mg) for use in our
clinical trial.
NR 44
TC 7
Z9 7
U1 2
U2 3
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
JAPAN
SN 0914-8779
EI 1435-5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD JUL
PY 2015
VL 33
IS 4
BP 410
EP 421
DI 10.1007/s00774-014-0602-x
PG 12
WC Endocrinology & Metabolism; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA CN1QT
UT WOS:000358195600006
PM 25158630
ER
PT J
AU Li, JT
Melton, AC
Su, G
Hamm, DE
LaFemina, M
Howard, J
Fang, XH
Bhat, S
Huynh, KM
O'Kane, CM
Ingram, RJ
Muir, RR
McAuley, DF
Matthay, MA
Sheppard, D
AF Li, John T.
Melton, Andrew C.
Su, George
Hamm, David E.
LaFemina, Michael
Howard, James
Fang, Xiaohui
Bhat, Sudarshan
Huynh, Kieu-My
O'Kane, Cecilia M.
Ingram, Rebecca J.
Muir, Roshell R.
McAuley, Daniel F.
Matthay, Michael A.
Sheppard, Dean
TI Unexpected Role for Adaptive alpha beta Th17 Cells in Acute Respiratory
Distress Syndrome
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID ACUTE LUNG INJURY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EVANS
BLUE-DYE; T-CELLS; TH17 CELLS; ALBUMIN CLEARANCE; HOST-DEFENSE; IL-17;
MICE; INTERLEUKIN-17
AB Acute respiratory distress syndrome (ARDS) is a devastating disorder characterized by increased alveolar permeability with no effective treatment beyond supportive care. Current mechanisms underlying ARDS focus on alveolar endothelial and epithelial injury caused by products of innate immune cells and platelets. However, the role of adaptive immune cells in ARDS remains largely unknown. In this study, we report that expansion of Ag-specific alpha beta Th17 cells contributes to ARDS by local secretion of IL-17A, which in turn directly increases alveolar epithelial permeability. Mice with a highly restrictive defect in Ag-specific alpha beta Th17 cells were protected from experimental ARDS induced by a single dose of endotracheal LPS. Loss of IL-17 receptor C or Ab blockade of IL-17A was similarly protective, further suggesting that IL-17A released by these cells was responsible for this effect. LPS induced a rapid and specific clonal expansion of alpha beta Th17 cells in the lung, as determined by deep sequencing of the hypervariable CD3R beta VJ region of the TCR. Our findings could be relevant to ARDS in humans, because we found significant elevation of IL-17A in bronchoalveolar lavage fluid from patients with ARDS, and rIL-17A directly increased permeability across cultured human alveolar epithelial monolayers. These results reveal a previously unexpected role for adaptive immune responses that increase alveolar permeability in ARDS and suggest that alpha beta Th17 cells and IL-17A could be novel therapeutic targets for this currently untreatable disease.
C1 [Li, John T.; Melton, Andrew C.; Huynh, Kieu-My; Sheppard, Dean] Univ Calif San Francisco, Lung Biol Ctr, Dept Med, San Francisco, CA 94143 USA.
[Li, John T.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94110 USA.
[Su, George] San Francisco Gen Hosp, Dept Med, San Francisco, CA 94110 USA.
[Hamm, David E.] Adapt Biotechnol, Seattle, WA 98102 USA.
[LaFemina, Michael] San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94121 USA.
[Howard, James] UCSF Benioff Childrens Hosp Oakland, Dept Pediat, Oakland, CA 94609 USA.
[Matthay, Michael A.] Cardiovasc Res Inst, Dept Anesthesia, San Francisco, CA 94158 USA.
[Fang, Xiaohui; Matthay, Michael A.] Cardiovasc Res Inst, Dept Med, San Francisco, CA 94158 USA.
[Bhat, Sudarshan] Univ Calif Berkeley, Berkeley, CA 94720 USA.
[O'Kane, Cecilia M.; Ingram, Rebecca J.; Muir, Roshell R.; McAuley, Daniel F.] Queens Univ Belfast, Ctr Infect & Immun, Belfast BT7 1NN, Antrim, North Ireland.
RP Sheppard, D (reprint author), Univ Calif San Francisco, Lung Biol Ctr, 1550 4th St,Mission Bay, San Francisco, CA 94143 USA.
EM dean.sheppard@ucsf.edu
RI Ingram, Rebecca/F-9711-2013
OI Ingram, Rebecca/0000-0003-1832-2457
FU National Institutes of Health [R37HL53949, K08HL111208, R37HL51856];
Health and Social Care Research and Development Division, Public Health
Agency Northern Ireland
FX This work was supported by National Institutes of Health Grants
R37HL53949 (to D.S.), K08HL111208 (to J.T.L.), and R37HL51856 (to
M.A.M.), as well as by a grant from the Health and Social Care Research
and Development Division, Public Health Agency Northern Ireland (to
C.M.O. and D.F.M.). The content is solely the responsibility of the
authors and does not necessarily represent the official views of the
National Institutes of Health or other funders.
NR 41
TC 9
Z9 9
U1 1
U2 5
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD JUL 1
PY 2015
VL 195
IS 1
BP 87
EP 95
DI 10.4049/jimmunol.1500054
PG 9
WC Immunology
SC Immunology
GA CM9XU
UT WOS:000358064500015
PM 26002979
ER
PT J
AU Reardon, DA
Okada, H
AF Reardon, David A.
Okada, Hideho
TI Re-defining response and treatment effects for neuro-oncology
immunotherapy clinical trials
SO JOURNAL OF NEURO-ONCOLOGY
LA English
DT Editorial Material
DE Immunotherapy; Glioblastoma; Vaccine; Immune checkpoint inhibitor;
Pseudoprogression
ID METASTATIC MELANOMA; T-CELLS; CANCER-IMMUNOTHERAPY; ASSESSMENT CRITERIA;
PLUS IPILIMUMAB; FOLLOW-UP; PHASE-II; GLIOBLASTOMA; ANTIBODY; SAFETY
AB In much of medical oncology, including neuro-oncology, there is great interest to evaluate the therapeutic potential of immune-based therapies including vaccines, adoptive T cell strategies and modulators of immune checkpoint regulators such as cytotoxic T lymphocyte antigen 4 and programmed death 1. Immune-based treatments exert an indirect anti-tumor effect by generating potent, tumor-targeting immune responses. Robust anti-tumor immune responses have been shown to achieve encouraging radiographic responses across the spectrum of applied immunotherapeutics which are felt to be indicative of a bona fide anti-tumor effect. Conversely, worsening of imaging findings, particularly early in the course of immunotherapy administration, can be challenging to interpret with growing evidence demonstrating that at least a subset of such patients ultimately will derive meaningful clinical benefit. The immune related response criteria were generated to provide guidance regarding the interpretation of such complex imaging findings, for general medical oncologists prescribing immunotherapeutics. An analogous effort that addresses challenges associated with imaging assessment and incorporates nuances associated with neuro-oncology patients is underway and is referred to as the immunotherapy response assessment in neuro-oncology criteria.
C1 [Reardon, David A.] Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02215 USA.
[Okada, Hideho] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
RP Reardon, DA (reprint author), Dana Farber Canc Inst, Ctr Neurooncol, 450 Brookline Ave,Dana 2134, Boston, MA 02215 USA.
EM david_reardon@dfci.harvard.edu
NR 50
TC 3
Z9 3
U1 1
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-594X
EI 1573-7373
J9 J NEURO-ONCOL
JI J. Neuro-Oncol.
PD JUL
PY 2015
VL 123
IS 3
SI SI
BP 339
EP 346
DI 10.1007/s11060-015-1748-7
PG 8
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA CN1EM
UT WOS:000358160000004
PM 25707876
ER
PT J
AU Moran, CJ
Kaplan, JL
Winter, HS
Masiakos, PT
AF Moran, Christopher J.
Kaplan, Jess L.
Winter, Harland S.
Masiakos, Peter T.
TI Occult Blood and Perianal Examination: Value Added in Pediatric
Inflammatory Bowel Disease Screening
SO JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
LA English
DT Article
DE fecal occult blood testing; inflammatory bowel disease; pediatric;
perianal examination; sensitivity and specificity
ID DIGITAL RECTAL EXAMINATION; DIAGNOSTIC DELAY; CHILDREN
AB Objectives:Pediatric inflammatory bowel disease (IBD) often presents insidiously and standard blood tests are normal in 20% of patients. We hypothesize that fecal occult blood testing (FOBT) and the perianal examination in addition to blood tests provide important information during the screening process for IBD. The aim of the present study was to measure the diagnostic value of adding FOBT and perianal examination to standard screening laboratories in evaluating children and adolescents for IBD.Methods:The medical records of consecutive patients undergoing ileocolonoscopy for IBD were reviewed. Laboratory test results, FOBT, and perianal examination before the decision to perform the ileocolonoscopy were recorded. Standard limits of laboratory tests were used. Multivariate logistic regression was performed on a discovery cohort and applied to an independent validation cohort.Results:The discovery cohort included 335 patients (85 IBD and 250 non-IBD). A total of 61.2% had FOBT and perianal examination performed before the decision to perform the ileocolonoscopy. A total of 119 patients had complete blood testing, FOBT, and perianal examination available for full analysis. The sensitivity of the laboratory testing was 80.5% for IBD, and the sensitivity of FOBT with perianal examination was 66.9%. The combined sensitivity of laboratory testing and FOBT with perianal examination was, however, 97.6%. The most predictive model included C-reactive protein, platelet counts, and FOBT with perianal examination and was superior to the laboratory value-only model (P<0.001) that was validated in a separate cohort.Conclusions:Perianal examination and FOBT improve sensitivity in screening children for IBD.
C1 [Moran, Christopher J.; Kaplan, Jess L.; Winter, Harland S.] MassGen Hosp Children, Div Pediat Gastroenterol Hepatol & Nutr, Boston, MA 02114 USA.
[Masiakos, Peter T.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
RP Moran, CJ (reprint author), MassGen Hosp Children, Div Pediat Gastroenterol Hepatol & Nutr, 175 Cambridge St,561, Boston, MA 02114 USA.
EM jmoran@mgh.harvard.edu
FU Harvard Catalyst \ The Harvard Clinical and Translational Science Center
(NCRR, NIH); Harvard Catalyst \ The Harvard Clinical and Translational
Science Center (NCATS, NIH) [UL1 TR001102]; Harvard University
FX The present work was supported in part by philanthropic donations from
Martin Schlaff (H.S.W) and the B. Hasso Family Foundation (May Serrano,
President) (H.S.W), conducted with support from Harvard Catalyst
vertical bar The Harvard Clinical and Translational Science Center (NCRR
and NCATS, NIH Award UL1 TR001102), and financial contributions from
Harvard University and its affiliated academic health care centers.
NR 16
TC 3
Z9 3
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0277-2116
EI 1536-4801
J9 J PEDIATR GASTR NUTR
JI J. Pediatr. Gastroenterol. Nutr.
PD JUL
PY 2015
VL 61
IS 1
BP 52
EP 55
DI 10.1097/MPG.0000000000000754
PG 4
WC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
SC Gastroenterology & Hepatology; Nutrition & Dietetics; Pediatrics
GA CN1HC
UT WOS:000358168300008
PM 25651490
ER
PT J
AU Hull, MA
Niemierko, A
Haynes, AB
Jacobson, A
Chen, YL
DeLaney, TF
Mullen, JT
AF Hull, Melissa A.
Niemierko, Andrzej
Haynes, Alex B.
Jacobson, Alex
Chen, Yen-Lin
DeLaney, Thomas F.
Mullen, John T.
TI Post-operative renal function following nephrectomy as part of en bloc
resection of retroperitoneal sarcoma (RPS)
SO JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Article
DE retroperitoneal sarcoma; nephrectomy; renal function; chronic kidney
disease
ID GLOMERULAR-FILTRATION-RATE; SOFT-TISSUE SARCOMAS; EXTENDED SURGERY
AB Background and ObjectivesAlthough resection of RPS with en bloc nephrectomy confers the potential benefit of improved locoregional tumor control, little has been published about the long-term post-operative renal function of these patients.
MethodsRetrospective review of 54 patients undergoing nephrectomy for RPS was performed. Clinicopathologic and treatment characteristics, pre- and post-operative creatinine (Cr) values, and estimated glomerular filtration rates (eGFR) were recorded. The primary outcome measure was progression of chronic kidney disease (CKD) stage.
ResultsMedian preoperative eGFR was 85ml/min. Post-nephrectomy, median nadir eGFR was 44ml/min, rebounding to 62ml/min at median follow-up of 50 months. Of 49 patients with preoperative eGFR 60ml/min (CKD stage 1,2), 51% preserved eGFR 60 postoperatively, whereas 49% progressed to CKD stage 3 (eGFR 30-59). Independent risk factors for progression of CKD stage were age and preoperative eGFR. Eleven patients died of recurrent disease, whereas no patient died of end stage renal disease (ESRD) or required dialysis.
ConclusionsAlthough progression of CKD stage occurs in nearly one-half of patients followed for more than 4 years after nephrectomy for RPS, no patient progressed to ESRD or had a limitation in systemic therapy options, even with progression to CKD stage 3. J. Surg. Oncol. 2015 111:98-102. (c) 2015 Wiley Periodicals, Inc.
C1 [Hull, Melissa A.; Haynes, Alex B.; Mullen, John T.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Niemierko, Andrzej; Jacobson, Alex; Chen, Yen-Lin; DeLaney, Thomas F.] Massachusetts Gen Hosp, Dept & Radiat Oncol, Boston, MA 02114 USA.
RP Mullen, JT (reprint author), Massachusetts Gen Hosp, Dept Surg, 55 Fruit St Yawkey 7B, Boston, MA 02114 USA.
EM jmullen@partners.org
NR 24
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-4790
EI 1096-9098
J9 J SURG ONCOL
JI J. Surg. Oncol.
PD JUL 1
PY 2015
VL 112
IS 1
BP 98
EP 102
DI 10.1002/jso.23949
PG 5
WC Oncology; Surgery
SC Oncology; Surgery
GA CN3AR
UT WOS:000358296100018
PM 26179132
ER
PT J
AU Partridge, AH
AF Partridge, Ann H.
TI More Options for Premenopausal Women With Early-Stage Hormone-Sensitive
Breast Cancer
SO ONCOLOGY-NEW YORK
LA English
DT Editorial Material
ID OVARIAN SUPPRESSION; TAMOXIFEN THERAPY; ADJUVANT; NONADHERENCE
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Partridge, AH (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 10
TC 0
Z9 0
U1 1
U2 1
PU UBM MEDICA
PI NORWALK
PA 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA
SN 0890-9091
J9 ONCOLOGY-NY
JI Oncology-NY
PD JUL
PY 2015
VL 29
IS 7
BP 482
EP +
PG 2
WC Oncology
SC Oncology
GA CN4KI
UT WOS:000358398600002
PM 26178335
ER
PT J
AU Rai, R
Jakobiec, FA
Fay, A
AF Rai, Ruju
Jakobiec, Frederick A.
Fay, Aaron
TI Ocular Metastatic Renal Carcinoma Presenting With Proptosis
SO OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY
LA English
DT Article
ID CELL-CARCINOMA; PROGNOSTIC-FACTORS; CANCER; ORBIT; EYE; SURVIVAL;
NEOPLASMS; DIAGNOSIS; IMMUNOHISTOCHEMISTRY; NEPHRECTOMY
AB Metastatic renal carcinoma is the third most common source of ocular and second most common source of orbital metastases. This is the first published case of von Hippel-Lindau (vHL) disease that developed renal cell carcinoma metastatic to an eye with a retinal hemangioblastoma. A 73-year-old woman had a history of vHL disease that included prior retinal hemangioblastomas, 2 cerebellar hemangioblastomas, and bilateral renal cell carcinomas with sacral metastasis. After presenting with progressive, painful proptosis secondary to a large mass observable by ocular CT, an enucleation-orbitotomy was performed, and the surgical specimen was sent for histopathological analysis. The ophthalmic renal metastatic tumor, like the primary tumor, was a clear cell variant that involved both the eyeball and orbit in continuity. The intraocular component was larger than the extraocular portion, which was interpreted as an outward extension of an initial retinal metastasis that probably first settled within a hemangioblastoma. Clusters of ectatic ghost vessels with thickened walls produced by periodic acid Schiff-positive, redundant basement membrane material were partially infiltrated by tumor cells at their periphery, thereby lending some support for this hypothesis. Immunohistochemical positivity for the biomarkers cytokeratin 18, vimentin, carbonic anhydrase IX, PAX2, and PAX 8 confirmed the diagnosis. The patient has refused further treatment. Her anophthalmic socket has comfortably retained a porous polyethylene implant without clinical evidence of local recurrence during 5 months of follow up.
C1 [Rai, Ruju; Jakobiec, Frederick A.] Massachusetts Eye & Ear Infirm, David G Cogan Lab Ophthalm Pathol, Dept Ophthalmol, Boston, MA 02114 USA.
[Rai, Ruju; Jakobiec, Frederick A.; Fay, Aaron] Harvard Univ, Sch Med, Boston, MA USA.
[Fay, Aaron] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Ophthalm Plast Surg, Boston, MA 02114 USA.
RP Jakobiec, FA (reprint author), Massachusetts Eye & Ear Infirm, David G Cogan Lab Ophthalm Pathol, 243 Charles St,Suite 328, Boston, MA 02114 USA.
EM Fred_Jakobiec@meei.harvard.edu
NR 42
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0740-9303
EI 1537-2677
J9 OPHTHAL PLAST RECONS
JI Ophthalmic Plast. Reconstr. Surg.
PD JUL-AUG
PY 2015
VL 31
IS 4
BP E100
EP E108
DI 10.1097/IOP.0000000000000119
PG 9
WC Ophthalmology; Surgery
SC Ophthalmology; Surgery
GA CM9QE
UT WOS:000358043000009
PM 24828963
ER
PT J
AU Lisi, AJ
Breuer, P
Gallagher, RM
Rodriguez, E
Rossi, MI
Schmader, K
Scholten, JD
Weiner, DK
AF Lisi, Anthony J.
Breuer, Paula
Gallagher, Rollin M.
Rodriguez, Eric
Rossi, Michelle I.
Schmader, Kenneth
Scholten, Joel D.
Weiner, Debra K.
TI Deconstructing Chronic Low Back Pain in the Older Adult-Step by Step
Evidence and Expert-Based Recommendations for Evaluation and Treatment:
Part II: Myofascial Pain
SO PAIN MEDICINE
LA English
DT Review
DE Low Back Pain; Myofascial Pain; Chronic Pain; Degenerative Disc Disease;
Elderly; Chronic Low Back Pain; Lumbar; Older Adults; Pain Disorder;
Spinal Stenosis
ID POSTTRAUMATIC-STRESS-DISORDER; MUSCULOSKELETAL PAIN; TRIGGER POINT;
SKELETAL-MUSCLE; MANAGEMENT; CARE; PREVALENCE; PHYSICIANS; DIAGNOSIS;
FRAMEWORK
AB ObjectiveTo present an algorithm of sequential treatment options for managing myofascial pain (MP) in older adults, along with a representative clinical case.
MethodsA modified Delphi process was used to synthesize evidence-based recommendations. A multidisciplinary expert panel developed the algorithm, which was subsequently refined through an iterative process of input from a primary care physician panel.
ResultsWe present an algorithm and supportive materials to help guide the care of older adults with MP, an important contributor to chronic low back pain (CLBP). Addressing any perpetuating factors should be the first step of managing MP. Patients should be educated on self-care approaches, home exercise, and the use of safe analgesics when indicated. Trigger point deactivation can be accomplished by manual therapy, injection therapy, dry needling, and/or acupuncture.
ConclusionsThe algorithm presented gives a structured approach to guide primary care providers in planning treatment for patients with MP as a contributor to CLBP.
C1 [Lisi, Anthony J.] VA Connecticut Healthcare Syst, Newington, CT USA.
[Lisi, Anthony J.] Univ Bridgeport, Coll Chiropract, Bridgeport, CT 06601 USA.
[Breuer, Paula] Univ Pittsburgh, Med Ctr, Ctr Rehab Serv, Pittsburgh, PA 15260 USA.
[Gallagher, Rollin M.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Gallagher, Rollin M.] Univ Penn, Dept Anesthesiol, Philadelphia, PA 19104 USA.
[Gallagher, Rollin M.] Philadelphia VA Med Ctr, Pain Serv, Philadelphia, PA USA.
[Rodriguez, Eric; Rossi, Michelle I.; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr Med, Pittsburgh, PA 15260 USA.
[Rossi, Michelle I.; Weiner, Debra K.] VA Pittsburgh Healthcare Syst, GRECC, Pittsburgh, PA 15240 USA.
[Schmader, Kenneth] Durham VA Med Ctr, GRECC, Durham, NC USA.
[Schmader, Kenneth] Duke Univ, Med Ctr, Dept Med, Div Geriatr, Durham, NC 27706 USA.
[Scholten, Joel D.] Washington DC VA Med Ctr, Washington, DC USA.
[Weiner, Debra K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA.
[Weiner, Debra K.] Univ Pittsburgh, Anesthesiol, Pittsburgh, PA USA.
[Weiner, Debra K.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA USA.
RP Weiner, DK (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr,Bldg 30,00GR, Pittsburgh, PA 15240 USA.
EM debra.weiner@va.gov
FU Veterans Administration Rehabilitation Research & Development Service
FX Veterans Administration Rehabilitation Research & Development Service.
NR 43
TC 1
Z9 1
U1 10
U2 26
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1526-2375
EI 1526-4637
J9 PAIN MED
JI Pain Med.
PD JUL
PY 2015
VL 16
IS 7
BP 1282
EP 1289
DI 10.1111/pme.12821
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA CM9GY
UT WOS:000358017000011
PM 26087225
ER
PT J
AU Accordino, RE
Lucarelli, J
Yan, AC
AF Accordino, Robert E.
Lucarelli, Jennifer
Yan, Albert C.
TI Cutaneous Disease in Autism Spectrum Disorder: A Review
SO PEDIATRIC DERMATOLOGY
LA English
DT Review
ID TUBEROUS SCLEROSIS; CANDIDATE GENE; ASSOCIATION; CHILDREN;
HYPOMELANOSIS; ITO; MANIFESTATIONS; EXPERIENCES; POPULATION; SYMPTOMS
AB Dermatologic comorbid symptoms and conditions in persons with autism spectrum disorder (ASD) are compelling for several reasons, including problems with tactile sensory dysfunction in this population, a large number of syndromes with dermatologic findings and high rates of autism, nutritional and hormonal problems in ASD and their dermatologic manifestations, and the potential for overrepresentation of dermatologic symptoms that are neurobehavioral in nature. The current article reviews the available literature on the prevalence of comorbid dermatologic symptoms and conditions in children with ASD and identifies strategies for diagnosing and managing cutaneous disease in this population.
C1 [Accordino, Robert E.] Massachusetts Gen Hosp, Div Child & Adolescent Psychiat, Boston, MA 02114 USA.
[Lucarelli, Jennifer] Boston Childrens Hosp, Div Dev Med, Boston, MA 02115 USA.
[Yan, Albert C.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Sect Pediat Dermatol, Philadelphia, PA 19104 USA.
RP Lucarelli, J (reprint author), Boston Childrens Hosp, Div Dev Med, Fegan 10,300 Longwood Ave, Boston, MA 02115 USA.
EM Jennifer.lucarelli@childrens.harvard.edu
NR 44
TC 0
Z9 0
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0736-8046
EI 1525-1470
J9 PEDIATR DERMATOL
JI Pediatr. Dermatol.
PD JUL-AUG
PY 2015
VL 32
IS 4
BP 455
EP 460
DI 10.1111/pde.12582
PG 6
WC Dermatology; Pediatrics
SC Dermatology; Pediatrics
GA CN1FJ
UT WOS:000358163100027
PM 25824343
ER
PT J
AU Boyers, LN
Karimkhani, C
Guild, SR
Dellavalle, RP
AF Boyers, Lindsay N.
Karimkhani, Chante
Guild, Samantha R.
Dellavalle, Robert P.
TI Lessons from a Legislative Struggle to Ban Indoor Tanning for Children
Younger than 18
SO PEDIATRIC DERMATOLOGY
LA English
DT Editorial Material
C1 [Boyers, Lindsay N.] Georgetown Univ, Sch Med, Washington, DC USA.
[Karimkhani, Chante] Columbia Univ, Coll Phys & Surg, New York, NY USA.
[Guild, Samantha R.] AIM Melanoma, Richmond, CA USA.
[Dellavalle, Robert P.] Eastern Colorado Hlth Care Syst, US Dept Vet Affairs, Dermatol Serv, Denver, CO USA.
[Dellavalle, Robert P.] Univ Colorado, Sch Med, Aurora, CO USA.
[Dellavalle, Robert P.] Univ Colorado Anschutz Med Campus, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA.
RP Dellavalle, RP (reprint author), Dept Veteran Affairs Med Ctr, Dermatol Serv, 1055 Clermont St,Box 165, Denver, CO 80220 USA.
EM robert.dellavalle@ucdenver.edu
NR 8
TC 0
Z9 0
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0736-8046
EI 1525-1470
J9 PEDIATR DERMATOL
JI Pediatr. Dermatol.
PD JUL-AUG
PY 2015
VL 32
IS 4
BP 553
EP 556
DI 10.1111/pde.12491
PG 4
WC Dermatology; Pediatrics
SC Dermatology; Pediatrics
GA CN1FJ
UT WOS:000358163100047
PM 26184402
ER
PT J
AU Paul, S
Cheng, CE
Kroshinsky, D
AF Paul, Suchismita
Cheng, Carol E.
Kroshinsky, Daniela
TI Combination Systemic Fluorouracil and Radiation for the Treatment of
Recalcitrant Condyloma with Associated Squamous Cell Carcinoma in an
Immunocompromised 15-Year-Old Girl
SO PEDIATRIC DERMATOLOGY
LA English
DT Article
ID WARTS; ACUMINATUM
AB Condylomata acuminata (CA), or anogenital warts, are typically benign lesions caused by human papillomavirus infection. Although they are rare, immunocompromised individuals are at a higher risk of CA undergoing transformation into invasive anal squamous cell carcinoma (SCC). These patients need aggressive evaluation and management. Treatment of CA is challenging, particularly for immunocompromised hosts, in whom warts are resistant to treatment and commonly recur. Currently, there is no gold standard treatment for CA, especially in children and immunodeficient individuals. We report the case of a 15-year-old immunocompromised girl with severe recalcitrant condyloma that resolved after a course of systemic 5-fluorouracil, mitomycin C, and radiation therapy for SCC.
C1 [Paul, Suchismita; Kroshinsky, Daniela] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Cheng, Carol E.] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA.
RP Paul, S (reprint author), Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA.
EM suchismita_paul@hms.harvard.edu
NR 12
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0736-8046
EI 1525-1470
J9 PEDIATR DERMATOL
JI Pediatr. Dermatol.
PD JUL-AUG
PY 2015
VL 32
IS 4
BP E148
EP E150
DI 10.1111/pde.12617
PG 3
WC Dermatology; Pediatrics
SC Dermatology; Pediatrics
GA CN1FJ
UT WOS:000358163100004
PM 25940810
ER
PT J
AU Schnall, S
Haidt, J
Clore, GL
Jordan, AH
AF Schnall, Simone
Haidt, Jonathan
Clore, Gerald L.
Jordan, Alexander H.
TI Landy and Goodwin (2015) Confirmed Most of Our Findings Then Drew the
Wrong Conclusions
SO PERSPECTIVES ON PSYCHOLOGICAL SCIENCE
LA English
DT Editorial Material
ID MORAL JUDGMENTS; DISGUST; MOOD; ATTENTION; EMOTION
C1 [Schnall, Simone] Univ Cambridge, Cambridge CB2 3EB, England.
[Haidt, Jonathan] New York Univ Stern Sch Business, New York, NY USA.
[Clore, Gerald L.] Univ Virginia, Charlottesville, VA 22903 USA.
[Jordan, Alexander H.] VA Boston Healthcare Syst, Boston, MA USA.
[Jordan, Alexander H.] Boston Univ, Sch Med, Boston, MA 02215 USA.
RP Schnall, S (reprint author), Univ Cambridge, Dept Psychol, Downing St,Off 406, Cambridge CB2 3EB, England.
EM ss877@cam.ac.uk
FU National Science Foundation [BCS-1252079]
FX Gerald L. Chore wishes to acknowledge funding support from National
Science Foundation Grant BCS-1252079.
NR 17
TC 5
Z9 5
U1 3
U2 14
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1745-6916
EI 1745-6924
J9 PERSPECT PSYCHOL SCI
JI Perspect. Psychol. Sci.
PD JUL
PY 2015
VL 10
IS 4
BP 537
EP 538
DI 10.1177/1745691615589078
PG 2
WC Psychology, Multidisciplinary
SC Psychology
GA CN0CU
UT WOS:000358081000008
PM 26177952
ER
PT J
AU Bachhuber, MA
McGinty, EE
Kennedy-Hendricks, A
Niederdeppe, J
Barry, CL
AF Bachhuber, Marcus A.
McGinty, Emma E.
Kennedy-Hendricks, Alene
Niederdeppe, Jeff
Barry, Colleen L.
TI Messaging to Increase Public Support for Naloxone Distribution Policies
in the United States: Results from a Randomized Survey Experiment
SO PLOS ONE
LA English
DT Article
ID OPIATE SUBSTITUTION TREATMENT; EMERGENCY MEDICAL-SERVICES; TAKE-HOME
NALOXONE; OPIOID OVERDOSE; HEROIN OVERDOSE; INTRANASAL NALOXONE;
SAN-FRANCISCO; DRUG-USERS; PREVENTION; DEATHS
AB Background
Barriers to public support for naloxone distribution include lack of knowledge, concerns about potential unintended consequences, and lack of sympathy for people at risk of overdose.
Methods
A randomized survey experiment was conducted with a nationally-representative web-based survey research panel (GfK KnowledgePanel). Participants were randomly assigned to read different messages alone or in combination: 1) factual information about naloxone; 2) pre-emptive refutation of potential concerns about naloxone distribution; and 3) a sympathetic narrative about a mother whose daughter died of an opioid overdose. Participants were then asked if they support or oppose policies related to naloxone distribution. For each policy item, logistic regression models were used to test the effect of each message exposure compared with the no-exposure control group.
Results
The final sample consisted of 1,598 participants (completion rate: 72.6%). Factual information and the sympathetic narrative alone each led to higher support for training first responders to use naloxone, providing naloxone to friends and family members of people using opioids, and passing laws to protect people who administer naloxone. Participants receiving the combination of the sympathetic narrative and factual information, compared to factual information alone, were more likely to support all policies: providing naloxone to friends and family members (OR: 2.0 [95% CI: 1.4 to 2.9]), training first responders to use naloxone (OR: 2.0 [95% CI: 1.2 to 3.4]), passing laws to protect people if they administer naloxone (OR: 1.5 [95% CI: 1.04 to 2.2]), and passing laws to protect people if they call for medical help for an overdose (OR: 1.7 [95% CI: 1.2 to 2.5]).
Conclusions
All messages increased public support, but combining factual information and the sympathetic narrative was most effective. Public support for naloxone distribution can be improved through education and sympathetic portrayals of the population who stands to benefit from these policies.
C1 [Bachhuber, Marcus A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA 19104 USA.
[Bachhuber, Marcus A.; Barry, Colleen L.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Bachhuber, Marcus A.] Univ Penn, Robert Wood Johnson Fdn, Clin Scholars Program, Philadelphia, PA 19104 USA.
[McGinty, Emma E.; Kennedy-Hendricks, Alene; Barry, Colleen L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA.
[McGinty, Emma E.; Barry, Colleen L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA.
[Niederdeppe, Jeff] Cornell Univ, Dept Commun, Ithaca, NY USA.
RP Bachhuber, MA (reprint author), Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA 19104 USA.
EM marcus.bachhuber@gmail.com
OI Bachhuber, Marcus/0000-0002-5610-8382
FU American International Group, Inc.; National Institute on Drug Abuse
[R01DA026414]
FX This work was funded by an unrestricted research grant from American
International Group, Inc., and by the National Institute on Drug Abuse
(R01DA026414). The funding bodies had no role in the design and conduct
of the study; collection, management, analysis, and interpretation of
the data; preparation, review, or approval of the manuscript; or
decision to submit the manuscript for publication.
NR 49
TC 4
Z9 4
U1 1
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 1
PY 2015
VL 10
IS 7
AR e0130050
DI 10.1371/journal.pone.0130050
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CN1CG
UT WOS:000358153000050
PM 26132859
ER
PT J
AU Lange, DC
Glidden, D
Secemsky, EA
Ordovas, K
Deeks, SG
Martin, JN
Bolger, AF
Hsue, PY
AF Lange, David C.
Glidden, David
Secemsky, Eric A.
Ordovas, Karen
Deeks, Steven G.
Martin, Jeffrey N.
Bolger, Ann F.
Hsue, Priscilla Y.
TI Mitral Annular and Coronary Artery Calcification Are Associated with
Mortality in HIV-Infected Individuals
SO PLOS ONE
LA English
DT Article
ID BEAM COMPUTED-TOMOGRAPHY; ACUTE MYOCARDIAL-INFARCTION; ALL-CAUSE
MORTALITY; COMBINATION ANTIRETROVIRAL THERAPY;
IMMUNODEFICIENCY-VIRUS-INFECTION; INTIMA-MEDIA THICKNESS; VALVE
CALCIFICATION; PROGNOSTIC VALUE; PREDICTIVE-VALUE; CALCIUM SCORE
AB Background
HIV infection increases cardiovascular risk. Coronary artery calcification (CAC) and mitral annular calcification (MAC) identify patients at risk for cardiovascular disease (CVD). The purpose of this study was to examine the association between MAC, CAC and mortality in HIV-infected individuals.
Methods and Results
We studied 152 asymptomatic HIV-infected individuals with transthoracic echocardiography (TTE) and computed tomography (CT). MAC was identified on TTE using standardized criteria. Presence of CAC, CAC score and CAC percentiles were determined using the modified Agatston criteria. Mortality data was obtained from the Social Security and National Death Indices (SSDI/NDI). The median age was 49 years; 87% were male. The median duration of HIV was 16 years; 84% took antiretroviral therapy; 64% had an undetectable viral load. CVD risk factors included hypertension (35%), smoking (62%) and dyslipidemia (35%). Twenty-five percent of individuals had MAC, and 42% had CAC. Over a median follow-up of 8 years, 11 subjects died. Subjects with CAC had significantly higher mortality compared to those with MAC only or no MAC. The Harrell's C-statistic of CAC was 0.66 and increased to 0.75 when MAC was added (p = 0.05). MAC, prior CVD, age and HIV viral load were independently associated with higher age-and gender-adjusted CAC percentiles in an adjusted model (p < 0.05 for all).
Conclusion
In HIV patients, the presence of MAC, traditional risk factors and HIV viral load were independently associated with CAC. Presence of CAC and MAC may be useful in identifying HIV-infected individuals at higher risk for death.
C1 [Lange, David C.] Cedars Sinai Med Ctr, Dept Med, Div Cardiol, Los Angeles, CA 90048 USA.
[Glidden, David] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Secemsky, Eric A.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA.
[Ordovas, Karen] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA.
[Deeks, Steven G.] Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV, AIDS Posit Hlth Program, San Francisco, CA 94143 USA.
[Martin, Jeffrey N.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Bolger, Ann F.; Hsue, Priscilla Y.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Div Cardiol, San Francisco, CA 94143 USA.
RP Hsue, PY (reprint author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Div Cardiol, San Francisco, CA 94143 USA.
EM phsue@medsfgh.ucsf.edu
FU National Heart, Lung and Blood Institute [RO1 HL095130, RO1 HL091526]
FX This work was supported by the National Heart, Lung and Blood Institute
RO1 HL095130 (P.Y.H.) and the National Heart, Lung and Blood Institute
RO1 HL091526 (P.Y.H.).
NR 49
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 1
PY 2015
VL 10
IS 7
AR e0130592
DI 10.1371/journal.pone.0130592
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CN1CG
UT WOS:000358153000075
PM 26132465
ER
PT J
AU Kue, RC
Temin, ES
Weiner, SG
Gates, J
Coleman, MH
Fisher, J
Dyer, S
AF Kue, Ricky C.
Temin, Elizabeth S.
Weiner, Scott G.
Gates, Jonathan
Coleman, Melissa H.
Fisher, Jonathan
Dyer, Sophia
TI TOURNIQUET USE IN A CIVILIAN EMERGENCY MEDICAL SERVICES SETTING: A
DESCRIPTIVE ANALYSIS OF THE BOSTON EMS EXPERIENCE
SO PREHOSPITAL EMERGENCY CARE
LA English
DT Article
DE tourniquet; emergency medical services; trauma; hemorrhage
ID HEMORRHAGE CONTROL; BATTLEFIELD; SURVIVAL; EVENTS; TRAUMA
AB Introduction. Despite the resurgence of early tourniquet use for control of exsanguinating limb hemorrhage in the military setting, its appropriate role in civilian emergency medical services (EMS) has been less clear. Objective. To describe the experience of prehospital tourniquet use in an urban, civilian EMS setting. Methods. A retrospective review of EMS prehospital care reports was performed from January 1, 2005 to December 1, 2012. Data, including the time duration of prehospital tourniquet placement, EMS scene time, mechanisms of injury, and patient demographics, underwent descriptive analysis. Outcomes data for participating receiving hospitals were also reviewed. Results. Ninety-eight cases of prehospital tourniquet use were identified. The most common causes of injury were penetrating gunshot or stabbing wounds (67.4%, 66/98); 7.1% (7/98) of cases were due to blunt trauma; 23.5% (23/98) of cases were from non-traumatic hemorrhage related to uncontrolled hemodialysis shunt or wound bleeding; 45.4% (44/97) of cases were placed on a lower extremity; 54.6% (53/97) were placed on an upper extremity Placement was successful in hemorrhage control in 91% (87/95, 95%CI: 85.9-97.3%) of cases. The average prehospital tourniquet placement time was 14.9 minutes. Half of all tourniquet placements were performed by basic life support providers. Hospital follow-up was available for 96.9% (95/98) of cases. Of these, the tourniquet was removed by EMS in 3.2% (3/95), the emergency department in 54.7% (52/95), or in the operating room (OR) in 31.6% (30/95) of the time; 46.7% (14/30) of these OR cases had a documented vascular injury needing repair. Ten deaths with hospital follow-up data were identified, none of which were due to tourniquet use. There was one case of forearm numbness potentially due to nerve injury and one case with potential vascular complication, representing an overall complication rate of 2.1% (2/95). Conclusion. The early use of tourniquets for extremity hemorrhage in an urban civilian EMS setting appears to be safe, with complications occurring infrequently.
C1 [Kue, Ricky C.] City Boston Emergency Med Serv, Boston, MA USA.
[Kue, Ricky C.] Boston Univ, Sch Med, Dept Emergency Med, Boston, MA 02118 USA.
[Temin, Elizabeth S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA.
[Weiner, Scott G.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Emergency Med, Boston, MA 02115 USA.
[Gates, Jonathan] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Vasc & Endovascular Surg,Trauma Burns & Surg, Boston, MA 02115 USA.
[Coleman, Melissa H.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Trauma Burns & Surg Crit Care, Boston, MA 02115 USA.
[Fisher, Jonathan] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Emergency Med, Boston, MA 02215 USA.
RP Kue, RC (reprint author), Boston Emergency Med Serv, Res Training & Qual Improvement Div, 785 Albany St, Boston, MA 02118 USA.
EM KUE@bostonems.org
NR 23
TC 17
Z9 17
U1 1
U2 2
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1090-3127
EI 1545-0066
J9 PREHOSP EMERG CARE
JI Prehosp. Emerg. Care
PD JUL-SEP
PY 2015
VL 19
IS 3
BP 399
EP 404
DI 10.3109/10903127.2014.995842
PG 6
WC Emergency Medicine; Public, Environmental & Occupational Health
SC Emergency Medicine; Public, Environmental & Occupational Health
GA CN1OL
UT WOS:000358189200007
PM 25665102
ER
PT J
AU Traeger, L
AF Traeger, Lara
TI Developing a quantitative analytic plan that corresponds to study aims
and design
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Traeger, Lara] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD JUL
PY 2015
VL 24
SU 2
SI SI
MA S5-1
BP 9
EP 10
PG 2
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA CN2MG
UT WOS:000358255000018
ER
PT J
AU Greer, J
AF Greer, Joseph
TI Applications of behavioral theory and conceptual models in supportive
oncology research
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Greer, Joseph] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD JUL
PY 2015
VL 24
SU 2
SI SI
MA S5-3
BP 10
EP 10
PG 1
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA CN2MG
UT WOS:000358255000020
ER
PT J
AU Temel, J
AF Temel, Jennifer
TI Performing a successful supportive care clinical trial
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Temel, Jennifer] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD JUL
PY 2015
VL 24
SU 2
SI SI
MA S5-2
BP 10
EP 10
PG 1
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA CN2MG
UT WOS:000358255000019
ER
PT J
AU Patenaude, AF
AF Patenaude, Andrea Farkas
TI Prophylactic mastectomy decision-making: what help do women need?
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Patenaude, Andrea Farkas] Dana Farber Canc Inst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD JUL
PY 2015
VL 24
SU 2
SI SI
MA S8-4
BP 17
EP 17
PG 1
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA CN2MG
UT WOS:000358255000032
ER
PT J
AU Recklitis, C
AF Recklitis, Christopher
TI Surviving cancer but succumbing to suicide: what explains the risk in
long-term survivors?
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Recklitis, Christopher] Dana Farber Canc Inst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 2
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD JUL
PY 2015
VL 24
SU 2
SI SI
MA S11-1
BP 18
EP 19
PG 2
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA CN2MG
UT WOS:000358255000036
ER
PT J
AU Park, E
Perez, G
Hyland, K
Ostroff, J
AF Park, Elyse
Perez, Giselle
Hyland, Kelly
Ostroff, Jamie
TI Integrating tobacco treatment into Cancer Care: details of
implementation
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Park, Elyse] Mass Gen Hosp, Boston, MA USA.
[Perez, Giselle] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Hyland, Kelly] MGH, Boston, MA USA.
Mem Sloan Kettering Canc Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD JUL
PY 2015
VL 24
SU 2
SI SI
MA S19-3
BP 33
EP 34
PG 2
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA CN2MG
UT WOS:000358255000063
ER
PT J
AU Semmel, E
Salley, C
Hewitt, L
Gerhardt, CA
Patenaude, AF
Vannatta, KA
AF Semmel, Eric
Salley, Christina
Hewitt, Larissa
Gerhardt, Cynthia A.
Patenaude, Andrea Farkas
Vannatta, Kathryn A.
TI Deficits in executive functioning and effortful control: explaining
emotional adjustment in pediatric brain tumor survivors (PBTS)
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Semmel, Eric; Gerhardt, Cynthia A.] Nationwide Childrens Hosp, Res Inst, Columbus, OH USA.
[Salley, Christina] Mem Sloan Kettering Canc Ctr, New York, NY USA.
[Hewitt, Larissa; Patenaude, Andrea Farkas] Dana Farber Canc Inst, Boston, MA USA.
Res Inst Nationwide Childrens, Columbus, OH USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD JUL
PY 2015
VL 24
SU 2
SI SI
MA D-4
BP 49
EP 50
PG 2
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA CN2MG
UT WOS:000358255000092
ER
PT J
AU Meyer, F
Farrell, E
Yuppa, D
AF Meyer, Fremonta
Farrell, Elizabeth
Yuppa, David
TI When ethical dilemmas split teams: case studies of fertility
preservation in the context of metastatic cancer
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Meyer, Fremonta; Farrell, Elizabeth; Yuppa, David] Dana Farber Canc Inst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD JUL
PY 2015
VL 24
SU 2
SI SI
MA K-1
BP 64
EP 65
PG 2
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA CN2MG
UT WOS:000358255000117
ER
PT J
AU Souza, P
Fasciano, K
Camuso, K
AF Souza, Phoebe
Fasciano, Karen
Camuso, Kristen
TI Improving the quality of psychosocial care for young adults in medical
oncology
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Souza, Phoebe; Fasciano, Karen; Camuso, Kristen] Dana Farber Canc Inst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD JUL
PY 2015
VL 24
SU 2
SI SI
MA Q-2
BP 77
EP 78
PG 2
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA CN2MG
UT WOS:000358255000140
ER
PT J
AU Stagl, J
Lechner, S
Carver, C
Bouchard, L
Gudenkauf, L
Jutagir, D
Diaz, A
Yu, QL
Blomberg, B
Ironson, G
Gluck, S
Antoni, M
AF Stagl, Jamie
Lechner, Suzanne
Carver, Charles
Bouchard, Laura
Gudenkauf, Lisa
Jutagir, Devika
Diaz, Alain
Yu, Qilu
Blomberg, Bonnie
Ironson, Gail
Glueck, Stefan
Antoni, Michael
TI A randomized controlled trial of cognitive-behavioral stress management
in breast cancer: survival and recurrence at 11-year follow-up
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Stagl, Jamie] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA.
[Lechner, Suzanne] Univ Miami, Miller Sch Med, Coral Gables, FL 33124 USA.
[Carver, Charles; Bouchard, Laura; Gudenkauf, Lisa; Jutagir, Devika; Diaz, Alain; Blomberg, Bonnie; Ironson, Gail; Antoni, Michael] Univ Miami, Coral Gables, FL 33124 USA.
[Yu, Qilu] Westat Corp, Rockville, MD USA.
[Glueck, Stefan] Celgene Corp, Summit, NJ USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD JUL
PY 2015
VL 24
SU 2
SI SI
MA U-1
BP 86
EP 87
PG 2
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA CN2MG
UT WOS:000358255000154
ER
PT J
AU Park, E
Perez, G
Goldman, R
Foxtree-McGrath, C
Yang, MS
Suarez, J
Mutchler, J
AF Park, Elyse
Perez, Giselle
Goldman, Roberta
Foxtree-McGrath, Cheyenne
Yang, Mai See
Suarez, July
Mutchler, Jan
TI Development of a resiliency program for interpreters in cancer care
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Park, Elyse] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Perez, Giselle] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Yang, Mai See; Suarez, July; Mutchler, Jan] Univ Massachusetts Boston, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD JUL
PY 2015
VL 24
SU 2
SI SI
MA X-2
BP 94
EP 94
PG 1
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA CN2MG
UT WOS:000358255000167
ER
PT J
AU Fujisawa, D
Temel, J
Traeger, L
Greer, J
Lennes, I
Mimura, M
Pirl, W
AF Fujisawa, Daisuke
Temel, Jennifer
Traeger, Lara
Greer, Joseph
Lennes, Inga
Mimura, Masaru
Pirl, William
TI Psychological Factors at Early Stage of Treatment as Predictors of
Receiving Chemotherapy at End of Life
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Fujisawa, Daisuke; Mimura, Masaru] Keio Univ, Sch Med, Tokyo 108, Japan.
[Temel, Jennifer; Traeger, Lara; Greer, Joseph; Lennes, Inga; Pirl, William] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD JUL
PY 2015
VL 24
SU 2
SI SI
MA P1-11
BP 109
EP 109
PG 1
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA CN2MG
UT WOS:000358255000192
ER
PT J
AU Landa-Ramirez, E
Greer, J
Riveros-Rosas, A
Cardenas-Lopez, G
Vite-Sierra, A
Sanchez-Roman, S
Salado-Avila, MM
Templos-Esteban, LA
AF Landa-Ramirez, Edgar
Greer, Joseph
Riveros-Rosas, Angelica
Cardenas-Lopez, Georgina
Vite-Sierra, Ariel
Sanchez-Roman, Sofia
Salado-Avila, Ma. Magdalena
Templos-Esteban, Luz Adriana
TI Brief Home-based Cognitive Behavioral Therapy on Depression and Anxiety
in Mexicans Patients with Terminal Cancer: A Single-case Research
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Landa-Ramirez, Edgar] Univ Nacl Autonoma Mexico, Behav Med Program, Fac Psychol, Mexico City, DF, Mexico.
[Greer, Joseph] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Riveros-Rosas, Angelica; Cardenas-Lopez, Georgina; Vite-Sierra, Ariel] Univ Nacl Autonoma Mexico, Mexico City, DF, Mexico.
[Sanchez-Roman, Sofia] Inst Nacl Ciencias Med & Nutr INCMNSZ, Mexico City, DF, Mexico.
[Salado-Avila, Ma. Magdalena; Templos-Esteban, Luz Adriana] Hosp Gen Dr Manuel Gea Gonzalez, Ciudad De Mexico, DF, Mexico.
NR 0
TC 0
Z9 0
U1 4
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD JUL
PY 2015
VL 24
SU 2
SI SI
MA P1-71
BP 142
EP 142
PG 1
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA CN2MG
UT WOS:000358255000252
ER
PT J
AU Irwin, K
Park, E
Henderson, D
Pirl, W
AF Irwin, Kelly
Park, Elyse
Henderson, David
Pirl, William
TI Schizophrenia and Lung Cancer Disparities: Eligibility for Screening and
Access to Smoking Cessation
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Irwin, Kelly; Henderson, David; Pirl, William] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Park, Elyse] Mass Gen Hosp, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD JUL
PY 2015
VL 24
SU 2
SI SI
MA P1-119
BP 167
EP 167
PG 1
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA CN2MG
UT WOS:000358255000297
ER
PT J
AU Stagl, J
Fujisawa, D
Greer, J
Traeger, L
El-Jawahri, A
Temel, J
Pirl, W
AF Stagl, Jamie
Fujisawa, Daisuke
Greer, Joseph
Traeger, Lara
El-Jawahri, Areej
Temel, Jennifer
Pirl, William
TI Daytime Physical Activity and Emotional Distress in Advanced NSCLC
Patients
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Stagl, Jamie] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA.
[Fujisawa, Daisuke] Keio Univ, Sch Med, Tokyo 108, Japan.
[Greer, Joseph; Traeger, Lara; El-Jawahri, Areej; Temel, Jennifer; Pirl, William] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD JUL
PY 2015
VL 24
SU 2
SI SI
MA P1-131
BP 173
EP 174
PG 2
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA CN2MG
UT WOS:000358255000309
ER
PT J
AU Samsel, C
Loucas, C
Muriel, A
AF Samsel, Chase
Loucas, Caitlyn
Muriel, Anna
TI Treatment of Steroid-induced Mood Disorder in Co-morbid Developmentally
Delayed Youth with Cancer
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Samsel, Chase] Dana Farber & Boston Childrens Hosp, Canc & Blood Disorders Ctr, Boston, MA USA.
[Loucas, Caitlyn; Muriel, Anna] Dana Farber Canc Inst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD JUL
PY 2015
VL 24
SU 2
SI SI
MA P1-134
BP 175
EP 176
PG 2
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA CN2MG
UT WOS:000358255000312
ER
PT J
AU de Arruda-Colli, MNF
Zadeh, S
Muriel, A
Pellentier, W
Wiener, L
AF de Arruda-Colli, Marina Noronha Ferraz
Zadeh, Sima
Muriel, Anna
Pellentier, Wendy
Wiener, Lori
TI In Good Times and in Bad: What Strengthens a Parental Relationship
during a Child's Cancer Trajectory?
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [de Arruda-Colli, Marina Noronha Ferraz; Zadeh, Sima; Wiener, Lori] NCI, NIH, Bethesda, MD 20892 USA.
[Muriel, Anna] Dana Farber Canc Inst, Boston, MA USA.
[Pellentier, Wendy] Alberta Childrens Prov Gen Hosp, Calgary, AB, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD JUL
PY 2015
VL 24
SU 2
SI SI
MA P1-155
BP 185
EP 185
PG 1
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA CN2MG
UT WOS:000358255000331
ER
PT J
AU Zhou, E
Partridge, A
Blackmon, J
Morgan, E
Recklitis, C
AF Zhou, Eric
Partridge, Ann
Blackmon, Jaime
Morgan, Evan
Recklitis, Christopher
TI Feasibility of an iPad-administered Group-based Stress Management
Intervention
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Zhou, Eric; Partridge, Ann; Blackmon, Jaime; Morgan, Evan; Recklitis, Christopher] Dana Farber Canc Inst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD JUL
PY 2015
VL 24
SU 2
SI SI
MA P1-179
BP 197
EP 198
PG 2
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA CN2MG
UT WOS:000358255000355
ER
PT J
AU Zhou, E
Partridge, A
Recklitis, C
AF Zhou, Eric
Partridge, Ann
Recklitis, Christopher
TI Delivering an Adapted Group Cognitive Behavioral Treatment for Insomnia
in a Cancer Survivorship Program
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Zhou, Eric; Partridge, Ann; Recklitis, Christopher] Dana Farber Canc Inst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD JUL
PY 2015
VL 24
SU 2
SI SI
MA P1-180
BP 198
EP 198
PG 1
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA CN2MG
UT WOS:000358255000356
ER
PT J
AU Tucker-Seeley, R
Miller, M
Gagne, J
AF Tucker-Seeley, Reginald
Miller, Melecia
Gagne, Joshua
TI Household Financial Well-being and Navigating Cancer Care: A Qualitative
Study of Conceptualizing Financial Well-being among Social Workers and
Resource Specialists
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Tucker-Seeley, Reginald] Harvard Univ, Chan Sch Publ Hlth, Dana Farber Canc Inst, Cambridge, MA 02138 USA.
[Miller, Melecia; Gagne, Joshua] Dana Farber Canc Inst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD JUL
PY 2015
VL 24
SU 2
SI SI
MA P1-217
BP 218
EP 218
PG 1
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA CN2MG
UT WOS:000358255000392
ER
PT J
AU Carr, A
Traeger, L
Cashavelly, B
Pirl, W
AF Carr, Alaina
Traeger, Lara
Cashavelly, Barbara
Pirl, William
TI Inpatient Acute Medical Oncology Registered Nurses: Challenges and
Sources of Support
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Carr, Alaina; Traeger, Lara; Cashavelly, Barbara; Pirl, William] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD JUL
PY 2015
VL 24
SU 2
SI SI
MA P2-42
BP 251
EP 252
PG 2
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA CN2MG
UT WOS:000358255000454
ER
PT J
AU Braun, I
AF Braun, Ilana
TI Systematic Review of Marijuana's Medicinal Aspects
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Braun, Ilana] Dana Farber Canc Inst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD JUL
PY 2015
VL 24
SU 2
SI SI
MA P2-46
BP 253
EP 254
PG 2
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA CN2MG
UT WOS:000358255000458
ER
PT J
AU Loucas, C
Brand, S
Wiener, L
Zadeh, S
AF Loucas, Caitlyn
Brand, Sarah
Wiener, Lori
Zadeh, Sima
TI Preparing Youth with Cancer for Amputation: A Systematic Review
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Loucas, Caitlyn; Brand, Sarah] Dana Farber Canc Inst, Boston, MA USA.
[Wiener, Lori; Zadeh, Sima] NCI, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD JUL
PY 2015
VL 24
SU 2
SI SI
MA P2-60
BP 261
EP 261
PG 1
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA CN2MG
UT WOS:000358255000472
ER
PT J
AU Muriel, A
Loucas, C
White, M
AF Muriel, Anna
Loucas, Caitlyn
White, Matthew
TI Psychosocial Screening and Predictors of Mood Disturbance in Parents of
children with Cancer
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Muriel, Anna; Loucas, Caitlyn] Dana Farber Canc Inst, Boston, MA USA.
[White, Matthew] Boston Childrens Hosp, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD JUL
PY 2015
VL 24
SU 2
SI SI
MA P2-98
BP 279
EP 280
PG 2
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA CN2MG
UT WOS:000358255000509
ER
PT J
AU Meyer, F
Braun, I
AF Meyer, Fremonta
Braun, Ilana
TI Impact of Fertility Preservation on Psychological Outcomes in Cancer
Patients and Survivors: A Systematic Review
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Meyer, Fremonta; Braun, Ilana] Dana Farber Canc Inst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD JUL
PY 2015
VL 24
SU 2
SI SI
MA P2-151
BP 308
EP 309
PG 2
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA CN2MG
UT WOS:000358255000562
ER
PT J
AU Perez, G
Kirchhoff, A
Krull, K
Leisenring, W
Recklitis, C
Armstrong, G
Nathan, P
Robison, L
Kuhlthau, K
Park, E
AF Perez, Giselle
Kirchhoff, Anne
Krull, Kevin
Leisenring, Wendy
Recklitis, Christopher
Armstrong, Gregory
Nathan, Paul
Robison, Leslie
Kuhlthau, Karen
Park, Elyse
TI Mental Health Care Insurance Coverage, Utilization, and Perceived Value
among Childhood Cancer Survivors: A Report from the Childhood Cancer
Survivor Study (CCSS)
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Perez, Giselle; Kuhlthau, Karen; Park, Elyse] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Kirchhoff, Anne] Huntsman Canc Inst, Salt Lake City, UT USA.
[Krull, Kevin; Armstrong, Gregory; Robison, Leslie] St Jude Childrens Res Hosp, Memphis, TN USA.
[Leisenring, Wendy] Fred Hutchinson Canc Res Ctr, Memphis, TN USA.
[Recklitis, Christopher] Dana Farber Canc Inst, Boston, MA USA.
[Nathan, Paul] Hosp Sick Children, Toronto, ON M5G 1X8, Canada.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD JUL
PY 2015
VL 24
SU 2
SI SI
MA P2-154
BP 310
EP 310
PG 1
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA CN2MG
UT WOS:000358255000565
ER
PT J
AU Hyland, K
Stagl, J
Lennes, I
Pirl, W
Perez, G
Park, E
AF Hyland, Kelly
Stagl, Jamie
Lennes, Inga
Pirl, William
Perez, Giselle
Park, Elyse
TI What Cancer Survivors Want in Survivorship Care: A Qualitative
Exploration of Preferences for Information and Resources
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Hyland, Kelly; Lennes, Inga; Pirl, William; Perez, Giselle; Park, Elyse] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Stagl, Jamie] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD JUL
PY 2015
VL 24
SU 2
SI SI
MA P2-163
BP 315
EP 315
PG 1
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA CN2MG
UT WOS:000358255000574
ER
PT J
AU Nisotel, L
Fishbein, J
MacDonald, J
Amoyal, N
Greer, J
AF Nisotel, Lauren
Fishbein, Joel
MacDonald, James
Amoyal, Nicole
Greer, Joseph
TI A Systematic Review of Interventions for Adherence to Oral Chemotherapy
in Patients with Cancer
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Nisotel, Lauren; Fishbein, Joel; MacDonald, James; Amoyal, Nicole] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA.
[Greer, Joseph] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD JUL
PY 2015
VL 24
SU 2
SI SI
MA P2-180
BP 325
EP 325
PG 1
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA CN2MG
UT WOS:000358255000591
ER
PT J
AU Manchikanti, L
Hirsch, JA
AF Manchikanti, Laxmaiah
Hirsch, Joshua A.
TI Untitled
SO SPINE
LA English
DT Letter
C1 [Manchikanti, Laxmaiah] Pain Management Ctr Paducah, Dept Anesthesiol & Perioperat Med, Paducah, KY 42003 USA.
[Manchikanti, Laxmaiah] Univ Louisville, Louisville, KY 40292 USA.
[Hirsch, Joshua A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Hirsch, Joshua A.] Harvard Univ, Sch Med, Boston, MA USA.
RP Manchikanti, L (reprint author), Pain Management Ctr Paducah, Dept Anesthesiol & Perioperat Med, Paducah, KY 42003 USA.
NR 3
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0362-2436
EI 1528-1159
J9 SPINE
JI SPINE
PD JUL 1
PY 2015
VL 40
IS 13
BP 1054
EP 1054
DI 10.1097/BRS.0000000000000950
PG 1
WC Clinical Neurology; Orthopedics
SC Neurosciences & Neurology; Orthopedics
GA CM8JJ
UT WOS:000357946000014
PM 25909349
ER
PT J
AU Katon, JG
Washington, DL
Cordasco, KM
Reiber, GE
Yano, EM
Zephyrin, LC
AF Katon, Jodie G.
Washington, Donna L.
Cordasco, Kristina M.
Reiber, Gayle E.
Yano, Elizabeth M.
Zephyrin, Laurie C.
TI Prenatal Care for Women Veterans Who Use Department of Veterans Affairs
Health Care
SO WOMENS HEALTH ISSUES
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; PRETERM BIRTH; MEDICAL-CENTER;
MENTAL-HEALTH; VA; PREGNANCY; RISK; AVAILABILITY; AFGHANISTAN;
DEPRESSION
AB Objective: The number of women Veterans of childbearing age enrolling in Department of Veterans Affairs (VA) health care is increasing. Our objective was to describe characteristics of women veterans and resumption of VA care after delivery by use of VA prenatal benefits.
Study design: We used data from the National Survey of Women Veterans, a population-based survey. VA-eligible women veterans with at least one live birth who had ever used VA and were younger than 45 years when VA pre-natal benefits became available were categorized based on self-reported receipt of VA prenatal benefits. Characteristics of by use of VA prenatal benefits were compared using chi(2) tests with Rao-Scott adjustment. All analyses used sampling weights.
Results: In our analytic sample, of those who potentially had the opportunity to use VA prenatal benefits, 25% used these benefits and 75% did not. Compared with women veterans not using VA prenatal benefits, those who did were more likely to be 18 to 24 years old (39.9% vs. 3.7%; p = .03), and more likely to have self-reported diagnosed depression (62.5% vs. 24.5%; p = .02) and current depression or posttraumatic stress disorder (PTSD) symptoms (depression, 46.1% vs. 8% [ p - .02]; PTSD, 52.5% vs. 14.8% [ p - .02]). Compared with women veterans not using VA prenatal benefits, those who did were more likely to resume VA use after delivery (p < .001).
Conclusion: Pregnant women veterans who use VA prenatal benefits are a high-risk group. Among those who opt not to use these benefits, pregnancy is an important point of attrition from VA health care, raising concerns regarding retention of women veterans within VA and continuity of care. Published by Elsevier Inc.
C1 [Katon, Jodie G.; Reiber, Gayle E.] VA Med Ctr, HSR&D, Dept Vet Affairs VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Katon, Jodie G.; Zephyrin, Laurie C.] VA Cent Off, Womens Vet Hlth Serv, Off Patient Serv, Washington, DC USA.
[Katon, Jodie G.; Reiber, Gayle E.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA.
[Washington, Donna L.; Cordasco, Kristina M.; Yano, Elizabeth M.] VA Greater Angeles Healthcare Syst, VA HSR&D Ctr Study Healthcare Innovat Implement &, North Hills, CA USA.
[Washington, Donna L.; Cordasco, Kristina M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Reiber, Gayle E.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA.
[Yano, Elizabeth M.] Univ Calif Los Angeles, Jonathan & Karin Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA.
[Zephyrin, Laurie C.] NYU, Dept Obstet & Gynecol, Langone Sch Med, New York, NY 10016 USA.
RP Katon, JG (reprint author), VA Med Ctr, 1660 S Columbian Way S-152, Seattle, WA 98108 USA.
EM jkaton@u.washington.edu
FU Department of Veterans Affairs (VA), Women's Health Services in the
Office of Patient Care Services; Health Services Research and
Development (HSRD) Service [SDR-08-270]; Office of Academic
Affiliations' Associated Health Postdoctoral Fellowship [TTP 61-026]; VA
HSR&D Senior Research Career Scientist awards [RCS-98-353, RCS-05-195]
FX This study used data from the National Survey of Women Veterans, which
was funded by the Department of Veterans Affairs (VA), Women's Health
Services in the Office of Patient Care Services and the Health Services
Research and Development (HSR&D) Service (#SDR-08-270). Dr. Katon was
supported by an Office of Academic Affiliations' Associated Health
Postdoctoral Fellowship (#TTP 61-026). Drs. Reiber (#RCS-98-353) and
Yano (#RCS-05-195) are supported by VA HSR&D Senior Research Career
Scientist awards. The authors gratefully acknowledge Su Sun Mor for data
analysis support and Mark Canning for project management.
NR 24
TC 1
Z9 1
U1 2
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1049-3867
EI 1878-4321
J9 WOMEN HEALTH ISS
JI Womens Health Iss.
PD JUL-AUG
PY 2015
VL 25
IS 4
BP 377
EP 381
DI 10.1016/j.whi.2015.03.004
PG 5
WC Public, Environmental & Occupational Health; Women's Studies
SC Public, Environmental & Occupational Health; Women's Studies
GA CN7HK
UT WOS:000358604800010
PM 25935821
ER
PT J
AU Slane, JD
Levine, MD
AF Slane, Jennifer D.
Levine, Michele D.
TI Association of Restraint and Disinhibition to Gestational Weight Gain
among Pregnant Former Smokers
SO WOMENS HEALTH ISSUES
LA English
DT Article
ID POSTPARTUM SMOKING RELAPSE; BODY-MASS INDEX; DIETARY RESTRAINT; EATING
BEHAVIORS; WOMEN; CESSATION; BIRTH; INTERVENTIONS; MANAGEMENT; BRAZIL
AB Introduction: Gaining excessive weight during pregnancy is associated with immediate maternal and fetal complications as well as longer term obesity. Prepregnancy body mass index, age, and smoking cessation have been related to gestational weight gain (GWG); however, less is known about how eating behaviors, that may be amenable to modification and have been related to weight gain outside of pregnancy, affect GWG.
Methods: The present study evaluated the relationship of dietary restraint and disinhibition to GWG in a sample of women (n = 248) who quit smoking before or early in pregnancy. Women self-reported height and prepregnancy weight during their third trimester. GWG was calculated by subtracting prepregnancy weight from third trimester weight. The Three-Factor Eating Questionnaire assessed restraint and disinhibition.
Results: Average GWG was 14.60 (+/- 7.64) kg and 47% of women had a GWG greater than the Institute of Medicine recommendations. Linear regression models were used to examine restraint and disinhibition as correlates of GWG, and multinomial logistic regressions were utilized to determine whether eating behaviors were associated with inadequate or excessive GWG. Restraint was associated positively with total GWG, but disinhibition was not associated with GWG. Thus, conscious attempts to restrict intake were associated with GWG beyond the influence of covariates.
Conclusion: These findings highlight the potential influence of modifiable eating behaviors on GWG and demonstrate the need for additional research to determine how these behaviors relate to GWG over the course of pregnancy. Copyright (C) 2015 by the Jacobs Institute of Women's Health. Published by Elsevier Inc.
C1 [Slane, Jennifer D.] VA Pittsburgh Healthcare Syst, VISN 4 Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA.
[Slane, Jennifer D.; Levine, Michele D.] Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA 15213 USA.
RP Levine, MD (reprint author), Univ Pittsburgh, Med Ctr, 3811 OHara St, Pittsburgh, PA 15213 USA.
EM levinem@upmc.edu
FU NIH [K01 DA15396, R01 DA021608]
FX NIH grants: K01 DA15396 and R01 DA021608; PI: Michele Levine, PhD. The
authors do not have any financial conflicts of interest to disclose.
This material is the result of work supported, in part, with resources
and the use of facilities at the VISN 4 Mental Illness Research,
Education, and Clinical Center, VA Pittsburgh Healthcare System. The
contents of this article do not represent the views of the Department of
Veterans Affairs or the United States Government.
NR 33
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1049-3867
EI 1878-4321
J9 WOMEN HEALTH ISS
JI Womens Health Iss.
PD JUL-AUG
PY 2015
VL 25
IS 4
BP 390
EP 395
DI 10.1016/j.whi.2015.03.005
PG 6
WC Public, Environmental & Occupational Health; Women's Studies
SC Public, Environmental & Occupational Health; Women's Studies
GA CN7HK
UT WOS:000358604800012
PM 26048757
ER
PT J
AU Drapkin, ML
Eddie, D
Buffington, AJ
McCrady, BS
AF Drapkin, Michelle L.
Eddie, David
Buffington, Angela J.
McCrady, Barbara S.
TI Alcohol-Specific Coping Styles of Adult Children of Individuals with
Alcohol Use Disorders and Associations with Psychosocial Functioning
SO ALCOHOL AND ALCOHOLISM
LA English
DT Article
ID PARENTAL ALCOHOL; COMMUNITY SAMPLE; FAMILY-HISTORY; YOUNG-ADULTS;
PERSONALITY; DRUG; LIFE; DRINKING; EVENTS; SYMPTOMATOLOGY
AB Parental alcohol use disorders (AUDs) have been conceptualized as a chronic stressor that can lead to deleterious long-term outcomes in children of individuals with AUDs. Yet, while many individuals are detrimentally affected by their parents' problematic alcohol use, and go on to manifest psychological problems, others do not. How individuals cope with the stress of having a parent with an AUD is believed to be an important moderator of this differential outcome. This study assessed whether individuals' alcohol-specific coping styles predicted alcohol use, positive or negative life events, and depression, using a sample of 465 college students, of whom 20% were adult children of individuals with alcohol use disorders, colloquially known as adult children of alcoholics (ACOAs), and a battery of well-validated, self-report measures. Participant ACOAs reported less 'engaged' and 'total' alcohol-specific coping strategies and more 'withdrawal' alcohol-specific coping strategies than their non adult children of alcoholics (NACOAs) counterparts. Across participants, women reported more 'engaged', 'tolerant/inactive', and 'total' coping than men. Although ACOAs reported significantly more negative life events, which predicted more passive coping styles, they did not differ significantly from NACOAs on measures of problematic alcohol use or depression, supporting theories of resilience in ACOAs regardless of their alcohol-specific coping styles. For NACOAs, 'tolerant' coping predicted greater depression and alcohol-related problems; 'engaged' coping predicted fewer alcohol problems. Results suggest that ACOAs cope differently with problematic alcohol use among relatives and friends compared with NACOAs and are more likely to experience negative life events. Additionally, alcohol-related coping strategies have more predictive utility in NACOAs than ACOAs.
C1 [Drapkin, Michelle L.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Drapkin, Michelle L.] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA.
[Eddie, David] Rutgers State Univ, Ctr Alcohol Studies, New Brunswick, NJ USA.
[Buffington, Angela J.] Fielding Grad Univ, Sch Psychol, Santa Barbara, CA USA.
[McCrady, Barbara S.] Univ New Mexico, Ctr Alcoholism Substance Abuse & Addict, Albuquerque, NM 87131 USA.
RP Drapkin, ML (reprint author), Univ Penn, Dept Psychiat, Philadelphia VA Med Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA.
EM michelledrapkin@gmail.com
NR 39
TC 0
Z9 0
U1 4
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0735-0414
EI 1464-3502
J9 ALCOHOL ALCOHOLISM
JI Alcohol Alcohol.
PD JUL-AUG
PY 2015
VL 50
IS 4
BP 463
EP 469
DI 10.1093/alcalc/agv023
PG 7
WC Substance Abuse
SC Substance Abuse
GA CM7JF
UT WOS:000357867100014
PM 25802055
ER
PT J
AU Spracklen, CN
Saftlas, AF
Triche, EW
Bjonnes, A
Keating, B
Saxena, R
Breheny, PJ
Dewan, AT
Robinson, JG
Hoh, J
Ryckman, KK
AF Spracklen, Cassandra N.
Saftlas, Audrey F.
Triche, Elizabeth W.
Bjonnes, Andrew
Keating, Brendan
Saxena, Richa
Breheny, Patrick J.
Dewan, Andrew T.
Robinson, Jennifer G.
Hoh, Josephine
Ryckman, Kelli K.
TI Genetic Predisposition to Dyslipidemia and Risk of Preeclampsia
SO AMERICAN JOURNAL OF HYPERTENSION
LA English
DT Article
DE blood pressure; dyslipidemia; genetic epidemiology; genetic risk score;
hypertension; preeclampsia
ID GENOME-WIDE ASSOCIATION; METAANALYSIS; HYPERTENSION; ECLAMPSIA;
PREGNANCY; COMMON; WOMEN; PATHOGENESIS; POPULATION; VARIANTS
AB BACKGROUND
Large epidemiologic studies support the role of dyslipidemia in preeclampsia; however, the etiology of preeclampsia or whether dyslipidemia plays a causal role remains unclear. We examined the association between the genetic predisposition to dyslipidemia and risk of preeclampsia using validated genetic markers of dyslipidemia.
METHODS
Preeclampsia cases (n = 164) and normotensive controls (n = 110) were selected from live birth certificates to nulliparous Iowa women during the period August 2002 to May 2005. Disease status was verified by medical chart review. Genetic predisposition to dyslipidemia was estimated by 4 genetic risk scores (GRS) (total cholesterol (TC), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), and triglycerides) on the basis of established loci for blood lipids. Logistic regression analyses were used to evaluate the relationships between each of the 4 genotype scores and preeclampsia. Replication analyses were performed in an independent, US population of preeclampsia cases (n = 516) and controls (n = 1,097) of European ancestry.
RESULTS
The GRS related to higher levels of TC, LDL-C, and triglycerides demonstrated no association with the risk of preeclampsia in either the Iowa or replication population. The GRS related to lower HDL-C was marginally associated with an increased risk for preeclampsia (odds ratio (OR) = 1.03, 95% confidence interval (CI) = 0.99-1.07; P = 0.10). In the independent replication population, the association with the HDL-C GRS was also marginally significant (OR = 1.03, 95% CI: 1.00-1.06; P = 0.04).
CONCLUSIONS
Our data suggest a potential effect between the genetic predisposition to dyslipidemic levels of HDL-C and an increased risk of preeclampsia, and, as such, suggest that dyslipidemia may be a component along the causal pathway to preeclampsia.
C1 [Spracklen, Cassandra N.; Saftlas, Audrey F.; Robinson, Jennifer G.; Ryckman, Kelli K.] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA 52242 USA.
[Triche, Elizabeth W.] Brown Univ, Sch Publ Hlth, Dept Epidemiol, Providence, RI 02912 USA.
[Bjonnes, Andrew; Saxena, Richa] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Bjonnes, Andrew; Saxena, Richa] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Bjonnes, Andrew; Saxena, Richa] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
[Keating, Brendan] Univ Penn, Perelman Sch Med, Penn Transplant Inst, Dept Surg, Philadelphia, PA 19104 USA.
[Keating, Brendan] Childrens Hosp Philadelphia, Abramson Res Ctr, Ctr Appl Genom, Philadelphia, PA 19104 USA.
[Breheny, Patrick J.] Univ Iowa, Coll Publ Hlth, Dept Biostat, Iowa City, IA USA.
[Dewan, Andrew T.] Yale Univ, Sch Publ Hlth, Div Chron Dis Epidemiol, New Haven, CT USA.
[Hoh, Josephine] Yale Univ, Sch Publ Hlth, Dept Environm Hlth Sci, New Haven, CT USA.
RP Ryckman, KK (reprint author), Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA 52242 USA.
EM kelli-ryckman@uiowa.edu
FU National Institute of Child Health and Human Development, National
Institutes of Health [R01 HD32579]; Verto Institute; Gertie Marx Grant
from the Society for Obstetric Anesthesia and Perinatology
FX The SOPHIA study was supported by the National Institute of Child Health
and Human Development, National Institutes of Health (R01 HD32579), and
the Verto Institute. The replication study was funded in part by a
Gertie Marx Grant from the Society for Obstetric Anesthesia and
Perinatology.
NR 37
TC 4
Z9 4
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0895-7061
EI 1941-7225
J9 AM J HYPERTENS
JI Am. J. Hypertens.
PD JUL
PY 2015
VL 28
IS 7
BP 915
EP 923
DI 10.1093/ajh/hpu242
PG 9
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA CM7JC
UT WOS:000357866800011
PM 25523295
ER
PT J
AU Orlov, S
Cherney, DZI
Pop-Busui, R
Lovblom, LE
Ficociello, LH
Smiles, AM
Warram, JH
Krolewski, AS
Perkins, BA
AF Orlov, Steven
Cherney, David Z. I.
Pop-Busui, Rodica
Lovblom, Leif E.
Ficociello, Linda H.
Smiles, Adam M.
Warram, James H.
Krolewski, Andrzej S.
Perkins, Bruce A.
TI Cardiac Autonomic Neuropathy and Early Progressive Renal Decline in
Patients with Nonmacroalbuminuric Type 1 Diabetes
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID GLOMERULAR-FILTRATION-RATE; HEART-RATE-VARIABILITY; BLOOD-PRESSURE;
UNITED-STATES; MICROALBUMINURIA; DYSFUNCTION; RISK; KIDNEY;
COMPLICATIONS; ALBUMINURIA
AB Background and objectives Cardiac autonomic neuropathy predicts future adverse renal outcomes in the general population. This study sought to determine its relationship withearly progressive renal decline in type 1 diabetes.
Design, setting, participants, & measurements A subset of participants with normoalbuminutia (n=204) or microalbumimuia (n=166) from the First Joslin Kidney Study underwent assessment for cardiac autonomic neuropathy using heart rate variability during baseline visits performed from January 1991 to April1992. Cardiac autonomic neuropathy was defined as an R-R variation (mean circular resultant) <20. Participants also had baseline and follow-up measurement of eGFR. Early progressive renal decline was evaluated according to two definitions: early GFR loss (slope of eGFR estimated by cystatin C <-3.3%/year) and incident advanced CKD (stage >= 3 defined by eGFR [calculated by Modification of Diet in Renal Disease method] <60 ml/min per 1.73 m(2)). Association with baseline cardiac autonomic neuropathy was assessed by adjusted logistic regression and Cox proportional hazards.
Results Among the 370 participants, 47 (13%) had baseline cardiac autonomic neuropathy, 51 (14%) had early GFR loss, and 68(18%) had incident advanced CKD over a median 14-year follow-up. Early GFR loss occurred in 15 (32%) of the 47 patients with baseline autonomic neuropathy and in 32 (10%) of the 323 without baseline autonomic neuropathy (P<0.001). Baseline autonomic neuropathy was strongly associated with odds of early GFR loss (adjusted odds ratio, 4.09; 95% confidence interval, 1.65 to 10.12; P=0.002). Incident advanced CKD was observed in 22 (47%) of those with baseline autonomic neuropathy and 46 (14%) of those without baseline autonomic neuropathy (P<0.001). Autonomic neuropathy was independently associated with incident advanced CKD (adjusted hazard ratio, 2.76; 95% confidence interval, 1.44 to 5.30; P=0.002).
Conclusions Cardiac autonomic neuropathy was a strong independent predictor of the long-term risk of early progressive renal decline in type 1 diabetes. Future research should explore the mechanisms by which autonomic neuropathy may be associated with renal function loss.
C1 [Orlov, Steven; Lovblom, Leif E.; Perkins, Bruce A.] Univ Toronto, Dept Med, Mt Sinai Hosp, Div Endocrinol & Metab, Toronto, ON M5T 3L9, Canada.
[Cherney, David Z. I.] Univ Toronto, Toronto Gen Hosp, Div Nephrol, Toronto, ON M5T 3L9, Canada.
[Pop-Busui, Rodica] Univ Michigan, Univ Michigan Hlth Syst, Dept Internal Med, Div Metab Endocrinol & Diabet, Ann Arbor, MI 48109 USA.
[Ficociello, Linda H.; Smiles, Adam M.; Warram, James H.; Krolewski, Andrzej S.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Genet & Epidemiol,Res Div,Dept Med, Boston, MA 02115 USA.
RP Perkins, BA (reprint author), Univ Toronto, Leadership Sinai Ctr Diabet, Mt Sinai Hosp, Div Endocrinol & Metab, L5-210,60 Murray St,Mail Box 16, Toronto, ON M5T 3L9, Canada.
EM bperkins@mtsinai.on.ca
FU National Institutes of Health [R01-DK41526]; University of Toronto
Internal Medicine Program
FX This research was supported by the National Institutes of Health grant
(R01-DK41526) to A.S.K. S.O. was supported by a Residency Research
Elective from the University of Toronto Internal Medicine Program.
NR 49
TC 4
Z9 4
U1 0
U2 2
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
EI 1555-905X
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD JUL
PY 2015
VL 10
IS 7
BP 1136
EP 1144
DI 10.2215/CJN.11441114
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA CM5UJ
UT WOS:000357754200007
PM 26092828
ER
PT J
AU Lakkis, FG
Palevsky, PM
AF Lakkis, Fadi G.
Palevsky, Paul M.
TI A New CJASN Series: Renal Immunology for the Clinician
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Editorial Material
C1 [Lakkis, Fadi G.] Univ Pittsburgh, Sch Med, Thomas E Starzl Transplantat Inst, Pittsburgh, PA USA.
[Lakkis, Fadi G.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA.
[Lakkis, Fadi G.] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA USA.
[Lakkis, Fadi G.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA.
[Palevsky, Paul M.] Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA.
[Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA.
RP Palevsky, PM (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Mail Stop 111 F-U,Univ Dr, Pittsburgh, PA 15240 USA.
EM ppalevsky@cjasn.org
OI Palevsky, Paul/0000-0002-7334-5400
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
EI 1555-905X
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD JUL
PY 2015
VL 10
IS 7
BP 1273
EP 1273
DI 10.2215/CJN.03870415
PG 1
WC Urology & Nephrology
SC Urology & Nephrology
GA CM5UJ
UT WOS:000357754200020
PM 26153102
ER
PT J
AU Haggerty, G
Siefert, CJ
Sinclair, SJ
Zodan, J
Babalola, R
Blais, MA
AF Haggerty, Greg
Siefert, Caleb J.
Sinclair, Samuel J.
Zodan, Jennifer
Babalola, Ronke
Blais, Mark A.
TI Validation of a Measure of Alliance for an Adolescent Inpatient Setting
SO CLINICAL PSYCHOLOGY & PSYCHOTHERAPY
LA English
DT Article
DE Adolescents; Alliance; Inpatient; I-TAS; SOS-10
ID THERAPEUTIC ALLIANCE; MENTAL-HEALTH; PSYCHOTHERAPY
AB The link between alliance and treatment outcome is robust. Nevertheless, few, if any, self-report measures exist to assess the alliance between hospitalized adolescents and their treatment team as a whole. The present study looks to extend the use of a brief self-report measure of inpatient treatment alliance designed for adult inpatients to be used with adolescents. The scale is designed incorporating items that tap the three factors of alliance (bond, goals and collaboration) to assess the alliance that the patient has with his or her treatment team. Our results show that the Inpatient-Treatment Alliance Scale is unifactoral, shows good psychometrics and is linked in theoretically meaningful ways to global clinician ratings of engagement in individual psychotherapy. Copyright (c) 2014 John Wiley & Sons, Ltd.
Key Practitioner Message Inpatient treatment of adolescents requires the assessment of alliance to be between the patient and his or her treatment team rather than an individual clinician. Assessment of the alliance can benefit clinicians treating hospitalized adolescents especially because these patients are difficult to engage with in treatment. This study shows that the Inpatient-Treatment Alliance Scale is a promising measure for assessing treatment alliance on an adolescent inpatient setting.
C1 [Haggerty, Greg; Zodan, Jennifer; Babalola, Ronke] Nassau Univ, Med Ctr, Von Tauber Inst Global Psychiat, Massapequa Pk, NY 11762 USA.
[Siefert, Caleb J.] Univ Michigan, Dearborn, MI 48128 USA.
[Sinclair, Samuel J.; Blais, Mark A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
RP Haggerty, G (reprint author), Nassau Univ, Med Ctr, Von Tauber Inst Global Psychiat, 320 1st Ave, Massapequa Pk, NY 11762 USA.
EM Ghag541@aol.com
FU American Psychoanalytic Association; National Institute of Mental Health
Grant [1R21MH097781-01A1]
FX This study was funded in part by a grant awarded to the first author
from the American Psychoanalytic Association and by the National
Institute of Mental Health Grant No. 1R21MH097781-01A1 received by the
first author.
NR 19
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1063-3995
EI 1099-0879
J9 CLIN PSYCHOL PSYCHOT
JI Clin. Psychol. Psychother.
PD JUL-AUG
PY 2015
VL 22
IS 4
BP 357
EP 363
DI 10.1002/cpp.1901
PG 7
WC Psychology, Clinical
SC Psychology
GA CM8OQ
UT WOS:000357961900006
PM 24771710
ER
PT J
AU Nguyen, T
Alsarraj, A
El-Serag, HB
AF Nguyen, T.
Alsarraj, A.
El-Serag, H. B.
TI Brief report: the length of newly diagnosed Barrett's esophagus may be
decreasing
SO DISEASES OF THE ESOPHAGUS
LA English
DT Article
DE Barrett's esophagus; epidemiological study; esophageal adenocarcinoma;
length; risk factor; Veterans Affair
ID HIGH-GRADE DYSPLASIA; RISK-FACTORS; PRAGUE C; ADENOCARCINOMA; THERAPY;
TRENDS; METAANALYSIS; VALIDATION; CRITERIA; CANCER
AB Few studies have examined the temporal trends of length in newly diagnosed Barrett's esophagus (BE) and arrived at conflicting results. The aim of this study was to identify whether there has been a change over time in the length of BE at the time of diagnosis. This is a retrospective, single-center, observational study from Houston, Texas on newly diagnosed BE between 2008 and 2013. All cases were defined by the presence of endoscopically visible BE and histologic confirmation of intestinalized columnar epithelium with goblet cells. The length of BE was measured using the Prague classification. We examined temporal changes in 1-year intervals in the length of BE at the time of diagnosis. Both the frequency and mean length of BE at diagnosis seemed to decrease over time from February 2008 to July 2013. The proportion of patients diagnosed with BE 3cm per year declined during the study period, while the proportion of patients with BE 1 and <3cm increased, and those with <1cm remained stable. The mean age and the gender of patients diagnosed with BE 3cm did not differ significantly by BE length or year of diagnosis. The mean length of newly diagnosed BE may be decreasing as a result of a decline in BE 3cm. These observations cannot be explained by changes in age and gender.
C1 [Nguyen, T.; El-Serag, H. B.] Baylor Coll Med, Houston VA HSR&D Ctr Excellence, Houston, TX 77030 USA.
[El-Serag, H. B.] Baylor Coll Med, Dept Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
[El-Serag, H. B.] Baylor Coll Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA.
[Nguyen, T.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
RP El-Serag, HB (reprint author), Michael E DeBakey VA Med Ctr, 2002 Holcombe Blvd 152, Houston, TX 77030 USA.
EM hasheme@bcm.edu
FU VA HSR&D Center for Innovations in Quality, Effectiveness and Safety at
the Michael E. DeBakey VA Medical Center, Houston, TX, USA [CIN 13-413]
FX This research reported here was supported in part with resources at the
VA HSR&D Center for Innovations in Quality, Effectiveness and Safety
(#CIN 13-413), at the Michael E. DeBakey VA Medical Center, Houston, TX,
USA.
NR 22
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1120-8694
EI 1442-2050
J9 DIS ESOPHAGUS
JI Dis. Esophagus
PD JUL
PY 2015
VL 28
IS 5
BP 418
EP 421
DI 10.1111/dote.12216
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CM8LY
UT WOS:000357954000003
PM 24708395
ER
PT J
AU Taudorff, EH
Lerche, CM
Vissing, AC
Philipsen, PA
Hannibal, J
D'Alvise, J
Hansen, SH
Janfelt, C
Paasch, U
Anderson, RR
Haedersdal, M
AF Taudorff, Elisabeth Hjardem
Lerche, Catharina Margrethe
Vissing, Anne-Cathrine
Philipsen, Peter Alshede
Hannibal, Jens
D'Alvise, Janina
Hansen, Steen Honore
Janfelt, Christian
Paasch, Uwe
Anderson, Richard Rox
Haedersdal, Merete
TI Topically applied methotrexate is rapidly delivered into skin by
fractional laser ablation
SO EXPERT OPINION ON DRUG DELIVERY
LA English
DT Article
DE desorption electro-spray ionization mass spectrometry imaging;
fluorescence microscopy; fractional erbium laser; franz skin
permeability cells; high performance liquid chromatography;
laser-assisted drug delivery
ID IONIZATION MASS-SPECTROMETRY; ASSISTED DRUG-DELIVERY;
HISTOLOGICAL-EVALUATION; PSORIASIS-VULGARIS; IN-VIVO; GEL; METABOLITES;
TISSUE
AB Objectives: Methotrexate (MTX) is a chemotherapeutic and anti-inflammatory drug that may cause systemic adverse effects. This study investigated kinetics and biodistribution of MTX delivered topically by ablative fractional laser (AFXL).
Methods: In vitro passive diffusion of 10 mg/ml MTX (1 w/v%) was measured from 0.25 to 24 h through AFXL-processed and intact porcine skin in Franz Cells (n = 46). A 2,940 nm fractional Erbium Yttrium Aluminium Garnet laser generated mid-dermal microchannels at 2.4% density, and 256 mJ/microchannel. HPLC quantified MTX-concentrations in extracts from mid-dermal skin sections, donor and receiver compartments. Fluorescence microscopy of UVC-activated MTX-fluorescence and desorption electro-spray ionization mass spectrometry imaging (DM-MSI) evaluated MTX biodistribution.
Results: AFXL-processed skin facilitated rapid MTX delivery through cone-shaped nnicrochannels of 690 pm ablation depth, lined by the 47 mu m thermal coagulation zone (CZ). Quantitatively, MIX was detectable by HPLC in mid-dermis after 15 min, significantly exceeded deposition in intact skin after 1.5 h, and saturated skin after 7 h at a 10-fold increased MTX-deposition versus intact skin (3.08 vs 0.30 mg/cm(3), p = 0.002). Transdermal permeation was < 1.5% of applied MTX before skin saturation, and increased up to 8.0% after 24 h. Qualitatively, MTX distributed into CZ within 15 min (p = 0.015) and further into surrounding dermal tissue after 1.5 h (p = 0.004). After skin saturation at 7 h, MTX fluorescence intensities in CZ and tissue were similar and DESI-MSI confirmed MIX biodistribution throughout the mid-dermal skin section.
Conclusions: MIX absorbs rapidly into mid-dermis of AFXL-processed skin with minimal transdermal permeation until skin saturation, suggesting a possible alternative to systemic MIX for some skin disorders.
C1 [Taudorff, Elisabeth Hjardem; Lerche, Catharina Margrethe; Vissing, Anne-Cathrine; Philipsen, Peter Alshede; Haedersdal, Merete] Univ Copenhagen, Bispebjerg Univ Hosp, Dept Dermatol, DK-2400 Copenhagen, Denmark.
[Hannibal, Jens] Univ Copenhagen, Bispebjerg Univ Hosp, Dept Clin Biochem, DK-2400 Copenhagen, Denmark.
[D'Alvise, Janina; Hansen, Steen Honore; Janfelt, Christian] Univ Copenhagen, Fac Hlth & Med Sci, Dept Pharm, DK-2400 Copenhagen, Denmark.
[Paasch, Uwe] Univ Leipzig, Aesthet & Laserdermatol, Dept Dermatol, Div Dermatopathol, Copenhagen, NV, Germany.
[Anderson, Richard Rox; Haedersdal, Merete] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA.
RP Taudorff, EH (reprint author), Univ Copenhagen, Bispebjerg Univ Hosp, Dept Dermatol D 92, Bispebjerg Bakke 23, DK-2400 Copenhagen, Denmark.
EM ehtaudorf@dadlnet.dk
FU Pantec Biosolutions AG, Ruggell, Liechtenstein; Bispebjerg University
Hospital
FX M Haedersdal received a research grant from Pantec Biosolutions AG,
Ruggell, Liechtenstein. The company had no influence on collection,
interpretation or presentation of data. Bispebjerg University Hospital
is acknowledged for financial support. All other authors have no
relevant affiliations or financial involvement with any organization or
entity with a financial interest in or financial conflict with the
subject matter or materials discussed in the manuscript. This includes
employment, consultancies, honoraria, stock ownership or options, expert
testimony, grants or patents received or pending, or royalties.
NR 37
TC 5
Z9 5
U1 2
U2 13
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1742-5247
EI 1744-7593
J9 EXPERT OPIN DRUG DEL
JI Expert Opin. Drug Deliv.
PD JUL
PY 2015
VL 12
IS 7
BP 1059
EP 1069
DI 10.1517/17425247.2015.1031216
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CM5XK
UT WOS:000357762100003
PM 25893560
ER
PT J
AU Karimi, M
Solati, N
Amiri, M
Mirshekari, H
Mohamed, E
Taheri, M
Hashemkhani, M
Saeidi, A
Estiar, MA
Kiani, P
Ghasemi, A
Basri, SMM
Aref, AR
Hamblint, MR
AF Karimi, Mandi
Solati, Navid
Amiri, Mohammad
Mirshekari, Hamed
Mohamed, Elmira
Taheri, Mandiar
Hashemkhani, Mahshid
Saeidi, Ahad
Estiar, Mehrdad Asghari
Kiani, Parnian
Ghasemi, Amir
Basri, Seyed Masoud Moosavi
Aref, Amir R.
Hamblint, Michael R.
TI Carbon nanotubes part I: preparation of a novel and versatile
drug-delivery vehicle
SO EXPERT OPINION ON DRUG DELIVERY
LA English
DT Review
DE addition reaction; carbon nanotubes; functional group;
functionalization; purification; synthesis
ID CHEMICAL-VAPOR-DEPOSITION; SOLID-PHASE EXTRACTION;
HYDROGEN-ARC-DISCHARGE; LOW-TEMPERATURE GROWTH; LARGE-SCALE SYNTHESIS;
LOW-COST SYNTHESIS; LOW-PRESSURE AIR; PROTEIN IMMOBILIZATION;
FIELD-EMISSION; CANCER-CELLS
AB Introduction: It is 23 years since carbon allotrope known as carbon nanotubes (CNT) was discovered by lijima, who described them as "rolled graphite sheets inserted into each other". Since then, CNTs have been studied in nanoelectronic devices. However, CNTs also possess the versatility to act as drug- and gene-delivery vehicles.
Areas covered: This review covers the synthesis, purification and functionalization of CNTs. Arc discharge, laser ablation and chemical vapor deposition are the principle synthesis methods. Non-covalent functionalization relies on attachment of biomolecules by coating the CNT with surfactants, synthetic polymers and biopolymers. Covalent functionalization often involves the initial introduction of carboxylic acids or amine groups, diazonium addition, 1,3-dipolar cycloaddition or reductive alkylation. The aim is to produce functional groups to attach the active cargo.
Expert opinion: In this review, the feasibility of CNT being used as a drug-delivery vehicle is explored. The molecular composition of CNT is extremely hydrophobic and highly aggregation-prone. Therefore, most of the efforts towards drug delivery has centered on chemical functionalization, which is usually divided in two categories; non-covalent and covalent. The biomedical applications of CNT are growing apace, and new drug-delivery technologies play a major role in these efforts.
C1 [Karimi, Mandi] Iran Univ Med Sci, Dept Nanotechnol, Sch Adv Technol Med, Tehran, Iran.
[Solati, Navid; Mohamed, Elmira; Taheri, Mandiar; Hashemkhani, Mahshid; Saeidi, Ahad; Kiani, Parnian] Iran Univ Med Sci, Sch Met & Mat Engn, Tehran, Iran.
[Amiri, Mohammad; Ghasemi, Amir] Sharif Univ Technol, Dept Mat Sci & Engn, Polymer Mat Res Grp, Tehran 113659466, Iran.
[Mirshekari, Hamed] Univ Kerala, Dept Biotechnol, Trivandrum 695001, Kerala, India.
[Estiar, Mehrdad Asghari; Aref, Amir R.] Univ Tehran Med Sci, Sch Med, Dept Med Genet, Tehran, Iran.
[Basri, Seyed Masoud Moosavi] Sharif Univ Technol, Biotechnol Res Ctr, Tehran 113658639, Iran.
[Hamblint, Michael R.] Harvard Univ, Massachusetts Gen Hosp, Dept Dermatol, Wellman Ctr Photomed,Sch Med, Boston, MA 02114 USA.
[Hamblint, Michael R.] Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
RP Hamblint, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
EM hamblin@helix.mgh.harvard.edu
FU NIH [R01A1050875]
FX This work was supported by NIH grant R01A1050875. The authors have no
other relevant affiliations or financial involvement with any
organization or entity with a financial interest in or financial
conflict with the subject matter or materials discussed in the
manuscript apart from those disclosed.
NR 154
TC 10
Z9 10
U1 11
U2 52
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1742-5247
EI 1744-7593
J9 EXPERT OPIN DRUG DEL
JI Expert Opin. Drug Deliv.
PD JUL
PY 2015
VL 12
IS 7
BP 1071
EP 1087
DI 10.1517/17425247.2015.1003806
PG 17
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CM5XK
UT WOS:000357762100004
PM 25601356
ER
PT J
AU Karimi, M
Solati, N
Ghasemi, A
Estiar, MA
Hashemkhani, M
Kiani, P
Mohamed, E
Saeidi, A
Taheri, M
Avci, P
Aref, AR
Amiri, M
Baniasadi, F
Hamblint, MR
AF Karimi, Mandi
Solati, Navid
Ghasemi, Amir
Estiar, Mehrdad Asghari
Hashemkhani, Mahshid
Kiani, Parnian
Mohamed, Elmira
Saeidi, Ahad
Taheri, Mandiar
Avci, Pinar
Aref, Amir R.
Amiri, Mohammad
Baniasadi, Fazel
Hamblint, Michael R.
TI Carbon nanotubes part II: a remarkable carrier for drug and gene
delivery
SO EXPERT OPINION ON DRUG DELIVERY
LA English
DT Review
DE biomolecule delivery; carbon nanotubes; drug delivery systems; gene
delivery; toxicology
ID ASSISTED MICROPARTICLE DELIVERY; HUMAN EPIDERMAL-KERATINOCYTES;
CANCER-CELLS; IN-VIVO; MAMMALIAN-CELLS; RNA INTERFERENCE; TARGETED
DELIVERY; AMPHOTERICIN-B; P53 GENE; DOXORUBICIN
AB Introduction: Carbon nanotubes (CNT) have recently been studied as novel and versatile drug and gene delivery vehicles. When CNT are suitably functionalized, they can interact with various cell types and are taken up by endocytosis.
Areas covered: Anti-cancer drugs cisplatin and doxorubicin have been delivered by CNT, as well as nnethotrexate, taxol and gemcitabine. The delivery of the antifungal compound annphotericin B and the oral administration of erythropoietin have both been assisted using CNT. Frequently, targeting moieties such as folic acid, epidermal growth factor or various antibodies are attached to the CNT-drug nanovehicle. Different kinds of functionalization (e.g., polycations) have been used to allow CNT to act as gene delivery vectors. Plasmid DNA, small interfering RNA and micro-RNA have all been delivered by CNT vehicles. Significant concerns are raised about the nanotoxicology of the CNT and their potentially damaging effects on the environment.
Expert opinion: CNT-mediated drug delivery has been studied for over a decade, and both in vitro and in vivo studies have been reported. The future success of CNTs as vectors in vivo and in clinical application will depend on achievement of efficacious therapy with minimal adverse effects and avoidance of possible toxic and environmentally damaging effects.
C1 [Karimi, Mandi] Iran Univ Med Sci, Sch Adv Technol Med, Dept Nanotechnol, Tehran, Iran.
[Solati, Navid; Hashemkhani, Mahshid; Kiani, Parnian; Mohamed, Elmira; Saeidi, Ahad; Taheri, Mandiar] Iran Univ Med Sci, Sch Met & Mat Engn, Tehran, Iran.
[Ghasemi, Amir; Amiri, Mohammad; Baniasadi, Fazel] Sharif Univ Technol, Dept Mat Sci & Engn, Polymer Mat Res Grp, Tehran 113659466, Iran.
[Estiar, Mehrdad Asghari] Univ Tehran Med Sci, Sch Med, Dept Med Genet, Tehran, Iran.
[Avci, Pinar; Hamblint, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Avci, Pinar; Hamblint, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Aref, Amir R.] Dana Farber Canc Inst, Ctr Canc Syst Biol, Dept Canc Biol, Boston, MA 02215 USA.
[Aref, Amir R.] Harvard Univ, Dept Genet, Sch Med, Boston, MA 02215 USA.
[Hamblint, Michael R.] Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
RP Hamblint, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
EM Hamblin@helix.mgh.harvard.edu
FU NIH [R01A1050875]
FX This work was supported by NIH grant R01A1050875. The authors have no
other relevant affiliations or financial involvement with any
organization or entity with a financial interest in or financial
conflict with the subject matter or materials discussed in the
manuscript apart from those disclosed.
NR 112
TC 15
Z9 15
U1 11
U2 53
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1742-5247
EI 1744-7593
J9 EXPERT OPIN DRUG DEL
JI Expert Opin. Drug Deliv.
PD JUL
PY 2015
VL 12
IS 7
BP 1089
EP 1105
DI 10.1517/17425247.2015.1004309
PG 17
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CM5XK
UT WOS:000357762100005
PM 25613837
ER
PT J
AU Kuehlewein, L
Sadda, SR
Sarraf, D
AF Kuehlewein, L.
Sadda, S. R.
Sarraf, D.
TI OCT angiography and sequential quantitative analysis of type 2
neovascularization after ranibizumab therapy
SO EYE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION; MACULAR
DEGENERATION; MOTION CORRECTION
AB Purpose To study the precise structural aspects of a type 2 neovascular membrane in a patient with age-related macular degeneration (AMD) using optical coherence tomography (OCT) angiography and perform sequential quantitative analysis of the membrane after ranibizumab therapy.
Patients and methods Split-spectrum amplitude-decorrelation (SSADA) OCT angiography macular cubes (3x3 mm) were acquired with a light source centered at 840 nm, a bandwidth of 45 nm, and an A-scan-rate of 70 000 scans per second. Visible pathologic vessels were outlined manually on average intensity projection en face images, and the area of the lesion and the vessel density were measured at baseline and follow-up.
Results At baseline, the neovascular lesion measured 4.12 mm(2) and the vessel density was 19.83 mm(-1). Four weeks after the first, and 2 and 4 weeks after the second ranibizumab injection, OCT angiography revealed a progressively smaller vascular lesion (2.32, 1.77 and 1.64 mm(2)), and vessel density (10.24, 8.52 and 7.57 mm(-1)), although the large central trunks of the lesion were unchanged.
Conclusions In this study, an obvious reduction in size and vessel density of the neovascular lesion was noted after treatment with ranibizumab using SSADA OCT angiography technology. Microvascular components can be delineated with precision, suggesting that this technique may be useful for the management of patients with neovascular AMD in a clinical setting as well as for future clinical trials.
C1 [Kuehlewein, L.; Sadda, S. R.] Doheny Eye Inst, Los Angeles, CA 90033 USA.
[Kuehlewein, L.; Sadda, S. R.; Sarraf, D.] Stein Eye Inst, Los Angeles, CA USA.
[Sarraf, D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
[Sarraf, D.] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
RP Sarraf, D (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA 90095 USA.
EM dsarraf@ucla.edu
FU Carl Zeiss Meditec; Optos; Allergan
FX Dr Sadda is a co-inventor of Doheny intellectual property related to
optical coherence tomography that has been licensed by Topcon Medical
Systems and is a member of the scientific advisory board for Heidelberg
Engineering. Dr Sadda receives research support from and serves as a
consultant for Carl Zeiss Meditec, Optos, and Allergan. He also serves
as a consultant for Alcon, Novartis, and Iconic.
NR 10
TC 33
Z9 35
U1 1
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUL
PY 2015
VL 29
IS 7
BP 932
EP 935
DI 10.1038/eye.2015.80
PG 4
WC Ophthalmology
SC Ophthalmology
GA CM5LC
UT WOS:000357728300014
PM 25976641
ER
PT J
AU Abramovitch, A
Dar, R
Mittelman, A
Wilhelm, S
AF Abramovitch, Amitai
Dar, Reuven
Mittelman, Andrew
Wilhelm, Sabine
TI Comorbidity Between Attention Deficit/Hyperactivity Disorder and
Obsessive-Compulsive Disorder Across the Lifespan: A Systematic and
Critical Review
SO HARVARD REVIEW OF PSYCHIATRY
LA English
DT Review
ID DEFICIT HYPERACTIVITY DISORDER; FUNCTIONAL MAGNETIC-RESONANCE;
COGNITIVE-BEHAVIORAL THERAPY; FAMILIAL RISK ANALYSIS; CLINICAL-FEATURES;
NEUROPSYCHOLOGICAL PERFORMANCE; SYMPTOM DIMENSIONS; CHILDHOOD-ONSET;
DISRUPTIVE BEHAVIOR; RESPONSE-INHIBITION
AB The concept of comorbidity between attention deficit/hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD) has been discussed for two decades. No review, however, has examined this question in light of the stark contrast in disorder-specific phenomenology and neurobiology. We review reported prevalence rates and the methodological, phenomenological, and theoretical issues concerning concomitant ADHD-OCD. Reported co-occurrence rates are highly inconsistent in the literature. Studies aimed at examining the potential for comorbidity have suffered from various methodological problems, including the existence of very few community samples, highly variable exclusionary criteria, and possible clinical misinterpretation of symptoms. Despite numerous studies suggesting an ADHD-OCD comorbidity, thus far etiological (i.e., genetic) backing has been provided only for a pediatric comorbidity. Additionally, inflated rates of ADHD-OCD co-occurrence may be mediated by the presence of tic disorders, and evidence of impaired neuronal maturational processes in pediatric OCD may lead to possibly transient phenotypical expressions that resemble ADHD symptomatology. Thus, clinicians are encouraged to consider the possibility that ADHD-like symptoms resulting from OCD-specific symptomatology may be misdiagnosed as ADHD. This suggestion may account for the lower co-occurrence rates reported in adolescents and adults and for the lack of a theoretical account for comorbidity in these age groups. Existing literature is summarized and critically reviewed, and recommendations are made for future research.
C1 [Abramovitch, Amitai; Wilhelm, Sabine] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Abramovitch, Amitai; Mittelman, Andrew; Wilhelm, Sabine] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Dar, Reuven] Tel Aviv Univ, Sch Psychol Sci, IL-69978 Tel Aviv, Israel.
RP Abramovitch, A (reprint author), SW Texas State Univ, Dept Psychol, San Marcos, TX 78666 USA.
EM abramovitch@txstate.edu
NR 157
TC 5
Z9 5
U1 8
U2 23
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1067-3229
EI 1465-7309
J9 HARVARD REV PSYCHIAT
JI Harv. Rev. Psychiatr.
PD JUL-AUG
PY 2015
VL 23
IS 4
BP 245
EP 262
DI 10.1097/HRP.0000000000000050
PG 18
WC Psychiatry
SC Psychiatry
GA CM8IA
UT WOS:000357941700002
PM 26052877
ER
PT J
AU Rose, AB
Liebson, ES
Goldblatt, MJ
Baldessarini, RJ
AF Rose, A. Blythe
Liebson, Elizabeth S.
Goldblatt, Mark J.
Baldessarini, Ross J.
TI Intensely Suicidal Behavior with a First Manic Episode
SO HARVARD REVIEW OF PSYCHIATRY
LA English
DT Article
ID BIPOLAR-I DISORDER; RANDOMIZED CONTROLLED-TRIAL; MIXED STATES;
INTERNATIONAL SOCIETY; DEPRESSIVE DISORDER; TASK-FORCE; ILLNESS;
ANTIDEPRESSANTS; LITHIUM; RISK
C1 [Rose, A. Blythe] Harvard Univ, Med Sch, Cambridge, MA 02138 USA.
[Rose, A. Blythe] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Rose, A. Blythe; Liebson, Elizabeth S.; Goldblatt, Mark J.; Baldessarini, Ross J.] McLean Hosp, Belmont, MA USA.
[Goldblatt, Mark J.] Boston Psychoanalyt Soc & Inst, Boston, MA USA.
RP Rose, AB (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
EM arose2@partners.org
FU Bruce J. Anderson Foundation; McLean Private Donors Research Fund
FX Supported, in part, by the Bruce J. Anderson Foundation and the McLean
Private Donors Research Fund (Dr. Baldessarini).
NR 46
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1067-3229
EI 1465-7309
J9 HARVARD REV PSYCHIAT
JI Harv. Rev. Psychiatr.
PD JUL-AUG
PY 2015
VL 23
IS 4
BP 288
EP 295
DI 10.1097/HRP.0000000000000096
PG 8
WC Psychiatry
SC Psychiatry
GA CM8IA
UT WOS:000357941700004
ER
PT J
AU Yamin, M
Holbrook, EH
Gray, ST
Busaba, NY
Lovett, B
Hamilos, DL
AF Yamin, Moshe
Holbrook, Eric H.
Gray, Stacey T.
Busaba, Nicolas Y.
Lovett, Brooke
Hamilos, Daniel L.
TI Profibrotic transforming growth factor beta 1 and activin A are
increased in nasal polyp tissue and induced in nasal polyp epithelium by
cigarette smoke and Toll-like receptor 3 ligation
SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY
LA English
DT Article
DE nasal polyposis; chronic rhinosinusitis; epithelium; inflammation;
profibrotic; transforming growth factor beta 1; TGF-beta 1; Activin A;
cigarette smoke; Toll-like receptor 3; TLR 3; airway remodeling
ID MESENCHYMAL TRANSITION; CHRONIC RHINOSINUSITIS; FLUTICASONE PROPIONATE;
MESSENGER-RNA; EXPRESSION; CELLS; ASTHMA;
TRANSFORMING-GROWTH-FACTOR-BETA-1; INFLAMMATION; EOSINOPHILS
AB BackgroundThe mechanism of airway remodeling in chronic rhinosinusitis with nasal polyposis (CRSwNP) remains unknown. We wished to determine whether profibrotic transforming growth factor beta 1 (TGF-1) and activin A and their downstream signaling proteins are increased in CRSwNP and if they are regulated in epithelial cells by noxious or inflammatory stimuli.
MethodsFrozen tissue from CRSwNP patients, healthy control (HC) middle turbinates, and sinus tissue from CRS without NP (CRSsNP) patients were immunostained for TGF-1, activin A, and downstream signaling proteins. Primary nasal epithelial cells (PNECs) from HCs and CRSwNP patients were cultured in media, cigarette smoke extract (CSE), or double-stranded RNA (dsRNA) (a ligand for Toll-like receptor-3) and examined for inflammatory and profibrotic genes using real-time polymerase chain reaction (PCR).
ResultsCRSwNP patients showed increased TGF-1 and activin A in the stroma, increased TGF-1 signaling (phosphorylated Smad2/3) in the stroma and epithelium, and increased Smad3-dependent Snail1 in the stroma. Immunostaining for TGF-1, pSmad2/3, and Snail1 in CRSwNP patients was highly correlated. Immunostaining for pSmad2/3 and Snail1 was similar in CRSwNP and CRSsNP patients. Compared to HCs, PNECs from CRSwNP patients were more responsive to CSE and dsRNA in terms of TGF-1 and activin A and more strongly induced by dsRNA in terms of chemokines.
ConclusionIncreased TGF-1 and activin A and increased downstream TGF-1 signaling is present in CRSwNP patients, primarily in the stroma. This may contribute to features of airway remodeling previously described. PNECs from CRSwNP patients are induced to produce TGF-1 and activin A by CSE and dsRNA, suggesting that cigarette smoke and viral infection might also contribute to airway remodeling. (C) 2015 ARS-AAOA, LLC.
C1 [Yamin, Moshe; Lovett, Brooke; Hamilos, Daniel L.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA.
[Holbrook, Eric H.; Gray, Stacey T.; Busaba, Nicolas Y.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA.
RP Hamilos, DL (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Bulfinch 422, Boston, MA 02114 USA.
EM dhamilos@partners.org
FU Flight Attendants Medical Research Institute (FAMRI); Merck
FX Flight Attendants Medical Research Institute (FAMRI); Merck.
NR 43
TC 1
Z9 1
U1 3
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2042-6976
EI 2042-6984
J9 INT FORUM ALLERGY RH
JI Int. Forum Allergy Rhinol.
PD JUL
PY 2015
VL 5
IS 7
BP 573
EP 582
DI 10.1002/alr.21516
PG 10
WC Otorhinolaryngology
SC Otorhinolaryngology
GA CM7PT
UT WOS:000357888100003
PM 25914020
ER
PT J
AU Yao, WC
Bleier, BS
AF Yao, William C.
Bleier, Benjamin S.
TI A simple, single stage technique to harvest optimal ethmoid bone grafts
for caudal septal deflections
SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY
LA English
DT Article
ID BATTEN GRAFT; ENDOSCOPIC SEPTOPLASTY; DEVIATION; CORRECT
AB BackgroundCurvature of the caudal septum is a challenging area to surgically address because it is a tip supporting structure. Several methods to straighten the caudal septal deviation have been described to date. One commonly described technique is the placement of a bony septal batten graft. However, the harvest and subsequent ex vivo shaping of the bone graft can be difficult and lead to fracture of the graft superstructure. Here we discuss a novel single stage endoscopic approach to harvest a preformed batten graft and apply it to correct a caudal septal curvature deformity.
MethodsDescription of a novel endoscopic technique for the single stage harvest of a bone graft for the correction of a caudal septal deflection utilizing an open Jansen-Middleton septum forceps.
ResultsWe have successfully utilized this technique in 10 patients with a caudal septal curvature deformity with no complications. All patients had symptomatic improvement of nasal obstruction symptoms.
ConclusionThe open Jansen-Middleton septum forceps allow for a reproducible, single stage, harvest of a bone graft from the perpendicular plate or vomer when addressing a caudal septal deformity using an endoscopic septoplasty approach. (C) 2015 ARS-AAOA, LLC.
C1 [Yao, William C.; Bleier, Benjamin S.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otolaryngol Head & Neck Surg, Boston, MA USA.
RP Yao, WC (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA.
EM will.yao@gmail.com
NR 14
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2042-6976
EI 2042-6984
J9 INT FORUM ALLERGY RH
JI Int. Forum Allergy Rhinol.
PD JUL
PY 2015
VL 5
IS 7
BP 622
EP 625
DI 10.1002/alr.21520
PG 4
WC Otorhinolaryngology
SC Otorhinolaryngology
GA CM7PT
UT WOS:000357888100011
PM 25885185
ER
PT J
AU Zhang, Z
Adappa, ND
Chiu, AG
Doghramji, LJ
Cohen, NA
Palmer, JN
AF Zhang, Zi
Adappa, Nithin D.
Chiu, Alexander G.
Doghramji, Laurel J.
Cohen, Noam A.
Palmer, James N.
TI Biofilm-forming bacteria and quality of life improvement after sinus
surgery
SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY
LA English
DT Article
DE chronic rhinosinusitis; quality of life; biofilm; bacteria; functional
endoscopic sinus surgery
ID CHRONIC RHINOSINUSITIS; ANTIMICROBIAL RESISTANCE; BACTERIOLOGICAL
FINDINGS; MAXILLARY SINUSITIS; SUSCEPTIBILITY; INFECTIONS; MICROSCOPY;
OUTCOMES; TRENDS
AB BackgroundIt remains unclear how much chronic rhinosinusitis (CRS) patients with bacterial biofilms can benefit from functional endoscopic sinus surgery (FESS). We aimed to evaluate whether biofilm-forming bacteria was associated with quality of life (QOL) improvement after FESS.
MethodsThis retrospective cohort study included adult CRS patients who underwent FESS from 2008 to 2011. Sinus samples were taken to evaluate for biofilm-formation in vitro using a modified Calgary Biofilm Detection Assay. QOL was measured before FESS, and 1-month, 3-month, and 6-month after FESS using 22-item Sino-Nasal Outcome Test (SNOT-22) scores. Patients' characteristics and medications were collected. Clinical significant QOL change was defined as a difference of at least 0.5 standard deviation (SD) of baseline SNOT-22 score in the reference group.
ResultsA total of 156 patients had complete data, and 15% had biofilm-forming bacteria (n = 24). Patients with biofilm-forming bacteria had significantly worse preoperative SNOT-22 scores compared to patients without biofilm-forming bacteria (48 20 vs 38 +/- 23, p = 0.048). Both groups had clinically significant QOL improvement after FESS, and the differences in their 1-month (23 +/- 19 vs 17 +/- 20) and 3-month (27 +/- 18 vs 18 +/- 19) post-FESS SNOT-22 scores were not significant. However, patients with biofilm-forming bacteria demonstrated significantly less QOL improvement than patients without biofilm-forming bacteria from pre-FESS to 6-month post-FESS visits after adjusting for clinical factors (35 +/- 25 vs 14 +/- 15; -coefficient = 0.71; 95% confidence interval [CI], 0.13 to 1.28; p = 0.016).
ConclusionCRS patients with biofilm-forming bacteria demonstrated clinically significant QOL improvement following FESS, but the degree of improvement was decreased overtime and became significantly worse than patients without biofilm-forming bacteria by 6-month follow-up. This QOL worsening was independent of other risk factors for CRS. (C) 2015 ARS-AAOA, LLC.
C1 [Zhang, Zi] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
[Adappa, Nithin D.; Doghramji, Laurel J.; Cohen, Noam A.; Palmer, James N.] Univ Penn, Perelman Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA.
[Chiu, Alexander G.] Univ Arizona, Dept Surg, Tucson, AZ USA.
[Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
RP Zhang, Z (reprint author), 8th Floor,Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM zizhang@mail.med.upenn.edu
OI Cohen, Noam/0000-0002-9462-3932
NR 38
TC 2
Z9 2
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2042-6976
EI 2042-6984
J9 INT FORUM ALLERGY RH
JI Int. Forum Allergy Rhinol.
PD JUL
PY 2015
VL 5
IS 7
BP 643
EP 649
DI 10.1002/alr.21505
PG 7
WC Otorhinolaryngology
SC Otorhinolaryngology
GA CM7PT
UT WOS:000357888100015
PM 25763837
ER
PT J
AU Jowett, N
Hadlock, TA
AF Jowett, Nate
Hadlock, Tessa A.
TI A Contemporary Approach to Facial Reanimation
SO JAMA FACIAL PLASTIC SURGERY
LA English
DT Article
ID QUALITY-OF-LIFE; GRACILIS MUSCLE TRANSFER; LYME-DISEASE; NERVE
ANASTOMOSIS; PARALYZED FACE; BELLS-PALSY; MANAGEMENT; RECONSTRUCTION;
SMILE; VALACICLOVIR
AB The management of acute facial nerve insult may entail medical therapy, surgical exploration, decompression, or repair depending on the etiology. When recovery is not complete, facial mimetic function lies on a spectrum ranging from flaccid paralysis to hyperkinesis resulting in facial immobility. Through systematic assessment of the face at rest and with movement, one may tailor the management to the particular pattern of dysfunction. Interventions for long-standing facial palsy include physical therapy, injectables, and surgical reanimation procedures. The goal of the management is to restore facial balance and movement. This article summarizes a contemporary approach to the management of facial nerve insults.
C1 [Jowett, Nate] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA.
RP Jowett, N (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA.
EM nathanjowett@meei.harvard.edu
NR 46
TC 8
Z9 8
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6076
EI 2168-6092
J9 JAMA FACIAL PLAST SU
JI JAMA Facial Plast. Surg.
PD JUL-AUG
PY 2015
VL 17
IS 4
BP 293
EP 300
DI 10.1001/jamafacial.2015.0399
PG 8
WC Surgery
SC Surgery
GA CN0CP
UT WOS:000358080400011
PM 26042960
ER
PT J
AU Kremer, S
Renard, F
Achard, S
Lana-Peixoto, MA
Palace, J
Asgari, N
Klawiter, EC
Tenembaum, SN
Banwell, B
Greenberg, BM
Bennett, JL
Levy, M
Villoslada, P
Saiz, A
Fujihara, K
Chan, KH
Schippling, S
Paul, F
Kim, HJ
de Seze, J
Wuerfel, JT
AF Kremer, Stephane
Renard, Felix
Achard, Sophie
Lana-Peixoto, Marco A.
Palace, Jacqueline
Asgari, Nasrin
Klawiter, Eric C.
Tenembaum, Silvia N.
Banwell, Brenda
Greenberg, Benjamin M.
Bennett, Jeffrey L.
Levy, Michael
Villoslada, Pablo
Saiz, Albert
Fujihara, Kazuo
Chan, Koon Ho
Schippling, Sven
Paul, Friedemann
Kim, Ho Jin
de Seze, Jerome
Wuerfel, Jens T.
CA Guthy-Jackson Charitable Fdn GJCF
TI Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis
Optica Spectrum Disorder
SO JAMA NEUROLOGY
LA English
DT Review
ID BRAIN-LESION DISTRIBUTION; VOXEL-BASED MORPHOMETRY; APPEARING
WHITE-MATTER; MULTIPLE-SCLEROSIS; COGNITIVE IMPAIRMENT; MRI
ABNORMALITIES; FUNCTIONAL MRI; DIFFUSION; DAMAGE; MS
AB Brain parenchymal lesions are frequently observed on conventional magnetic resonance imaging (MRI) scans of patients with neuromyelitis optica (NMO) spectrum disorder but the specific morphological and temporal patterns distinguishing them uneqtaivcally from lesions caused by other disorders have not been identified. This literature review summarizes the literature on advanced quantitative imaging measures reported for patients with NMO spectrum disorder, including proton MR spectroscopy, diffusion tensor imaging, magnetization transfer imaging, quantitative MR voltametry, and ultrahigh-field strength MRI. It was undertaken to consider the advanced MRI techniques used for patients with NMO different specialists in the field. Although quantitative measures such as proton MR spectroscopy or magnetization transfer imaging have not reproducibly revealed diffuse brain injury, preliminary data from diffusion-weighted imaging and brain tissue volumetry indicate greater white matter than gray matter degradation. These findings could be confirmed by ultrahigh-field MRI. The use of nonconventional MR I techniques may further our understanding of the pathogenic processes hi NMO spectrum disorders and may help us identify the distinct radiographic features corresponding to specific phenotypic manifestations of this disease.
C1 [Kremer, Stephane] Univ Strasbourg, CNRS, ICube UMR 7357, Federat Med Translat Strasbourg,UdS, Strasbourg, France.
[Kremer, Stephane] Hop Univ Strasbourg, Dept Radiol, Strasbourg, France.
[Renard, Felix; Achard, Sophie] Grenoble Image Parole Signal Automat, CNRS, Grenoble, France.
[Lana-Peixoto, Marco A.] Univ Fed Minas Gerais, CIEM MS Res Ctr, Belo Horizonte, MG, Brazil.
[Palace, Jacqueline] Oxford Univ Hosp Trust, Dept Neurol, Oxford, England.
[Asgari, Nasrin] Univ Southern Denmark, Inst Mol Med, Dept Neurobiol, Odense, Denmark.
[Asgari, Nasrin] Vejle Hosp, Dept Neurol, Vejle, Denmark.
[Klawiter, Eric C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA USA.
[Tenembaum, Silvia N.] Natl Pediat Hosp Dr Juan P Garrahan, Dept Neurol & Neurophysiol, Buenos Aires, DF, Argentina.
[Banwell, Brenda] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.
[Banwell, Brenda] Childrens Hosp Philadelphia, Dept Pediat, Div Child Neurol, Philadelphia, PA 19104 USA.
[Greenberg, Benjamin M.] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA.
[Greenberg, Benjamin M.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA.
[Bennett, Jeffrey L.] Univ Colorado Denver, Dept Neurol, Aurora, CO USA.
[Levy, Michael] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA.
[Villoslada, Pablo; Saiz, Albert] Hosp Clin Barcelona, Inst Biomed Res August Pi Sunyer, Barcelona, Spain.
[Fujihara, Kazuo] Tohoku Univ, Grad Sch Med, Dept Multiple Sclerosis Therapeut, Sendai, Miyagi 980, Japan.
[Chan, Koon Ho] Univ Hong Kong, Univ Dept Med, Li Ka Shing Fac Med, Res Ctr Heart Brain Hormone & Hlth Aging, Hong Kong, Hong Kong, Peoples R China.
[Schippling, Sven] Univ Zurich Hosp, Neuroimmunol & Multiple Sclerosis Res Sect, CH-8091 Zurich, Switzerland.
[Schippling, Sven] Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland.
[Schippling, Sven] Fed Tech High Sch Zurich, Neurosci Ctr Zurich, Zurich, Switzerland.
[Schippling, Sven] Univ Zurich, Zurich, Switzerland.
[Paul, Friedemann; Wuerfel, Jens T.] Charite, NeuroCure Clin Res Ctr, D-13353 Berlin, Germany.
[Paul, Friedemann; Wuerfel, Jens T.] Charite, Clin & Expt Multiple Sclerosis Res Ctr, D-13353 Berlin, Germany.
[Paul, Friedemann; Wuerfel, Jens T.] Charite, Dept Neurol, D-13353 Berlin, Germany.
[Kim, Ho Jin] Res Inst, Dept Neurol, Goyang, South Korea.
[Kim, Ho Jin] Natl Canc Ctr Hosp, Goyang, South Korea.
[de Seze, Jerome] Hop Univ Strasbourg, Dept Neurol, Strasbourg, France.
[de Seze, Jerome] Hop Univ Strasbourg, Clin Invest Ctr INSERM 1434, Strasbourg, France.
[de Seze, Jerome] UMR INSERM 1119, Strasbourg, France.
[de Seze, Jerome] Federat Med Translat, Strasbourg, France.
[Wuerfel, Jens T.] Univ Med Gottingen, Inst Neuroradiol, Gottingen, Germany.
RP Wuerfel, JT (reprint author), Univ Med Gottingen, Inst Neuroradiol, Robert Koch Str 40, D-37075 Gottingen, Germany.
EM jens.wuerfel@charite.de
RI Aktas, Orhan/B-7623-2009; De Seze, Jerome/M-8316-2016; Sato,
Douglas/F-2508-2013;
OI Aktas, Orhan/0000-0002-2020-9210; De Seze, Jerome/0000-0002-7197-7578;
paul, friedemann/0000-0002-6378-0070; Sato, Douglas/0000-0002-7695-6020;
Hooper, Douglas/0000-0002-8578-5104
FU Bayer Schering Pharma; Biogen Idec; Genzyme; Kael-GemVax; Merck Serono;
Novartis; Teva-Handok; UCB; German Research Council; German Ministry of
Education and Research (Competence Network Multiple Sclerosis [KKNMS]);
GJCF; Bayer; Teva; Merck; Sanofi; Chugai Pharma; Bayer Schering;
National MS Society; Roche; Bayer Healthcare; Genzyme Corp; Teva
Neuroscience; Ministry of Education, Culture, Sports, Science and
Technology in Japan; Ichiro Kanehara Foundation; German Ministry of
Science (BMBF/KKNMS); Canadian MS Research Foundation; Canadian MS
Society; Canadian Institutes of Health Research; Multiple Sclerosis
Association of America; DioGenix; Amplimmune; Biogen; National
Institutes of Health; Patient-Centered Outcomes Research Institute;
Acorda Therapeutics; Viropharma; Acorda; NeuralStem; Genentech; European
Commission; Instituto Salud Carlos III; Marato TV3; Eisai; Mitsubishi
Tanabe Pharma Corp; Novartis Pharma; Astellas Pharma; Takeda
Pharmaceutical Company Limited; Asahi Kasei Medical; Daiichi Sankyo;
Nihon Pharmaceutical; Biogen Idec Japan; Chemo-Sero-Therapeutic Research
Institute; Teva Pharmaceutical; Mitsubishi Tanabe Pharma; Teijin Pharma;
Chugai Pharmaceutical; Ono Pharmaceutical; Genzyme Japan; Ministry of
Education, Science and Technology in Japan [22229008]; Ministry of
Health, Welfare and Labour of Japan; Teva Pharmaceuticals; Opexa
Therapeutics; US Department of Veterans Affairs; German Research Council
(DFG); German Ministry of Education and Research (BMBF-EDEN); Alexion;
Terumo BCT
FX Dr Kim has given talks, consulted, and received honoraria and/or
research support from Bayer Schering Pharma, Biogen Idec, Genzyme,
Kael-GemVax, Merck Serono, Novartis, Teva-Handok, and UCB. He serves on
a steering committee for MedImmune. Dr Paul has received funding from
the German Research Council, the German Ministry of Education and
Research (Competence Network Multiple Sclerosis [KKNMS]), and the GJCF.
He has received travel compensation, speaker honoraria, and research
support from Biogen Idec, Bayer, Teva, Merck, Novartis, and Sanofi and
has served as a steering committee member of the OCTIMS study sponsored
by Novartis. Dr Tenembaum has provided consulting services to Genzyme
Corp and Biogen Idec and has received lecture fees from Merck Serono. Dr
Palace is partly funded by highly specialized services to run a national
congenital myasthenia service and a neuromyelitis service. She has
received support for scientific meetings and honoraria for advisory work
from Merck Serono, Biogen Idec, Novartis, Teva, Chugai Pharma, and Bayer
Schering and unrestricted grants from Merck Serono, Novartis, Biogen
Idec, and Bayer Schering. Her hospital trust receives funds for her role
as clinical leader for the RSS, and she has received grants from the
National MS Society and the GJCF for unrelated research studies. Dr
Klawiter has received research funding from Roche. He has received
consulting fees and/or speaking honoraria from Biogen Idec, Bayer
Healthcare, Genzyme Corp, and Teva Neuroscience. Dr Sato receives a
scholarship from the Ministry of Education, Culture, Sports, Science and
Technology in Japan and has received research support from the Ichiro
Kanehara Foundation. Dr de Seze has received honoraria from Bayer
Schering, Biogen Idec, LFB, Merck Serono, Novartis, Sanofi, and Teva. He
serves as a consultant for Alexion and Chugai. DrWuerfel serves on
advisory boards for Novartis and Biogen Idec. He received a research
grant from Novartis and speaker honoraria from Bayer, Novartis, and
Biogen Idec. He is supported by the German Ministry of Science
(BMBF/KKNMS). Dr Banwell serves as a senior editor for Multiple
Sclerosis and Related Disorders and on the editorial board of Neurology.
She serves as a consultant for Biogen Idec, Novartis, Teva Neuroscience,
and Merck Serono. She has been funded by the Canadian MS Research
Foundation, the Canadian MS Society, and the Canadian Institutes of
Health Research. Dr Greenberg serves as a section editor for JAMA
Neurology. He has received consulting fees or honoraria from the
Multiple Sclerosis Association of America, DioGenix, Amplimmune,
Novartis, and Biogen. He has received grant funding from the National
Institutes of Health, the Patient-Centered Outcomes Research Institute,
the GJCF, Acorda Therapeutics, and Biogen Idec. Dr Bennett serves as a
consultant for Novartis Pharmaceuticals, Alnaylam Pharmaceuticals,
MedImmune, Chugai Pharmaceuticals, EMD Serono, AbbVie, Genentech,
Genzyme, Apsara Therapeutics, and Questcor Pharmaceuticals; receives
license royalties for a patent regarding "Compositions and Methods for
the Treatment of Neuromyelitis Optica"; and serves on the editorial
boards of the Multiple Sclerosis Journal and the Journal of
Neuro-Ophthalmology. Dr Levy receives research support from the National
Institutes of Health, the GJCF, Viropharma, Acorda, Sanofi, NeuralStem,
and Genentech and serves as a consultant for Chugai Pharmaceuticals,
GlaxoSmithKline, and MedImmune.; Dr Villoslada serves as a board member
for Roche, Novartis, Neurotec Pharma, and Bionure Farma and as a
consultant for Novartis, Roche, TFS, Heidelberg Engineering, MedImmune,
Digna Biotec, and Neurotec Pharma. He has received research support from
the European Commission, the Instituto Salud Carlos III, Marato TV3,
Novartis, and Roche and travel expenses from Novartis. He holds patents
with Digna Biotec and Bionure Farma and stock/stock options of Bionure
Farma. Dr Saiz has received compensation for consulting services and
speaking from Bayer Schering, Merck Serono, Biogen Idec, Sanofi, Teva
Pharmaceutical Industries, and Novartis. Dr Fujihara serves on
scientific advisory boards for Bayer Schering Pharma, Biogen Idec,
Mitsubishi Tanabe Pharma Corp, Novartis Pharma, Chugai Pharmaceutical,
Ono Pharmaceutical, Nihon Pharmaceutical, Merck Serono, Alexion
Pharmaceuticals, MedImmune, and Medical Review; has received funding for
travel and speaker honoraria from Bayer Schering Pharma, Biogen Idec,
Eisai, Mitsubishi Tanabe Pharma Corp, Novartis Pharma, Astellas Pharma,
Takeda Pharmaceutical Company Limited, Asahi Kasei Medical, Daiichi
Sankyo, and Nihon Pharmaceutical; serves as an editorial board member of
Clinical and Experimental Neuroimmunology (2009 to the present) and an
advisory board member of the Sri Lanka Journal of Neurology; has
received research support from Bayer Schering Pharma, Biogen Idec Japan,
Asahi Kasei Medical, The Chemo-Sero-Therapeutic Research Institute, Teva
Pharmaceutical, Mitsubishi Tanabe Pharma, Teijin Pharma, Chugai
Pharmaceutical, Ono Pharmaceutical, Nihon Pharmaceutical, and Genzyme
Japan; and is funded as the secondary investigator (grant 22229008,
2010-2015) by the Grants-in-Aid for Scientific Research from the
Ministry of Education, Science and Technology in Japan and as the
secondary investigator by the Grants-in-Aid for Scientific Research from
the Ministry of Health, Welfare and Labour of Japan (2010 to the
present). Dr Stuve serves on the editorial boards of JAMA Neurology, the
Multiple Sclerosis Journal, and Therapeutic Advances in Neurological
Disorders. He has received grant support from Teva Pharmaceuticals and
Opexa Therapeutics. Dr. Steve has served on data monitoring committees
for Pfizer and Sanofi without monetary compensation. He is funded by a
Merit grant from the US Department of Veterans Affairs. Dr Aktas
receives research support from the German Research Council (DFG), the
German Ministry of Education and Research (BMBF-EDEN), Bayer, Biogen
Idec, Merck Serono, Novartis, and Teva and serves on an advisory board
for MedImmune. He is an academic editor for PLOS ONE. Dr Wingerchuk has
received research support from Alexion, Terumo BCT, and the GJCF;
receives financial compensation for participation in a relapse
adjudication panel for MedImmune; and has served as a consultant to
Alexion, MedImmune, and Chugai Pharmaceuticals. No other disclosures are
reported.
NR 57
TC 10
Z9 11
U1 1
U2 9
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6149
EI 2168-6157
J9 JAMA NEUROL
JI JAMA Neurol.
PD JUL
PY 2015
VL 72
IS 7
BP 815
EP 822
DI 10.1001/jamaneurol.2015.0248
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA CM8EP
UT WOS:000357931000016
PM 26010909
ER
PT J
AU Sloane, JA
Mainero, C
Kinkel, RP
AF Sloane, Jacob A.
Mainero, Caterina
Kinkel, R. Philip
TI No Evidence of Disease Activity in Multiple Sclerosis
SO JAMA NEUROLOGY
LA English
DT Letter
C1 [Sloane, Jacob A.] Beth Israel Deaconess Med Ctr, Multiple Sclerosis Ctr, Boston, MA 02115 USA.
[Mainero, Caterina] Massachusetts Gen Hosp, AA Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Kinkel, R. Philip] Univ Calif San Diego, Multiple Sclerosis Ctr, San Diego, CA 92103 USA.
RP Sloane, JA (reprint author), Beth Israel Deaconess Med Ctr, Multiple Sclerosis Ctr, 330 Brookline Ave,Ks212, Boston, MA 02115 USA.
EM jsloane@bidmc.harvard.edu
NR 2
TC 0
Z9 0
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6149
EI 2168-6157
J9 JAMA NEUROL
JI JAMA Neurol.
PD JUL
PY 2015
VL 72
IS 7
BP 835
EP 836
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA CM8EP
UT WOS:000357931000024
PM 26167901
ER
PT J
AU Goldstein, JE
Jackson, ML
Fox, SM
Deremeik, JT
Massof, RW
AF Goldstein, Judith E.
Jackson, Mary Lou
Fox, Sandra M.
Deremeik, James T.
Massof, Robert W.
CA Low Vision Res Network Study Grp
TI Clinically Meaningful Rehabilitation Outcomes of Low Vision Patients
Served by Outpatient Clinical Centers
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; VISUAL DISABILITY VARIABLES; RANDOMIZED
CONTROLLED-TRIAL; MACULAR DEGENERATION; INTERVENTION TRIAL; SERVICE;
QUESTIONNAIRE; PARTICIPATION; DIFFICULTY; PEOPLE
AB IMPORTANCE To facilitate comparative clinical outcome research in low vision rehabilitation, we must use patient-centered measurements that reflect clinically meaningful changes in visual ability.
OBJECTIVE To quantify the effects of currently provided low vision rehabilitation (LVR) on patients who present for outpatient LVR services in the United States.
DESIGN, SETTING, AND PARTICIPANTS Prospective, observational study of new patients seeking outpatient LVR services. From April 2008 through May 2011, 779 patients from 28 clinical centers in the United States were enrolled in the Low Vision Rehabilitation Outcomes Study. The Activity Inventory, a visual function questionnaire, was administered to measure overall visual ability and visual ability in 4 functional domains (reading, mobility, visual motor function, and visual information processing) at baseline and 6 to 9 months after usual LVR care. The Geriatric Depression Scale, Telephone Interview for Cognitive Status, and Medical Outcomes Study 36-Item Short-Form Health Survey physical functioning questionnaires were also administered to measure patients' psychological, cognitive, and physical health states, respectively, and clinical findings of patients were provided by study centers.
MAIN OUTCOMES AND MEASURES Mean changes in the study population and minimum clinically important differences in the individual in overall visual ability and in visual ability in 4 functional domains as measured by the Activity Inventory. RESULTS Baseline and post-rehabilitation measures were obtained for 468 patients. Minimum clinically important differences (95% CIs) were observed in nearly half (47%[95% CI, 44%-50%]) of patients in overall visual ability. The prevalence rates of patients with minimum clinically important differences in visual ability in functional domains were reading (44%[95% CI, 42%-48%]), visual motor function (38%[95% CI, 36%-42%]), visual information processing (33%[95% CI, 31%-37%]), and mobility (27%[95% CI, 25%-31%]). The largest average effect size (Cohen d = 0.87) for the population was observed in overall visual ability. Age (P = .006) was an independent predictor of changes in overall visual ability, and logMAR visual acuity (P = .002) was predictive of changes in visual information processing.
CONCLUSIONS AND RELEVANCE Forty-four to fifty percent of patients presenting for outpatient LVR show clinically meaningful differences in overall visual ability after LVR, and the average effect sizes in overall visual ability are large, close to 1 SD.
C1 [Goldstein, Judith E.; Deremeik, James T.; Massof, Robert W.] Johns Hopkins Univ, Wilmer Eye Inst, Lions Vis Res & Rehabil Ctr, Sch Med, Baltimore, MD 21287 USA.
[Jackson, Mary Lou] Harvard Univ, Sch Med, Dept Ophthalmol, Massachusetts Eye & Ear, Boston, MA USA.
[Fox, Sandra M.] South Texas Vet Hlth Care Syst, San Antonio Polytrauma Rehabil Ctr, San Antonio, TX USA.
[Fox, Sandra M.] Univ Texas Hlth Sci Ctr San Antonio, Lions Low Vis Ctr Texas, San Antonio, TX 78229 USA.
RP Goldstein, JE (reprint author), Johns Hopkins Univ, Wilmer Eye Inst, Lions Vis Res & Rehabil Ctr, Sch Med, 600 N Wolfe St,Wilmer 317, Baltimore, MD 21287 USA.
EM jgolds28@jhmi.edu
FU National Eye Institute, National Institutes of Health, Bethesda,
Maryland [EY012045, EY018696]; Reader's Digest Partners for Sight
Foundation
FX This work was supported by grants EY012045 and EY018696 from the
National Eye Institute, National Institutes of Health, Bethesda,
Maryland, and a grant from Reader's Digest Partners for Sight
Foundation.
NR 35
TC 6
Z9 6
U1 2
U2 12
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUL
PY 2015
VL 133
IS 7
BP 762
EP 769
DI 10.1001/jamaophthalmol.2015.0693
PG 8
WC Ophthalmology
SC Ophthalmology
GA CM6TO
UT WOS:000357823100008
PM 25856370
ER
PT J
AU Fay, A
Nallasamy, N
Bernardini, F
Wladis, EJ
Durand, ML
Devoto, MH
Meyer, D
Hartstein, M
Honavar, S
Osaki, MH
Osaki, TH
Santiago, YM
Sales-Sanz, M
Vadala, G
Verity, D
AF Fay, Aaron
Nallasamy, Nambi
Bernardini, Francesco
Wladis, Edward J.
Durand, Marlene L.
Devoto, Martin H.
Meyer, Dale
Hartstein, Morris
Honavar, Santosh
Osaki, Midori H.
Osaki, Tammy H.
Santiago, Yvette M.
Sales-Sanz, Marco
Vadala, Giuseppe
Verity, David
TI Multinational Comparison of Prophylactic Antibiotic Use for Eyelid
Surgery
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID ANTIMICROBIAL PROPHYLAXIS; INFECTION; RISK; ARTHROPLASTY; HIP
AB IMPORTANCE Antibiotic stewardship is important in controlling resistance, adverse reactions, and cost. The literature regarding antibiotic use for eyelid surgery is lacking.
OBJECTIVES To determine standard care and assess factors influencing antibiotic prescribing practices for eyelid surgery.
DESIGN, SETTING, AND PARTICIPANTS A survey study was conducted from February 2, 2014, to March 24, 2014. The survey was distributed to 2397 oculoplastic surgeons in private and academic oculoplastic surgery practices in 43 countries. All surgeons were members of ophthalmic plastic and reconstructive surgery societies. Data were analyzed by geographic location. Linear regression was performed to quantify contributions to rates of prescribing postoperative antibiotics for routine eyelid surgical procedures.
MAIN OUTCOMES AND MEASURES Rates of prescribing prophylactic intravenous, oral, and topical antibiotics as well as factors that influence surgeons' prescribing practices.
RESULTS A total of 782 responses were received from 2397 surgeons (average response rate, 36.7%; 2.5% margin of error) from 43 countries. Topical antibiotic use was common in all regions (85.2%). Perioperative intravenous antibiotic use was uncommon in all regions (13.5%). Geographic location was the greatest predictor of antibiotic prescribing practices (range, 2.9% in the United Kingdom to 86.7% in India; mean, 24%). Within Europe, Italy had the highest rate of antibiotic prescriptions for eyelid surgery (41.7%) and the United Kingdom had the lowest rate (2.9%.) In South America, Venezuela had the highest rate of antibiotic prescriptions for eyelid surgery (83.3%) and Chile had the lowest rate (0%). The practice locations that were associated with routinely prescribing postoperative oral antibiotics were India (odds ratio [OR], 15.83; 95% CI, 4.85-51.68; P < .001), Venezuela (OR, 13.47; 95% CI, 1.43-127.19; P = .02), and Southeast Asia (OR, 2.80; 95% CI, 1.15-6.84; P = .02). Conversely, practice location in the United Kingdom (OR, 0.048; 95% CI, 0.0063-0.37; P = .004), Australia and New Zealand (OR, 0.15; 95% CI, 0.033-0.67; P = .01), and the United States and Canada (OR, 0.41; 95% CI, 0.23-0.72; P = .002) were associated with decreased rates of postoperative oral antibiotic use. Surgeons' concern for allergic reactions was associated with decreased rates of prescribing antibiotics (OR, 0.34; 95% CI, 0.23-0.49; P < .001), while surgeons' concern for infection was associated with increased rates of prescribing antibiotics (OR 1.80; 95% CI, 1.45-2.23; P < .001).
CONCLUSIONS AND RELEVANCE These results from members of ophthalmic plastic and reconstructive surgery societies confirm that antibiotic prescribing practices for routine eyelid surgical procedures vary widely throughout the world. No standard of care has been established that would require the routine use of postoperative prophylactic antibiotics following eyelid surgery.
C1 [Fay, Aaron] Harvard Univ, Dept Ophthalmol, Sch Med, Boston, MA 02114 USA.
[Nallasamy, Nambi] Duke Univ, Ctr Eye, Durham, NC USA.
[Bernardini, Francesco] Oculoplast Bernardini, Genoa, Italy.
[Wladis, Edward J.; Meyer, Dale] Albany Med Coll, Dept Ophthalmol, Lions Eye Inst, Slingerlands, NY USA.
[Durand, Marlene L.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Durand, Marlene L.] Massachusetts Eye & Ear Infirm, Infect Dis Serv, Boston, MA 02114 USA.
[Durand, Marlene L.] Harvard Univ, Dept Med, Sch Med, Boston, MA 02114 USA.
[Devoto, Martin H.] Consultores Oftalmol, Buenos Aires, DF, Argentina.
[Hartstein, Morris] Tel Aviv Univ, Sackler Sch Med, Assaf Harofeh Med Ctr, Dept Ophthalmol, IL-69978 Tel Aviv, Israel.
[Honavar, Santosh] Ophthalm & Facial Plast Surg & Ocular Oncol Ctr S, Hyderabad, Andhra Pradesh, India.
[Osaki, Midori H.; Osaki, Tammy H.] Univ Fed Sao Paulo, Dept Ophthalmol, Ophthalm Plast Surg Div, Sao Paulo, Brazil.
[Santiago, Yvette M.] St Lukes Med Ctr, Inst Eye, Quezon City, Philippines.
[Sales-Sanz, Marco] Hosp Univ Ramon y Cajal, Dept Ophthalmol, Oculoplast & Orbital Surg Unit, Madrid, Spain.
[Vadala, Giuseppe] Ivrea Hosp, Dept Ophthalmol, Turin, Italy.
[Verity, David] Moorfields Eye Hosp, Ophthalm Plast & Reconstruct Surg, London, England.
RP Fay, A (reprint author), Harvard Univ, Dept Ophthalmol, Sch Med, Zero Emerson Pl,Ste 2A, Boston, MA 02114 USA.
EM aaronfay@gmail.com
RI Osaki, Tammy /G-1539-2016; Menezes, Isabel/D-9281-2012
NR 30
TC 2
Z9 3
U1 1
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUL
PY 2015
VL 133
IS 7
BP 778
EP 784
DI 10.1001/jamaophthalmol.2015.0789
PG 7
WC Ophthalmology
SC Ophthalmology
GA CM6TO
UT WOS:000357823100010
PM 25905446
ER
PT J
AU Lane, AM
Kim, IK
Gragoudas, ES
AF Lane, Anne Marie
Kim, Ivana K.
Gragoudas, Evangelos S.
TI Long-term Risk of Melanoma-Related Mortality for Patients With Uveal
Melanoma Treated With Proton Beam Therapy
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID COLLABORATIVE OCULAR MELANOMA; CHOROIDAL MELANOMA; SURVIVAL RATES;
IODINE-125 BRACHYTHERAPY; FOLLOW-UP; ENUCLEATION; TRIAL; DEATH; PLAQUE
AB IMPORTANCE Little is known about the long-term risk of dying of uveal melanoma after treatment with radiotherapy.
OBJECTIVE To determine the long-term risk of dying of this disease, we evaluated melanoma-related mortality rates up to 25 years after proton beam therapy in a large series of patients with uveal melanoma.
DESIGN, SETTING, AND PARTICIPANTS In this analysis, we included 3088 patients with uveal melanoma, identified from a hospital-based cohort and treated with proton irradiation between January 1975 and December 2005. Vital status and cause of death were ascertained through active follow-up and searches of government databases (the Social Security Death Index and the National Death Index) through December 31, 2008. Cumulative rates of melanoma-related mortality were calculated using the Kaplan-Meier method. Patient and tumor characteristics of known prognostic significance for melanoma-associated death were evaluated, including patient age and tumor dimensions.
MAIN OUTCOMES AND MEASURES The primary outcome measure was cumulative rates of melanoma-specific mortality, and secondary measures included annual melanoma-specific mortality hazard rates and cumulative all-cause mortality rates.
RESULTS Of 1490 deceased patients, 620 (41.6%) died of ocular melanoma. In addition, 19 patients were alive, but their melanoma metastasized, by the end of the observation period (mean follow-up after diagnosis of metastasis, 5.3 years). All-cause mortality rates in this cohort were 49.0% (95% CI, 47.0-51.1) at 15 years, 58.6% (95% CI, 56.4%-60.8%) at 20 years, and 66.8% (95% CI, 64.2%-69.4%) at 25 years. Melanoma-related mortality rates were 24.6% (95% CI, 22.8-26.4) at 15 years after treatment, 25.8% (95% CI, 24.0-27.8) at 20 years after treatment, and 26.4% (95% CI, 24.5-28.5) at 25 years after treatment. The 20-year mortality rate was 8.6% (95% CI, 6.2-11.9) for younger patients (<= 60 years) with small tumors (<= 11 mm) and 40.1% (95% CI, 36.1-44.3) for older patients (>60 years) with large tumors (>11 mm).
CONCLUSIONS AND RELEVANCE In this large series of patients with ocular melanoma treated conservatively with proton beam irradiation, the cumulative melanoma-related mortality rates continued to increase up to 23 years after treatment. Annual rates decreased considerably (to <1%) 14 years after treatment. Information regarding the long-term risk of dying of uveal melanoma may be useful to clinicians when counseling patients.
C1 [Lane, Anne Marie; Kim, Ivana K.; Gragoudas, Evangelos S.] Massachusetts Eye & Ear Infirm, Retina Serv, Boston, MA 02114 USA.
RP Gragoudas, ES (reprint author), Massachusetts Eye & Ear Infirm, Retina Serv, 243 Charles St, Boston, MA 02114 USA.
EM evangelos_gragoudas@meei.harvard.edu
FU MEEI Melanoma Research Fund
FX The MEEI Melanoma Research Fund provided financial support only.
NR 19
TC 5
Z9 6
U1 1
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUL
PY 2015
VL 133
IS 7
BP 792
EP 796
DI 10.1001/jamaophthalmol.2015.0887
PG 5
WC Ophthalmology
SC Ophthalmology
GA CM6TO
UT WOS:000357823100012
PM 25905597
ER
PT J
AU Reddy, AK
Gonzalez, MA
Henry, CR
Yeh, S
Sobrin, L
Albini, TA
AF Reddy, Ashvini K.
Gonzalez, Marco A.
Henry, Christopher R.
Yeh, Steven
Sobrin, Lucia
Albini, Thomas A.
TI Diagnostic Sensitivity of Indocyanine Green Angiography for Birdshot
Chorioretinopathy
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID RETINOCHOROIDITIS
AB IMPORTANCE To describe a cohort of patients with birdshot chorioretinopathy who did not manifest birdshot lesions on clinical examination but had retinal vasculitis, low-grade to moderate vitritis, and hypocyanescent lesions on indocyanine green angiography (ICGA).
OBSERVATIONS Case series of 3 patients with mild to moderate vitritis and retinal vasculitis without definite birdshot lesions on clinical examination evaluated from January 2007 to December 2014 at 4 academic ophthalmology centers. All patients' results were positive for human leukocyte antigen-A29. All cases had hypocyanescent lesions visible on ICGA but not detectable on fluorescein angiography.
CONCLUSIONS AND RELEVANCE Patients with retinal vasculitis and low-grade vitritis with or without macular edema may have birdshot chorioretinopathy evident on ICGA before lesions are visible on clinical examination or fluorescein angiography. Expanding birdshot chorioretinopathy diagnostic criteria to include the presence of hypocyanescent lesions on ICGA could improve the sensitivity of diagnosis.
C1 [Reddy, Ashvini K.] Univ Virginia, Dept Ophthalmol, Charlottesville, VA USA.
[Gonzalez, Marco A.; Henry, Christopher R.; Albini, Thomas A.] Univ Miami, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
[Yeh, Steven] Emory Univ, Atlanta, GA 30322 USA.
[Sobrin, Lucia] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
RP Albini, TA (reprint author), Univ Miami, Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM talbini@med.miami.edu
OI Albini, Thomas/0000-0003-2199-9047
FU Santen
FX All authors have completed and submitted the ICMJE Form for Disclosure
of Potential Conflicts of Interest. Dr Sobrin reported receiving
personal fees from Santen outside of this work. No other disclosures
were reported.
NR 14
TC 1
Z9 1
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUL
PY 2015
VL 133
IS 7
BP 840
EP 843
DI 10.1001/jamaophthalmol.2015.0822
PG 4
WC Ophthalmology
SC Ophthalmology
GA CM6TO
UT WOS:000357823100019
PM 25906054
ER
PT J
AU Schatz, M
Zeiger, RS
Yang, SJ
Chen, WS
Sajjan, S
Allen-Ramey, F
Camargo, CA
AF Schatz, Michael
Zeiger, Robert S.
Yang, Su-Jau
Chen, Wansu
Sajjan, Shiva
Allen-Ramey, Felicia
Camargo, Carlos A., Jr.
TI Prospective Study on the Relationship of Obesity to Asthma Impairment
and Risk
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
LA English
DT Article
DE Asthma; BMI; Overweight; Obesity; Asthma control; Asthma risk; Asthma
impairment; Asthma exacerbations; Short-acting beta-agonists
ID BODY-MASS INDEX; PERSISTENT ASTHMA; BARIATRIC SURGERY; WEIGHT-LOSS;
ADULTS; SEVERITY; PHENOTYPE; DISEASE; AGE; EXACERBATIONS
AB BACKGROUND: Although studies consistently show an association between obesity and increased asthma incidence, the role of obesity in asthma control is less clear.
OBJECTIVE: The objective of this study was to evaluate the association between baseline body mass index (BMI) and measures of subsequent asthma control in a large real-world cohort of adults with persistent asthma.
METHODS: In Kaiser Permanente Southern California (KPSC), a large managed care organization, we identified adults with persistent asthma in 2006, continuous health plan enrollment in 2007 and 2008, and a BMI measurement in 2006 or 2007. Each patient's last BMI measure in 2006 or 2007 was categorized into a BMI group: normal (<25 kg/m(2)), overweight (25-29.9 kg/m(2)), or obese (>= 30 kg/m(2)). Asthma control outcomes in 2008 included asthma hospitalizations or emergency department visits (EDHO), oral corticosteroid dispensings linked to an asthma encounter (OCS), and dispensing of >= 7 short-acting beta-agonist canisters (SABA7). Multivariable analyses were conducted to assess the relationships of BMI categories with the risk of the asthma control outcomes after controlling for potential confounders.
RESULTS: In the 10,233 eligible adults-after adjusting for potential demographic, comorbidity, and prior utilization confounders-we found an increased relative risk (RR) of EDHO in overweight and obese (RR 1.40, 95% CI 1.10-1.78) individuals. Only obesity was associated in adjusted analyses with a significant increased relative risk of SABA7 (RR 1.27, 95% CI 1.15-1.40).
CONCLUSIONS: Elevated BMI, particularly obesity, is associated with subsequent poor asthma control, especially in the risk domain (exacerbations). These findings further support the importance of facilitating weight loss in overweight and obese adults with asthma. (C) 2015 American Academy of Allergy, Asthma & Immunology
C1 [Schatz, Michael; Zeiger, Robert S.] Kaiser Permanente Med Ctr, Dept Allergy, San Diego, CA 92111 USA.
[Schatz, Michael; Zeiger, Robert S.] Kaiser Permanente Med Ctr, Dept Allergy, Los Angeles, CA 90034 USA.
[Yang, Su-Jau; Chen, Wansu] Kaiser Permanente Med Ctr, Dept Res & Evaluat, San Diego, CA 92111 USA.
[Yang, Su-Jau; Chen, Wansu] Kaiser Permanente Med Ctr, Dept Res & Evaluat, Los Angeles, CA 90034 USA.
[Sajjan, Shiva; Allen-Ramey, Felicia] Merck & Co Inc, Dept Global Hlth Outcomes, West Point, PA USA.
[Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA.
RP Schatz, M (reprint author), Kaiser Permanente Med Ctr, Dept Allergy, 7060 Clairemont Mesa Blvd, San Diego, CA 92111 USA.
EM michael.x.schatz@kp.org
FU Merck and Co., Inc.
FX This study was supported by a research grant from Merck and Co., Inc.
NR 40
TC 8
Z9 8
U1 1
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2213-2198
EI 2213-2201
J9 J ALLER CL IMM-PRACT
JI J. Allergy Clin. Immunol.-Pract.
PD JUL-AUG
PY 2015
VL 3
IS 4
BP 560
EP +
DI 10.1016/j.jaip.2015.03.017
PG 7
WC Allergy; Immunology
SC Allergy; Immunology
GA CM4XX
UT WOS:000357690800014
PM 25975622
ER
PT J
AU Teodorescu, M
Broytman, O
Curran-Everett, D
Sorkness, RL
Crisafi, G
Bleecker, ER
Erzurum, S
Gaston, BM
Wenzel, SE
Jarjour, NN
AF Teodorescu, Mihaela
Broytman, Oleg
Curran-Everett, Douglas
Sorkness, Ronald L.
Crisafi, Gina
Bleecker, Eugene R.
Erzurum, Serpil
Gaston, Benjamin M.
Wenzel, Sally E.
Jarjour, Nizar N.
CA Natl Inst Hlth
Natl Heart Lung Blood Inst
Severe Asthma Res Program SARP Inv
TI Obstructive Sleep Apnea Risk, Asthma Burden, and Lower Airway
Inflammation in Adults in the Severe Asthma Research Program (SARP) II
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
LA English
DT Article
DE Asthma; Sleep apnea; Obstructive; Airway inflammation
ID QUALITY-OF-LIFE; TO-CONTROL ASTHMA; BODY-MASS INDEX; DAYTIME SLEEPINESS;
PERSISTENT ASTHMA; NOCTURNAL ASTHMA; TREAT ASTHMA; QUESTIONNAIRE;
ASSOCIATION; PHENOTYPE
AB BACKGROUND: Obstructive sleep apnea (OSA) may worsen asthma, but large studies are lacking and the underlying mechanisms are unknown.
OBJECTIVE: The objective of this study was to determine the prevalence of OSA risk among patients with asthma of different severity compared with normal controls (NC), and among asthmatics, to test the relationship of OSA risk with asthma burden and airway inflammation.
METHODS: Subjects with severe (SA, n = 94) and nonsevere asthma (NSA, n = 161), and NC (n = 146) were recruited in an add-on substudy, to the observational Severe Asthma Research Program (SARP) II; subjects completed sleep quality, sleepiness and OSA risk (Sleep Apnea scale of the Sleep Disorders Questionnaire [SA-SDQ]) questionnaires, and clinical assessments. Sputum was induced in a subset of asthmatics.
RESULTS: Relative to NC, despite similar sleep duration, the subjects with SA and NSA had worse sleep quality, were sleepier, and had higher SA-SDQ scores. Among asthmatics, higher SA-SDQ was associated with increased asthma symptoms, beta-agonist use, health care utilization, and worse asthma quality of life. A significant association of SA-SDQ with sputum polymorphonuclear cells% was noted: each increase in SA-SDQ by its standard deviation (6.85 units) was associated with a rise in % sputum neutrophils of 7.78 (95% CI 2.33-13.22, P = .0006), independent of obesity and other confounders.
CONCLUSIONS: OSA symptoms are more prevalent among asthmatics, in whom they are associated with higher disease burden. OSA risk is associated with a neutrophilic airway inflammation in asthma, which suggests that OSA may be an important contributor to the neutrophilic asthma. Further studies are necessary to confirm these findings and better understand the mechanistic underpinnings of this relationship. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology
C1 [Teodorescu, Mihaela; Broytman, Oleg] William S Middleton Mem Vet Adm Med Ctr, Med Serv, James B Skatrud Pulm Sleep Res Lab, Madison, WI USA.
[Teodorescu, Mihaela; Broytman, Oleg; Sorkness, Ronald L.; Crisafi, Gina; Jarjour, Nizar N.] Univ Wisconsin, Sch Med & Publ Hlth, Div Allergy Pulm & Crit Care Med, Madison, WI 53792 USA.
[Teodorescu, Mihaela] Univ Wisconsin, Sch Med & Publ Hlth, Ctr Sleep Med & Sleep Res Wisconsin Sleep, Madison, WI 53792 USA.
[Curran-Everett, Douglas] Natl Jewish Hlth, Div Biostat & Bioinformat, Denver, CO USA.
[Curran-Everett, Douglas] Univ Colorado, Colorado Sch Publ Hlth, Dept Biostat & Informat, Denver, CO 80202 USA.
[Bleecker, Eugene R.] Wake Forest Univ, Bowman Gray Sch Med, Dept Med, Winston Salem, NC 27103 USA.
[Erzurum, Serpil] Cleveland Clin, Lerner Res Inst, Dept Pathobiol, Cleveland, OH 44106 USA.
[Gaston, Benjamin M.] Univ Virginia, Sch Med, Dept Pediat, Div Resp Med, Charlottesville, VA 22908 USA.
[Wenzel, Sally E.] Univ Pittsburgh, Sch Med, Asthma Inst, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA.
RP Teodorescu, M (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, K4-910 CSC 9988,600 Highland Ave, Madison, WI 53792 USA.
EM mt3@medicine.wisc.edu
FU National Institutes of Health (NIH) [HL069170, HL069174, HL069167,
HL069116, UL1RR025011]; Department of Medicine and University of
Wisconsin School of Medicine and Public Health; Medical Education and
Research Committee-New Investigator Award; University of Wisconsin;
Department of Veterans Affairs for asthma-sleep apnea research
FX National Institutes of Health (NIH) HL069170, HL069174, HL069167,
HL069116, UL1RR025011; and additional resources from the William S.
Middleton Memorial Veterans Hospital, Madison, Wis. Dr. Teodorescu
received funding from the Department of Medicine and University of
Wisconsin School of Medicine and Public Health, Medical Education and
Research Committee-New Investigator Award, University of Wisconsin, and
Department of Veterans Affairs for asthma-sleep apnea research. Mrs.
Crisafi, Drs. Broytman, Curran-Everett, Sorkness, Bleecker, Erzurum,
Gaston, Wenzel, and Jarjour report no conflicts of interest related to
this work. The content of this article is solely the responsibility of
the authors and does not represent the views of the Department of
Veterans Affairs, NIH, or the United States Government.
NR 61
TC 10
Z9 10
U1 1
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2213-2198
EI 2213-2201
J9 J ALLER CL IMM-PRACT
JI J. Allergy Clin. Immunol.-Pract.
PD JUL-AUG
PY 2015
VL 3
IS 4
BP 566
EP +
DI 10.1016/j.jaip.2015.04.002
PG 11
WC Allergy; Immunology
SC Allergy; Immunology
GA CM4XX
UT WOS:000357690800015
PM 26004304
ER
PT J
AU Waseem, M
Leber, MJ
Wasserman, EJ
Sullivan, AF
Camargo, CA
Hasegawa, K
AF Waseem, Muhammad
Leber, Mark J.
Wasserman, Eric J.
Sullivan, Ashley F.
Camargo, Carlos A., Jr.
Hasegawa, Kohei
TI Factors associated with concordance with the nonlevel-A guideline
recommendations for emergency department patients with acute asthma
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
LA English
DT Letter
ID CARE
C1 [Waseem, Muhammad] Lincoln Med & Mental Hlth Ctr, Dept Emergency Med, New York, NY USA.
[Leber, Mark J.] Brooklyn Med Ctr, Dept Emergency Med, New York, NY USA.
[Wasserman, Eric J.] Newark Beth Israel Med Ctr, Dept Emergency Med, Newark, NJ USA.
[Sullivan, Ashley F.; Camargo, Carlos A., Jr.; Hasegawa, Kohei] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA.
RP Hasegawa, K (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, 326 Cambridge St,Suite 410, Boston, MA 02114 USA.
EM khasegawa1@partners.org
NR 9
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2213-2198
EI 2213-2201
J9 J ALLER CL IMM-PRACT
JI J. Allergy Clin. Immunol.-Pract.
PD JUL-AUG
PY 2015
VL 3
IS 4
BP 618
EP +
DI 10.1016/j.jaip.2015.03.007
PG 5
WC Allergy; Immunology
SC Allergy; Immunology
GA CM4XX
UT WOS:000357690800028
PM 25869584
ER
PT J
AU Zharikov, AD
Cannon, JR
Tapias, V
Bai, Q
Horowitz, MP
Shah, V
El Ayadi, A
Hastings, TG
Greenamyre, JT
Burton, EA
AF Zharikov, Alevtina D.
Cannon, Jason R.
Tapias, Victor
Bai, Qing
Horowitz, Max P.
Shah, Vipul
El Ayadi, Amina
Hastings, Teresa G.
Greenamyre, J. Timothy
Burton, Edward A.
TI shRNA targeting alpha-synuclein prevents neurodegeneration in a
Parkinson's disease model
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; TRANSGENIC MICE; IN-VIVO; DOPAMINE NEURONS;
LEWY BODIES; LOCUS TRIPLICATION; OXIDATIVE STRESS; ROTENONE MODEL;
GENE-THERAPY; DOUBLE-BLIND
AB Multiple convergent lines of evidence implicate both alpha-synuclein (encoded by SCNA) and mitochondrial dysfunction in the pathogenesis of sporadic Parkinson's disease (PD). Occupational exposure to the mitochondrial complex I inhibitor rotenone increases PD risk; rotenone-exposed rats show systemic mitochondrial defects but develop specific neuropathology, including alpha-synuclein aggregation and degeneration of substantia nigra dopaminergic neurons. Here, we inhibited expression of endogenous alpha-synuclein in the adult rat substantia nigra by adeno-associated virus-mediated delivery of a short hairpin RNA (shRNA) targeting the endogenous rat Snca transcript. Knockdown of alpha-synuclein by similar to 35% did not affect motor function or cause degeneration of nigral dopaminergic neurons in control rats. However, in rotenone-exposed rats, progressive motor deficits were substantially attenuated contralateral to alpha-synuclein knockdown. Correspondingly, rotenone-induced degeneration of nigral dopaminergic neurons, their dendrites, and their striatel terminals was decreased ipsilateral to alpha-synuclein knockdown. These data show that alpha-synuclein knockdown is neuroprotective in the rotenone model of PD and indicate that endogenous alpha-synuclein contributes to the specific vulnerability of dopaminergic neurons to systemic mitochondrial inhibition. Our findings are consistent with a model in which genetic variants influencing alpha-synuclein expression modulate cellular susceptibility to environmental exposures in PD patients. shRNA targeting the SNCA transcript should be further evaluated as a possible neuroprotective therapy in PD.
C1 [Zharikov, Alevtina D.; Cannon, Jason R.; Tapias, Victor; Bai, Qing; Horowitz, Max P.; Shah, Vipul; El Ayadi, Amina; Hastings, Teresa G.; Greenamyre, J. Timothy; Burton, Edward A.] Univ Pittsburgh, Sch Med, Pittsburgh Inst Neurodegenerat Dis, Pittsburgh, PA 15213 USA.
[Zharikov, Alevtina D.; Cannon, Jason R.; Tapias, Victor; Bai, Qing; Horowitz, Max P.; Shah, Vipul; El Ayadi, Amina; Hastings, Teresa G.; Greenamyre, J. Timothy; Burton, Edward A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA.
[Zharikov, Alevtina D.; Cannon, Jason R.; Greenamyre, J. Timothy; Burton, Edward A.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
[Burton, Edward A.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA 15213 USA.
RP Burton, EA (reprint author), Univ Pittsburgh, 7015 BST 3,3501 Fifth Ave, Pittsburgh, PA 15213 USA.
EM eab25@pitt.edu
OI Burton, Edward/0000-0002-8072-4636
FU BLRD VA [I01 BX000548]; NIEHS NIH HHS [R01 ES022644, ES018058, ES019879,
ES020327, ES020718, ES022644, K99 ES019879, R00 ES019879, R01 ES020327,
R01 ES020718, RC1 ES018058]; NINDS NIH HHS [NS059806, P01 NS059806]
NR 71
TC 12
Z9 12
U1 3
U2 9
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JUL
PY 2015
VL 125
IS 7
BP 2721
EP 2735
DI 10.1172/JCI64502
PG 15
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CM3AK
UT WOS:000357553300020
PM 26075822
ER
PT J
AU Li, H
Fu, YX
Wu, Q
Zhou, Y
Crossman, DK
Yang, PA
Li, J
Luo, B
Morel, LM
Kabarowski, JH
Yagita, H
Ware, CF
Hsu, HC
Mountz, JD
AF Li, Hao
Fu, Yang-Xin
Wu, Qi
Zhou, Yong
Crossman, David K.
Yang, PingAr
Li, Jun
Luo, Bao
Morel, Laurence M.
Kabarowski, Janusz H.
Yagita, Hideo
Ware, Carl F.
Hsu, Hui-Chen
Mountz, John D.
TI Interferon-induced mechanosensing defects impede apoptotic cell
clearance in lupus
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID SPLENIC MARGINAL ZONE; AUTOIMMUNE BXD2 MICE; PRECURSOR B-CELLS;
DENDRITIC CELLS; I INTERFERON; T-CELL; PATHOGENIC AUTOANTIBODIES;
ADAPTIVE IMMUNITY; LYMPHOID-TISSUES; ACTIN DYNAMICS
AB Systemic lupus erythematosus (SLE) is a severe autoimmune disease that is associated with increased circulating apoptotic cell autoantigens (AC-Ags) as well as increased type I IFN signaling. Here, we describe a pathogenic mechanism in which follicular translocation of marginal zone (MZ) B cells in the spleens of BXD2 lupus mice disrupts marginal zone macrophages (MZMs), which normally clear AC debris and prevent follicular entry of AC-Ags. Phagocytosis of ACs by splenic MZMs required the megakaryoblastic leukemia 1 (MKL1) transcriptional coactivator-mediated mechanosensing pathway, which was maintained by MZ B cells through expression of membrane lymphotoxin-alpha 1 beta 2 (mLT). Specifically, type I IFN-induced follicular shuttling of mLT-expressing MZ B cells disengaged interactions between these MZ B cells and up receptor-expressing MZMs, thereby downregulating MKL1 in MZMs. Loss of MKL1 expression in MZMs led to defective F-actin polymerization, inability to clear ACs, and, eventually, MZM dissipation. Aggregation of plasmacytoid DCs in the splenic perifollicular region, follicular translocation of MZ B cells, and loss of MKL1 and MZMs were also observed in an additional murine lupus model and in the spleens of patients with SLE. Collectively, the results suggest that lupus might be interrupted by strategies that maintain or enhance mechanosensing signaling in the MZM barrier to prevent follicular entry of AC-Ags.
C1 [Li, Hao; Wu, Qi; Yang, PingAr; Li, Jun; Luo, Bao; Hsu, Hui-Chen; Mountz, John D.] Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.
[Fu, Yang-Xin] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA.
[Zhou, Yong] UAB, Dept Med, Div Pulm Allergy & Crit Care Med, Birmingham, AL USA.
[Crossman, David K.] UAB, Heflin Ctr Genom Sci, Birmingham, AL USA.
[Crossman, David K.] UAB, Dept Genet, Div Genet Res, Birmingham, AL USA.
[Morel, Laurence M.] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL USA.
[Kabarowski, Janusz H.; Mountz, John D.] UAB, Dept Microbiol, Birmingham, AL USA.
[Yagita, Hideo] Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan.
[Ware, Carl F.] Sanford Burnham Med Res Inst, Infect & Inflammatory Dis Ctr, La Jolla, CA USA.
[Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Hsu, HC (reprint author), Shelby Rm 311,1825 Univ Blvd, Birmingham, AL 35294 USA.
EM rheu078@uab.edu; jdmountz@uab.edu
RI Li, Hao/N-7406-2015;
OI Li, Hao/0000-0002-2171-8826; fu, yang-xin/0000-0001-8441-6617; Crossman,
David/0000-0002-0981-169X
FU NIH [R01-AI-071110, R01-AI-083705, R01-A1058150, R01-HL-124076, 5
R01-AI048073, P30-AR-048311, P30-AI-027767]; Department of Veterans
Affairs [1I01BX000600-01]; Lupus Research Institute; Rheumatology
Research Foundation; American Heart Association [14GRNT20180023];
American Thoracic Society Recognition Award; UAB RDCC [P30-AR-048311];
Cancer Center [CA-013148]; Center for AIDS Research grant [AI-027767]
FX This worked was supported by grants from the NIH (R01-AI-071110, to J.D.
Mountz; R01-AI-083705, to H.C. Hsu; R01-A1058150, to L.M. Morel;
R01-HL-124076, to Y. Zhou; 5 R01-AI048073, to C.F. Ware; P30-AR-048311,
to the UAB Rheumatic Diseases Core Centers [RDCC], including the
Comprehensive Flow Cytometry Core and the Analytic Imaging and
Immunore-agent Core; and P30-AI-027767, to the UAB Center for AIDS
Research Comprehensive Flow Cytometry Core). Support was also provided
by a Merit Review grant from the Department of Veterans Affairs
(1I01BX000600-01, to J.D. Mountz); Novel Research grants from the Lupus
Research Institute (to J.H. Kabarowski and H.C. Hsu); the Rheumatology
Research Foundation (to J.D. Mountz); the American Heart Association
(14GRNT20180023, to Y. Zhou); an American Thoracic Society Recognition
Award (to Y. Zhou); and the UAB RDCC P30 Pilot and Feasibility Project
(P30-AR-048311, to J. Li). We thank Michael Crowley and Bing Xue,
supported by a Cancer Center grant (CA-013148) and a Center for AIDS
Research grant (AI-027767), for performing the GeneChip analysis. We
thank UAB Tissue Procurement for providing normal and SLE splenic tissue
sections. We also thank Fiona Hunter for careful review of the
manuscript.
NR 62
TC 9
Z9 9
U1 2
U2 6
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JUL
PY 2015
VL 125
IS 7
BP 2877
EP 2890
DI 10.1172/JCI81059
PG 14
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CM3AK
UT WOS:000357553300032
PM 26098211
ER
PT J
AU De Souza, A
Carter, JB
Harris, NL
Ferry, JA
Duncan, LM
AF De Souza, Aieska
Carter, Joi B.
Harris, Nancy L.
Ferry, Judith A.
Duncan, Lyn M.
TI Contribution of longitudinal follow up and clinical pathological
correlation in the diagnosis CD30-positive skin infiltrates
SO JOURNAL OF CUTANEOUS PATHOLOGY
LA English
DT Article
DE anaplastic large cell lymphoma; CD30; CD30+lymphoproliferative disorder;
lymphomatoid papulosis
ID LARGE-CELL LYMPHOMA; LYMPHOPROLIFERATIVE DISORDERS; CUTANEOUS LYMPHOMAS;
PAPULOSIS; CLASSIFICATION; EXPRESSION; SPECTRUM; DISEASE
AB The diagnosis of a CD30+ cutaneous infiltrate is often difficult and requires clinicopathologic correlation. To further evaluate this challenge, initial clinical and histopathologic diagnoses were correlated with final clinicopathologic diagnosis in 44 cases with CD30 immunopositivity. Dermatopathologic evaluation confirmed the initial clinical diagnosis in 65% of the suspected benign cases, all cases of suspected lymphomatoid papulosis (LyP), and 72% of clinically malignant cases. In the 25 patients with clinical suspicion for lymphoma, the histopathologic diagnoses included lymphoma in 18, LyP in 2, CD30+ lymphoproliferative disorder (CD30 LPD) in 3 and hypersensitivity reaction in 2 patients. Clinicopathologic correlation led to a change in three cases diagnosed histopathologically as anaplastic large cell lymphoma (ALCL) reclassified as LyP type C, and one patient diagnosed as CD30 LPD clinically evolved as herpes virus infection. Furthermore, five cases reported as CD30 LPD received more specific diagnoses after clinicopathologic correlation (LyP type C in three, and ALCL in two patients). Clinicopathologic correlation is essential in establishing the correct diagnosis of CD30 LPD, in particular the distinction of ALCL from LyP type C. In this setting, the histopathologic diagnosis of CD30 LPD is advisable in the absence of clinical data.
C1 [De Souza, Aieska; Carter, Joi B.] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA.
[Harris, Nancy L.; Ferry, Judith A.; Duncan, Lyn M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Harris, Nancy L.; Ferry, Judith A.; Duncan, Lyn M.] Harvard Univ, Sch Med, Boston, MA USA.
RP Duncan, LM (reprint author), Massachusetts Gen Hosp, Dermatopathol Unit WRN 825, 55 Fruit St, Boston, MA 02114 USA.
EM duncan@helix.mgh.harvard.edu
NR 22
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0303-6987
EI 1600-0560
J9 J CUTAN PATHOL
JI J. Cutan. Pathol.
PD JUL
PY 2015
VL 42
IS 7
BP 452
EP 458
DI 10.1111/cup.12510
PG 7
WC Dermatology; Pathology
SC Dermatology; Pathology
GA CN0RS
UT WOS:000358121700003
PM 25931140
ER
PT J
AU Ronis, SD
Baldwin, CD
Blumkin, A
Kuhlthau, K
Szilagyi, PG
AF Ronis, Sarah D.
Baldwin, Constance D.
Blumkin, Aaron
Kuhlthau, Karen
Szilagyi, Peter G.
TI Patient-Centered Medical Home and Family Burden in Attention-Deficit
Hyperactivity Disorder
SO JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS
LA English
DT Article
ID HEALTH-CARE NEEDS; QUALITY-OF-LIFE; DEFICIT/HYPERACTIVITY DISORDER;
CHILDREN; ADHD; ADOLESCENTS; CHILDHOOD; DIAGNOSIS; PATTERNS; COSTS
AB Objective:
Attention-deficit hyperactivity disorder (ADHD) can impair child health and functioning, but its effects on the family's economic burden are not well understood. The authors assessed this burden in US families of children with ADHD, and the degree to which access to a patient-centered medical home (PCMH) might reduce this burden.
Methods:
We conducted cross-sectional analyses of 2005-2006 and 2009-2010 National Surveys of Children with Special Health Care Needs, focusing on families of children with ADHD. They defined family economic burden as (1) family financial problems (annual expenses for the child's health care or illness-related financial problems for the family) and/or (2) family employment problems (job loss, work time loss, or failure to change jobs to avoid insurance loss). Relative risk models assessed associations between PCMH and family economic burden, adjusted for child age, sex, ethnicity, ADHD severity, poverty status, caregiver education, and insurance.
Results:
In 2009, 26% of families reported financial problems because of the child's ADHD, 2.1% reported out-of-pocket expenses >5% of income, and 36% reported employment problems. Only 38% reported care that met all 5 criteria for a PCMH (similar to rates in 2005-2006). In multivariable analysis, care in a PCMH was associated with 48% lower relative risk (RR) of financial problems (RR = 0.52, p < .001) and 36% lower relative risk of employment problems (RR = 0.64, p < .001). Among PCMH components, family-centered care and care coordination were more strongly associated with lower burden.
Conclusions:
The economic burdens of families with ADHD are significant but may be alleviated by family-centered care and care coordination in a medical home.
C1 [Ronis, Sarah D.] Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Dept Pediat, Div Gen Pediat & Adolescent Med, Cleveland, OH 44106 USA.
[Baldwin, Constance D.; Blumkin, Aaron] Univ Rochester, Dept Pediat, Div Gen Pediat, Rochester, NY USA.
[Kuhlthau, Karen] Massachusetts Gen Hosp, Child & Adolescent Hlth Policy, Boston, MA 02114 USA.
[Szilagyi, Peter G.] Univ Calif Los Angeles, Dept Pediat, Div Gen Pediat, Los Angeles, CA 90024 USA.
RP Ronis, SD (reprint author), Rainbow Babies & Childrens Hosp, Dept Pediat, 11100 Euclid Ave,Mailstop RBC 6019, Cleveland, OH 44106 USA.
EM sarah.ronis@uhhospitals.org
FU NRSA [T32HP12002-24-00]
FX An NRSA training grant T32HP12002-24-00 supported S. D. Ronis for this
study.
NR 28
TC 0
Z9 0
U1 3
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0196-206X
EI 1536-7312
J9 J DEV BEHAV PEDIATR
JI J. Dev. Behav. Pediatr.
PD JUL-AUG
PY 2015
VL 36
IS 6
BP 417
EP 425
DI 10.1097/DBP.0000000000000161
PG 9
WC Behavioral Sciences; Psychology, Developmental; Pediatrics
SC Behavioral Sciences; Psychology; Pediatrics
GA CM9CA
UT WOS:000358002400002
PM 26035140
ER
PT J
AU Uchida, M
Spencer, AE
Biederman, J
Castro, VM
Kenworthy, T
Chan, J
Rosales, AM
Newton-Cheh, C
Perlis, RH
AF Uchida, Mai
Spencer, Andrea E.
Biederman, Joseph
Castro, Victor M.
Kenworthy, Tara
Chan, James
Rosales, Ana M.
Newton-Cheh, Christopher
Perlis, Roy H.
TI A Systematic Evaluation of the QTc Interval and Antidepressants in
Youth: An Electronic Health Record Study
SO JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS
LA English
DT Article
ID CHILDREN; SUICIDE
AB Objective:
The US Food and Drug Administration announced that citalopram was associated with dose-related prolongation of the QTc interval in adults. This study aimed to assess how antidepressants affect QTc intervals in children. The authors hypothesized that some antidepressants would show an association with QTc prolongation.
Methods:
An electronic medical record review was conducted of children aged 5 to 18 years in the Partners Healthcare system with at least 1 prescription of an antidepressant or methadone between February 1990 and August 2011. The authors extracted lifetime diagnoses and QTc interval of patients who had received an electrocardiogram 14 to 90 days after antidepressant or methadone prescription (N = 297). The mean QTc per medication was calculated as compared with the mean of all QTc measurements across medications. The number of patients taking medications who had QTc values in normal, borderline, abnormal, or high were also calculated.
Results:
Mean QTc values for all medications were in the normal range. The highest mean QTc was in patients on escitalopram (436 milliseconds). The mean QTc for sertraline (416 milliseconds) was significantly lower than all other drugs measured (t(331) = -2.21, p < .05). After controlling for confounding effects, none of the differences in mean QTc compared with other study drugs reached statistical significance. The greatest percentages of abnormal and high QTc values were found among patients taking paroxetine (18.8%), followed by escitalopram (15.4%). None of the children had documented ventricular arrhythmia.
Conclusion:
The results suggest that most antidepressants are not associated with prolonged QTc at doses typically prescribed for children.
C1 [Uchida, Mai; Spencer, Andrea E.; Biederman, Joseph; Kenworthy, Tara; Chan, James] Massachusetts Gen Hosp, Clin & Res Program Pediat Psychopharmacol, Boston, MA 02114 USA.
[Uchida, Mai; Spencer, Andrea E.; Biederman, Joseph; Kenworthy, Tara; Chan, James] Massachusetts Gen Hosp, Clin & Res Program Adult ADHD, Boston, MA 02114 USA.
[Castro, Victor M.] Partners HealthCare Syst, Partners Res Comp, Boston, MA USA.
[Rosales, Ana M.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
[Newton-Cheh, Christopher] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Newton-Cheh, Christopher] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
[Perlis, Roy H.] Massachusetts Gen Hosp, Ctr Expt Drugs & Diagnost, Boston, MA 02114 USA.
RP Biederman, J (reprint author), Massachusetts Gen Hosp, Clin & Res Program Pediat Psychopharmacol, 55 Fruit St,Warren 705, Boston, MA 02114 USA.
EM jbiederman@partners.org
FU Pediatric Psychopharmacology Council Fund, Massachusetts General
Hospital
FX Supported in part by the Pediatric Psychopharmacology Council Fund,
Massachusetts General Hospital.
NR 16
TC 3
Z9 3
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0196-206X
EI 1536-7312
J9 J DEV BEHAV PEDIATR
JI J. Dev. Behav. Pediatr.
PD JUL-AUG
PY 2015
VL 36
IS 6
BP 434
EP 439
DI 10.1097/DBP.0000000000000188
PG 6
WC Behavioral Sciences; Psychology, Developmental; Pediatrics
SC Behavioral Sciences; Psychology; Pediatrics
GA CM9CA
UT WOS:000358002400006
PM 26154713
ER
PT J
AU Becker, SJE
Ring, D
AF Becker, Stephanie J. E.
Ring, David
TI Epidemiology of Trapeziometacarpal Arthrosis
SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME
LA English
DT Letter
ID OSTEOARTHRITIS; PREVALENCE; JOINT; THUMB; HAND
C1 [Becker, Stephanie J. E.; Ring, David] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Orthopaed Hand & Upper Extrem Serv, Boston, MA 02163 USA.
RP Becker, SJE (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Orthopaed Hand & Upper Extrem Serv, Boston, MA 02163 USA.
OI Ring, David/0000-0002-6506-4879
NR 7
TC 0
Z9 0
U1 1
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0363-5023
EI 1531-6564
J9 J HAND SURG-AM
JI J. Hand Surg.-Am. Vol.
PD JUL
PY 2015
VL 40
IS 7
BP 1506
EP 1506
DI 10.1016/j.jhsa.2015.04.038
PG 1
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA CM7YD
UT WOS:000357911500040
PM 26095062
ER
PT J
AU Schiehser, DM
Twamley, EW
Liu, L
Matevosyan, A
Filoteo, JV
Jak, AJ
Orff, HJ
Hanson, KL
Sorg, SF
Delano-Wood, L
AF Schiehser, Dawn M.
Twamley, Elizabeth W.
Liu, Lin
Matevosyan, Adelina
Filoteo, J. Vincent
Jak, Amy J.
Orff, Henry J.
Hanson, Karen L.
Sorg, Scott F.
Delano-Wood, Lisa
TI The Relationship Between Postconcussive Symptoms and Quality of Life in
Veterans With Mild to Moderate Traumatic Brain Injury
SO JOURNAL OF HEAD TRAUMA REHABILITATION
LA English
DT Article
ID WORLD-HEALTH-ORGANIZATION; WHOQOL-BREF; HEAD-INJURY; FATIGUE;
COMPLAINTS; INSOMNIA; SWEDEN
AB Objective:
To assess the relationship between postconcussive symptoms and quality of life (QOL) in Veterans with mild to moderate traumatic brain injury (TBI).
Methods:
Sixty-one Operation Enduring Freedom/Operation Iraqi Freedom/Persian Gulf War Veterans with a history of mild or moderate TBI, more than 6 months postinjury, and 21 demographically matched Veteran controls were administered self-report measures of QOL (World Health Organization Quality of Life-BREF) and postconcussive symptom severity (Neurobehavioral Symptom Inventory).
Results:
Perceived QOL was significantly worse in Veterans with mild-moderate TBI than in controls. In the TBI group, QOL was predominantly associated with affective symptoms, and moderate to strong correlations with fatigue and depression were evident across all QOL areas. Multivariate analyses revealed depression and fatigue to be the best predictors of Psychological, Social, and Environmental QOL, whereas sleep difficulty best predicted Physical QOL in mild-moderate TBI.
Conclusion:
Veterans with post-acute mild-moderate TBI evidence worse QOL than demographically matched Veteran controls. Affective symptoms, and specifically those of fatigue, depression, and sleep difficulty, appear to be the most relevant postconcussive symptoms predicting QOL in this population. These findings underscore the importance of examining specific symptoms as they relate to post-acute TBI QOL and provide guidance for treatment and intervention studies.
C1 [Schiehser, Dawn M.; Twamley, Elizabeth W.; Matevosyan, Adelina; Filoteo, J. Vincent; Jak, Amy J.; Hanson, Karen L.; Delano-Wood, Lisa] VA San Diego Healthcare Syst, San Diego, CA USA.
[Schiehser, Dawn M.; Twamley, Elizabeth W.; Filoteo, J. Vincent; Jak, Amy J.; Orff, Henry J.; Hanson, Karen L.; Delano-Wood, Lisa] Univ Calif San Diego, Sch Med, Dept Psychiat, La Jolla, CA 92093 USA.
[Liu, Lin] Univ Calif San Diego, Sch Med, Dept Family & Prevent Med, La Jolla, CA 92093 USA.
[Twamley, Elizabeth W.; Jak, Amy J.; Orff, Henry J.; Hanson, Karen L.; Delano-Wood, Lisa] VASDHS, Ctr Excellence Stress & Mental Hlth, San Diego, CA USA.
[Sorg, Scott F.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Schiehser, DM (reprint author), VA San Diego Healthcare Syst 151B, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.
EM dschiehser@ucsd.edu
FU VA Career Development award; Department of Defense award
FX This study was supported by VA Career Development (D.M.S. and L.D-W.)
and Department of Defense (L.D-W.) awards. The authors thank Russell
Kim, Elisa Lanni, and Norman Luc for their help with data collection and
compilation. They also thank the patients, staff, and volunteers
associated with the VA San Diego Healthcare System for their involvement
in this study.
NR 31
TC 4
Z9 4
U1 4
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0885-9701
EI 1550-509X
J9 J HEAD TRAUMA REHAB
JI J. Head Trauma Rehabil.
PD JUL-AUG
PY 2015
VL 30
IS 4
BP E21
EP E28
DI 10.1097/HTR.0000000000000065
PG 8
WC Clinical Neurology; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA CM8JB
UT WOS:000357944800003
PM 24922041
ER
PT J
AU Linnstaedt, SD
Hu, JM
Bortsov, AV
Soward, AC
Swor, R
Jones, J
Lee, D
Peak, D
Domeier, R
Rathlev, N
Hendry, P
McLean, SA
AF Linnstaedt, Sarah D.
Hu, JunMei
Bortsov, Andrey V.
Soward, April C.
Swor, Robert
Jones, Jeffrey
Lee, David
Peak, David
Domeier, Robert
Rathlev, Niels
Hendry, Phyllis
McLean, Samuel A.
TI mu-Opioid Receptor Gene A118 G Variants and Persistent Pain Symptoms
Among Men and Women Experiencing Motor Vehicle Collision
SO JOURNAL OF PAIN
LA English
DT Article
DE Opioid-induced hyperalgesia; A118 G; mu-opioid receptor 1; motor vehicle
collision; pain
ID PERITRAUMATIC DISTRESS INVENTORY; SINGLE NUCLEOTIDE POLYMORPHISM;
POSTTRAUMATIC-STRESS-DISORDER; INDUCED HYPERALGESIA;
EMERGENCY-DEPARTMENT; ENDOGENOUS OPIOIDS; POSTOPERATIVE PAIN; SWIM
STRESS; ANALGESIA; OPRM1
AB The mu-opioid receptor 1 (OPRM1) binds endogenous opioids. Increasing evidence suggests that endogenous OPRM1 agonists released at the time of trauma may contribute to the development of posttraumatic musculoskeletal pain (MSP). In this prospective observational study, we evaluated the hypothesis that individuals with an AG or GG genotype at the OPRM1 A118 G allele, which results in a reduced response to opioids, would have less severe MSP 6 weeks after motor vehicle collision (MVC). Based on previous evidence, we hypothesized that this effect would be sex-dependent and most pronounced among women with substantial peritraumatic distress. European American men and women >= 18 years of age presenting to the emergency department after MVC and discharged to home after evaluation (N = 948) were enrolled. Assessments included genotyping and 6-week evaluation of overall MSP severity (0-10 numeric rating scale). In linear regression modeling, a significant A118 G Allele x Sex interaction was observed: an AG/GG genotype predicted reduced MSP severity among women with substantial peritraumatic distress (beta = -.925, P = .014) but not among all women. In contrast, men with an AG/GG genotype experienced increased MSP severity at 6 weeks (beta = .827, P = .019). Further studies are needed to understand the biologic mechanisms mediating observed sex differences in A118 G effects.
Perspective: These results suggest a sex-dependent mechanism by which an emotional response to trauma (distress) contributes to a biologic mechanism (endogenous opioid release) that increases MSP in the weeks after stress exposure. These results also support the hypothesis that endogenous opioids influence pain outcomes differently in men and women. (C) 2015 by the American Pain Society
C1 [Linnstaedt, Sarah D.; Hu, JunMei; Bortsov, Andrey V.; Soward, April C.; McLean, Samuel A.] Univ N Carolina, Dept Anesthesiol, TRYUMPH Res Program, Chapel Hill, NC 27599 USA.
[Linnstaedt, Sarah D.; Hu, JunMei; Bortsov, Andrey V.; Soward, April C.; McLean, Samuel A.] Univ N Carolina, Dept Anesthesiol, Chapel Hill, NC 27599 USA.
[McLean, Samuel A.] Univ N Carolina, Dept Emergency Med, Chapel Hill, NC 27599 USA.
[Swor, Robert] William Beaumont Hosp, Dept Emergency Med, Royal Oak, MI 48072 USA.
[Jones, Jeffrey] Spectrum Hlth, Dept Emergency Med, Grand Rapids, MI USA.
[Lee, David] N Shore Univ Hosp, Dept Emergency Med, Manhasset, NY USA.
[Peak, David] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
[Domeier, Robert] St Joseph Mercy Hosp, Dept Emergency Med, Ann Arbor, MI 48104 USA.
[Rathlev, Niels] Baystate Med Ctr, Dept Emergency Med, Springfield, MA USA.
[Hendry, Phyllis] Univ Florida, Coll Med, Dept Emergency Med, Jacksonville, FL USA.
RP McLean, SA (reprint author), Univ N Carolina, Med Sch Wing C,CB 7010, Chapel Hill, NC 27599 USA.
EM smclean@aims.unc.edu
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases of
the National Institutes of Health [R01AR056328]
FX Supported by the National Institute of Arthritis and Musculoskeletal and
Skin Diseases of the National Institutes of Health under Award Number
R01AR056328.
NR 50
TC 6
Z9 6
U1 0
U2 1
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1526-5900
J9 J PAIN
JI J. Pain
PD JUL
PY 2015
VL 16
IS 7
BP 637
EP 644
DI 10.1016/j.jpain.2015.03.011
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA CM5ZL
UT WOS:000357767400005
PM 25842347
ER
PT J
AU Bolognini, N
Spandri, V
Ferraro, F
Salmaggi, A
Molinari, ACL
Fregni, F
Maravita, A
AF Bolognini, Nadia
Spandri, Viviana
Ferraro, Francesco
Salmaggi, Andrea
Molinari, Alessandro C. L.
Fregni, Felipe
Maravita, Angelo
TI Immediate and Sustained Effects of 5-Day Transcranial Direct Current
Stimulation of the Motor Cortex in Phantom Limb Pain
SO JOURNAL OF PAIN
LA English
DT Article
DE Phantom limb pain; transcranial direct current stimulation; motor
cortex; phantom movement; neuroplasticity
ID CORTICAL REORGANIZATION; ELECTRICAL-STIMULATION; BRAIN-STIMULATION;
NEUROPATHIC PAIN; VISUAL FEEDBACK; PARIETAL CORTEX; DC STIMULATION;
DOUBLE-BLIND; AMPUTEES; AMPUTATION
AB The study explored the analgesic effects of transcranial direct current stimulation (tDCS) over the motor cortex on postamputation phantom limb pain (PIP). Eight subjects with unilateral lower or upper limb amputation and chronic PLP were enrolled in a crossover, double-blind, sham-controlled treatment program. For 5 consecutive days, anodal (active or sham) tDCS was applied over the motor cortex for 15 minutes at an intensity of 1.5 mA. The 5-day treatment with active, but not sham, tDCS induced a sustained decrease in background PLP and in the frequency of PLP paroxysms, which lasted for 1 week after the end of treatment. Moreover, on each day of active tDCS, patients reported an immediate PLP relief, along with an increased ability to move their phantom limb. Patients' immediate responses to sham tDCS, on the contrary, were variable, marked by an increase or decrease of PLP levels from baseline. These results show that a 5-day treatment of motor cortex stimulation with tDCS can induce stable relief from PLP in amputees. Neuromodulation targeting the motor cortex appears to be a promising option for the management of this debilitating neuropathic pain condition, which is often refractory to classic pharmacologic and surgical treatments.
Perspective: The study describes sustained and immediate effects of motor cortex stimulation by tDCS on postamputation PLP, whose analgesic action seems linked to the motor reactivation of the phantom limb. These results are helpful for the exploitation of tDCS as a therapeutic tool for the management of neuropathic pain. (C) 2015 by the American Pain Society
C1 [Bolognini, Nadia; Spandri, Viviana; Maravita, Angelo] Univ Milano Bicocca, Dept Psychol, I-20126 Milan, Italy.
[Bolognini, Nadia] IRCCS, Ist Auxol Italiano, Neuropsychol Lab, Milan, Italy.
[Spandri, Viviana; Salmaggi, Andrea] Azienda Osped Alessandro Manzoni, Dept Neurosci, Lecce, Italy.
[Ferraro, Francesco] Azienda Osped Carlo Poma, Dept Rehabil, Mantua, Italy.
[Molinari, Alessandro C. L.] Azienda Osped Alessandro Manzoni, Vasc Surg Unit, Lecce, Italy.
[Fregni, Felipe] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Spaulding Neuromodulat Ctr, Boston, MA USA.
[Fregni, Felipe] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA USA.
RP Bolognini, N (reprint author), Univ Milano Bicocca, Dept Psychol, Bldg U6,Piazza Ateneo Nuovo 1, I-20126 Milan, Italy.
EM nadia.bolognini@unimib.it
RI BOLOGNINI, NADIA/J-5746-2016
OI BOLOGNINI, NADIA/0000-0002-2921-8658
FU ATE from the University of Milano-Bicocca [2009-ATE-0293]
FX Supported by the institutional fund ATE (2009-ATE-0293) from the
University of Milano-Bicocca to N.B. and A.M.
NR 48
TC 12
Z9 12
U1 3
U2 10
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1526-5900
J9 J PAIN
JI J. Pain
PD JUL
PY 2015
VL 16
IS 7
BP 657
EP 665
DI 10.1016/j.jpain.2015.03.013
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA CM5ZL
UT WOS:000357767400007
PM 25863170
ER
PT J
AU Webel, AR
Wantland, D
Rose, CD
Kemppainen, J
Holzemer, WL
Chen, WT
Johnson, MO
Nicholas, P
Eller, LS
Chaiphibalsarisdi, P
Sefcik, E
Nokes, K
Corless, IB
Tyer-Viola, L
Kirksey, K
Voss, J
Sullivan, K
Rivero-Mendez, M
Brion, J
Iipinge, S
Phillips, JC
Portillo, C
AF Webel, Allison R.
Wantland, Dean
Rose, Carol Dawson
Kemppainen, Jeanne
Holzemer, William L.
Chen, Wei-Ti
Johnson, Mallory O.
Nicholas, Patrice
Eller, Lucille Sanzero
Chaiphibalsarisdi, Puangtip
Sefcik, Elizabeth
Nokes, Kathleen
Corless, Inge B.
Tyer-Viola, Lynda
Kirksey, Kenn
Voss, Joachim
Sullivan, Kathy
Rivero-Mendez, Marta
Brion, John
Iipinge, Scholastika
Phillips, J. Craig
Portillo, Carmen
TI A Cross-Sectional Relationship Between Social Capital, Self-Compassion,
and Perceived HIV Symptoms
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
DE Symptom; HIV; self-compassion; social capital
ID SUB-SAHARAN AFRICA; PSYCHOLOGICAL SYMPTOMS; INTERNATIONAL SAMPLE; STRESS
REDUCTION; CONTROLLED-TRIAL; MANAGEMENT; HIV/AIDS; CARE; ADHERENCE;
DISEASE
AB Context. Individual resources of social capital and self-compassion are associated with health behaviors and perceived symptoms, suggesting that both are positive resources that can be modified to improve a person's symptom experience.
Objectives. The aim was to examine the relationship between self-compassion and social capital and its impact on current HIV symptom experience in adult people living with HIV (PLWH). We further explored the impact of age on this relationship.
Methods. We conducted a cross-sectional analysis of 2182 PLWH at 20 sites in five countries. Social capital, self-compassion, and HIV symptom experience were evaluated using valid and reliable scales. To account for inflated significance associated with a large sample size, we took a random sample of 28% of subjects (n = 615) and conducted correlation analyses and zero-inflated Poisson regression, controlling for known medical and demographic variables impacting HIV symptom experience.
Results. Controlling for age, sex at birth, year of HIV diagnosis, comorbid health conditions, employment, and income, our model significantly predicted HIV symptom experience (overall model z = 5.77, P < 0.001). Employment status and social capital were consistent, negative, and significant predictors of HIV symptom experience. Self-compassion did not significantly predict HIV symptom experience. For those reporting symptoms, an increase in age was significantly associated with an increase in symptoms.
Conclusion. Employment and social capital modestly predicted current HIV symptom experience. Social capital can be incorporated into symptom management interventions, possibly as a way to reframe a person's symptom appraisal. This may be increasingly important as PLWH age. The relationship between employment status and HIV symptom experience was significant and should be explored further. (C) 2015 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
C1 [Webel, Allison R.] Case Western Reserve Univ, Frances Payne Bolton Sch Nursing, Cleveland, OH 44106 USA.
[Wantland, Dean; Holzemer, William L.; Eller, Lucille Sanzero] Rutgers Sch Nursing, Newark, NJ USA.
[Kemppainen, Jeanne] Univ North Carolina Wilmington, Wilmington, NC USA.
[Chen, Wei-Ti] Yale Univ, New Haven, CT USA.
[Johnson, Mallory O.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Nicholas, Patrice; Corless, Inge B.; Tyer-Viola, Lynda] Brigham & Womens Hosp, Global Hlth & Acad Partnerships, Boston, MA 02115 USA.
[Nicholas, Patrice; Corless, Inge B.; Tyer-Viola, Lynda] Massachusetts Gen Hosp, Inst Hlth Profess, Boston, MA 02114 USA.
[Chaiphibalsarisdi, Puangtip] Suan Sunandha Rajabhat Univ, Bangkok, Thailand.
[Sefcik, Elizabeth] Texas A&M Univ Corpus Christi, Corpus Christi, TX USA.
[Nokes, Kathleen] CUNY Hunter Coll, New York, NY 10021 USA.
[Nokes, Kathleen] Hunter Bellevue Sch Nursing, New York, NY USA.
[Kirksey, Kenn] Seton Family Hosp, Ctr Nursing Res, Austin, TX USA.
[Voss, Joachim] Univ Washington, Seattle, WA 98195 USA.
[Sullivan, Kathy] Univ Hawaii Manoa, Sch Nursing & Dent Hyg, Honolulu, HI 96822 USA.
[Rivero-Mendez, Marta] Univ Puerto Rico, San Juan, PR 00936 USA.
[Brion, John] Ohio State Univ, Coll Nursing, Columbus, OH 43210 USA.
[Iipinge, Scholastika] Univ Namibia, Windhoek, Namibia.
[Phillips, J. Craig] Univ Ottawa, Ottawa, ON, Canada.
[Rose, Carol Dawson; Portillo, Carmen] Univ Calif Sch Nursing San Francisco, Community Hlth Syst, San Francisco, CA USA.
RP Webel, AR (reprint author), Case Western Reserve Univ, Frances Payne Bolton Sch Nursing, 10900 Euclid Ave, Cleveland, OH 44106 USA.
EM allison.webel@case.edu
FU NIH [UL1 RR024131, T32NR007081, KL2RR024990, R15NR011130]; International
Pilot Award, University of Washington Center for AIDS Research [P30
AI027757]; University of British Columbia School of Nursing Helen Shore
Fund; Duke University School of Nursing Office of Research Affairs; MGH
Institute of Health Professions; University of Washington School of
Nursing Research and Intramural Funding Program; Rutgers College of
Nursing; City University of New York; Irwin Belk Distinguished
Professorship Fund-University of North Carolina Wilmington
FX This project was supported in part by: NIH UL1 RR024131; NIH
T32NR007081; NIH KL2RR024990; NIH R15NR011130; International Pilot
Award, University of Washington Center for AIDS Research (P30 AI027757);
University of British Columbia School of Nursing Helen Shore Fund; Duke
University School of Nursing Office of Research Affairs; MGH Institute
of Health Professions; University of Washington School of Nursing
Research and Intramural Funding Program; Rutgers College of Nursing;
City University of New York; and the Irwin Belk Distinguished
Professorship Fund-University of North Carolina Wilmington. The contents
of this manuscript are solely the responsibility of the authors and do
not necessarily represent the official views of the NIH or any other
funders. These funding agencies had no role in the study design; in the
collection, analysis, and interpretation of data; in the writing of the
report; or in the decision to submit the paper for publication. The
authors declare no conflicts of interest.
NR 65
TC 1
Z9 1
U1 2
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD JUL
PY 2015
VL 50
IS 1
BP 59
EP 68
DI 10.1016/j.jpainsymman.2014.12.013
PG 10
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA CM3GM
UT WOS:000357570100009
PM 25659523
ER
PT J
AU Howard, SA
Krajewski, KM
Weissman, BN
Seltzer, SE
Ramaiya, NH
Van den Abbeele, AD
AF Howard, Stephanie A.
Krajewski, Katherine M.
Weissman, Barbara N.
Seltzer, Steven E.
Ramaiya, Nikhil H.
Van den Abbeele, Annick D.
TI Cancer Imaging Training in the 21st Century: An Overview of Where We
Are, and Where We Need To Be
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Article
DE Cancer imaging; residency curriculum; oncoradiology
ID GASTROINTESTINAL STROMAL TUMORS; POSITRON-EMISSION-TOMOGRAPHY; IMATINIB
MESYLATE; RESPONSE CRITERIA; COMPUTED-TOMOGRAPHY; TARGETED THERAPIES;
LUNG-CANCER; IMMUNOTHERAPY; PROGRESSION; TOXICITIES
AB Advances in cancer care over the past decade have significantly changed treatment algorithms and life expectancies. Time from cancer diagnosis to death is rapidly increasing, as new, targeted therapies are developed, many prolonging life even in advanced disease. Tumors are now genotyped at diagnosis, allowing personalization of treatment. The FDA is continually approving new drugs that quickly become the standard of care for common tumors; the impact of these drugs and their side effects is monitored with imaging, and accurate interpretation of imaging studies has become essential as these patients live longer. Oncologists rely on radiologists to understand new patterns of treatment response and novel drug side effects that are associated with new drug classes, increasing the knowledge required for accurate image interpretation. These factors have led to the demand for dedicated cancer imaging training for radiologists, who can integrate findings throughout the body on various imaging modalities. In addition, we need to expand radiology's focus beyond diagnosis, staging, and restaging of tumors, and include education about the influence of genomics on tumor characterization and guidance for cancer care, the spectrum of treatment response, and the imaging characteristics of adverse events associated with various therapies. The time has come, therefore, to formally incorporate, as part of radiology residency, a distinct cancer imaging curriculum that is standardized, tested, and will allow the new generation of radiologists to effectively communicate with and assist their oncologic colleagues and optimally contribute to the care of patients with cancer.
C1 [Howard, Stephanie A.; Krajewski, Katherine M.; Ramaiya, Nikhil H.; Van den Abbeele, Annick D.] Dana Farber Canc Inst, Dept Radiol, Boston, MA 02115 USA.
[Howard, Stephanie A.; Krajewski, Katherine M.; Weissman, Barbara N.; Seltzer, Steven E.; Ramaiya, Nikhil H.; Van den Abbeele, Annick D.] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA.
[Howard, Stephanie A.; Krajewski, Katherine M.; Weissman, Barbara N.; Seltzer, Steven E.; Ramaiya, Nikhil H.; Van den Abbeele, Annick D.] Harvard Univ, Sch Med, Boston, MA USA.
RP Howard, SA (reprint author), Dana Farber Canc Inst, Dept Radiol, 450 Brookline Ave, Boston, MA 02115 USA.
EM sahoward@parmers.org
NR 31
TC 3
Z9 3
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD JUL
PY 2015
VL 12
IS 7
BP 714
EP 720
DI 10.1016/j.jacr.2015.03.044
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CM8QR
UT WOS:000357967200019
PM 26143565
ER
PT J
AU Perry, DJ
Kwan, SW
Bhargava, P
AF Perry, Don J.
Kwan, Sharon W.
Bhargava, Puneet
TI Patient-Centered Clinical Training in Radiology
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Editorial Material
C1 [Perry, Don J.; Kwan, Sharon W.; Bhargava, Puneet] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA.
[Bhargava, Puneet] Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Diagnost Imaging Serv, Seattle, WA USA.
RP Perry, DJ (reprint author), Univ Washington, Med Ctr, Dept Radiol, RR215,Mailbox 357115,1959 NE Pacific St, Seattle, WA 98195 USA.
EM perrymed@gmail.com
NR 12
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD JUL
PY 2015
VL 12
IS 7
BP 724
EP 727
DI 10.1016/j.jacr.2014.12.013
PG 4
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CM8QR
UT WOS:000357967200021
PM 26143566
ER
PT J
AU Pfister, DG
Spencer, S
Brizel, DM
Burtness, B
Busse, PM
Caudell, JJ
Cmelak, AJ
Colevas, AD
Dunphy, F
Eisele, DW
Foote, RL
Gilbert, J
Gillison, ML
Haddad, RI
Haughey, BH
Hicks, WL
Hitchcock, YJ
Jimeno, A
Kies, MS
Lydiatt, WM
Maghami, E
McCaffrey, T
Mell, LK
Mittal, BB
Pinto, HA
Ridge, JA
Rodriguez, CR
Samant, S
Shah, JR
Weber, RS
Wolf, GT
Worden, F
Yom, SS
McMillian, N
Hughes, M
AF Pfister, David G.
Spencer, Sharon
Brizel, David M.
Burtness, Barbara
Busse, Paul M.
Caudell, Jimmy J.
Cmelak, Anthony J.
Colevas, A. Dimitrios
Dunphy, Frank
Eisele, David W.
Foote, Robert L.
Gilbert, Jill
Gillison, Maura L.
Haddad, Robert I.
Haughey, Bruce H.
Hicks, Wesley L., Jr.
Hitchcock, Ying J.
Jimeno, Antonio
Kies, Merrill S.
Lydiatt, William M.
Maghami, Ellie
McCaffrey, Thomas
Mell, Loren K.
Mittal, Bharat B.
Pinto, Harlan A.
Ridge, John A.
Rodriguez, Cristina R.
Samant, Sandeep
Shah, Jatin R.
Weber, Randal S.
Wolf, Gregory T.
Worden, Frank
Yom, Sue S.
McMillian, Nicole
Hughes, Miranda
TI Head and Neck Cancers, Version 1.2015 Featured Updates to the NCCN
Guidelines
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Article
ID PROTON-BEAM THERAPY; CARBON ION RADIOTHERAPY; INTENSITY-MODULATED
RADIOTHERAPY; SALIVARY-GLAND TUMORS; RANDOMIZED CLINICAL-TRIAL;
SQUAMOUS-CELL CARCINOMA; FAST-NEUTRON THERAPY; QUALITY-OF-LIFE;
HUMAN-PAPILLOMAVIRUS; RADIATION-THERAPY
AB These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Head and Neck (H&N) Cancers. These Insights describe the different types of particle therapy that may be used to treat H&N cancers, in contrast to traditional radiation therapy (RT) with photons (x-ray). Research is ongoing regarding the different types of particle therapy, including protons and carbon ions, with the goals of reducing the long-term side effects from RI and improving the therapeutic index. For the 2015 update, the NCCN H&N Cancers Panel agreed to delete recommendations for neutron therapy for salivary gland cancers, because of its limited availability, which has decreased over the past 2 decades; the small number of patients in the United States who currently receive this treatment; and concerns that the toxicity of neutron therapy may offset potential disease control advantages.
C1 [Pfister, David G.; Shah, Jatin R.] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA.
[Spencer, Sharon] Univ Alabama Birmingham, Comprehens Canc Ctr, Birmingham, AL USA.
[Brizel, David M.; Dunphy, Frank] Duke Canc Inst, Durham, NC USA.
[Burtness, Barbara] Yale Canc Ctr, Smilow Canc Hosp, New Haven, CT USA.
[Busse, Paul M.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Caudell, Jimmy J.; McCaffrey, Thomas] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[Cmelak, Anthony J.; Gilbert, Jill] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Colevas, A. Dimitrios; Pinto, Harlan A.] Stanford Canc Inst, Stanford, CA USA.
[Eisele, David W.] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
[Foote, Robert L.] Mayo Clin, Ctr Canc, Rochester, NY USA.
[Gillison, Maura L.] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA.
[Gillison, Maura L.] Solove Res Inst, Columbus, OH USA.
[Haddad, Robert I.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
[Haughey, Bruce H.] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA.
[Haughey, Bruce H.] Washington Univ, Sch Med, St Louis, MO 63130 USA.
[Hicks, Wesley L., Jr.] Roswell Pk Canc Inst, Buffalo, NY USA.
[Hitchcock, Ying J.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
[Jimeno, Antonio] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA.
[Kies, Merrill S.; Weber, Randal S.] Univ Texas MD Anderson Canc Ctr, Houston, TX USA.
[Lydiatt, William M.] Fred & Pamela Buffett Canc Ctr, Omaha, NE USA.
[Maghami, Ellie] City Hope Comprehens Canc Ctr, Duarte, CA USA.
[Mell, Loren K.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.
[Mittal, Bharat B.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA.
[Ridge, John A.] Fox Chase Canc Ctr, Philadelphia, PA USA.
[Rodriguez, Cristina R.] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA USA.
[Samant, Sandeep] Univ Tennessee, Hlth Sci Ctr, St Jude Childrens Res Hosp, Knoxville, TN 37996 USA.
[Wolf, Gregory T.; Worden, Frank] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI 48109 USA.
[Yom, Sue S.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
[McMillian, Nicole; Hughes, Miranda] Natl Comprehens Canc Network, New York, NY USA.
RP Pfister, DG (reprint author), Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA.
FU Eisai; Bristol-Myers Squibb; Genentech BioOncology; Merck; Novartis
Oncology; Novocure; Boehringer Ingelheim Pharmaceuticals, Inc.
FX Supported by an educational grant from Eisai; a contribution from
Exelixis Inc.; educational grants from Bristol-Myers Squibb, Genentech
BioOncology, Merck, Novartis Oncology, Novocure; and by an independent
educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
NR 72
TC 33
Z9 33
U1 0
U2 2
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
EI 1540-1413
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD JUL
PY 2015
VL 13
IS 7
BP 847
EP 856
PG 10
WC Oncology
SC Oncology
GA CM7UI
UT WOS:000357901600005
PM 26150579
ER
PT J
AU Bevers, TB
Ward, JH
Arun, BK
Colditz, GA
Cowan, KH
Daly, MB
Garber, JE
Gemignani, ML
Gradishar, WJ
Jordan, JA
Korde, LA
Kounalakis, N
Krontiras, H
Kumar, S
Kurian, A
Laronga, C
Layman, RM
Loftus, LS
Mahoney, MC
Merajver, SD
Meszoely, IM
Mortimer, J
Newman, L
Pritchard, E
Pruthi, S
Seewaldt, V
Specht, MC
Visvanathan, K
Wallace, A
Bergman, MA
Kumar, R
AF Bevers, Therese B.
Ward, John H.
Arun, Banu K.
Colditz, Graham A.
Cowan, Kenneth H.
Daly, Mary B.
Garber, Judy E.
Gemignani, Mary L.
Gradishar, William J.
Jordan, Judith A.
Korde, Larissa A.
Kounalakis, Nicole
Krontiras, Helen
Kumar, Shicha
Kurian, Allison
Laronga, Christine
Layman, Rachel M.
Loftus, Loretta S.
Mahoney, Martin C.
Merajver, Sofia D.
Meszoely, Ingrid M.
Mortimer, Joanne
Newman, Lisa
Pritchard, Elizabeth
Pruthi, Sandhya
Seewaldt, Victoria
Specht, Michelle C.
Visvanathan, Kale
Wallace, Anne
Bergman, Mary Ann
Kumar, Rashmi
CA Clinical Practice
TI Breast Cancer Risk Reduction, Version 2.2015
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; BRCA2 MUTATION CARRIERS; REDUCING
SALPINGO-OOPHORECTOMY; SURGICAL ADJUVANT BREAST;
ESTROGEN-PLUS-PROGESTIN; HORMONE-REPLACEMENT THERAPY; BILATERAL
PROPHYLACTIC MASTECTOMY; MENOPAUSAL HOT FLASHES; BONE-MINERAL DENSITY;
STAR P-2 TRIAL
AB Breast cancer is the most frequently diagnosed malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. To assist women who are at increased risk of developing breast cancer and their physicians in the application of individualized strategies to reduce breast cancer risk, NCCN has developed these guidelines for breast cancer risk reduction.
C1 [Bevers, Therese B.; Arun, Banu K.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Ward, John H.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
[Colditz, Graham A.] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA.
[Colditz, Graham A.] Washington Univ, Sch Med, St Louis, MO 63130 USA.
[Cowan, Kenneth H.] Fred & Pamela Buffett Canc Ctr, New York, NY USA.
[Daly, Mary B.] Fox Chase Canc Ctr, Philadelphia, PA USA.
[Garber, Judy E.] Dana Farber Canc Inst, Boston, MA USA.
[Gemignani, Mary L.] Mem Sloan Kettering Canc Ctr, New York, NY USA.
[Gradishar, William J.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA.
[Korde, Larissa A.] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA USA.
[Kounalakis, Nicole] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA.
[Krontiras, Helen] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL USA.
[Kumar, Shicha; Mahoney, Martin C.] Roswell Pk Canc Inst, Buffalo, NY USA.
[Kurian, Allison] Stanford Canc Inst, Stanford, CA USA.
[Laronga, Christine; Loftus, Loretta S.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[Layman, Rachel M.] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA.
[Layman, Rachel M.] Solove Res Inst, Columbus, OH USA.
[Merajver, Sofia D.; Newman, Lisa] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
[Meszoely, Ingrid M.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Mortimer, Joanne] City Hope Comprehens Canc Ctr, Duarte, CA USA.
[Pritchard, Elizabeth] Univ Tennessee, Hlth Sci Ctr, St Jude Childrens Res Hosp, Knoxville, TN 37996 USA.
[Pruthi, Sandhya] Mayo Clin, Ctr Canc, Rochester, MN USA.
[Seewaldt, Victoria] Duke Canc Inst, Durham, NC USA.
[Specht, Michelle C.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Visvanathan, Kale] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
[Wallace, Anne] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.
RP Bevers, TB (reprint author), Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 238
TC 4
Z9 4
U1 1
U2 12
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
EI 1540-1413
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD JUL
PY 2015
VL 13
IS 7
BP 880
EP 915
PG 36
WC Oncology
SC Oncology
GA CM7UI
UT WOS:000357901600008
PM 26150582
ER
PT J
AU Kronish, DP
Penson, RT
AF Kronish, Daniel P.
Penson, Richard T.
TI Theorist's Toy: Equipoise
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Editorial Material
C1 [Kronish, Daniel P.] Massachusetts Gen Hosp, Dept Med, Div Hematol Oncol, Boston, MA 02114 USA.
[Kronish, Daniel P.; Penson, Richard T.] Dana Farber Canc Inst, Inst Review Board, Boston, MA 02115 USA.
[Penson, Richard T.] Massachusetts Gen Hosp, Med, Hematol Oncol, Boston, MA 02114 USA.
RP Kronish, DP (reprint author), Massachusetts Gen Hosp, Dept Med, Div Hematol Oncol, Boston, MA 02114 USA.
NR 5
TC 0
Z9 0
U1 0
U2 1
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
EI 1540-1413
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD JUL
PY 2015
VL 13
IS 7
BP 936
EP 938
PG 3
WC Oncology
SC Oncology
GA CM7UI
UT WOS:000357901600011
PM 26150585
ER
PT J
AU Levesque, MH
Montesi, SB
Sharma, A
AF Levesque, Marie-Helene
Montesi, Sydney B.
Sharma, Amita
TI Diffuse Parenchymal Abnormalities in Acutely Dyspneic Patients A
Pattern-based Approach
SO JOURNAL OF THORACIC IMAGING
LA English
DT Review
DE acute respiratory failure; emergency thoracic imaging; computed
tomography; pattern-based approach; airspace opacity; linear opacity;
nodular opacity; cystic opacity; aspiration; incidental findings; CTPA
ID HIGH-RESOLUTION CT; THIN-SECTION CT; CHRONIC EOSINOPHILIC PNEUMONIA;
ACUTE INTERSTITIAL PNEUMONIA; RESPIRATORY-DISTRESS-SYNDROME; HYDROSTATIC
PULMONARY-EDEMA; SYSTEMIC-LUPUS-ERYTHEMATOSUS; COMPUTED-TOMOGRAPHY
FINDINGS; CRAZY-PAVING APPEARANCE; HYPERSENSITIVITY PNEUMONITIS
AB Acute dyspnea is a common presenting complaint in the Emergency Room. Evaluation with chest radiography is vital for initial assessment and may reveal diffuse parenchymal abnormalities that require further assessment with computed tomography (CT). The aim of this review is to outline a pattern-based approach for the analysis of diffuse pulmonary abnormalities in an acutely dyspneic patient with emphasis on CT appearances. Specific disease entities may be differentiated by their distribution in the lungs and by their radiologic findings. Recognition of the predominant finding and its distribution can generate an appropriate differential diagnosis that is further refined by the presence or absence of ancillary findings. Incorporation of the clinical history, laboratory data, and prior studies narrows the differential diagnosis, indicates the optimum modality for further evaluation, and, in some situations, provides important prognostic data.
C1 [Levesque, Marie-Helene; Sharma, Amita] Massachusetts Gen Hosp, Dept Radiol, Thorac Imaging Div, Boston, MA 02114 USA.
[Montesi, Sydney B.] Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA.
RP Sharma, A (reprint author), Massachusetts Gen Hosp, Dept Radiol, Thorac Imaging Div, 55 Fruit St,Founders 202, Boston, MA 02114 USA.
EM asharma2@partners.org
NR 95
TC 0
Z9 0
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0883-5993
EI 1536-0237
J9 J THORAC IMAG
JI J. Thorac. Imaging
PD JUL
PY 2015
VL 30
IS 4
BP 220
EP 232
DI 10.1097/RTI.0000000000000133
PG 13
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CL9RX
UT WOS:000357316900002
PM 25730554
ER
PT J
AU Thomas, GM
Brill, A
Mezouar, S
Crescence, L
Gallant, M
Dubois, C
Wagner, DD
AF Thomas, G. M.
Brill, A.
Mezouar, S.
Crescence, L.
Gallant, M.
Dubois, C.
Wagner, D. D.
TI Tissue factor expressed by circulating cancer cell-derived
microparticles drastically increases the incidence of deep vein
thrombosis in mice
SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS
LA English
DT Article
DE cancer; cell-derived microparticles; neutrophils; tissue factor; venous
thrombosis
ID EXTRACELLULAR DNA TRAPS; HUMAN PANCREATIC-CANCER; VENOUS
THROMBOEMBOLISM; P-SELECTIN; RISK-FACTORS; PLATELET-AGGREGATION;
PULMONARY-EMBOLISM; TUMOR-CELLS; IN-VIVO; MODEL
AB BackgroundThe risk of thrombotic complications such as deep vein thrombosis (DVT) during tumor development is well known. Tumors release into the circulation procoagulant microparticles (MPs) that can participate in thrombus formation following vessel injury. The importance of this MP tissue factor (TF) in the initiation of cancer-associated DVT remains uncertain.
ObjectiveTo investigate how pancreatic cancer MPs promote DVT invivo.
MethodsWe combined a DVT mouse model in which thrombosis is induced by flow restriction in the inferior vena cava with one of subcutaneous pancreatic cancer in C57BL/6J mice. We infused high-TF and low-TF tumor MPs to determine the importance of TF in experimental cancer-associated DVT.
ResultsBoth tumor-bearing mice and mice infused with tumor MPs subjected to 3h of partial flow restriction developed an occlusive thrombus; fewer than one-third of the control mice did. We observed that MPs adhered to neutrophil extracellular traps (NETs), which are functionally important players during DVT, whereas neither P-selectin nor glycoproteinIb were required for MP recruitment in DVT. The thrombotic phenotype induced by MP infusion was suppressed by hirudin, suggesting the importance of thrombin generation. TF carried by tumor MPs was essential to promote DVT, as mice infused with low-TF tumor MPs had less thrombosis than mice infused with high-TF tumor MPs.
ConclusionsTF expressed on tumor MPs contributes to the increased incidence of cancer-associated venous thrombosis in mice invivo. These MPs may adhere to NETs formed at the site of thrombosis.
C1 [Thomas, G. M.; Brill, A.; Gallant, M.; Wagner, D. D.] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
[Thomas, G. M.; Brill, A.; Wagner, D. D.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Thomas, G. M.; Mezouar, S.; Crescence, L.; Dubois, C.] Aix Marseille Univ, INSERM, VRCM, UMR S 1076, Marseille, France.
[Brill, A.] Univ Birmingham, Coll Med & Dent Sci, Inst Biomed Res, Ctr Cardiovasc Sci, Birmingham, W Midlands, England.
[Wagner, D. D.] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA.
RP Wagner, DD (reprint author), Boston Childrens Hosp, Program Cellular & Mol Med, Mailstop BCH3146,Blackfan Circle,3rd Floor, Boston, MA 02115 USA.
EM denisa.wagner@childrens.harvard.edu
OI Thomas, Grace/0000-0003-4502-7154
FU NHLBI NIH HHS [R01 HL102101]
NR 66
TC 15
Z9 15
U1 3
U2 14
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1538-7933
EI 1538-7836
J9 J THROMB HAEMOST
JI J. Thromb. Haemost.
PD JUL
PY 2015
VL 13
IS 7
BP 1310
EP 1319
DI 10.1111/jth.13002
PG 10
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA CM2DB
UT WOS:000357488900018
PM 25955268
ER
PT J
AU Melrose, RJ
Brewster, P
Marquine, MJ
MacKay-Brandt, A
Reed, B
Farias, ST
Mungas, D
AF Melrose, Rebecca J.
Brewster, Paul
Marquine, Maria J.
MacKay-Brandt, Anna
Reed, Bruce
Farias, Sarah T.
Mungas, Dan
TI Early Life Development in a Multiethnic Sample and the Relation to Late
Life Cognition
SO JOURNALS OF GERONTOLOGY SERIES B-PSYCHOLOGICAL SCIENCES AND SOCIAL
SCIENCES
LA English
DT Article
DE Cognition; Longitudinal change; Minority and diverse populations
ID NEUROPSYCHOLOGICAL ASSESSMENT SCALES; INCIDENT ALZHEIMERS-DISEASE; HEAD
CIRCUMFERENCE; RISK-FACTORS; SOCIOECONOMIC POSITION; LEG LENGTH;
OLD-AGE; MAXIMUM-LIKELIHOOD; MEXICAN-AMERICANS; AFRICAN-AMERICANS
AB Objectives. Poor quality of early life conditions has been associated with poorer late life cognition and increased risk of dementia. Early life physical development can be captured using adult measures of height and head circumference. Availability of resources may be reflected by socioeconomic indicators, such as parental education and family size. We sought to determine the association between early life development and experience and late life semantic memory, episodic memory, and executive functioning abilities, as well as rate of cognitive decline.
Method. This study was conducted using the UC Davis Aging Diversity cohort, an ethnically diverse sample of Caucasian, African American, and Hispanic individuals from northern California. We used latent variable modeling to measure growth and childhood socioeconomic environment (SES) and examine their associations with longitudinal cognitive outcomes using mixed effects modeling.
Results. Growth was positively related to higher childhood SES. Higher childhood SES was associated with better semantic memory. Both low growth and low SES were associated with increased rate of cognitive decline.
Discussion. These findings demonstrate that early life experiences influence the trajectory of cognitive aging. Early life development and experience appears to provide a distal basis upon which additional risk and protective factors interact in the development of dementia.
C1 [Melrose, Rebecca J.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Melrose, Rebecca J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Brewster, Paul] Univ Victoria, Dept Psychol, Victoria, BC V8W 2Y2, Canada.
[Marquine, Maria J.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
[MacKay-Brandt, Anna] Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA.
[Reed, Bruce; Farias, Sarah T.; Mungas, Dan] Univ Calif Davis, Sch Med, Dept Neurol, Davis, CA 95616 USA.
RP Melrose, RJ (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM rebecca.melrose@va.gov
FU National Institute on Aging at the National Institutes of Health [R13
AG030995, R01 AG10220, P30 AG10129, R01 AG AG031563, R01 AG021028, P50
CA098252]; VA Career Development Award; Canadian Institutes for Health
Research; Training in Research on Addictions in Interdisciplinary
NeuroAIDS (TRAIN) [T32DA031098]; [T32 MH02004]
FX This work was supported by the National Institute on Aging at the
National Institutes of Health (R13 AG030995 to D. Mungas, R01 AG10220 to
D. Mungas, P30 AG10129 to DeCarli, R01 AG AG031563 to B. Reed, R01
AG021028 to S. Tomaszewski Farias, P50 CA098252); VA Career Development
Award (R. J. Melrose); Doctoral Research Award from the Canadian
Institutes for Health Research (P. Brewster); Training in Research on
Addictions in Interdisciplinary NeuroAIDS (TRAIN, T32DA031098 to M. J.
Marquine) and a T32 MH02004 (A. MacKay-Brandt).
NR 71
TC 4
Z9 4
U1 2
U2 12
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079-5014
EI 1758-5368
J9 J GERONTOL B-PSYCHOL
JI J. Gerontol. Ser. B-Psychol. Sci. Soc. Sci.
PD JUL
PY 2015
VL 70
IS 4
BP 519
EP 531
DI 10.1093/geronb/gbt126
PG 13
WC Geriatrics & Gerontology; Gerontology; Psychology; Psychology,
Multidisciplinary
SC Geriatrics & Gerontology; Psychology
GA CM7NC
UT WOS:000357879600003
PM 24389122
ER
PT J
AU Schneider, BC
Gross, AL
Bangen, KJ
Skinner, JC
Benitez, A
Glymour, MM
Sachs, BC
Shih, RA
Sisco, S
Manly, JJ
Luchsinger, JA
AF Schneider, Brooke C.
Gross, Alden L.
Bangen, Katherine J.
Skinner, Jeannine C.
Benitez, Andreana
Glymour, M. Maria
Sachs, Bonnie C.
Shih, Regina A.
Sisco, Shannon
Manly, Jennifer J.
Luchsinger, Jose A.
TI Association of Vascular Risk Factors With Cognition in a Multiethnic
Sample
SO JOURNALS OF GERONTOLOGY SERIES B-PSYCHOLOGICAL SCIENCES AND SOCIAL
SCIENCES
LA English
DT Article
DE Cardiovascular disease; Cognitive decline; Ethnic differences; Racial
differences
ID HIGH BLOOD-PRESSURE; OLDER-ADULTS; ALZHEIMERS-DISEASE;
AFRICAN-AMERICANS; ETHNIC DISPARITIES; HEART-FAILURE; DIABETES-MELLITUS;
METABOLIC DISEASE; IMPAIRMENT; DECLINE
AB Objectives. To examine the relationship between cardiovascular risk factors (CVRFs) and cognitive performance in a multiethnic sample of older adults.
Method. We used longitudinal data from the Washington Heights-Inwood Columbia Aging Project. A composite score including smoking, stroke, heart disease, diabetes, hypertension, and central obesity represented CVRFs. Multiple group parallel process multivariate random effects regression models were used to model cognitive functioning and examine the contribution of CVRFs to baseline performance and change in general cognitive processing, memory, and executive functioning.
Results. Presence of each CVRF was associated with a 0.1 SD lower score in general cognitive processing, memory, and executive functioning in black and Hispanic participants relative to whites. Baseline CVRFs were associated with poorer baseline cognitive performances among black women and Hispanic men. CVRF increase was related to baseline cognitive performance only among Hispanics. CVRFs were not related to cognitive decline. After adjustment for medications, CVRFs were not associated with cognition in Hispanic participants.
Discussion. CVRFs are associated with poorer cognitive functioning, but not cognitive decline, among minority older adults. These relationships vary by gender and medication use. Consideration of unique racial, ethnic, and cultural factors is needed when examining relationships between CVRFs and cognition.
C1 [Schneider, Brooke C.] VA Greater Los Angeles Healthcare Syst, Psychol Serv, Los Angeles, CA USA.
[Gross, Alden L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Gross, Alden L.] Johns Hopkins Univ, Ctr Aging & Hlth, Baltimore, MD USA.
[Bangen, Katherine J.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
[Skinner, Jeannine C.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Benitez, Andreana] Med Univ S Carolina, Ctr Biomed Imaging, Dept Radiol & Radiol Sci, Charleston, SC USA.
[Glymour, M. Maria] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA.
[Glymour, M. Maria] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Sachs, Bonnie C.] Virginia Commonwealth Univ, Sch Med, Dept Neurol, Richmond, VA 23284 USA.
[Shih, Regina A.] RAND Corp, Arlington, VA USA.
[Sisco, Shannon] North Florida South Georgia Vet Hlth Syst, Dept Vet Affairs, Gainesville, FL USA.
[Manly, Jennifer J.] Columbia Univ Coll Phys & Surg, Dept Neurol, Cognit Neurosci Div, New York, NY 10032 USA.
[Luchsinger, Jose A.] Columbia Univ, Med Ctr, Joseph P Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA.
[Luchsinger, Jose A.] Columbia Univ, Med Ctr, Dept Med, New York, NY 10032 USA.
RP Luchsinger, JA (reprint author), Columbia Univ, Med Ctr, Dept Med, PH9 Ctr,Room 210,630 West 168th St, New York, NY 10032 USA.
EM jal94@columbia.edu
OI Glymour, M. Maria/0000-0001-9644-3081
FU National Institute on Aging [T32AG023480, R03 AG045494-01, T32AG000258,
R21 AG03438501, R01 AG028786, 1R01AG037212-01]; National Institutes of
Health [T32 MH1993417, UL1 TR000062, KL2 TR000060]; National Institute
of Minority Health and Health Disparities [P60 MD000206]
FX A. L. Gross was supported by a National Institute on Aging (T32AG023480
and R03 AG045494-01). K. J. Bangen was supported by the National
Institutes of Health (T32 MH1993417). J. C. Skinner was supported by the
National Institute on Aging (T32AG000258). A. Benitez was supported by
the Litwin Foundation and National Institutes of Health grants (UL1
TR000062 and KL2 TR000060). M. M. Glymour was partially supported by a
pilot grant from the National Institute on Aging-funded Harvard Program
on the Global Development of Aging and by a National Institute on Aging
grant (R21 AG03438501). J. J. Manly was supported by the National
Institute on Aging (R01 AG028786). J. A. Luchsinger was supported by
grants from the National Institute of Minority Health and Health
Disparities (P60 MD000206) and National Institute on Aging
(1R01AG037212-01). This content is solely the responsibility of the
authors and does not necessarily represent the official view of the
supporting institutions.
NR 74
TC 3
Z9 3
U1 0
U2 9
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079-5014
EI 1758-5368
J9 J GERONTOL B-PSYCHOL
JI J. Gerontol. Ser. B-Psychol. Sci. Soc. Sci.
PD JUL
PY 2015
VL 70
IS 4
BP 532
EP 544
DI 10.1093/geronb/gbu040
PG 13
WC Geriatrics & Gerontology; Gerontology; Psychology; Psychology,
Multidisciplinary
SC Geriatrics & Gerontology; Psychology
GA CM7NC
UT WOS:000357879600004
PM 24821298
ER
PT J
AU Carvalho, JO
Tommet, D
Crane, PK
Thomas, ML
Claxton, A
Habeck, C
Manly, JJ
Romero, HR
AF Carvalho, Janessa O.
Tommet, Doug
Crane, Paul K.
Thomas, Michael L.
Claxton, Amy
Habeck, Christian
Manly, Jennifer J.
Romero, Heather R.
TI Deconstructing Racial Differences: The Effects of Quality of Education
and Cerebrovascular Risk Factors
SO JOURNALS OF GERONTOLOGY SERIES B-PSYCHOLOGICAL SCIENCES AND SOCIAL
SCIENCES
LA English
DT Article
DE African American; Cognitive decline; Education quality; Latent growth
curve modeling; Race; Vascular
ID NEUROPSYCHOLOGICAL TEST-PERFORMANCE; ETHNICALLY DIVERSE ELDERS; OLDER
AFRICAN-AMERICANS; ALZHEIMERS-DISEASE; ATRIAL-FIBRILLATION;
CARDIOVASCULAR HEALTH; COGNITIVE DYSFUNCTION; MULTIETHNIC COHORT;
BIFACTOR MODEL; READING LEVEL
AB Objectives. To evaluate the effects of vascular conditions and education quality on cognition over time in White and African American (AA) older adults.
Method. We investigated cross-sectional and longitudinal racial differences in executive functioning (EF) and memory composites among Whites (n = 461) and AAs (n = 118) enrolled in a cohort study. We examined whether cerebrovascular risk factors and Shipley Vocabulary scores (a proxy for education quality) accounted for racial differences.
Results. On average, AAs had lower quality of education and more cerebrovascular risk factors including hypertension, diabetes, and obesity. AAs had lower mean EF and memory at baseline, but there were no group differences in rates of decline. Cross-sectional racial differences in EF and memory persisted after controlling for vascular disease, but disappeared when controlling for Shipley Vocabulary.
Discussion. Quality of education appears to be more important than cerebrovascular risk factors in explaining cross-sectional differences in memory and EF performance between White and AA older adults. Further investigation is needed regarding the relative contribution of education quality and cerebrovascular risk factors to cognitive decline among ethnically/racially diverse older adults.
C1 [Carvalho, Janessa O.; Tommet, Doug] Brown Univ, Dept Psychiat & Human Behav, Alpert Med Sch, Providence, RI 02912 USA.
[Carvalho, Janessa O.] Bridgewater State Univ, Dept Psychol, Bridgewater, MA USA.
[Crane, Paul K.] Univ Washington, Dept Med, Seattle, WA USA.
[Thomas, Michael L.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
[Claxton, Amy] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Claxton, Amy] Univ Washington, Sch Med, Seattle, WA USA.
[Habeck, Christian; Manly, Jennifer J.] Columbia Univ, Dept Neurol, Cognit Neurosci Div, New York, NY USA.
[Romero, Heather R.] Duke Univ, Med Ctr, Dept Psychiat, Joseph & Kathleen Bryan Alzheimers Dis Res Ctr, Durham, NC 27710 USA.
[Romero, Heather R.] Univ Notre Dame, Dept Psychol, Indiana, PA USA.
RP Romero, HR (reprint author), Duke Univ, Med Ctr, Joseph & Kathleen Bryan Alzheimers Dis Res Ctr, Box 3503, Durham, NC 27710 USA.
EM heather.romero@duke.edu
FU National Institute on Aging (NIA) [P30 AG028377, R13 AG030995]; National
Institute of Health/NIA [5R01AG026114-02]
FX Data provided by the Joseph and Kathleen Bryan Alzheimer's Disease
Research Center were supported by National Institute on Aging (NIA) (P30
AG028377). This research project began at the 2012 Friday Harbor
Advanced Psychometrics Workshop, which is supported by NIA (R13
AG030995). C. Habeck received support from National Institute of
Health/NIA (5R01AG026114-02). The contents do not necessarily represent
views of the funding entities. Funders had no deciding roles in the
design and conduct of this study.
NR 52
TC 3
Z9 3
U1 1
U2 12
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079-5014
EI 1758-5368
J9 J GERONTOL B-PSYCHOL
JI J. Gerontol. Ser. B-Psychol. Sci. Soc. Sci.
PD JUL
PY 2015
VL 70
IS 4
BP 545
EP 556
DI 10.1093/geronb/gbu086
PG 12
WC Geriatrics & Gerontology; Gerontology; Psychology; Psychology,
Multidisciplinary
SC Geriatrics & Gerontology; Psychology
GA CM7NC
UT WOS:000357879600005
PM 25098527
ER
PT J
AU Sisco, S
Gross, AL
Shih, RA
Sachs, BC
Glymour, MM
Bangen, KJ
Benitez, A
Skinner, J
Schneider, BC
Manly, JJ
AF Sisco, Shannon
Gross, Alden L.
Shih, Regina A.
Sachs, Bonnie C.
Glymour, M. Maria
Bangen, Katherine J.
Benitez, Andreana
Skinner, Jeannine
Schneider, Brooke C.
Manly, Jennifer J.
TI The Role of Early-Life Educational Quality and Literacy in Explaining
Racial Disparities in Cognition in Late Life
SO JOURNALS OF GERONTOLOGY SERIES B-PSYCHOLOGICAL SCIENCES AND SOCIAL
SCIENCES
LA English
DT Article
DE Cognition; Life events and contexts; Minority and diverse populations
ID NEUROPSYCHOLOGICAL TEST-PERFORMANCE; DIVERSE OLDER PERSONS;
AFRICAN-AMERICAN; ALZHEIMERS-DISEASE; WHITE ELDERS; DECLINE; MEMORY;
ADULTS; SCORES; RACE
AB Objectives. Racial disparities in late-life cognition persist even after accounting for educational attainment. We examined whether early-life educational quality and literacy in later life help explain these disparities.
Method. We used longitudinal data from the Washington Heights-Inwood Columbia Aging Project (WHICAP). Educational quality (percent white students; urban/rural school; combined grades in classroom) was operationalized using canonical correlation analysis. Late-life literacy (reading comprehension and ability, writing) was operationalized using confirmatory factor analysis. We examined whether these factors attenuated race-related differences in late-life cognition.
Results. The sample consisted of 1,679 U.S.-born, non-Hispanic, community-living adults aged 65-102 (71% black, 29% white; 70% women). Accounting for educational quality and literacy reduced disparities by 29% for general cognitive functioning, 26% for memory, and 32% for executive functioning but did not predict differences in rate of cognitive change.
Discussion. Early-life educational quality and literacy in late life explain a substantial portion of race-related disparities in late-life cognitive function.
C1 [Sisco, Shannon] North Florida South Georgia Vet Hlth Syst, Dept Vet Affairs, Gainesville, FL 32608 USA.
[Gross, Alden L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Gross, Alden L.] Johns Hopkins Univ, Ctr Aging & Hlth, Baltimore, MD USA.
[Shih, Regina A.] RAND Corp, Arlington, VA USA.
[Sachs, Bonnie C.] Virginia Commonwealth Univ, Dept Neurol, Sch Med, Richmond, VA 23284 USA.
[Glymour, M. Maria] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA.
[Glymour, M. Maria] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Bangen, Katherine J.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
[Benitez, Andreana] Med Univ S Carolina, Ctr Biomed Imaging, Dept Radiol & Radiol Sci, Charleston, SC USA.
[Skinner, Jeannine] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Schneider, Brooke C.] VA Greater Los Angeles Healthcare Syst, Dept Psychol, Los Angeles, CA USA.
[Manly, Jennifer J.] Columbia Univ Coll Phys & Surg, Dept Neurol, Cognit Neurosci Div, New York, NY 10032 USA.
RP Sisco, S (reprint author), North Florida South Georgia Vet Hlth Syst, Dept Vet Affairs, 1601 SW Archer Rd, Gainesville, FL 32608 USA.
EM Shannon.Sisco@va.gov
OI Glymour, M. Maria/0000-0001-9644-3081
FU National Institute on Aging [T32 AG023480, R03 AG045494, R01 AG043960,
R21 AG03438501, T32 AG000258, R01 AG028786]; National Institutes of
Health [T32 MH1993417, UL1 TR000062, KL2 TR000060]; Litwin Foundation
FX A. L. Gross was supported by the National Institute on Aging (T32
AG023480 and R03 AG045494). R. A. Shih was supported by the National
Institute on Aging (R01 AG043960). M. M. Glymour was partially supported
by a pilot grant from the National Institute on Aging-funded Harvard
Program on the Global Demography of Aging and by a National Institute on
Aging grant (R21 AG03438501). K. J. Bangen was supported by the National
Institutes of Health (T32 MH1993417). A. Benitez was supported by the
Litwin Foundation and National Institutes of Health (UL1 TR000062 and
KL2 TR000060). J. Skinner was supported by the National Institute on
Aging (T32 AG000258). J. J. Manly was supported by the National
Institute on Aging (R01 AG028786). The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the supporting institutions.
NR 58
TC 9
Z9 9
U1 3
U2 17
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079-5014
EI 1758-5368
J9 J GERONTOL B-PSYCHOL
JI J. Gerontol. Ser. B-Psychol. Sci. Soc. Sci.
PD JUL
PY 2015
VL 70
IS 4
BP 557
EP 567
DI 10.1093/geronb/gbt133
PG 11
WC Geriatrics & Gerontology; Gerontology; Psychology; Psychology,
Multidisciplinary
SC Geriatrics & Gerontology; Psychology
GA CM7NC
UT WOS:000357879600006
PM 24584038
ER
PT J
AU Bhanot, H
Reddy, MM
Nonami, A
Weisberg, EL
Bonal, D
Kirschmeier, PT
Salgia, S
Podar, K
Galinsky, I
Chowdary, TK
Neuberg, D
Tonon, G
Stone, RM
Asara, J
Griffin, JD
Sattler, M
AF Bhanot, H.
Reddy, M. M.
Nonami, A.
Weisberg, E. L.
Bonal, D.
Kirschmeier, P. T.
Salgia, S.
Podar, K.
Galinsky, I.
Chowdary, T. K.
Neuberg, D.
Tonon, G.
Stone, R. M.
Asara, J.
Griffin, J. D.
Sattler, M.
TI Pathological glycogenesis through glycogen synthase 1 and suppression of
excessive AMP kinase activity in myeloid leukemia cells
SO LEUKEMIA
LA English
DT Article
ID ACTIVATED PROTEIN-KINASE; RABBIT SKELETAL-MUSCLE; PHOSPHORYLASE-KINASE;
CANCER GENOMICS; GROWTH-FACTOR; PROLIFERATION; METABOLISM; LIVER; MICE;
SITE
AB The rapid proliferation of myeloid leukemia cells is highly dependent on increased glucose metabolism. Through an unbiased metabolomics analysis of leukemia cells, we found that the glycogenic precursor UDP-D-glucose is pervasively upregulated, despite low glycogen levels. Targeting the rate-limiting glycogen synthase 1 (GYS1) not only decreased glycolytic flux but also increased activation of the glycogen-responsive AMP kinase (AMPK), leading to significant growth suppression. Further, genetic and pharmacological hyper-activation of AMPK was sufficient to induce the changes observed with GYS1 targeting. Cancer genomics data also indicate that elevated levels of the glycogenic enzymes GYS1/2 or GBE1 (glycogen branching enzyme 1) are associated with poor survival in AML. These results suggest a novel mechanism whereby leukemic cells sustain aberrant proliferation by suppressing excess AMPK activity through elevated glycogenic flux and provide a therapeutic entry point for targeting leukemia cell metabolism.
C1 [Bhanot, H.; Reddy, M. M.; Nonami, A.; Weisberg, E. L.; Salgia, S.; Galinsky, I.; Stone, R. M.; Griffin, J. D.; Sattler, M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Bhanot, H.; Reddy, M. M.; Nonami, A.; Weisberg, E. L.; Stone, R. M.; Asara, J.; Griffin, J. D.; Sattler, M.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Bonal, D.; Kirschmeier, P. T.] Dana Farber Canc Inst, Ctr Biomed Imaging Oncol, Lurie Family Imaging Ctr, Boston, MA 02215 USA.
[Podar, K.] Natl Ctr Tumor Dis NCT, Heidelberg, Germany.
[Podar, K.] Heidelberg Univ, German Canc Res Ctr DKFZ, Heidelberg, Germany.
[Chowdary, T. K.] Natl Inst Sci Educ & Res, Sch Biol Sci, Bhubaneswar, Orissa, India.
[Neuberg, D.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
[Tonon, G.] Ist Sci San Raffaele, I-20132 Milan, Italy.
[Asara, J.] Dana Farber Canc Inst, Oncol, Boston, MA 02215 USA.
RP Sattler, M (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA.
EM martin_sattler@dfci.harvard.edu
FU National Institutes of Health grant [CA134660, CA6696]; Gloria Spivak
Faculty Advancement Fund
FX This work is supported in part by National Institutes of Health grant
CA134660 (MS), CA6696 (JDG) and by the Gloria Spivak Faculty Advancement
Fund (MS).
NR 63
TC 3
Z9 3
U1 3
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
EI 1476-5551
J9 LEUKEMIA
JI Leukemia
PD JUL
PY 2015
VL 29
IS 7
BP 1555
EP 1563
DI 10.1038/leu.2015.46
PG 9
WC Oncology; Hematology
SC Oncology; Hematology
GA CM3ZE
UT WOS:000357623100015
PM 25703587
ER
PT J
AU Elshahat, B
Gill, HS
Filipyev, I
Shrestha, S
Hesser, J
Kumar, J
Karellas, A
Zygmanski, P
Sajo, E
AF Elshahat, Bassem
Gill, Hardeep Singh
Filipyev, Ilya
Shrestha, Suman
Hesser, Juergen
Kumar, Jayant
Karellas, Andrew
Zygmanski, Piotr
Sajo, Erno
TI Technical Note: Nanometric organic photovoltaic thin film detectors for
dose monitoring in diagnostic x-ray imaging
SO MEDICAL PHYSICS
LA English
DT Article
DE dose monitoring; x-ray; thin-film; photovoltaic; organic
ID SOLAR-CELLS
AB Purpose: To fabricate organic photovoltaic (OPV) cells with nanometric active layers sensitive to ionizing radiation and measure their dosimetric characteristics in clinical x-ray beams in the diagnostic tube potential range of 60-150 kVp.
Methods: Experiments were designed to optimize the detector's x-ray response and find the best parameter combination by changing the active layer thickness and the area of the electrode. The OPV cell consisted of poly (3-hexylthiophene-2,5-diyl): [6,6]-phenyl C-61 butyric acid methyl ester photoactive donor and acceptor semiconducting organic materials sandwiched between an aluminum electrode as an anode and an indium tin oxide electrode as a cathode. The authors measured the radiation-induced electric current at zero bias voltage in all fabricated OPV cells.
Results: The net OPV current as a function of beam potential (kVp) was proportional to kVp(-0.5) when normalized to x-ray tube output, which varies with kVp. Of the tested configurations, the best combination of parameters was 270 nm active layer thicknesses with 0.7 cm(2) electrode area, which provided the highest signal per electrode area. For this cell, the measured current ranged from approximately 0.7 to 2.4 nA/cm(2) for 60-150 kVp, corresponding to about 0.09 nA-0.06 nA/mGy air kerma, respectively. When compared to commercial amorphous silicon thin film photovoltaic cells irradiated under the same conditions, this represents 2.5 times greater sensitivity. An additional 40% signal enhancement was observed when a 1 mm layer of plastic scintillator was attached to the cells' beam-facing side.
Conclusions: Since both OPVs can be produced as flexible devices and they do not require external bias voltage, they open the possibility for use as thin film in vivo detectors for dose monitoring in diagnostic x-ray imaging. (C) 2015 American Association of Physicists in Medicine.
C1 [Elshahat, Bassem; Sajo, Erno] Univ Massachusetts Lowell, Dept Phys & Appl Phys, Med Phys Program, Lowell, MA 01854 USA.
[Elshahat, Bassem] Vancouver Isl Hlth Author, Dept Med Imaging, Royal Jubilee Hosp, Victoria, BC V8R 1J8, Canada.
[Gill, Hardeep Singh; Kumar, Jayant] Univ Massachusetts Lowell, Dept Phys & Appl Phys, Lowell, MA 01854 USA.
[Filipyev, Ilya; Zygmanski, Piotr] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA.
[Filipyev, Ilya; Zygmanski, Piotr] Brigham & Womens Hosp, Boston, MA 02215 USA.
[Shrestha, Suman; Karellas, Andrew] Univ Massachusetts, Sch Med, Dept Radiol, Worcester, MA 01655 USA.
[Hesser, Juergen] Heidelberg Univ, Univ Med Ctr Mannheim, Dept Radiat Oncol, D-68167 Mannheim, Germany.
RP Sajo, E (reprint author), Univ Massachusetts Lowell, Dept Phys & Appl Phys, Med Phys Program, Lowell, MA 01854 USA.
EM Erno_Sajo@uml.edu
RI Shrestha, Suman/E-6979-2013
OI Shrestha, Suman/0000-0003-1378-9605
NR 12
TC 3
Z9 3
U1 2
U2 5
PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0094-2405
J9 MED PHYS
JI Med. Phys.
PD JUL
PY 2015
VL 42
IS 7
BP 4027
EP 4032
DI 10.1118/1.4922202
PG 6
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CM4WN
UT WOS:000357686400024
PM 26133603
ER
PT J
AU Dutta, J
Huang, C
Li, QZ
El Fakhri, G
AF Dutta, Joyita
Huang, Chuan
Li, Quanzheng
El Fakhri, Georges
TI Pulmonary imaging using respiratory motion compensated simultaneous
PET/MR
SO MEDICAL PHYSICS
LA English
DT Article
DE PET/MR; motion compensation; multimodal imaging; pulmonary; gating; MAP
reconstruction
ID POSITRON-EMISSION-TOMOGRAPHY; ATTENUATION CORRECTION; LUNG-CANCER;
LESION DETECTION; SPATIAL-RESOLUTION; 4-DIMENSIONAL PET; OPTICAL-FLOW;
CT IMAGES; GATED PET; 3-D PET
AB Purpose: Pulmonary positron emission tomography (PET) imaging is confounded by blurring artifacts caused by respiratory motion. These artifacts degrade both image quality and quantitative accuracy. In this paper, the authors present a complete data acquisition and processing framework for respiratory motion compensated image reconstruction (MCIR) using simultaneous whole body PET/magnetic resonance (MR) and validate it through simulation and clinical patient studies.
Methods: The authors have developed an MCIR framework based on maximum a posteriori or MAP estimation. For fast acquisition of high quality 4D MR images, the authors developed a novel Golden-angle RAdial Navigated Gradient Echo (GRANGE) pulse sequence and used it in conjunction with sparsity-enforcing k-t FOCUSS reconstruction. The authors use a 1D slice-projection navigator signal encapsulated within this pulse sequence along with a histogram-based gate assignment technique to retrospectively sort the MR and PET data into individual gates. The authors compute deformation fields for each gate via nonrigid registration. The deformation fields are incorporated into the PET data model as well as utilized for generating dynamic attenuation maps. The framework was validated using simulation studies on the 4D XCAT phantom and three clinical patient studies that were performed on the Biograph mMR, a simultaneous whole body PET/MR scanner.
Results: The authors compared MCIR (MC) results with ungated (UG) and one-gate (OG) reconstruction results. The XCAT study revealed contrast-to-noise ratio (CNR) improvements for MC relative to UG in the range of 21%-107% for 14 mm diameter lung lesions and 39%-120% for 10 mm diameter lung lesions. A strategy for regularization parameter selection was proposed, validated using XCAT simulations, and applied to the clinical studies. The authors' results show that the MC image yields 19%-190% increase in the CNR of high-intensity features of interest affected by respiratory motion relative to UG and a 6%-51% increase relative to OG.
Conclusions: Standalone MR is not the traditional choice for lung scans due to the low proton density, high magnetic susceptibility, and low T-2(*) relaxation time in the lungs. By developing and validating this PET/MR pulmonary imaging framework, the authors show that simultaneous PET/MR, unique in its capability of combining structural information from MR with functional information from PET, shows promise in pulmonary imaging. (C) 2015 American Association of Physicists in Medicine.
C1 [Dutta, Joyita; Huang, Chuan; Li, Quanzheng; El Fakhri, Georges] Massachusetts Gen Hosp, Dept Radiol, Ctr Adv Med Imaging Sci, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA.
[Dutta, Joyita; Huang, Chuan; Li, Quanzheng; El Fakhri, Georges] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Huang, Chuan] SUNY Stony Brook, Dept Radiol, Stony Brook, NY 11794 USA.
[Huang, Chuan] SUNY Stony Brook, Dept Psychiat, Stony Brook, NY 11794 USA.
RP Li, QZ (reprint author), Massachusetts Gen Hosp, Dept Radiol, Ctr Adv Med Imaging Sci, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA.
EM li.quanzheng@mgh.harvard.edu
OI Huang, Chuan/0000-0001-6052-0663
FU NCI NIH HHS [R01 CA165221, 1R01CA165221]; NHLBI NIH HHS [1R01HL110241,
R01 HL110241]; NIBIB NIH HHS [1R01EB013293, R01 EB013293]
NR 81
TC 4
Z9 4
U1 2
U2 8
PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0094-2405
J9 MED PHYS
JI Med. Phys.
PD JUL
PY 2015
VL 42
IS 7
BP 4227
EP 4240
DI 10.1118/1.4921616
PG 14
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA CM4WN
UT WOS:000357686400042
PM 26133621
ER
PT J
AU Zadra, G
Batista, JL
Loda, M
AF Zadra, Giorgia
Batista, Julie L.
Loda, Massimo
TI Dissecting the Dual Role of AMPK in Cancer: From Experimental to Human
Studies
SO MOLECULAR CANCER RESEARCH
LA English
DT Review
ID ACTIVATED PROTEIN-KINASE; ACETYL-COA-CARBOXYLASE; RANDOMIZED
CONTROLLED-TRIALS; PRACTICE RESEARCH DATALINK; POPULATION-BASED COHORT;
NEGATIVE BREAST-CANCER; TUMOR-SUPPRESSOR LKB1; FATTY-ACID SYNTHESIS;
LOW-DOSE ASPIRIN; GROWTH IN-VIVO
AB The precise role of 5'AMP-activated kinase (AMPK) in cancer and its potential as a therapeutic target is controversial. Although it is well established that activation of this energy sensor inhibits the main anabolic processes that sustain cancer cell proliferation and growth, AMPK activation can confer on cancer cells the plasticity to survive under metabolic stress such as hypoxia and glucose deprivation, which are commonly observed in fast growing tumors. Thus, AMPK is referred to as both a "conditional" tumor suppressor and "contextual" oncogene. To add a further layer of complexity, AMPK activation in human cancer tissues and its correlation with tumor aggressiveness and progression appears to vary in different contexts. The current review discusses the different faces of this metabolic regulator, the therapeutic implications of its modulation, and provides an overview of the most relevant data available on AMPK activation and AMPK-activating drugs in human studies. (C) 2015 AACR.
C1 [Zadra, Giorgia; Loda, Massimo] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Zadra, Giorgia; Loda, Massimo] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Pathol, Boston, MA 02115 USA.
[Batista, Julie L.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Batista, Julie L.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA.
[Loda, Massimo] Broad Inst, Cambridge, MA USA.
[Loda, Massimo] Kings Coll London, Div Canc Studies, London WC2R 2LS, England.
RP Loda, M (reprint author), Dana Farber Canc Inst, Dept Pathol, 450 Longwood Ave,D1536, Boston, MA 02115 USA.
EM massimo_loda@dfci.harvard.edu
FU NIH/NCI grant [2R01CA131945]; DF/HCC SPORE in Prostate Cancer [NIH/NCI
P50 CA90381]; Prostate Cancer Foundation; DOD synergist idea development
award [PC130716]; Department of Defense Prostate Cancer Research Program
[W81XWH-12-1-0072]; Dana-Farber Cancer Institute Mazzone Awards Program
FX This work was supported by the NIH/NCI grant 2R01CA131945, the DF/HCC
SPORE in Prostate Cancer (NIH/NCI P50 CA90381), the Prostate Cancer
Foundation, the DOD synergist idea development award (PC130716) to M.
Loda. J.L. Batista is supported, in part, by the Department of Defense
Prostate Cancer Research Program (W81XWH-12-1-0072) and the Dana-Farber
Cancer Institute Mazzone Awards Program.
NR 144
TC 25
Z9 25
U1 3
U2 13
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1541-7786
EI 1557-3125
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD JUL
PY 2015
VL 13
IS 7
BP 1059
EP 1072
DI 10.1158/1541-7786.MCR-15-0068
PG 14
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA CM9WF
UT WOS:000358059500001
PM 25956158
ER
PT J
AU Talekar, M
Ouyang, Q
Goldberg, MS
Amiji, MM
AF Talekar, Meghna
Ouyang, Qijun
Goldberg, Michael S.
Amiji, Mansoor M.
TI Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian
Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID PYRUVATE-KINASE; DRUG-RESISTANCE; TARGETED DELIVERY; LUNG-CANCER;
IN-VIVO; SIRNA; COMBINATION; GROWTH; M2; IDENTIFICATION
AB Tumor multidrug resistance (MDR) is a serious clinical challenge that significantly limits the effectiveness of cytotoxic chemotherapy. As such, complementary therapeutic strategies are being explored to prevent relapse. The altered metabolic state of cancer cells, which perform aerobic glycolysis, represents an interesting target that can enable discrimination between healthy cells and cancer cells. We hypothesized that cosilencing of genes responsible for aerobic glycolysis and for MDR would have synergistic antitumor effect. In this study, siRNA duplexes against pyruvate kinase M2 and multidrug resistance gene-1 were encapsulated in hyaluronic acid-based self-assembling nanoparticles. The particles were characterized for morphology, size, charge, encapsulation efficiency, and transfection efficiency. In vivo studies included biodistribution assessment, gene knockdown confirmation, therapeutic efficacy, and safety analysis. The benefit of active targeting of cancer cells was confirmed by modifying the particles' surface with a peptide targeted to epidermal growth factor receptor, which is overexpressed on the membranes of the SKOV-3 cancer cells. To augment the studies involving transplantation of a paclitaxel-resistant cell line, an in vivo paclitaxel resistance model was developed by injecting repeated doses of paclitaxel following tumor inoculation. The nanoparticles accumulated significantly in the tumors, hindering tumor volume doubling time (P < 0.05) upon combination therapy in both the wild-type (2-fold) and resistant (8-fold) xenograft models. Although previous studies indicated that silencing of MDR-1 alone sensitized MDR ovarian cancer to paclitaxel only modestly, these data suggest that concurrent silencing of PKM-2 improves the efficacy of paclitaxel against MDR ovarian cancer. (C) 2014 AACR.
C1 [Talekar, Meghna; Ouyang, Qijun; Amiji, Mansoor M.] Northeastern Univ, Bouve Coll Hlth Sci, Sch Pharm, Dept Pharmaceut Sci, Boston, MA 02115 USA.
[Goldberg, Michael S.] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
RP Amiji, MM (reprint author), Northeastern Univ, Bouve Coll Hlth Sci, Sch Pharm, Dept Pharmaceut Sci, Boston, MA 02115 USA.
EM michael_goldberg1@dfci.harvard.edu; m.amiji@neu.edu
FU National Cancer Institute's (NCI) Cancer Nanotechnology Platform
Partnership (CNPP) grant [U01-CA151452]; Dana-Farber Cancer
Institute-Northeastern University Collaborative Grant on Development of
Cancer Therapeutics; Ovarian Cancer Research Fund
FX This study was partially supported by the National Cancer Institute's
(NCI) Cancer Nanotechnology Platform Partnership (CNPP) grant
U01-CA151452, the Dana-Farber Cancer Institute-Northeastern University
Collaborative Grant on Development of Cancer Therapeutics, and the
Ovarian Cancer Research Fund.
NR 23
TC 5
Z9 5
U1 1
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD JUL
PY 2015
VL 14
IS 7
BP 1521
EP 1531
DI 10.1158/1535-7163.MCT-15-0100
PG 11
WC Oncology
SC Oncology
GA CM9UZ
UT WOS:000358055900001
PM 25964202
ER
PT J
AU Grabiner, B
Wagle, N
Van Allen, E
Garraway, L
Lorch, J
Sabatini, D
AF Grabiner, Brian
Wagle, Nikhil
Van Allen, Eliezer
Garraway, Levi
Lorch, Jochen
Sabatini, David
TI mTOR mutations in cancer
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Meeting Abstract
C1 [Grabiner, Brian; Sabatini, David] Whitehead Inst, Cambridge, MA 02142 USA.
[Wagle, Nikhil; Van Allen, Eliezer; Garraway, Levi; Lorch, Jochen] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD JUL
PY 2015
VL 14
IS 7
SU S
MA PR04
DI 10.1158/1538-8514.PI3K14-PR04
PG 2
WC Oncology
SC Oncology
GA CN1EF
UT WOS:000358159200111
ER
PT J
AU Papageorgiou, A
Tamayo, P
Mesirov, J
Avruch, J
Rapley, J
AF Papageorgiou, Angela
Tamayo, Pablo
Mesirov, Jill
Avruch, Joseph
Rapley, Joseph
TI A genome-wide siRNA screen in mammalian cells for regulators of S6
phosphorylation
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Meeting Abstract
C1 [Papageorgiou, Angela; Tamayo, Pablo; Avruch, Joseph; Rapley, Joseph] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Mesirov, Jill] MIT, Broad Inst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD JUL
PY 2015
VL 14
IS 7
SU S
MA A30
DI 10.1158/1538-8514.PI3K14-A30
PG 2
WC Oncology
SC Oncology
GA CN1EF
UT WOS:000358159200025
ER
PT J
AU Wulf, GM
Juvekar, A
Lyssiotis, CM
Hu, H
Baek, K
Yadegarynia, S
Scully, R
Winer, E
Asara, J
Cantley, LC
Matulonis, U
AF Wulf, Gerburg M.
Juvekar, Ashish
Lyssiotis, Costas M.
Hu, Hai
Baek, Kim
Yadegarynia, Sina
Scully, Ralph
Winer, Eric
Asara, John
Cantley, Lewis C.
Matulonis, Ursula
TI Combination treatments that include PI3K-inhibitors for the treatment of
triple-negative breast cancer
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Meeting Abstract
C1 [Wulf, Gerburg M.; Juvekar, Ashish; Hu, Hai; Yadegarynia, Sina; Scully, Ralph; Asara, John] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Lyssiotis, Costas M.; Cantley, Lewis C.] Weill Cornell Canc Ctr, New York, NY USA.
[Baek, Kim] Emory Sch Med, Atlanta, GA USA.
[Winer, Eric; Matulonis, Ursula] Dana Farber Canc Inst, Boston, MA 02115 USA.
RI Cantley, Lewis/D-1800-2014
OI Cantley, Lewis/0000-0002-1298-7653
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD JUL
PY 2015
VL 14
IS 7
SU S
MA IA21
DI 10.1158/1538-8514.PI3K14-IA21
PG 2
WC Oncology
SC Oncology
GA CN1EF
UT WOS:000358159200104
ER
PT J
AU Zhao, JJ
AF Zhao, Jean J.
TI Targeting PI3K isoforms in cancer: From mouse genetics to human therapy
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Meeting Abstract
C1 [Zhao, Jean J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD JUL
PY 2015
VL 14
IS 7
SU S
MA IA13
DI 10.1158/1538-8514.PI3K14-IA13
PG 1
WC Oncology
SC Oncology
GA CN1EF
UT WOS:000358159200097
ER
PT J
AU Krom, RJ
Bhargava, P
Lobritz, MA
Collins, JJ
AF Krom, Russell J.
Bhargava, Prerna
Lobritz, Michael A.
Collins, James J.
TI Engineered Phagemids for Nonlytic, Targeted Antibacterial Therapies
SO NANO LETTERS
LA English
DT Article
DE Antimicrobial peptides; phagemids; targeted bacterial killing; bacterial
toxins; synthetic gene networks; bacteriophage resistance
ID ESCHERICHIA-COLI; BACTERIOPHAGE RESISTANCE; ANTIMICROBIAL PEPTIDE; GUT
MICROBIOTA; MECHANISMS; PROTEINS; GYRASE; HEALTH; TOXIN
AB The increasing incidence of antibiotic-resistant bacterial infections is creating a global public health threat. Because conventional antibiotic drug discovery has failed to keep pace with the rise of resistance, a growing need exists to develop novel antibacterial methodologies. Replication-competent bacteriophages have been utilized in a limited fashion to treat bacterial infections. However, this approach can result in the release of harmful endotoxins, leading to untoward side effects. Here, we engineer bacterial phagemids to express antimicrobial peptides (AMPs) and protein toxins that disrupt intracellular processes, leading to rapid, nonlytic bacterial death. We show that this approach is highly modular, enabling one to readily alter the number and type of AMPs and toxins encoded by the phagemids. Furthermore, we demonstrate the effectiveness of engineered phagemids in an in vivo murine peritonitis infection model. This work shows that targeted, engineered phagemid therapy can serve as a viable, nonantibiotic means to treat bacterial infections, while avoiding the health issues inherent to lytic and replicative bacteriophage use.
C1 [Krom, Russell J.; Bhargava, Prerna; Lobritz, Michael A.; Collins, James J.] MIT, Dept Biol Engn, Inst Med Engn & Sci, Cambridge, MA 02139 USA.
[Krom, Russell J.; Bhargava, Prerna; Lobritz, Michael A.; Collins, James J.] MIT, Synthet Biol Ctr, Cambridge, MA 02139 USA.
[Krom, Russell J.; Collins, James J.] Harvard MIT Program Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Bhargava, Prerna; Lobritz, Michael A.; Collins, James J.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
[Krom, Russell J.; Bhargava, Prerna; Lobritz, Michael A.; Collins, James J.] Harvard Univ, Wyss Inst Biol Inspired Engn, Boston, MA 02115 USA.
[Krom, Russell J.] Boston Univ, Dept Mol & Translat Med, Boston, MA 02215 USA.
[Lobritz, Michael A.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
RP Collins, JJ (reprint author), MIT, Dept Biol Engn, Inst Med Engn & Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
EM jimjc@mit.edu
FU Defense Threat Reduction Agency [HDTRA1-14-1-0006]; Howard Hughes
Medical Institute; Wyss Institute for Biologically Inspired Engineering
FX This work was supported by supported by the Defense Threat Reduction
Agency Grant HDTRA1-14-1-0006, the Howard Hughes Medical Institute, and
the Wyss Institute for Biologically Inspired Engineering. Additionally,
we would like to thank Caleb Bashor for his help in figure layout and
design.
NR 29
TC 7
Z9 7
U1 4
U2 21
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1530-6984
EI 1530-6992
J9 NANO LETT
JI Nano Lett.
PD JUL
PY 2015
VL 15
IS 7
BP 4808
EP 4813
DI 10.1021/acs.nanolett.5b01943
PG 6
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
Physics
GA CM8PM
UT WOS:000357964100084
PM 26044909
ER
PT J
AU Bigelow, CA
Bryant, AS
AF Bigelow, Catherine A.
Bryant, Allison S.
TI Short Interpregnancy Intervals: An Evidence-Based Guide for Clinicians
SO OBSTETRICAL & GYNECOLOGICAL SURVEY
LA English
DT Article
ID WOMEN DELAYING INITIATION; LOW-BIRTH-WEIGHT; PERINATAL OUTCOMES; UTERINE
RUPTURE; INTERDELIVERY INTERVAL; SUBSEQUENT PREGNANCY; METHOTREXATE
TREATMENT; MATERNAL MORBIDITY; ECTOPIC PREGNANCY; INDUCED-ABORTION
AB The interpregnancy interval (IPI) is the period of time between one birth outcome (live birth, miscarriage, stillbirth, or abortion) and conception of a subsequent pregnancy. Short IPI has been associated with obstetric, fetal, and maternal morbidity. While the literature has largely supported an ideal IPI of 18 to 23 months after live birth to minimize morbidity in a subsequent pregnancy, there are few references that can guide clinicians counseling patients about IPI after other pregnancy outcomes. In this article, we attempt to review, synthesize, and provide evidence-based IPI recommendations using the available literature.
Target Audience
Obstetricians and gynecologists, family physicians
Learning Objectives
After completing this activity, the learner will be better able to discuss the definition of the interpregnancy interval, identify risk factors for short interpregnancy intervals, and interpret the available evidence for perinatal and maternal morbidity associated with short interpregnancy intervals.
C1 [Bigelow, Catherine A.] Massachusetts Gen Hosp, Vincent Dept Obstet & Gynecol, Boston, MA 02114 USA.
[Bigelow, Catherine A.] Harvard Univ, Sch Med, Boston, MA USA.
[Bryant, Allison S.] Harvard Univ, Sch Med, Obstet Gynecol & Reprod Biol, Boston, MA USA.
RP Bigelow, CA (reprint author), Massachusetts Gen Hosp, Vincent Dept Obstet & Gynecol, Boston, MA 02114 USA.
EM cbigelow@partners.org
NR 49
TC 3
Z9 3
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0029-7828
EI 1533-9866
J9 OBSTET GYNECOL SURV
JI Obstet. Gynecol. Surv.
PD JUL
PY 2015
VL 70
IS 7
BP 458
EP 464
DI 10.1097/OGX.0000000000000195
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA CM5OO
UT WOS:000357737800017
PM 26185917
ER
PT J
AU Mounir, Z
Lin, F
Lin, VG
Korn, JM
Yu, Y
Valdez, R
Aina, OH
Buchwalter, G
Jaffe, AB
Korpal, M
Zhu, P
Brown, M
Cardiff, RD
Rocnik, JL
Yang, Y
Pagliarini, R
AF Mounir, Z.
Lin, F.
Lin, V. G.
Korn, J. M.
Yu, Y.
Valdez, R.
Aina, O. H.
Buchwalter, G.
Jaffe, A. B.
Korpal, M.
Zhu, P.
Brown, M.
Cardiff, R. D.
Rocnik, J. L.
Yang, Y.
Pagliarini, R.
TI TMPRSS2: ERG blocks neuroendocrine and luminal cell differentiation to
maintain prostate cancer proliferation
SO ONCOGENE
LA English
DT Article
ID ANDROGEN RECEPTOR; MOLECULAR CHARACTERIZATION; GENOME BROWSER; GENE
FUSIONS; IN-VIVO; PROGRESSION; EXPRESSION; TRANSDIFFERENTIATION;
ADENOCARCINOMA; HYBRIDIZATION
AB The biological outcome of TMPRSS2: ERG chromosomal translocations in prostate cancer (PC) remains poorly understood. To address this, we compared the transcriptional effects of TMPRSS2: ERG expression in a transgenic mouse model with those of ERG knockdown in a TMPRSS2: ERG-positive PC cell line. This reveals that ERG represses the expression of a previously unreported set of androgen receptor (AR)-independent neuronal genes that are indicative of neuroendocrine (NE) cell differentiation-in addition to previously reported AR-regulated luminal genes. Cell sorting and proliferation assays performed after sustained ERG knockdown indicate that ERG drives proliferation and blocks the differentiation of prostate cells to both NE and luminal cell types. Inhibition of ERG expression in TMPRSS2: ERG-positive PC cells through blockade of AR signaling is tracked with increased NE gene expression. We also provide evidence that these NE cells are resistant to pharmacological AR inhibition and can revert to the phenotype of parental cells upon restoration of AR/ERG signaling. Our findings highlight an ERG-regulated mechanism capable of repopulating the parent tumor through the transient generation of an anti-androgen therapy-resistant cell population, suggesting that ERG may have a direct role in preventing resistance to anti-androgen therapy.
C1 [Mounir, Z.; Lin, F.; Lin, V. G.; Korn, J. M.; Yu, Y.; Valdez, R.; Jaffe, A. B.; Korpal, M.; Zhu, P.; Rocnik, J. L.; Yang, Y.; Pagliarini, R.] Novartis Inst BioMed Res, Cambridge, MA 02139 USA.
[Aina, O. H.; Cardiff, R. D.] Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA.
[Buchwalter, G.; Brown, M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Buchwalter, G.; Brown, M.] Harvard Univ, Sch Med, Boston, MA USA.
[Buchwalter, G.; Brown, M.] Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02115 USA.
RP Pagliarini, R (reprint author), Novartis Inst BioMed Res, 250 Massachusetts Ave, Cambridge, MA 02139 USA.
EM raymond.pagliarini@novartis.com
OI Brown, Myles/0000-0002-8213-1658
FU Novartis Institutes for Biomedical Research; Novartis
FX ZM is the recipient of presidential postdoctoral fellowship from the
Novartis Institutes for Biomedical Research. ZM, FL, VGL, JMK, YY, RV,
ABJ, YY and RP are all employees of Novartis Institutes for Biomedical
Research. MK and PZ are employees of H3 Biomedicine. MB is a consultant
to Novartis and the recipient of sponsored research support from
Novartis. JLR is an employee of Sanofi. The other authors declare no
conflict of interest.
NR 46
TC 10
Z9 11
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD JUL
PY 2015
VL 34
IS 29
BP 3815
EP 3825
DI 10.1038/onc.2014.308
PG 11
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
GA CM9BV
UT WOS:000358001600007
PM 25263440
ER
PT J
AU Boucher, J
Lucca, J
Hooper, C
Pedulla, L
Berry, DL
AF Boucher, Jean
Lucca, Joan
Hooper, Catherine
Pedulla, Lillian
Berry, Donna L.
TI A Structured Nursing Intervention to Address Oral Chemotherapy Adherence
in Patients With Non-Small Cell Lung Cancer
SO ONCOLOGY NURSING FORUM
LA English
DT Article
DE lung cancer; oral chemotherapy; adherence; knowledge; oncology nursing
ID MEDICATION ADHERENCE; PREDICTIVE-VALIDITY; FOLLOW-UP; THERAPIES;
EDUCATION; AGENTS; PEOPLE; SAFETY
AB Purpose/Objectives: To evaluate a nurse-led intervention to enhance medication knowledge and adherence using the Multinational Association for Supportive Care in Cancer Oral Agent Teaching Tool (MOATT).
Design: Longitudinal, descriptive feasibility study.
Setting: An ambulatory thoracic oncology disease center located at the Dana-Farber Cancer Institute in Boston, MA. Sample: 30 adult patients with lung cancer who received the oral agent erlotinib.
Methods: Structured, nurse-led education sessions using the MOATT were provided, with a 72-hour follow-up telephone contact. Participants completed a Knowledge Rating Scale (KRS) and adapted Morisky Medication Adherence Scale-8 (MMAS-8) at the end of the first cycle of oral chemotherapy.
Main Research Variables: Knowledge and adherence; feasibility.
Findings: Twenty-seven participants completed the study outcome measures reporting high knowledge levels and MMAS-8 scores. Structured, nurse-led education and follow-up monitoring sessions ranged from 14-30 minutes. Several participants also initiated contact for assistance with prescription procurement and symptom management. Participants reported a median of two side effects.
Conclusions: The structured, nurse-led teaching, using the MOATT tool, and follow-up nurse contacts were feasible as integrated into the thoracic oncology setting. Adherence and knowledge outcomes were encouraging. Additional studies should include objective adherence measures and strategies for delivering supportive care to patients at home.
Implications for Nursing: Structured teaching with patients is important to enhance proper oral anticancer medication knowledge and adherence, including follow-up monitoring of administration and side effects at 72 hours.
C1 [Boucher, Jean; Berry, Donna L.] Dana Farber Canc Inst, Phyllis F Cantor Ctr, Boston, MA 02115 USA.
[Boucher, Jean] Univ Massachusetts, Worcester Grad Sch Nursing, Amherst, MA 01003 USA.
[Lucca, Joan; Hooper, Catherine] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA.
[Pedulla, Lillian] Dana Farber Canc Inst, Nursing Care Serv, Boston, MA 02115 USA.
[Pedulla, Lillian] Dana Farber Canc Inst, Patient Care Serv, Boston, MA 02115 USA.
RP Boucher, J (reprint author), Dana Farber Canc Inst, Phyllis F Cantor Ctr, Boston, MA 02115 USA.
EM donna_berry@dfci.harvard.edu
NR 48
TC 4
Z9 4
U1 6
U2 18
PU ONCOLOGY NURSING SOC
PI PITTSBURGH
PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA
SN 0190-535X
EI 1538-0688
J9 ONCOL NURS FORUM
JI Oncol. Nurs. Forum
PD JUL
PY 2015
VL 42
IS 4
BP 383
EP 389
DI 10.1188/15.ONF.383-389
PG 7
WC Oncology; Nursing
SC Oncology; Nursing
GA CM7UH
UT WOS:000357901500006
PM 26148317
ER
PT J
AU Sarris, J
Price, LH
Carpenter, LL
Tyrka, AR
Ng, CH
Papakostas, GI
Jaeger, A
Fava, M
Mischoulon, D
AF Sarris, J.
Price, L. H.
Carpenter, L. L.
Tyrka, A. R.
Ng, C. H.
Papakostas, G. I.
Jaeger, A.
Fava, M.
Mischoulon, D.
TI Is S-Adenosyl Methionine (SAMe) for Depression Only Effective in Males?
A Re-Analysis of Data from a Randomized Clinical Trial
SO PHARMACOPSYCHIATRY
LA English
DT Article
DE S-adenosyl methionine; SAMe; antidepressant; gender; depression; RCT;
one-carbon cycle
ID DOUBLE-BLIND; SAM-E; DISORDER; ADENOSYLMETHIONINE; AUGMENTATION;
ESCITALOPRAM; PLACEBO
AB Objective: The aim of this study was to examine whether gender differences may have affected treatment response to S-adenosyl methionine (SAMe) in a recent failed randomized clinical trial (RCT) for adults with major depressive disorder.
Methods: Data from a 2-site, 12-week, double-blind RCT (n = 189) assessing the efficacy of SAMe vs. placebo and a comparator selective serotonin reuptake inhibitor (escitalopram) were subjected to post-hoc analyses to evaluate effects of patient gender on treatment response.
Results: When assessing the efficacy outcomes within each gender separately, SAMe was superior to placebo among males (n = 51), but not among females (n = 62). Males showed a significant reduction of depression severity from baseline to study endpoint on the 17-item Hamilton Depression Rating Scale (4.3 point difference; p = 0.034; d = 0.95), while females did not show significant change. This finding emerged despite equivalence on baseline measures of depression severity between the gender groups.
Conclusion: Results of this secondary data analysis suggest that gender might impact the antidepressant efficacy of SAMe, with greater therapeutic effect found in males. The underlying mechanism is still relatively unknown. Further work is needed to replicate this observation in independent samples.
C1 [Sarris, J.; Ng, C. H.] Univ Melbourne, Dept Psychiat, Melbourne Clin, Melbourne, Vic, Australia.
[Sarris, J.] Swinburne Univ Technol, Ctr Human Psychopharmacol, Melbourne, Vic, Australia.
[Price, L. H.; Carpenter, L. L.; Tyrka, A. R.] Brown Univ, Mood Disorders Res Program, Providence, RI 02912 USA.
[Price, L. H.; Carpenter, L. L.; Tyrka, A. R.] Brown Univ, Dept Psychiat & Human Behav, Lab Clin & Translat Neurosci, Butler Hosp,Alpert Med Sch, Providence, RI 02912 USA.
[Papakostas, G. I.; Jaeger, A.; Fava, M.; Mischoulon, D.] Harvard Univ, Sch Med, Dept Psychiat, Depress Clin & Res Program,Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Sarris, J (reprint author), Univ Melbourne, Dept Psychiat, Melbourne Clin, 2 Salisbury St, Melbourne, Vic, Australia.
EM jsarris@unimelb.edu.au
FU NIH; National Center for Complementary Added Alternative Medicine
(NCCAM), R01 grant [R01AT001638]; CR Roper Fellowship
FX The study was supported by the NIH and the National Center for
Complementary Added Alternative Medicine (NCCAM), R01 grant R01AT001638.
Its contents are solely the responsibility of the authors and do not
necessarily represent the official views of the National Center for
Complementary and Alternative Medicine, National Institutes of Health.
SAMe tosylate and matching placebo were supplied by Pharmavite LLC,
California. Dr. Jerome Sarris is supported by a CR Roper Fellowship.
NR 16
TC 4
Z9 4
U1 3
U2 9
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0176-3679
EI 1439-0795
J9 PHARMACOPSYCHIATRY
JI Pharmacopsychiatry
PD JUL
PY 2015
VL 48
IS 4-5
BP 141
EP 144
DI 10.1055/s-0035-1549928
PG 4
WC Pharmacology & Pharmacy; Psychiatry
SC Pharmacology & Pharmacy; Psychiatry
GA CM8HH
UT WOS:000357939300003
PM 26011569
ER
PT J
AU Figlewicz, DP
AF Figlewicz, Dianne P.
TI Modulation of Food Reward by Endocrine and Environmental Factors: Update
and Perspective
SO PSYCHOSOMATIC MEDICINE
LA English
DT Review
ID NUCLEUS-ACCUMBENS DOPAMINE; CONDITIONED PLACE PREFERENCE; STRESS-INDUCED
REINSTATEMENT; OPIOID RECEPTOR STIMULATION; HIGH-FAT DIET; REINFORCING
EFFICACY; INTRAVENTRICULAR INSULIN; SUBTHALAMIC NUCLEUS; METABOLIC
SYNDROME; PROGRESSIVE RATIO
AB Objective
Palatable foods are frequently high in energy density. Chronic consumption of high-energy density foods can contribute to the development of cardiometabolic pathology including obesity, diabetes, and cardiovascular disease. This article reviews the contributions of extrinsic and intrinsic factors that influence the reward components of food intake.
Methods
A narrative review was conducted to determine the behavioral and central nervous system (CNS) related processes involved in the reward components of high-energy density food intake.
Results
The rewarding aspects of food, particularly palatable and preferred foods, are regulated by CNS circuitry. Overlaying this regulation is modulation by intrinsic endocrine systems and metabolic hormones relating to energy homeostasis, developmental stage, or gender. It is now recognized that extrinsic or environmental factors, including ambient diet composition and the provocation of stress or anxiety, also contribute substantially to the expression of food reward behaviors such as motivation for, and seeking of, preferred foods.
Conclusions
High-energy density food intake is influenced by both physiological and pathophysiological processes. Contextual, behavioral, and psychological factors and CNS-related processes represent potential targets for multiple types of therapeutic intervention.
C1 [Figlewicz, Dianne P.] VA Puget Sound Hlth Care Syst, BSR&D Program, Seattle, WA 98108 USA.
[Figlewicz, Dianne P.] Univ Washington, Dept Psychiat & Behav Sci, Sch Med, Seattle, WA 98195 USA.
RP Figlewicz, DP (reprint author), VA Puget Sound Hlth Care Syst 151, 1660 South Columbian Way, Seattle, WA 98108 USA.
EM latte@uw.edu
FU National Institutes of Health [DK40963]; American Recovery and
Reinvestment Act
FX The author's research described in this article is the result of work
supported by resources from the VA Puget Sound Health Care System,
Seattle, WA, and was supported by National Institutes of Health Grant
DK40963 and by the American Recovery and Reinvestment Act. The author
declared no conflicts of interest.
NR 98
TC 3
Z9 3
U1 1
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0033-3174
EI 1534-7796
J9 PSYCHOSOM MED
JI Psychosom. Med.
PD JUL-AUG
PY 2015
VL 77
IS 6
BP 664
EP 670
DI 10.1097/PSY.0000000000000146
PG 7
WC Psychiatry; Psychology; Psychology, Multidisciplinary
SC Psychiatry; Psychology
GA CM5KI
UT WOS:000357726300007
PM 25738439
ER
PT J
AU Silva, PS
Aiello, LP
AF Silva, Paolo S.
Aiello, Lloyd Paul
TI Untitled Reply
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Letter
C1 [Silva, Paolo S.; Aiello, Lloyd Paul] Harvard Univ, Sch Med, Joslin Diabet Ctr, Beetham Eye Inst,Dept Ophthalmol, Boston, MA 02115 USA.
RP Silva, PS (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Beetham Eye Inst,Dept Ophthalmol, Boston, MA 02115 USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2015
VL 35
IS 7
BP E37
EP E38
DI 10.1097/IAE.0000000000000640
PG 2
WC Ophthalmology
SC Ophthalmology
GA CM2AD
UT WOS:000357481000006
PM 26057398
ER
PT J
AU Seidman, LJ
Nordentoft, M
AF Seidman, Larry J.
Nordentoft, Merete
TI New Targets for Prevention of Schizophrenia: Is It Time for
Interventions in the Premorbid Phase?
SO SCHIZOPHRENIA BULLETIN
LA English
DT Article
DE clinical high risk; family high risk; prodrome; premorbid; prenatal;
perinatal; primary prevention; endop henotype; critical period; early
intervention
ID RANDOMIZED CONTROLLED-TRIAL; ULTRA-HIGH RISK; YOUNG-PEOPLE; 1ST-EPISODE
PSYCHOSIS; FUTURE-DIRECTIONS; BRAIN-DEVELOPMENT; CLINICAL-TRIAL;
FAMILIAL RISK; FOLLOW-UP; PSYCHIATRY
AB A number of influences have converged that make this Special Theme Issue timely: "A New Direction: Considering Developmentally Sensitive Targets for Very Early Intervention in Schizophrenia". These factors include: 1. the substantial knowledge about premorbid developmental vulnerabilities to psychosis, especially regarding schizophrenia; 2. the promising results emerging from interventions during the clinical high-risk (CHR) phase of psychosis and; 3. the recognition that the CHR period is a relatively late phase of developmental derailment. These factors have together led to a perspective that even earlier intervention is warranted. This paper briefly summarizes the articles comprising the Special Theme including new data on early neurocognitive development, proposed potential targets for psychosocial and psychopharmacological interventions during the premorbid period as early as pregnancy, and ethical challenges. These thought experiments must be empirically tested, and the ethical challenges overcome as posed by the various interventions, which range from relatively low risk, supportive, psychosocial to higher risk, experimental, pharmacological interventions. All of the interventions proposed require careful study of ethics, safety, potential stigma, feasibility, efficacy and tolerability, and the meaning to the people involved.
C1 [Seidman, Larry J.] Harvard Univ, Beth Israel Deaconess Med Ctr, Massachusetts Mental Hlth Ctr, Publ Psychiat Div,Dept Psychiat,Med Sch, Boston, MA 02215 USA.
[Seidman, Larry J.] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Nordentoft, Merete] Univ Copenhagen, Inst Clin Med, Copenhagen, Denmark.
[Nordentoft, Merete] Mental Hlth Ctr Copenhagen, Mental Hlth Serv Capital Reg Denmark, Copenhagen, Denmark.
RP Seidman, LJ (reprint author), Massachusetts Mental Hlth Ctr, Commonwealth Res Ctr, Room 542,75 Fenwood Rd, Boston, MA 02115 USA.
EM lseidman@bidmc.harvard.edu
FU Commonwealth Research Center [SCDMH82101008006]; NIMH [R21 MH092840]
FX Supported by the Commonwealth Research Center (SCDMH82101008006) and
NIMH R21 MH092840.
NR 59
TC 8
Z9 8
U1 8
U2 19
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD JUL
PY 2015
VL 41
IS 4
BP 795
EP 800
DI 10.1093/schbul/sbv050
PG 6
WC Psychiatry
SC Psychiatry
GA CM7QV
UT WOS:000357891500007
PM 25925393
ER
PT J
AU Liu, CH
Keshavan, MS
Tronick, E
Seidman, LJ
AF Liu, Cindy H.
Keshavan, Matcheri S.
Tronick, Ed
Seidman, Larry J.
TI Perinatal Risks and Childhood Premorbid Indicators of Later Psychosis:
Next Steps for Early Psychosocial Interventions
SO SCHIZOPHRENIA BULLETIN
LA English
DT Article
DE psychosis; schizophrenia; early intervention; prevention; stress;
psychological; parenting
ID SEVERE MENTAL-ILLNESS; SCHIZOPHRENIA-SPECTRUM DISORDERS;
GENOTYPE-ENVIRONMENT INTERACTION; COGNITIVE REMEDIATION THERAPY;
JERUSALEM INFANT DEVELOPMENT; NEW-ENGLAND FAMILY; CLINICAL HIGH-RISK;
1966 BIRTH COHORT; ADULT SCHIZOPHRENIA; OBSTETRIC COMPLICATIONS
AB Schizophrenia and affective psychoses are debilitating disorders that together affect 2%-3% of the adult population. Approximately 50%-70% of the offspring of parents with schizophrenia manifest a range of observable difficulties including socioemotional, cognitive, neuromotor, speech-language problems, and psychopathology, and roughly 10% will develop psychosis. Despite the voluminous work on pre-morbid vulnerabilities to psychosis, especially on schizophrenia, the work on premorbid intervention approaches is scarce. While later interventions during the clinical high-risk (CHR) phase of psychosis, characterized primarily by attenuated positive symptoms, are promising, the CHR period is a relatively late phase of developmental derailment. This article reviews and proposes potential targets for psychosocial interventions during the premorbid period, complementing biological interventions described by others in this Special Theme issue. Beginning with pregnancy, parents with psychoses may benefit from enhanced prenatal care, social support, parenting skills, reduction of symptoms, and programs that are family-centered. For children at risk, we propose preemptive early intervention and cognitive remediation. Empirical research is needed to evaluate these interventions for parents and determine whether interventions for parents and children positively influence the developmental course of the offspring.
C1 [Liu, Cindy H.; Keshavan, Matcheri S.; Seidman, Larry J.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med,Dept Psychiat, Massachusetts Mental Hlth Ctr,Div Publ Psychiat, Boston, MA 02215 USA.
[Liu, Cindy H.; Tronick, Ed] Univ Massachusetts, Dept Psychol, Boston, MA 02125 USA.
[Tronick, Ed] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Newborn Med, Boston, MA 02115 USA.
[Seidman, Larry J.] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Liu, CH (reprint author), 75 Fenwood Rd, Boston, MA 02115 USA.
EM cliu@bidmc.harvard.edu
FU Commonwealth Research Center [SCDMH82101008006]; NIMH [R21 MH092840]
FX Commonwealth Research Center (SCDMH82101008006) and NIMH (R21 MH092840).
NR 247
TC 6
Z9 6
U1 19
U2 35
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD JUL
PY 2015
VL 41
IS 4
BP 801
EP 816
DI 10.1093/schbul/sbv047
PG 16
WC Psychiatry
SC Psychiatry
GA CM7QV
UT WOS:000357891500008
PM 25904724
ER
PT J
AU Agnew-Blais, JC
Buka, SL
Fitzmaurice, GM
Smoller, JW
Goldstein, JM
Seidman, LJ
AF Agnew-Blais, Jessica C.
Buka, Stephen L.
Fitzmaurice, Garrett M.
Smoller, Jordan W.
Goldstein, Jill M.
Seidman, Larry J.
TI Early Childhood IQ Trajectories in Individuals Later Developing
Schizophrenia and Affective Psychoses in the New England Family Studies
SO SCHIZOPHRENIA BULLETIN
LA English
DT Article
DE IQ; cognition; schizophrenia; affective psychosis; cognitive development
ID ADULT SCHIZOPHRENIA; STANFORD-BINET; BIRTH COHORT; RISK-FACTORS;
PERFORMANCE; DISORDER; CHILDREN; DECLINE; UPDATE; DEFECT
AB Individuals who develop schizophrenia in adulthood exhibit, on average, deficits in childhood cognition relative to healthy controls. However, it remains unclear when in childhood such deficits emerge and whether they are stable across childhood or change (increase or decrease) across development. Importantly, whether the trajectory of childhood cognition differs among youth who later develop affective psychoses (AP) vs schizophrenia as adults remains unresolved. Subjects in the Collaborative Perinatal Project were administered the Stanford-Binet IQ test at age 4 and the Wechsler Intelligence Scale for Children at age 7. A total of 9809 (54.7%) participants in the New England Study sites were tested at both ages, including 37 who later developed schizophrenia spectrum psychoses (SSP) and 39 who later developed AP. Logistic regression models examined the association of level of and change in childhood IQ and later SSP or AP. Lower overall childhood IQ was associated with higher risk of SSP. Additionally, there was a small mean increase in IQ in the SSP group relative to a mean decrease in the control group from age 4 to 7 such that positive change in IQ was significantly associated with a higher risk of SSP. Neither overall level nor change in IQ was associated with risk of AP. The results are consistent with neurocognitive impairment throughout early childhood specifically for children who later develop schizophrenia, affirming the theory of atypical neurodevelopment in premorbid schizophrenia.
C1 [Agnew-Blais, Jessica C.] Kings Coll London, Inst Psychiat Psychol & Neurosci, MRC Social Genet & Dev Psychiat Ctr, London SE5 8AF, England.
[Buka, Stephen L.] Brown Univ, Dept Epidemiol, Providence, RI 02912 USA.
[Fitzmaurice, Garrett M.] Harvard Univ, McLean Hosp, Sch Med, Lab Psychiat Biostat, Belmont, MA USA.
[Fitzmaurice, Garrett M.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Smoller, Jordan W.] Massachusetts Gen Hosp, Dept Psychiat, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA.
[Goldstein, Jill M.] Harvard Univ, Brigham & Womens Hosp, Dept Psychiat, Sch Med,Connors Ctr Womens Hlth & Gender Biol, Boston, MA 02115 USA.
[Goldstein, Jill M.] Harvard Univ, Brigham & Womens Hosp, Dept Med, Sch Med,Connors Ctr Womens Hlth & Gender Biol, Boston, MA 02115 USA.
[Goldstein, Jill M.; Seidman, Larry J.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Seidman, Larry J.] Harvard Univ, Sch Med, Dept Psychiat,Beth Israel Deaconess Med Ctr, Massachusetts Mental Hlth Ctr,Div Publ Psychiat, Boston, MA 02115 USA.
RP Agnew-Blais, JC (reprint author), Kings Coll London, Inst Psychiat Psychol & Neurosci, MRC Social Genet & Dev Psychiat Ctr, 16 De Crespigny Pk,Denmark Hill, London SE5 8AF, England.
EM jessica.agnew-blais@kcl.ac.uk
RI Agnew-Blais, Jessica/L-9236-2015
OI Agnew-Blais, Jessica/0000-0002-0755-6867
FU National Institute of Mental Health [T32MH017119, R21 MH091461, RO1
MH56956, R01MH63951]; Commonwealth of Massachusetts [SCDMH82101008006];
Stanley Medical Research Institute
FX J.C.A.-B. was supported during work on this manuscript by National
Institute of Mental Health (T32MH017119). L.J.S. is supported by the
Commonwealth of Massachusetts (SCDMH82101008006) and National Institute
of Mental Health (R21 MH091461). Ascertainment and assessment of
subjects were originally funded under National Institute of Mental
Health (RO1 MH56956 to J.M.G., P.I., Stanley Medical Research Institute
[S.L.B. and J.M.G., 1994-1997]) and National Institute of Mental Health
(R01MH63951 to L.J.S., P.I.). The funders played no role in the design
and conduct of the study; collection, management, analysis, and
interpretation of the data; and preparation, review, or approval of the
manuscript.
NR 38
TC 7
Z9 8
U1 2
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0586-7614
EI 1745-1701
J9 SCHIZOPHRENIA BULL
JI Schizophr. Bull.
PD JUL
PY 2015
VL 41
IS 4
BP 817
EP 823
DI 10.1093/schbul/sbv027
PG 7
WC Psychiatry
SC Psychiatry
GA CM7QV
UT WOS:000357891500009
PM 25904723
ER
PT J
AU Karambelkar, A
Kasekar, R
Palevsky, PM
AF Karambelkar, Ameet
Kasekar, Riyaj
Palevsky, Paul M.
TI Perioperative Pharmacologic Management of Patients with End Stage Renal
Disease
SO SEMINARS IN DIALYSIS
LA English
DT Article
ID SUCCINYLCHOLINE-INDUCED HYPERKALEMIA; HEMODIALYSIS-PATIENTS; DIALYSIS
PATIENTS; PHARMACOKINETICS; FAILURE; MORPHINE; HYDROMORPHONE;
INSUFFICIENCY; SUXAMETHONIUM; METABOLISM
AB The pharmacokinetics of numerous medications used in the perioperative period are altered in patients with end-stage renal disease. Clearance of drugs, or their metabolites, that are normally excreted by the kidney is markedly reduced in ESRD. In addition, patients with ESRD may also have alterations in gastrointestinal absorption, volume of distribution, protein binding, and metabolic clearance of pharmacologic agents. Finally, drug removal may be augmented during dialysis. All of these factors contribute to the need for dose adjustment of medications, including analgesics, anesthetics, neuromuscular blockers, and antimicrobial agents, which may be used in the perioperative management of the ESRD patient.
C1 [Karambelkar, Ameet; Kasekar, Riyaj; Palevsky, Paul M.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA.
[Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Med Serv, Renal Sect, Pittsburgh, PA 15240 USA.
RP Palevsky, PM (reprint author), VA Pittsburgh Healthcare Syst, Room 7E123 111F-U,Univ Dr, Pittsburgh, PA 15240 USA.
EM palevsky@pitt.edu
OI Palevsky, Paul/0000-0002-7334-5400
NR 54
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-0959
EI 1525-139X
J9 SEMIN DIALYSIS
JI Semin. Dial.
PD JUL-AUG
PY 2015
VL 28
IS 4
BP 392
EP 396
DI 10.1111/sdi.12384
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA CM4WZ
UT WOS:000357687800012
PM 25876523
ER
PT J
AU Austin, JH
Mieure, KD
Weber, LM
McCarthy, BC
AF Austin, Jennifer H.
Mieure, Katherine D.
Weber, Lynn M.
McCarthy, Bryan C., Jr.
TI National characteristics of residency program interview processes
SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
LA English
DT Letter
ID MULTIPLE MINI-INTERVIEWS
C1 [Austin, Jennifer H.] Univ Chicago Med, Dept Pharm Serv, Internal Med, Chicago, IL 60637 USA.
[Mieure, Katherine D.] Massachusetts Gen Hosp, Dept Pharm, Pharm, Clin Serv, Boston, MA 02114 USA.
[Weber, Lynn M.] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA.
[McCarthy, Bryan C., Jr.] Univ Chicago Med, Dept Pharm Serv, Ambulatory Care Pharm Serv & Clin, Chicago, IL USA.
[McCarthy, Bryan C., Jr.] Univ Chicago Med, Dept Pharm Serv, Qual Outcomes & Utilizat, Chicago, IL USA.
RP Austin, JH (reprint author), Univ Chicago Med, Dept Pharm Serv, Internal Med, Chicago, IL 60637 USA.
EM jennifer.austin@uchospitals.edu
NR 4
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC HEALTH-SYSTEM PHARMACISTS
PI BETHESDA
PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA
SN 1079-2082
EI 1535-2900
J9 AM J HEALTH-SYST PH
JI Am. J. Health-Syst. Pharm.
PD JUL 1
PY 2015
VL 72
IS 13
BP 1085
EP 1086
DI 10.2146/ajhp150052
PG 2
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CM1LJ
UT WOS:000357442100004
PM 26092955
ER
PT J
AU Reddy, A
Shea, JA
Canamucio, A
Werner, RM
AF Reddy, Ashok
Shea, Judy A.
Canamucio, Anne
Werner, Rachel M.
TI The Effect of Organizational Climate on Patient-Centered Medical Home
Implementation
SO AMERICAN JOURNAL OF MEDICAL QUALITY
LA English
DT Article
DE medical home; organizational climate; veterans; primary care delivery
ID HEALTH-CARE; PERFORMANCE; READINESS; SERVICES; CULTURE; SAFETY; MODEL
AB Organizational climate is a key determinant of successful adoption of innovations; however, its relation to medical home implementation is unknown. This study examined the association between primary care providers' (PCPs') perception of organization climate and medical home implementation in the Veterans Health Administration. Multivariate regression was used to test the hypothesis that organizational climate predicts medical home implementation. This analysis of 191 PCPs found that higher scores in 2 domains of organizational climate (communication and cooperation, and orientation to quality improvement) were associated with a statistically significantly higher percentage (from 7 to 10 percentage points) of PCPs implementing structural changes to support the medical home model. In addition, some aspects of a better organizational climate were associated with improved organizational processes of care, including a higher percentage of patients contacted within 2 days of hospital discharge (by 2 to 3 percentage points) and appointments made within 3 days of a patient request (by 2 percentage points).
C1 [Reddy, Ashok; Shea, Judy A.; Canamucio, Anne; Werner, Rachel M.] Philadelphia VA Med Ctr, VISN Ctr Evaluat PACT 4, Philadelphia, PA USA.
[Reddy, Ashok; Shea, Judy A.; Werner, Rachel M.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Reddy, Ashok; Shea, Judy A.; Werner, Rachel M.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
[Reddy, Ashok] Univ Penn, Robert Wood Johnson Clin Scholar Program, Philadelphia, PA 19104 USA.
RP Reddy, A (reprint author), Univ Penn, Perelman Sch Med, Blockley Hall 1303,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM ashokr@upenn.edu
FU Veterans Administration's PACT (Patient-Aligned Care Team) Demonstration
Laboratory initiative; VA Office of Patient Care Services
FX The authors disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: This work was
undertaken as part of the Veterans Administration's PACT
(Patient-Aligned Care Team) Demonstration Laboratory initiative,
supporting and evaluating VA's transition to a patient-centered medical
home. Funding for the PACT Demonstration Laboratory initiative is
provided by the VA Office of Patient Care Services. Ashok Reddy MD, is a
Robert Wood Johnson Foundation Clinical Scholar at University of
Pennsylvania.
NR 20
TC 1
Z9 1
U1 2
U2 9
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1062-8606
EI 1555-824X
J9 AM J MED QUAL
JI Am. J. Med. Qual.
PD JUL-AUG
PY 2015
VL 30
IS 4
BP 309
EP 316
DI 10.1177/1062860614532516
PG 8
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA CM5AQ
UT WOS:000357698700001
PM 24788252
ER
PT J
AU Palen, BN
Kapur, VK
AF Palen, Brian N.
Kapur, Vishesh K.
TI Tailoring Therapy for Obesity Hypoventilation Syndrome
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Editorial Material
ID POSITIVE-PRESSURE VENTILATION; NONINVASIVE VENTILATION;
RANDOMIZED-TRIAL; SLEEP; SUPPORT; MANAGEMENT; EFFICACY; IMPACT
C1 [Palen, Brian N.; Kapur, Vishesh K.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA.
[Palen, Brian N.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
RP Palen, BN (reprint author), Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA.
OI Kapur, Vishesh/0000-0002-5417-1097
NR 14
TC 1
Z9 1
U1 0
U2 2
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PD JUL 1
PY 2015
VL 192
IS 1
BP 8
EP 10
PG 3
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA CM6YY
UT WOS:000357838800006
PM 26131989
ER
PT J
AU Giordano, S
Hage, FG
Xing, DQ
Chen, YF
Allon, S
Chen, CJ
Oparil, S
AF Giordano, Samantha
Hage, Fadi G.
Xing, Dongqi
Chen, Yiu-Fai
Allon, Steven
Chen, Chongjia
Oparil, Suzanne
TI Estrogen and Cardiovascular Disease: Is Timing Everything?
SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES
LA English
DT Article
ID POSTMENOPAUSAL HORMONE-THERAPY; RANDOMIZED CONTROLLED-TRIAL;
CORONARY-HEART-DISEASE; RAT CAROTID-ARTERY; ADVENTITIAL FIBROBLAST
MIGRATION; PROTEIN TRANSGENIC MICE; SMOOTH-MUSCLE-CELLS; REPLACEMENT
THERAPY; NEOINTIMA FORMATION; BALLOON INJURY
C1 [Giordano, Samantha; Hage, Fadi G.; Xing, Dongqi; Chen, Yiu-Fai; Allon, Steven; Chen, Chongjia; Oparil, Suzanne] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Vasc Biol & Hypertens Program, Birmingham, AL 35294 USA.
[Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Div Cardiol, Birmingham, AL USA.
RP Giordano, S (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, 703 19th St South,Zeigler Res Bldg,Room 1047, Birmingham, AL 35294 USA.
EM sgiordan@uab.edu
OI Hage, Fadi/0000-0002-1397-4942
FU National Heart, Lung and Blood Institute [R01 HL087980, T32 HL07457];
Veterans Affairs Biomedical Laboratory Research & Development Service
Merit Award OMB [4040-0001]
FX Supported, in part, by National Heart, Lung and Blood Institute Grant
R01 HL087980 (S.O.) and T32 HL07457 (S.O. and S.G.) and by Veterans
Affairs Biomedical Laboratory Research & Development Service Merit Award
OMB 4040-0001 (F.G.H.).
NR 58
TC 5
Z9 5
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0002-9629
EI 1538-2990
J9 AM J MED SCI
JI Am. J. Med. Sci.
PD JUL
PY 2015
VL 350
IS 1
BP 27
EP 35
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA CM2KA
UT WOS:000357507400002
PM 26110752
ER
PT J
AU Khosroshahi, A
Wallace, ZS
Crowe, JL
Akamizu, T
Azumi, A
Carruthers, MN
Chari, ST
Della-Torre, E
Frulloni, L
Goto, H
Hart, PA
Kamisawa, T
Kawa, S
Kawano, M
Kim, MH
Kodama, Y
Kubota, K
Lerch, MM
Lohr, M
Masaki, Y
Matsui, S
Mimori, T
Nakamura, S
Nakazawa, T
Ohara, H
Okazaki, K
Ryu, JH
Saeki, T
Schleinitz, N
Shimatsu, A
Shimosegawa, T
Takahashi, H
Takahira, M
Tanaka, A
Topazian, M
Umehara, H
Webster, GJ
Witzig, TE
Yamamoto, M
Zhang, W
Chiba, T
Stone, JH
AF Khosroshahi, A.
Wallace, Z. S.
Crowe, J. L.
Akamizu, T.
Azumi, A.
Carruthers, M. N.
Chari, S. T.
Della-Torre, E.
Frulloni, L.
Goto, H.
Hart, P. A.
Kamisawa, T.
Kawa, S.
Kawano, M.
Kim, M. H.
Kodama, Y.
Kubota, K.
Lerch, M. M.
Lohr, M.
Masaki, Y.
Matsui, S.
Mimori, T.
Nakamura, S.
Nakazawa, T.
Ohara, H.
Okazaki, K.
Ryu, J. H.
Saeki, T.
Schleinitz, N.
Shimatsu, A.
Shimosegawa, T.
Takahashi, H.
Takahira, M.
Tanaka, A.
Topazian, M.
Umehara, H.
Webster, G. J.
Witzig, T. E.
Yamamoto, M.
Zhang, W.
Chiba, T.
Stone, J. H.
TI International Consensus Guidance Statement on the Management and
Treatment of IgG4-Related Disease
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Article
ID IMMUNOGLOBULIN G4-ASSOCIATED CHOLANGITIS; IGG4-POSITIVE PLASMA-CELLS;
CHURG-STRAUSS-SYNDROME; SERUM IGG4 LEVELS; AUTOIMMUNE PANCREATITIS;
SYSTEMIC-DISEASE; CORTICOSTEROID-TREATMENT; DIAGNOSTIC-CRITERIA;
CLINICOPATHOLOGICAL-ENTITY; RETROSPECTIVE MULTICENTER
C1 [Khosroshahi, A.] Emory Univ, Sch Med, Atlanta, GA USA.
[Wallace, Z. S.; Stone, J. H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Crowe, J. L.] Univ Tennessee, Coll Med, Chattanooga, TN USA.
[Akamizu, T.] Wakayama Med Univ, Tokyo, Japan.
[Azumi, A.] Kobe Kaisei Hosp, Kobe, Hyogo, Japan.
[Carruthers, M. N.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
[Chari, S. T.; Ryu, J. H.; Topazian, M.; Witzig, T. E.] Mayo Clin, Rochester, MN USA.
[Della-Torre, E.] Ist Sci San Raffaele, I-20132 Milan, Italy.
[Frulloni, L.] Univ Verona, I-37100 Verona, Italy.
[Goto, H.] Tokyo Med Univ, Tokyo 1608402, Japan.
[Hart, P. A.] Ohio State Univ, Coll Med, Columbus, OH 43210 USA.
[Hart, P. A.] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA.
[Kamisawa, T.] Tokyo Metropolitan Komagome Hosp, Tokyo, Japan.
[Kawa, S.] Shinshu Univ, Matsumoto, Nagano 390, Japan.
[Kawano, M.; Takahira, M.] Kanazawa Univ, Grad Sch Med Sci, Kanazawa, Ishikawa, Japan.
[Kawano, M.; Takahira, M.] Kanazawa Univ Hosp, Kanazawa, Ishikawa, Japan.
[Kim, M. H.] Univ Ulsan, Coll Med, Ulsan 680749, South Korea.
[Kim, M. H.] Asan Med Ctr, Ulsan, South Korea.
[Kodama, Y.; Mimori, T.; Chiba, T.] Kyoto Univ, Grad Sch Med, Kyoto, Japan.
[Kubota, K.] Yokohama City Univ, Yokohama, Kanagawa 232, Japan.
[Kubota, K.] Yokohama City Univ Med, Yokohama, Kanagawa, Japan.
[Lerch, M. M.] Ernst Moritz Arndt Univ Greifswald, Sch Med, Greifswald, Germany.
[Lohr, M.] Karolinska Inst, Stockholm, Sweden.
[Masaki, Y.; Umehara, H.] Kanazawa Med Univ, Kanazawa, Ishikawa, Japan.
[Matsui, S.] Toyama Univ, Toyama 930, Japan.
[Nakamura, S.] Kyushu Univ, Fukuoka 812, Japan.
[Nakamura, S.] Kyushu Univ, Dent Hosp, Fukuoka 812, Japan.
[Nakazawa, T.; Ohara, H.] Nagoya City Univ, Grad Sch Med, Nagoya, Aichi, Japan.
[Okazaki, K.] Kansai Med Univ, Hirakata, Osaka, Japan.
[Saeki, T.] Nagaoka Red Cross Hosp, Nagaoka, Niigata, Japan.
[Schleinitz, N.] Aix Marseille Univ, Assistance Publ Hop Marseille, Marseille, France.
[Shimatsu, A.] Natl Hosp Org Kyoto Med Ctr, Kyoto, Japan.
[Shimosegawa, T.] Tohoku Univ, Tokyo, Japan.
[Takahashi, H.; Yamamoto, M.] Sapporo Med Univ, Sch Med, Sapporo, Hokkaido, Japan.
[Tanaka, A.] Teikyo Univ, Sch Med, Tokyo 173, Japan.
[Webster, G. J.] UCL, London, England.
[Webster, G. J.] Univ Coll London Hosp, London, England.
[Zhang, W.] Chinese Acad Med Sci, Beijing 100730, Peoples R China.
[Zhang, W.] Beijing Union Med Coll Hosp, Beijing, Peoples R China.
RP Chiba, T (reprint author), Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Kyoto, Japan.
EM chiba@kuhp.kyoto-u.ac.jp; jhstone@mgh.harvard.edu
RI Lerch, Markus M./E-2206-2016; Hart, Phil/A-9842-2016;
OI Lerch, Markus M./0000-0002-9643-8263; Hart, Phil/0000-0003-4346-6196;
Della Torre, Emanuel/0000-0002-9192-4270; Lohr,
Matthias/0000-0002-7647-198X; Frulloni, Luca/0000-0001-7417-2655
FU Chiesi Pharmaceuticals; Genentech; Japanese Ministry of Health, Labor,
and Welfare; Amgen
FX The Second International Symposium on IgG4-Related Disease was funded by
the Japanese Ministry of Health, Labor, and Welfare, Amgen, and
Genentech.Dr. Frulloni has received consulting fees, speaking fees,
and/or honoraria from Chiesi Pharmaceuticals (less than $10,000). Dr.
Stone has received consulting fees, speaking fees, and/or honoraria from
Genentech (less than $10,000).
NR 78
TC 74
Z9 83
U1 5
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2326-5191
EI 2326-5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
PD JUL
PY 2015
VL 67
IS 7
BP 1688
EP 1699
DI 10.1002/art.39132
PG 12
WC Rheumatology
SC Rheumatology
GA CL5QA
UT WOS:000357013500002
PM 25809420
ER
PT J
AU Baker, JF
Billig, E
Michaud, K
Ibrahim, S
Caplan, L
Cannon, GW
Stokes, A
Majithia, V
Mikuls, TR
AF Baker, Joshua F.
Billig, Erica
Michaud, Kaleb
Ibrahim, Said
Caplan, Liron
Cannon, Grant W.
Stokes, Andrew
Majithia, Vikas
Mikuls, Ted R.
TI Weight Loss, the Obesity Paradox, and the Risk of Death in Rheumatoid
Arthritis
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Article
ID BODY-MASS INDEX; DISEASE-ACTIVITY; US VETERANS; MORTALITY-RISKS;
OLDER-ADULTS; HEALTH; ASSOCIATION; POPULATION; CATEGORIES; OVERWEIGHT
AB ObjectiveIn contrast to what is observed in the general population, a low body mass index (BMI) has been associated with accelerated mortality in patients with rheumatoid arthritis (RA). The aim of this study was to assess whether weight loss might explain these seemingly paradoxical observations.
MethodsOur study included patients identified from the Veterans Affairs (VA) RA Registry. Dates of death were abstracted from VA electronic medical records. The BMI at each study visit and the change from the previous visit were determined. The maximum BMI of each patient was also obtained from medical records. The annualized rate of BMI loss was determined from the slope of change (per year) in BMI over visits within the preceding 13 months. Cox multivariable proportional hazards models were used to assess associations between BMI measures and mortality.
ResultsIn a sample of 1,674 patients, 312 deaths occurred over 9,183 person-years. A loss in BMI of 1 kg/m(2) was associated with a greater risk of death, after adjustment for demographics, comorbidities, BMI, smoking, and RA therapies (hazard ratio [HR] 1.99, 95% confidence interval [95% CI] 1.53-2.59, P<0.001). This association remained significant in a subsample analysis adjusting for C-reactive protein and physical function (HR 1.81, 95% CI 1.36-2.41, P<0.001). Weight loss at an annualized rate of 3 kg/m(2) was associated with the greatest risk of death (HR 2.49, 95% CI 1.73-3.57, P<0.001). Low BMI (<20 kg/m(2)) in patients with a history of obesity (>30 kg/m(2)) was associated with the greatest risk (HR 8.52, 95% CI 4.10-17.71, P<0.001).
ConclusionWeight loss is a strong predictor of death in patients with RA. These observations may explain the observed obesity paradox and do not support a biologically protective role of obesity.
C1 [Baker, Joshua F.; Ibrahim, Said] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Baker, Joshua F.; Billig, Erica; Ibrahim, Said] Univ Penn, Philadelphia, PA 19104 USA.
[Michaud, Kaleb; Mikuls, Ted R.] Nebraska Western Iowa VA Med Ctr, Omaha, NE USA.
[Michaud, Kaleb; Mikuls, Ted R.] Univ Nebraska Med Ctr, Omaha, NE USA.
[Michaud, Kaleb] Natl Data Bank Rheumat Dis, Wichita, KS USA.
[Caplan, Liron] Denver VA Med Ctr, Denver, CO USA.
[Cannon, Grant W.] Salt Lake City VA Med Ctr, Salt Lake City, UT USA.
[Cannon, Grant W.] Univ Utah, Salt Lake City, UT USA.
[Stokes, Andrew] Boston Univ, Sch Publ Hlth, Boston, MA USA.
[Majithia, Vikas] GV Sonny Montgomery VA Med Ctr, Montgomery, MS USA.
[Majithia, Vikas] Univ Mississippi, Med Ctr, Jackson, MS USA.
RP Baker, JF (reprint author), Hosp Univ Penn, Div Rheumatol, Dept Med, 8 Penn Tower Bldg,3600 Spruce St, Philadelphia, PA 19104 USA.
EM bakerjo@uphs.upenn.edu
OI Stokes, Andrew/0000-0002-8502-3636
FU VA Clinical Science Research and Development Career Development Award
[IK2 CX000955]; Rheumatology Research Foundation; NIH from National
Institute of Arthritis and Musculoskeletal and Skin Diseases
[1-K24-AR-055259-01]; VA Health Service Research and Development Career
Development Award [07-221]; VA Merit Award; Nebraska Arthritis Outcomes
Research Center at the University of Nebraska Medical Center; VA Health
Services Research and Development Program of the Veterans Health
Administration
FX Dr. Baker's work was supported by a VA Clinical Science Research and
Development Career Development Award (IK2 CX000955). Dr. Michaud's work
was supported by a Rheumatology Research Foundation Investigator Award.
Dr. Ibrahim's work was supported by the NIH (grant 1-K24-AR-055259-01
from the National Institute of Arthritis and Musculoskeletal and Skin
Diseases). Dr. Caplan's work was supported by a VA Health Service
Research and Development Career Development Award (07-221). Dr. Mikuls'
work was supported by a VA Merit Award. The VA Rheumatoid Arthritis
Registry is supported by the Nebraska Arthritis Outcomes Research Center
at the University of Nebraska Medical Center and by the VA Health
Services Research and Development Program of the Veterans Health
Administration.
NR 33
TC 14
Z9 14
U1 1
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2326-5191
EI 2326-5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
PD JUL
PY 2015
VL 67
IS 7
BP 1711
EP 1717
DI 10.1002/art.39136
PG 7
WC Rheumatology
SC Rheumatology
GA CL5QA
UT WOS:000357013500005
PM 25940140
ER
PT J
AU Grayson, PC
Carmona-Rivera, C
Xu, LJ
Lim, N
Gao, Z
Asare, AL
Specks, U
Stone, JH
Seo, P
Spiera, RF
Langford, CA
Hoffman, GS
Kallenberg, CGM
St Clair, EW
Tchao, NK
Ytterberg, SR
Phippard, DJ
Merkel, PA
Kaplan, MJ
Monach, PA
AF Grayson, Peter C.
Carmona-Rivera, Carmelo
Xu, Lijing
Lim, Noha
Gao, Zhong
Asare, Adam L.
Specks, Ulrich
Stone, John H.
Seo, Philip
Spiera, Robert F.
Langford, Carol A.
Hoffman, Gary S.
Kallenberg, Cees G. M.
St Clair, E. William
Tchao, Nadia K.
Ytterberg, Steven R.
Phippard, Deborah J.
Merkel, Peter A.
Kaplan, Mariana J.
Monach, Paul A.
CA Rituximab ANCA-Associated
TI Neutrophil-Related Gene Expression and Low-Density Granulocytes
Associated With Disease Activity and Response to Treatment in
Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Article
ID SMALL-VESSEL VASCULITIS; ANCA-ASSOCIATED VASCULITIS;
WEGENERS-GRANULOMATOSIS; TREATMENT RESISTANCE; NETTING NEUTROPHILS;
EXTRACELLULAR TRAPS; RELAPSE; TRANSCRIPTION; PROTEINASE-3; PREDICTORS
AB ObjectiveTo discover biomarkers involved in the pathophysiology of antineutrophil cytoplasmic antibody-associated vasculitis (AAV) and to determine whether low-density granulocytes (LDGs) contribute to gene expression signatures in AAV.
MethodsThe source of clinical data and linked biologic specimens was a randomized controlled treatment trial in AAV. RNA sequencing of whole blood from patients with AAV was performed during active disease at the baseline visit and during remission 6 months later. Gene expression was compared between patients who met versus those who did not meet the primary trial outcome of clinical remission at 6 months (responders versus nonresponders). Measurement of neutrophil-related gene expression was confirmed in peripheral blood mononuclear cells (PBMCs) to validate the findings in whole blood. A negative-selection strategy isolated LDGs from PBMC fractions.
ResultsDifferential expression between responders (n=77) and nonresponders (n=35) was detected in 2,346 transcripts at the baseline visit (P<0.05). Unsupervised hierarchical clustering demonstrated a cluster of granulocyte-related genes, including myeloperoxidase (MPO) and proteinase 3 (PR3). A granulocyte multigene composite score was significantly higher in nonresponders than in responders (P<0.01) and during active disease than during remission (P<0.01). This signature strongly overlapped an LDG signature identified previously in lupus (false discovery rate by gene set enrichment analysis <0.01). Transcription of PR3 measured in PBMCs was associated with active disease and treatment response (P<0.01). LDGs isolated from patients with AAV spontaneously formed neutrophil extracellular traps containing PR3 and MPO.
ConclusionIn AAV, increased expression of a granulocyte gene signature is associated with disease activity and decreased response to treatment. The source of this signature is likely LDGs, a potentially pathogenic cell type in AAV.
C1 [Grayson, Peter C.; Carmona-Rivera, Carmelo; Kaplan, Mariana J.] NIAMSD, NIH, Bethesda, MD 20892 USA.
[Xu, Lijing; Lim, Noha; Gao, Zhong; Asare, Adam L.; Tchao, Nadia K.; Phippard, Deborah J.] Immune Tolerance Network, Bethesda, MD USA.
[Specks, Ulrich; Ytterberg, Steven R.] Mayo Clin Fdn, Rochester, MN USA.
[Stone, John H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Seo, Philip] Johns Hopkins Univ, Baltimore, MD USA.
[Spiera, Robert F.] Hosp Special Surg, New York, NY 10021 USA.
[Langford, Carol A.; Hoffman, Gary S.] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
[Kallenberg, Cees G. M.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands.
[St Clair, E. William] Duke Univ, Med Ctr, Durham, NC USA.
[Merkel, Peter A.] Univ Penn, Philadelphia, PA 19104 USA.
[Monach, Paul A.] Boston Univ, Sch Med, Boston, MA 02118 USA.
RP Grayson, PC (reprint author), NIAMSD, NIH, 10 Ctr Dr,Bldg 10,Room 216G, Bethesda, MD 20892 USA.
EM peter.grayson@nih.gov
FU Immune Tolerance Network (NIH), an international clinical research
consortium headquartered at the University of California San Francisco
[N01-AI-15416]; NIH through National Institute of Arthritis and
Musculoskeletal and Skin Diseases Intramural Research Program; National
Center for Advancing Translational Sciences (Boston University-Clinical
and Translational Science Institute) [KL2-TR-000158]; Rheumatology
Scientist Development Award from Rheumatology Research Foundation;
Genentech; ChemoCentryx; GlaxoSmithKline; Eli Lilly; MedImmune
FX The Rituximab in ANCA-Associated Vasculitis (RAVE) trial was performed
with the support of the Immune Tolerance Network (NIH contract
N01-AI-15416, protocol number ITN-21AI), an international clinical
research consortium headquartered at the University of California San
Francisco. Additional support was provided by the NIH through the
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Intramural Research Program and the National Center for Advancing
Translational Sciences (Boston University-Clinical and Translational
Science Institute grant KL2-TR-000158). Dr. Grayson's work was supported
by a Rheumatology Scientist Development Award from the Rheumatology
Research Foundation.; Drs. Specks and Stone have received consulting
fees, speaking fees, and/or honoraria from Genentech (less than
$10,000). Dr. Kallenberg has received consulting fees from ChemoCentryx,
GlaxoSmithKline, Eli Lilly, and MedImmune (less than $10,000 each).
NR 38
TC 19
Z9 20
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2326-5191
EI 2326-5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
PD JUL
PY 2015
VL 67
IS 7
BP 1922
EP 1932
DI 10.1002/art.39153
PG 11
WC Rheumatology
SC Rheumatology
GA CL5QA
UT WOS:000357013500028
PM 25891759
ER
PT J
AU Da Silva, N
Smith, TB
AF Da Silva, Nicolas
Smith, Tegan B.
TI Exploring the role of mononuclear phagocytes in the epididymis
SO ASIAN JOURNAL OF ANDROLOGY
LA English
DT Review
DE antigen-presenting cells; autoimmunity; dendritic cells; epididymis;
macrophages; peripheral tolerance; sperm maturation; spermatozoa
ID CD103(+) DENDRITIC CELLS; SPERM QUALITY-CONTROL; REGULATORY T-CELLS;
MOUSE EPIDIDYMIS; RAT EPIDIDYMIS; BASAL-CELLS; IN-VIVO; MURINE
EPIDIDYMIS; GENE-EXPRESSION; LUMINAL FACTORS
AB The onslaught of foreign antigens carried by spermatozoa into the epididymis, an organ that has not demonstrated immune privilege, a decade or more after the establishment of central immune tolerance presents a unique biological challenge. Historically, the physical confinement of spermatozoa to the epididymal tubule enforced by a tightly interwoven wall of epithelial cells was considered sufficient enough to prevent cross talk between gametes and the immune system and, ultimately, autoimmune destruction. The discovery of an intricate arrangement of mononuclear phagocytes (MPs) comprising dendritic cells and macrophages in the murine epididymis suggests that we may have underestimated the existence of a sophisticated mucosal immune system in the posttesticular environment. This review consolidates our current knowledge of the physiology of MPs in the steady state epididymis and speculates on possible interactions between auto-antigenic spermatozoa, pathogens and the immune system by drawing on what is known about the immune system in the intestinal mucosa. Ultimately, further investigation will provide valuable information regarding the origins of pathologies arising as a result of autoimmune or inflammatory responses in the epididymis, including epididymitis and infertility.
C1 [Da Silva, Nicolas] Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Div Nephrol, Ctr Syst Biol, Boston, MA USA.
RP Da Silva, N (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM dasilva.nicolas@mgh.harvard.edu
FU National Institutes of Health [5R01HD069623]
FX Our research is supported by National Institutes of Health grant
5R01HD069623. We thank Claire R Barton for her help in proofing this
manuscript.
NR 73
TC 3
Z9 3
U1 0
U2 0
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
INDIA
SN 1008-682X
EI 1745-7262
J9 ASIAN J ANDROL
JI Asian J. Androl.
PD JUL
PY 2015
VL 17
IS 4
BP 591
EP 596
DI 10.4103/1008-682X.153540
PG 6
WC Andrology; Urology & Nephrology
SC Endocrinology & Metabolism; Urology & Nephrology
GA CL9HR
UT WOS:000357288800011
PM 25966624
ER
PT J
AU Leuchter, AF
Cook, IA
Feifel, D
Goethe, JW
Husain, M
Carpenter, LL
Thase, ME
Krystal, AD
Philip, NS
Bhati, MT
Burke, WJ
Howland, RH
Sheline, YI
Aaronson, ST
Iosifescu, DV
O'Reardon, JP
Gilmer, WS
Jain, R
Burgoyne, KS
Phillips, B
Manberg, PJ
Massaro, J
Hunter, AM
Lisanby, SH
George, MS
AF Leuchter, Andrew F.
Cook, Ian A.
Feifel, David
Goethe, John W.
Husain, Mustafa
Carpenter, Linda L.
Thase, Michael E.
Krystal, Andrew D.
Philip, Noah S.
Bhati, Mahendra T.
Burke, William J.
Howland, Robert H.
Sheline, Yvette I.
Aaronson, Scott T.
Iosifescu, Dan V.
O'Reardon, John P.
Gilmer, William S.
Jain, Rakesh
Burgoyne, Karl S.
Phillips, Bill
Manberg, Paul J.
Massaro, Joseph
Hunter, Aimee M.
Lisanby, Sarah H.
George, Mark S.
TI Efficacy and Safety of Low-field Synchronized Transcranial Magnetic
Stimulation (sTMS) for Treatment of Major Depression
SO BRAIN STIMULATION
LA English
DT Article
DE Synchronized Transcranial Magnetic Stimulation (sTMS); Low-intensity
magnetic field; Static magnet; Major Depressive Disorder; Clinical
treatment trial; Neuromodulation; Individual Alpha Frequency (IAF);
Alpha oscillations; Electroencephalogram (EEG); Oscillatory synchrony
ID SHAM-CONTROLLED TRIALS; ALPHA-FREQUENCY; RATING-SCALE; DOUBLE-BLIND;
METAANALYSIS; RTMS; TMS; MEDICATION; MULTISITE; EEG
AB Background: Transcranial Magnetic Stimulation (TMS) customarily uses high-field electromagnets to achieve therapeutic efficacy in Major Depressive Disorder (MDD). Low-field magnetic stimulation also may be useful for treatment of MDD, with fewer treatment-emergent adverse events.
Objective/Hypothesis: To examine efficacy, safety, and tolerability of low-field magnetic stimulation synchronized to an individual's alpha frequency (IAF) (synchronized TMS, or sTMS) for treatment of MDD.
Methods: Six-week double-blind sham-controlled treatment trial of a novel device that used three rotating neodymium magnets to deliver sTMS treatment. IAF was determined from a single-channel EEG prior to first treatment. Subjects had baseline 17-item Hamilton Depression Rating Scale (HamD(17)) >= 17.
Results: 202 subjects comprised the intent-to-treat (ITT) sample, and 120 subjects completed treatment per-protocol (PP). There was no difference in efficacy between active and sham in the ITT sample. Subjects in the PP sample (N = 59), however, had significantly greater mean decrease in HamD(17) than sham (N = 60) (-9.00 vs. -6.56, P = 0.033). PP subjects with a history of poor response or intolerance to medication showed greater improvement with sTMS than did treatment-naive subjects (-8.58 vs. -4.25, P = 0.017). Efficacy in the PP sample reflects exclusion of subjects who received fewer than 80% of scheduled treatments or were inadvertently treated at the incorrect IAF; these subgroups failed to separate from sham. There was no difference in adverse events between sTMS and sham, and no serious adverse events attributable to sTMS.
Conclusions: Results suggest that sTMS may be effective, safe, and well tolerated for treating MDD when administered as intended. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Leuchter, Andrew F.; Cook, Ian A.; Hunter, Aimee M.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Leuchter, Andrew F.; Cook, Ian A.; Hunter, Aimee M.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Neuromodulat Div, Los Angeles, CA 90024 USA.
[Feifel, David] UCSD Sch Med, Dept Psychiat, San Diego, CA USA.
[Goethe, John W.] Hartford Hosp, Inst Living, Hartford, CT 06115 USA.
[Husain, Mustafa] UT Southwestern Med Sch, Dept Psychiat, Dallas, TX USA.
[Carpenter, Linda L.; Philip, Noah S.] Brown Univ, Alpert Med Sch, Butler Hosp, Dept Psychiat & Human Behav, Providence, RI 02912 USA.
[Thase, Michael E.; Bhati, Mahendra T.; Sheline, Yvette I.] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA.
[Husain, Mustafa; Krystal, Andrew D.; Lisanby, Sarah H.] Duke Univ, Sch Med, Dept Psychiat & Behav Sci, Durham, NC USA.
[Burke, William J.] Univ Nebraska, Sch Med, Dept Psychiat, Omaha, NE 68198 USA.
[Howland, Robert H.] Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA USA.
[Sheline, Yvette I.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA.
[Aaronson, Scott T.] Sheppard Pratt Hlth Syst, Baltimore, MD USA.
[Iosifescu, Dan V.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.
[O'Reardon, John P.] Rowan Univ, Sch Osteopath Med, Dept Psychiat, Stratford, NJ USA.
[Gilmer, William S.] Chicago TMS Specialists, Chicago, IL USA.
[Jain, Rakesh] RD Clin Res, Lake Jackson, TX USA.
[Burgoyne, Karl S.] Harbor UCLA Med Ctr, Torrance, CA 90509 USA.
[Massaro, Joseph] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[George, Mark S.] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA.
[George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Phillips, Bill; Manberg, Paul J.] NeoSync Inc, Waltham, MA USA.
[Manberg, Paul J.] NeoSync Inc, Newport Beach, CA USA.
RP Leuchter, AF (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Semel Inst Neurosci & Human Behav,Neuromodulat Di, 760 Westwood Plaza, Los Angeles, CA 90024 USA.
EM afl@ucla.edu
RI Philip, Noah/C-3714-2016; Burke, William/C-1203-2012; Howland,
Robert/K-6937-2015
OI Philip, Noah/0000-0002-4889-8775; Howland, Robert/0000-0002-6533-6010
FU NeoSync, Inc.
FX Sponsorship of and financial support for the conduct of this research
was provided by NeoSync, Inc. As the study sponsor, the company was
involved in study design, as well in the collection, analysis, and
interpretation of data. The authors of this article have final authority
and responsibility for the data analyses and interpretation of the
results presented here. All individuals who participated in the writing
of this report and in the decision to submit the article for publication
are listed as co-authors on this manuscript. Because this was an
industry-sponsored study, most of the authors have some financial
relationship to the study sponsor.
NR 48
TC 7
Z9 7
U1 1
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1935-861X
EI 1876-4754
J9 BRAIN STIMUL
JI Brain Stimul.
PD JUL-AUG
PY 2015
VL 8
IS 4
BP 787
EP 794
DI 10.1016/j.brs.2015.05.005
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA CM2WD
UT WOS:000357542100014
PM 26143022
ER
PT J
AU Nagashima, M
Sasakawa, T
Schaller, SJ
Martyn, JAJ
AF Nagashima, M.
Sasakawa, T.
Schaller, S. J.
Martyn, J. A. J.
TI Block of postjunctional muscle-type acetylcholine receptors in vivo
causes train-of-four fade in mice
SO BRITISH JOURNAL OF ANAESTHESIA
LA English
DT Article
DE acetylcholine; neuromuscular monitoring; neuromuscular block;
neuromuscular transmission; receptors; nicotinic
ID NEUROMUSCULAR-JUNCTION; TETANIC FADE; ALPHA-CONOTOXINS;
MYASTHENIA-GRAVIS; POSITIVE FEEDBACK; RELEASE; MOUSE; ALPHA-3-BETA-2;
HEMIDIAPHRAGM; BUNGAROTOXIN
AB Background: Train-of-four (TOP) fade during nerve-mediated muscle contraction is postulated to be attributable to inhibition of prejunctional nicotinic alpha 3 beta 2 acetylcholine receptors (nAChRs), while decrease of twitch tension is attributable to block of postjunctional muscle nAChRs. The validity of these presumptions was tested using specific prejunctional and postjunctional nAChR antagonists, testing the hypothesis that fade is not always a prejunctional phenomenon.
Methods: Pentobarbital anaesthetized mice had TOP fade measured after administration of: either 0.9% saline; the prejunctional alpha 3 beta 2 nAChR antagonist, dihydro-beta-erythroidine (DH beta E); the postjunctional nAChR antagonists, alpha-bungarotoxin (alpha-BTX) or alpha-conotoxin GI; and a combination of alpha-BTX and DH beta E; or a combination of alpha-conotoxin GI and DHOE.
Results: Saline caused no neuromuscular changes. Administration of muscle nAChR antagonists, alpha-BTX or alpha-conotoxin GI caused significant decrease of twitch tension and TOP fade compared with baseline (P<0.01). DH beta E alone caused no change of twitch tension or fade even after 90 min, but its coadministration with alpha-BTX or alpha-conotoxin GI significantly accelerated the onset of paralysis and degree of fade compared with alpha-BTX or alpha-conotoxin GI alone (P<0.01).
Conclusions: Occupation of postjunctional nAChRs alone by alpha-BTX or alpha-conotoxin GI causes fade. As the prejunctional effects of DH beta E on fade became manifest only when co-administered with alpha-BTX or alpha-conotoxin GI, specific inhibition of prejunctional nAChR alone is not necessary and sufficient to cause fade. Fade observed during repetitive nerve stimulation can be because of block of either postjunctional nAChRs alone, or block of prejunctional and postjunctional nAChRs together.
C1 [Nagashima, M.; Sasakawa, T.; Schaller, S. J.; Martyn, J. A. J.] Massachusetts Gen Hosp, Shriners Hosp Children Boston, Dept Anaesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Nagashima, M.; Sasakawa, T.; Schaller, S. J.; Martyn, J. A. J.] Harvard Univ, Sch Med, Boston, MA USA.
[Schaller, S. J.] Tech Univ Munich, Klin Anaesthesiol, Klinikum Rechts Isar, D-80290 Munich, Germany.
RP Martyn, JAJ (reprint author), Massachusetts Gen Hosp, Shriners Hosp Children Boston, Dept Anaesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
EM jmartyn@mgh.harvard.edu
OI Schaller, Stefan/0000-0002-6683-9584; Nagashima,
Michio/0000-0001-7416-5367
FU National Institutes of Health, Bethesda, Maryland [GM P50-21500];
Shriners Hospitals Research Philantrophy, Tampa, Florida
FX National Institutes of Health (GM P50-21500) (Project I), Bethesda,
Maryland, and from Shriners Hospitals Research Philantrophy, Tampa,
Florida to J.A.J. Martyn.
NR 35
TC 0
Z9 1
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0007-0912
EI 1471-6771
J9 BRIT J ANAESTH
JI Br. J. Anaesth.
PD JUL
PY 2015
VL 115
IS 1
BP 122
EP 127
DI 10.1093/bja/aev037
PG 6
WC Anesthesiology
SC Anesthesiology
GA CM0EG
UT WOS:000357350600021
PM 25835024
ER
PT J
AU Hazelton, WD
Curtius, K
Inadomi, JM
Vaughan, TL
Meza, R
Rubenstein, JH
Hur, C
Luebeck, EG
AF Hazelton, William D.
Curtius, Kit
Inadomi, John M.
Vaughan, Thomas L.
Meza, Rafael
Rubenstein, Joel H.
Hur, Chin
Luebeck, E. Georg
TI The Role of Gastroesophageal Reflux and Other Factors during Progression
to Esophageal Adenocarcinoma
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID BODY-MASS INDEX; INTERNATIONAL BEACON CONSORTIUM; BARRETTS-ESOPHAGUS;
HELICOBACTER-PYLORI; UNITED-STATES; RISK-FACTORS; GENETIC POLYMORPHISMS;
CIGARETTE-SMOKING; CANCER INCIDENCE; POOLED ANALYSIS
AB Background: U.S. esophageal adenocarcinoma (EAC) incidence increased over 5-fold between 1975 and 2009. Symptomatic gastroesophageal reflux disease (sGERD) elevates the risk for EAC. However, a simple calculation suggests that changes in sGERD prevalence can explain at most approximately 16% of this trend. Importantly, a mechanistic understanding of the influence of sGERD and other factors (OF) on EAC is lacking.
Methods: A multiscale model was developed to estimate temporal trends for sGERD and OF, and their mechanistic role during carcinogenesis. Model calibration was to Surveillance, Epidemiology, and End Results (SEER) incidence and age-dependent sGERD data using maximum likelihood and Markov chain Monte Carlo (MCMC) methods.
Results: Among men, 77.8% [ 95% credibility interval (CI), 64.9%-85.6%] of the incidence trend is attributable to OF, 13.4% (95% CI, 11.4%-17.3%) to sGERD, and 8.8% (95% CI, 4.2%-13.7%) to sGERD-OF interactions. Among women, 32.6% (95% CI, 27.0%-39.9%) of the trend is attributable to OF, 13.6%(95% CI, 12.5%-15.9%) to sGERD, and 47.4% (95% CI, 30.7%-64.6%) to interactions. The predicted trends were compared with historical trends for obesity, smoking, and proton pump inhibitor use. Interestingly, predicted OF cohort trends correlated most highly with median body mass index (BMI) at age 50 (r = 0.988 for men; r = 0.998 for women).
Conclusions: sGERD and OF mechanistically increase premalignant cell promotion, which increases EAC risk exponentially with exposure duration.
Impact: Surveillance should target individuals with long-duration sGERD and OF exposures. (C) 2015 AACR.
C1 [Hazelton, William D.; Luebeck, E. Georg] Fred Hutchinson Canc Res Ctr, Program Computat Biol, Seattle, WA 98109 USA.
[Hazelton, William D.; Vaughan, Thomas L.; Luebeck, E. Georg] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA.
[Curtius, Kit] Univ Washington, Dept Appl Math, Seattle, WA 98195 USA.
[Inadomi, John M.] Univ Washington, Div Gastroenterol, Seattle, WA 98195 USA.
[Vaughan, Thomas L.] Univ Washington, Dept Epidemiol, Sch Med, Seattle, WA 98195 USA.
[Meza, Rafael] Univ Michigan, Sch Publ Hlth, Sch Med, Dept Epidemiol, Ann Arbor, MI 48109 USA.
[Rubenstein, Joel H.] Univ Michigan, Sch Med, Div Gastroenterol, Ann Arbor, MI USA.
[Rubenstein, Joel H.] Vet Affairs Ctr Clin Management Res, Ann Arbor, MI USA.
[Hur, Chin] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA.
[Hur, Chin] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
[Hur, Chin] Harvard Univ, Sch Med, Boston, MA USA.
RP Hazelton, WD (reprint author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave North,M2-B500, Seattle, WA 98109 USA.
EM hazelton@fhcrc.org
OI Hur, Chin/0000-0002-2819-7576
FU National Cancer Institute (NCI) [UO1 CA152926, UO1 CA182940]; National
Science Foundation [DGE-0718124]
FX This research was supported by the National Cancer Institute (NCI) under
grant nos. UO1 CA152926 and UO1 CA182940 (to W.D. Hazelton, J.M.
Inadomi, C. Hur, and E.G. Luebeck), and by a Graduate Research
Fellowship from the National Science Foundation, DGE-0718124 (to K.
Curtius).
NR 60
TC 5
Z9 5
U1 1
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD JUL
PY 2015
VL 24
IS 7
BP 1012
EP 1023
DI 10.1158/1055-9965.EPI-15-0323-T
PG 12
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA CM1FF
UT WOS:000357425700002
PM 25931440
ER
PT J
AU Thrift, AP
Gong, J
Peters, U
Chang-Claude, J
Rudolph, A
Slattery, ML
Chan, AT
Locke, A
Kahali, B
Justice, AE
Pers, TH
Gallinger, S
Hayes, RB
Baron, JA
Caan, BJ
Ogino, S
Berndt, SI
Chanock, SJ
Casey, G
Haile, RW
Du, MM
Harrison, TA
Thornquist, M
Duggan, DJ
Le Marchand, L
Lindor, NM
Seminara, D
Song, MY
Wu, K
Thibodeau, SN
Cotterchio, M
Win, AK
Jenkins, MA
Hopper, J
Ulrich, CM
Potter, JD
Newcomb, PA
Hoffmeister, M
Brenner, H
White, E
Hsu, L
Campbell, PT
AF Thrift, Aaron P.
Gong, Jian
Peters, Ulrike
Chang-Claude, Jenny
Rudolph, Anja
Slattery, Martha L.
Chan, Andrew T.
Locke, Adame.
Kahali, Bratati
Justice, Anne E.
Pers, Tune H.
Gallinger, Steven
Hayes, Richard B.
Baron, John A.
Caan, Bette J.
Ogino, Shuji
Berndt, Sonja I.
Chanock, Stephen J.
Casey, Graham
Haile, Robert W.
Du, Mengmeng
Harrison, Tabitha A.
Thornquist, Mark
Duggan, David J.
Le Marchand, Loic
Lindor, Noralane M.
Seminara, Daniela
Song, Mingyang
Wu, Kana
Thibodeau, Stephen N.
Cotterchio, Michelle
Win, Aung Ko
Jenkins, Mark A.
Hopper, Johnl.
Ulrich, Cornelia M.
Potter, John D.
Newcomb, Polly A.
Hoffmeister, Michael
Brenner, Hermann
White, Emily
Hsu, Li
Campbell, Peter T.
TI Mendelian Randomization Study of Body Mass Index and Colorectal Cancer
Risk
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; INSTRUMENTAL VARIABLES; MICROSATELLITE
INSTABILITY; SUSCEPTIBILITY LOCI; CIGARETTE-SMOKING; PHYSICAL-ACTIVITY;
COLON-CANCER; OBESITY; DESIGN; HEALTH
AB Background: High body mass index (BMI) is consistently linked to increased risk of colorectal cancer for men, whereas the association is less clear for women. As risk estimates from observational studies may be biased and/or confounded, we conducted a Mendelian randomization study to estimate the causal association between BMI and colorectal cancer.
Methods: Weused data from 10,226 colorectal cancer cases and 10,286 controls of European ancestry. The Mendelian randomization analysis used a weighted genetic risk score, derived from 77 genome-wide association study-identified variants associated with higher BMI, as an instrumental variable (IV). We compared the IV odds ratio (IV-OR) with the OR obtained using a conventional covariate-adjusted analysis.
Results: Individuals carrying greater numbers of BMI-increasing alleles had higher colorectal cancer risk[ per weighted allele OR, 1.31; 95% confidence interval (CI), 1.10-1.57]. Our IV estimation results support the hypothesis that genetically influenced BMI is directly associated with risk for colorectal cancer (IV-OR per 5 kg/m(2), 1.50; 95% CI, 1.13-2.01). In the sex-specific IV analyses higher BMI was associated with higher risk of colorectal cancer among women (IV-OR per 5 kg/m(2), 1.82; 95% CI, 1.26-2.61). For men, genetically influenced BMI was not associated with colorectal cancer (IV-OR per 5 kg/m(2), 1.18; 95% CI, 0.73-1.92).
Conclusions: High BMI was associated with increased colorectal cancer risk for women. Whether abdominal obesity, rather than overall obesity, is a more important risk factor for men requires further investigation.
Impact: Overall, conventional epidemiologic and Mendelian randomization studies suggest a strong association between obesity and the risk of colorectal cancer. (C) 2015 AACR.
C1 [Thrift, Aaron P.; Gong, Jian; Peters, Ulrike; Du, Mengmeng; Harrison, Tabitha A.; Thornquist, Mark; Potter, John D.; Newcomb, Polly A.; White, Emily; Hsu, Li] Fred Hutchinson Canc Res Ctr, Publ Hlth Sci Div, Seattle, WA 98104 USA.
[Thrift, Aaron P.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Thrift, Aaron P.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA.
[Peters, Ulrike; Du, Mengmeng; Potter, John D.; Newcomb, Polly A.; White, Emily] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA.
[Chang-Claude, Jenny; Rudolph, Anja] German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Germany.
[Slattery, Martha L.] Univ Utah, Hlth Sci Ctr, Dept Internal Med, Salt Lake City, UT USA.
[Chan, Andrew T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
[Chan, Andrew T.] Harvard Univ, Sch Med, Boston, MA USA.
[Chan, Andrew T.] Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA.
[Chan, Andrew T.; Du, Mengmeng] Harvard Univ, Sch Med, Boston, MA USA.
[Locke, Adame.] Univ Michigan, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
[Kahali, Bratati] Univ Michigan, Dept Internal Med, Div Gastroenterol, Ann Arbor, MI 48109 USA.
[Kahali, Bratati] Univ Michigan, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA.
[Justice, Anne E.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA.
[Pers, Tune H.] Boston Childrens Hosp, Div Endocrinol & Genet, Boston, MA USA.
[Pers, Tune H.] Boston Childrens Hosp, Ctr Basic & Translat Obes Res, Boston, MA USA.
[Pers, Tune H.] MIT, Broad Inst, Cambridge, MA 02139 USA.
[Pers, Tune H.] Harvard Univ, Cambridge, MA 02138 USA.
[Pers, Tune H.] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
[Pers, Tune H.] Tech Univ Denmark, Dept Syst Biol, Ctr Biol Sequence Anal, DK-2800 Lyngby, Denmark.
[Gallinger, Steven] Univ Toronto, Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada.
[Hayes, Richard B.] NYU, Sch Med, Dept Populat Hlth, Div Epidemiol, New York, NY USA.
[Baron, John A.] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC USA.
[Caan, Bette J.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA.
[Ogino, Shuji] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Ogino, Shuji] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Ogino, Shuji; Song, Mingyang] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Berndt, Sonja I.; Chanock, Stephen J.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
[Casey, Graham] Univ So Calif, USC Norris Comprehens Canc Ctr, Los Angeles, CA USA.
[Haile, Robert W.] Stanford Univ, Div Oncol, Dept Med, Stanford, CA 94305 USA.
[Duggan, David J.] Translat Genom Res Inst, Phoenix, AZ USA.
[Le Marchand, Loic] Univ Hawaii, Ctr Canc, Epidemiol Program, Honolulu, HI 96822 USA.
[Lindor, Noralane M.] Mayo Clin, Dept Hlth Sci Res, Scottsdale, AZ USA.
[Seminara, Daniela] NCI, Div Canc Control & Populat Sci, NIH, Bethesda, MD 20892 USA.
[Song, Mingyang; Wu, Kana] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Thibodeau, Stephen N.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA.
[Thibodeau, Stephen N.] Mayo Clin, Dept Lab Genet, Rochester, MN USA.
[Cotterchio, Michelle] Canc Care Ontario, Prevent & Canc Control, Toronto, ON, Canada.
[Win, Aung Ko; Jenkins, Mark A.; Hopper, Johnl.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia.
[Ulrich, Cornelia M.] Populat Sci Huntsman Canc Inst, Salt Lake City, UT USA.
[Potter, John D.] Massey Univ, Ctr Publ Hlth Res, Wellington, New Zealand.
[Hoffmeister, Michael; Brenner, Hermann] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany.
[Brenner, Hermann] German Canc Consortium DKTK, Heidelberg, Germany.
[Hsu, Li] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA.
[Campbell, Peter T.] Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA.
RP Thrift, AP (reprint author), Baylor Coll Med, Dan L Duncan Canc Ctr, 1 Baylor Plaza, Houston, TX 77030 USA.
EM aaron.thrift@bcm.edu
RI Hoffmeister, Michael/B-5745-2012; Song, Mingyang/M-6701-2013; Jenkins,
Mark/P-7803-2015; Gallinger, Steven/E-4575-2013; Brenner,
Hermann/B-4627-2017;
OI Hoffmeister, Michael/0000-0002-8307-3197; Song,
Mingyang/0000-0002-1324-0316; Jenkins, Mark/0000-0002-8964-6160;
Brenner, Hermann/0000-0002-6129-1572; Potter, John/0000-0001-5439-1500;
Locke, Adam/0000-0001-6227-198X; Hayes, Richard/0000-0002-0918-661X;
Win, Aung Ko/0000-0002-2794-5261
FU Mayo Clinic Cooperative Family Registry for Colon Cancer Studies
[U01/U24 CA074800]; University of Hawaii Colorectal Cancer Family
Registry [U01/U24 CA074806]; Familial Colorectal Neoplasia Collaborative
Group [U01 CA074799]; NIH [R01 CA151993, R01 CA137178, P01 CA53996, R01
AG14358, 1U54CA155626-01, R25 CA094880, R01 DK062370, UM1 CA167551, R01
CA48998, P01 CA 055075, UM1 CA167552, R01 137178, R01 CA 151993, P50 CA
127003, U01 CA074783, U01 HG004446, R01 CA076366, K05 CA154337];
National Cancer Institute, NIH, U.S. Department of Health and Human
Services [U01 CA137088, R01 CA059045]; National Cancer Institute, NIH
[U01 CA122839, R01 CA143237]; NIH: Australasian Colorectal Cancer Family
Registry [U01 CA074778, U01/U24 CA097735]; Ontario Registry for Studies
of Familial Colorectal Cancer [U01/U24 CA074783]; Seattle Colorectal
Cancer Family Registry [U01/U24 CA074794]; German Research Council
(Deutsche Forschungsgemeinschaft) [BR 1704/6-1, BR 1704/6-3, BR
1704/6-4, CH 117/1-1]; German Federal Ministry of Education and Research
[01KH0404, 01ER0814]; NHS by the NIH [R01 CA151993, R01 CA137178, P50 CA
127003, P01 CA 087969]; PHS by the NIH [R01 CA042182]; Ontario Research
Fund; Canadian Institutes of Health Research; Ontario Institute for
Cancer Research; Ontario Ministry of Research and Innovation; Intramural
Research Program of the Division of Cancer Epidemiology and Genetics;
Division of Cancer Prevention, National Cancer Institute, NIH, DHHS;
NIH, Genes, Environment and Health Initiative (GEI) [Z01 CP 010200]; NIH
GEI [U01 HG 004438]; National Heart, Lung, and Blood Institute, NIH,
U.S. Department of Health and Human Services [HHSN268201100046C,
HHSN268201100001C, HHSN268201100002C, HHSN268201100003C,
HHSN268201100004C, HHSN271201100004C]
FX N.M. Lindor was supported through the Mayo Clinic Cooperative Family
Registry for Colon Cancer Studies (U01/U24 CA074800). L. Le Marchand was
supported through the University of Hawaii Colorectal Cancer Family
Registry (U01/U24 CA074806). J.A. Baron was supported through the
Familial Colorectal Neoplasia Collaborative Group (U01 CA074799). This
work was supported by grants from the NIH (R01 CA151993 to S. Ogino; R01
CA137178 to A.T. Chan; P01 CA53996 and R01 AG14358 to L. Hsu). M. Song
was supported by a grant from the NIH (1U54CA155626-01). M. Du was
supported by a grant from the NIH (R25 CA094880). A.E. Locke was
supported by a grant from the NIH (R01 DK062370).; GECCO is supported by
National Cancer Institute, NIH, U.S. Department of Health and Human
Services (U01 CA137088; R01 CA059045).; CCFR is supported by NIH (UM1
CA167551) and through cooperative agreements with members of the Colon
Cancer Family Registry and PIs. This genome-wide scan was supported by
the National Cancer Institute, NIH by U01 CA122839 and R01 CA143237 to
Graham Casey. The content of this article does not necessarily reflect
the views or policies of the National Cancer Institute or any of the
collaborating centers in the Colon Cancer Family Registry (CCFR), nor
does mention of trade names, commercial products, or organizations imply
endorsement by the U.S. Government or the CCFR. The following CCFR
centers contributed data to this article and were supported by NIH:
Australasian Colorectal Cancer Family Registry (U01 CA074778 and U01/U24
CA097735), Ontario Registry for Studies of Familial Colorectal Cancer
(U01/U24 CA074783), Seattle Colorectal Cancer Family Registry (U01/U24
CA074794).; DACHS is supported by German Research Council (Deutsche
Forschungsgemeinschaft, BR 1704/6-1, BR 1704/6-3, BR 1704/6-4 and CH
117/1-1), and the German Federal Ministry of Education and Research
(01KH0404 and 01ER0814).; DALS is supported by NIH (R01 CA48998 to M.L.
Slattery).; HPFS is supported by the NIH (P01 CA 055075, UM1 CA167552,
R01 137178, R01 CA 151993, and P50 CA 127003), NHS by the NIH (R01
CA137178, P01 CA 087969, R01 CA151993, and P50 CA 127003), and PHS by
the NIH (R01 CA042182).; OFCCR is supported by NIH, through funding
allocated to the Ontario Registry for Studies of Familial Colorectal
Cancer (U01 CA074783); see CCFR section above. Additional funding toward
genetic analyses of OFCCR includes the Ontario Research Fund, the
Canadian Institutes of Health Research, and the Ontario Institute for
Cancer Research, through generous support from the Ontario Ministry of
Research and Innovation.; PLCO is supported by the Intramural Research
Program of the Division of Cancer Epidemiology and Genetics and
supported by contracts from the Division of Cancer Prevention, National
Cancer Institute, NIH, DHHS. In addition, a subset of control samples
was genotyped as part of the Cancer Genetic Markers of Susceptibility
(CGEMS) Prostate Cancer GWAS (Yeager, M. and colleagues. Genome-wide
association study of prostate cancer identifies a second risk locus at
8q24. Nat Genet 2007 May;39(5):64-59), Colon CGEMS pancreatic cancer
scan (PanScan) (Amundadottir, L. and colleagues. Genome-wide association
study identifies variants in the ABO locus associated with
susceptibility to pancreatic cancer. Nat Genet. 2009 Sep;41(9):986-90,
and Petersen, G.M. and colleagues. A genome-wide association study
identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1,
1q32.1 and 5p15.33. Nat Genet. 2010 Mar;42(3):224-8), and the Lung
Cancer and Smoking study (Landi M.T., and colleagues. A genome-wide
association study of lung cancer identifies a region of chromosome 5p15
associated with risk for adenocarcinoma. Am J Hum Genet. 2009
Nov;85(5):679-91). The prostate and PanScan study datasets were accessed
with appropriate approval through the dbGaP online resource
(http://cgems.cancer.gov/data/) accession numbers phs000207. v1.p1 and
phs000206.v3.p2, respectively, and the lung datasets were accessed from
the dbGaP website (http://www.ncbi.nlm.nih.gov/gap) through accession
number phs000093.v2.p2. Funding for the Lung Cancer and Smoking study
was provided by NIH, Genes, Environment and Health Initiative (GEI) Z01
CP 010200, NIH U01 HG004446, and NIH GEI U01 HG 004438. For the lung
study, the GENEVA Coordinating Center provided assistance with genotype
cleaning and general study coordination, and the Johns Hopkins
University Center for Inherited Disease Research conducted genotyping.;
PMH is supported by NIH (R01 CA076366 to P.A. Newcomb).; VITAL is
supported by NIH (K05 CA154337).; The WHI program is funded by the
National Heart, Lung, and Blood Institute, NIH, U.S. Department of
Health and Human Services through contracts HHSN268201100046C,
HHSN268201100001C, HHSN268201100002C, HHSN268201100003C,
HHSN268201100004C, and HHSN271201100004C.
NR 33
TC 13
Z9 14
U1 2
U2 10
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD JUL
PY 2015
VL 24
IS 7
BP 1024
EP 1031
DI 10.1158/1055-9965.EPI-14-1309
PG 8
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA CM1FF
UT WOS:000357425700003
PM 25976416
ER
PT J
AU Tan, ASL
Nagler, RH
Hornik, RC
DeMichele, A
AF Tan, Andy S. L.
Nagler, Rebekah H.
Hornik, Robert C.
DeMichele, Angela
TI Evolving Information Needs among Colon, Breast, and Prostate Cancer
Survivors: Results from a Longitudinal Mixed-Effects Analysis
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID QUALITY-OF-LIFE; CARE PLANS; HEALTH; RECURRENCE; FEAR; POPULATION;
PREVENTION; BEHAVIORS; DIAGNOSIS; DISTRESS
AB Background: This study describes how cancer survivors' information needs about recurrence, late effects, and family risks of cancer evolve over the course of their survivorship period.
Methods: Three annual surveys were conducted from 2006 to 2008 in a cohort of Pennsylvania cancer survivors diagnosed with colon, breast, or prostate cancer in 2005 (round 1, N = 2,013; round 2, N = 1,293; round 3, N = 1,128). Outcomes were information seeking about five survivorship topics. Key predictors were survey round, cancer diagnosis, and the interaction between these variables. Mixed-effects logistic regression analyses were performed to predict information seeking about each topic, adjusting for demographic variables, clinical characteristics, and clustering of repeated observations within individuals.
Results: Information seeking about reducing risks of cancer recurrence was the most frequently reported topic across survivors and over time. Breast cancer survivors were more likely to seek about survivorship topics at round 1 compared with other survivors. In general, information seeking declined over time, but cancer-specific patterns emerged: the decline was sharpest for breast cancer survivors, whereas in later years female colon cancer survivors actually sought more information (about how to reduce the risk of family members getting colon cancer or a different cancer).
Conclusion: Cancer survivors' information needs varied over time depending on the topic, and these trends differed by cancer type.
Impact: Clinicians may need to intervene at distinct points during the survivorship period with information to address concerns about cancer recurrence, late effects, and family members' risks. (C) 2015 AACR.
C1 [Tan, Andy S. L.] Dana Farber Canc Inst, Ctr Community Based Res, Div Populat Sci, Dept Med Oncol, Boston, MA 02215 USA.
[Tan, Andy S. L.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02115 USA.
[Nagler, Rebekah H.] Univ Minnesota, Sch Journalism & Mass Commun, Minneapolis, MN USA.
[Hornik, Robert C.] Univ Penn, Annenberg Sch Commun, Philadelphia, PA 19104 USA.
[DeMichele, Angela] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
RP Tan, ASL (reprint author), Dana Farber Canc Inst, 450 Brookline Ave LW662, Boston, MA 02215 USA.
EM andy_tan@dfci.harvard.edu
FU NCI [P20CA095856, P50CA095856]
FX This study is supported by P20CA095856 and P50CA095856 from the NCI (PI:
R.C. Hornik). A.S.L. Tan conducted this work while being a CECCR
postdoctoral research fellow at the Annenberg School for Communication
(supported by P20CA095856).
NR 37
TC 7
Z9 7
U1 2
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD JUL
PY 2015
VL 24
IS 7
BP 1071
EP 1078
DI 10.1158/1055-9965.EPI-15-0041
PG 8
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA CM1FF
UT WOS:000357425700009
PM 25979968
ER
PT J
AU Farvid, MS
Eliassen, AH
Cho, E
Chen, WY
Willett, WC
AF Farvid, Maryam S.
Eliassen, A. Heather
Cho, Eunyoung
Chen, Wendy Y.
Willett, Walter C.
TI Adolescent and Early Adulthood Dietary Carbohydrate Quantity and Quality
in Relation to Breast Cancer Risk
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID TOTAL-ENERGY-INTAKE; GLYCEMIC INDEX; INSULIN INDEX; UNITED-STATES;
PROSPECTIVE COHORT; COLORECTAL-CANCER; C-PEPTIDE; LOAD; HEALTH; WOMEN
AB Background: We investigated quantity and quality of dietary carbohydrate as well as insulin load and insulin index during adolescence and also early adulthood in relation to risk of breast cancer in the Nurses' Health Study II.
Methods: During 20 years of follow-up of 90,534 premenopausal women who completed a diet questionnaire in 1991, 2,833 invasive breast cancer cases were documented. In 1998, 44,263 of these women also completed a questionnaire about their diet during high school; among these women, we documented 1,118 cases of breast cancer. Multivariable-adjusted Cox proportional hazards regression was used to model relative risks (RR) and 95% confidence intervals (95% CI) for breast cancer across categories of dietary carbohydrate, glycemic index (GI), glycemic load (GL), as well as insulin load and insulin index scores.
Results: Adolescent or early adult intakes of GI or GL were not associated with risk of breast cancer. Comparing women in the highest versus lowest quintile, the multivariable-adjusted RRs were 1.14 (0.95-1.38) for adolescent GI scores and 1.03 (0.91-1.16) for early adulthood GI scores. We also did not observe associations with insulin index and insulin load scores in adolescence or early adulthood and breast cancer risk.
Conclusions: We found that diets high in GI, GL, insulin index, and insulin load during adolescence or early adulthood were not associated with an increased risk of breast cancer in this cohort study. Impact: Diets with a high glucose or insulin response in adolescence or early adulthood were not significant predictors of breast cancer incidence. (C) 2015 AACR.
C1 [Farvid, Maryam S.; Willett, Walter C.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Farvid, Maryam S.] Shahid Beheshti Univ Med Sci, Fac Nutr Sci & Food Technol, Dept Community Nutr, Tehran, Iran.
[Eliassen, A. Heather; Cho, Eunyoung; Chen, Wendy Y.; Willett, Walter C.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.
[Eliassen, A. Heather; Cho, Eunyoung; Chen, Wendy Y.; Willett, Walter C.] Harvard Univ, Sch Med, Boston, MA USA.
[Eliassen, A. Heather; Willett, Walter C.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Cho, Eunyoung] Brown Univ, Warren Alpert Med Sch, Dept Dermatol, Providence, RI 02912 USA.
[Chen, Wendy Y.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Farvid, MS (reprint author), Harvard Univ, TH Chan Sch Publ Hlth, Dept Nutr, 655 Huntington Ave, Boston, MA 02115 USA.
EM mfarvid@hsph.harvard.edu
FU NIH [R01 CA050385, UM1 CA176726]; Breast Cancer Research Foundation;
Japan Pharmaceutical Manufacturers Association
FX The study was supported by the NIH grants (R01 CA050385, UM1 CA176726)
and a grant from The Breast Cancer Research Foundation. M.S. Farvid was
supported by the Japan Pharmaceutical Manufacturers Association.
NR 47
TC 1
Z9 1
U1 4
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD JUL
PY 2015
VL 24
IS 7
BP 1111
EP 1120
DI 10.1158/1055-9965.EPI-14-1401
PG 10
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA CM1FF
UT WOS:000357425700014
PM 25805068
ER
PT J
AU Singh, I
Ozturk, N
Cordero, J
Mehta, A
Hasan, D
Cosentino, C
Sebastian, C
Kruger, M
Looso, M
Carraro, G
Bellusci, S
Seeger, W
Braun, T
Mostoslavsky, R
Barreto, G
AF Singh, Indrabahadur
Ozturk, Nihan
Cordero, Julio
Mehta, Aditi
Hasan, Diya
Cosentino, Claudia
Sebastian, Carlos
Krueger, Marcus
Looso, Mario
Carraro, Gianni
Bellusci, Saverio
Seeger, Werner
Braun, Thomas
Mostoslavsky, Raul
Barreto, Guillermo
TI High mobility group protein-mediated transcription requires DNA damage
marker gamma-H2AX
SO CELL RESEARCH
LA English
DT Article
DE HMGA2; gamma-H2AX; TGF beta 1; ATM; Gata6; transcription;
chromatin-associated proteins; DNA damage
ID GENERATION SEQUENCING DATA; CELL-CYCLE ARREST; HISTONE H1;
ATAXIA-TELANGIECTASIA; CANCER-CELLS; H2AX PHOSPHORYLATION; LUNG
DEVELOPMENT; GENE-EXPRESSION; HMG PROTEINS; CHROMATIN
AB The eukaryotic genome is organized into chromatins, the physiological template for DNA-dependent processes including replication, recombination, repair, and transcription. Chromatin-mediated transcription regulation involves DNA methylation, chromatin remodeling, and histone modifications. However, chromatin also contains non-histone chromatin-associated proteins, of which the high-mobility group (HMG) proteins are the most abundant. Although it is known that HMG proteins induce structural changes of chromatin, the processes underlying transcription regulation by HMG proteins are poorly understood. Here we decipher the molecular mechanism of transcription regulation mediated by the HMG AT-hook 2 protein (HMGA2). We combined proteomic, ChIP-seq, and transcriptome data to show that HMGA2-induced transcription requires phosphorylation of the histone variant H2AX at S139 (H2AXS139ph; gamma-H2AX) mediated by the protein kinase ataxia telangiectasia mutated (ATM). Furthermore, we demonstrate the biological relevance of this mechanism within the context of TGF beta 1 signaling. The interplay between HMGA2, ATM, and H2AX is a novel mechanism of transcription initiation. Our results link H2AXS139ph to transcription, assigning a new function for this DNA damage marker. Controlled chromatin opening during transcription may involve intermediates with DNA breaks that may require mechanisms that ensure the integrity of the genome.
C1 [Singh, Indrabahadur; Ozturk, Nihan; Cordero, Julio; Mehta, Aditi; Hasan, Diya; Barreto, Guillermo] Max Planck Inst Heart & Lung Res, LOEWE Res Grp Lung Canc Epigenet, D-61231 Bad Nauheim, Germany.
[Krueger, Marcus] Max Planck Inst Heart & Lung Res, Div Biomol Mass Spectrometry, D-61231 Bad Nauheim, Germany.
[Looso, Mario] Max Planck Inst Heart & Lung Res, Grp Bioinformat, D-61231 Bad Nauheim, Germany.
[Seeger, Werner] Max Planck Inst Heart & Lung Res, Dept Lung Dev & Remodeling, D-61231 Bad Nauheim, Germany.
[Braun, Thomas] Max Planck Inst Heart & Lung Res, Dept Cardiac Dev & Remodeling, D-61231 Bad Nauheim, Germany.
[Cosentino, Claudia; Sebastian, Carlos; Mostoslavsky, Raul] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02118 USA.
[Carraro, Gianni] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA.
[Bellusci, Saverio] Univ Giessen, Excellence Cluster Cardio Pulm Syst, Lung Matrix Remodeling, D-35932 Giessen, Germany.
[Bellusci, Saverio; Barreto, Guillermo] Kazan Volga Reg Fed Univ, Inst Fundamental Med & Biol, Kazan 420008, Russia.
[Bellusci, Saverio; Seeger, Werner; Braun, Thomas; Barreto, Guillermo] German Ctr Lung Res, Giessen, Germany.
RP Barreto, G (reprint author), Max Planck Inst Heart & Lung Res, LOEWE Res Grp Lung Canc Epigenet, Pk Str 1, D-61231 Bad Nauheim, Germany.
EM guillermo.barreto@mpi-bn.mpg.de
FU "LOEWE-Initiative der Landesforderung" [III L4-18/15.004 2009]; DFG [BA
4036/1-1]; NIH [R01GM093072-01]; Fondazione Umberto Veronesi; ECCPS;
[HL086322]; [HL074832]
FX We thank Bender R and Goth K for technical support; Bessler M, Kwon J
for reagents; and Dimmeler S, Renkawitz R and Schaprian A for helpful
discussions. Barreto G is funded by the "LOEWE-Initiative der
Landesforderung" (III L4-18/15.004 2009) and the DFG grant BA 4036/1-1.
R. Mostoslavsky is supported by NIH grants R01GM093072-01. Cosentino C
receives a Fellowship from the Fondazione Umberto Veronesi. Bellusci S
is supported by HL086322, HL074832 and the ECCPS. This work was done
according to the program of competitive growth of the Kazan Federal
University and the Russian Government.
NR 58
TC 12
Z9 12
U1 2
U2 8
PU INST BIOCHEMISTRY & CELL BIOLOGY
PI SHANGHAI
PA SIBS, CAS, 319 YUEYANG ROAD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1001-0602
EI 1748-7838
J9 CELL RES
JI Cell Res.
PD JUL
PY 2015
VL 25
IS 7
BP 837
EP 850
DI 10.1038/cr.2015.67
PG 14
WC Cell Biology
SC Cell Biology
GA CM2MZ
UT WOS:000357516000010
PM 26045162
ER
PT J
AU Tan, TC
Neilan, TG
Francis, S
Plana, JC
Scherrer-Crosbie, M
AF Tan, Timothy C.
Neilan, Tomas G.
Francis, Sanjeev
Plana, Juan Carlos
Scherrer-Crosbie, Marielle
TI Anthracycline-Induced Cardiomyopathy in Adults
SO COMPREHENSIVE PHYSIOLOGY
LA English
DT Article
ID LEFT-VENTRICULAR DYSFUNCTION; CARDIOVASCULAR-MAGNETIC-RESONANCE; ACUTE
LYMPHOBLASTIC-LEUKEMIA; CONGESTIVE-HEART-FAILURE; HIGH-DOSE
CHEMOTHERAPY; DOXORUBICIN-INDUCED CARDIOTOXICITY; CHILDHOOD-CANCER
SURVIVORS; COLLEGE-OF-CARDIOLOGY; TERM-FOLLOW-UP; TRASTUZUMAB-INDUCED
CARDIOTOXICITY
AB Anthracyclines are one of the most commonly used antineoplastic agent classes, and a core part of the treatment in breast cancers, hematological malignancies, and sarcomas. Their benefit is decreased by their well-recognized cardiotoxicity. The purpose of this review is to outline the presentation, mechanisms, diagnosis, and treatment of anthracyclines-induced cardiotoxicity. Symptomatic heart failure occurs in 2% to 5% of patients treated with anthrayclines and may be higher in older patients or patients with cardiovascular risk factors. The mechanisms involved in anthracycline-induced cardiotoxicity involve myocyte loss by apoptosis in the presence of a limited regenerative capacity. Once symptomatic, anthracycline-induced cardiotoxicity is associated with markedly decreased survival. Left ventricular ejection fraction (LVEF), mostly determined using echocardiography, is used to monitor patients treated with anthracyclines. As more than 1/3 of patients treated with anthracyclines do not recover their baseline LVEF once it is decreased, more sensitive echocardiographic indices of LV function such as myocardial deformation or biomarkers have been studied in patients monitoring. Cardioprotective treatments such as angiotensin-converting enzyme inhibitors, beta-blockers, iron chelators, statins, and metformin are also the topic of research efforts. (C) 2015 American Physiological Society.
C1 [Tan, Timothy C.; Scherrer-Crosbie, Marielle] Massachusetts Gen Hosp, Div Cardiol, Cardiac Ultrasound Lab, Boston, MA 02114 USA.
[Tan, Timothy C.] Univ Western Sydney, Blacktown Hosp, Div Cardiol, Penrith, NSW 1797, Australia.
[Neilan, Tomas G.; Francis, Sanjeev; Scherrer-Crosbie, Marielle] Massachusetts Gen Hosp, Div Cardiol, Cardiooncol Program, Boston, MA 02114 USA.
[Neilan, Tomas G.; Francis, Sanjeev] Massachusetts Gen Hosp, Div Radiol, Cardiac MR PET CT Program, Boston, MA 02114 USA.
[Plana, Juan Carlos] Baylor Coll Med, Div Cardiol, Houston, TX 77030 USA.
RP Scherrer-Crosbie, M (reprint author), Massachusetts Gen Hosp, Div Cardiol, Cardiac Ultrasound Lab, Boston, MA 02114 USA.
EM marielle@crosbie.com
NR 218
TC 3
Z9 3
U1 1
U2 11
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 2040-4603
J9 COMPR PHYSIOL
JI Compr. Physiol.
PD JUL
PY 2015
VL 5
IS 3
BP 1517
EP 1540
DI 10.1002/cphy.c140059
PG 24
WC Physiology
SC Physiology
GA CM3PY
UT WOS:000357596400019
PM 26140726
ER
PT J
AU Lu, DF
Wu, Y
Harris, G
Cai, WL
AF Lu, Difei
Wu, Yin
Harris, Gordon
Cai, Wenli
TI Iterative mesh transformation for 3D segmentation of livers with cancers
in CT images
SO COMPUTERIZED MEDICAL IMAGING AND GRAPHICS
LA English
DT Article
DE Image segmentation; Mesh deformation; Dynamic-programming; Liver
segmentation
ID STATISTICAL SHAPE MODEL; AUTOMATED SEGMENTATION; PROBABILISTIC ATLAS;
LEVEL-SET
AB Segmentation of diseased liver remains a challenging task in clinical applications due to the high interpatient variability in liver shapes, sizes and pathologies caused by cancers or other liver diseases. In this paper, we present a multi-resolution mesh segmentation algorithm for 3D segmentation of livers, called iterative mesh transformation that deforms the mesh of a region-of-interest (ROI) in a progressive manner by iterations between mesh transformation and contour optimization. Mesh transformation deforms the 3D mesh based on the deformation transfer model that searches the optimal mesh based on the affine transformation subjected to a set of constraints of targeting vertices. Besides, contour optimization searches the optimal transversal contours of the ROI by applying the dynamic-programming algorithm to the intersection polylines of the 3D mesh on 2D transversal image planes. The initial constraint set for mesh transformation can be defined by a very small number of targeting vertices, namely landmarks, and progressively updated by adding the targeting vertices selected from the optimal transversal contours calculated in contour optimization. This iterative 3D mesh transformation constrained by 2D optimal transversal contours provides an efficient solution to a progressive approximation of the mesh of the targeting ROI. Based on this iterative mesh transformation algorithm, we developed a semi-automated scheme for segmentation of diseased livers with cancers using as little as five user-identified landmarks. The evaluation study demonstrates that this semi-automated liver segmentation scheme can achieve accurate and reliable segmentation results with significant reduction of interaction time and efforts when dealing with diseased liver cases. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Lu, Difei; Wu, Yin; Harris, Gordon; Cai, Wenli] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Lu, Difei; Wu, Yin; Harris, Gordon; Cai, Wenli] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Lu, Difei] Zhejiang Police Coll, Dept Informat, Hangzhou, Zhejiang, Peoples R China.
RP Cai, WL (reprint author), Massachusetts Gen Hosp, Dept Radiol, 25 New Chardon St,400C, Boston, MA 02114 USA.
EM Cai.Wenli@mgh.harvard.edu
FU NCI NIH HHS [R41 CA189637]
NR 31
TC 2
Z9 2
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0895-6111
EI 1879-0771
J9 COMPUT MED IMAG GRAP
JI Comput. Med. Imaging Graph.
PD JUL
PY 2015
VL 43
BP 1
EP 14
DI 10.1016/j.compmedimag.2015.01.006
PG 14
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA CL8MW
UT WOS:000357229800001
PM 25728595
ER
PT J
AU Davis, JS
Weiss, ST
Tantisira, KG
AF Davis, Joshua S.
Weiss, Scott T.
Tantisira, Kelan G.
TI Asthma Pharmacogenomics: 2015 Update
SO CURRENT ALLERGY AND ASTHMA REPORTS
LA English
DT Review
DE Asthma; Genes; Pharmacogenomics; Pharmacogenetics; GWAS; Systems biology
ID GENOME-WIDE ASSOCIATION; IMPROVED LUNG-FUNCTION; SMOOTH-MUSCLE-CELLS;
BETA(2)-ADRENERGIC RECEPTOR; INHALED CORTICOSTEROIDS; BRONCHODILATOR
RESPONSE; BETA-AGONIST; PERSISTENT ASTHMA; CLINICAL-RESPONSE; ACTING
BETA(2)-AGONISTS
AB There is evidence that genetic factors are implicated in the observed differences in therapeutic responses to the common classes of asthma therapy such as beta 2-agonists, corticosteroids, and leukotriene modifiers. Pharmacogenomics explores the roles of genetic variation in drug response and continues to be a field of great interest in asthma therapy. Prior studies have focused on candidate genes and recently emphasized genome-wide association analyses. Newer integrative omics and system-level approaches have recently revealed novel understanding of drug response pathways. However, the current known genetic loci only account for a fraction of variability in drug response and ongoing research is needed. While the field of asthma pharmacogenomics is not yet fully translatable to clinical practice, ongoing research should hopefully achieve this goal in the near future buttressed by the recent precision medicine efforts in the USA and worldwide.
C1 [Davis, Joshua S.; Weiss, Scott T.; Tantisira, Kelan G.] Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA.
[Davis, Joshua S.; Weiss, Scott T.; Tantisira, Kelan G.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Davis, Joshua S.] Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA.
[Weiss, Scott T.; Tantisira, Kelan G.] Brigham & Womens Hosp, Pulm & Crit Care Div, Boston, MA 02115 USA.
[Weiss, Scott T.] Partners HealthCare Syst, Partners Personalized Med, Boston, MA USA.
RP Tantisira, KG (reprint author), Brigham & Womens Hosp, Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA.
EM rejda@channing.harvard.edu; restw@channing.harvard.edu;
rekgt@channing.harvard.edu
FU NIH [U01 HL65899, R01 HL092197, R01 NR013391]
FX This work was supported by NIH (U01 HL65899, R01 HL092197, and R01
NR013391).
NR 100
TC 4
Z9 4
U1 2
U2 16
PU CURRENT MEDICINE GROUP
PI PHILADELPHIA
PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA
SN 1529-7322
EI 1534-6315
J9 CURR ALLERGY ASTHM R
JI Curr. Allergy Asthma Rep.
PD JUL
PY 2015
VL 15
IS 7
AR 42
DI 10.1007/s11882-015-0544-y
PG 12
WC Allergy; Immunology
SC Allergy; Immunology
GA CM1GL
UT WOS:000357429200008
PM 26143396
ER
PT J
AU Wanner, M
Mihm, MC
Farinelli, WA
Doukas, A
Zurakowski, D
Piris, A
Avram, MM
Klein, JA
Anderson, RR
AF Wanner, Molly
Mihm, Martin C., Jr.
Farinelli, William A.
Doukas, Apostolos
Zurakowski, David
Piris, Adriano
Avram, Mathew M.
Klein, Jeffrey A.
Anderson, R. Rox
TI Use of Photodynamic Therapy and Sterile Water to Target Adipose Tissue
SO DERMATOLOGIC SURGERY
LA English
DT Article
ID ACID; FAT
AB BACKGROUND
Neither photodynamic therapy (PDT) nor sterile water has not been well studied for the treatment of adipose tissue.
OBJECTIVE
This investigation studied 2 different modalities, verteporfin PDT and sterile water, on adipose tissue compared with control.
MATERIALS AND METHODS
Four light-skinned pigs were used. Test sites received verteporfin PDT or sterile water injection. Control sites received injection of verteporfin without PDT, normal saline injection, no intervention, exposure to laser only, or insertion of a needle or cannula only. Sites were evaluated clinically, by ultrasound, and with histology 4 to 6 weeks after treatment.
RESULTS
There was a decrease in adipose tissue by ultrasound after verteporfin PDT (15%, p < .001) and sterile water (2%, p = .23). Verteporfin without PDT showed a decrease in adipose tissue (17%, p = .21). All other control sites showed an increase in adipose tissue. Histologically, verteporfin PDT and sterile water showed moderate damage (median Grade 2, p < .001) 4 to 6 weeks after intervention.
CONCLUSION
Verteporfin decreased adipose tissue after treatment. Sterile water injection had a statistically significant effect on adipose tissue histologically but did not substantially decrease the adipose tissue by ultrasound 4 to 6 weeks after intervention. Longer follow-up may be needed.
C1 [Wanner, Molly; Avram, Mathew M.] Harvard Univ, Sch Med, Dept Dermatol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Mihm, Martin C., Jr.; Piris, Adriano] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Wanner, Molly; Farinelli, William A.; Doukas, Apostolos; Anderson, R. Rox] Harvard Univ, Sch Med, Dept Dermatol, Wellman Ctr Photomed,Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Zurakowski, David] Harvard Univ, Sch Med, Dept Anesthesia, Boston Childrens Hosp, Boston, MA 02115 USA.
[Zurakowski, David] Harvard Univ, Sch Med, Dept Surg, Boston Childrens Hosp, Boston, MA 02115 USA.
[Klein, Jeffrey A.] Univ Calif Irvine, Dept Dermatol, Irvine, CA 92717 USA.
RP Wanner, M (reprint author), 50 Staniford St,Suite 200, Boston, MA 02114 USA.
EM mwanner@partners.org
FU ASDS Cutting Edge Research Grant Program
FX Supported by the ASDS Cutting Edge Research Grant Program. Equipment
provided by Candela Corporation and HK Surgical.
NR 18
TC 1
Z9 1
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1076-0512
EI 1524-4725
J9 DERMATOL SURG
JI Dermatol. Surg.
PD JUL
PY 2015
VL 41
IS 7
BP 803
EP 811
DI 10.1097/DSS.0000000000000385
PG 9
WC Dermatology; Surgery
SC Dermatology; Surgery
GA CM2AI
UT WOS:000357481500006
PM 26079592
ER
PT J
AU Tirumani, SH
Tirumani, H
Jagannathan, JP
Shinagare, AB
Hornick, JL
Ramaiya, NH
Wagner, AJ
AF Tirumani, S. H.
Tirumani, H.
Jagannathan, J. P.
Shinagare, A. B.
Hornick, J. L.
Ramaiya, N. H.
Wagner, A. J.
TI Metastasis in dedifferentiated liposarcoma: Predictors and outcome in
148 patients
SO EJSO
LA English
DT Article
DE Dedifferentiated liposarcoma; Metastasis; Predictors; Survival
ID SOFT-TISSUE SARCOMAS; RETROPERITONEAL; RECURRENCE; PATTERNS; GRADE
AB Objective: To describe the pattern of dedifferentiated liposarcoma (DDLPS) metastases and to analyze their predictors and outcome.
Materials and methods: In this retrospective study, we reviewed the imaging and clinical records of all consenting patients with histopathology-confirmed DDLPS seen from 2000 through 2012. The predictive value of clinical and histopathologic parameters for metastasis later in the disease course was analyzed using univariate and multivariate analyses. Survival of patients with and without metastasis was compared using Log-rank test.
Results: Records of 148 patients (57 women, 91 men; mean age 59 years, range 30-87 years) were reviewed. Distant metastases were observed in 44/148 patients (29.7%), 9/44 (20.5%) at presentation and 35/44 (79.5%) developing them later at a median interval of 8 months (IQR = 0.80-26 months). Median duration of follow-up was 38 months (IQR = 18-74 months) with 77/148 patients (31 with metastases) deceased at the time of analysis. Median survival was 28 months (IQR = 10-56 months) for patients with metastases and 38 months (IQR, 17-65 months) for patients without metastases (p = 0.0123, Log-Rank test; Hazard ratio 1.79 [95% confidence interval 1.11-2.84]). Lung was the most common site of metastases (33 patients, 22.3%). On univariate analysis, grade and local recurrence were associated with subsequent risk of metastasis where as age, tumor size, site, de novo dedifferentiation, number of previous surgical resections, margin positivity and chemoradiation were not. On multivariate analysis, high tumor grade (p-value = 0.0005, OR 5.05; 95% CI 2.01-13.48) and local recurrence (p-value = 0.0025, OR 4.46; 95% CI 1.67-13.40) predicted metastasis.
Conclusion: Lung was most frequent site of DDLPS metastases. Risk of developing metastatic disease was statistically associated with tumor grade and local recurrence. Metastatic disease was associated with decreased survival. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Tirumani, S. H.; Tirumani, H.; Jagannathan, J. P.; Shinagare, A. B.; Ramaiya, N. H.] Harvard Univ, Sch Med, Dept Imaging, Dana Farber Canc Inst, Boston, MA 02215 USA.
[Tirumani, S. H.; Jagannathan, J. P.; Shinagare, A. B.; Ramaiya, N. H.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Radiol, Boston, MA 02215 USA.
[Hornick, J. L.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02215 USA.
[Wagner, A. J.] Harvard Univ, Sch Med, Ctr Sarcoma & Bone Oncol, Dana Farber Canc Inst, Boston, MA 02215 USA.
[Wagner, A. J.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02215 USA.
RP Tirumani, SH (reprint author), Harvard Univ, Sch Med, Dept Imaging, Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM stirumani@partners.org
NR 16
TC 7
Z9 7
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0748-7983
EI 1532-2157
J9 EJSO-EUR J SURG ONC
JI EJSO
PD JUL
PY 2015
VL 41
IS 7
BP 899
EP 904
DI 10.1016/j.ejso.2015.01.012
PG 6
WC Oncology; Surgery
SC Oncology; Surgery
GA CL8ME
UT WOS:000357228000014
PM 25659772
ER
PT J
AU Duchemann, B
Friboulet, L
Besse, B
AF Duchemann, Boris
Friboulet, Luc
Besse, Benjamin
TI Therapeutic management of ALK(+) nonsmall cell lung cancer patients
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Article
ID ANAPLASTIC LYMPHOMA KINASE; EML4-ALK FUSION GENE; TYROSINE KINASE;
CRIZOTINIB RESISTANCE; CLINICAL-FEATURES; PULMONARY ADENOCARCINOMA;
1ST-LINE CRIZOTINIB; ACQUIRED-RESISTANCE; BRAIN METASTASES;
GROWTH-FACTOR
AB With therapeutic approaches based on oncogene addiction offering significant anticancer benefit, the identification of anaplastic lymphoma kinase (ALK) rearrangements is a key aspect of the management of lung cancers. The EML4-ALK gene fusion is detected in 4-8% of all lung cancers, predominantly in light smokers or nonsmokers. Crizotinib, the first agent to be approved in this indication, is associated with a median progression-free survival of 10.9 months when given as first-line treatment and 7.7 months when administered after chemotherapy. Median overall survival with crizotinib in the second-line setting is 20.3 months. Second-generation ALK inhibitors are currently being evaluated, with early studies giving impressive results, notably in patients resistant to crizotinib or with brain metastases. Among available chemotherapies, pemetrexed appears to be particularly active in this population. Despite this progress, several questions remain unanswered. What detection strategies should be favoured? What underlies the mechanisms of resistance and what options are available to overcome them? What are the best approaches for progressing patients? This review provides an overview of current data in the literature and addresses these questions.
C1 [Duchemann, Boris] Hop Avicenne, Dept Med Oncol, F-93009 Bobigny, France.
[Duchemann, Boris] Univ Paris 13, Paris, France.
[Friboulet, Luc] Harvard Univ, Sch Med, Massachusetts Gen Hosp Canc Ctr, Dept Med, Boston, MA USA.
[Besse, Benjamin] Gustave Roussy, Dept Canc Med, Villejuif, France.
[Besse, Benjamin] Univ Paris Sud, Paris, France.
RP Besse, B (reprint author), Gustave Roussy, Dept Canc Med, 114 Rue Edouard Vaillant, F-94805 Villejuif, France.
EM benjamin.besse@gustaveroussy.fr
NR 94
TC 4
Z9 4
U1 0
U2 7
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
EI 1399-3003
J9 EUR RESPIR J
JI Eur. Resp. J.
PD JUL
PY 2015
VL 46
IS 1
BP 230
EP 242
DI 10.1183/09031936.00236414
PG 13
WC Respiratory System
SC Respiratory System
GA CL7FG
UT WOS:000357137300027
PM 25929953
ER
PT J
AU Dumas, O
Matran, R
Zerimech, F
Decoster, B
Huyvaert, H
Ahmed, I
Le Moual, N
Nadif, R
AF Dumas, Orianne
Matran, Regis
Zerimech, Farid
Decoster, Brigitte
Huyvaert, Helene
Ahmed, Ismail
Le Moual, Nicole
Nadif, Rachel
TI Occupational exposures and fluorescent oxidation products in 723 adults
of the EGEA study
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Letter
ID IN-HOSPITAL WORKERS; CLEANING PRODUCTS; ASTHMA; FEMALES; STRESS
C1 [Dumas, Orianne; Le Moual, Nicole; Nadif, Rachel] INSERM, U1168, VIMA, Aging & Chron Dis,Epidemiol & Publ Hlth Approache, F-94807 Villejuif, France.
[Dumas, Orianne; Le Moual, Nicole; Nadif, Rachel] Univ Versailles, St Quentin En Yvelines, UMR S 1168, Montigny Le Bretonneux, France.
[Dumas, Orianne] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.
[Dumas, Orianne] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
[Matran, Regis; Decoster, Brigitte; Huyvaert, Helene] Univ Lille Nord France, Lille, France.
[Zerimech, Farid; Huyvaert, Helene] CHRU, Ctr Biol Pathol, Biochim Lab, Lille, France.
[Ahmed, Ismail] INSERM, UMR 1181, Biostat Biomath Pharmacoepidemiol & Infect Dis B2, Villejuif,